sexe,age,poids,taille,surface corporelle,IMC,creatinine plasmatique,clairance creatinine,date de début de conditionnement/admission,motif d'admission,type de greffe,date de la greffe/début du protocole,Protocole
Female,27,52.088032706755456,186.01421938110911,1.6405550164370861,15.053783540966739,110.75258965128188,0.7381251653894099,2022-10-11,Cancer diagnosis,greffe haplo-identique,2022-01-24,Protocole 3 LAL thiotepa Bu Flu
Male,57,92.24368116828958,157.17499757608604,2.0068217246318154,37.33960344838479,115.73668725292995,0.9187792420465252,2022-08-20,Symptoms management,auto-greffe,2022-07-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,43,94.03045596913475,188.09418630655458,2.216515164217916,26.57772462133642,74.75352952264777,1.694634630046824,2022-06-15,Treatment follow-up,pas de greffe,2022-05-29,Protocole 3 LAL thiotepa Bu Flu
Female,37,44.57845115857658,172.54016189735123,1.4616935744419863,14.974232527425956,106.23215743884282,0.6003074069137382,2022-07-16,Symptoms management,greffe haplo-identique,2022-05-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,100.99103986102006,142.70658686355486,2.0008391713344924,49.59007962472102,105.9042820336799,0.8211613815514358,2022-06-05,Cancer diagnosis,allo-greffe,2022-12-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,76,67.96951325902646,172.62055100118906,1.805311209709944,22.810203656494977,134.79603680443142,0.4482130673232702,2022-08-04,Cancer diagnosis,auto-greffe,2022-02-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,49.313563979467105,183.98349280553887,1.5875279300807914,14.568293155466938,76.11480839948216,0.5668984707360477,2022-12-31,Cancer diagnosis,pas de greffe,2022-11-24,Protocole 3 LAL thiotepa Bu Flu
Male,30,75.16039743866276,189.00021443855098,1.986435335608457,21.040907837309824,129.74680199861473,0.8850190001365948,2022-03-09,Treatment follow-up,auto-greffe,2022-03-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,96.11988689500359,170.81915076873895,2.1356184019435522,32.941254490177435,103.99641274074735,0.937098528264106,2022-09-13,Cancer diagnosis,auto-greffe,2022-11-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,43.283876229259846,182.21227921421448,1.4801326649398878,13.036795869382376,91.14534935706757,0.42871876482450044,2022-07-26,Cancer diagnosis,greffe haplo-identique,2022-07-09,Protocole 3 LAL thiotepa Bu Flu
Female,73,114.00367484493873,197.52432262948213,2.5010274916865143,29.21983024353595,95.16269726247732,1.1147934645872728,2022-03-18,Treatment follow-up,pas de greffe,2022-09-25,Protocole 3 LAL thiotepa Bu Flu
Male,69,116.98738246775778,196.64416373724094,2.527893611134959,30.25358890063228,89.01226734215575,1.296029874936418,2022-04-08,Cancer diagnosis,pas de greffe,2022-06-14,Protocole 3 LAL thiotepa Bu Flu
Female,21,46.719058390631425,183.68049807979682,1.543928963086843,13.84739192705451,76.96544225969515,1.0032583356852123,2022-04-29,Cancer diagnosis,greffe haplo-identique,2022-02-23,Protocole 3 LAL thiotepa Bu Flu
Male,72,107.86328433615148,187.8081783992757,2.372153671440068,30.580504034633393,113.06381788605754,0.901003358594102,2022-01-17,Cancer diagnosis,allo-greffe,2022-08-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,52,89.8656218991988,163.52537130445637,2.0204035067676434,33.606500905417136,101.35312505461414,1.0836938677503605,2022-02-25,Symptoms management,allo-greffe,2022-08-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,92.27811861042542,188.17507001552656,2.1962367706815793,26.060008848572227,112.02145018297733,0.9496053151917259,2022-07-26,Symptoms management,greffe haplo-identique,2022-08-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,104.10589384846458,148.35982769505873,2.071307455677202,47.29798909414769,109.76278363894693,1.2119244181418476,2022-02-23,Cancer diagnosis,allo-greffe,2022-07-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,42,50.507105028178536,199.68148716477214,1.6737627142006544,12.667090438899354,121.25762931270663,0.5669398472785891,2022-12-16,Symptoms management,allo-greffe,2022-06-27,Protocole 3 LAL thiotepa Bu Flu
Male,60,110.46195975219119,164.9025812065412,2.2494111753146395,40.62167588027284,133.30738214632504,0.9206955298323027,2022-08-05,Symptoms management,auto-greffe,2022-12-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,91.57510337650777,151.47492874130046,1.9629436694833926,39.91130274969906,85.37125939380967,1.206752624127757,2022-12-24,Treatment follow-up,allo-greffe,2022-03-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,82.9328977791341,175.42240674915922,2.010271438768193,26.949872209809232,76.10925939548918,1.3166674542939114,2022-01-21,Treatment follow-up,greffe haplo-identique,2022-09-08,Protocole 3 LAL thiotepa Bu Flu
Male,65,69.4170666225294,196.63828726193412,1.9472240274727393,17.95271315996693,76.13183218059021,0.9497925155268154,2022-04-16,Treatment follow-up,pas de greffe,2022-01-23,Protocole 3 LAL thiotepa Bu Flu
Male,22,89.87881933003786,186.04752302013216,2.155208916679639,25.966270328899153,112.508888585023,1.3092423203090768,2022-03-07,Symptoms management,auto-greffe,2022-12-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,113.74904229167694,175.66341907759897,2.3559349220967682,36.86252548159679,117.19510447178124,1.0649589632728655,2022-04-11,Symptoms management,allo-greffe,2022-04-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,41.689495320109145,154.35807046044604,1.3369856286190385,17.497175809422874,110.80294986595118,0.38147464611348547,2022-02-15,Treatment follow-up,auto-greffe,2022-09-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,61,82.94658824210038,192.70708802315065,2.107156818083873,22.3358842113143,97.83701755952012,0.9302290906545846,2022-07-14,Symptoms management,pas de greffe,2022-02-05,Protocole 3 LAL thiotepa Bu Flu
Male,66,73.12340745599002,169.9133263351493,1.8577645911303455,25.328037279737263,88.88278521279213,0.8455474593728197,2022-07-30,Cancer diagnosis,pas de greffe,2022-10-23,Protocole 3 LAL thiotepa Bu Flu
Female,32,41.36152185568356,197.93385190318898,1.5080197962774988,10.557384943554052,115.62176744546166,0.5365969069171205,2022-10-23,Cancer diagnosis,greffe haplo-identique,2022-03-18,Protocole 3 LAL thiotepa Bu Flu
Male,68,65.31134719839666,142.71185585281438,1.6090631821489845,32.06775334877504,118.89724161526985,0.5493091875901753,2022-07-26,Symptoms management,allo-greffe,2022-09-26,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,44,114.61804200931978,177.58036061951074,2.3777856898989285,36.34654363665333,87.99897685820973,1.7366571915792552,2022-03-04,Treatment follow-up,pas de greffe,2022-07-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,28,70.38256932541525,181.22145087589962,1.882288156113704,21.431171446165454,131.28715143535712,0.8339277342180069,2022-11-04,Symptoms management,greffe haplo-identique,2022-07-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,68,56.190137467373546,143.30524810304507,1.495580674177738,27.36124808526463,96.78014694621609,0.5805957031518071,2022-01-18,Treatment follow-up,pas de greffe,2022-01-04,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,47.10552220923518,142.87890983543292,1.3673154619021717,23.074673623939965,94.36267064951976,0.45066357669192914,2022-02-19,Treatment follow-up,allo-greffe,2022-06-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,21,94.80117950276579,154.1221512003388,2.014596852508636,39.910173564028305,104.32193437689622,1.5019399680916379,2022-02-20,Cancer diagnosis,pas de greffe,2022-01-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,77,57.75004282111317,183.09299264886312,1.7138024783858719,17.22696867712496,95.19368435758572,0.5308260501679734,2022-07-06,Treatment follow-up,auto-greffe,2022-01-13,Protocole 3 LAL thiotepa Bu Flu
Female,43,114.72744688913816,169.1622325919298,2.321849780726725,40.0922576286587,110.99486917535494,1.3925271239671466,2022-04-29,Cancer diagnosis,pas de greffe,2022-01-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,57,62.38955939046473,146.40213911064964,1.5928629843543909,29.10831552495174,93.47432826109002,0.7694229952611796,2022-06-28,Treatment follow-up,greffe haplo-identique,2022-03-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,61,62.58174658589127,198.73740664645027,1.8587132660859003,15.84486133864951,91.38364350483582,0.7514045230193294,2022-04-05,Treatment follow-up,greffe haplo-identique,2022-11-04,Protocole 3 LAL thiotepa Bu Flu
Male,71,58.361701791962204,188.48394825842036,1.7480341323922173,16.427792402130628,132.89615096231543,0.4208546584103616,2022-05-29,Cancer diagnosis,auto-greffe,2022-10-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,101.80276735825149,153.80330535348102,2.085505675012294,43.03563802942598,121.3694175213586,0.8387843448316478,2022-11-29,Treatment follow-up,allo-greffe,2022-05-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,75.76091434718242,143.736395241754,1.7392208287751607,36.6700675055074,112.71839464266122,0.9895181885032125,2022-07-04,Treatment follow-up,allo-greffe,2022-12-08,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,32,65.53495974962937,169.77235167274677,1.7579995128201655,22.737311310192016,105.95425254767804,0.9277819177687958,2022-08-24,Symptoms management,allo-greffe,2022-12-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,111.09747083382375,182.28284421962042,2.3717763484356635,33.43586625814369,94.25994344781958,1.26047787245739,2022-09-14,Symptoms management,allo-greffe,2022-05-02,Protocole 3 LAL thiotepa Bu Flu
Female,24,55.46659188546666,188.48630830800101,1.704136563623133,15.612478914793165,122.17060428014548,0.7314594456554023,2022-10-26,Symptoms management,auto-greffe,2022-04-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,90.13934810866829,193.07805562698297,2.198732593785277,24.179570353029067,85.1235889723151,0.8971433152228312,2022-01-22,Cancer diagnosis,greffe haplo-identique,2022-06-10,Protocole 3 LAL thiotepa Bu Flu
Male,32,87.81404731284479,152.54022715467687,1.9289587522570655,37.73941957407943,104.5885638110333,1.2594213570735695,2022-08-22,Cancer diagnosis,pas de greffe,2022-02-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,56,41.59847479819717,157.64248928419144,1.349659125443399,16.739051265885063,88.72310682116141,0.5470001634304213,2022-09-03,Cancer diagnosis,greffe haplo-identique,2022-09-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,70.00549073190787,140.3068390367731,1.6517876780267922,35.56103750926542,125.57717020614086,0.603925709599442,2022-02-05,Cancer diagnosis,allo-greffe,2022-03-29,Protocole 8 Aplasie medullaire thymo
Female,48,87.95682141052242,188.12129584145447,2.143889975789263,24.853846005223772,127.59681284328651,0.880815666927119,2022-02-01,Cancer diagnosis,greffe haplo-identique,2022-09-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,83.63707905840026,195.0572905377678,2.12877260082115,21.982368430425232,76.50567473873444,0.9869293569400904,2022-05-15,Symptoms management,pas de greffe,2022-10-09,Protocole 3 LAL thiotepa Bu Flu
Female,56,57.2937434738769,184.32209905785808,1.712738471635041,16.863681228183566,109.54938570840925,0.6101604339200969,2022-09-06,Symptoms management,greffe haplo-identique,2022-05-12,Protocole 3 LAL thiotepa Bu Flu
Female,43,96.62734521261919,190.48646252469234,2.2611575927131815,26.63003972365487,82.7304806684002,1.5735253281865884,2022-10-24,Treatment follow-up,auto-greffe,2022-03-03,Protocole 3 LAL thiotepa Bu Flu
Male,69,59.86235779547184,172.7797987020743,1.6950095156839724,20.052470725586186,88.07648877595776,0.670223540695202,2022-06-03,Symptoms management,auto-greffe,2022-10-18,Protocole 3 LAL thiotepa Bu Flu
Male,27,56.32927261677434,174.15148028832283,1.650742779762403,18.572903513461988,125.33096749963514,0.7053776551134534,2022-01-28,Symptoms management,pas de greffe,2022-07-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,78,86.19182427510111,175.8279557300558,2.051756176150299,27.879836285816324,104.9776132923596,0.7070149076786815,2022-05-08,Treatment follow-up,greffe haplo-identique,2022-08-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,116.08920518027948,187.18090455903808,2.456831882458048,33.13360987080001,87.96424224197843,1.5213574579949813,2022-07-24,Treatment follow-up,auto-greffe,2022-04-26,Protocole 3 LAL thiotepa Bu Flu
Male,39,112.48656683723271,176.24299813830203,2.34668618538748,36.21403506041152,84.40909838573103,1.8693915617567962,2022-08-12,Treatment follow-up,greffe haplo-identique,2022-08-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,110.19699571581172,164.23726778383582,2.2421748800830748,40.853223632788115,78.51531292408275,1.7738801933938548,2022-06-18,Treatment follow-up,auto-greffe,2022-03-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,87.65678807403529,179.23982093877052,2.0890978248502017,27.284534606523184,76.57498760143638,1.876066069484153,2022-08-29,Treatment follow-up,pas de greffe,2022-12-18,Protocole 3 LAL thiotepa Bu Flu
Male,37,59.1770084561243,149.99413079967943,1.5702268012669771,26.302950970740113,121.9334894133003,0.6942801244793423,2022-08-22,Symptoms management,allo-greffe,2022-05-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,23,116.9848173055401,181.17354100335734,2.4263915592040246,35.64018551180013,76.98277718706667,2.4693877652603065,2022-11-21,Treatment follow-up,allo-greffe,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Male,32,109.17425846985347,186.53051779484915,2.378394122223045,31.377653237925536,78.56566514436854,2.0843887390739972,2022-02-22,Cancer diagnosis,allo-greffe,2022-10-03,Protocole 3 LAL thiotepa Bu Flu
Male,41,99.37260089899434,160.79674091730007,2.1067873357472413,38.4336979494436,119.01556216451917,1.1480626881990348,2022-10-01,Treatment follow-up,auto-greffe,2022-08-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,50.83289202128235,193.26830286032703,1.6519674104294466,13.608916599458528,117.46216405509455,0.6371184615537375,2022-06-05,Symptoms management,pas de greffe,2022-08-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,69.67553215415279,150.72938337746524,1.707999967318192,30.667929018033995,114.83449960937904,0.8679858400434233,2022-09-28,Treatment follow-up,pas de greffe,2022-11-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,50,71.59292901190537,174.70780105214936,1.8639744870804529,23.455545386724918,129.61916820271188,0.69041610516221,2022-03-16,Symptoms management,greffe haplo-identique,2022-12-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,105.11233618793982,165.1732183286033,2.196066107472388,38.527819166301875,91.64455482329173,1.29032628768227,2022-12-06,Symptoms management,auto-greffe,2022-03-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,96.14942336314901,147.5704155542598,1.9852798823817117,44.15176642278999,116.6264979846257,1.0419775090715444,2022-06-12,Cancer diagnosis,greffe haplo-identique,2022-08-29,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,26,71.38557428308242,147.21424607751405,1.708554741659872,32.939027996002466,112.658301916602,1.0032741250193724,2022-11-22,Treatment follow-up,auto-greffe,2022-03-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,70,65.74417594936506,154.51403302761935,1.6798146205603406,27.537304664088428,76.71961036330855,0.8331370367625001,2022-11-10,Cancer diagnosis,greffe haplo-identique,2022-05-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,64.40574085345368,156.52554678652942,1.6734149883196565,26.28779268534059,127.64778023344684,0.7077831033591768,2022-06-27,Treatment follow-up,greffe haplo-identique,2022-03-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,23,61.14649075892046,171.53485446983134,1.7069103336529419,20.781016194515093,91.92400545729956,1.0809259995682168,2022-04-06,Treatment follow-up,greffe haplo-identique,2022-07-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,83.71153935259858,193.46867687610506,2.12102967380686,22.364747795620005,92.02444262944533,1.1749857093131544,2022-09-13,Treatment follow-up,auto-greffe,2022-10-27,Protocole 3 LAL thiotepa Bu Flu
Male,39,99.98752828178816,184.00759908397265,2.2606823587305973,29.530738997416243,82.89939328204075,1.6919337666492353,2022-11-01,Treatment follow-up,pas de greffe,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Male,36,67.90089307734573,195.04792395837887,1.9180377870840455,17.84813417536341,128.55305048591848,0.7629462498762852,2022-08-28,Symptoms management,auto-greffe,2022-12-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,110.55292430612067,164.55485205079,2.247963282060741,40.82712985210402,126.78657792830678,0.7508551223746834,2022-07-08,Treatment follow-up,pas de greffe,2022-07-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,71,42.01656074415386,141.1403758422942,1.2834667868955614,21.092009646634697,117.70833197401487,0.34208173744265175,2022-05-23,Treatment follow-up,allo-greffe,2022-12-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,64,50.55139480445529,177.13316021158448,1.5771218788611108,16.111404496144154,118.97443393415831,0.4484980836845578,2022-09-19,Cancer diagnosis,pas de greffe,2022-06-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,57.68748464393329,193.67826317648033,1.7616920396199343,15.378707577074815,89.24361424344956,1.041429667206854,2022-03-03,Cancer diagnosis,pas de greffe,2022-09-09,Protocole 3 LAL thiotepa Bu Flu
Female,30,110.98986583331654,183.98394005232558,2.3816633322750493,32.788646998219924,124.43726456482077,1.3626774195952234,2022-07-13,Treatment follow-up,allo-greffe,2022-12-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,73.20478395776406,193.10883891132227,1.981616261823078,19.630671609891596,95.13694951118562,0.7160321910167227,2022-06-26,Cancer diagnosis,allo-greffe,2022-04-02,Protocole 3 LAL thiotepa Bu Flu
Male,25,107.90719908399237,143.56947248233067,2.0744597455679488,52.35114809903475,112.70360368224563,1.5292481401094795,2022-06-19,Symptoms management,auto-greffe,2022-12-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,30,112.59099891129371,157.86566627836692,2.2220019164457097,45.178134958436495,129.76637302477366,1.325567033314843,2022-09-26,Cancer diagnosis,greffe haplo-identique,2022-06-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,72,75.63429909524365,164.49528957127663,1.859023484042141,27.951933493278027,120.27104160862433,0.5939284522237821,2022-08-04,Treatment follow-up,greffe haplo-identique,2022-11-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,82.71540832264799,161.24326744594842,1.9247873407837925,31.814363412930994,87.41477527496855,1.5244987244950463,2022-02-12,Cancer diagnosis,pas de greffe,2022-09-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,91.64429542997345,180.83459872422122,2.145567743398471,28.02479104150085,112.55207852930621,0.8029301561935633,2022-11-26,Cancer diagnosis,allo-greffe,2022-06-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,48.40580478404469,153.43175427879655,1.4363328638984438,20.56207522985493,102.5457618938492,0.4458165073118974,2022-06-25,Treatment follow-up,greffe haplo-identique,2022-01-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,37,46.175810417095484,147.2213691888324,1.3741730880190324,21.304572374421124,108.56663539376231,0.6084471705775211,2022-05-31,Cancer diagnosis,allo-greffe,2022-05-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,77,77.62614365394131,147.71111235686544,1.7846758207878712,35.578011757474144,94.9563600783104,0.7153062274204985,2022-12-25,Symptoms management,greffe haplo-identique,2022-05-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,78,56.37811006378718,148.15507710704847,1.523218745111269,25.684873754260817,117.32872821799747,0.41377604391287837,2022-01-30,Treatment follow-up,auto-greffe,2022-05-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,76.66196199258373,167.24692628271265,1.8871993878394522,27.40713506472396,82.02998346825886,0.8956202411604055,2022-12-30,Cancer diagnosis,allo-greffe,2022-01-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,75.00037141557195,145.4026888418355,1.7404705356726333,35.47468425120507,117.2213636784953,0.6842501061636083,2022-08-03,Symptoms management,pas de greffe,2022-07-07,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,47,80.73039405603083,160.71848773688066,1.8984545503505195,31.253984879953926,119.27311972091846,0.8742687307335643,2022-03-01,Cancer diagnosis,allo-greffe,2022-02-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,43,85.80421032617292,196.76044648775152,2.1655686149822895,22.16322727476271,124.67808560427602,0.9271664571314612,2022-06-06,Cancer diagnosis,greffe haplo-identique,2022-09-16,Protocole 3 LAL thiotepa Bu Flu
Male,39,47.97336317624599,146.42718048261335,1.396881875639666,22.37467655390864,100.01944370170096,0.6728288550534716,2022-02-16,Cancer diagnosis,pas de greffe,2022-09-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,40,74.37779437424223,194.33082469604113,2.003739429154834,19.695177902057228,128.47066290894668,0.8040940230818531,2022-05-16,Symptoms management,greffe haplo-identique,2022-07-16,Protocole 3 LAL thiotepa Bu Flu
Male,30,40.261772393211444,150.78664594452144,1.2986036965989964,17.707902716218136,76.69550863152911,0.8020162099949671,2022-07-27,Cancer diagnosis,greffe haplo-identique,2022-07-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,52.94635214918954,151.29583065926195,1.4916957472760686,23.13034569824917,103.70974511201531,0.7374240880921384,2022-10-01,Treatment follow-up,auto-greffe,2022-03-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,47,115.15661060372022,143.93654375341265,2.1457480255312857,55.583607968431195,128.63912796243397,1.1562885859003629,2022-06-07,Cancer diagnosis,auto-greffe,2022-01-02,Protocole 8 Aplasie medullaire thymo
Female,51,107.28176440097685,160.87254157351364,2.189538897657326,41.45358174617029,106.89016078961815,1.2406397372407367,2022-05-21,Symptoms management,pas de greffe,2022-03-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,27,116.16689329494389,171.8077258534775,2.354568240467636,39.35473536355492,107.80480083140736,1.691181504942818,2022-02-17,Cancer diagnosis,pas de greffe,2022-08-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,59.39938026995131,153.17709865967288,1.5897785251004268,25.315950356848347,85.05425989118147,0.746868379248911,2022-10-10,Cancer diagnosis,allo-greffe,2022-05-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,48.043796179296734,145.21476165231365,1.3921075560148313,22.783255637538318,129.32648664949,0.44888654974951964,2022-10-12,Treatment follow-up,auto-greffe,2022-02-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,52,61.717631532638116,157.53147480100753,1.64337639535886,24.869930610704564,104.63935783840718,0.7208822982132846,2022-07-09,Cancer diagnosis,auto-greffe,2022-07-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,21,75.2423017807602,173.85192773654398,1.9062047234637582,24.894479564680648,106.32172821674988,1.1696461900860857,2022-02-11,Cancer diagnosis,greffe haplo-identique,2022-05-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,41.831982310320214,167.7581234367069,1.396190735538908,14.864192681097197,89.24080014010062,0.7487043105928723,2022-02-10,Cancer diagnosis,greffe haplo-identique,2022-09-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,74.6194136309925,149.7588205206115,1.7618578714682815,33.27108854028263,82.7449043312543,1.377751087605982,2022-08-21,Symptoms management,greffe haplo-identique,2022-07-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,54,81.39114222460248,178.83105386244677,2.010753295761314,25.450204217455443,106.00219923385771,0.9171243460967019,2022-06-17,Symptoms management,auto-greffe,2022-08-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,55.20438114041721,179.64507741509155,1.6597519329056434,17.105780822498744,74.312591459339,0.670643931948092,2022-05-12,Cancer diagnosis,allo-greffe,2022-07-27,Protocole 3 LAL thiotepa Bu Flu
Female,73,44.627428400919,191.9854534050736,1.5427083936171846,12.107799324869632,105.43898143885932,0.3938609882409941,2022-06-04,Treatment follow-up,greffe haplo-identique,2022-10-28,Protocole 3 LAL thiotepa Bu Flu
Male,29,74.34089031742658,147.7698316862686,1.746849612684812,34.04522436918226,134.52013301253007,0.851983045259284,2022-03-08,Cancer diagnosis,auto-greffe,2022-03-26,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,35,117.57054758288652,195.24997303729887,2.525186805275726,30.840156679993413,110.56582864237612,1.550723678949235,2022-07-26,Treatment follow-up,greffe haplo-identique,2022-04-19,Protocole 3 LAL thiotepa Bu Flu
Female,72,72.07744120815158,169.75271959463305,1.8435579780614144,25.013005518521453,76.29463056044132,0.892240232618751,2022-01-03,Cancer diagnosis,auto-greffe,2022-07-28,Protocole 3 LAL thiotepa Bu Flu
Male,74,42.520937329293396,195.41225087938065,1.5192388511848718,11.13523161948526,113.59210808874406,0.34313586164572585,2022-05-11,Cancer diagnosis,greffe haplo-identique,2022-08-03,Protocole 3 LAL thiotepa Bu Flu
Male,41,44.84677690110495,189.40690217063684,1.536074459745429,12.500852589804849,114.13873759908392,0.5402575806963736,2022-11-05,Cancer diagnosis,pas de greffe,2022-08-25,Protocole 3 LAL thiotepa Bu Flu
Male,41,66.70905862395425,183.89359855181021,1.8459692460393127,19.726570511471976,92.98181290697174,0.9864827619537583,2022-05-22,Symptoms management,greffe haplo-identique,2022-06-27,Protocole 3 LAL thiotepa Bu Flu
Female,24,62.804743589958385,170.93355493265955,1.7268659866025882,21.495017213860105,91.69598546076905,1.1034880068065485,2022-04-16,Treatment follow-up,greffe haplo-identique,2022-02-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,65.44492725735401,152.67712679435894,1.66599515279729,28.075534458986727,101.62077424535914,0.6529559046673283,2022-01-05,Cancer diagnosis,greffe haplo-identique,2022-08-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,96.69785532686936,173.9714376014847,2.1617036044258553,31.94926984511631,134.31415043892466,0.8099302038335477,2022-04-10,Symptoms management,pas de greffe,2022-07-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,89.31361008133712,186.0544226409481,2.148461475210028,25.801065905795333,113.16313543859118,1.2825255841460064,2022-05-25,Treatment follow-up,pas de greffe,2022-05-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,106.23258953907563,144.74819258699767,2.066732211972535,50.702744603992016,106.27322329656974,1.1801041680219444,2022-06-30,Symptoms management,greffe haplo-identique,2022-05-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,57,46.926123526363455,190.41124966794803,1.5754418976845268,12.942836734408248,115.98614884257486,0.46639528028358884,2022-08-31,Cancer diagnosis,auto-greffe,2022-05-08,Protocole 3 LAL thiotepa Bu Flu
Female,23,106.20535169748366,177.34360101941493,2.2873346641867536,33.76877885778016,106.1273983906373,1.6261936043429528,2022-11-08,Symptoms management,pas de greffe,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,112.60144025805221,169.00926745558675,2.2991959302509684,39.420570645279525,93.98114740924353,1.7306292730066137,2022-10-25,Treatment follow-up,greffe haplo-identique,2022-09-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,85.46404892525777,150.06672326464292,1.887481403818809,37.9502520393447,109.68254838901247,1.1146811574497197,2022-12-10,Cancer diagnosis,greffe haplo-identique,2022-08-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,33,87.355711687307,172.70907632994957,2.04716092550283,29.286062388614624,81.66544262603715,1.589660076318933,2022-07-18,Cancer diagnosis,greffe haplo-identique,2022-06-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,62.82222956906962,157.33056255019275,1.6569597928769588,25.37973916739205,109.1682492955594,0.5994400651292914,2022-06-13,Symptoms management,greffe haplo-identique,2022-04-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,69,117.10578356517003,148.17660809158025,2.1954712096466027,53.33582855060871,117.15832088653704,0.9856689091748253,2022-01-15,Treatment follow-up,greffe haplo-identique,2022-05-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,74,114.81122257084488,160.02214829409044,2.2590766602049293,44.83572002368416,123.16189941109215,0.854514433385417,2022-11-28,Cancer diagnosis,auto-greffe,2022-06-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,38,44.03553554964028,175.20825790585127,1.4639548290697262,14.344788176410535,78.12608082496928,0.7984999977376624,2022-12-04,Cancer diagnosis,pas de greffe,2022-04-05,Protocole 3 LAL thiotepa Bu Flu
Female,33,113.1815856146842,142.9105149253954,2.1196723200812615,55.41756071833251,118.00628273224424,1.4253513292745752,2022-05-13,Cancer diagnosis,allo-greffe,2022-09-18,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,76,81.68931956473287,192.31074185608517,2.0889746053993803,22.088091474229273,79.33918459474958,0.915218991383358,2022-11-07,Treatment follow-up,allo-greffe,2022-08-01,Protocole 2 LAM Endoxan TBI
Male,77,72.06402388312586,153.90382577038483,1.755224659253169,30.424235700425932,123.53468507325906,0.5104317128451932,2022-06-01,Symptoms management,allo-greffe,2022-03-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,74,108.5055037348773,195.7185696568444,2.4287938244965668,28.32615981504202,128.79548390564003,0.7722582765130785,2022-03-08,Treatment follow-up,auto-greffe,2022-03-12,Protocole 3 LAL thiotepa Bu Flu
Male,49,98.10522604820625,156.90215550335648,2.0678035470509655,39.85055029737257,125.04232870790909,0.9916170502062785,2022-10-06,Cancer diagnosis,greffe haplo-identique,2022-03-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,25,73.2701897528768,143.1244248380833,1.706747537647567,35.76842419615546,113.12525088181539,1.0345062166712584,2022-11-25,Cancer diagnosis,greffe haplo-identique,2022-06-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,45,80.5908141256488,178.41944206305172,1.9985389171220787,25.316355708811628,100.50382366909854,1.0580204622009475,2022-12-02,Treatment follow-up,auto-greffe,2022-12-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,47.976635931898656,190.10519437857312,1.5916978792283092,13.275223004437736,124.06632214208818,0.558568868960254,2022-08-01,Treatment follow-up,pas de greffe,2022-10-14,Protocole 3 LAL thiotepa Bu Flu
Female,33,53.60798156684738,147.18588508501495,1.480459595919231,24.74555097173112,93.07622760366922,0.8559373225778535,2022-08-14,Cancer diagnosis,allo-greffe,2022-10-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,75,73.19202676202325,182.94216545250845,1.9285794908935265,21.869363462796414,80.82091045064115,0.8175623721985281,2022-10-22,Cancer diagnosis,auto-greffe,2022-02-24,Protocole 3 LAL thiotepa Bu Flu
Female,52,81.04859936457783,155.71150125261858,1.8723276572135523,33.42751792001084,103.865193015871,0.9537304687647982,2022-07-25,Cancer diagnosis,auto-greffe,2022-05-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,113.68535225315122,193.39610570445544,2.471296578350381,30.395483937861762,90.66371016273331,1.9505475891650652,2022-08-04,Treatment follow-up,greffe haplo-identique,2022-10-10,Protocole 3 LAL thiotepa Bu Flu
Female,27,92.19899964843674,147.88034199249955,1.9461086243076902,42.160457651169786,101.82513444086308,1.4210755387277427,2022-06-06,Symptoms management,auto-greffe,2022-10-09,Protocole 6 FlUDARABINE cy (Fanconi)
Female,22,71.62355520897864,161.09639350700454,1.7902743764198927,27.59842121373971,116.30718914520975,1.0092501562234646,2022-07-05,Symptoms management,pas de greffe,2022-06-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,64,101.0580106493718,185.93889047385892,2.284647697958874,29.23009820988671,118.70004438747816,0.8986714800722512,2022-05-25,Symptoms management,auto-greffe,2022-08-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,112.6002426928695,152.48021392014573,2.183861837641767,48.42976273864459,112.21802461874177,1.2821299285400527,2022-01-27,Treatment follow-up,allo-greffe,2022-09-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,77,81.40781854920857,144.21421545750198,1.8058673419487066,39.142627412389565,97.86833785231026,0.7278333605506923,2022-06-22,Treatment follow-up,auto-greffe,2022-09-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,38,51.503166887364486,161.2290222371124,1.5187536227084915,19.81287473633177,90.53566279142954,0.8059014261063833,2022-09-26,Symptoms management,pas de greffe,2022-01-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,116.27839517975343,190.7256205197903,2.4820057454553357,31.965459823320742,128.49321756110317,1.5082299982676628,2022-11-20,Treatment follow-up,auto-greffe,2022-05-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,74.49349964213548,156.71038248260854,1.8007640987298137,30.33352182857874,85.3343390092802,0.8002137099563718,2022-10-30,Treatment follow-up,pas de greffe,2022-03-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,62.61264690894973,152.6333341011748,1.6293128284488367,26.875916412220914,107.92463314655612,0.7010164977403816,2022-11-21,Symptoms management,greffe haplo-identique,2022-12-23,Protocole 6 FlUDARABINE cy (Fanconi)
Male,79,64.26519800051264,163.41194604484915,1.7079634614408568,24.066240145992918,117.59472617593799,0.46300464002174146,2022-05-20,Cancer diagnosis,auto-greffe,2022-10-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,83.92728419710832,192.26865881343127,2.1171644014808333,22.703153018849843,114.47889153776546,0.8858588138761896,2022-04-23,Cancer diagnosis,auto-greffe,2022-05-19,Protocole 3 LAL thiotepa Bu Flu
Female,24,108.70514592589248,164.66528545310263,2.229845777185066,40.090917985595624,81.23724956217416,2.1558591579607995,2022-06-02,Symptoms management,greffe haplo-identique,2022-06-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,118.422416423134,147.02155209906184,2.1991568754266426,54.786292538290134,126.79391971240442,1.478794564928063,2022-11-03,Symptoms management,pas de greffe,2022-07-12,Protocole 8 Aplasie medullaire thymo
Male,56,91.92225770747365,159.7477093073586,2.019651379647928,36.020638254202424,106.99198633814866,1.0023426768908819,2022-07-14,Treatment follow-up,pas de greffe,2022-04-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,28,107.08503651992777,153.2164775111999,2.1348427010582154,45.61606743451459,134.98343678950292,1.234053061896829,2022-06-17,Symptoms management,allo-greffe,2022-10-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,22,106.63921001574921,190.80820239063192,2.3774190001076434,29.290233849582513,105.203102828217,1.6612610437933233,2022-09-12,Cancer diagnosis,allo-greffe,2022-03-23,Protocole 3 LAL thiotepa Bu Flu
Male,39,87.32031584043588,198.63604470814764,2.195004566004514,22.1309053203178,87.13529290362382,1.4057564337906314,2022-03-30,Symptoms management,greffe haplo-identique,2022-12-06,Protocole 3 LAL thiotepa Bu Flu
Female,21,62.30229590363571,174.10837786529413,1.7358436691215386,20.552502635010274,87.19988376405186,1.1808714155249218,2022-07-09,Cancer diagnosis,greffe haplo-identique,2022-10-23,Protocole 3 LAL thiotepa Bu Flu
Female,20,66.92369963204699,145.9899238133395,1.647404171095086,31.40032748340209,96.942102617196,1.1505785038229575,2022-04-12,Symptoms management,pas de greffe,2022-02-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,72,101.36658569149999,142.18242116665283,2.000871100505315,50.14215646483537,128.37947598699546,0.7457197341912863,2022-11-15,Symptoms management,allo-greffe,2022-09-09,Protocole 8 Aplasie medullaire thymo
Female,59,88.18772563873415,171.71248085373458,2.0509437631297893,29.909173815559672,124.07453939422487,0.7996095881391906,2022-02-20,Cancer diagnosis,greffe haplo-identique,2022-08-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,69,66.9283085971581,152.95018239116308,1.6862760587779229,28.609472559944635,74.35913488681634,0.8875674637149696,2022-09-25,Cancer diagnosis,pas de greffe,2022-01-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,54.467518399133034,173.84962159442642,1.6218265990745622,18.021464859451147,111.20812684544286,0.8094975302111054,2022-01-30,Cancer diagnosis,greffe haplo-identique,2022-11-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,112.6694058536378,156.8926493818475,2.2159147589812824,45.772097091465575,96.86074080702522,1.6317254797977485,2022-06-14,Treatment follow-up,pas de greffe,2022-01-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,109.19864882227385,179.63790201975914,2.3342983824449095,33.83929574123158,100.84805727036324,1.2031152142025958,2022-11-25,Cancer diagnosis,greffe haplo-identique,2022-05-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,77.49254913349077,184.9731785146379,1.9954144044967714,22.648655636474082,133.19394596157446,0.7272529221771727,2022-05-28,Treatment follow-up,auto-greffe,2022-09-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,64.79560640560634,163.24781416507508,1.7141357648499476,24.31368628757689,80.77698976482229,0.8801414791215358,2022-04-05,Treatment follow-up,auto-greffe,2022-04-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,76.83919904234428,165.00416139767256,1.876668709327697,28.222340983947184,106.43850610822565,0.8221771727185553,2022-05-01,Treatment follow-up,pas de greffe,2022-08-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,51.09090641985067,193.30363628862995,1.6563059627643313,13.672992016661087,112.90153541763414,0.5216621842162192,2022-08-28,Cancer diagnosis,greffe haplo-identique,2022-06-16,Protocole 3 LAL thiotepa Bu Flu
Male,73,49.133657116497645,140.0023205787329,1.3823114714561586,25.067361388264434,116.09678895755874,0.39382310230158896,2022-07-23,Treatment follow-up,pas de greffe,2022-04-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,72,40.74402125323323,162.28402393430514,1.3552473862156371,15.470785123263544,114.07101891387649,0.337337782053084,2022-06-29,Treatment follow-up,pas de greffe,2022-06-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,104.59278105333088,170.84249033499162,2.227909532512334,35.83520753023419,133.776989943339,1.1836254438202811,2022-06-09,Cancer diagnosis,auto-greffe,2022-12-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,33,68.72522846927183,176.13014634345495,1.8336806146670193,22.153829061977763,119.02186360413035,0.8581055828661234,2022-01-08,Cancer diagnosis,allo-greffe,2022-02-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,119.38500167022977,142.99937657822704,2.1776631723295505,58.382337824357485,95.3916830831923,2.085873698341056,2022-09-04,Cancer diagnosis,allo-greffe,2022-08-27,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,53,109.06884708100716,170.92077647900277,2.275603218730961,37.3345574901219,116.11189918174799,1.1350389106109269,2022-02-21,Symptoms management,allo-greffe,2022-08-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,40,110.06120239957282,162.58635449405446,2.2295022905833357,41.63571875219498,88.48181466810993,1.7276180612241858,2022-01-21,Symptoms management,pas de greffe,2022-08-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,91.46349669063457,159.65873824076075,2.014044195470805,35.88082458213436,89.65663375847653,0.9351403807881081,2022-05-05,Cancer diagnosis,greffe haplo-identique,2022-01-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,51.22834561414069,143.54340984247813,1.4292083482787394,24.862443755884463,115.7632225815992,0.7006676681380005,2022-12-22,Treatment follow-up,greffe haplo-identique,2022-10-29,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,58,119.55793176942139,151.96201270619875,2.2464950445497474,51.77359468333861,76.90161756970129,1.770615552362286,2022-09-27,Cancer diagnosis,greffe haplo-identique,2022-12-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,111.09418225242015,189.45364350695826,2.417942054272316,30.951763102973583,80.72668259487087,1.6628802180400364,2022-10-15,Treatment follow-up,pas de greffe,2022-12-11,Protocole 3 LAL thiotepa Bu Flu
Female,48,91.36833821491126,176.35080861510363,2.115608680867169,29.37925748087778,81.42354940673117,1.4338411063402539,2022-07-12,Symptoms management,allo-greffe,2022-04-30,Protocole 3 LAL thiotepa Bu Flu
Female,47,56.614029489645915,191.57520999225085,1.7357230792306702,15.425720079516353,76.84551136128046,0.9516034633911611,2022-06-21,Treatment follow-up,greffe haplo-identique,2022-11-04,Protocole 3 LAL thiotepa Bu Flu
Male,48,53.39220644249251,184.973161996527,1.656311602765412,15.604879783715537,113.23411208271467,0.6024984312934336,2022-04-25,Treatment follow-up,greffe haplo-identique,2022-07-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,95.43422802854678,170.65082897848293,2.126938992882147,32.770823897839065,77.07151462200245,1.5650173869884556,2022-09-26,Symptoms management,greffe haplo-identique,2022-08-24,Protocole 3 LAL thiotepa Bu Flu
Male,59,58.19189082247631,155.2985899546776,1.5843960110618314,24.128339989876213,75.93320382758534,0.8621508625387819,2022-09-09,Cancer diagnosis,greffe haplo-identique,2022-10-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,87.3304235713753,195.38935172402586,2.177118052188592,22.875141156081202,131.41441765772348,0.8583669822806299,2022-08-17,Cancer diagnosis,auto-greffe,2022-01-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,103.6281835406142,193.70593705911773,2.361343449916506,27.617987051629274,78.7932739606423,2.082385323328449,2022-03-31,Treatment follow-up,allo-greffe,2022-05-03,Protocole 3 LAL thiotepa Bu Flu
Male,73,66.84234322480914,199.82971426342806,1.9262143606416473,16.73907793368382,102.4138764509209,0.6073445903007618,2022-05-29,Treatment follow-up,greffe haplo-identique,2022-02-19,Protocole 3 LAL thiotepa Bu Flu
Female,51,58.053923807836384,189.24201899950037,1.7469212403729437,16.210500836545446,90.6596514333971,0.7915439683240294,2022-07-01,Cancer diagnosis,pas de greffe,2022-08-05,Protocole 3 LAL thiotepa Bu Flu
Female,57,68.83048560832665,157.0171381065577,1.7326573894121309,27.9181553039336,97.50935167552112,0.8137296872506159,2022-03-18,Treatment follow-up,allo-greffe,2022-12-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,110.08506897909922,195.50464481434074,2.4450711367816065,28.801443795427392,124.06629249921832,1.4418762218768109,2022-01-17,Treatment follow-up,allo-greffe,2022-09-16,Protocole 3 LAL thiotepa Bu Flu
Female,30,96.8013389095915,144.34273899693173,1.970093793366525,46.46131314486257,90.96616051163902,1.6257796703015375,2022-03-29,Cancer diagnosis,auto-greffe,2022-01-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,22,53.87417859524115,189.20523325195393,1.6826959624505042,15.0492332271256,115.55974906329146,0.7640531708787138,2022-10-08,Cancer diagnosis,allo-greffe,2022-05-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,87.10893490523145,143.30720627475205,1.862147662634461,42.41570054308779,112.69642659828853,1.1164863064721624,2022-04-23,Cancer diagnosis,allo-greffe,2022-01-06,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,63,79.9329757952081,191.50624972651372,2.0620691081223153,21.79516084280223,96.98351607550362,0.8814268687221716,2022-11-25,Cancer diagnosis,pas de greffe,2022-01-13,Protocole 3 LAL thiotepa Bu Flu
Female,32,99.60388528519896,179.27763129105907,2.227152430878001,30.990177844992488,133.19648769365617,1.121694952433151,2022-08-07,Symptoms management,auto-greffe,2022-04-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,81.60859787425619,193.29623152554882,2.0932851924651326,21.841836002551634,125.63682227871539,1.0465126100191675,2022-12-30,Symptoms management,auto-greffe,2022-08-31,Protocole 3 LAL thiotepa Bu Flu
Female,47,105.96614393792161,194.8175553575878,2.3946737838990466,27.91971315857643,130.88700611315178,1.0457335680937556,2022-12-26,Cancer diagnosis,pas de greffe,2022-03-14,Protocole 3 LAL thiotepa Bu Flu
Female,70,118.50091302951867,151.9107590045564,2.2361650978260323,51.350494390142785,85.4288404218937,1.3485986750136798,2022-07-10,Symptoms management,greffe haplo-identique,2022-11-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,64.27085521258901,185.90910415877846,1.8218227377555287,18.595709906627917,96.07781075760602,1.0777461324015263,2022-02-20,Treatment follow-up,pas de greffe,2022-07-23,Protocole 3 LAL thiotepa Bu Flu
Female,67,51.421875064497435,188.38117345226954,1.640368620985169,14.4901510645146,110.0008307441631,0.47396067303330824,2022-09-02,Cancer diagnosis,auto-greffe,2022-01-02,Protocole 3 LAL thiotepa Bu Flu
Male,35,69.02021039373889,189.44720170653963,1.9058160777742705,19.230912386406484,117.17700853687734,0.8589950771715748,2022-11-27,Symptoms management,auto-greffe,2022-06-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,97.02944833887963,143.82705937502047,1.9688871805724788,46.90534772789172,122.03227989429172,0.9828479751469517,2022-05-15,Treatment follow-up,auto-greffe,2022-12-02,Protocole 8 Aplasie medullaire thymo
Female,70,90.31656884740127,189.70648673611038,2.1815921154884244,25.095916913118693,116.87705024063192,0.7512832937477807,2022-02-08,Symptoms management,auto-greffe,2022-01-27,Protocole 3 LAL thiotepa Bu Flu
Male,71,40.53675407210819,171.71745216390624,1.3905302873621501,13.747385084045584,117.02783398187027,0.331952846862527,2022-06-13,Cancer diagnosis,greffe haplo-identique,2022-05-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,64,61.8962257343517,185.81922130792154,1.7874180997442906,17.92597952871345,120.14985286783661,0.5437784848033338,2022-09-14,Cancer diagnosis,auto-greffe,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,53.11200735799274,167.2919483491163,1.5710233034245904,18.977658944771658,86.24422238114597,0.9408554258406768,2022-08-17,Cancer diagnosis,auto-greffe,2022-02-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,108.6110046134202,164.98458766886117,2.2310399799972402,39.90130312021719,117.67886626916047,0.7947573411154305,2022-09-27,Symptoms management,allo-greffe,2022-12-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,44.07955768577874,188.74508585085167,1.5202156188140146,12.373310789673504,101.98008814451347,0.690378390158706,2022-07-22,Cancer diagnosis,auto-greffe,2022-12-29,Protocole 3 LAL thiotepa Bu Flu
Male,33,109.80035034334732,156.558025874725,2.185185352557055,44.79742519933804,114.30046306035979,1.42760157115874,2022-07-16,Symptoms management,pas de greffe,2022-05-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,37,105.38416598296789,164.71049692067962,2.1958216853976973,38.84479268727821,112.10533130172371,1.3447879986079259,2022-12-10,Treatment follow-up,allo-greffe,2022-10-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,42.5222277002097,146.06271346068294,1.3134889882681042,19.93137589928957,97.37899141113449,0.39421359446290805,2022-11-14,Treatment follow-up,pas de greffe,2022-08-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,78,77.41616585884788,184.04847256487054,1.9894392759818889,22.85426313626662,125.51595149284114,0.5311191112189176,2022-09-08,Symptoms management,greffe haplo-identique,2022-07-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,87.97095126243629,140.73407379022166,1.8544623619172471,44.41613553493436,96.97442199985323,1.4615294849000453,2022-07-15,Cancer diagnosis,allo-greffe,2022-07-01,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,31,106.21162827194789,168.2879001666445,2.2282362167297705,37.503023654817206,107.67579900456015,1.4933030950147785,2022-10-04,Cancer diagnosis,allo-greffe,2022-06-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,73,84.36025077375622,174.87625632971634,2.0243383581878565,27.58520190316489,125.54365956954422,0.6252956166383936,2022-06-26,Treatment follow-up,allo-greffe,2022-06-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,30,75.00740759266834,141.17213327242078,1.7150441961499097,37.63623752473034,94.02610167100488,1.2187536062035502,2022-07-05,Treatment follow-up,pas de greffe,2022-10-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,28,101.01259979319201,168.02561967065725,2.171322221007999,35.77869840993796,99.8444887719287,1.5737544728015787,2022-08-27,Symptoms management,pas de greffe,2022-06-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,45,76.60142902343682,155.51720741448656,1.8190993135862514,31.67232705249492,134.935881049714,0.7490322749976468,2022-02-12,Cancer diagnosis,pas de greffe,2022-08-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,53,86.49723922754566,160.086116381984,1.9612217780492787,33.75164217940862,109.48276609912233,0.9546479425385005,2022-07-13,Symptoms management,pas de greffe,2022-07-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,52,81.17897513004147,177.19333098674736,1.9989144977394306,25.855254644635046,105.39145108077469,0.941430698255763,2022-05-11,Symptoms management,pas de greffe,2022-12-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,111.3988258747602,179.79024615894915,2.358696810967225,34.46262540138711,93.84800289229395,1.0056640301539164,2022-09-26,Symptoms management,allo-greffe,2022-06-11,Protocole 3 LAL thiotepa Bu Flu
Male,68,52.87170884406234,189.7141486720782,1.669207332853704,14.690071333287273,89.88305926167537,0.588227740336893,2022-06-16,Treatment follow-up,pas de greffe,2022-11-21,Protocole 3 LAL thiotepa Bu Flu
Male,63,74.53816587403378,182.57191371701742,1.9442633272569694,22.362006344747705,133.54476625370387,0.5969116546404005,2022-01-12,Cancer diagnosis,pas de greffe,2022-05-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,55.778524391160204,161.38428585374052,1.5812949444506652,21.41630441632122,127.3855421646069,0.3892192922949764,2022-05-09,Symptoms management,allo-greffe,2022-03-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,82.85993213377921,179.71407059182087,2.033817954046273,25.65549573187292,86.94342712449935,1.5619147599700756,2022-12-15,Symptoms management,auto-greffe,2022-10-11,Protocole 3 LAL thiotepa Bu Flu
Male,64,78.03981298078658,184.51141620362068,1.999946972446369,22.922909269203522,74.04132975455833,1.1125591398676145,2022-03-07,Symptoms management,greffe haplo-identique,2022-11-25,Protocole 3 LAL thiotepa Bu Flu
Female,43,55.01840443577271,170.83302068620534,1.6158039126682395,18.85230038734846,97.00722154904788,0.7640876205242699,2022-12-21,Treatment follow-up,allo-greffe,2022-09-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,73,99.38187746206773,186.31954611909174,2.267939979437755,28.627957365974144,88.80642716592507,1.0413701028764413,2022-04-21,Symptoms management,allo-greffe,2022-02-16,Protocole 3 LAL thiotepa Bu Flu
Male,74,73.67956146044128,155.55170318064916,1.7842662104236886,30.450714743418555,119.66644525730088,0.5643987991803734,2022-10-25,Cancer diagnosis,greffe haplo-identique,2022-05-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,42,89.87119896977546,143.5977129700994,1.8933581742751648,43.58383978537602,91.69248304545698,1.3340754162584492,2022-10-21,Treatment follow-up,pas de greffe,2022-11-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,38,64.74010039682648,142.999381728066,1.6036238761144075,31.659572702067702,122.24422197180587,0.7502615726900407,2022-01-08,Treatment follow-up,greffe haplo-identique,2022-09-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,37,55.45466458321923,198.17199213305878,1.7471851451793294,14.12061241107365,98.24991332333664,0.807440697071345,2022-09-19,Cancer diagnosis,auto-greffe,2022-05-30,Protocole 3 LAL thiotepa Bu Flu
Female,32,47.49757211793454,150.16184156539728,1.4075513508606117,21.064552595203587,105.20888839221014,0.6771895347026309,2022-12-29,Treatment follow-up,auto-greffe,2022-07-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,28,50.59019856839855,175.07878842125155,1.5685512309971608,16.504383974078436,76.9369456387185,1.0228618225796502,2022-03-23,Symptoms management,greffe haplo-identique,2022-09-17,Protocole 3 LAL thiotepa Bu Flu
Female,25,104.43201016381474,173.94593098906682,2.2463255943505978,34.51477841695848,103.34368348135699,1.6140427912565407,2022-06-30,Treatment follow-up,pas de greffe,2022-01-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,73.96595618472304,163.1499014134746,1.8308724741295508,27.788061061304592,105.08306500597169,0.7136569639215543,2022-08-07,Symptoms management,allo-greffe,2022-08-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,61,87.17873311219779,172.1106462912231,2.0415400027913577,29.430326669273175,92.51795763969716,1.0339013713251355,2022-10-16,Symptoms management,auto-greffe,2022-02-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,45.15280774141495,185.39562840487514,1.5248982812582883,13.136684889161463,121.5586988317914,0.521059832925458,2022-11-05,Symptoms management,greffe haplo-identique,2022-09-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,65.35329066320614,177.97742218065434,1.797483596220967,20.631824536263444,92.39055285569745,0.9726186485999255,2022-05-24,Treatment follow-up,allo-greffe,2022-10-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,97.5690854650021,194.7243455912335,2.2972856155029078,25.731892495776663,106.64209349826314,0.8640920080816609,2022-02-15,Symptoms management,allo-greffe,2022-07-30,Protocole 3 LAL thiotepa Bu Flu
Male,21,113.98520263209113,194.77415116633043,2.483354087619522,30.045942716186744,91.52523747404337,2.0583635192341947,2022-08-02,Symptoms management,greffe haplo-identique,2022-10-27,Protocole 3 LAL thiotepa Bu Flu
Female,51,63.02133667732251,167.9748632120977,1.7148048486163086,22.335671728552402,115.98943993448853,0.6716247146974041,2022-06-08,Cancer diagnosis,allo-greffe,2022-11-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,40,98.68663064427432,169.61996532884194,2.156335811065591,34.30081043441423,128.553061556722,1.0662115948381101,2022-08-07,Symptoms management,pas de greffe,2022-09-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,76.67009915997932,174.6421967795884,1.928574210294548,25.137822406879426,100.48123707556306,0.900798140455236,2022-07-15,Cancer diagnosis,pas de greffe,2022-10-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,41.54946199184743,145.09901306624414,1.2940876160070895,19.734970780209345,112.3241341374522,0.3493564303806348,2022-03-05,Symptoms management,auto-greffe,2022-03-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,48,41.53884055786955,143.86445069133498,1.2884058279746815,20.070000652859207,104.57512998911128,0.5075528702190146,2022-08-14,Symptoms management,pas de greffe,2022-07-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,71.77744920729822,184.41397328268994,1.917518984435525,21.105729634094974,125.1515305609252,0.5735243419364826,2022-05-30,Cancer diagnosis,allo-greffe,2022-03-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,104.42130859085117,181.07822462194204,2.2917984915012872,31.846130892776138,88.35117099393871,1.756418904105665,2022-05-31,Symptoms management,pas de greffe,2022-10-30,Protocole 3 LAL thiotepa Bu Flu
Male,25,115.25807172234784,189.1172548584364,2.460650892007099,32.226195623553025,74.07835228830321,2.4851086418465664,2022-01-26,Treatment follow-up,greffe haplo-identique,2022-04-18,Protocole 3 LAL thiotepa Bu Flu
Female,36,71.33294533789555,178.83954625856873,1.8824593530742737,22.30298733431129,81.9505705913677,1.2573002952347456,2022-11-09,Symptoms management,pas de greffe,2022-04-04,Protocole 3 LAL thiotepa Bu Flu
Male,47,78.37868358095939,145.3107017342776,1.7786747182599894,37.11955531466372,134.12262501237154,0.7548251680087595,2022-02-27,Treatment follow-up,auto-greffe,2022-11-18,Protocole 8 Aplasie medullaire thymo
Female,42,106.95703794432886,173.59327269693884,2.2710143508724316,35.49307162039074,100.39832632285128,1.4500282832346751,2022-01-05,Treatment follow-up,greffe haplo-identique,2022-07-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,75.91089787880813,149.84734392856427,1.777564377828697,33.8069529752694,79.83136049627062,1.571611010075589,2022-01-05,Cancer diagnosis,pas de greffe,2022-12-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,71,117.76573244830806,146.21664179396006,2.187039470062313,55.08398195395392,87.9888837838669,1.28264869465615,2022-07-08,Treatment follow-up,auto-greffe,2022-10-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,35,59.54593922037803,143.8847214323642,1.542702433785936,28.762245518521574,100.35479966966406,0.8653081697692622,2022-07-10,Treatment follow-up,pas de greffe,2022-02-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,40,57.77255547154809,156.5152564600036,1.5848489531935364,23.583498110971828,132.19730643735915,0.6069689507264746,2022-06-27,Cancer diagnosis,greffe haplo-identique,2022-10-12,Protocole 6 FlUDARABINE cy (Fanconi)
Female,65,86.82496834203577,183.29625387023378,2.1025574004251215,25.842674374301904,128.05818633298975,0.706262347969767,2022-08-18,Symptoms management,allo-greffe,2022-03-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,95.09327134939609,195.953848570896,2.2751002721559503,24.76522014950919,128.99059298606022,0.6655376194735726,2022-08-16,Treatment follow-up,pas de greffe,2022-04-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,72.61995648573824,174.9921350611575,1.8788236001320737,23.714770407088064,122.97108114832542,0.6397570777744418,2022-01-27,Symptoms management,greffe haplo-identique,2022-11-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,95.75900631718685,164.7002682949852,2.0930794718748373,35.30132589570981,81.15908946617051,1.179892565910341,2022-06-17,Symptoms management,allo-greffe,2022-12-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,95.74524876059138,173.32021503442195,2.146999657384302,31.87269548666287,117.76053743530142,1.0727747962981287,2022-11-25,Cancer diagnosis,pas de greffe,2022-10-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,63.74142650698589,184.23609442693024,1.8061216484845433,18.778994790433178,93.77348936447989,1.0290481670761582,2022-02-18,Symptoms management,pas de greffe,2022-11-13,Protocole 3 LAL thiotepa Bu Flu
Female,29,66.97646846224367,188.42860324283214,1.8723338379381977,18.863774084123122,106.18303322091403,0.9724283225594929,2022-09-27,Treatment follow-up,allo-greffe,2022-12-20,Protocole 3 LAL thiotepa Bu Flu
Male,62,55.40451633171795,155.61539135618364,1.5475604001729408,22.879159680661722,78.74507553804361,0.7622261957239889,2022-11-04,Cancer diagnosis,allo-greffe,2022-02-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,56.3351918388978,168.5734560015905,1.6241765420253562,19.824461371360584,79.07787904262892,0.6233512261053787,2022-09-03,Treatment follow-up,allo-greffe,2022-12-29,Protocole 3 LAL thiotepa Bu Flu
Male,37,56.200034376428334,194.82419843528106,1.7439679094765868,14.80644456650496,120.7571324960497,0.6657765859274836,2022-01-04,Symptoms management,pas de greffe,2022-05-14,Protocole 3 LAL thiotepa Bu Flu
Male,63,74.72057210571231,161.19920704031057,1.8291540981374705,28.755067155985163,119.33111027621874,0.6696451624324622,2022-10-21,Cancer diagnosis,greffe haplo-identique,2022-05-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,46,42.92317243702843,154.66323733656895,1.3579638358245736,17.943932226933402,129.72962229659825,0.43196445996822264,2022-08-20,Cancer diagnosis,auto-greffe,2022-02-19,Protocole 6 FlUDARABINE cy (Fanconi)
Male,53,85.24527607786646,182.3603702690247,2.0780172246402047,25.633587479874606,123.28935673319438,0.8354712144130743,2022-03-11,Symptoms management,greffe haplo-identique,2022-03-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,108.11238489565235,162.15362130120567,2.2067330502565072,41.11706852468719,128.16930806623753,1.288699312168989,2022-04-16,Symptoms management,greffe haplo-identique,2022-05-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,25,61.013403122555715,141.35764274134442,1.5478220218738776,30.534208056210172,84.8412460523514,1.1486389917071216,2022-06-01,Symptoms management,greffe haplo-identique,2022-12-08,Protocole 6 FlUDARABINE cy (Fanconi)
Female,64,40.85189137062247,141.49765685461975,1.267154172307044,20.403922817983496,113.81459082343287,0.37887445343549475,2022-12-10,Symptoms management,allo-greffe,2022-05-28,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,60,81.44552606220198,172.3659906029865,1.9747319635201126,27.41347387818295,96.6627723337989,0.9361931876472769,2022-01-11,Symptoms management,auto-greffe,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,58.463545673673636,141.4096180833429,1.5154122711431317,29.23662599033657,107.50323680656759,0.6042561798381331,2022-11-13,Cancer diagnosis,auto-greffe,2022-11-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,31,47.222610047947285,193.15055525993392,1.59173851073322,12.657795223328222,85.92597756995077,0.8319926834433937,2022-08-10,Cancer diagnosis,pas de greffe,2022-07-28,Protocole 2 LAM Endoxan TBI
Female,57,115.94953285333872,198.3736743454517,2.5276984959288487,29.464625679179605,133.77698699701284,0.9991557428336152,2022-04-16,Symptoms management,allo-greffe,2022-06-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,98.54180418832009,170.64604491866962,2.1612605082250047,33.839820863412065,90.39985133447797,1.7410776361246831,2022-07-13,Symptoms management,allo-greffe,2022-06-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,50.32785754490533,155.88486739603636,1.4762331379895188,20.71097417534813,129.23733429028874,0.3731960562742625,2022-06-29,Cancer diagnosis,allo-greffe,2022-02-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,52,49.30301674158986,141.3345845344304,1.3912645514330029,24.68178701770632,130.62226839245164,0.46132442366655163,2022-06-25,Symptoms management,pas de greffe,2022-03-28,Protocole 9 LAL thiotepa-thymo melphalan
Male,71,96.1552371642171,143.28098369284803,1.9562731694125357,46.8377295315101,89.77014394101134,1.0264968385212019,2022-09-30,Treatment follow-up,greffe haplo-identique,2022-01-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,50,119.37623705166273,184.2774801230751,2.4719735789701445,35.15388722861645,75.501303203225,1.976393651284744,2022-03-25,Cancer diagnosis,allo-greffe,2022-07-27,Protocole 3 LAL thiotepa Bu Flu
Male,43,50.72824523928631,188.7616793977187,1.630912216135754,14.23712095080949,112.29242050726515,0.6086093698219243,2022-07-07,Cancer diagnosis,pas de greffe,2022-12-08,Protocole 3 LAL thiotepa Bu Flu
Male,43,63.30790359454209,140.00640610502995,1.569103783508594,32.29699506102589,128.23116997794153,0.6651254494483739,2022-07-30,Treatment follow-up,allo-greffe,2022-05-29,Protocole 9 LAL thiotepa-thymo melphalan
Male,33,106.29137959503397,177.88250287828168,2.2917349466646297,33.59166889558347,122.91267939007895,1.2851465041307923,2022-05-26,Treatment follow-up,pas de greffe,2022-04-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,71,75.69625348598998,160.0783098828271,1.8346456153785107,29.539926089839085,115.07693574767637,0.6303803838080431,2022-10-06,Cancer diagnosis,allo-greffe,2022-02-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,65,89.13477404231507,172.74762310941736,2.0681325682984935,29.869159837641142,88.84433178645052,1.045071993832082,2022-11-09,Cancer diagnosis,allo-greffe,2022-08-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,82.78956292940393,172.4041578356703,1.991179499304866,27.853522045726866,122.92125640133227,0.9354403577945393,2022-08-25,Symptoms management,allo-greffe,2022-12-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,71.57355547825262,169.77008642815971,1.8371965886699368,24.833060820870177,125.36159327111753,0.9436317685845437,2022-01-06,Treatment follow-up,greffe haplo-identique,2022-03-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,50.41919712483934,154.64270452508762,1.4716733676110823,21.083225452167934,110.72091785959415,0.7336547625457681,2022-03-06,Symptoms management,allo-greffe,2022-01-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,43,109.01503472121055,191.2764729206558,2.406704255061726,29.796365132741187,82.28237303210007,1.784920292411182,2022-01-25,Symptoms management,auto-greffe,2022-08-08,Protocole 3 LAL thiotepa Bu Flu
Female,75,113.18824166934282,144.46649572714105,2.1312430274559597,54.233425543004394,110.36020860758356,0.9259118895667044,2022-06-23,Symptoms management,pas de greffe,2022-11-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,54,97.30006031351897,188.21823407720075,2.2554653084733034,27.465639830065488,100.97594922760234,1.1509623566264315,2022-10-29,Cancer diagnosis,greffe haplo-identique,2022-02-25,Protocole 3 LAL thiotepa Bu Flu
Female,73,73.41906017711177,167.33795811476548,1.8473551376632558,26.219227398003472,80.13353871993769,0.8525832681650996,2022-10-27,Treatment follow-up,allo-greffe,2022-03-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,34,62.51588895118527,150.5155045545207,1.6167191201251823,27.59484338170354,92.4247645917352,0.9958075777900526,2022-02-21,Cancer diagnosis,allo-greffe,2022-02-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,47,53.59087839053814,191.11212863287298,1.686701814894083,14.672846560350798,120.78564717312493,0.5730941786090545,2022-09-12,Treatment follow-up,greffe haplo-identique,2022-04-22,Protocole 3 LAL thiotepa Bu Flu
Female,78,74.51255829013895,189.92104653663978,1.9826681693130348,20.65776273837279,125.94135111439721,0.5094719986183951,2022-06-07,Cancer diagnosis,pas de greffe,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,55.24969539445252,187.87882812271505,1.6980583703524696,15.652157260372796,76.76151953412122,1.0696399277857294,2022-05-03,Cancer diagnosis,pas de greffe,2022-06-04,Protocole 3 LAL thiotepa Bu Flu
Male,28,70.6331074625792,153.82045636301814,1.737240534122373,29.85245980011856,74.27651883925867,1.4792524533539955,2022-05-08,Cancer diagnosis,greffe haplo-identique,2022-09-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,96.46852201349446,183.92238279144257,2.220030056921817,28.5178286524329,84.62785230861343,1.4090610677261683,2022-10-02,Cancer diagnosis,greffe haplo-identique,2022-09-03,Protocole 3 LAL thiotepa Bu Flu
Male,57,78.13640160266017,186.451719649723,2.011678848765749,22.476082650128802,128.96782011679676,0.6984215699815134,2022-06-29,Treatment follow-up,auto-greffe,2022-10-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,106.29808848693447,167.90593880677554,2.226611797026322,37.70451338820946,134.91016126216206,0.8426340842222354,2022-09-14,Symptoms management,greffe haplo-identique,2022-02-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,71.69583345262065,180.54325273101904,1.8962095948084854,21.99537610626373,96.89945355335163,1.1304016389304163,2022-03-20,Symptoms management,greffe haplo-identique,2022-04-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,99.72494381928755,198.1521813659337,2.3428801810774025,25.398383999660176,106.9630347516293,1.0359232363763304,2022-07-09,Treatment follow-up,auto-greffe,2022-06-23,Protocole 3 LAL thiotepa Bu Flu
Female,40,78.79600305970897,158.042877684472,1.8598944917499773,31.54672868867363,108.89606954031905,1.0049847859565275,2022-11-06,Symptoms management,greffe haplo-identique,2022-04-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,66,65.6946051961637,186.12072990021852,1.8429390679636846,18.964448297136464,120.47935723089503,0.5604234359509621,2022-03-26,Cancer diagnosis,greffe haplo-identique,2022-05-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,68,90.46967318076145,192.877980912916,2.201616066599756,24.318552395396807,109.0881836506324,0.8293260567111568,2022-02-01,Symptoms management,allo-greffe,2022-10-09,Protocole 3 LAL thiotepa Bu Flu
Male,33,51.64455027274296,163.9015533636598,1.5333896740075013,19.22464640797602,121.47148730068636,0.6318317301794164,2022-06-10,Symptoms management,allo-greffe,2022-03-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,73.40105613356212,151.34222353975773,1.756628640118137,32.04660947705879,95.94054427394599,1.0200908863441476,2022-08-25,Treatment follow-up,auto-greffe,2022-04-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,67,46.999273177432066,150.69537179849112,1.402633727604765,20.696233385252835,98.25400174287867,0.48498829579636654,2022-07-15,Treatment follow-up,greffe haplo-identique,2022-09-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,61.234369027706705,185.02110979684895,1.7740138821967237,17.88762509210089,123.5981740007065,0.7293845526053699,2022-04-19,Symptoms management,greffe haplo-identique,2022-05-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,106.62555686191102,166.59278340125437,2.2213014390551464,38.41925540087081,120.40409981532424,1.1069552139986643,2022-08-04,Symptoms management,pas de greffe,2022-07-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,42,83.0166992878193,156.4015230599751,1.899118085383237,33.93778594101035,93.22486125169996,1.2120688654429106,2022-03-21,Treatment follow-up,pas de greffe,2022-02-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,75.93086413019265,165.34135230632785,1.8674486276642328,27.77508340179178,91.49771647944559,0.8413921399079783,2022-10-07,Cancer diagnosis,auto-greffe,2022-12-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,73.93893268785337,179.09082789166487,1.9178825613227832,23.052948975663252,85.45594221092344,1.3699454213121216,2022-07-22,Treatment follow-up,allo-greffe,2022-10-07,Protocole 3 LAL thiotepa Bu Flu
Female,65,95.3532397384191,167.60288715946797,2.106964528004417,33.944738089729356,81.67867769611802,1.2160614519706812,2022-03-21,Cancer diagnosis,auto-greffe,2022-03-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,96.41055710928089,174.87049306297035,2.1640600768370297,31.52764438659191,83.57827696197728,1.0574080637848797,2022-08-15,Treatment follow-up,allo-greffe,2022-05-22,Protocole 3 LAL thiotepa Bu Flu
Female,41,88.04803316841625,156.53729110824713,1.9566695485209453,35.93221842266932,94.63424553996919,1.2793048110204415,2022-06-23,Symptoms management,auto-greffe,2022-11-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,108.78426867200913,157.06149402743378,2.1785456262472396,44.09878741443167,98.12420741473667,1.3704002994002447,2022-04-07,Cancer diagnosis,allo-greffe,2022-01-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,69,48.48073416740615,158.2342062370168,1.459766960926691,19.36281260483374,85.79305013194352,0.5572408320228616,2022-11-14,Symptoms management,pas de greffe,2022-11-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,58,100.45809389857683,194.5716104890574,2.330134302072823,26.53542124286461,110.45600212934252,1.0358025343527508,2022-10-26,Symptoms management,greffe haplo-identique,2022-01-24,Protocole 3 LAL thiotepa Bu Flu
Male,36,50.24514137300475,162.37996142930973,1.5054349794216664,19.05588857478221,118.97760729975198,0.6099997887309481,2022-09-03,Cancer diagnosis,pas de greffe,2022-09-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,71,47.32815101483058,176.34206402732764,1.522602289626426,15.219756300316114,75.59936678203121,0.5999540294208711,2022-05-15,Treatment follow-up,greffe haplo-identique,2022-02-21,Protocole 3 LAL thiotepa Bu Flu
Male,23,91.69042664304204,157.9505451856228,2.0057246457584883,36.752064074633545,79.25720203223966,1.8799167706467286,2022-01-22,Cancer diagnosis,greffe haplo-identique,2022-06-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,39,100.73165777068309,174.95642828076848,2.2125683328028685,32.90835497115442,87.0778957204313,1.6227324956622244,2022-02-26,Treatment follow-up,allo-greffe,2022-07-17,Protocole 3 LAL thiotepa Bu Flu
Male,54,53.71180183743011,180.40398122635366,1.640614966874157,16.503554308068985,99.01679472432059,0.647928096283461,2022-02-02,Symptoms management,pas de greffe,2022-11-16,Protocole 3 LAL thiotepa Bu Flu
Male,75,67.88902162515055,182.7250218800669,1.856297312294316,20.333095704827205,108.42726557918061,0.5652517358145855,2022-12-25,Symptoms management,auto-greffe,2022-09-27,Protocole 3 LAL thiotepa Bu Flu
Male,20,115.89500886151373,149.50348913176458,2.1938492426271807,51.851589749209566,88.39035941068295,2.185287506356463,2022-05-12,Symptoms management,auto-greffe,2022-10-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,51,105.44631013993202,194.78137520948832,2.388571010494104,27.79307066766446,134.8050781799304,0.9669024145786486,2022-08-12,Treatment follow-up,greffe haplo-identique,2022-06-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,44.23884547749094,163.66948002091766,1.4181902430784676,16.514612169159985,112.64784047247863,0.3981725144376717,2022-01-11,Treatment follow-up,greffe haplo-identique,2022-09-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,43,79.32311266816959,178.3879290367731,1.982582896797438,24.92693151071018,131.7161369517596,0.8113346063401042,2022-01-17,Cancer diagnosis,auto-greffe,2022-01-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,75.23799582232283,160.75629383319315,1.8329530941923782,29.11395779121711,105.53947238220043,0.7623958584133286,2022-11-14,Treatment follow-up,allo-greffe,2022-04-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,83.61627882473476,170.22843760128495,1.9884296220306341,28.855367513742106,99.12326369327445,1.2770539500667202,2022-03-27,Treatment follow-up,auto-greffe,2022-02-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,49.466363952835394,190.35970048312933,1.6173024717146218,13.650858437042597,124.62960435425754,0.622923505975106,2022-02-20,Cancer diagnosis,pas de greffe,2022-01-09,Protocole 3 LAL thiotepa Bu Flu
Female,70,111.10250503398943,161.26536134921741,2.23090574662136,42.721024892299404,97.79859307355422,1.104477282790376,2022-07-13,Symptoms management,auto-greffe,2022-02-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,57.769561210682454,174.31159178536328,1.6724818693068126,19.012819764183128,117.08756761975103,0.4317142040520138,2022-05-04,Symptoms management,auto-greffe,2022-10-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,89.03230259834851,155.62693495819408,1.961846095281137,36.76021790280569,108.45242488090602,0.9463546808885832,2022-05-04,Cancer diagnosis,greffe haplo-identique,2022-01-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,31,99.60526604521203,169.86601685333932,2.1679194968087963,34.51988127184051,99.87537784486086,1.5097945939678592,2022-03-19,Cancer diagnosis,auto-greffe,2022-11-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,32,58.591677339285795,152.97848000381623,1.5779087549522615,25.036594076863835,111.49923786974259,0.7882342309066008,2022-06-16,Symptoms management,pas de greffe,2022-11-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,78,91.11365145372088,199.77908275019598,2.248616964655127,22.82881780620372,93.91973555458867,0.8353832895440982,2022-11-25,Symptoms management,greffe haplo-identique,2022-07-08,Protocole 3 LAL thiotepa Bu Flu
Female,39,98.52383412200854,195.21117943494505,2.311382093840187,25.85424938204012,105.39730721285771,1.311295788693141,2022-10-24,Treatment follow-up,greffe haplo-identique,2022-01-04,Protocole 3 LAL thiotepa Bu Flu
Female,58,106.19246600148307,182.06620159288855,2.3174494434538238,32.03576082951991,77.1512798788365,1.5675879882062178,2022-06-27,Treatment follow-up,allo-greffe,2022-10-25,Protocole 3 LAL thiotepa Bu Flu
Female,79,112.20621789495043,185.29372927509428,2.4031870367868433,32.68101074021404,87.35158318967521,1.0882871013990634,2022-12-21,Cancer diagnosis,pas de greffe,2022-05-27,Protocole 3 LAL thiotepa Bu Flu
Male,72,89.39650700898179,188.08417762659536,2.1611512173604313,25.27062742655536,89.12950924816194,0.9472736370879641,2022-01-18,Cancer diagnosis,greffe haplo-identique,2022-11-21,Protocole 3 LAL thiotepa Bu Flu
Male,70,112.16046184024337,157.2684006667149,2.2135502185187077,45.347865343078475,92.41459176540994,1.179953201899084,2022-10-19,Cancer diagnosis,pas de greffe,2022-01-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,116.7500389334636,198.03704509825937,2.5342560120986786,29.76899401946985,92.39000446188506,1.4918270420810376,2022-04-15,Treatment follow-up,auto-greffe,2022-09-30,Protocole 3 LAL thiotepa Bu Flu
Female,25,57.05555043528531,196.16177030165747,1.763213431566313,14.82754173285016,131.3106309152862,0.6940062081885082,2022-02-14,Symptoms management,pas de greffe,2022-01-20,Protocole 3 LAL thiotepa Bu Flu
Male,24,42.7979066320608,164.36517485092858,1.3978639862733815,15.841741224765908,129.9942924876163,0.530424694713252,2022-10-12,Symptoms management,allo-greffe,2022-07-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,54,119.7934803455434,181.94104376295687,2.460541429242388,36.18860305623634,104.51364030068865,1.3690716031681107,2022-07-28,Treatment follow-up,greffe haplo-identique,2022-10-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,106.5795941620028,184.80229513350125,2.339049760499575,31.20752599902086,93.45969396117584,1.2670892260818647,2022-11-11,Symptoms management,pas de greffe,2022-12-12,Protocole 3 LAL thiotepa Bu Flu
Male,53,75.59222952340286,171.12990521183565,1.8956156338810455,25.81221863724822,91.92831940559975,0.9936068804989798,2022-11-04,Cancer diagnosis,auto-greffe,2022-02-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,48.10017426797675,152.6879436277987,1.4283164815338183,20.631801822024624,80.34895027450054,0.573697605042307,2022-01-18,Treatment follow-up,allo-greffe,2022-11-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,48,116.37270526693506,143.23414703187447,2.1517786684444444,56.72284404982316,101.34201184077178,1.4672933172434655,2022-02-02,Treatment follow-up,greffe haplo-identique,2022-11-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,73,66.99791315191067,180.32757333285713,1.8319366723232156,20.60331007757961,75.34582001949738,0.8274550635722842,2022-01-08,Cancer diagnosis,auto-greffe,2022-02-14,Protocole 3 LAL thiotepa Bu Flu
Male,26,84.58583766992156,190.75486096116788,2.117070808137836,23.245903306542015,112.72178379213986,1.1881250615912269,2022-10-27,Treatment follow-up,auto-greffe,2022-01-26,Protocole 3 LAL thiotepa Bu Flu
Female,70,119.71361792221147,180.81985307608204,2.452130525113739,36.61435027720227,74.86120219287706,1.5547204190860384,2022-09-18,Treatment follow-up,pas de greffe,2022-04-28,Protocole 3 LAL thiotepa Bu Flu
Male,52,58.42695156988835,172.05300893341197,1.6710386673834223,19.73734276467031,101.52715575334607,0.7033656961582477,2022-01-07,Treatment follow-up,allo-greffe,2022-12-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,73.41279075844513,186.093629856034,1.9480512135422645,21.198675147231135,83.94149797100678,1.0810667970868557,2022-12-06,Treatment follow-up,pas de greffe,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Male,77,47.90359322044894,144.22129057339723,1.3853116413681263,23.03081653398357,130.24450282645063,0.3218227499685339,2022-11-11,Symptoms management,allo-greffe,2022-02-08,Protocole 8 Aplasie medullaire thymo
Female,21,76.12005358559313,151.3648620278998,1.7890020036430339,33.22377267909603,116.85908622744981,1.0765917916271517,2022-02-13,Cancer diagnosis,auto-greffe,2022-11-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,58,105.42626664482624,141.7994970539174,2.037795076554596,52.43236491691841,130.28080388287285,0.9216154652129418,2022-08-17,Cancer diagnosis,pas de greffe,2022-05-15,Protocole 9 LAL thiotepa-thymo melphalan
Female,69,73.19393425880193,158.78809517005794,1.7967814897568006,29.02947714644467,124.99748129195822,0.577430449738065,2022-05-25,Cancer diagnosis,auto-greffe,2022-03-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,66,45.981434321171065,192.52695436084514,1.5681434092403579,12.405076104661608,133.07795641166186,0.3551203945412155,2022-08-06,Treatment follow-up,greffe haplo-identique,2022-07-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,42.204867107908726,193.89230517046897,1.5076839276930074,11.226422670082595,130.78412416196073,0.5199157831749798,2022-10-26,Symptoms management,greffe haplo-identique,2022-09-05,Protocole 3 LAL thiotepa Bu Flu
Female,34,66.23815961666885,189.75532846447678,1.8685291106868762,18.39586853646159,76.41357309503545,1.2761776029695715,2022-05-10,Cancer diagnosis,pas de greffe,2022-01-04,Protocole 3 LAL thiotepa Bu Flu
Male,48,105.98582309264037,187.6411948471816,2.350372693967033,30.101725940510534,75.98667986468848,1.7822377520431212,2022-10-22,Treatment follow-up,allo-greffe,2022-09-02,Protocole 3 LAL thiotepa Bu Flu
Female,54,71.31353573746563,165.36944702150166,1.809932470352661,26.077227812578823,87.82162972712254,0.9699211554143984,2022-06-22,Symptoms management,greffe haplo-identique,2022-02-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,52.83326003585049,164.70691943357173,1.5547421637023373,19.47528044663715,120.92695890279822,0.43083415997794705,2022-05-12,Treatment follow-up,greffe haplo-identique,2022-07-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,41.33635653353596,141.22510988466857,1.2734174812597414,20.72565916021214,106.60190685660042,0.5870312521468285,2022-04-12,Cancer diagnosis,pas de greffe,2022-02-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,33,98.91949709401896,172.51341802843234,2.177214106333468,33.23809614796152,90.21909001777097,1.6294263631786616,2022-09-28,Treatment follow-up,pas de greffe,2022-02-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,31,56.78793346116801,141.96645862733934,1.4964756565424542,28.176339202100486,128.92945986244737,0.6668035496429161,2022-11-30,Symptoms management,auto-greffe,2022-06-08,Protocole 8 Aplasie medullaire thymo
Male,77,110.14568712722772,158.70978918042417,2.2036080756023284,43.728045580228525,108.51197944982707,0.8881736074207965,2022-10-26,Cancer diagnosis,greffe haplo-identique,2022-02-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,105.75370216586823,194.5135939659848,2.390405165766963,27.9508914348874,134.91184705674982,0.9689536474389602,2022-01-10,Symptoms management,greffe haplo-identique,2022-12-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,44.52390057698202,178.78983783373013,1.4870198537757526,13.92860246356057,112.64973493975809,0.5269892627892663,2022-12-17,Treatment follow-up,auto-greffe,2022-01-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,91.35765045920111,150.19174821147774,1.9522896269480703,40.499790524509834,119.62802400846674,0.9121745423193405,2022-05-17,Symptoms management,pas de greffe,2022-10-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,41,83.5641488514574,167.79851201078785,1.9735712015083031,29.678625479269673,114.11634121138368,1.006873366697915,2022-03-10,Symptoms management,allo-greffe,2022-11-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,59.74231963571612,151.71256986858592,1.5867210111355934,25.95607086450981,86.5838674349514,0.8337423398270364,2022-01-09,Treatment follow-up,auto-greffe,2022-10-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,69,116.97603311682391,186.92384075495107,2.4645040850304887,33.478616119327555,133.03305591151286,0.8670879970383263,2022-03-12,Cancer diagnosis,pas de greffe,2022-01-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,52,119.86214148433815,153.15822801660477,2.2581871536955873,51.09770168016706,88.82026522133475,1.6493777918838406,2022-03-08,Symptoms management,allo-greffe,2022-11-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,56,54.89598235393337,160.11598910676344,1.5625588444552765,21.412686374500908,99.15039565113085,0.6459410708919864,2022-03-31,Treatment follow-up,allo-greffe,2022-08-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,73.66443848189716,197.93380192758718,2.012508272970074,18.802601827299046,121.98540351022999,0.5871047028476335,2022-09-02,Cancer diagnosis,allo-greffe,2022-01-02,Protocole 3 LAL thiotepa Bu Flu
Male,58,66.78305305966414,191.67202391631997,1.8856507087340206,18.17811355307408,118.96290961355672,0.6393461402616968,2022-10-12,Treatment follow-up,auto-greffe,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Male,51,84.978109030595,162.10907372709863,1.9561670672538107,32.336455528635184,85.64830205724036,1.2264386129187728,2022-11-04,Treatment follow-up,allo-greffe,2022-07-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,68.29697633036128,188.7090813686001,1.8921078533649758,19.178554713831737,78.07957634827456,0.8990073697205887,2022-09-03,Symptoms management,greffe haplo-identique,2022-04-21,Protocole 3 LAL thiotepa Bu Flu
Female,43,88.92531458398557,145.75856571460173,1.897485639638347,41.855953321040374,132.4835686621674,0.9042793844959166,2022-09-12,Treatment follow-up,allo-greffe,2022-05-05,Protocole 8 Aplasie medullaire thymo
Male,55,40.020533625137546,160.89851886726936,1.3374150631974084,15.458906932117843,89.18649255413145,0.5297490904105009,2022-07-10,Cancer diagnosis,pas de greffe,2022-07-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,53.18102073494185,152.06859279898634,1.4988109163578383,22.99734044990309,118.90691294927765,0.4907317522887003,2022-01-13,Treatment follow-up,allo-greffe,2022-04-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,25,61.991278787872076,141.3095811691677,1.5599111122873595,31.04469353297172,97.73857226551897,1.0130478251204542,2022-06-27,Symptoms management,allo-greffe,2022-05-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,30,84.84951689795105,159.57668135373154,1.939358737160473,33.32042375548455,80.19073623552296,1.6165359299251016,2022-10-11,Treatment follow-up,pas de greffe,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,61.31570208542633,163.1458388456878,1.6669501134922997,23.036670096716634,106.25689775499757,0.8335188313018402,2022-12-16,Symptoms management,greffe haplo-identique,2022-11-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,70,118.29671135479673,160.16198364305183,2.294112994228305,46.116229670100566,115.74699881373604,0.9936386495862439,2022-12-09,Treatment follow-up,allo-greffe,2022-05-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,46.93028072953566,170.92196567700293,1.4927059537841751,16.064136826969655,109.53363434317076,0.45820928250382026,2022-04-20,Cancer diagnosis,greffe haplo-identique,2022-01-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,100.51061858164178,182.59317402273828,2.257859905469163,30.14691453419193,123.67114449728537,1.0949210462385746,2022-11-25,Symptoms management,pas de greffe,2022-09-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,84.79435172961067,185.29629342636977,2.0891305394422357,24.696389172576236,102.77732170889271,0.7791947978380702,2022-09-26,Treatment follow-up,greffe haplo-identique,2022-06-13,Protocole 3 LAL thiotepa Bu Flu
Female,54,66.70045083061416,181.2497679251715,1.8325332522034694,20.3036375025299,85.7420232009402,0.9291824470931461,2022-07-08,Cancer diagnosis,greffe haplo-identique,2022-06-08,Protocole 3 LAL thiotepa Bu Flu
Female,28,111.1759317993905,155.25526052046186,2.189663105436762,46.123061798747436,119.35410871793042,1.448968453723846,2022-09-24,Treatment follow-up,greffe haplo-identique,2022-01-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,85.67592985840614,159.12585589356314,1.946025555687209,33.83586794961286,76.70569959605886,1.008351738839896,2022-12-08,Symptoms management,auto-greffe,2022-03-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,34,117.86553849204304,143.6875245174706,2.1689608015924424,57.08851146185509,79.69013925688218,2.1774872853819067,2022-01-13,Symptoms management,pas de greffe,2022-08-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,21,42.240254744510025,188.26234097181745,1.4862564121389927,11.917896769943528,83.84592752558177,0.8326433546590324,2022-04-22,Cancer diagnosis,greffe haplo-identique,2022-12-29,Protocole 3 LAL thiotepa Bu Flu
Male,68,42.593320497446825,153.0335096676919,1.3455900527407143,18.187307986417537,87.41047561156736,0.4872793586746059,2022-06-14,Treatment follow-up,auto-greffe,2022-02-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,50,85.70905693013616,161.0235757174228,1.957973642021167,33.0558084831477,133.20891512455833,0.8042729051767391,2022-12-17,Treatment follow-up,greffe haplo-identique,2022-02-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,73,66.09981495659892,160.24467603463134,1.7153023246378847,25.741451068109473,122.0982554587641,0.503770916283327,2022-01-19,Symptoms management,auto-greffe,2022-01-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,53,89.11149292806662,195.16555075769995,2.1979468700071365,23.395234176879946,115.39162410246621,0.9331386755806931,2022-01-10,Treatment follow-up,pas de greffe,2022-02-16,Protocole 3 LAL thiotepa Bu Flu
Male,28,108.76045461737864,176.90622712051237,2.3118295836770693,34.752397690749376,97.38387355205658,1.7372787016361022,2022-01-06,Cancer diagnosis,greffe haplo-identique,2022-10-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,90.09895201418135,176.43569231816525,2.101366683306845,28.94322012852662,101.00492448608036,1.115031673859105,2022-02-20,Treatment follow-up,greffe haplo-identique,2022-01-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,40.10171681004512,187.43113291474924,1.4449442716602143,11.41509434497818,76.01848038490425,0.5495061393706252,2022-10-25,Treatment follow-up,allo-greffe,2022-01-11,Protocole 3 LAL thiotepa Bu Flu
Female,53,69.93247201253212,194.05301078328483,1.9415491198717856,18.571120568457417,79.95798875878862,1.056826695204423,2022-03-27,Treatment follow-up,allo-greffe,2022-09-21,Protocole 2 LAM Endoxan TBI
Female,68,68.46041988056311,197.5929264064705,1.938448313243251,17.534636685966156,114.78869027113217,0.5964038767134535,2022-03-26,Cancer diagnosis,greffe haplo-identique,2022-03-21,Protocole 3 LAL thiotepa Bu Flu
Male,69,64.50889793712335,145.5415956608036,1.6149241416729194,30.45407117677569,127.65896099581005,0.4983037659488536,2022-08-16,Cancer diagnosis,pas de greffe,2022-05-18,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,64,66.91430139817334,199.79788037126244,1.9270973845166173,16.76243840819871,89.64302087082393,0.7879226056955565,2022-06-03,Treatment follow-up,greffe haplo-identique,2022-06-12,Protocole 3 LAL thiotepa Bu Flu
Female,46,78.59429496607987,153.19645927772422,1.8288101557078416,33.4883358660388,91.91616239818647,1.1163348833410622,2022-08-26,Cancer diagnosis,greffe haplo-identique,2022-06-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,29,91.91824552976293,198.73215166339367,2.2525979267931397,23.273701341145483,108.02311386207914,1.311823832190634,2022-02-11,Cancer diagnosis,auto-greffe,2022-09-04,Protocole 3 LAL thiotepa Bu Flu
Male,33,76.1622726679247,187.36743990012414,1.9909747784805372,21.6946001021566,100.94265044270564,1.121286187383403,2022-12-22,Cancer diagnosis,allo-greffe,2022-09-21,Protocole 3 LAL thiotepa Bu Flu
Female,77,56.854281031518276,197.48999341756388,1.766049545255901,14.577162032933336,128.3218619735953,0.38767747862647906,2022-04-24,Cancer diagnosis,auto-greffe,2022-03-15,Protocole 3 LAL thiotepa Bu Flu
Male,41,46.37895587102348,141.39778707832883,1.3496791519104525,23.197209344260617,120.97093338750767,0.5271602238397107,2022-01-04,Treatment follow-up,pas de greffe,2022-01-06,Protocole 8 Aplasie medullaire thymo
Male,39,44.20088386541324,193.9759015483688,1.5432565042997264,11.74722794010458,76.67698012969818,0.808639275303474,2022-04-02,Symptoms management,auto-greffe,2022-04-26,Protocole 3 LAL thiotepa Bu Flu
Female,33,42.49421674894384,162.3579662391198,1.3843645361563774,16.120652772881172,131.7279417287768,0.47940571180103353,2022-01-25,Treatment follow-up,greffe haplo-identique,2022-02-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,109.66257872228134,155.40114675043716,2.1757304322056363,45.40984459247268,116.81760262579462,1.3559728931115214,2022-11-14,Cancer diagnosis,auto-greffe,2022-10-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,73,104.57677114961407,178.9409474959547,2.2799285146919486,32.65996864497001,76.89273001707649,1.2655877266124318,2022-11-02,Treatment follow-up,greffe haplo-identique,2022-06-01,Protocole 3 LAL thiotepa Bu Flu
Male,42,41.05050730913131,172.49363267751548,1.4024731260058427,13.796610120820741,89.99307946035093,0.6208733154844819,2022-06-29,Treatment follow-up,allo-greffe,2022-10-27,Protocole 3 LAL thiotepa Bu Flu
Male,31,80.9092237463739,160.57042598169832,1.8996804206968163,31.381009869261117,105.22561509484197,1.1640471260525298,2022-02-21,Symptoms management,allo-greffe,2022-12-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,84.40705285298573,156.52050161428332,1.9156833892556935,34.45373227313964,87.3863847435505,1.4622746991192268,2022-08-20,Treatment follow-up,pas de greffe,2022-05-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,88.83883321107669,177.3547135841497,2.0920474964932048,28.24342592401397,131.49708180925052,0.7225118255196821,2022-06-24,Symptoms management,allo-greffe,2022-12-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,40,67.93152735689657,196.9170946733498,1.9276409736488256,17.518807486026002,100.66079688907712,0.937299787674175,2022-12-31,Cancer diagnosis,greffe haplo-identique,2022-09-13,Protocole 3 LAL thiotepa Bu Flu
Male,67,75.29149990531945,161.22211892025473,1.8362594188110122,28.966545126654697,109.56741040022482,0.6967146061309631,2022-04-21,Symptoms management,greffe haplo-identique,2022-04-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,103.02020824480427,147.90847366613065,2.057341985174069,47.09082646885282,112.74343961082519,1.4721655002287883,2022-11-07,Treatment follow-up,allo-greffe,2022-11-23,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,71,62.030796416424764,166.17532258240158,1.692137668793748,22.46333821930898,79.45915095619304,0.7481351006613102,2022-03-12,Treatment follow-up,allo-greffe,2022-04-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,73,110.38503812463438,186.79551232266545,2.3932445288334248,31.63569176149036,101.30020646540505,1.0140098827159838,2022-07-20,Symptoms management,greffe haplo-identique,2022-08-26,Protocole 3 LAL thiotepa Bu Flu
Female,47,53.681403425126064,143.81891778995399,1.4644302405569396,25.953254676213337,77.78551588610186,0.8914060494970638,2022-09-30,Cancer diagnosis,greffe haplo-identique,2022-04-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,72,99.2659342039711,176.23959536516327,2.2044518137958917,31.959005764589193,76.3215824813901,1.228370233339804,2022-03-21,Cancer diagnosis,allo-greffe,2022-11-08,Protocole 3 LAL thiotepa Bu Flu
Male,64,103.68593032798645,145.78807747193474,2.0491307400541903,48.78382071690617,86.20745251893764,1.2695684258458946,2022-04-24,Symptoms management,greffe haplo-identique,2022-06-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,78.34401297603934,164.6824061727192,1.89310742241727,28.887596265719623,82.88751814105208,0.827036602029502,2022-09-30,Cancer diagnosis,allo-greffe,2022-10-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,76.1739222212509,167.76054761333617,1.8840690971119993,27.066160195033213,88.10126980185325,1.020729295605032,2022-03-04,Treatment follow-up,allo-greffe,2022-06-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,93.15427418278951,141.5830898956466,1.9140612709182883,46.47078557484344,127.71381732817095,1.0029230171094596,2022-03-21,Symptoms management,auto-greffe,2022-10-26,Protocole 9 LAL thiotepa-thymo melphalan
Female,46,85.32677085142271,172.35843903134696,2.0211925132027497,28.722365592641392,98.4950714097187,1.1310092792287556,2022-10-27,Treatment follow-up,greffe haplo-identique,2022-09-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,56.50915957239906,157.603304662908,1.5728627732342149,22.750356635512855,114.61548983610429,0.6231382774364447,2022-08-03,Symptoms management,auto-greffe,2022-09-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,28,86.00142295698222,180.60614905880126,2.0771498778265687,26.365776841035732,96.15434382441323,1.391304708092143,2022-10-20,Symptoms management,auto-greffe,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,70.68022808488867,193.06937077459253,1.9469482646320952,18.961434052586544,106.05418593886775,0.62017239894934,2022-04-06,Symptoms management,auto-greffe,2022-12-25,Protocole 3 LAL thiotepa Bu Flu
Female,56,44.52222062048182,158.29114036851013,1.3991538190550172,17.769025132513764,112.09687747637717,0.46337232484322877,2022-02-05,Symptoms management,auto-greffe,2022-04-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,41,92.28915352583316,140.66748337456875,1.8989824006884553,46.64050318356994,129.91650626009823,0.9767626127812147,2022-12-21,Cancer diagnosis,allo-greffe,2022-11-30,Protocole 9 LAL thiotepa-thymo melphalan
Female,58,112.85683338049463,192.67780547435785,2.4576980528613763,30.399362620221908,80.60459128698722,1.5945914683023779,2022-06-19,Symptoms management,greffe haplo-identique,2022-02-06,Protocole 3 LAL thiotepa Bu Flu
Female,50,65.56568378201627,147.0604790839373,1.6365716934807866,30.316889575775203,122.14891566135415,0.6709605589519791,2022-05-29,Treatment follow-up,greffe haplo-identique,2022-02-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,62,110.43016899462702,146.22713880965142,2.1179056511845866,51.6454150613867,102.17380955670352,1.1708742543373596,2022-04-27,Symptoms management,greffe haplo-identique,2022-09-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,71.15581997990901,180.8284501660599,1.8905464118477981,21.76090272207414,103.44060517260338,0.6210123474261295,2022-01-10,Cancer diagnosis,allo-greffe,2022-12-01,Protocole 3 LAL thiotepa Bu Flu
Male,41,95.82152934914288,197.40690639832553,2.2922473006958484,24.588861049712797,118.84621590201647,1.1086142024386993,2022-06-23,Symptoms management,greffe haplo-identique,2022-07-17,Protocole 3 LAL thiotepa Bu Flu
Male,44,116.01274702056352,170.83756624882065,2.346352687022586,39.75016710515909,101.50059010757305,1.5239681122065083,2022-09-01,Cancer diagnosis,allo-greffe,2022-01-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,86.71954582162545,142.76183879251306,1.8544422507370153,42.54933025326148,76.92951560669945,1.6282640700246893,2022-03-23,Symptoms management,allo-greffe,2022-05-15,Protocole 6 FlUDARABINE cy (Fanconi)
Female,74,60.773212350199884,164.18721851519,1.6648477321108173,22.544131122885357,111.83166281697035,0.4981485259577976,2022-01-02,Cancer diagnosis,pas de greffe,2022-07-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,48.765491171276054,197.16681574391401,1.6342630527777864,12.544257421265756,121.16491241979236,0.5813485224081096,2022-03-23,Treatment follow-up,allo-greffe,2022-11-12,Protocole 3 LAL thiotepa Bu Flu
Female,70,59.23409662890891,191.15107869896053,1.7734665885377023,16.211315693014125,121.04446488105455,0.4757648779105573,2022-11-07,Cancer diagnosis,auto-greffe,2022-06-01,Protocole 3 LAL thiotepa Bu Flu
Male,66,95.30044048314016,170.81851288343424,2.1264916020202955,32.66066586893455,126.3380640771731,0.7752823795144923,2022-01-09,Cancer diagnosis,allo-greffe,2022-09-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,64,56.41071654100614,142.8668343886073,1.4962193557436128,27.637501081936517,85.86103801614186,0.6935001790513448,2022-11-17,Cancer diagnosis,pas de greffe,2022-03-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,60,89.45816290869072,173.08732906420235,2.073917018647964,29.85997382766225,121.51678840027091,0.8179771708582495,2022-02-11,Symptoms management,auto-greffe,2022-06-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,77.65186166074349,197.38006910030398,2.0633663042845516,19.931743002974606,98.32218954753054,1.1517471160516393,2022-11-02,Cancer diagnosis,auto-greffe,2022-09-22,Protocole 3 LAL thiotepa Bu Flu
Male,57,98.04855572255826,149.80711079420615,2.0199264872721634,43.689426548560256,88.67111707012626,1.274690112348332,2022-03-08,Treatment follow-up,auto-greffe,2022-09-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,105.38229226065985,147.3616740374499,2.0769442699308303,48.52868777488236,88.4845389151749,1.3729219384397768,2022-11-05,Symptoms management,auto-greffe,2022-07-24,Protocole 6 FlUDARABINE cy (Fanconi)
Female,77,80.03371189867391,158.74336771777087,1.8785944034591784,31.76009409715726,89.83954681689328,0.7794952266853092,2022-07-28,Treatment follow-up,allo-greffe,2022-05-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,54,66.82412511672011,157.18766951229603,1.7081445826047728,27.045581988517455,80.2351134963907,0.9947976829884752,2022-04-02,Symptoms management,auto-greffe,2022-07-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,67.54809722239168,157.3057453410155,1.7180175736340628,27.29756759907193,79.89312498422154,1.1273076331366778,2022-06-19,Cancer diagnosis,auto-greffe,2022-10-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,83.33640961850136,159.0102163827534,1.918574450963214,32.95981221418082,116.57810936998764,0.7049261643461475,2022-09-05,Treatment follow-up,auto-greffe,2022-10-21,Protocole 6 FlUDARABINE cy (Fanconi)
Female,74,41.79597800549985,170.5080952507388,1.4069818563605052,14.37621258359843,97.82119211700706,0.39166339122659105,2022-11-24,Treatment follow-up,allo-greffe,2022-04-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,41.2605146966296,193.2330512758651,1.4881844972279341,11.0502427274136,84.15143933791713,0.41540376761637005,2022-05-03,Symptoms management,allo-greffe,2022-05-31,Protocole 3 LAL thiotepa Bu Flu
Male,42,42.605911771581745,181.26943846055966,1.4646908757988997,12.966437914917966,99.57057109729762,0.5824148568421087,2022-05-27,Treatment follow-up,greffe haplo-identique,2022-09-26,Protocole 3 LAL thiotepa Bu Flu
Male,34,46.96450552517237,186.67775744238526,1.5605579994588197,13.476732371900006,80.77913637572365,0.8559411723373689,2022-02-23,Symptoms management,pas de greffe,2022-07-08,Protocole 3 LAL thiotepa Bu Flu
Male,66,77.97390872531355,181.91307285233694,1.9849764439219029,23.562506394854093,108.48268338840462,0.7387340369100415,2022-03-30,Cancer diagnosis,allo-greffe,2022-02-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,91.8793127200301,181.54390534109336,2.1525262452426204,27.8775363357432,110.45692823781991,1.2361639029152138,2022-09-14,Cancer diagnosis,auto-greffe,2022-04-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,39,64.18090557398283,142.80459270851205,1.5955953330058423,31.471793336510302,74.20313712529794,1.2133118839006973,2022-02-04,Cancer diagnosis,allo-greffe,2022-10-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,35,57.21524637666774,143.73930914250658,1.5114452232696327,27.69240446171429,79.40858861410122,1.0507541113903753,2022-02-14,Treatment follow-up,auto-greffe,2022-12-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,70,89.30429048668714,166.4006162593918,2.0317130820232903,32.252431661106456,113.22269872787555,0.7668393063092548,2022-08-07,Treatment follow-up,auto-greffe,2022-10-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,64,46.23505195742149,180.41984628961055,1.5222170387802185,14.20374062530643,121.45233389469833,0.40183390792119145,2022-06-03,Symptoms management,allo-greffe,2022-05-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,108.07864880636242,188.7838958483682,2.3806808304729348,30.325643006233268,127.98814977004893,0.9969114290231543,2022-05-13,Cancer diagnosis,pas de greffe,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,117.59144908465406,183.3054023870439,2.4469452550145783,34.99654835719303,110.91155057721295,1.0455018788445085,2022-12-04,Symptoms management,auto-greffe,2022-10-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,114.78778014017921,173.48994287194833,2.351980573126819,38.13704587201204,92.33190985400493,1.6230772688322153,2022-03-28,Treatment follow-up,auto-greffe,2022-09-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,112.18220810328003,181.73768768703792,2.3797604396425776,33.96518527295508,112.15164181033961,0.9863798700932133,2022-10-11,Treatment follow-up,auto-greffe,2022-03-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,113.74886767164881,156.20725084374996,2.221635902861383,46.617041050233794,122.16435148403886,1.344941613279273,2022-09-12,Cancer diagnosis,allo-greffe,2022-01-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,31,80.89886481125573,163.7879851768069,1.9184963781367992,30.156320236525048,94.71619078091886,1.2930407309639935,2022-06-12,Cancer diagnosis,greffe haplo-identique,2022-02-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,111.43382314694956,159.1146353813951,2.2192811736124116,44.014601578992654,75.46525106061586,1.497132965798413,2022-02-03,Cancer diagnosis,auto-greffe,2022-01-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,118.24490093320095,182.83334397971515,2.450573098853458,35.37297741538067,129.2053838804624,1.3092016359210366,2022-06-10,Symptoms management,greffe haplo-identique,2022-09-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,91.7129585861833,147.88673217984666,1.941014178196561,41.934578158422916,74.36995599746739,1.4901155106516226,2022-06-07,Symptoms management,auto-greffe,2022-07-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,58,87.8268322257463,193.35742743624917,2.171914819478001,23.491216106874806,116.29352503740867,0.8601081043509134,2022-12-25,Cancer diagnosis,auto-greffe,2022-06-08,Protocole 3 LAL thiotepa Bu Flu
Female,24,118.4296156275707,145.04497130657165,2.184390342136508,56.29307425581419,100.53382121193034,1.8979012965196493,2022-06-02,Cancer diagnosis,pas de greffe,2022-05-24,Protocole 6 FlUDARABINE cy (Fanconi)
Female,39,41.972212363912206,163.3165348364753,1.3798909259123435,15.73626092729729,93.66319301340366,0.6286107156291377,2022-05-01,Symptoms management,allo-greffe,2022-06-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,111.02326194487398,174.24045726680802,2.3180897265089877,36.56924371019291,106.45927243389613,1.0573550722319993,2022-03-25,Cancer diagnosis,auto-greffe,2022-10-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,56.372555741501785,191.41434549072687,1.7312901307742765,15.3857531125646,96.2611513307113,0.9597678187497546,2022-10-01,Cancer diagnosis,greffe haplo-identique,2022-10-27,Protocole 3 LAL thiotepa Bu Flu
Female,70,68.78446361145676,184.34098385640542,1.8767433152028614,20.241679907227105,129.49977527039792,0.5164007731060565,2022-06-20,Symptoms management,allo-greffe,2022-08-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,91.35177239608545,191.17181096345405,2.2025164751358166,24.995928254182765,97.37934229029037,0.9381021708255477,2022-03-18,Treatment follow-up,auto-greffe,2022-12-28,Protocole 3 LAL thiotepa Bu Flu
Male,70,109.6716935793686,173.69286374417533,2.300313416415867,36.35219160553774,118.29339582306696,0.9013627253214475,2022-04-06,Symptoms management,greffe haplo-identique,2022-04-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,101.49825496368362,147.92517290040018,2.0422038010846,46.38466287171919,93.97150481855431,1.185105432524071,2022-06-03,Treatment follow-up,pas de greffe,2022-03-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,23,107.55583155084166,156.2083864565427,2.1603190929781055,44.07834395459774,133.50827453280573,1.309119055592102,2022-05-22,Cancer diagnosis,allo-greffe,2022-10-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,77,68.21916644410408,167.2209830540412,1.7801120498370588,24.396350494758522,98.70934725054656,0.6047225749257555,2022-05-16,Treatment follow-up,allo-greffe,2022-05-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,60.657930165854566,177.54258663124972,1.729592583797918,19.24343073779726,91.5385552045172,0.7822939338053562,2022-12-29,Treatment follow-up,allo-greffe,2022-12-28,Protocole 3 LAL thiotepa Bu Flu
Male,25,77.5959730512798,197.4558225712884,2.0630194084736293,19.902117873581417,75.91768685284426,1.6325314646730107,2022-09-08,Symptoms management,auto-greffe,2022-01-15,Protocole 2 LAM Endoxan TBI
Male,66,79.04450271251682,141.8030671455572,1.7645233008780934,39.30976272496216,98.32035601028375,0.8262804025539005,2022-12-04,Cancer diagnosis,pas de greffe,2022-08-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,47,119.64713831112006,190.5229712556668,2.5163646779780637,32.96154985535027,122.56159459329109,1.2609514491988314,2022-11-16,Treatment follow-up,pas de greffe,2022-01-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,94.32572890275385,167.6458210642109,2.0958500177853017,33.56175831009331,109.6999684438659,0.9434486385688444,2022-03-21,Treatment follow-up,greffe haplo-identique,2022-11-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,73.7088047259317,148.94851064701325,1.7463308110227902,33.22362671795734,103.88118671844722,0.6110006319839981,2022-11-05,Cancer diagnosis,greffe haplo-identique,2022-09-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,71,78.60926802180984,195.85029028466832,2.0679866726102327,20.493933051692334,97.36945531822869,0.7736911088597931,2022-04-23,Treatment follow-up,auto-greffe,2022-11-23,Protocole 3 LAL thiotepa Bu Flu
Male,47,59.183731712625836,170.13105979803902,1.672406034486429,20.447260526176272,108.79945520379934,0.7026290096668809,2022-07-29,Cancer diagnosis,greffe haplo-identique,2022-06-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,63.18711871591497,174.67082279019266,1.7509478398102658,20.710368210946537,131.20593806049206,0.6822487318087354,2022-04-15,Symptoms management,pas de greffe,2022-09-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,77.14992902001974,154.969771632184,1.8223844942571246,32.1248822684995,93.07142819092905,1.3239893646077354,2022-04-27,Treatment follow-up,pas de greffe,2022-12-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,107.41707882695556,172.7668633951799,2.2704693459971557,35.98756318553499,93.81850778909575,1.860536446456789,2022-09-18,Cancer diagnosis,auto-greffe,2022-08-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,79.53830105052904,144.06492099493494,1.7840869947115354,38.32302825406952,129.99809185622544,0.7733003885168099,2022-07-24,Symptoms management,allo-greffe,2022-05-08,Protocole 8 Aplasie medullaire thymo
Male,20,105.05072807224388,191.4649444949179,2.3637030634333356,28.656327134583908,111.98144765517588,1.563513871746063,2022-10-04,Cancer diagnosis,pas de greffe,2022-09-16,Protocole 3 LAL thiotepa Bu Flu
Female,51,112.71704733638248,197.53704920384914,2.4869544586479204,28.886337406722816,91.72126957282063,1.5190674450217896,2022-08-31,Cancer diagnosis,greffe haplo-identique,2022-07-28,Protocole 3 LAL thiotepa Bu Flu
Male,33,43.357002367058676,177.7433964570708,1.4631037083427083,13.723734218121383,92.64248314206642,0.6955051373498777,2022-01-22,Symptoms management,greffe haplo-identique,2022-04-27,Protocole 3 LAL thiotepa Bu Flu
Female,51,71.18087326305435,165.6981424190242,1.810044388302558,25.925553206989854,133.51580251701182,0.6590041529192205,2022-09-16,Cancer diagnosis,greffe haplo-identique,2022-12-04,Protocole 6 FlUDARABINE cy (Fanconi)
Female,44,64.02621672895819,145.3026585198415,1.6075498528372276,30.325691984107706,123.96629095996795,0.6886411484192261,2022-01-07,Treatment follow-up,allo-greffe,2022-10-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,65,90.88576744383815,192.7732592490834,2.20607403985142,24.456950161066025,121.1392702229596,0.7815192732003216,2022-12-01,Symptoms management,greffe haplo-identique,2022-09-27,Protocole 3 LAL thiotepa Bu Flu
Male,69,60.38055428795219,191.7916715509636,1.793544553550939,16.414876024207864,124.03663442014766,0.48003507799729295,2022-08-11,Treatment follow-up,pas de greffe,2022-01-21,Protocole 3 LAL thiotepa Bu Flu
Female,70,117.03175313386267,190.08800590108274,2.485867419607833,32.38875700341659,78.11327091627508,1.4566138348542765,2022-02-17,Cancer diagnosis,pas de greffe,2022-02-17,Protocole 3 LAL thiotepa Bu Flu
Male,29,43.09712925450021,172.02491831675607,1.435055180868209,14.563495357703582,87.70218347139927,0.7575798568613193,2022-09-25,Symptoms management,pas de greffe,2022-07-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,48.95379068734322,171.4542867274133,1.5269193081442631,16.65289067013282,114.5683863429403,0.4035505528616222,2022-10-08,Cancer diagnosis,auto-greffe,2022-01-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,92.60992099410963,167.46770813340763,2.0755970506030503,33.021390723734605,102.74972805785133,0.8136875907658359,2022-02-21,Cancer diagnosis,allo-greffe,2022-08-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,73.68782797478832,177.36286008234265,1.9053640599097035,23.424503183345607,86.63796298715707,1.405730240766343,2022-08-05,Cancer diagnosis,allo-greffe,2022-08-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,76.23259999746386,161.15918496730708,1.8473392039129934,29.351520731910753,88.05928295170081,0.8296256705191031,2022-07-08,Treatment follow-up,allo-greffe,2022-03-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,114.19240826655299,155.74778955085512,2.222687010692515,47.07533820521373,90.16874279292503,1.3543766147306107,2022-05-31,Treatment follow-up,greffe haplo-identique,2022-07-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,46,71.6331689669287,168.68624708987284,1.8320852145533473,25.174149781676306,101.11377539622046,0.9249094036925783,2022-05-31,Symptoms management,allo-greffe,2022-09-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,46.68016722266402,146.2842277501211,1.3772529233358701,21.814104858942592,93.5317348187906,0.6931718492407162,2022-03-22,Cancer diagnosis,auto-greffe,2022-08-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,87.74126325137586,172.66489823239954,2.0514111870504728,29.430373167402717,114.11376900494558,0.694139395694302,2022-11-17,Symptoms management,allo-greffe,2022-09-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,45.18648796445109,181.1278898217048,1.5078068338424233,13.773297646380069,84.14609288964722,0.753292268192213,2022-07-26,Symptoms management,allo-greffe,2022-09-28,Protocole 3 LAL thiotepa Bu Flu
Male,36,109.26656516278435,148.75955683670387,2.12488207585769,49.37618587500366,110.45285581931185,1.4289307582150848,2022-10-30,Cancer diagnosis,allo-greffe,2022-11-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,31,90.03324061384087,174.29578797861876,2.0878228038542646,29.636649093553775,102.96721032224598,1.3237255061042088,2022-09-22,Cancer diagnosis,allo-greffe,2022-09-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,115.95119029206904,158.78972055459283,2.261504974842224,45.98650904304433,120.55448481078827,1.5896675343302062,2022-01-16,Cancer diagnosis,allo-greffe,2022-02-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,50,63.883309799758116,177.96950350925454,1.777113837377183,20.169551036062735,100.55429502140755,0.7941394968031655,2022-09-24,Cancer diagnosis,auto-greffe,2022-12-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,58,41.491146470631236,176.2531792969522,1.4252627904008393,13.356157015750385,95.36806490755961,0.49548877549802994,2022-10-03,Symptoms management,allo-greffe,2022-07-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,116.9766351604433,162.13591734918737,2.295291923467088,44.498017091539424,105.43933390259282,1.171055739292421,2022-11-04,Treatment follow-up,greffe haplo-identique,2022-12-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,106.63969124508661,147.8480895367,2.0927437213281097,48.78512756394141,96.19026523162128,1.4781771798951953,2022-03-24,Symptoms management,greffe haplo-identique,2022-05-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,37,97.11137903834424,157.97327798005477,2.0643133695581053,38.913730022949814,133.95675779347397,1.0370751358818917,2022-10-18,Cancer diagnosis,pas de greffe,2022-10-23,Protocole 6 FlUDARABINE cy (Fanconi)
Male,57,110.78618180232142,177.20631792066035,2.335237993681339,35.27988749111841,86.23933594470584,1.480900183976951,2022-02-01,Cancer diagnosis,pas de greffe,2022-07-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,99.33660744867284,165.72728300990593,2.1384564822872005,36.167734250051836,82.75223245672849,1.6172190291663378,2022-02-10,Symptoms management,greffe haplo-identique,2022-09-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,105.94909211208477,148.4530971247002,2.09022000846197,48.07493596442844,104.82696789902033,1.1230050417109523,2022-09-17,Cancer diagnosis,auto-greffe,2022-03-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,107.60288943676909,143.02018607754232,2.0675660186777813,52.60527024450232,82.89015187677715,1.298138403663796,2022-08-28,Cancer diagnosis,allo-greffe,2022-11-29,Protocole 6 FlUDARABINE cy (Fanconi)
Male,37,104.97538422876895,184.56101600423426,2.319863715387445,30.818218381957983,88.74193166979664,1.6922453261872814,2022-12-12,Cancer diagnosis,allo-greffe,2022-04-20,Protocole 3 LAL thiotepa Bu Flu
Female,56,63.25083577065226,168.04689095536145,1.7182926200791324,22.397797019608255,98.89066106786868,0.7462043527222831,2022-10-31,Symptoms management,greffe haplo-identique,2022-01-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,67.21168299162417,174.83876809293037,1.806716470385813,21.9871679968432,108.92720193958806,0.9683990830083801,2022-08-02,Treatment follow-up,allo-greffe,2022-01-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,75.07739387422751,147.98442211652508,1.756755591241699,34.28287119139548,104.05145004534037,0.7115196593644821,2022-09-20,Symptoms management,greffe haplo-identique,2022-07-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,67,103.99916427943585,157.43793810984855,2.132644028567316,41.95764099356128,103.6371800223973,1.017430203078302,2022-06-11,Symptoms management,pas de greffe,2022-04-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,79.74075601543447,188.87916683174385,2.045412723818338,22.35178607087405,121.27821595577814,0.6666346950974993,2022-08-13,Symptoms management,auto-greffe,2022-02-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,51,71.53766663448623,153.15934280076024,1.744567919065554,30.49634430888732,126.99906219539682,0.6962925793404496,2022-07-06,Symptoms management,allo-greffe,2022-05-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,23,58.87978851897336,151.72529870966926,1.5752912870855371,25.57703743345484,102.7177118164328,0.9314815785063553,2022-05-28,Symptoms management,greffe haplo-identique,2022-06-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,74,93.81776718559942,183.40608514731434,2.1862416632693447,27.89058419559052,117.02495825463765,0.7348827224787724,2022-11-23,Cancer diagnosis,auto-greffe,2022-06-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,107.41901578022792,144.7152035873896,2.0780041665149587,51.292379757244476,84.9156912935774,1.194729632837596,2022-01-24,Symptoms management,pas de greffe,2022-07-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,22,90.37503711220113,166.3485177237548,2.04353679403327,32.65958168964537,128.83017546038568,1.1496890664536243,2022-07-07,Cancer diagnosis,auto-greffe,2022-10-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,40,84.80796298709151,168.9241077942332,1.9948621145221477,29.720312006743097,114.49984357948816,1.028724876818719,2022-10-24,Symptoms management,greffe haplo-identique,2022-06-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,73,97.82830893642108,158.5570896936728,2.0757443079138604,38.91286566939404,134.25702161572173,0.678062683618564,2022-06-09,Treatment follow-up,pas de greffe,2022-06-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,88.2221761333271,176.54442333593178,2.0800062240090664,28.305430125869,129.26137185136997,1.0048063573519204,2022-05-22,Treatment follow-up,auto-greffe,2022-09-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,67.01070182544575,154.0840004422694,1.6935561705171989,28.224683178068627,96.76727337934184,1.0579760857875387,2022-06-04,Cancer diagnosis,auto-greffe,2022-08-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,89.07093107405242,148.71983454899478,1.9182322687291775,40.27153697259606,79.25339582096872,1.857516059724727,2022-11-09,Treatment follow-up,auto-greffe,2022-03-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,113.3374439227887,163.4973621669212,2.268771884872549,42.398638752322306,108.16936700736996,1.6735337281858107,2022-04-08,Cancer diagnosis,greffe haplo-identique,2022-11-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,32,81.53595384484963,181.75120291066133,2.0289062250227325,24.682808191242017,105.40588029763347,1.1603141155116405,2022-02-24,Treatment follow-up,greffe haplo-identique,2022-11-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,92.21681575989794,167.5856396027541,2.0719163198495356,32.8349621132638,132.3630441947699,0.7160487623417449,2022-08-04,Treatment follow-up,allo-greffe,2022-08-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,55.39939678574779,152.77111827867034,1.5332815026495792,23.73681913414944,110.66582330664906,0.7648067378221356,2022-08-06,Treatment follow-up,greffe haplo-identique,2022-05-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,64,53.63045297540065,169.96343818700748,1.5912273546634894,18.56523493691776,81.07910159759169,0.6982060909617507,2022-09-19,Cancer diagnosis,auto-greffe,2022-04-17,Protocole 3 LAL thiotepa Bu Flu
Male,50,42.56115540745728,165.958757952199,1.400733586418215,15.45300899806663,88.80251309014778,0.599098408457362,2022-12-29,Symptoms management,auto-greffe,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,95.5347851126432,143.63178056786765,1.952337010688697,46.30847105974475,98.4416835251551,0.8626407630190149,2022-11-15,Treatment follow-up,greffe haplo-identique,2022-05-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,53,91.73233431210431,142.1175213777245,1.9029780741591042,45.41791530764465,92.19151225585682,1.202314991711734,2022-10-18,Symptoms management,greffe haplo-identique,2022-08-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,27,83.10392220662791,184.89062189385973,2.0659364206229136,24.31038041999115,102.20960385973083,1.276073716103325,2022-06-21,Treatment follow-up,allo-greffe,2022-08-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,99.52638312769072,165.63690384081877,2.1399144551792117,36.27638596640293,85.00583334116841,1.0244659903187343,2022-05-13,Cancer diagnosis,auto-greffe,2022-02-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,64.87101363557188,165.6000073090288,1.7274451536714568,23.655382822963404,112.8954473831473,0.502784994850011,2022-09-01,Symptoms management,pas de greffe,2022-04-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,94.12834009178741,198.13735324186686,2.276104138095342,23.97660483302297,130.13487267442846,0.8740040898091473,2022-01-13,Symptoms management,pas de greffe,2022-05-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,92.67306202617391,155.60441664719943,2.0014118458042813,38.27451298500873,102.99594890669918,1.1247173191020787,2022-09-26,Symptoms management,greffe haplo-identique,2022-11-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,30,97.72114926727542,190.82177043977083,2.275920004000251,26.83692324755008,78.4253532384961,1.9036726530951038,2022-12-20,Treatment follow-up,auto-greffe,2022-05-01,Protocole 3 LAL thiotepa Bu Flu
Male,62,54.33030169630687,143.2451629041137,1.4703129785031335,26.477817557084368,91.63370752373554,0.6423163312738388,2022-10-15,Cancer diagnosis,greffe haplo-identique,2022-11-20,Protocole 6 FlUDARABINE cy (Fanconi)
Female,78,54.32270845906278,196.45325502651605,1.7217459564380944,14.075471674187385,86.0043878936551,0.5439011774328261,2022-08-12,Cancer diagnosis,pas de greffe,2022-01-30,Protocole 2 LAM Endoxan TBI
Female,54,116.91353293497956,168.27886164413155,2.3377384746499983,41.28627047657096,86.85627582614872,1.6077907850214002,2022-06-22,Cancer diagnosis,greffe haplo-identique,2022-01-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,78.65290242598785,158.66917699320697,1.86188310410444,31.24133726445312,86.66643677990189,1.0083732186728087,2022-09-02,Cancer diagnosis,allo-greffe,2022-03-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,91.39387253876248,141.47306339058693,1.8951525241453058,45.66353872175722,81.09604956650202,1.3774237165550136,2022-08-08,Symptoms management,allo-greffe,2022-12-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,27,66.97358032399278,160.27987653566507,1.7267919183561986,26.070269335934476,127.81788947552522,0.8223521292312616,2022-11-01,Cancer diagnosis,auto-greffe,2022-08-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,49,100.852623708013,145.10528009328587,2.0162016138228003,47.89837384314711,101.90142126982072,1.2508805954956828,2022-11-08,Treatment follow-up,allo-greffe,2022-09-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,90.41363168966186,160.23515657441294,2.006063200390137,35.21423806749214,75.91115367685705,1.0752493348351762,2022-06-26,Symptoms management,greffe haplo-identique,2022-10-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,41.33633352079364,185.7196822048689,1.4603054023232667,11.98439428832933,87.43947219421102,0.5712302283803792,2022-03-15,Cancer diagnosis,allo-greffe,2022-05-10,Protocole 3 LAL thiotepa Bu Flu
Female,62,42.96556889496636,196.51500012925214,1.5314643298479351,11.125746352684292,119.60578176336598,0.3891620646034977,2022-09-03,Treatment follow-up,greffe haplo-identique,2022-01-29,Protocole 3 LAL thiotepa Bu Flu
Female,58,103.46184661926014,171.0670159858928,2.217287467551974,35.35474147849305,78.90838996155802,1.4932702035361018,2022-05-11,Cancer diagnosis,greffe haplo-identique,2022-01-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,56.71761822140441,199.37981295470192,1.7723452849120416,14.267754122212244,83.37976819868268,0.765261428252424,2022-10-21,Treatment follow-up,greffe haplo-identique,2022-10-21,Protocole 3 LAL thiotepa Bu Flu
Male,52,83.69480401766893,175.62141982116722,2.020629736358153,27.135856186434694,104.55645057003163,0.9783580907465167,2022-04-24,Cancer diagnosis,auto-greffe,2022-09-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,60.86376417668953,152.88852963806664,1.6077392178332017,26.03808259306965,123.26442755362763,0.5897758699053327,2022-02-04,Cancer diagnosis,pas de greffe,2022-10-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,43.955419403974936,187.09654870228132,1.5114293517547663,12.556854894916901,101.11413787811259,0.6399910694154027,2022-09-24,Symptoms management,pas de greffe,2022-05-03,Protocole 3 LAL thiotepa Bu Flu
Female,70,42.103353948658196,161.183860043385,1.3729915746097425,16.205916201790753,77.66955297986183,0.5270252598156007,2022-06-11,Treatment follow-up,allo-greffe,2022-06-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,101.9012620194799,185.6072838494736,2.292113075567147,29.579411683498513,101.01227263003858,0.8827007050282902,2022-11-24,Cancer diagnosis,pas de greffe,2022-03-08,Protocole 3 LAL thiotepa Bu Flu
Male,24,117.71490807547085,187.3835401320474,2.4753134594711357,33.52498472658643,76.5903920887175,2.476182601652351,2022-04-06,Symptoms management,allo-greffe,2022-09-26,Protocole 3 LAL thiotepa Bu Flu
Male,58,67.25636350498888,153.93129285051748,1.6958166654993578,28.384388846107832,134.16118359325407,0.57093656340369,2022-05-22,Symptoms management,pas de greffe,2022-06-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,60,74.33872582562529,173.0368135343906,1.8902774810323564,24.82779180845147,106.22230533163602,0.7776011261741517,2022-07-13,Cancer diagnosis,allo-greffe,2022-03-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,80.43311097452984,192.1246106973876,2.0718470109999085,21.790583791376413,100.16154203542457,0.7026546384222236,2022-04-19,Cancer diagnosis,auto-greffe,2022-02-24,Protocole 3 LAL thiotepa Bu Flu
Female,71,71.15488645870232,173.70561789054466,1.8529258783400764,23.58180268640939,123.15692108486198,0.5536846725482547,2022-12-06,Cancer diagnosis,auto-greffe,2022-11-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,99.7319024301959,149.6467151018443,2.0361013665510956,44.53482266613213,74.63578607330763,1.150657798800952,2022-05-03,Cancer diagnosis,allo-greffe,2022-11-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,52,111.60044580952078,183.18055456744636,2.382985496375075,33.25884709628364,109.67340256340185,1.2436975756218602,2022-02-06,Treatment follow-up,allo-greffe,2022-08-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,54.47765620149379,186.73671644653984,1.6810197499311101,15.622803799932374,93.05568739457831,0.9431939054015464,2022-10-27,Cancer diagnosis,auto-greffe,2022-10-22,Protocole 3 LAL thiotepa Bu Flu
Male,73,110.68939888737154,159.39247590649978,2.213786182668125,43.568278031651346,97.5646860285639,1.0557368579610102,2022-12-22,Treatment follow-up,allo-greffe,2022-06-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,65.54950765018938,179.6354079937347,1.8085454983471452,20.313536771697663,91.4776412438584,0.8558948851787745,2022-09-29,Treatment follow-up,auto-greffe,2022-12-01,Protocole 3 LAL thiotepa Bu Flu
Male,37,92.54843817277839,171.34420886242384,2.0987852915547536,31.523195316624008,123.33657621888452,1.0734502808890716,2022-03-20,Treatment follow-up,pas de greffe,2022-05-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,57,76.97474962098846,140.47745094708958,1.7331102912624161,39.00632623864568,104.14020579045233,0.8520703424730433,2022-03-06,Symptoms management,auto-greffe,2022-06-27,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,55,119.73270327679732,146.11414197254766,2.2044551610408614,56.082618640097735,84.18600629690364,1.6790333008148273,2022-09-10,Treatment follow-up,auto-greffe,2022-06-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,39,74.80777085027847,190.8572661482345,1.9914823227887126,20.53663650901015,90.24575653616834,1.1628101151970058,2022-12-16,Treatment follow-up,auto-greffe,2022-09-07,Protocole 3 LAL thiotepa Bu Flu
Female,60,74.20113442997454,156.86394941014814,1.7981072608439568,30.15534175300329,133.34514732093936,0.6182880035653715,2022-09-10,Treatment follow-up,pas de greffe,2022-08-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,78,94.09536811498452,180.56278906903432,2.172436043382782,28.861024048313933,86.8307822852127,0.9331548657681755,2022-11-07,Symptoms management,greffe haplo-identique,2022-04-21,Protocole 3 LAL thiotepa Bu Flu
Female,24,85.95747096899139,188.1309893030971,2.1194380840336877,24.2863892109833,112.05996982500588,1.235829679210299,2022-03-21,Cancer diagnosis,allo-greffe,2022-06-13,Protocole 3 LAL thiotepa Bu Flu
Female,61,107.8832736080617,175.34284844418121,2.2922914599151953,35.08956637850224,126.99572133526831,0.9320938057144771,2022-06-25,Symptoms management,auto-greffe,2022-02-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,28,94.61601775836243,176.72096367499466,2.155138165031306,30.296225390490292,127.28725212752039,1.1562860349999051,2022-06-06,Treatment follow-up,allo-greffe,2022-06-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,81.94203102455171,196.3547013842508,2.1140865529851096,21.25318956422438,79.07787788639492,0.9786516537382549,2022-07-10,Cancer diagnosis,allo-greffe,2022-03-09,Protocole 3 LAL thiotepa Bu Flu
Male,59,44.8498915318322,162.43831036575693,1.4225701115819185,16.997477312531576,85.34754829259941,0.5911842692930211,2022-10-09,Symptoms management,pas de greffe,2022-04-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,49.487822289648605,172.03164038863966,1.5378078957967818,16.72174830099223,131.7415199392834,0.6104203994135003,2022-01-26,Treatment follow-up,auto-greffe,2022-07-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,66.37726287084479,164.9714401601844,1.7440655449022295,24.389438865345138,92.97332024256517,0.6346122875553556,2022-12-28,Treatment follow-up,auto-greffe,2022-07-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,69.47238908463353,164.915500005975,1.7839620217760912,25.544022165780838,96.12924543185248,0.7026228094844588,2022-05-07,Symptoms management,greffe haplo-identique,2022-03-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,94.54710387481575,190.13427246372405,2.2346168456552404,26.15335541688587,134.18517359120108,0.6067403684852326,2022-07-21,Symptoms management,greffe haplo-identique,2022-12-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,113.5193304299373,170.0948889711355,2.315950603097632,39.23623189929793,105.60905367222153,1.283910127534424,2022-12-12,Treatment follow-up,auto-greffe,2022-10-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,63.07513947927571,173.57930398853534,1.743921093541192,20.93448754734689,113.5915333554112,0.6555392301705666,2022-07-19,Cancer diagnosis,auto-greffe,2022-08-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,56.065668695586254,172.7936554466104,1.6404430159571175,18.777657869257013,104.81569715370165,0.6166181089627045,2022-10-13,Treatment follow-up,pas de greffe,2022-10-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,101.89596274372857,189.4883955820997,2.315893305964637,28.378650525453867,94.1407421025513,1.6085354653977708,2022-09-18,Symptoms management,auto-greffe,2022-04-08,Protocole 3 LAL thiotepa Bu Flu
Female,44,57.43539717993485,147.33997142678635,1.5332001553919217,26.45687016562661,98.53692046517533,0.777175998719296,2022-05-28,Symptoms management,greffe haplo-identique,2022-06-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,53,69.55956569910931,180.16585690631507,1.8657928579956409,21.429492128426716,102.10991724360322,0.8231437665932416,2022-01-19,Treatment follow-up,greffe haplo-identique,2022-04-18,Protocole 3 LAL thiotepa Bu Flu
Female,31,61.714677511168325,168.29405358914062,1.6985462120672732,21.789683481255192,90.2001334304367,1.0357985183865863,2022-03-16,Treatment follow-up,pas de greffe,2022-08-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,112.53002986955278,153.1092134299188,2.1876791584140087,48.0027129998898,125.17071189456514,1.173710714266587,2022-06-03,Cancer diagnosis,allo-greffe,2022-10-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,42,96.96515789859711,198.56477881525313,2.3126382920163473,24.592986778201137,105.23659979231404,1.2541297805790856,2022-04-10,Treatment follow-up,greffe haplo-identique,2022-07-01,Protocole 3 LAL thiotepa Bu Flu
Male,32,104.36337003892356,193.0616402210074,2.3657605893892493,27.999876223244172,104.77568917989187,1.4940971162652952,2022-05-12,Treatment follow-up,allo-greffe,2022-10-16,Protocole 3 LAL thiotepa Bu Flu
Male,61,51.15107870536883,187.30488688957766,1.6313633537617984,14.579968302052047,110.2710939673357,0.5089647542881325,2022-04-25,Symptoms management,pas de greffe,2022-07-19,Protocole 3 LAL thiotepa Bu Flu
Female,47,111.59950874478642,163.7767746931985,2.253232714689332,41.60616188498603,125.31352661108751,1.150309702075384,2022-12-05,Symptoms management,auto-greffe,2022-09-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,53.8407054740742,165.6646165260816,1.5740517273951362,19.617841560332238,106.19923051754694,0.6055574152945659,2022-07-30,Cancer diagnosis,greffe haplo-identique,2022-09-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,48.1015389324366,154.75799222718425,1.437986399663473,20.08411954567729,127.85843356236289,0.3971098756355433,2022-12-06,Cancer diagnosis,allo-greffe,2022-01-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,54,67.87020897759305,188.5378373985393,1.8853309777524123,19.093350450330114,129.79488697602267,0.6245792568974249,2022-02-11,Treatment follow-up,greffe haplo-identique,2022-02-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,114.84405878627724,149.28197126913395,2.1822610270188787,51.533994907257295,102.25293447692687,1.341524805096652,2022-05-10,Cancer diagnosis,auto-greffe,2022-11-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,50,61.46982879833773,192.00270948433484,1.8106455019028005,16.674287631077796,82.41976830640489,0.9322676777283672,2022-12-22,Treatment follow-up,allo-greffe,2022-08-21,Protocole 3 LAL thiotepa Bu Flu
Male,76,88.79987068678975,195.81764634020726,2.197762857063843,23.158406932691666,130.54061062108548,0.6046640812595365,2022-07-31,Cancer diagnosis,greffe haplo-identique,2022-06-14,Protocole 3 LAL thiotepa Bu Flu
Male,70,66.41956853361097,160.49706443299968,1.7207996986665337,25.784686967826847,97.05108204655497,0.6653669300442452,2022-07-28,Treatment follow-up,allo-greffe,2022-05-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,46.04317269806528,177.486869416668,1.5066573174664397,14.616143004082282,101.34700805723577,0.46062199666907355,2022-08-17,Treatment follow-up,auto-greffe,2022-07-15,Protocole 3 LAL thiotepa Bu Flu
Female,50,110.23575882932934,170.44565948274,2.2845621153641313,37.944654590607605,118.95121382350817,1.1584135555027812,2022-10-03,Symptoms management,greffe haplo-identique,2022-07-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,100.40560611932435,177.88813038351464,2.2274153901246034,31.729557892314375,97.12422272996906,1.1486504750436792,2022-09-09,Cancer diagnosis,auto-greffe,2022-01-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,49.23799196052384,168.76966463906055,1.5193089977828709,17.28667862986192,101.16125440178341,0.5881293910808877,2022-08-16,Symptoms management,greffe haplo-identique,2022-10-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,52,84.72614003827127,150.81659953489722,1.884004919512448,37.24938717873072,95.53413224544079,1.0839494610349492,2022-01-07,Symptoms management,auto-greffe,2022-06-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,38,103.2750670177493,198.33382298996338,2.3853103025005464,26.254389201104978,114.8862070532166,1.2734892089704097,2022-06-10,Symptoms management,pas de greffe,2022-11-29,Protocole 3 LAL thiotepa Bu Flu
Male,42,69.51015250122072,142.19620492066701,1.6569784992511718,34.37733688034994,117.59221995562856,0.8045688816840024,2022-08-19,Symptoms management,pas de greffe,2022-10-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,48,69.62940640057309,176.54430616798643,1.8478722931070637,22.340107669284347,81.02155984114769,1.098113987844075,2022-03-09,Cancer diagnosis,greffe haplo-identique,2022-01-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,32,41.49674698120562,164.70948601066408,1.3778916932913763,15.295963158099097,123.13728074330184,0.505493706666852,2022-10-30,Symptoms management,greffe haplo-identique,2022-10-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,64,107.67262284478299,164.08299182346448,2.2153032206456964,39.99246376473935,87.53249903396828,1.2984255731227716,2022-06-26,Symptoms management,auto-greffe,2022-05-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,108.59477182711623,182.86433473629,2.3486468152489675,32.475129863153626,85.87445161442537,1.3172666824643495,2022-04-24,Treatment follow-up,allo-greffe,2022-03-31,Protocole 3 LAL thiotepa Bu Flu
Male,57,65.18866758064283,164.63350167904443,1.7266086391144242,24.051140388638117,88.14532818271701,0.8525471389037528,2022-06-07,Treatment follow-up,auto-greffe,2022-03-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,96.55715520724189,195.1506745132777,2.287841897204565,25.35387521822569,92.54532955920641,1.463587976349525,2022-08-25,Cancer diagnosis,greffe haplo-identique,2022-05-30,Protocole 3 LAL thiotepa Bu Flu
Male,24,71.43062773037295,187.90359573748114,1.9308944240315813,20.23085721620915,90.35036163674738,1.2737378791325034,2022-12-22,Treatment follow-up,pas de greffe,2022-06-21,Protocole 3 LAL thiotepa Bu Flu
Female,62,118.6381556767679,158.75335951218452,2.287296182784894,47.07372192818129,128.86445083833775,0.997363258941505,2022-02-07,Cancer diagnosis,allo-greffe,2022-04-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,59,60.91903191384678,180.23695855875056,1.7464138677185828,18.752764200951663,121.92929349376314,0.562079127495176,2022-08-11,Cancer diagnosis,allo-greffe,2022-02-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,110.74183345232265,165.84422908168133,2.258680415886453,40.263449698538665,106.31944815699045,1.113928266240644,2022-07-31,Treatment follow-up,allo-greffe,2022-10-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,116.01412861756903,195.3299172997945,2.5089301697734236,30.406984309083292,88.89604854051599,1.4500598110848975,2022-04-19,Cancer diagnosis,pas de greffe,2022-01-10,Protocole 3 LAL thiotepa Bu Flu
Female,30,97.79424709056872,140.1505124189451,1.951204317663562,49.78791363278817,78.29914698472324,1.9081673715887428,2022-07-30,Treatment follow-up,pas de greffe,2022-12-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,64,77.32750820735615,194.97769424248952,2.0464833829297597,20.340618540066032,134.87431718762838,0.6051817913709496,2022-09-28,Treatment follow-up,allo-greffe,2022-01-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,77.56328559768195,141.38477212589657,1.7453324627229254,38.80171533536415,130.42374323768564,0.7764167467165298,2022-11-28,Treatment follow-up,pas de greffe,2022-12-30,Protocole 8 Aplasie medullaire thymo
Female,28,43.18668237501175,158.80648845508392,1.3802501158204665,17.124320881513306,118.63239932416352,0.5662810840645232,2022-05-25,Symptoms management,allo-greffe,2022-10-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,26,72.62974819179799,163.39770172832448,1.815636858855647,27.20336640557772,100.79213854745554,1.1409332410338384,2022-03-09,Symptoms management,auto-greffe,2022-08-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,90.66614072049612,173.8842105392942,2.0926730846925596,29.98643481751974,82.20031493507916,1.3634184252783346,2022-09-13,Treatment follow-up,pas de greffe,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,64.00927355727367,169.19531896137633,1.7344603272110728,22.35971231208562,124.4683258741319,0.6999671028038037,2022-09-24,Symptoms management,auto-greffe,2022-05-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,40,44.69245752047067,199.37334653231596,1.5732560733687182,11.243461540592541,93.98462004755665,0.6604576114252654,2022-01-05,Symptoms management,auto-greffe,2022-10-30,Protocole 3 LAL thiotepa Bu Flu
Male,50,81.99167956114613,165.7938257080574,1.9432014128087953,29.828614177416345,134.31239683883072,0.76306879978038,2022-05-04,Symptoms management,auto-greffe,2022-06-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,58,59.12807307413385,190.43248248042332,1.7685450501433204,16.30465704328574,88.59467700461596,0.7600942598620543,2022-04-21,Symptoms management,auto-greffe,2022-05-14,Protocole 3 LAL thiotepa Bu Flu
Male,31,114.96143534291399,147.03037184586196,2.1668475941383054,53.178742848797505,120.38898408251157,1.4456375800718948,2022-11-21,Cancer diagnosis,auto-greffe,2022-08-27,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,29,101.39102434413113,198.48803679268943,2.3643712677572895,25.735394990659294,100.02792666145217,1.56267522228643,2022-06-10,Cancer diagnosis,pas de greffe,2022-12-17,Protocole 3 LAL thiotepa Bu Flu
Male,32,40.46746764543906,199.4107800597887,1.4971871116476003,10.176741975274869,76.74367827839438,0.790960282721395,2022-07-17,Symptoms management,auto-greffe,2022-07-02,Protocole 2 LAM Endoxan TBI
Female,23,115.29710490895442,194.33383797907845,2.494779488409166,30.529630406635466,91.48393787891757,2.04798568820929,2022-05-08,Treatment follow-up,auto-greffe,2022-12-09,Protocole 3 LAL thiotepa Bu Flu
Female,68,42.84414294919085,142.233040321117,1.3010522143010892,21.1782696079065,100.21906503736423,0.42750491568862126,2022-07-01,Cancer diagnosis,greffe haplo-identique,2022-02-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,26,67.73113352394631,157.99540207411738,1.724110694600716,27.133101969206038,102.61014547743763,1.0451301955954795,2022-10-18,Cancer diagnosis,pas de greffe,2022-04-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,119.15406795557286,160.5591071141402,2.305263949695973,46.22096253031579,95.06504523359754,1.479702624096384,2022-06-24,Treatment follow-up,allo-greffe,2022-03-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,91.48618815602993,151.69657637496542,1.9634254031090133,39.756118283318685,105.43924976311254,1.0845841131453589,2022-06-06,Cancer diagnosis,auto-greffe,2022-07-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,39,94.47133332901618,195.26346515274338,2.2636499473823952,24.77753285886626,115.82972427592954,1.1441129456139123,2022-03-30,Treatment follow-up,auto-greffe,2022-07-08,Protocole 3 LAL thiotepa Bu Flu
Female,45,80.36808937251078,172.57675214013534,1.9628256162719457,26.984791137934693,127.33651207831207,0.8327637321176073,2022-05-31,Treatment follow-up,auto-greffe,2022-03-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,48,75.16000781074003,180.70997337872456,1.942375622403284,23.015614393243826,116.59210569392657,0.8237074644683302,2022-07-07,Symptoms management,greffe haplo-identique,2022-10-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,53.076053388251616,149.05634797986784,1.4824269406053632,23.88898344386276,76.94991554323448,0.756806876710899,2022-11-03,Cancer diagnosis,auto-greffe,2022-03-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,51.79070535121366,191.06002860568393,1.6579047725896072,14.187704973968978,133.35570045863227,0.43151682282877774,2022-05-04,Treatment follow-up,pas de greffe,2022-09-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,68.97718592544385,170.08229994227293,1.805223780045109,23.844445776318537,78.0835210544435,1.1532977390807226,2022-12-10,Treatment follow-up,allo-greffe,2022-01-07,Protocole 3 LAL thiotepa Bu Flu
Female,77,72.91219288541186,149.43081570219888,1.73967816767476,32.65275470639335,92.85289640579774,0.6870886234492499,2022-11-26,Cancer diagnosis,greffe haplo-identique,2022-10-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,66,80.78126132740609,184.83739023093594,2.036568295723155,23.644545703127683,90.06413300453687,0.9218451617025512,2022-08-25,Symptoms management,allo-greffe,2022-12-14,Protocole 3 LAL thiotepa Bu Flu
Female,60,103.64494254766427,172.0708234788719,2.225750223931807,35.00528685777944,93.31386128276988,1.2341258382418547,2022-06-21,Cancer diagnosis,allo-greffe,2022-06-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,116.70627106171041,183.45855931920562,2.438736259286883,34.675140981674744,108.59391656786673,1.6419082494732562,2022-12-02,Cancer diagnosis,greffe haplo-identique,2022-12-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,92.03205696374026,153.75550344035918,1.98259336694193,38.92940711649213,114.04639301585257,0.8966337151636927,2022-12-10,Treatment follow-up,pas de greffe,2022-04-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,67,40.62778051760199,155.98694230428757,1.3267968168519457,16.697313741082727,80.01359096930533,0.5148132304525008,2022-08-31,Symptoms management,allo-greffe,2022-06-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,108.56963928852987,184.25437063935763,2.357283662611254,31.979583122840374,87.87659563590962,1.4757103588857008,2022-04-06,Cancer diagnosis,auto-greffe,2022-04-13,Protocole 3 LAL thiotepa Bu Flu
Male,62,69.75844695594819,159.2670802393551,1.7567508019625477,27.50076445786298,93.61241297523479,0.807282372786784,2022-07-19,Symptoms management,greffe haplo-identique,2022-08-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,50.329504916777594,161.76567842323902,1.503845672819473,19.233126649459802,134.04813203806873,0.41717606414591085,2022-12-14,Cancer diagnosis,pas de greffe,2022-02-21,Protocole 6 FlUDARABINE cy (Fanconi)
Female,65,104.7163891749125,171.8281477972074,2.235647010247118,35.46712953569828,129.19885244439723,0.8442766324425726,2022-10-12,Cancer diagnosis,allo-greffe,2022-02-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,50,42.953511046215766,165.5290501937625,1.4053522577362134,15.676540289705496,108.00016639048013,0.49714635266064255,2022-07-08,Treatment follow-up,pas de greffe,2022-07-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,82.82561838092546,148.04645692707342,1.8455682160313047,37.78928288708673,79.460023861279,1.4621935817474943,2022-01-19,Cancer diagnosis,auto-greffe,2022-08-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,117.01058002356332,140.4527923694121,2.136616139617998,59.31497836413182,102.71901952297549,1.2815241338734265,2022-08-05,Treatment follow-up,auto-greffe,2022-12-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,64,103.32594959821563,196.1743678902982,2.372873483604423,26.848800103174394,128.29355045243784,0.8501306554134527,2022-04-12,Cancer diagnosis,auto-greffe,2022-04-28,Protocole 3 LAL thiotepa Bu Flu
Male,28,104.0713200240695,155.72256127256728,2.12172967366284,42.916864666854124,91.11825058815222,1.7766881935559378,2022-12-11,Symptoms management,greffe haplo-identique,2022-07-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,81.38328092273572,168.01562854877346,1.9489073218939637,28.82941515661532,82.52668250015994,0.9313592308522802,2022-07-31,Cancer diagnosis,greffe haplo-identique,2022-04-24,Protocole 3 LAL thiotepa Bu Flu
Female,64,100.42672541908303,150.74091221491602,2.0506378547248194,44.19641305965517,93.98876383166244,1.1278580930399966,2022-03-04,Treatment follow-up,auto-greffe,2022-04-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,44,88.86366788987459,146.04071911459894,1.8986628307690492,41.66547232697755,106.31806979080217,1.1144379384705798,2022-10-03,Treatment follow-up,allo-greffe,2022-06-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,31,51.43651285050992,187.09597134701713,1.6349961208303865,14.694088309175916,106.35089243444754,0.7321909906451837,2022-01-16,Symptoms management,greffe haplo-identique,2022-02-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,48.87420368197678,159.3805507839149,1.4709782744409983,19.24017632484449,134.85056483689684,0.32719584856051703,2022-11-16,Symptoms management,auto-greffe,2022-11-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,32,76.71569586938799,163.63234031201225,1.8673487484318902,28.651406417384795,104.75551225144227,1.0984963113718884,2022-11-28,Symptoms management,auto-greffe,2022-06-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,70,43.01596806141701,169.46827583783408,1.4230095202367254,14.97796733249788,102.36578655207055,0.40854548642028754,2022-01-05,Cancer diagnosis,pas de greffe,2022-11-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,114.24173455502184,163.74751265592968,2.279546730948684,42.60645147384207,96.50246643925657,1.6441971031977494,2022-02-27,Symptoms management,auto-greffe,2022-12-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,86.5394711762499,174.33298182554245,2.0471310585902374,28.47443530312481,84.85285958412138,1.1473615096821046,2022-02-16,Treatment follow-up,auto-greffe,2022-05-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,114.47531716868193,186.47275345587323,2.4350751525693615,32.921611692774775,127.97684804954663,0.9441946637457801,2022-11-04,Symptoms management,pas de greffe,2022-08-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,110.23211275126046,185.5993684743923,2.3839166251402304,32.00038055464428,121.36903329080396,1.0596123908723714,2022-08-07,Treatment follow-up,pas de greffe,2022-07-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,101.7450888310531,145.41073786393068,2.027233229535229,48.119432728631395,89.89073229536392,1.8235766794965904,2022-01-15,Cancer diagnosis,auto-greffe,2022-06-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,60.62532506666341,141.6020032566949,1.544224677587057,30.23536985230605,130.18056056283447,0.5497868806630726,2022-05-18,Symptoms management,pas de greffe,2022-11-15,Protocole 8 Aplasie medullaire thymo
Male,49,43.895864019106796,147.7410724967755,1.3421812707052916,20.11041843900744,118.47129872399626,0.4682948140137955,2022-11-14,Symptoms management,pas de greffe,2022-01-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,57,114.74621205849982,167.87166752546176,2.3131650971780955,40.717729121527974,105.0434318529137,1.2592589656670283,2022-04-27,Symptoms management,allo-greffe,2022-12-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,69.20484686672405,173.52812323951807,1.8264254095440138,22.98247373369517,110.23157923858172,0.8370843436427511,2022-11-20,Cancer diagnosis,allo-greffe,2022-12-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,74,44.37671687284181,160.1415780637537,1.4050066695477614,17.304018112469052,117.55600580300128,0.34603640073997627,2022-10-15,Treatment follow-up,auto-greffe,2022-05-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,52,50.257110624716205,189.9018447831878,1.628216306022087,13.936032460124634,87.61823578836498,0.7010567706313655,2022-07-09,Symptoms management,pas de greffe,2022-08-07,Protocole 3 LAL thiotepa Bu Flu
Male,77,83.48603047260539,193.09512213499994,2.1161249471271555,22.390882248601073,82.73153905804244,0.8829797861282311,2022-07-03,Symptoms management,pas de greffe,2022-05-30,Protocole 3 LAL thiotepa Bu Flu
Female,47,78.77439581151013,148.22691035558813,1.8009631147333616,35.85345134864437,78.74450072228625,1.2921570436440215,2022-12-16,Symptoms management,greffe haplo-identique,2022-03-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,20,117.01760644015165,142.01358932915974,2.1485195358453573,58.021827316853475,89.7516357843677,2.172989298328624,2022-10-09,Treatment follow-up,auto-greffe,2022-02-28,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,52,45.980669026475525,145.69543999917505,1.3641413462594938,21.661242647602222,122.83248545039959,0.45752225293443816,2022-03-09,Treatment follow-up,allo-greffe,2022-11-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,36,119.42776127546244,144.48914797864344,2.1893692313140227,57.205110793265014,110.7760528554865,1.5572568424316737,2022-04-10,Cancer diagnosis,allo-greffe,2022-02-23,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,28,47.8432946713546,166.25366395662545,1.4864315055854402,17.309265073638347,118.92730186276395,0.625784842138161,2022-12-15,Symptoms management,allo-greffe,2022-10-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,43,119.36393499973038,156.71246444459396,2.279486809911149,48.603332390476616,129.35738414853012,1.2431431481242805,2022-09-07,Treatment follow-up,greffe haplo-identique,2022-11-21,Protocole 6 FlUDARABINE cy (Fanconi)
Female,54,93.46982531381171,156.27704380609026,2.0143366694987375,38.271991042133756,131.94790246420055,0.846125716925026,2022-06-13,Treatment follow-up,allo-greffe,2022-05-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,57,51.639723912068504,167.8336885673386,1.551601801433446,18.332666283959906,103.15987485714223,0.5770569832393592,2022-02-16,Cancer diagnosis,pas de greffe,2022-01-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,72.36485472201426,164.41924810840237,1.8179792660829768,26.76839787733627,83.55040386934006,1.2390358413041371,2022-07-30,Cancer diagnosis,greffe haplo-identique,2022-12-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,87.67555670766603,153.98182334369466,1.936523379991972,36.97767629691284,97.70232731147563,1.0344731411021522,2022-07-25,Cancer diagnosis,auto-greffe,2022-07-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,46,115.41186391375996,186.18517647786328,2.4431297238050202,33.29356136209499,131.21956758890673,1.148278438027479,2022-05-31,Symptoms management,auto-greffe,2022-05-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,56.24605094215865,179.56235492947926,1.6749521852758682,17.44461748468478,133.94997253651684,0.6998390254344784,2022-09-30,Treatment follow-up,allo-greffe,2022-03-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,39,94.02326092714267,169.4702517771761,2.103842100527957,32.73771472974273,75.28116300893383,1.7520151888081903,2022-06-13,Treatment follow-up,greffe haplo-identique,2022-09-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,53.61228566387159,194.8519860543318,1.7034654497456354,14.120648729149636,91.32771355903964,0.9050075876296926,2022-03-02,Cancer diagnosis,greffe haplo-identique,2022-02-24,Protocole 3 LAL thiotepa Bu Flu
Female,47,76.12779369608376,141.98888892341574,1.732796458770391,37.76022051192539,100.35087350680209,0.9798791987340594,2022-09-01,Cancer diagnosis,pas de greffe,2022-06-11,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,57,51.91391855056403,195.0790381539801,1.6772428845552267,13.641514851483574,123.18311135112519,0.48582318636092087,2022-03-18,Cancer diagnosis,greffe haplo-identique,2022-11-09,Protocole 3 LAL thiotepa Bu Flu
Male,31,63.03407921656127,170.34339676124407,1.7270269223168841,21.72325033343021,87.152318207477,1.0949403769171027,2022-05-08,Symptoms management,pas de greffe,2022-06-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,114.27839814351815,170.92697194007727,2.3293573596854102,39.11496502905796,121.86081323235285,1.0159262416274701,2022-07-10,Treatment follow-up,greffe haplo-identique,2022-04-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,70.10263856419755,168.9461585976796,1.8138029028185452,24.560529275296915,123.26682690972729,0.8846544655319212,2022-12-13,Treatment follow-up,allo-greffe,2022-12-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,29,57.424994127712026,199.43195485153797,1.783596463159922,14.43814725611007,119.16620464657436,0.7429136435349891,2022-09-05,Symptoms management,pas de greffe,2022-11-10,Protocole 3 LAL thiotepa Bu Flu
Female,52,49.22318730417924,181.10587914688386,1.5736200843150654,15.00737152400859,87.13056655300167,0.6904772429682089,2022-10-19,Treatment follow-up,pas de greffe,2022-10-16,Protocole 3 LAL thiotepa Bu Flu
Female,59,114.76934422617882,142.07272430194985,2.128222615272182,56.85968946998455,79.89319850723732,1.616101428743711,2022-01-03,Cancer diagnosis,allo-greffe,2022-04-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,53,83.42662889624339,141.28527776543433,1.8094623538989847,41.79370523935444,106.88394180816597,0.943146134747615,2022-08-04,Symptoms management,greffe haplo-identique,2022-06-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,34,117.4496934840193,165.51040787525469,2.3237390053151934,42.87471733580222,131.03442857084212,1.3195924966153383,2022-01-02,Treatment follow-up,auto-greffe,2022-11-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,37,63.190220454190076,184.75306106451998,1.8008166865074686,18.51256451915605,134.7257899920547,0.6709711699063184,2022-10-19,Treatment follow-up,allo-greffe,2022-04-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,53.713422997977474,171.72524592781355,1.6006900225590524,18.2143859847104,129.0686189488095,0.3757015845205893,2022-02-19,Cancer diagnosis,allo-greffe,2022-09-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,72.4728073269421,146.6965849972631,1.7184871689970542,33.67713027085944,102.21359572802955,1.142330864169297,2022-10-08,Symptoms management,pas de greffe,2022-10-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,60,46.07403777255519,174.60009911125232,1.4948552105233506,15.113578365662386,95.74428732814019,0.5346885619126944,2022-11-12,Symptoms management,greffe haplo-identique,2022-04-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,75.58884484106818,168.040789410764,1.878386508988562,26.768761745863202,78.78735427449797,0.8128277652063423,2022-05-17,Cancer diagnosis,auto-greffe,2022-07-21,Protocole 3 LAL thiotepa Bu Flu
Female,72,92.24878388745407,167.3165269654182,2.0706108959564085,32.95209015180401,123.88719759700027,0.7032514508292642,2022-01-04,Cancer diagnosis,allo-greffe,2022-06-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,76,113.37468805605322,140.25642686655056,2.101687724177604,57.63291200782302,97.55792255892081,1.0330017065851749,2022-10-18,Cancer diagnosis,greffe haplo-identique,2022-03-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,67,98.41536296016002,159.73469968649556,2.089680228526379,38.57130735811791,100.77737835538143,0.9901254093890117,2022-03-12,Symptoms management,greffe haplo-identique,2022-04-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,61.77322614749956,153.0126394370819,1.620363846261137,26.38430567439342,93.12548910525308,1.004212719783127,2022-04-02,Symptoms management,greffe haplo-identique,2022-03-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,73,90.81899850793629,198.24794524365706,2.2363586377117803,23.107838255333704,94.65250025769797,0.8928673133986078,2022-04-14,Symptoms management,auto-greffe,2022-01-19,Protocole 3 LAL thiotepa Bu Flu
Female,44,83.33435765773645,179.89309273973734,2.0406477274065065,25.751060289317817,117.23051728893928,0.9478118790785666,2022-10-28,Cancer diagnosis,pas de greffe,2022-02-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,67.2933565223012,171.9860873621268,1.7930050112819012,22.750217758437735,77.17741679971007,1.1262437784559136,2022-09-22,Treatment follow-up,greffe haplo-identique,2022-05-31,Protocole 3 LAL thiotepa Bu Flu
Male,60,111.83183499464035,150.91399857874188,2.165191124963802,49.10281593708168,82.81210992059576,1.5004761327495877,2022-05-19,Treatment follow-up,auto-greffe,2022-07-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,33,117.53621445091305,190.2979066337179,2.4925943403332296,32.456648882293166,108.62573495684234,1.6080155804960807,2022-12-26,Treatment follow-up,allo-greffe,2022-05-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,50.62726926138974,157.37284268349907,1.4876675704836895,20.44207246948804,119.05458008929045,0.6260539561026998,2022-02-19,Treatment follow-up,pas de greffe,2022-09-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,43,86.2233693790183,195.65751585301427,2.164758792130044,22.523294707690322,106.17247046959065,1.094088126503179,2022-05-29,Cancer diagnosis,allo-greffe,2022-03-26,Protocole 3 LAL thiotepa Bu Flu
Female,41,93.72058907611515,141.63796101743722,1.9202425441489048,46.717078658971175,77.13243078532174,1.6707085290534032,2022-07-12,Treatment follow-up,auto-greffe,2022-11-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,60,44.48459855967389,149.42085482457534,1.3588114438028538,19.92449131760761,130.6123570519665,0.3784276836326093,2022-10-31,Treatment follow-up,auto-greffe,2022-07-13,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,47,44.788389033168485,169.612329573775,1.4526472962006127,15.568637392615372,125.92715361386556,0.4594058351007841,2022-09-02,Treatment follow-up,allo-greffe,2022-11-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,118.92599203685407,198.21313368740397,2.558900238954015,30.2699656098453,131.27738899165092,1.3714527637058063,2022-04-25,Treatment follow-up,greffe haplo-identique,2022-11-12,Protocole 3 LAL thiotepa Bu Flu
Male,74,73.54879539860997,156.1089337072001,1.7858723378168586,30.180056571079206,81.87143065994289,0.8234829728995907,2022-01-13,Treatment follow-up,greffe haplo-identique,2022-10-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,23,58.522413518357546,186.33279534641264,1.740421796041779,16.855577238132597,133.93500780856402,0.7100378274756799,2022-07-29,Symptoms management,pas de greffe,2022-01-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,103.67681698003591,158.89634896519325,2.1391760933736106,41.0632972259333,125.7407554409355,1.328406778020597,2022-12-07,Cancer diagnosis,greffe haplo-identique,2022-08-01,Protocole 6 FlUDARABINE cy (Fanconi)
Female,23,82.80894886389063,167.71554032780395,1.9641472282085017,29.439515651330673,89.43232109119577,1.5046522360367272,2022-10-16,Cancer diagnosis,pas de greffe,2022-11-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,61.57881847094905,185.19780933905366,1.779845677026446,17.953935527650906,96.81432915070503,1.0600844422367308,2022-12-04,Treatment follow-up,allo-greffe,2022-10-31,Protocole 3 LAL thiotepa Bu Flu
Female,69,88.17003297411517,151.06964331256188,1.9235250794263985,38.63372602087094,80.917397844008,1.0744963567713939,2022-10-21,Treatment follow-up,greffe haplo-identique,2022-09-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,50,104.20451119526774,177.18097474526382,2.2646471926863194,33.19344647678948,111.35470158584658,1.1697363213143435,2022-03-17,Treatment follow-up,auto-greffe,2022-05-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,90.61121286360623,199.10087528059415,2.2385990033066707,22.857861931026108,75.50614987744488,1.7667414028768833,2022-06-24,Treatment follow-up,pas de greffe,2022-07-07,Protocole 3 LAL thiotepa Bu Flu
Female,78,104.47370701571894,175.5846554321127,2.257332487206385,33.887059530258135,97.53049422130678,0.9224137604190338,2022-02-26,Treatment follow-up,pas de greffe,2022-07-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,53.59169738329317,163.38252890047787,1.5595536261799365,20.07642055294808,101.4774325801198,0.4474302886396586,2022-08-29,Treatment follow-up,auto-greffe,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,86.90990859092865,182.13703175493038,2.096923194484671,26.1982802591862,74.71634667009613,1.2278201616447184,2022-08-12,Treatment follow-up,allo-greffe,2022-12-15,Protocole 3 LAL thiotepa Bu Flu
Female,44,55.83244598852992,151.09232476777115,1.5307817594177533,24.456924761559982,117.7929878547732,0.6319838105288651,2022-05-02,Symptoms management,greffe haplo-identique,2022-07-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,25,112.26871341668625,183.98969581476257,2.3953825043108607,33.16436932743895,92.37265845459788,1.9412463268832534,2022-04-09,Treatment follow-up,auto-greffe,2022-05-13,Protocole 3 LAL thiotepa Bu Flu
Female,63,89.07906453103145,153.7409842725595,1.9504346423781502,37.687413552351195,85.64598305002795,1.1123126536287524,2022-12-16,Cancer diagnosis,greffe haplo-identique,2022-07-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,45.45562584627043,167.00056550165903,1.452116771165363,16.29865466698208,84.47955204726968,0.5081740167754937,2022-01-06,Cancer diagnosis,pas de greffe,2022-02-11,Protocole 3 LAL thiotepa Bu Flu
Female,31,67.80686538804727,162.14006352927694,1.7475545979182765,25.792473342450425,109.73121467322667,0.9354864101982409,2022-01-13,Treatment follow-up,allo-greffe,2022-08-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,76.21054754101016,181.77608493808194,1.9616641859933617,23.064369712803554,116.96777496420918,0.7691929278726587,2022-03-08,Cancer diagnosis,pas de greffe,2022-05-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,85.10250702359735,149.71315157384817,1.8812646849436676,37.96841333336406,96.6925994239605,1.4424428964415728,2022-10-28,Symptoms management,greffe haplo-identique,2022-01-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,59,83.48985521720931,175.70427906294452,2.018630230021873,27.04388193384285,104.97607933470896,0.8947379985480659,2022-07-15,Treatment follow-up,auto-greffe,2022-02-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,70.25922266678444,169.01147249310395,1.8161784266798378,24.596367285159644,87.97387956094619,1.3199700011769393,2022-07-24,Symptoms management,greffe haplo-identique,2022-11-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,23,48.867658577148504,168.69956166355513,1.513270242947852,17.17092228541032,133.67994456390394,0.5940303569613273,2022-02-22,Treatment follow-up,pas de greffe,2022-12-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,62,105.72326604738544,175.6576553833589,2.2712637838727336,34.26386953787004,130.70315986911342,0.876287446552135,2022-07-24,Symptoms management,pas de greffe,2022-02-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,109.52584238365434,169.674897076143,2.2720393454158954,38.043583050727804,105.71234490823606,1.2375331762039212,2022-01-31,Symptoms management,auto-greffe,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,105.146243796098,142.2430358399679,2.038267300969568,51.967489540049975,101.11843835557325,1.6319594216804063,2022-11-20,Treatment follow-up,auto-greffe,2022-08-30,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,44,94.71088768675554,182.70803353272407,2.192439030153518,28.371651745448485,111.49672938527863,1.1325998913024093,2022-05-09,Symptoms management,allo-greffe,2022-02-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,58.188496115910056,176.58081055401107,1.689425593464168,18.661653479977076,95.89985898770712,0.716317553374777,2022-04-13,Treatment follow-up,auto-greffe,2022-07-06,Protocole 3 LAL thiotepa Bu Flu
Male,68,104.79544027570662,199.12217420593606,2.4075746160449887,26.43036345026031,106.00975214915806,0.988545281459173,2022-08-27,Cancer diagnosis,auto-greffe,2022-01-28,Protocole 3 LAL thiotepa Bu Flu
Female,32,95.90779591568587,157.96474714508898,2.0514257055266683,38.435590454547054,116.1799735415871,1.2382658515758131,2022-07-03,Symptoms management,auto-greffe,2022-04-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,20,119.4945652917252,146.34178879628888,2.2039767363806773,55.797075280955156,122.09087104105892,1.6312244078639238,2022-11-13,Symptoms management,allo-greffe,2022-12-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,59,93.45080355741564,156.0575764654718,2.0127169256395403,38.37190175069123,86.9315670347084,1.209366834030697,2022-09-22,Symptoms management,auto-greffe,2022-01-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,72,89.8915005802208,168.90593211557024,2.053669324158963,31.508579550505665,111.08666773176805,0.7642458816998565,2022-04-04,Cancer diagnosis,allo-greffe,2022-02-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,113.79589463345394,155.85992213455307,2.2196232961674887,46.844400419616775,83.14002508310809,1.349715687296292,2022-11-16,Treatment follow-up,greffe haplo-identique,2022-12-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,85.09399708522005,179.97751487747522,2.0625635428857447,26.270142130301185,90.50983990893744,1.4755335012782722,2022-08-01,Symptoms management,greffe haplo-identique,2022-02-15,Protocole 3 LAL thiotepa Bu Flu
Female,60,89.37017440575168,176.37651257158439,2.0924998134608144,28.728377772957256,115.84603224697099,0.8571738872546921,2022-09-26,Cancer diagnosis,allo-greffe,2022-07-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,77.79707807454284,182.40964074653078,1.9854286594745987,23.381249159011666,115.38181609104811,0.5899754885250621,2022-03-18,Cancer diagnosis,greffe haplo-identique,2022-04-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,92.8558882815475,175.8947866939548,2.130001738559573,30.012592635008147,126.30911157760428,0.8474622551756072,2022-08-31,Symptoms management,allo-greffe,2022-12-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,91.77707001470134,189.77661762801526,2.199566997994502,25.48289617395146,119.82967215180372,0.6807964699052018,2022-05-26,Treatment follow-up,greffe haplo-identique,2022-09-10,Protocole 3 LAL thiotepa Bu Flu
Female,49,83.23481763114519,151.85276274234633,1.873754179718469,36.096046459120615,101.69042738085425,1.0345080051507762,2022-08-20,Symptoms management,allo-greffe,2022-07-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,61,57.28261828097233,190.047820133586,1.738968143584252,15.85977695883844,128.98335647512525,0.4872858285175488,2022-12-06,Symptoms management,greffe haplo-identique,2022-01-05,Protocole 3 LAL thiotepa Bu Flu
Male,28,104.45583130933176,174.92321432322183,2.252883939866641,34.137977780216225,93.02311062842293,1.746736349770673,2022-08-15,Symptoms management,allo-greffe,2022-01-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,84.11867430258926,175.64706726969254,2.025887901627899,27.265320923271496,116.81435700715818,0.6700982799010408,2022-01-19,Treatment follow-up,greffe haplo-identique,2022-11-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,44.317848892210534,169.97904564050344,1.446557758913091,15.338676896819543,94.8626457195034,0.48664493362211525,2022-08-19,Treatment follow-up,pas de greffe,2022-10-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,47.12032476606335,192.58437044752924,1.5876815801975945,12.70475219582391,103.87844886039386,0.5040113419204029,2022-03-01,Treatment follow-up,greffe haplo-identique,2022-09-26,Protocole 3 LAL thiotepa Bu Flu
Male,51,103.27814768089794,150.86693616755042,2.0804151371031745,45.375382471160485,118.92219750452976,1.0735024121839785,2022-04-03,Symptoms management,pas de greffe,2022-01-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,22,41.485909954450115,183.76523198239417,1.4552269646175702,12.284965071594462,134.90021877144983,0.5040080549089722,2022-10-24,Treatment follow-up,pas de greffe,2022-07-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,74.13592963986872,145.64407856556613,1.731847051961858,34.9496695079489,98.18746608822012,1.1640273049254608,2022-11-16,Symptoms management,auto-greffe,2022-05-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,49,68.16238195433185,162.4755604918456,1.7539416888579002,25.82073918579021,128.0581703775781,0.6727386229107378,2022-05-03,Symptoms management,auto-greffe,2022-02-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,66.50192088953081,174.81180649840223,1.7970130252351102,21.76169245231286,84.26044427409913,1.2825190084916978,2022-05-29,Symptoms management,pas de greffe,2022-02-02,Protocole 3 LAL thiotepa Bu Flu
Female,58,59.73615810396281,159.47715399076452,1.6267343296004568,23.487691519776874,110.56194918562579,0.6153368969218407,2022-07-25,Symptoms management,auto-greffe,2022-09-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,99.81383516996266,186.26604588650838,2.2725370307382997,28.76890633385513,86.55577663373342,1.2332550830536728,2022-02-25,Symptoms management,pas de greffe,2022-12-13,Protocole 3 LAL thiotepa Bu Flu
Female,31,48.49554367517829,191.26354374425412,1.6051505241910466,13.25676129090754,116.03223390778051,0.6327281847286342,2022-11-19,Treatment follow-up,allo-greffe,2022-12-08,Protocole 3 LAL thiotepa Bu Flu
Male,33,51.92640663277916,196.86916869705453,1.6851235123888342,13.397780399710772,99.99481260127531,0.7717241309781966,2022-07-01,Cancer diagnosis,allo-greffe,2022-09-21,Protocole 3 LAL thiotepa Bu Flu
Female,53,89.01342345507506,194.3115303122956,2.191925493581944,23.575361460422783,81.85708857248345,1.313971563741131,2022-09-14,Symptoms management,allo-greffe,2022-04-18,Protocole 3 LAL thiotepa Bu Flu
Female,43,101.8397290895237,145.0175165082559,2.025431682001279,48.425744758576904,102.46692403428726,1.3389759420180058,2022-09-05,Symptoms management,greffe haplo-identique,2022-12-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,55,75.75095705901526,196.4785533160071,2.0332949760902794,19.622657370411666,113.5342206757372,0.787676285285693,2022-07-19,Symptoms management,auto-greffe,2022-04-25,Protocole 3 LAL thiotepa Bu Flu
Male,72,117.86962787450815,173.12727212876814,2.380852271581813,39.325200009479325,84.34546554205392,1.3198257250629486,2022-04-05,Cancer diagnosis,allo-greffe,2022-10-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,111.35163342378773,141.5007170632132,2.0920707428835787,55.61338254428599,121.27570873009036,1.1732163365446548,2022-06-28,Symptoms management,allo-greffe,2022-01-18,Protocole 8 Aplasie medullaire thymo
Male,52,66.81763323895562,160.3148624512925,1.724968573145616,25.998214035975764,81.55151612888264,1.0014037758891225,2022-11-17,Treatment follow-up,pas de greffe,2022-11-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,49.18780619034631,187.71858735413642,1.601515384210014,13.958633306545854,127.71960938568907,0.5027999533217496,2022-02-17,Cancer diagnosis,auto-greffe,2022-06-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,96.59502572568785,185.763620328912,2.2325770911517484,27.99196778678028,111.55153337855506,0.9741632467984497,2022-04-07,Treatment follow-up,pas de greffe,2022-03-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,57.614471226299,171.6638229956052,1.6575014991259167,19.55122708822076,98.90878716214121,0.5501398695758148,2022-09-16,Cancer diagnosis,greffe haplo-identique,2022-09-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,90.70336837760053,158.69958799585407,1.9996240751813399,36.01403786554184,86.80680527655669,1.1900110607796188,2022-04-26,Treatment follow-up,auto-greffe,2022-09-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,21,66.3056811126124,186.754100566481,1.8546381676633972,19.011240146204045,129.6458414684358,0.8452917196732952,2022-02-02,Treatment follow-up,allo-greffe,2022-10-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,68.17407593626926,166.7901796271927,1.7772299272344705,24.50633168333734,110.00410694365026,0.6713862871391776,2022-05-07,Treatment follow-up,greffe haplo-identique,2022-01-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,83.76206642640429,145.23079185070725,1.8382382291928803,39.71275096193822,75.5413154396008,1.370630368253122,2022-08-12,Symptoms management,pas de greffe,2022-02-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,71,85.5603115203781,148.45988305709915,1.8784060798279292,38.8198746673388,97.5676114901466,0.8403946482654552,2022-11-17,Treatment follow-up,allo-greffe,2022-06-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,75,81.93213592025306,164.53979132014456,1.9351354063111275,30.263028891232686,124.43882579698871,0.5944005909806874,2022-01-04,Cancer diagnosis,greffe haplo-identique,2022-06-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,78,97.46901284667976,153.51393773640172,2.038712282120869,41.35908708429401,83.39168618163012,1.0064750311979709,2022-02-09,Cancer diagnosis,greffe haplo-identique,2022-04-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,25,75.86194700131911,149.59560902498717,1.7754979085287308,33.898953587350555,133.30537699815434,0.9089534893497129,2022-11-20,Treatment follow-up,allo-greffe,2022-03-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,68,90.81118686277927,169.95408124116193,2.0705428588820696,31.43953800304886,99.4464383923501,0.9131668094989807,2022-02-03,Symptoms management,pas de greffe,2022-05-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,81.42030946449096,179.86371021185374,2.0169117583077805,25.167823128907244,98.59217772015025,1.0896358866603426,2022-07-24,Cancer diagnosis,pas de greffe,2022-06-06,Protocole 3 LAL thiotepa Bu Flu
Male,30,45.796774908591374,177.00884209153892,1.5005956315647726,14.616553246637942,89.77618596528984,0.7793525002976655,2022-08-27,Symptoms management,greffe haplo-identique,2022-04-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,92.64331627983506,151.24988446657707,1.9728920455292707,40.49710607201227,90.14331620725329,1.6986152811918525,2022-08-12,Treatment follow-up,greffe haplo-identique,2022-10-15,Protocole 6 FlUDARABINE cy (Fanconi)
Female,24,104.83606325784763,192.77241145197576,2.369335392124596,28.21115999347688,124.47689467047977,1.3568987787411568,2022-09-20,Symptoms management,auto-greffe,2022-11-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,96.57600378434182,154.24324400063668,2.034166230801172,40.59354032692489,113.799368190286,1.2022562825865462,2022-12-10,Symptoms management,allo-greffe,2022-09-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,40,104.66135086679515,186.30388300438645,2.3273026868845665,30.153832808343562,87.11786543192667,1.6685783862390309,2022-07-16,Cancer diagnosis,pas de greffe,2022-11-05,Protocole 3 LAL thiotepa Bu Flu
Male,76,73.00185905426207,144.6029891875916,1.7123965528769536,34.91237378375653,90.52097802760905,0.7168563883807636,2022-01-29,Cancer diagnosis,allo-greffe,2022-06-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,56,53.672073182465745,154.27018939743516,1.5165751707943782,22.55196275514884,94.38685805692216,0.663412470781831,2022-08-01,Treatment follow-up,auto-greffe,2022-07-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,43.63514143294808,168.14243976326622,1.4275969649837639,15.434113810783687,113.91798742605323,0.4415599547590749,2022-11-13,Symptoms management,pas de greffe,2022-08-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,87.22984942411114,166.4545721322988,2.008302715053966,31.482822824307508,124.50856663552398,1.1481943360501121,2022-07-10,Symptoms management,pas de greffe,2022-03-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,40,81.85664629715222,166.0171257364437,1.9429076964320713,29.69943354877405,114.2106577930346,0.9954393812339655,2022-06-24,Cancer diagnosis,pas de greffe,2022-12-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,94.09388107727672,171.07441992652696,2.114569572955604,32.150759001929934,86.65175062074643,1.3422751537502333,2022-01-25,Treatment follow-up,pas de greffe,2022-09-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,28,113.70837161912823,166.4445813477746,2.292871944253597,41.04432500917571,133.79560416057842,1.3220142043906287,2022-04-14,Symptoms management,pas de greffe,2022-08-08,Protocole 6 FlUDARABINE cy (Fanconi)
Male,66,111.15430082419854,185.47223687090235,2.3930476159355463,32.31234310638008,126.66501231009367,0.901921676775724,2022-12-07,Treatment follow-up,pas de greffe,2022-07-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,88.13016919633925,151.3684545418126,1.9249911622999392,38.46394723466141,114.90714591064099,0.8415349569784504,2022-05-09,Symptoms management,auto-greffe,2022-10-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,42,90.26645869528781,149.2937057332338,1.9347849523077494,40.49891688199759,78.64392186570213,1.5622654233930158,2022-04-16,Symptoms management,allo-greffe,2022-09-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,56.746666348599845,184.26935001533735,1.7042977800902268,16.712220058708205,96.98469099990184,0.5932360447731758,2022-07-17,Symptoms management,greffe haplo-identique,2022-02-08,Protocole 3 LAL thiotepa Bu Flu
Male,71,102.95873866962009,192.13348356931053,2.344131035663345,27.89055133720268,132.09869477515866,0.746932370474923,2022-07-19,Symptoms management,allo-greffe,2022-02-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,62.72969122862306,149.13988077717073,1.612063780016299,28.202367446336144,115.36830446546006,0.7023233248137316,2022-04-26,Symptoms management,greffe haplo-identique,2022-10-21,Protocole 6 FlUDARABINE cy (Fanconi)
Female,49,42.740742591083645,140.9080963404094,1.2934145888011415,21.526338644717274,80.21737048666719,0.6734146150142035,2022-10-22,Symptoms management,auto-greffe,2022-04-20,Protocole 6 FlUDARABINE cy (Fanconi)
Female,33,59.96180383656579,160.88918727436766,1.6370031805075098,23.164395620548817,114.28090760598889,0.7797444454240182,2022-06-18,Symptoms management,greffe haplo-identique,2022-04-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,56,58.67657363656324,180.3768812868954,1.714634505689522,18.03445399376725,85.45135074097495,0.8011108306935747,2022-07-04,Treatment follow-up,pas de greffe,2022-10-18,Protocole 3 LAL thiotepa Bu Flu
Female,60,99.31761262416711,180.71205573244185,2.232828919887626,30.41249277967376,78.96333678058208,1.397520766154834,2022-09-11,Symptoms management,greffe haplo-identique,2022-01-14,Protocole 3 LAL thiotepa Bu Flu
Male,51,78.39890731224106,148.23198007532997,1.796696448936504,35.68011043157006,107.58664457548906,0.9007601344015685,2022-03-29,Cancer diagnosis,pas de greffe,2022-04-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,80.22793964948772,191.9811394854844,2.0684301127291715,21.767497789052836,112.69955434252945,0.7711973822255518,2022-02-11,Cancer diagnosis,pas de greffe,2022-03-18,Protocole 3 LAL thiotepa Bu Flu
Female,69,66.61760968577127,161.96384886958413,1.73122022374708,25.395271971961666,128.75740390284955,0.5102026222613858,2022-09-12,Symptoms management,pas de greffe,2022-03-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,65,47.49528598372151,169.76609451336245,1.4965784318136826,16.479673059754,126.15752850479068,0.3921625353588352,2022-10-24,Treatment follow-up,pas de greffe,2022-07-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,84.39087475131295,159.76736484990028,1.9352653906717845,33.06125568454947,124.69724637261335,1.1091445158320385,2022-12-24,Symptoms management,allo-greffe,2022-08-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,29,87.26913153233065,169.93830089558423,2.0296666347263863,30.218862366085617,74.15974336317962,1.8141906243319377,2022-12-31,Cancer diagnosis,allo-greffe,2022-12-25,Protocole 3 LAL thiotepa Bu Flu
Female,27,109.1351512742994,161.18536624953595,2.21051711702931,42.00620369346551,89.74611555409811,1.9085122047182792,2022-11-08,Treatment follow-up,auto-greffe,2022-09-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,99.62447431965415,186.0686641979293,2.2691770937500033,28.775280327013032,134.5816071168857,0.9972856511074115,2022-03-17,Cancer diagnosis,auto-greffe,2022-02-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,106.2588516680393,181.93009252131353,2.317307028713797,32.103770156625664,103.94895487504812,0.9938264124315934,2022-05-04,Cancer diagnosis,auto-greffe,2022-09-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,68,72.1745960798394,182.692380513486,1.9138202610968387,21.624371436929483,99.56582032934165,0.724893300141573,2022-09-18,Symptoms management,pas de greffe,2022-01-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,76.14090676114655,169.12890828507898,1.8913273143739193,26.61842491098346,97.29527532446389,0.9564812674950549,2022-04-01,Symptoms management,pas de greffe,2022-01-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,95.11871140611241,156.65940225777163,2.0345106204093963,38.75725656441775,131.07021629129514,0.6954702169835745,2022-06-28,Treatment follow-up,auto-greffe,2022-10-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,64.11485863275743,143.11218401894038,1.5964907216036477,31.30440618524605,124.4502016557741,0.7584665866180405,2022-07-15,Cancer diagnosis,greffe haplo-identique,2022-02-10,Protocole 8 Aplasie medullaire thymo
Male,69,42.869605824938915,148.742761905811,1.3308877125411505,19.37661042149265,84.22463715339782,0.5019219561128193,2022-07-30,Treatment follow-up,greffe haplo-identique,2022-03-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,116.67783769074074,177.40813372258796,2.3978924445056,37.07159889290594,115.92219041077001,1.607633832143103,2022-05-30,Symptoms management,pas de greffe,2022-03-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,115.39747871906411,192.95135642321293,2.4869716103605843,30.995642864969813,106.56582018126389,1.5491130645629425,2022-12-10,Cancer diagnosis,greffe haplo-identique,2022-07-18,Protocole 3 LAL thiotepa Bu Flu
Female,51,48.29423176213665,142.56497743931533,1.3829383031970246,23.761265257783442,130.43093225244314,0.45769079046534256,2022-08-31,Symptoms management,auto-greffe,2022-03-16,Protocole 8 Aplasie medullaire thymo
Female,52,52.10151409581332,166.57557258331894,1.5526714919568616,18.7770652196982,108.78846313921174,0.585352770889312,2022-04-26,Cancer diagnosis,allo-greffe,2022-09-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,41,81.6150092147148,161.17769022395424,1.9115525011561265,31.41667204100449,128.6827491834651,0.8720721183088657,2022-08-10,Symptoms management,pas de greffe,2022-09-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,52.29691950870743,145.0968865951492,1.4518302815594306,24.84047639700449,122.12438515072188,0.5055453813605655,2022-11-15,Symptoms management,auto-greffe,2022-09-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,33,109.32832262640731,166.72657218826586,2.250181256562934,39.329918113280634,126.22417061647371,1.2871863940220611,2022-10-01,Symptoms management,pas de greffe,2022-03-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,116.33736942053376,146.5723077658989,2.176378025488267,54.152110564483465,94.37343740297297,2.0203144799287394,2022-03-04,Cancer diagnosis,allo-greffe,2022-12-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,80.1626847833609,172.87823987865252,1.962027285551483,26.822026642942966,134.773684847967,0.5287064747677764,2022-03-13,Symptoms management,auto-greffe,2022-05-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,20,79.05619674298563,184.23237020056132,2.0114057069761313,23.291852888559397,121.31219169120607,1.0861260197191491,2022-08-10,Symptoms management,pas de greffe,2022-02-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,48.47314180115853,185.27597621656082,1.5794609371812611,14.120918585193055,126.4176944477777,0.5432015234756172,2022-12-18,Symptoms management,greffe haplo-identique,2022-04-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,83.22343741726613,159.87037919825679,1.9224523182990874,32.561892603222006,122.76633630282691,1.0074363931947967,2022-10-18,Symptoms management,pas de greffe,2022-01-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,43,47.620338554326366,192.43819575615254,1.5954772912388349,12.859080817532952,110.26214535376151,0.5818422825376808,2022-10-26,Treatment follow-up,greffe haplo-identique,2022-05-15,Protocole 3 LAL thiotepa Bu Flu
Male,44,94.30996300203142,199.24716121793773,2.2846706790843267,23.755998517973243,105.31728116513402,1.1939789552568811,2022-08-31,Cancer diagnosis,auto-greffe,2022-07-15,Protocole 3 LAL thiotepa Bu Flu
Male,46,70.68240566258021,150.85352351261298,1.7210050313494223,31.059925176213977,96.87254284488941,0.9525899153960461,2022-11-21,Symptoms management,allo-greffe,2022-09-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,40.341266308233145,153.1378968638659,1.3099805638155217,17.20220701742111,115.55670671575714,0.3878929272502197,2022-05-31,Cancer diagnosis,allo-greffe,2022-12-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,53,84.42501069380981,156.23186356004436,1.9141198116287301,34.588513514154606,119.03084202666528,0.8570346378420178,2022-07-29,Treatment follow-up,pas de greffe,2022-12-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,74,60.77756790382506,164.28685688413927,1.6654124947810114,22.518407581498284,99.7903674749357,0.5582980801478624,2022-11-04,Symptoms management,auto-greffe,2022-06-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,34,49.553260610213016,150.72773851161887,1.4403945165256993,21.811516906444623,107.88627773304032,0.6762065851826367,2022-01-05,Symptoms management,auto-greffe,2022-09-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,56,64.15875661088648,152.1616185068649,1.6467560913050057,27.710585400302545,118.58756721872865,0.6311950271704323,2022-06-02,Cancer diagnosis,pas de greffe,2022-08-04,Protocole 6 FlUDARABINE cy (Fanconi)
Female,31,77.26304640911599,144.6995421682586,1.7622529331893435,36.90094718906998,130.33525603713622,0.8974368949498962,2022-06-19,Cancer diagnosis,auto-greffe,2022-03-26,Protocole 8 Aplasie medullaire thymo
Female,73,40.18493075678204,146.98481275623953,1.280904034364885,18.600229266745362,78.44195490051132,0.47671313919657415,2022-07-24,Symptoms management,pas de greffe,2022-10-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,88.97009878700484,165.32350252979072,2.021334017142662,32.55179018044919,76.81939227671593,1.8981158536132408,2022-01-10,Symptoms management,auto-greffe,2022-04-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,99.91683547450444,166.8865367455313,2.1521807180233297,35.875343360543475,120.12704095876303,1.3631617841008599,2022-11-20,Treatment follow-up,pas de greffe,2022-11-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,35,108.7595840891219,174.12227222910485,2.293557759627454,35.87227219608564,101.18724048484879,1.5674676573513748,2022-07-27,Symptoms management,greffe haplo-identique,2022-11-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,103.59908338928554,182.92705238680915,2.294381722235211,30.95993499581187,75.65865646891052,1.3312598422138868,2022-09-19,Treatment follow-up,greffe haplo-identique,2022-12-15,Protocole 3 LAL thiotepa Bu Flu
Female,31,65.6109992817795,189.24498025040606,1.8571597387834653,18.32010317018593,82.98482427092611,1.196938882190084,2022-04-09,Symptoms management,greffe haplo-identique,2022-03-30,Protocole 3 LAL thiotepa Bu Flu
Male,50,63.436480483037684,185.02171869177576,1.8056336719901689,18.530778212214695,79.94643195828309,0.9918591569561781,2022-07-27,Cancer diagnosis,pas de greffe,2022-11-26,Protocole 3 LAL thiotepa Bu Flu
Male,45,99.9356434619591,196.35887289318524,2.334716870298642,25.919066263856703,111.97780126108339,1.1775506223811611,2022-05-19,Cancer diagnosis,pas de greffe,2022-05-30,Protocole 3 LAL thiotepa Bu Flu
Female,50,78.32660329972444,153.0171637022435,1.8246243661637607,33.45253224553509,107.85825639660072,0.9077492757220322,2022-03-23,Cancer diagnosis,auto-greffe,2022-03-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,50,57.59974047477036,187.5963106409288,1.73249168724492,16.367107710379337,119.63704890759384,0.6018175494204525,2022-05-14,Symptoms management,auto-greffe,2022-11-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,83.01022159936211,177.60201565722792,2.0236643521235234,26.316964365805877,78.66842663431352,1.2164008215516358,2022-02-06,Symptoms management,auto-greffe,2022-01-01,Protocole 3 LAL thiotepa Bu Flu
Male,22,74.35953979060798,180.0003350431216,1.9282074343776865,22.950389806488158,88.76257708095936,1.3729549946996817,2022-10-03,Symptoms management,greffe haplo-identique,2022-06-29,Protocole 3 LAL thiotepa Bu Flu
Male,72,93.44736971448279,171.65962013971924,2.1108937014820697,31.712522429055518,104.33365931589763,0.8459000647870644,2022-12-12,Symptoms management,greffe haplo-identique,2022-02-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,118.27464651942903,191.38782325515857,2.5075622925477754,32.28962882240576,81.4228634838895,2.078021398660546,2022-05-28,Symptoms management,greffe haplo-identique,2022-11-01,Protocole 3 LAL thiotepa Bu Flu
Male,57,51.513777746722376,157.58584340900512,1.5016511387840612,20.74383259834208,95.65240945502626,0.620830552770613,2022-12-18,Cancer diagnosis,allo-greffe,2022-04-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,87.9268274767955,141.18639890897109,1.8569742518213697,44.109860157168505,79.57809345348612,0.9667984077447848,2022-08-11,Symptoms management,greffe haplo-identique,2022-03-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,37,115.2397083680353,162.555094918724,2.281130429570931,43.61149540228486,100.63509966429862,1.638164075719395,2022-10-24,Treatment follow-up,greffe haplo-identique,2022-04-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,79,65.11924739795002,167.60002141915808,1.7411671738852421,23.182551489784288,121.64436190081665,0.45353909238237783,2022-12-24,Symptoms management,auto-greffe,2022-12-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,52,45.03638874496852,154.5537857270825,1.3904979499776584,18.854033068056488,80.59269886967219,0.6829958036490706,2022-09-17,Symptoms management,allo-greffe,2022-05-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,47,75.75018001071541,168.47337603636512,1.8828088179460616,26.688312341819714,118.49086108597723,0.8257512994427894,2022-11-17,Treatment follow-up,auto-greffe,2022-09-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,73.86837394404678,158.31798470502514,1.802366661446576,29.47121448962693,134.95807447339647,0.8818305869088556,2022-09-03,Cancer diagnosis,greffe haplo-identique,2022-04-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,67,74.16234687661296,184.19583794207824,1.9479615860552504,21.85867531577351,89.15080080693133,0.84342909756875,2022-03-01,Symptoms management,allo-greffe,2022-11-22,Protocole 3 LAL thiotepa Bu Flu
Female,29,73.66267396095654,170.25432848719404,1.866472392404822,25.412720245074883,112.02378541657554,1.0137426493921888,2022-01-29,Treatment follow-up,greffe haplo-identique,2022-04-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,70.9904158007586,150.9523883994157,1.725315817997142,31.154425140243017,101.74356210298733,1.1628977521758799,2022-01-27,Treatment follow-up,allo-greffe,2022-12-11,Protocole 6 FlUDARABINE cy (Fanconi)
Male,26,44.559911298079825,153.6719688749285,1.3791713798578173,18.869265988457002,112.01341580512643,0.6298637746336581,2022-06-30,Cancer diagnosis,pas de greffe,2022-06-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,21,97.98476818356315,180.98451932876884,2.2194672891411367,29.914084224657206,119.7809897957213,1.3520262914064274,2022-11-03,Symptoms management,pas de greffe,2022-10-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,49.705389123291035,161.53991622652015,1.4934490649893304,19.047753905954128,115.00223165386942,0.46222713674673604,2022-03-14,Symptoms management,allo-greffe,2022-11-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,98.11258792841565,145.02421614739626,1.9880686578876672,46.64914386636796,122.64190307421154,1.2110995752820715,2022-06-27,Cancer diagnosis,allo-greffe,2022-09-07,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,42,118.65372245081369,143.00765259779814,2.171046235220957,58.01800774637724,117.21743543695773,1.3777890584319716,2022-12-01,Symptoms management,allo-greffe,2022-12-06,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,47,62.52976030318577,175.31915430565226,1.7450457408275766,20.343610385176813,104.42610915919222,0.7734426544146691,2022-11-06,Cancer diagnosis,greffe haplo-identique,2022-05-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,55.077414581174374,186.17455932750488,1.6877017071670468,15.890328538979636,85.80263980877362,0.8023851991023259,2022-01-06,Cancer diagnosis,pas de greffe,2022-05-29,Protocole 3 LAL thiotepa Bu Flu
Female,48,82.65250186571255,144.3249644345199,1.8203189122447332,39.68012994961998,91.13357119243176,1.1588652653448788,2022-02-16,Treatment follow-up,auto-greffe,2022-06-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,74,66.10576613970628,168.46545863763473,1.7588299623548544,23.292580527152943,94.69766919365826,0.6398990894993308,2022-06-22,Cancer diagnosis,allo-greffe,2022-09-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,54,94.12726473436366,165.838171340694,2.0823259869173185,34.225234945769095,98.42208795717937,1.1423227322877678,2022-01-02,Cancer diagnosis,auto-greffe,2022-01-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,84.02524378860215,192.12976442311253,2.1176343125905284,22.762527353507377,81.40363653619222,0.8745070465456801,2022-10-27,Symptoms management,allo-greffe,2022-12-28,Protocole 3 LAL thiotepa Bu Flu
Male,36,64.2700861303581,163.05806835072806,1.7061779978418878,24.172651762290926,120.55425051075937,0.7700646676632632,2022-12-14,Cancer diagnosis,pas de greffe,2022-01-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,80.3993647921596,160.47339516406254,1.8931131794856269,31.22098029913055,125.56144307072353,1.0316248903731033,2022-06-09,Cancer diagnosis,auto-greffe,2022-02-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,65,71.2138994637257,187.03453508020488,1.9234993124111635,20.35734600457026,95.71751309394352,0.7750007587630067,2022-01-19,Cancer diagnosis,greffe haplo-identique,2022-07-06,Protocole 3 LAL thiotepa Bu Flu
Male,64,49.97926959165465,173.83076720514742,1.5534848618393264,16.540042116626452,103.99906405951921,0.5072727928578995,2022-06-15,Treatment follow-up,greffe haplo-identique,2022-03-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,53.031051569034204,170.5456109853078,1.5850177961701866,18.23262268026716,92.49033100797698,0.9078336160752746,2022-03-27,Cancer diagnosis,greffe haplo-identique,2022-04-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,81.38380732674108,161.96223104908614,1.913483081096119,31.02490798491298,124.45392064232425,0.953643874018717,2022-07-26,Symptoms management,greffe haplo-identique,2022-02-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,56,106.01890258693267,159.68327508962776,2.1685533827934447,41.57808107258849,84.79934948858775,1.4586045816471829,2022-10-14,Symptoms management,auto-greffe,2022-09-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,99.00874629093019,157.60264038587752,2.08193552018482,39.86085252662461,115.41150670893055,0.8459609236443005,2022-01-01,Symptoms management,auto-greffe,2022-11-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,52,66.78976930502354,153.24677396332714,1.6861623652995867,28.439847396177694,122.51712597228833,0.6662900358939162,2022-11-26,Treatment follow-up,greffe haplo-identique,2022-10-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,63,87.89728379707718,173.1145980590336,2.0559063258905104,29.329730420332712,112.49957096486283,0.83556995846589,2022-05-12,Treatment follow-up,pas de greffe,2022-04-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,101.91136233627202,175.6665244462161,2.2299984319371613,33.02513407565081,125.90810211187264,1.1691487575723853,2022-10-04,Treatment follow-up,allo-greffe,2022-11-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,34,113.3272631209819,156.03483029398672,2.2162907117752444,46.54695704107714,86.84143025258989,1.9212363806658823,2022-10-10,Cancer diagnosis,pas de greffe,2022-06-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,71,115.89680129141078,199.77525534736816,2.5360354597905794,29.039428215268046,107.18901260769906,1.0361861276842381,2022-11-10,Treatment follow-up,greffe haplo-identique,2022-10-22,Protocole 3 LAL thiotepa Bu Flu
Female,45,48.66166376829325,173.10662457098852,1.5296746532203809,16.239011053487438,128.56153403442835,0.49942124912187025,2022-11-26,Cancer diagnosis,greffe haplo-identique,2022-02-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,79.50924315360845,198.34137097455863,2.0929758381200942,20.211148720311844,120.21709974245232,1.0012565602737389,2022-11-27,Cancer diagnosis,greffe haplo-identique,2022-10-27,Protocole 3 LAL thiotepa Bu Flu
Female,69,41.67174324955825,155.33752163115065,1.3409351337402164,17.269864297192985,117.15543706156471,0.35075597060138697,2022-12-08,Cancer diagnosis,allo-greffe,2022-08-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,75.08247630317376,147.67909557690993,1.7550017564194655,34.42710782726224,98.02018307626403,1.1277074439557238,2022-07-01,Cancer diagnosis,auto-greffe,2022-08-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,77,53.58162608397167,142.1010387069884,1.4543044081986638,26.535140066182294,83.69388029918451,0.5601834047588309,2022-08-17,Symptoms management,allo-greffe,2022-11-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,32,52.729794019747715,191.1099922271771,1.6730868448315854,14.437409841719763,78.8962336768364,1.0025154223913662,2022-09-11,Treatment follow-up,allo-greffe,2022-01-14,Protocole 3 LAL thiotepa Bu Flu
Female,44,107.01384243976774,187.30496612107174,2.3596270969904927,30.50291704768304,95.50109552640248,1.4940679210698327,2022-02-18,Symptoms management,pas de greffe,2022-02-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,117.62553528186648,172.75986252449843,2.375860739036708,39.41086012275462,118.8466800625775,1.580810829162901,2022-02-11,Symptoms management,auto-greffe,2022-10-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,72.84957395298687,167.56706428463852,1.8414358257808165,25.944762180386114,118.86228451593077,0.5703287299069324,2022-12-11,Treatment follow-up,greffe haplo-identique,2022-05-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,113.8448617946384,155.8974969881895,2.2203684002854676,46.84196975647273,97.81186783397843,1.1315856344797826,2022-12-26,Symptoms management,allo-greffe,2022-05-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,104.39695590930695,164.62778422016055,2.1849637379827893,38.519582340452985,120.7468316231143,1.3209071174945328,2022-07-24,Cancer diagnosis,greffe haplo-identique,2022-03-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,72,63.877273834662105,195.5874126537369,1.8629122002254521,16.69800434483623,89.23589145696424,0.6760568580020038,2022-07-21,Treatment follow-up,pas de greffe,2022-11-27,Protocole 3 LAL thiotepa Bu Flu
Male,41,48.70399836495616,148.10963865691363,1.415541867093518,22.202300245231253,92.56948489503478,0.7234349184048096,2022-11-01,Cancer diagnosis,allo-greffe,2022-05-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,21,43.252408775304716,180.90641696059998,1.4742830928638944,13.216070743706222,132.58675497376464,0.5391686377219918,2022-06-26,Symptoms management,pas de greffe,2022-08-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,56.714946359201086,160.8002963383178,1.5916256697487472,21.93430287919514,122.2278503659877,0.39311959380599054,2022-04-22,Cancer diagnosis,allo-greffe,2022-06-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,62.26815222480855,170.5949320438437,1.7177691603167342,21.39605610543997,81.45179686197994,0.8175673469240118,2022-01-21,Cancer diagnosis,pas de greffe,2022-07-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,52.63724205121015,192.57519319386768,1.6780136287027796,14.19359607246096,76.8779550722136,0.8083095924482865,2022-05-27,Cancer diagnosis,pas de greffe,2022-04-01,Protocole 2 LAM Endoxan TBI
Male,58,109.83773927483824,185.339334110906,2.3779807877836787,31.97542965306233,118.3106649304123,1.0573263273802485,2022-12-09,Cancer diagnosis,pas de greffe,2022-07-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,87.19285352586867,161.8573555240087,1.9799554352651296,33.28250530697101,109.06213829672019,0.8994135063602742,2022-10-21,Treatment follow-up,allo-greffe,2022-09-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,33,63.78356213791673,141.28908027003393,1.5821856218195287,31.951523702787867,106.7622089696306,0.8878559306164945,2022-11-15,Symptoms management,greffe haplo-identique,2022-02-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,60,69.21805197580855,144.37253657981728,1.6660987149676865,33.20857183246887,89.99013840687557,0.854637496967236,2022-02-19,Treatment follow-up,auto-greffe,2022-09-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,24,45.94373197821458,143.47034869387383,1.3531407136334024,22.32039942599629,121.70658191185825,0.6081877899555105,2022-08-04,Treatment follow-up,auto-greffe,2022-08-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,69,95.53731748169027,187.49892364629795,2.230666579240856,27.175371197217885,90.02846028338801,1.0464514221157708,2022-10-13,Treatment follow-up,pas de greffe,2022-02-07,Protocole 3 LAL thiotepa Bu Flu
Female,66,91.20384010991368,148.48721061525123,1.9395448933047592,41.365190301547024,116.58391088544934,0.8040327297397779,2022-08-08,Treatment follow-up,pas de greffe,2022-10-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,45,57.867135243572335,199.05447487011503,1.7887543942136583,14.60454705529153,131.73248969485266,0.5796024222263694,2022-02-05,Symptoms management,allo-greffe,2022-01-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,60.93150532131251,151.13539643043325,1.5993841880756983,26.675313278021434,78.5608523025569,0.6786467508119589,2022-01-06,Symptoms management,allo-greffe,2022-09-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,105.61636561610166,167.68031259035928,2.2179686152201423,37.56358803959881,77.6084308520839,1.3230853472353628,2022-05-24,Cancer diagnosis,pas de greffe,2022-03-04,Protocole 3 LAL thiotepa Bu Flu
Male,64,72.33318600948552,161.29037957367655,1.8002042343426905,27.804857051972434,108.56955418075376,0.7032514494462275,2022-07-21,Symptoms management,auto-greffe,2022-05-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,46,105.99804136465673,177.75890918519224,2.287775254158761,33.54556317025211,98.7798700345143,1.4009568116791622,2022-07-24,Treatment follow-up,pas de greffe,2022-07-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,109.97243843747496,152.76611694908564,2.1602509108071617,47.122657573011466,111.6491813614916,1.0123426523667747,2022-02-19,Treatment follow-up,allo-greffe,2022-09-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,28,42.05914251763291,187.10923970967835,1.4785178557629277,12.013510881135948,103.44927195740229,0.6324387940801284,2022-08-08,Treatment follow-up,allo-greffe,2022-06-19,Protocole 3 LAL thiotepa Bu Flu
Male,65,60.585254204385485,187.59939828729915,1.7768384246109232,17.214882084615354,104.9536041224178,0.6013098866297516,2022-06-26,Symptoms management,pas de greffe,2022-07-09,Protocole 3 LAL thiotepa Bu Flu
Male,38,72.75453596276091,187.11627185515255,1.9446191807926074,20.779589472255143,110.94084452278463,0.9290439998956084,2022-11-12,Treatment follow-up,greffe haplo-identique,2022-11-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,94.46686968896306,181.12673929467314,2.1801169743168898,28.794821243906227,78.07072109617295,1.0923761109669776,2022-05-09,Treatment follow-up,allo-greffe,2022-08-06,Protocole 3 LAL thiotepa Bu Flu
Male,52,43.973200233867175,172.55559910594346,1.4518017456251238,14.768281489294077,88.63197168173974,0.6063841465814148,2022-08-14,Treatment follow-up,auto-greffe,2022-02-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,88.21879200265101,184.50509732530014,2.126343810679204,25.914591586725916,102.75695783157197,1.0373770229547539,2022-11-17,Cancer diagnosis,pas de greffe,2022-05-23,Protocole 3 LAL thiotepa Bu Flu
Female,65,72.61559701889087,169.54614873231426,1.8493012803977456,25.261204461891044,128.18261484626228,0.5901053507560243,2022-03-14,Symptoms management,pas de greffe,2022-07-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,29,106.14394234664701,191.47793133274848,2.3760507911728053,28.95061275537071,77.09808053570494,2.1224727859292343,2022-12-10,Symptoms management,auto-greffe,2022-02-02,Protocole 3 LAL thiotepa Bu Flu
Male,57,88.37385729847801,153.91369557822773,1.943789752670432,37.3051919737604,118.65936968412629,0.8585535141589276,2022-02-19,Symptoms management,greffe haplo-identique,2022-10-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,70,108.34058416771911,141.61841908911867,2.0644492306278677,54.01964042172401,110.19806958622321,0.9558345612758529,2022-05-23,Treatment follow-up,allo-greffe,2022-05-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,27,71.4001794364007,182.39580255612236,1.9019794536039325,21.461971987419208,87.0685818297753,1.2870155065563993,2022-11-05,Cancer diagnosis,auto-greffe,2022-06-28,Protocole 3 LAL thiotepa Bu Flu
Male,76,95.2843560692778,142.65505793888386,1.9431357343602622,46.82170823522464,112.58600417182112,0.752288936959291,2022-01-02,Cancer diagnosis,auto-greffe,2022-02-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,43,100.76086171665497,178.72821228271306,2.236615044280295,31.543192779927924,128.6975497177001,1.054777440073269,2022-06-25,Cancer diagnosis,allo-greffe,2022-05-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,37,101.47393803169346,164.43350526012443,2.152886648916597,37.52959565001657,95.97381270542961,1.5125386988728724,2022-08-10,Treatment follow-up,auto-greffe,2022-05-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,112.29898599380314,167.45290697934067,2.2855094044079953,40.048887105270005,99.86577015992685,1.624276728409824,2022-11-19,Treatment follow-up,pas de greffe,2022-08-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,86.6128330301807,143.69664413558442,1.8593587190146341,41.945849335782874,121.3867683901332,0.9612804998058344,2022-12-14,Symptoms management,pas de greffe,2022-12-14,Protocole 8 Aplasie medullaire thymo
Male,37,94.17363619222446,197.59399133088738,2.273527890829369,24.12025371343271,124.55498848558273,1.0816155986979872,2022-05-07,Cancer diagnosis,allo-greffe,2022-03-01,Protocole 3 LAL thiotepa Bu Flu
Female,23,85.68020745125729,166.63150765336542,1.991441559360686,30.857892505863052,124.2012154656835,1.1210062364225581,2022-12-27,Cancer diagnosis,greffe haplo-identique,2022-10-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,66,81.34325097746186,144.8456975152975,1.8090989105992004,38.77129673298262,93.30497825881545,0.8960163464690268,2022-03-19,Cancer diagnosis,allo-greffe,2022-06-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,33,84.87990033504765,152.9623578244838,1.8990808951785716,36.27736396137073,110.3060666489112,1.1435541745805071,2022-09-30,Treatment follow-up,pas de greffe,2022-09-24,Protocole 6 FlUDARABINE cy (Fanconi)
Female,49,42.51784605631543,171.5854364409023,1.423556107868599,14.441436924547576,115.45823764534104,0.46543091516029006,2022-04-28,Treatment follow-up,greffe haplo-identique,2022-11-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,41.38737242157606,160.51674094725394,1.3584474530263548,16.063019557324917,129.77198604550796,0.3765072411314128,2022-01-18,Symptoms management,pas de greffe,2022-08-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,43,101.87313662256608,173.33914620265602,2.2147612439130953,33.90520479202212,114.37630838311475,1.1999491454618672,2022-11-04,Symptoms management,allo-greffe,2022-11-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,47,52.5707170920711,179.01519745312908,1.6168348108856334,16.40454152916638,121.76009174384774,0.5576855432520883,2022-02-06,Cancer diagnosis,pas de greffe,2022-07-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,58.74560465962606,150.90835557007722,1.5692534137956986,25.795788347924862,84.39312884567745,0.957130130282201,2022-06-13,Cancer diagnosis,greffe haplo-identique,2022-02-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,77,92.51823086897727,144.76962931797365,1.9288619261149065,44.14407234008596,111.94013210582567,0.7231852463227714,2022-08-14,Cancer diagnosis,pas de greffe,2022-01-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,57,100.70583957965601,183.94054180858313,2.2683747666782996,29.764578149487413,117.94358939111228,0.98429642983741,2022-02-11,Symptoms management,pas de greffe,2022-07-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,47.088283639988134,155.98049916640733,1.4283687264240672,19.35406739889655,88.6066161302159,0.509287836422259,2022-04-02,Treatment follow-up,auto-greffe,2022-01-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,69,109.1940568100279,158.25147818250608,2.190897894251696,43.60170283393543,103.70142670165146,1.0383412852887166,2022-01-14,Cancer diagnosis,pas de greffe,2022-01-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,60.05857424627536,166.08043167034106,1.664544810678703,21.773993460763734,110.28948509918774,0.5445539453943619,2022-01-09,Treatment follow-up,auto-greffe,2022-12-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,116.11915357076968,173.6277022158381,2.3665200551853895,38.51818598067719,119.48109508489514,1.174333427378768,2022-03-10,Symptoms management,greffe haplo-identique,2022-11-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,75.8194810319099,166.3221464517518,1.8716049877107213,27.408208237987182,122.38026380974799,0.9465195991346526,2022-01-05,Cancer diagnosis,allo-greffe,2022-07-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,113.2683147650574,168.8285040522106,2.3047607816514857,39.738996353970705,108.62474507101953,1.2020575615816373,2022-01-31,Symptoms management,greffe haplo-identique,2022-05-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,32,62.96606035061933,190.7616542329798,1.8266172311602686,17.303117684098062,132.55039658547062,0.712552304323184,2022-08-29,Treatment follow-up,greffe haplo-identique,2022-08-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,56.36376803515595,171.37627946780773,1.6380385342309371,19.191043883839093,88.98921114390066,0.7301435581632596,2022-07-22,Symptoms management,pas de greffe,2022-01-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,96.01311887955916,196.07370850381378,2.286776496617303,24.974215295478334,90.44842813717186,1.4595946129564412,2022-11-29,Cancer diagnosis,greffe haplo-identique,2022-08-03,Protocole 3 LAL thiotepa Bu Flu
Female,41,56.60145387368672,156.26005605201303,1.5674241391290251,23.18097161472516,130.1984828696264,0.5977565741242232,2022-06-27,Treatment follow-up,pas de greffe,2022-12-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,48,110.92070766266791,181.61508084973846,2.365543940857862,33.62860212401013,98.04890669221729,1.4455236690364077,2022-09-07,Cancer diagnosis,pas de greffe,2022-12-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,110.89159433111082,149.08722360190728,2.1429807848735627,49.89049045176049,107.32879235312673,0.9757954776666563,2022-10-11,Cancer diagnosis,allo-greffe,2022-07-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,72,60.996347238242514,145.4627777237589,1.569916673326405,28.827041617437377,106.82163295928493,0.5392883415526848,2022-01-27,Symptoms management,pas de greffe,2022-11-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,56,119.71879280618462,168.06831936689792,2.3641381036677407,42.38289462403455,102.54592028660119,1.3620427272990059,2022-01-07,Treatment follow-up,auto-greffe,2022-05-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,28,105.96965459994598,165.96254084208996,2.210266017773382,38.473470933487384,108.84804346552093,1.5144202843247716,2022-11-15,Treatment follow-up,auto-greffe,2022-05-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,64.83352902650694,153.9376140449585,1.665025756261833,27.359626225163836,104.53649515582009,0.6891110551058676,2022-02-05,Cancer diagnosis,greffe haplo-identique,2022-06-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,33,84.14185731480711,171.47366060781835,2.0019512900688996,28.616548784023674,112.22719437118042,1.1142054273538133,2022-02-10,Symptoms management,auto-greffe,2022-11-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,30,100.53014001632877,162.20870139280242,2.128305498570615,38.20744464219983,113.40567515464375,1.3543212339629238,2022-08-06,Cancer diagnosis,allo-greffe,2022-07-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,69.28584899709787,171.8234235853473,1.8184953930759749,23.46820140844421,107.80865021906018,1.0621978042038822,2022-12-25,Treatment follow-up,auto-greffe,2022-11-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,50.11218081204501,149.34292309302268,1.4418255755423481,22.468496282592593,109.81570648204892,0.608439750771433,2022-01-19,Symptoms management,pas de greffe,2022-02-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,59,94.18297010792321,178.74256498472278,2.1624642357331387,29.479248654022864,82.62798640390965,1.2823238951203606,2022-05-25,Symptoms management,auto-greffe,2022-09-04,Protocole 3 LAL thiotepa Bu Flu
Female,53,45.85884741506506,146.76620871242508,1.3673300393092427,21.289770705760457,74.92803004018546,0.7395466547052051,2022-10-18,Symptoms management,auto-greffe,2022-01-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,44,60.78675656597872,152.85111948580374,1.6065252177552574,26.01786904189925,132.8109297510847,0.6102585751529712,2022-02-17,Symptoms management,greffe haplo-identique,2022-06-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,72,116.15095118447385,199.4919737513379,2.537013911016365,29.185821113560262,107.3052255391932,1.0222998927768618,2022-11-23,Cancer diagnosis,allo-greffe,2022-09-24,Protocole 3 LAL thiotepa Bu Flu
Male,27,110.43164498651433,152.47778619887464,2.162712594164236,47.49855368219464,85.63492971619844,2.023897634870857,2022-03-14,Symptoms management,greffe haplo-identique,2022-09-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,58,63.75584367432385,172.74915037642916,1.7491083304764714,21.3642748709224,96.68263678665608,0.751022359088638,2022-07-10,Symptoms management,pas de greffe,2022-07-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,50,109.32534048403092,185.1145115951485,2.370988249694084,31.90361586361137,106.63169628309595,1.2815764952498696,2022-06-29,Treatment follow-up,greffe haplo-identique,2022-05-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,117.2721161699464,178.77670821042943,2.413246021310422,36.692127100198704,76.35872919893751,1.5997968487065124,2022-03-14,Cancer diagnosis,pas de greffe,2022-06-15,Protocole 3 LAL thiotepa Bu Flu
Male,56,86.53009135513496,146.461744935681,1.8762661035889687,40.338407995297686,124.1720478415147,0.8129991813979413,2022-06-27,Symptoms management,greffe haplo-identique,2022-09-06,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,58,57.41639825934931,166.81599640738557,1.6311187099789852,20.632913518218235,129.7179002222295,0.5041008057142938,2022-02-28,Treatment follow-up,allo-greffe,2022-10-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,40,72.5606304332502,141.50265960839587,1.6888130438242066,36.23863593611691,74.554837570246,1.3517386217166651,2022-08-13,Cancer diagnosis,allo-greffe,2022-09-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,75,71.89958663617584,143.33589895086934,1.6919574368080446,34.995841792555495,129.6385298996591,0.5006948867500103,2022-01-22,Symptoms management,greffe haplo-identique,2022-02-06,Protocole 8 Aplasie medullaire thymo
Male,64,112.79764059402811,164.51611409858668,2.2704031402923985,41.67572175711188,111.7537886920251,1.0654151199357218,2022-08-22,Cancer diagnosis,greffe haplo-identique,2022-07-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,32,67.97730348732935,168.39555664474696,1.783183471893092,23.971912145577708,122.88622596389253,0.8297590265401634,2022-07-08,Cancer diagnosis,greffe haplo-identique,2022-04-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,64,80.08650656431722,179.26312048881252,1.9969808514471201,24.921687484624535,116.29282065693224,0.7269215455559794,2022-03-07,Treatment follow-up,auto-greffe,2022-05-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,77.18097816155506,184.70422295424444,1.9899506274011016,22.62333510083842,132.41359101018628,0.8500305164566464,2022-11-24,Symptoms management,greffe haplo-identique,2022-02-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,52.07435571345804,172.4861042530001,1.579565934442059,17.503128395715642,124.95129038248469,0.590406099061303,2022-04-27,Treatment follow-up,allo-greffe,2022-10-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,34,48.692492256894646,158.872372865256,1.465898642241903,19.291466349084825,86.65300940342856,0.8272784713365929,2022-02-18,Cancer diagnosis,greffe haplo-identique,2022-08-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,97.7687831368155,143.83460199715708,1.976425927599153,47.257795424146245,119.39785929064385,0.8529674069471639,2022-08-10,Treatment follow-up,allo-greffe,2022-06-23,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,37,50.341960610679976,142.6236491703219,1.4122434996884081,24.74839490079391,84.72540126012223,0.8500044893037701,2022-04-17,Cancer diagnosis,greffe haplo-identique,2022-04-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,66,114.28621359640421,191.49705978379077,2.4656233084789974,31.16517887203722,101.74772366749761,1.1544320246868636,2022-12-27,Symptoms management,auto-greffe,2022-04-02,Protocole 3 LAL thiotepa Bu Flu
Male,70,41.049731775462355,181.74219388047612,1.4395667086428028,12.427929791611959,105.70401927936129,0.3775585991947092,2022-10-07,Cancer diagnosis,allo-greffe,2022-05-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,45.50466718807822,195.40110599937148,1.5715935204509073,11.917959554697818,88.47247881626214,0.4857626992833204,2022-12-22,Cancer diagnosis,allo-greffe,2022-11-07,Protocole 2 LAM Endoxan TBI
Male,27,48.07625862018111,147.6895672372188,1.4043940795073588,22.04098641618226,102.12512475985417,0.7388291292524176,2022-02-15,Symptoms management,allo-greffe,2022-07-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,36,67.0422364039221,156.79850124998316,1.7088106803484087,27.268715366501123,95.08776062568123,1.0184148336186838,2022-07-29,Treatment follow-up,greffe haplo-identique,2022-12-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,112.3606447502652,160.7810886944489,2.2401306254917523,43.46546123152155,78.5944184676615,1.7274650675408212,2022-12-02,Symptoms management,pas de greffe,2022-12-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,31,51.014738831961495,178.49133221160582,1.590395539248714,16.0125834321828,81.80395314248248,0.9440943049874149,2022-06-14,Treatment follow-up,greffe haplo-identique,2022-09-19,Protocole 3 LAL thiotepa Bu Flu
Male,55,42.70334439605343,184.2272504981424,1.4782797552448308,12.582129417498919,122.65215764256804,0.4110296258666578,2022-08-05,Treatment follow-up,auto-greffe,2022-11-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,81.89582503046583,186.27728466956512,2.0585412791349347,23.601628226639395,94.50153070091788,1.155477933151551,2022-11-25,Symptoms management,pas de greffe,2022-03-02,Protocole 3 LAL thiotepa Bu Flu
Male,20,93.44820188331536,189.43395159543417,2.2174974728937324,26.040859337274345,89.94014457352623,1.7316739246681496,2022-06-08,Symptoms management,allo-greffe,2022-02-26,Protocole 3 LAL thiotepa Bu Flu
Male,41,90.98255332764825,179.8628156522945,2.1320554907794347,28.123887054132236,88.17682200666906,1.418751639927039,2022-04-22,Cancer diagnosis,greffe haplo-identique,2022-03-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,113.72632510410077,193.43601206595736,2.471996875843822,30.393894080566174,124.1114968796941,1.4890262621947294,2022-06-05,Treatment follow-up,auto-greffe,2022-02-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,76.69719856803246,172.48715521095605,1.9169769019684304,25.778994994721682,87.08340275438108,0.8073382887015488,2022-09-21,Cancer diagnosis,greffe haplo-identique,2022-11-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,83.2652523313814,194.5204871961866,2.1211106531205743,22.005594466527114,78.57773569702088,0.8977628521403367,2022-07-19,Treatment follow-up,auto-greffe,2022-11-17,Protocole 3 LAL thiotepa Bu Flu
Male,50,118.26645000470756,144.6437500929152,2.179863836143669,56.527817096624766,109.91904689402224,1.3449267136424206,2022-01-13,Cancer diagnosis,greffe haplo-identique,2022-09-10,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,33,83.10898263364308,155.52622708455337,1.8948487557532114,34.35901403698951,121.78087470306258,1.0141919478419652,2022-08-28,Treatment follow-up,auto-greffe,2022-12-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,75,113.89973387333426,192.60212641545598,2.46854269549638,30.704395682041163,81.01487649112639,1.2692255186849737,2022-07-02,Cancer diagnosis,allo-greffe,2022-06-02,Protocole 3 LAL thiotepa Bu Flu
Female,54,67.71596168074277,171.87570766250983,1.7980490070200672,22.922503724544693,91.90378408350631,0.880082958894093,2022-09-19,Symptoms management,pas de greffe,2022-01-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,110.9437150365877,162.0980230095134,2.235058840436104,42.22282315241894,83.15260089400275,1.5380571131060403,2022-02-21,Treatment follow-up,greffe haplo-identique,2022-08-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,66.27151101485138,160.6450204141184,1.7196727918621346,25.679841367343638,83.78913934936963,0.9117688257798133,2022-12-25,Symptoms management,auto-greffe,2022-05-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,82.85154549625231,162.27145467903478,1.9325027533459684,31.464175461160995,104.76335799255745,0.8457644613768281,2022-02-06,Treatment follow-up,greffe haplo-identique,2022-10-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,46,104.65737806198125,158.22052880184748,2.14469278426626,41.806536256765426,81.86129186052875,1.6691163583332091,2022-05-24,Cancer diagnosis,greffe haplo-identique,2022-06-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,101.42961285361883,148.82713409817265,2.047727642594975,45.79315122215866,130.00827093875776,1.3002969236908357,2022-08-16,Treatment follow-up,auto-greffe,2022-08-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,74,57.31684409828716,169.3115958988632,1.6418490885251686,19.994422423413305,77.23736164792072,0.6802464416499696,2022-05-03,Cancer diagnosis,auto-greffe,2022-07-13,Protocole 3 LAL thiotepa Bu Flu
Male,38,63.25004289615979,194.16552909603172,1.8469929047177354,16.777087256599863,100.45241672298134,0.8920066869404335,2022-01-29,Symptoms management,greffe haplo-identique,2022-08-19,Protocole 3 LAL thiotepa Bu Flu
Female,65,75.25077754523043,198.42464668001566,2.036582714227766,19.11259954613916,127.68642655647989,0.6138963139902912,2022-01-31,Treatment follow-up,pas de greffe,2022-05-22,Protocole 3 LAL thiotepa Bu Flu
Male,47,109.65530248034474,142.7717850630075,2.0853778818732946,53.79536496142372,128.94234516801845,1.0984607023592623,2022-06-20,Treatment follow-up,greffe haplo-identique,2022-09-11,Protocole 8 Aplasie medullaire thymo
Male,23,95.76847834610535,194.5561859671692,2.2750060978488293,25.30069779887259,121.1608291329332,1.2844396858796379,2022-06-05,Cancer diagnosis,pas de greffe,2022-05-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,108.61120403406997,148.33827780437906,2.11549829674253,49.359205781685965,117.80554237753483,1.1012219514016348,2022-01-31,Symptoms management,allo-greffe,2022-10-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,94.23133582731506,163.4875167040329,2.068658119148706,35.25544115523349,126.80058404253236,0.8050747393404454,2022-11-08,Treatment follow-up,greffe haplo-identique,2022-12-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,35,101.63891273162024,192.91933550809884,2.3338161111239284,27.309169680164004,77.96656764089207,1.9011150405258956,2022-03-17,Cancer diagnosis,auto-greffe,2022-08-25,Protocole 3 LAL thiotepa Bu Flu
Male,61,101.34711969849967,146.3545843811321,2.0298204341557713,47.314989605255896,111.06782936996538,1.0011928073340002,2022-12-07,Cancer diagnosis,pas de greffe,2022-02-07,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,28,67.81746247990145,172.11886484288232,1.8006684452173587,22.8920449213653,94.75190833051727,1.113368927159794,2022-07-23,Cancer diagnosis,greffe haplo-identique,2022-07-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,41.31743214352615,191.38230705095265,1.4820617663175646,11.280536404142147,79.03658943232766,0.8640116453928083,2022-11-17,Cancer diagnosis,greffe haplo-identique,2022-03-07,Protocole 2 LAM Endoxan TBI
Male,26,43.9248944845407,149.18132497968585,1.3491534340298854,19.737030249406164,99.61754559247285,0.6981475922428051,2022-02-15,Treatment follow-up,auto-greffe,2022-06-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,31,54.67963683362168,185.77775883729902,1.6798032610487175,15.843027741708411,90.91216498822908,0.9105370514673955,2022-05-10,Treatment follow-up,pas de greffe,2022-07-01,Protocole 3 LAL thiotepa Bu Flu
Female,43,48.4191873894451,185.82305039239748,1.580910523350722,14.022270040708175,98.9763874937264,0.6590602757363426,2022-04-08,Treatment follow-up,auto-greffe,2022-05-06,Protocole 3 LAL thiotepa Bu Flu
Male,35,69.75872935092374,171.63831502976586,1.8237073629476446,23.67936634201151,128.71451251380944,0.7903652689708626,2022-04-26,Treatment follow-up,auto-greffe,2022-04-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,47,85.57421941055381,167.24422379255086,1.9938651674832975,30.594312037783876,123.75414803582609,0.8931689845792744,2022-06-23,Symptoms management,allo-greffe,2022-10-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,71,118.87891629378517,158.4750379730389,2.287607967934781,47.335079228664306,113.42524367553347,1.0044115791434876,2022-11-12,Cancer diagnosis,pas de greffe,2022-10-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,74.32155402075267,192.85371827378975,1.9953548863400827,19.982910751768287,111.3658471703636,0.9825080686725961,2022-10-14,Treatment follow-up,auto-greffe,2022-01-14,Protocole 3 LAL thiotepa Bu Flu
Female,58,105.64190019989299,199.7295801218874,2.4209624102251244,26.482039334720934,129.04680671378992,0.9323313718688881,2022-05-04,Cancer diagnosis,pas de greffe,2022-02-11,Protocole 3 LAL thiotepa Bu Flu
Male,60,108.76344701180557,196.54130025702293,2.4367846127482604,28.1562824606831,112.15458419807726,1.0775152466717763,2022-07-21,Treatment follow-up,auto-greffe,2022-04-01,Protocole 3 LAL thiotepa Bu Flu
Male,73,98.80476966027847,199.15940822070962,2.3379656075151094,24.910145011938244,126.58725319972237,0.7263237411249933,2022-04-25,Treatment follow-up,greffe haplo-identique,2022-07-10,Protocole 3 LAL thiotepa Bu Flu
Male,59,48.68083791230373,160.42963432239554,1.4728891699252091,18.914238355958467,82.3867347192568,0.6647422408226709,2022-02-18,Cancer diagnosis,pas de greffe,2022-03-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,53.003923007644225,148.66519987079232,1.4794742692242173,23.98221965016073,117.66562439037065,0.46297509986067914,2022-10-29,Cancer diagnosis,auto-greffe,2022-03-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,33,40.15267041137471,173.05605046100763,1.3893106360964966,13.407285520526225,97.46183307642416,0.6122533073263188,2022-10-21,Treatment follow-up,auto-greffe,2022-03-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,80.78596389632564,159.74757762646732,1.893362825376031,31.656824489531626,114.20826962939603,1.0315615882963267,2022-08-24,Treatment follow-up,auto-greffe,2022-06-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,63,115.01075830264708,169.5010676335658,2.327041894387514,40.03073745424948,96.40531664285987,1.275838520128115,2022-06-19,Cancer diagnosis,auto-greffe,2022-01-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,42.03627588963195,177.52991459495496,1.4397816644447177,13.33770616221007,114.44120318286718,0.37241930239637955,2022-06-06,Treatment follow-up,allo-greffe,2022-12-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,112.14778802554407,176.75297795492477,2.346537372418996,35.89692378271962,86.2424373571657,1.2281349948263938,2022-06-01,Cancer diagnosis,allo-greffe,2022-01-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,41.63677982100586,160.7925849519633,1.3637046617878892,16.10442041986109,128.07833611243845,0.4379663004630904,2022-01-30,Treatment follow-up,allo-greffe,2022-03-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,41,71.94733826464652,152.16326698253667,1.7438576363471276,31.073851316685413,116.41673502822627,0.84977121278915,2022-02-21,Symptoms management,allo-greffe,2022-09-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,69,44.04525866692599,144.01745722843918,1.3274124951468922,21.235812755037074,102.07594121491415,0.4255020178728725,2022-03-26,Cancer diagnosis,auto-greffe,2022-05-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,60,70.3417954088688,186.4863055886895,1.908881402686123,20.226445019758984,99.83659693258724,0.7828547131576717,2022-08-20,Cancer diagnosis,auto-greffe,2022-12-21,Protocole 3 LAL thiotepa Bu Flu
Female,52,44.336205636254455,173.79602129774034,1.4630121267648348,14.678404880505983,128.06066571533344,0.42314863408644615,2022-02-21,Symptoms management,allo-greffe,2022-08-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,71,109.35492525239155,140.87186244476757,2.068616821011133,55.1048513660443,80.08285941267874,1.3086254761896048,2022-07-11,Treatment follow-up,greffe haplo-identique,2022-07-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,77,77.84185331070816,171.9219844099852,1.928062203016853,26.336031721774784,131.15406778799385,0.5193252698572017,2022-08-08,Cancer diagnosis,auto-greffe,2022-02-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,56,74.42684597140975,190.82701276098032,1.9862480463556385,20.438541979463842,132.60879131188835,0.6547930905708634,2022-09-03,Treatment follow-up,auto-greffe,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,70.79076351657218,156.81816772742366,1.7560433608521269,28.78616735922362,131.17698981031822,0.7345350348851074,2022-01-10,Treatment follow-up,allo-greffe,2022-02-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,25,109.54394978315206,189.5947729247268,2.4019066664963384,30.47443598198212,129.24211826985325,1.3537849212462023,2022-02-24,Symptoms management,allo-greffe,2022-11-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,76,85.42491863303451,159.8757401850437,1.9477459976358658,33.420999773928294,118.77528079652835,0.6393018858631165,2022-03-22,Cancer diagnosis,auto-greffe,2022-06-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,77,85.42175677763876,197.72658769036153,2.1660353235397185,21.8493416619636,106.26983263793599,0.7033420052056424,2022-07-16,Treatment follow-up,allo-greffe,2022-11-16,Protocole 3 LAL thiotepa Bu Flu
Male,45,67.64725419540886,164.6172365258259,1.758779883597361,24.96315996252008,90.08541259017717,0.9908018530825471,2022-11-27,Symptoms management,allo-greffe,2022-05-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,90.78814652574891,145.37325576724103,1.9147213639414318,42.95958882236584,95.47378789573283,1.0565802466338705,2022-08-30,Cancer diagnosis,allo-greffe,2022-02-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,61,94.76090477730467,191.58865177265614,2.245681905039638,25.816040646994708,104.77378414989633,0.992364372091313,2022-03-31,Treatment follow-up,allo-greffe,2022-05-31,Protocole 3 LAL thiotepa Bu Flu
Female,32,41.45517462493367,178.55455199597804,1.4339155923040925,13.002800404950804,93.37851865126773,0.6659214863926982,2022-12-06,Cancer diagnosis,allo-greffe,2022-11-21,Protocole 3 LAL thiotepa Bu Flu
Male,45,90.97382000112015,171.8679239611681,2.084031988078872,30.798301705286786,124.37739949151685,0.9650861159752245,2022-02-06,Symptoms management,allo-greffe,2022-01-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,52,61.447653636673955,174.76866515452684,1.7271624451490124,20.11769250293454,83.38467733005643,0.9006773208569568,2022-06-04,Cancer diagnosis,greffe haplo-identique,2022-06-14,Protocole 3 LAL thiotepa Bu Flu
Female,67,40.468490716628985,165.9869975870707,1.3659798346215202,14.6882098549648,89.30433372762054,0.4594463826675761,2022-03-02,Cancer diagnosis,greffe haplo-identique,2022-02-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,79.32815481079338,180.5520784337729,1.9946360869289224,24.33449669402536,97.16528862394905,1.0091918109261382,2022-08-23,Symptoms management,allo-greffe,2022-05-31,Protocole 3 LAL thiotepa Bu Flu
Female,37,67.34825702519545,196.96112101969422,1.9195621753703365,17.360624586625214,124.8519514686439,0.771677351543629,2022-09-28,Cancer diagnosis,greffe haplo-identique,2022-11-17,Protocole 3 LAL thiotepa Bu Flu
Female,62,53.46141077926161,160.74102756647994,1.5450136734213533,20.691259832612367,86.81708020870579,0.6671098383517438,2022-05-25,Symptoms management,allo-greffe,2022-03-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,46.51867477414466,155.43772817506178,1.4172309782545447,19.253711223055028,117.67380870576682,0.3953188503523378,2022-10-04,Treatment follow-up,auto-greffe,2022-10-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,65,52.97321066191852,178.81244001852738,1.6220930455290303,16.56764716673516,113.16069410134551,0.4876289263780301,2022-04-17,Treatment follow-up,allo-greffe,2022-11-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,116.74236606873873,141.4185172975546,2.1414904152669894,58.37352663036428,101.9988211830798,1.001477949699007,2022-11-13,Treatment follow-up,greffe haplo-identique,2022-12-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,51,68.31866139886239,156.17541286557986,1.7215702740352974,28.01005895873068,133.823946528532,0.6310489164461047,2022-05-12,Treatment follow-up,allo-greffe,2022-03-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,24,114.00485757973777,171.0320568704676,2.3272829463828075,38.97340216861002,126.62649668471131,1.4505217910646966,2022-10-17,Treatment follow-up,greffe haplo-identique,2022-07-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,43,48.834946940938366,184.0932222683,1.5802762365466716,14.40970604222979,92.46467930169625,0.7115314327237207,2022-02-06,Symptoms management,allo-greffe,2022-01-24,Protocole 3 LAL thiotepa Bu Flu
Female,31,95.24380986614614,158.06810762720465,2.044980901075376,38.11959267648531,107.74622919313437,1.338223588626453,2022-07-23,Symptoms management,greffe haplo-identique,2022-06-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,58,47.84296873175534,188.33040459629737,1.5820420750778168,13.488921946838662,119.44582762153387,0.45617186121142966,2022-10-15,Treatment follow-up,greffe haplo-identique,2022-03-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,83.73587348393883,190.5819727481345,2.1054524426907806,23.054086525311376,92.20546674578222,0.7820131885934231,2022-10-22,Treatment follow-up,auto-greffe,2022-10-16,Protocole 3 LAL thiotepa Bu Flu
Female,36,73.18998701025271,168.51382916585032,1.8509400740416964,25.773925899654298,104.01299321701646,1.0164006135785837,2022-06-14,Cancer diagnosis,allo-greffe,2022-06-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,91.85897300998874,191.72595202158902,2.2118210855452687,24.989627342492575,116.41465660849218,0.7452300187889522,2022-04-09,Symptoms management,auto-greffe,2022-10-14,Protocole 3 LAL thiotepa Bu Flu
Male,74,81.71626672916291,146.2529222945296,1.8220289978284068,38.203170989704866,101.98646919109872,0.7344756459281735,2022-10-19,Cancer diagnosis,allo-greffe,2022-03-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,76,47.89222803075725,152.80911145140925,1.425791087510553,20.510041580878323,79.74770152655913,0.5338193897224152,2022-04-20,Symptoms management,auto-greffe,2022-03-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,68.22906152450506,141.4785169730455,1.637490155945784,34.08697014324863,122.81535351187733,0.5323942169385246,2022-08-15,Treatment follow-up,pas de greffe,2022-09-27,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,24,97.37164643320234,147.42862080751132,1.996898118151948,44.799060670377166,105.71957153288221,1.4838930881111374,2022-12-17,Symptoms management,auto-greffe,2022-02-13,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,66,40.131517757195624,143.37559119112734,1.2642389106840293,19.52248696548419,86.29703356500941,0.4779571259337464,2022-01-16,Cancer diagnosis,pas de greffe,2022-12-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,48.138223829543875,180.75144496513525,1.5546572965738534,14.734198157259245,122.82613994697074,0.609655905045566,2022-09-12,Cancer diagnosis,allo-greffe,2022-04-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,112.29761747647275,158.97714755187044,2.2269033621252277,44.43254010195932,93.04152642029337,1.7098633002468044,2022-03-24,Cancer diagnosis,allo-greffe,2022-04-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,65,55.253389570695305,182.28033066903964,1.6726231993763905,16.629504534012643,118.88770733604619,0.48411745356864455,2022-01-05,Treatment follow-up,pas de greffe,2022-05-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,111.72197546617026,195.5412983542069,2.463413402924655,29.218748974846847,91.10976451186889,1.481700537202423,2022-01-19,Symptoms management,auto-greffe,2022-07-08,Protocole 3 LAL thiotepa Bu Flu
Female,75,81.54683936797484,177.33518569631818,2.0042402205676377,25.930882962856053,119.4456703254265,0.6163360649979998,2022-06-07,Treatment follow-up,allo-greffe,2022-06-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,45.01524596194266,161.71549649902184,1.4220156713819554,17.212991350518575,94.32770769076184,0.6097835128140664,2022-08-08,Cancer diagnosis,greffe haplo-identique,2022-01-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,75.55459062309146,189.5341016311935,1.9944486468598726,21.032269333234584,115.28682031904113,0.9466338682581724,2022-02-15,Treatment follow-up,allo-greffe,2022-10-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,50,107.73471943573193,186.10884425611832,2.359989649249973,31.104387999281418,94.97247489300528,1.4179729384369582,2022-11-25,Cancer diagnosis,allo-greffe,2022-10-21,Protocole 3 LAL thiotepa Bu Flu
Male,40,118.87445568923647,187.5592138710299,2.4886408304322223,33.79183172185927,100.1563826298798,1.6484562076250502,2022-10-21,Treatment follow-up,auto-greffe,2022-02-09,Protocole 3 LAL thiotepa Bu Flu
Male,26,90.94713669237143,168.31548920419942,2.0620790347565956,32.10264847385633,103.461576351039,1.391817505347807,2022-08-25,Symptoms management,auto-greffe,2022-02-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,67.54098103676998,178.6000453496115,1.8305146723230878,21.17406465402483,76.13674682182469,1.4661807498568455,2022-01-19,Treatment follow-up,allo-greffe,2022-02-25,Protocole 3 LAL thiotepa Bu Flu
Female,24,43.35047204111723,169.32828353111546,1.4279415080016011,15.119409119865347,97.13470106357535,0.7190265313283167,2022-08-28,Cancer diagnosis,greffe haplo-identique,2022-04-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,34,55.533280003094575,157.89164863746595,1.5606481144716966,22.275887008800634,116.61423226635769,0.7010922020796184,2022-02-07,Cancer diagnosis,greffe haplo-identique,2022-07-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,48.87961824674947,181.79210267745486,1.5710867239613933,14.79032712459757,90.24975034793414,0.5792152995329377,2022-08-04,Symptoms management,pas de greffe,2022-07-30,Protocole 3 LAL thiotepa Bu Flu
Female,32,87.62949392591048,151.09031676926128,1.9177509973053122,38.38636956301838,120.7978694069534,1.0881337687012178,2022-03-11,Symptoms management,greffe haplo-identique,2022-07-19,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,30,118.84159088903759,165.14346014858725,2.3348751768312828,43.57583293150004,119.60747187093048,1.5179949780391355,2022-06-01,Cancer diagnosis,allo-greffe,2022-10-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,28,115.70088554587075,175.4263892605277,2.374458335047624,37.596449545105955,103.69411342389807,1.7356737943052556,2022-09-29,Treatment follow-up,pas de greffe,2022-09-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,80.14899552626605,169.57980058882856,1.9430539163574374,27.87082622145721,88.91854268078944,1.001528329060985,2022-10-01,Symptoms management,auto-greffe,2022-05-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,58,63.79411673572123,176.91342451147884,1.770595917841841,20.382575061336123,132.41821843734778,0.5486738273945987,2022-09-26,Symptoms management,allo-greffe,2022-07-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,58,78.51616236549191,178.25928548577977,1.971761409555064,24.70897566148316,98.8909914143823,0.9042399478184383,2022-07-20,Cancer diagnosis,pas de greffe,2022-12-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,107.15437611706683,179.6933055575708,2.3127018860484228,33.18532814091105,120.17939922036133,0.8420857141756144,2022-10-08,Cancer diagnosis,pas de greffe,2022-05-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,51.65006002379713,173.1571696339181,1.5761748885216715,17.226215415586474,82.81770876937932,0.5630260375859691,2022-02-15,Symptoms management,greffe haplo-identique,2022-08-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,117.72488537604269,153.94914689040783,2.2437348372383257,49.672235178479546,114.79143329971242,1.0967736966011319,2022-06-26,Treatment follow-up,pas de greffe,2022-07-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,23,45.31459614178847,189.67793329950226,1.5451697986949198,12.595183402738641,108.05154281057082,0.6814915994258467,2022-10-08,Symptoms management,allo-greffe,2022-07-04,Protocole 3 LAL thiotepa Bu Flu
Female,68,118.34287173285723,186.01226115565163,2.472809084303047,34.202587266132596,97.22722433880037,1.217178342153189,2022-10-08,Cancer diagnosis,greffe haplo-identique,2022-04-03,Protocole 3 LAL thiotepa Bu Flu
Male,45,107.4060335118873,181.1233992306646,2.3246114303467595,32.740066564706574,87.39922193055048,1.6214823322990757,2022-05-12,Cancer diagnosis,greffe haplo-identique,2022-05-18,Protocole 3 LAL thiotepa Bu Flu
Female,72,52.093812761571165,193.77406656945163,1.6745173385782643,13.873781092228619,119.13535539459363,0.4129732260388898,2022-06-04,Treatment follow-up,greffe haplo-identique,2022-10-13,Protocole 3 LAL thiotepa Bu Flu
Female,64,61.971145346936076,140.81232990951267,1.5569112373420582,31.25418322802247,82.30331871424632,0.7947916047251244,2022-11-30,Treatment follow-up,auto-greffe,2022-11-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,43,118.02112098836248,174.8344333815479,2.394098984717741,38.61053279519854,98.33488603986984,1.6169305044257916,2022-03-24,Cancer diagnosis,pas de greffe,2022-03-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,102.62283279463611,174.12313280080213,2.2279168859855845,33.84784737842891,90.22314183770602,1.4375896856790356,2022-10-30,Treatment follow-up,greffe haplo-identique,2022-05-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,32,103.55168975450361,152.76790967387853,2.0962516273758673,44.37035645383545,90.78922622101757,1.710858667895523,2022-02-27,Cancer diagnosis,auto-greffe,2022-03-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,73.15949745297245,172.98495481571555,1.8749438777706635,24.448603009417884,82.84783143290906,1.4227056664149333,2022-09-02,Cancer diagnosis,auto-greffe,2022-01-20,Protocole 3 LAL thiotepa Bu Flu
Female,49,114.91426140705723,177.3962056838093,2.379621465728983,36.51617477535491,132.12182703987045,1.0992798194005,2022-04-15,Symptoms management,allo-greffe,2022-07-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,73.45580506495024,141.28727133447254,1.6979047759341304,36.79764687678869,110.29970787706682,0.9434511886891029,2022-01-08,Symptoms management,allo-greffe,2022-02-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,30,56.15139648820157,185.62147695304824,1.7015438373165854,16.29686671928347,92.13934540102099,0.9310556242014816,2022-06-05,Cancer diagnosis,greffe haplo-identique,2022-10-24,Protocole 3 LAL thiotepa Bu Flu
Male,42,115.29890554230711,169.56964561609828,2.330426436461612,40.098576900060614,99.23511855884676,1.5814423735436152,2022-08-28,Treatment follow-up,allo-greffe,2022-01-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,78.50416122377811,147.07692859276918,1.7908836207104932,36.29138761274055,77.34753664048795,1.0290501837994728,2022-11-02,Symptoms management,auto-greffe,2022-01-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,108.91349509222155,159.84527370958284,2.199072243374178,42.626737619670344,76.1198665051893,1.7090297856613115,2022-02-21,Cancer diagnosis,auto-greffe,2022-02-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,54.99760927771562,154.88996918382668,1.5382690494161062,22.92436024633034,84.19557725709056,1.0886876141918325,2022-01-16,Treatment follow-up,greffe haplo-identique,2022-02-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,68,40.91563395530112,150.57976988298566,1.3082077164330292,18.04496426651286,125.10225259314872,0.3270575317965288,2022-07-03,Treatment follow-up,auto-greffe,2022-12-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,40,54.68408368839513,169.10563050146902,1.6027222025285912,19.122505885554453,77.23766760318239,0.9833300071162788,2022-01-27,Symptoms management,auto-greffe,2022-07-20,Protocole 3 LAL thiotepa Bu Flu
Female,33,59.58714744666445,176.61136273326395,1.7097569118918743,19.1036042310811,91.4906598705075,0.9678924824155705,2022-11-28,Symptoms management,pas de greffe,2022-09-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,94.47538337741464,158.6744138586547,2.0406171507579485,37.523631084383695,123.41141006634932,0.7655319984320909,2022-12-19,Treatment follow-up,greffe haplo-identique,2022-08-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,67,46.60822803629262,157.55585716639388,1.4282272733148011,18.77558539555269,95.35882242065504,0.4955552442577245,2022-10-11,Treatment follow-up,greffe haplo-identique,2022-01-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,79,80.67188423106359,143.70858595982963,1.7945320041077584,39.06220622882387,80.07859939476943,0.8534991064486555,2022-10-21,Treatment follow-up,auto-greffe,2022-07-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,41,49.85729662180283,144.37520654141306,1.4140325999472887,23.91902591159071,114.1201929263519,0.6007156235638372,2022-11-07,Cancer diagnosis,pas de greffe,2022-06-26,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,44,64.45784161279141,158.23858383831438,1.68322751928834,25.742515557781392,104.00471646868674,0.8263451094829029,2022-01-17,Treatment follow-up,allo-greffe,2022-11-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,32,101.71407609365309,190.8961522498491,2.3224045104114936,27.911727027422998,104.38786068502623,1.4615790872545873,2022-05-28,Treatment follow-up,allo-greffe,2022-03-11,Protocole 3 LAL thiotepa Bu Flu
Male,38,87.53820217791719,158.99460071328426,1.9662500619789984,34.62843546000836,74.69021799581353,1.660357358875746,2022-06-08,Treatment follow-up,greffe haplo-identique,2022-03-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,59.64843164297021,148.40361052022513,1.5680882395882239,27.08383098868961,130.2185245825992,0.731630164342886,2022-11-16,Treatment follow-up,greffe haplo-identique,2022-08-19,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,28,105.90051232074788,197.9168308446225,2.412899004617585,27.035387876473468,131.93693267452124,1.2485823865793966,2022-07-26,Treatment follow-up,auto-greffe,2022-05-05,Protocole 3 LAL thiotepa Bu Flu
Male,41,55.45672881111073,194.29948603385276,1.7300621299952696,14.68963297592155,81.90969210107943,0.9309399188215527,2022-10-16,Cancer diagnosis,auto-greffe,2022-01-25,Protocole 3 LAL thiotepa Bu Flu
Female,69,110.52600467543343,154.470218074415,2.1777266462674643,46.3206827360259,105.86318013397624,1.0295451273920633,2022-10-07,Cancer diagnosis,auto-greffe,2022-01-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,54,88.11150631157898,142.61459968848516,1.8683019028411327,43.32161628591289,120.28793635335583,0.874936443304948,2022-06-06,Cancer diagnosis,greffe haplo-identique,2022-12-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,74,106.6127019335726,145.09232531948408,2.0728861275562886,50.64307503505771,85.47555159085526,1.1433481069951996,2022-06-18,Symptoms management,allo-greffe,2022-12-09,Protocole 6 FlUDARABINE cy (Fanconi)
Female,23,63.587130589407735,198.51405784300078,1.8725309165149933,16.13565850126307,120.78291190749758,0.8554942547412903,2022-10-21,Cancer diagnosis,auto-greffe,2022-06-17,Protocole 3 LAL thiotepa Bu Flu
Male,71,43.87924333255877,154.45599799786888,1.3720840110659018,18.392873078205028,85.63602154102597,0.4910426800582976,2022-09-09,Cancer diagnosis,greffe haplo-identique,2022-04-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,52.43481759442589,150.64373236074232,1.481269784497881,23.105620025665356,108.64603781157825,0.7641493072070424,2022-02-11,Cancer diagnosis,greffe haplo-identique,2022-01-29,Protocole 6 FlUDARABINE cy (Fanconi)
Male,76,45.815940994971996,190.38654495744873,1.556593387819041,12.639913608914487,82.07458088759219,0.4961984629589048,2022-04-01,Treatment follow-up,auto-greffe,2022-10-03,Protocole 3 LAL thiotepa Bu Flu
Female,21,75.65115933143929,170.44365008728153,1.892548232893728,26.04077682485339,132.131523856521,0.9462886021196679,2022-11-27,Cancer diagnosis,pas de greffe,2022-07-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,41.56741502805163,181.97685456679136,1.4495504513159712,12.552224829977902,82.38378501870528,0.7638450665566341,2022-09-13,Symptoms management,pas de greffe,2022-12-25,Protocole 3 LAL thiotepa Bu Flu
Female,45,88.47700118427187,142.58595515602755,1.8719848143971254,43.51879843678584,106.91463401477814,1.0919037300128227,2022-05-24,Symptoms management,greffe haplo-identique,2022-11-30,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,51,57.72327351804756,182.94470804873316,1.7127112539103657,17.24690810765861,99.30275875966801,0.7185337110125106,2022-01-08,Symptoms management,pas de greffe,2022-03-01,Protocole 3 LAL thiotepa Bu Flu
Male,62,54.65910153716061,169.31968464442838,1.6033698744293936,19.065473111366828,114.92149403147758,0.5152563248876516,2022-02-10,Symptoms management,pas de greffe,2022-08-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,73,96.18402992803175,180.65321038373352,2.1969646860399643,29.472135255457225,83.54031763557325,1.0713938603357525,2022-05-31,Symptoms management,greffe haplo-identique,2022-08-17,Protocole 3 LAL thiotepa Bu Flu
Female,28,63.327835083126345,142.64399382804623,1.5840643327232118,31.12344495297321,94.94896769567436,1.03750433601977,2022-01-25,Cancer diagnosis,allo-greffe,2022-03-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,72,78.56263244855637,197.74326070695898,2.0773401202084707,20.091513094989303,76.79075455219417,0.9662366542646483,2022-01-22,Cancer diagnosis,allo-greffe,2022-08-24,Protocole 3 LAL thiotepa Bu Flu
Male,53,103.74641922626331,154.66176396030673,2.1111874095780636,43.37177517545273,113.78557054138128,1.1017236717152763,2022-06-05,Cancer diagnosis,auto-greffe,2022-03-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,103.71994140779464,161.19967196148335,2.15507286102664,39.91479980510709,102.14556511101875,1.1987515357889964,2022-08-26,Cancer diagnosis,allo-greffe,2022-11-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,21,77.61902356837516,147.5602944384974,1.7836826738659188,35.64750583934904,102.79879905527547,1.2479425680609308,2022-11-14,Treatment follow-up,allo-greffe,2022-11-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,62,55.5437508731963,160.76435551889472,1.5749299201544256,21.490953113799105,115.52871162908822,0.5208436580898006,2022-08-31,Cancer diagnosis,greffe haplo-identique,2022-06-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,76,103.50578052393897,146.2070024673573,2.0502892687814462,48.42038720469136,87.25207932439868,1.054475021751986,2022-01-02,Symptoms management,auto-greffe,2022-12-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,50.0343182856846,151.73048815652325,1.4521757180621717,21.733129949544686,103.38050732175634,0.7125292491036415,2022-03-10,Treatment follow-up,allo-greffe,2022-05-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,39,112.49551815601282,197.6827910231796,2.4854257407869778,28.787071878809204,101.12445324337003,1.5605148696237574,2022-04-16,Symptoms management,pas de greffe,2022-08-20,Protocole 3 LAL thiotepa Bu Flu
Male,68,101.03728881847968,191.87452399829195,2.3205891073247695,27.443977413042,106.77241141468163,0.9462864749403483,2022-09-07,Cancer diagnosis,pas de greffe,2022-09-24,Protocole 3 LAL thiotepa Bu Flu
Female,64,49.871875152751024,169.78022764983223,1.5336284423221507,17.301409070051545,90.58432024254773,0.5811440075115014,2022-04-05,Cancer diagnosis,greffe haplo-identique,2022-09-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,55.13040004686266,155.88693837168438,1.5450736475175604,22.686718838191084,105.69815398210464,0.8475729868595383,2022-03-31,Treatment follow-up,greffe haplo-identique,2022-10-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,46,106.03969603163682,192.9773070348201,2.3841638983425715,28.47449240326947,87.84004518849679,1.5760546794624777,2022-06-07,Symptoms management,pas de greffe,2022-08-14,Protocole 3 LAL thiotepa Bu Flu
Male,31,90.89916018673482,199.70054416669714,2.2455271438515476,22.792993898138864,113.85626727860509,1.2086399098197718,2022-12-10,Cancer diagnosis,allo-greffe,2022-05-19,Protocole 3 LAL thiotepa Bu Flu
Female,39,87.56306140821013,144.19876202535676,1.8727938913569593,42.111224829689846,125.81558339512682,0.9762822170594943,2022-07-22,Symptoms management,pas de greffe,2022-07-08,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,48,81.8342606096245,194.22119166295454,2.1011866762523908,21.694114795730368,129.1867256251873,0.8094175246087859,2022-04-25,Treatment follow-up,greffe haplo-identique,2022-10-30,Protocole 3 LAL thiotepa Bu Flu
Male,68,55.72941781193117,191.93382544119896,1.7237201653412664,15.12799831544369,86.72307983130159,0.6426134533083816,2022-10-04,Symptoms management,greffe haplo-identique,2022-03-25,Protocole 3 LAL thiotepa Bu Flu
Male,32,100.5632210842839,183.926643184447,2.26668233339241,29.72691807031405,109.40984958766228,1.3787134539981674,2022-07-27,Treatment follow-up,greffe haplo-identique,2022-12-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,97.26785160154148,155.88939000797927,2.0523039934527074,40.025448605404335,133.00589023067857,0.6398917371534409,2022-09-27,Symptoms management,pas de greffe,2022-09-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,28,102.47087818404958,165.3171844484816,2.1692418714937673,37.49423162269569,115.04784825046173,1.3855030430020683,2022-04-10,Treatment follow-up,auto-greffe,2022-01-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,79,44.796812141679716,186.03668862097305,1.5214987668974715,12.943445764967834,98.55316857781798,0.3851002994508247,2022-06-25,Treatment follow-up,allo-greffe,2022-10-02,Protocole 3 LAL thiotepa Bu Flu
Male,51,44.316194092025746,148.09613671456168,1.3502116232199488,20.20575099874351,88.17487795386094,0.6212624410773108,2022-12-02,Symptoms management,auto-greffe,2022-08-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,60.01922928307147,148.62448281781016,1.574124704868644,27.171255201879582,87.95338906136743,1.0425527170311433,2022-08-20,Symptoms management,auto-greffe,2022-05-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,69.85529026650102,152.81390274738132,1.7219868638335565,29.913936456283924,87.464328956709,1.320026950299184,2022-07-06,Treatment follow-up,allo-greffe,2022-07-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,49,100.07945828629931,170.84263641821587,2.179311722701703,34.28881025881917,118.98047570976738,1.0631098470527374,2022-08-06,Cancer diagnosis,greffe haplo-identique,2022-10-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,23,81.12391724490648,187.24855518791514,2.054151372173808,23.137261903194368,96.7166729894435,1.3630159252620455,2022-03-16,Cancer diagnosis,auto-greffe,2022-09-06,Protocole 3 LAL thiotepa Bu Flu
Male,24,88.50063738203897,143.80816338051184,1.8802418668230851,42.793648870186956,99.7547211483704,1.4293494942915554,2022-11-04,Cancer diagnosis,pas de greffe,2022-06-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,59.962591917818465,176.59972871579194,1.715078348208948,19.226504459276157,113.46237329791802,0.6238999675092306,2022-12-14,Symptoms management,auto-greffe,2022-06-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,79.00872900190915,153.77834801287486,1.8371045927181857,33.41063217811208,116.64004756029422,0.5832927527154982,2022-03-11,Cancer diagnosis,greffe haplo-identique,2022-03-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,58,114.28486145996328,165.7220219585521,2.2936820423113793,41.61292649112662,121.6990503523235,1.0695051317832507,2022-10-01,Treatment follow-up,pas de greffe,2022-05-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,32,99.15637139599163,178.7528481023369,2.218888848208002,31.032351443655163,134.06892938167567,1.1093887135516742,2022-04-06,Symptoms management,greffe haplo-identique,2022-06-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,115.76820696135803,185.8555853046993,2.4447317430934103,33.51491119307969,109.48001518843435,1.1308700091521202,2022-12-24,Treatment follow-up,allo-greffe,2022-05-04,Protocole 3 LAL thiotepa Bu Flu
Female,58,115.90673392512852,177.92277496547408,2.393419667497145,36.61386546514775,91.77871544426677,1.4382952602435426,2022-01-27,Treatment follow-up,allo-greffe,2022-05-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,56.737291538499235,156.43439048231426,1.5701790077923612,23.18484150559685,128.08508288993045,0.7382760773588843,2022-12-20,Symptoms management,allo-greffe,2022-05-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,35,44.53827232126757,171.16000766193486,1.4551795452182275,15.202981669044277,85.35743129420864,0.7609372277301502,2022-11-04,Treatment follow-up,pas de greffe,2022-08-21,Protocole 3 LAL thiotepa Bu Flu
Female,27,71.77404392144854,152.01069791184293,1.7408827987590616,31.06126295451925,85.31977095615511,1.3202728186614117,2022-09-12,Treatment follow-up,allo-greffe,2022-02-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,41,54.92783213932483,168.6308345722862,1.604033645991393,19.316057079967745,101.04229921046365,0.747466850831027,2022-09-01,Cancer diagnosis,greffe haplo-identique,2022-04-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,111.76349451063403,161.40519645086218,2.238502028113378,42.900756147203346,89.0144507089111,1.4997035205718565,2022-11-08,Symptoms management,auto-greffe,2022-08-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,107.16623528812049,150.56684939399378,2.1171050995238585,47.271485326568275,123.4792932879493,1.229508440502662,2022-04-28,Treatment follow-up,auto-greffe,2022-07-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,70,112.0426020997379,147.90226422181718,2.1454962220541693,51.21928848674526,96.3389127305137,1.1306989513331471,2022-02-28,Treatment follow-up,allo-greffe,2022-04-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,39,91.77672349172731,192.75438922130945,2.216752271616501,24.701538106070654,103.07814853109033,1.2489780818348677,2022-04-08,Cancer diagnosis,allo-greffe,2022-05-18,Protocole 3 LAL thiotepa Bu Flu
Female,24,49.82370417218441,169.40658848420327,1.5311999424431013,17.361027254235772,86.9603821251693,0.923081539280472,2022-06-01,Treatment follow-up,greffe haplo-identique,2022-06-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,72.79224730485207,142.3267856166619,1.6964248826341233,35.93451976442553,127.84083772071342,0.9094542641749872,2022-05-09,Treatment follow-up,pas de greffe,2022-03-29,Protocole 8 Aplasie medullaire thymo
Male,64,108.53529596548535,158.1141297200998,2.1833310346995645,43.41398290479494,123.97082019325978,0.9241290365881063,2022-06-23,Treatment follow-up,greffe haplo-identique,2022-03-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,31,51.4532520637189,196.77415234411143,1.677023658166968,13.288523499420917,121.02154137703516,0.6436416666830229,2022-09-16,Treatment follow-up,greffe haplo-identique,2022-11-02,Protocole 3 LAL thiotepa Bu Flu
Female,52,84.82138346673074,178.1381604523012,2.048707262979284,26.729536326430154,87.8858727637837,1.1796046000625464,2022-01-13,Treatment follow-up,greffe haplo-identique,2022-06-23,Protocole 3 LAL thiotepa Bu Flu
Male,61,47.31435034980951,157.46605805700472,1.4385954028450194,19.08178376224072,102.45576064456549,0.5067002217075671,2022-11-17,Treatment follow-up,auto-greffe,2022-06-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,107.43658149343378,142.99023324005893,2.0657512654305625,52.54597223514364,130.8743493235594,1.0489456265667825,2022-05-05,Cancer diagnosis,greffe haplo-identique,2022-05-25,Protocole 8 Aplasie medullaire thymo
Female,78,106.64055413046101,147.13271328760925,2.0876830642091733,49.26107730202355,74.1213814099296,1.2389052161470377,2022-07-29,Cancer diagnosis,allo-greffe,2022-04-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,117.32086749323996,176.19642898369176,2.3962654913182537,37.79036278655868,113.4093286861173,1.6810469816302898,2022-02-19,Symptoms management,greffe haplo-identique,2022-04-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,73,100.82200786245855,173.86977231309373,2.206675450082885,33.35087029159963,85.50019749328027,1.0973130155173074,2022-10-08,Cancer diagnosis,allo-greffe,2022-08-12,Protocole 3 LAL thiotepa Bu Flu
Female,42,90.46225133071839,161.20994202065913,2.0126968014252946,34.80837493314454,105.23474453721823,1.1700429925861582,2022-06-02,Symptoms management,auto-greffe,2022-08-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,78,100.2217253625194,163.73528188784928,2.1350144712961763,37.38327378406017,124.47200541037458,0.6933449895007359,2022-12-22,Symptoms management,allo-greffe,2022-07-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,52,43.57929517085882,188.06306290634296,1.50883101634007,12.321772666099061,114.38680506607636,0.4656444679597191,2022-05-21,Treatment follow-up,greffe haplo-identique,2022-12-01,Protocole 3 LAL thiotepa Bu Flu
Female,32,97.47186602684624,185.90529100882642,2.24354231436795,28.20303067609344,94.15526951803149,1.5528371358149997,2022-11-21,Cancer diagnosis,pas de greffe,2022-01-10,Protocole 3 LAL thiotepa Bu Flu
Male,23,45.76196642841779,148.93689315409702,1.375948673185829,20.630041321719563,120.49162507023888,0.6171648477878023,2022-11-26,Treatment follow-up,allo-greffe,2022-02-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,37,112.65964850980127,183.34383978899257,2.395334153624107,33.51473167982329,111.38261376917015,1.446957299786781,2022-05-20,Symptoms management,auto-greffe,2022-07-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,57.45822441207607,192.52937020993386,1.7529654049509975,15.500946623518196,94.69759755659021,0.6067548268871308,2022-06-24,Treatment follow-up,auto-greffe,2022-10-21,Protocole 3 LAL thiotepa Bu Flu
Male,36,54.12144025028454,173.72810508856037,1.6161008682891391,17.932018569375867,121.01389761010248,0.6460036015593074,2022-08-31,Symptoms management,greffe haplo-identique,2022-05-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,97.8280773030747,175.95187917465532,2.1866408812961033,31.599171726304323,134.95802861034076,0.8960294884131237,2022-07-16,Symptoms management,greffe haplo-identique,2022-03-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,73.13793460826349,197.81008097750887,2.004676530251504,18.691572963402805,102.00845975715463,1.1850071388282468,2022-05-08,Symptoms management,greffe haplo-identique,2022-08-26,Protocole 3 LAL thiotepa Bu Flu
Female,27,75.89171500894705,183.25943006867476,1.965527384661396,22.597568107116807,134.6285187653895,0.8847147067533022,2022-11-06,Treatment follow-up,allo-greffe,2022-07-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,65.07702706567903,190.8554153557516,1.8574402211659211,17.86564624481733,90.13285420365033,0.9426271360792613,2022-12-23,Cancer diagnosis,greffe haplo-identique,2022-03-02,Protocole 3 LAL thiotepa Bu Flu
Male,71,87.52165546894959,185.38924335945688,2.1229940522340165,25.465162968210095,116.93686626778117,0.7172666969913449,2022-09-22,Symptoms management,auto-greffe,2022-05-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,73.73980184686894,194.1885582717074,1.9943967208075777,19.55485911894404,92.27753379644778,0.8324051416450552,2022-09-10,Symptoms management,greffe haplo-identique,2022-04-24,Protocole 3 LAL thiotepa Bu Flu
Female,67,107.06615727893906,176.38689750826686,2.2903825075109787,34.41276531905692,93.70326431441522,1.158478181474056,2022-02-16,Symptoms management,allo-greffe,2022-03-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,78.50255937515219,195.95756051627103,2.0671484673228364,20.443712625182297,74.96769306655351,1.4252900342194246,2022-12-24,Symptoms management,pas de greffe,2022-08-10,Protocole 3 LAL thiotepa Bu Flu
Male,21,45.1827973557013,151.2766978555333,1.377911501738754,19.7437227371608,88.61318217424063,0.8427315392026162,2022-11-22,Symptoms management,auto-greffe,2022-06-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,64.8619574293599,175.2921463134925,1.777153758423758,21.108877205941567,88.93331682918323,0.8407582873733356,2022-03-30,Cancer diagnosis,greffe haplo-identique,2022-11-14,Protocole 3 LAL thiotepa Bu Flu
Female,62,45.86219700765224,143.94100062274669,1.3541551823142766,22.135320815316273,96.2172246344538,0.5163737256717639,2022-03-21,Cancer diagnosis,pas de greffe,2022-04-23,Protocole 6 FlUDARABINE cy (Fanconi)
Male,77,109.88624890345973,170.4110362153709,2.2807058813165435,37.839719985637885,79.22438210216124,1.213647430743474,2022-09-30,Cancer diagnosis,allo-greffe,2022-09-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,89.00021880704942,163.8233728197344,2.0124829900361334,33.16189564727124,91.31082738893794,1.610954451601778,2022-08-16,Treatment follow-up,greffe haplo-identique,2022-04-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,104.11203950701493,175.18621738723488,2.250863685202262,33.92353356999627,76.53784402029551,2.0026179222197733,2022-06-02,Treatment follow-up,auto-greffe,2022-07-30,Protocole 3 LAL thiotepa Bu Flu
Male,26,68.83134895188446,167.72487752991367,1.7907733876405323,24.467596736365177,106.71020512795471,1.021298469468193,2022-08-06,Symptoms management,pas de greffe,2022-11-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,65.54648815501515,191.48659309822213,1.8672077866248447,17.876096211476543,94.41014294363194,0.7810580185056892,2022-08-21,Symptoms management,auto-greffe,2022-01-02,Protocole 3 LAL thiotepa Bu Flu
Male,55,48.319980681884516,173.55051259710416,1.5262478879795405,16.042607218158718,119.51830757781889,0.47728605595585444,2022-03-30,Symptoms management,greffe haplo-identique,2022-09-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,56.658521299638956,192.34506651687738,1.7398904058818514,15.314510956533345,123.55243343752215,0.7069755830786371,2022-04-09,Symptoms management,pas de greffe,2022-10-16,Protocole 3 LAL thiotepa Bu Flu
Female,31,90.91016901363145,199.2222015368867,2.2429719875514693,22.90535331289918,79.12153703989854,1.739449205686514,2022-08-20,Symptoms management,pas de greffe,2022-11-15,Protocole 3 LAL thiotepa Bu Flu
Female,22,79.76174074358795,177.43729567896136,1.9827525463487394,25.334060539568785,76.26278709934635,1.714081475842402,2022-07-29,Treatment follow-up,allo-greffe,2022-06-21,Protocole 3 LAL thiotepa Bu Flu
Female,21,104.61369015346887,184.61044658108307,2.316173811946412,30.69558933460865,80.64627416456553,2.1439698749648337,2022-10-25,Symptoms management,pas de greffe,2022-06-21,Protocole 3 LAL thiotepa Bu Flu
Female,48,68.0136622527362,184.48299073534014,1.866916934357588,19.9840496179549,123.54907724043858,0.7034155831265444,2022-07-22,Treatment follow-up,greffe haplo-identique,2022-03-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,69.49007757114823,190.3835823764521,1.9170122809851755,19.171840509687236,104.23647797171505,0.9166546924796937,2022-06-27,Treatment follow-up,allo-greffe,2022-01-07,Protocole 3 LAL thiotepa Bu Flu
Male,41,108.53203920014539,147.19677894040612,2.106574799031679,50.09119007490768,98.40748112245217,1.5164655389817916,2022-02-18,Treatment follow-up,auto-greffe,2022-04-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,66,96.37477776186635,169.6499736642644,2.1311172414956405,33.48542353880898,122.97503261155387,0.8054631319740913,2022-09-23,Treatment follow-up,pas de greffe,2022-09-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,70,105.21263388947442,198.63698438457456,2.4094213410279592,26.66537319191644,123.31735376778849,0.8294863423561146,2022-08-31,Symptoms management,greffe haplo-identique,2022-06-24,Protocole 3 LAL thiotepa Bu Flu
Female,67,83.79856460135048,197.93508124893052,2.146487809119305,21.389027171899716,133.60180633729908,0.6359377607488763,2022-01-17,Cancer diagnosis,pas de greffe,2022-12-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,46.62413021498317,179.68270538909593,1.5254826060993203,14.441030565099656,83.00085103467072,0.756776147887567,2022-05-27,Treatment follow-up,greffe haplo-identique,2022-05-11,Protocole 3 LAL thiotepa Bu Flu
Female,49,40.729676603530976,146.46454036462615,1.2872724570165177,18.986546432636626,83.18518116246706,0.6188336069942609,2022-11-16,Symptoms management,allo-greffe,2022-11-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,70.15768362160902,187.69153601496407,1.912532018772764,19.915254681873776,114.92323273582454,0.9326691168168453,2022-08-06,Symptoms management,allo-greffe,2022-12-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,76.70025949366072,141.07615581080293,1.7337001021463938,38.53803786984622,89.2410455111298,0.9907812507984785,2022-06-03,Cancer diagnosis,pas de greffe,2022-06-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,38,55.192204233549624,194.75530529251307,1.7279543609964299,14.551211223676372,86.45547477298071,0.904384091381619,2022-10-14,Cancer diagnosis,auto-greffe,2022-01-06,Protocole 3 LAL thiotepa Bu Flu
Female,21,76.96287399019899,149.5923396008098,1.7883151896094345,34.39240671136797,125.04724029212652,1.0172357866335209,2022-06-03,Cancer diagnosis,greffe haplo-identique,2022-01-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,37,93.84072547114414,150.17999816755338,1.9785656967792988,41.60707322614783,114.21394135780469,1.1753763994498168,2022-10-20,Symptoms management,allo-greffe,2022-11-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,33,59.290662077555425,168.34555123629096,1.6651092048446952,20.921027574889184,133.3324482794023,0.6608482243868108,2022-08-28,Symptoms management,allo-greffe,2022-05-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,77,109.32108833645512,166.5031741018144,2.248598835589042,39.43291772216912,118.83134061890478,0.8049724239093571,2022-12-14,Cancer diagnosis,auto-greffe,2022-11-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,51.69577371610729,188.1987204380359,1.6439348514924692,14.595591739688317,117.88619303040639,0.4933380571176819,2022-07-20,Cancer diagnosis,pas de greffe,2022-07-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,76,56.95237974940827,155.06309937260937,1.5662421872279275,23.686176170718714,115.60490458026956,0.4379082162546043,2022-09-09,Treatment follow-up,allo-greffe,2022-01-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,32,82.31544959769559,146.92446017709088,1.832890324988859,38.13231282253932,127.74960917691591,0.9665248699551773,2022-12-10,Cancer diagnosis,auto-greffe,2022-11-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,51,77.11929417864687,143.0054647436706,1.7502762087359276,37.71010821569816,107.08085462496126,0.8902433282695357,2022-08-30,Symptoms management,pas de greffe,2022-09-17,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,49,103.77103520498396,166.46647622144553,2.1905351048713375,37.4474781746186,99.3970345920485,1.3195067531176528,2022-11-25,Treatment follow-up,allo-greffe,2022-02-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,90.55835877874118,190.10879505907138,2.1868254813995134,25.056714499945066,129.49772536474,1.1363700219519286,2022-10-09,Symptoms management,auto-greffe,2022-07-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,75.43136039412241,170.41412141204376,1.8896331954817467,25.97411628538872,86.29885254868037,1.238267841758314,2022-05-10,Cancer diagnosis,greffe haplo-identique,2022-10-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,68.01725224309195,152.97244023435726,1.7000625032351004,29.06649692433591,91.16028465374725,0.7254023435359032,2022-09-03,Cancer diagnosis,auto-greffe,2022-04-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,102.86753135016033,191.59619529974069,2.339814073012801,28.02235020641455,134.27521109423884,0.9256977966012931,2022-10-30,Symptoms management,pas de greffe,2022-04-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,53.8244451383365,197.20785675419873,1.7171199617314075,13.839842093492203,76.14718064139645,1.158444532611806,2022-11-14,Symptoms management,allo-greffe,2022-01-31,Protocole 2 LAM Endoxan TBI
Male,76,56.23168201851179,158.02666966775217,1.5711023588552087,22.51750662122587,75.77120092728647,0.6596664265326206,2022-02-04,Symptoms management,allo-greffe,2022-08-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,41.94822872079901,140.83840907882268,1.281050111422473,21.14810247271729,113.38203422617568,0.5703741901081116,2022-03-22,Cancer diagnosis,allo-greffe,2022-04-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,79,56.995276660375694,161.0806091482861,1.5969444680935396,21.96606880091667,93.41994094118934,0.5168881981928504,2022-08-01,Symptoms management,auto-greffe,2022-06-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,103.3230990122375,176.39878958883057,2.250066023866213,33.20520930694655,109.93737066167017,1.2400613927181303,2022-02-13,Treatment follow-up,greffe haplo-identique,2022-08-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,68.58141566450166,170.56859431078504,1.802608886042186,23.57264440524027,115.2074442525577,0.6614292457830099,2022-07-13,Treatment follow-up,pas de greffe,2022-11-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,62,105.96648173995204,182.24435214249098,2.3161146112926962,31.90511827771189,80.10680696225319,1.4330495277266653,2022-04-04,Symptoms management,auto-greffe,2022-03-23,Protocole 3 LAL thiotepa Bu Flu
Female,69,61.54087337478077,148.3839445656451,1.5926635223358154,27.95051609899883,107.3612544010721,0.5652517694665391,2022-08-20,Cancer diagnosis,auto-greffe,2022-05-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,29,115.73003611690443,188.79707267381207,2.4635956129713525,32.46800291059799,98.86702384078028,1.8046172736107813,2022-02-11,Symptoms management,pas de greffe,2022-03-13,Protocole 3 LAL thiotepa Bu Flu
Female,74,56.7547616956673,164.9489945692473,1.6125928809354715,20.85945508547299,99.62867936450093,0.5221909850946559,2022-11-24,Treatment follow-up,pas de greffe,2022-08-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,56.99328991825322,181.30029753270472,1.6941812525644462,17.339105678981486,79.50972118363909,0.7168090778059585,2022-10-16,Treatment follow-up,allo-greffe,2022-09-15,Protocole 3 LAL thiotepa Bu Flu
Female,67,97.75344574334791,164.64169051560552,2.1143880491705134,36.062218589307896,112.31039780813461,0.8824751262932905,2022-02-11,Symptoms management,greffe haplo-identique,2022-02-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,26,87.65695097925615,158.61989621384345,1.965263374118903,34.83942972027799,109.93733964176283,1.2624479802410902,2022-11-13,Treatment follow-up,auto-greffe,2022-06-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,42,90.41185898855085,159.80913210330004,2.0033749799336023,35.40154476845248,106.63419621226544,1.1540442955143941,2022-12-16,Symptoms management,allo-greffe,2022-07-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,117.3230998913671,196.415031023633,2.530042835877579,30.41123726151692,112.11634042308151,1.6859322121262035,2022-06-03,Treatment follow-up,greffe haplo-identique,2022-11-12,Protocole 3 LAL thiotepa Bu Flu
Female,38,59.97763544510059,160.8161964014609,1.6368478515999483,23.19154960151713,122.74531177940425,0.6922326861107555,2022-12-04,Cancer diagnosis,auto-greffe,2022-09-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,65.33871422777385,176.93047094958365,1.7919890779336278,20.872060114151115,82.44331652579135,1.2768521805542399,2022-04-03,Cancer diagnosis,greffe haplo-identique,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,104.69446830981927,149.8049722004428,2.087246452645514,46.652108714583164,89.91998375161323,1.0834523657249828,2022-03-18,Symptoms management,auto-greffe,2022-02-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,57.36353727644357,199.51355679537988,1.7830064616624062,14.410899912261485,91.30713763522739,0.5933454437138869,2022-01-22,Cancer diagnosis,pas de greffe,2022-08-30,Protocole 3 LAL thiotepa Bu Flu
Female,68,116.28435919119114,146.48601180152917,2.1752414944357383,54.1912281490135,100.71037680938039,1.154641287970637,2022-10-21,Cancer diagnosis,auto-greffe,2022-08-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,57,59.607263884197614,161.81218990402783,1.6368314498927905,22.765474993209452,86.08315499961965,0.7982273558647163,2022-06-28,Cancer diagnosis,pas de greffe,2022-05-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,99.62124008336559,170.23930074920912,2.1704742346343244,34.374175500983334,127.26717593678605,0.8480034957632625,2022-02-08,Treatment follow-up,pas de greffe,2022-05-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,23,47.54659761010126,178.30262964754968,1.5345722698193782,14.955603685354816,105.84365395656465,0.7299749982943831,2022-08-05,Treatment follow-up,auto-greffe,2022-03-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,90.63305543056211,158.39343649736134,1.9969199275872727,36.12536622779476,125.72091546607112,0.9511963942320608,2022-01-09,Treatment follow-up,pas de greffe,2022-03-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,72,112.48669491963228,195.5663767126724,2.4719883671189034,29.411202229625083,129.15604738250536,0.8225509857554998,2022-09-29,Symptoms management,auto-greffe,2022-12-18,Protocole 3 LAL thiotepa Bu Flu
Male,27,88.68962455656028,165.45262223742867,2.0189333644372125,32.39854503344104,102.21676244848395,1.361747674314269,2022-07-10,Cancer diagnosis,allo-greffe,2022-12-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,116.17194424190372,147.56815663234806,2.1822057943597177,53.34773107047034,101.74368070644972,1.8871580673224642,2022-06-24,Treatment follow-up,auto-greffe,2022-11-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,45,44.87292686603898,155.8327118525225,1.3937030891253113,18.47851814177779,129.49770686080115,0.4572075868725596,2022-04-24,Symptoms management,auto-greffe,2022-09-08,Protocole 6 FlUDARABINE cy (Fanconi)
Male,69,95.17405741331456,187.92129563996093,2.228928004695811,26.950485190442784,97.44650903419638,0.9631150098138584,2022-07-21,Cancer diagnosis,pas de greffe,2022-03-15,Protocole 3 LAL thiotepa Bu Flu
Female,47,51.61693976268728,191.54498235952545,1.657220381667969,14.068593882197238,95.31520594564249,0.6994883960574649,2022-08-14,Treatment follow-up,auto-greffe,2022-07-10,Protocole 3 LAL thiotepa Bu Flu
Female,58,116.34448490740732,165.05359570775582,2.3095860364248004,42.70668103274584,123.83528267543456,1.069997486030144,2022-01-12,Symptoms management,auto-greffe,2022-03-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,82.24010041884154,167.68090060883486,1.9571871897354494,29.249364603870458,84.5819825869433,1.039833967158156,2022-05-17,Symptoms management,allo-greffe,2022-11-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,54,79.66168938551255,197.41345271106354,2.090075035228687,20.440712208798548,111.57100539554678,0.8528332426892542,2022-02-23,Symptoms management,greffe haplo-identique,2022-11-05,Protocole 3 LAL thiotepa Bu Flu
Male,56,111.19743346700965,155.08756833903908,2.188691869711006,46.23179867597539,109.55432306565771,1.1841644894934458,2022-03-06,Symptoms management,greffe haplo-identique,2022-04-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,30,118.07159155245198,189.70326635587995,2.4943584446449387,32.80921200888009,88.30661065374763,2.042736692363757,2022-08-28,Treatment follow-up,allo-greffe,2022-10-20,Protocole 3 LAL thiotepa Bu Flu
Female,28,114.33286669521144,166.221379260429,2.2976175339829257,41.38065202909476,120.58167676506713,1.4749432147708605,2022-05-17,Treatment follow-up,pas de greffe,2022-11-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,79,60.21460467271605,141.049405210048,1.5359790737547299,30.266299211387665,119.65698384648479,0.4263449532248075,2022-04-01,Treatment follow-up,greffe haplo-identique,2022-01-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,64,102.06605955369207,183.48116800077796,2.280789326097704,30.3178469465451,126.55630547596346,0.8512922038169484,2022-10-31,Treatment follow-up,allo-greffe,2022-01-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,54,111.69936384633225,147.27734650739367,2.137676952639874,51.49662866013887,116.7535061133556,1.1427381415397873,2022-06-28,Cancer diagnosis,greffe haplo-identique,2022-11-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,34,106.8092725611852,167.64410788007203,2.23021830096414,38.004267748910905,99.5394248298407,1.5797457627746545,2022-03-18,Cancer diagnosis,pas de greffe,2022-06-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,59.627086919623835,171.84023038983392,1.6870694803697996,20.192677066812657,91.59224505576653,0.7233398281616952,2022-07-24,Cancer diagnosis,auto-greffe,2022-04-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,74,117.93146598161465,156.8209638858346,2.266551845603209,47.953626842918965,129.9886484307671,0.8316406480220999,2022-10-26,Symptoms management,pas de greffe,2022-11-15,Protocole 6 FlUDARABINE cy (Fanconi)
Female,49,42.20825313567828,157.63246905406305,1.3594720335724153,16.98658287155348,85.63627117077576,0.6229433092808275,2022-08-04,Cancer diagnosis,greffe haplo-identique,2022-08-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,44.2338533689159,162.45542419994717,1.412840854944932,16.760475707856767,79.28433689551699,0.5811605721485965,2022-05-26,Treatment follow-up,auto-greffe,2022-06-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,81.94801637390391,152.95606920718362,1.8659557026924913,35.027167334628665,113.23181983255787,1.1659916789180638,2022-10-31,Treatment follow-up,pas de greffe,2022-07-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,24,89.6050973003394,175.46892445253252,2.0898504763602292,29.10263333485328,79.70125262369045,1.8113111540966953,2022-04-09,Cancer diagnosis,greffe haplo-identique,2022-10-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,68,42.92136345036985,163.71425529421995,1.3971040537771389,16.014025494609324,127.59504608788927,0.33638738153521264,2022-10-16,Symptoms management,pas de greffe,2022-07-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,65,96.99503656199788,196.1229915840147,2.2987289204724948,25.21694624836187,98.73264198298766,1.0233342731389392,2022-06-06,Treatment follow-up,auto-greffe,2022-06-12,Protocole 3 LAL thiotepa Bu Flu
Female,64,101.27905770906213,173.37356711942178,2.208513295152412,33.694101709086056,77.8938001724652,1.3724541849226979,2022-12-27,Cancer diagnosis,greffe haplo-identique,2022-03-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,45.01653144578543,195.47070099926302,1.563419770021887,11.781719759993317,86.52052390389868,0.5347516238343996,2022-07-22,Symptoms management,allo-greffe,2022-08-03,Protocole 3 LAL thiotepa Bu Flu
Female,61,75.14817703656794,189.9530589367359,1.9912744454533142,20.826959211246855,117.3012990628811,0.7029269962288417,2022-06-06,Symptoms management,allo-greffe,2022-06-01,Protocole 3 LAL thiotepa Bu Flu
Female,22,54.3357366526969,165.96875752141463,1.5827222242827645,19.72572043711315,87.32587049379751,1.0197463199181354,2022-09-28,Treatment follow-up,auto-greffe,2022-03-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,107.83377719352058,171.5482410162189,2.2668317831822824,36.6422622985945,123.56928263210904,1.1999053525504808,2022-03-05,Cancer diagnosis,pas de greffe,2022-12-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,42,116.96948519274619,168.15413273929417,2.3374310649103136,41.36732968611982,86.30520191633784,1.8447145991399945,2022-04-05,Symptoms management,auto-greffe,2022-11-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,65.80840534553639,166.4102821031731,1.7441326480446342,23.764082616697266,86.80205815848082,0.7686731442878412,2022-01-12,Treatment follow-up,auto-greffe,2022-11-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,93.42838316845284,188.75323555683502,2.213274950026244,26.223461819487177,116.1828537781038,0.8488244667185096,2022-12-01,Treatment follow-up,pas de greffe,2022-03-31,Protocole 3 LAL thiotepa Bu Flu
Male,57,58.252851230887856,157.5945025668209,1.5969005667951826,23.454979602674936,118.03328459471552,0.5689292865291397,2022-10-18,Cancer diagnosis,greffe haplo-identique,2022-07-20,Protocole 6 FlUDARABINE cy (Fanconi)
Female,79,43.96656066560563,194.95452934444467,1.543038141447032,11.567934867990754,127.75355849057735,0.2915726784497352,2022-09-06,Treatment follow-up,auto-greffe,2022-02-19,Protocole 3 LAL thiotepa Bu Flu
Female,67,102.29219288480293,149.2897082971802,2.0596097012170858,45.89683625919311,91.66509159377793,1.1314330895516238,2022-03-14,Cancer diagnosis,auto-greffe,2022-04-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,61,111.80400625695137,156.41041684940143,2.203993296526585,45.70103323002343,121.2704189617636,1.01157265925896,2022-08-15,Cancer diagnosis,pas de greffe,2022-05-24,Protocole 6 FlUDARABINE cy (Fanconi)
Female,21,67.45100341217378,179.62771456923937,1.8345503224625452,20.90459345766539,77.81084362084788,1.432724724996872,2022-10-29,Treatment follow-up,greffe haplo-identique,2022-02-22,Protocole 3 LAL thiotepa Bu Flu
Female,47,78.22244319677884,163.51477972076572,1.88492009619487,29.256161806920645,97.8174790006931,1.0329168518214429,2022-09-19,Cancer diagnosis,auto-greffe,2022-09-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,41.2188110120351,188.81178913259885,1.4703171854607895,11.562113944421379,92.7274082958795,0.6852954066625326,2022-09-26,Treatment follow-up,pas de greffe,2022-04-09,Protocole 3 LAL thiotepa Bu Flu
Female,47,55.08527212979213,159.03525942729976,1.5599590934616148,21.77953764492336,97.51760310421925,0.7296304212714632,2022-12-26,Symptoms management,auto-greffe,2022-02-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,50,62.30176462426926,154.13146598120164,1.6332195806268324,26.225134818550394,126.25065443311303,0.6168459571953786,2022-12-30,Symptoms management,auto-greffe,2022-01-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,23,104.1223041964041,190.72052665093346,2.3486556847864466,28.625224125212,134.91873049865808,1.2540789829091932,2022-02-03,Treatment follow-up,greffe haplo-identique,2022-08-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,41,95.58149471312733,159.08545744875863,2.055184893687857,37.7670319419696,104.0796125697824,1.2627310189345071,2022-04-16,Cancer diagnosis,allo-greffe,2022-01-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,33,96.75460294786572,163.20820926577602,2.0943804099265213,36.323495548077965,100.03959275221717,1.437311833606803,2022-04-09,Symptoms management,pas de greffe,2022-02-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,56.04474695600314,199.0951534757225,1.7605426480928383,14.138832066285374,79.20754035562109,0.7960143698746867,2022-10-15,Treatment follow-up,greffe haplo-identique,2022-03-08,Protocole 2 LAM Endoxan TBI
Female,26,56.96201265979204,191.48638736028698,1.740645635404872,15.534937651964807,116.54166792910725,0.7738850402661723,2022-03-28,Symptoms management,allo-greffe,2022-02-28,Protocole 3 LAL thiotepa Bu Flu
Male,60,65.24027746009384,182.59182939825848,1.8190612362095289,19.568300981123922,105.03598376051563,0.6901367948641202,2022-11-15,Symptoms management,pas de greffe,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,90.43099497186998,186.74977509770855,2.165895245546973,25.929678634903023,109.66640148764995,1.1109204309716427,2022-09-29,Symptoms management,pas de greffe,2022-07-27,Protocole 3 LAL thiotepa Bu Flu
Male,67,92.18719733825743,162.23356653845136,2.03823574400956,35.02589006297427,77.35068782500257,1.2083612661664587,2022-06-01,Symptoms management,allo-greffe,2022-01-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,67.65687841415215,162.18688512655459,1.745872781366367,25.720564150914687,83.5593798377749,0.9333882814959449,2022-01-23,Cancer diagnosis,auto-greffe,2022-07-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,69.717977080286,153.7647651866874,1.7256374325513772,29.487035898123167,79.67134965988222,0.9844533141480823,2022-08-23,Symptoms management,allo-greffe,2022-11-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,64,45.25129341599046,184.15679605721306,1.5214515376345255,13.343061755496812,119.26239914206677,0.4005055617271688,2022-10-23,Symptoms management,greffe haplo-identique,2022-06-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,54.22402361558265,199.1187655918778,1.7318118841708698,13.676260299668494,96.63301848466838,0.7247974339941227,2022-06-30,Treatment follow-up,pas de greffe,2022-11-28,Protocole 3 LAL thiotepa Bu Flu
Female,47,78.21955763616556,145.64455690686074,1.7789082804856895,36.87455927002134,133.22426082899324,0.758372346383171,2022-04-15,Treatment follow-up,pas de greffe,2022-09-28,Protocole 8 Aplasie medullaire thymo
Male,78,112.73958708551835,150.08458997485636,2.167978750258754,50.05001750255388,75.53516220936709,1.285246609153102,2022-03-27,Treatment follow-up,auto-greffe,2022-03-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,56.945641092928334,196.27758072644417,1.7620342305475254,14.78151995260623,89.75870897559494,0.9868915159069697,2022-10-16,Cancer diagnosis,pas de greffe,2022-03-11,Protocole 3 LAL thiotepa Bu Flu
Male,69,69.54284501971489,150.23065161923415,1.7035475177443997,30.813097054063228,108.16817633082255,0.6339847309848546,2022-05-07,Symptoms management,allo-greffe,2022-10-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,43,50.48506373770569,167.13965468659953,1.530981540634698,18.071903869094342,122.01003780455663,0.5574508538936153,2022-06-16,Treatment follow-up,pas de greffe,2022-07-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,64,107.1135071686405,169.42884222134307,2.245249151347146,37.3138063385311,102.37016345236206,1.1044649510549305,2022-05-19,Cancer diagnosis,pas de greffe,2022-09-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,52.13277399412061,170.4549621114511,1.5711186757577007,17.942854584012917,125.87975938186051,0.684493605441465,2022-11-16,Treatment follow-up,allo-greffe,2022-10-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,32,55.98030082744486,150.35133928445296,1.5290441097983865,24.76399033916469,126.64769472077387,0.6630239218037162,2022-09-15,Cancer diagnosis,auto-greffe,2022-01-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,53,65.34351313858738,199.07652222190598,1.9009032462220716,16.48778781698038,105.97389884810977,0.7450584143896305,2022-02-19,Treatment follow-up,pas de greffe,2022-06-19,Protocole 3 LAL thiotepa Bu Flu
Male,62,107.13658142726602,151.8007044229622,2.125467826289272,46.49328267489507,125.54038876350941,0.9245202362578192,2022-02-28,Cancer diagnosis,auto-greffe,2022-02-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,47,51.60755113901729,191.07861095314752,1.6550511226022386,14.134781537176497,122.97285921580813,0.5420688270537903,2022-05-06,Symptoms management,allo-greffe,2022-02-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,49.53265114726491,141.49496840307978,1.395291776435928,24.740563122099434,114.09251914954183,0.6451871146456012,2022-04-29,Treatment follow-up,greffe haplo-identique,2022-12-23,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,46,71.90347129148813,168.75137318003783,1.8358928736637816,25.249642085996502,111.460698082183,0.8422159382055538,2022-09-19,Cancer diagnosis,auto-greffe,2022-07-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,63.51027154932089,149.23465758468498,1.6225779922851564,28.517049058718005,80.22910514503495,1.055481821873489,2022-09-28,Cancer diagnosis,allo-greffe,2022-02-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,115.76690814485262,161.1233237497163,2.2762511224310344,44.59309441886247,121.81232162793118,0.8447742968506443,2022-08-26,Symptoms management,pas de greffe,2022-11-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,57,42.92820935947789,157.34767978646323,1.3697783823286263,17.338921756008034,131.03894876690066,0.37764867816077935,2022-10-19,Cancer diagnosis,pas de greffe,2022-07-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,71,95.22523893762256,147.04851364780183,1.9722188468500665,44.038325075189896,100.93528975180381,0.9041190734474917,2022-06-17,Treatment follow-up,pas de greffe,2022-06-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,45.66343463485016,196.74656974952018,1.5797436612898978,11.796528898448429,74.76565345536157,0.6616503510392783,2022-05-28,Treatment follow-up,auto-greffe,2022-09-03,Protocole 3 LAL thiotepa Bu Flu
Female,44,60.28783880280094,184.67842486549407,1.7586187058034188,17.676545359928852,120.3671027851228,0.6678218816473547,2022-07-08,Cancer diagnosis,pas de greffe,2022-10-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,90.01553818667647,161.75427640697893,2.011107920523372,34.40376242135935,110.4388185428731,0.7924306663639827,2022-08-26,Treatment follow-up,pas de greffe,2022-05-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,29,102.36837013989074,174.522889183002,2.227705827737528,33.609418669321066,80.44370627774495,1.9618427751298901,2022-08-29,Treatment follow-up,allo-greffe,2022-01-09,Protocole 3 LAL thiotepa Bu Flu
Male,33,83.44564906819204,190.51519347938404,2.101432314269338,22.990290811407736,109.22482964727945,1.135360033561815,2022-09-07,Cancer diagnosis,pas de greffe,2022-07-16,Protocole 3 LAL thiotepa Bu Flu
Female,28,41.25431678465589,183.90251786716595,1.4517013705752204,12.19815221607999,118.31214417746128,0.5424073928434935,2022-07-26,Symptoms management,auto-greffe,2022-03-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,100.55292683302753,186.3564144536885,2.2814884826594075,28.95383028754528,101.44501743359831,1.046273175668266,2022-04-10,Cancer diagnosis,greffe haplo-identique,2022-11-03,Protocole 3 LAL thiotepa Bu Flu
Female,30,76.37127891126778,149.02842223484495,1.7780678652373954,34.386807398738945,128.73890867571205,0.9063176314086322,2022-11-03,Cancer diagnosis,allo-greffe,2022-05-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,33,95.13246426229378,176.02166383360145,2.156732008543867,30.704109272515787,84.31302782140051,1.676815740350992,2022-09-20,Symptoms management,greffe haplo-identique,2022-12-01,Protocole 3 LAL thiotepa Bu Flu
Male,79,51.11957814763979,144.36733838200814,1.4317818576462515,24.52727846837585,118.22702137485575,0.3663260910548232,2022-03-23,Treatment follow-up,pas de greffe,2022-05-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,69,97.53457643120477,181.3436829048296,2.2165588507988674,29.65881118172742,100.10430434097194,0.9607971422359828,2022-02-23,Symptoms management,allo-greffe,2022-10-07,Protocole 3 LAL thiotepa Bu Flu
Female,45,47.19149720387964,162.38185432595532,1.4589801255580435,17.897351307982728,110.71214030765327,0.5624185264384252,2022-01-22,Symptoms management,allo-greffe,2022-03-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,43,48.78372704356268,179.99422154882618,1.5617644022650652,15.057672640193054,98.70342485471116,0.6658585682579166,2022-02-24,Cancer diagnosis,allo-greffe,2022-06-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,58.926015584976895,194.36217856923022,1.7836439576437428,15.598525944246571,92.26768340137765,0.6563820301824331,2022-06-01,Treatment follow-up,pas de greffe,2022-12-22,Protocole 3 LAL thiotepa Bu Flu
Female,29,88.9182666496514,166.5312315238207,2.0281127276725033,32.06266375908518,127.30919502446247,1.0767669037983119,2022-11-02,Symptoms management,pas de greffe,2022-02-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,21,99.57618817401473,149.5071835719157,2.033562517461252,44.54832472250076,98.22547532758185,1.6755053662093744,2022-01-15,Cancer diagnosis,pas de greffe,2022-05-11,Protocole 6 FlUDARABINE cy (Fanconi)
Male,22,43.495811474176435,152.36452274842296,1.356795505432057,18.736122890830178,75.35351801573096,0.9460049645373164,2022-01-14,Symptoms management,greffe haplo-identique,2022-01-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,52.32906657624923,177.40264341995712,1.6058326620242098,16.627341414873335,101.58696153947483,0.7440564059951255,2022-05-27,Treatment follow-up,pas de greffe,2022-03-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,55.75172738121473,182.048225184196,1.679079031683679,16.822302154068886,88.7638225039524,0.8985185753290899,2022-01-01,Treatment follow-up,allo-greffe,2022-08-08,Protocole 3 LAL thiotepa Bu Flu
Male,49,78.39079876542742,165.94860234525927,1.900938619899475,28.465439371550254,128.9424884498317,0.7683833369579883,2022-03-22,Symptoms management,allo-greffe,2022-04-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,64.28401491941463,158.82638201145045,1.6840755385885824,25.483419718577615,104.7649366182451,0.681780427205975,2022-01-02,Symptoms management,allo-greffe,2022-03-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,66,74.10674443963259,164.18247130478983,1.8384042327255339,27.491862169769917,111.03308887080595,0.6859690736617658,2022-09-11,Symptoms management,auto-greffe,2022-05-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,52.29733150961022,175.716305172205,1.597697463298933,16.93773773903576,129.02668785285996,0.4559870436680933,2022-06-12,Treatment follow-up,pas de greffe,2022-04-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,106.20116793655625,152.23960041216876,2.1192257083115518,45.821998010671486,121.41050431559805,0.9354730027974193,2022-06-10,Symptoms management,allo-greffe,2022-05-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,69,53.843559238305836,173.17884696974608,1.6093964971066554,17.953291108708473,81.00519468515947,0.6554608285681965,2022-10-08,Symptoms management,allo-greffe,2022-07-17,Protocole 3 LAL thiotepa Bu Flu
Female,78,113.90570114353443,179.92534201962076,2.385984669564884,35.18526188679653,91.00446131383808,1.0778094112918428,2022-09-19,Treatment follow-up,pas de greffe,2022-05-17,Protocole 3 LAL thiotepa Bu Flu
Female,37,95.53184241471817,151.99766832830653,2.008358734150875,41.34988460381037,110.93776780465998,1.2318943368273931,2022-07-23,Treatment follow-up,greffe haplo-identique,2022-05-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,23,89.10839810956341,163.99119918205355,2.0147368909542465,33.134281164778045,81.397774467314,1.778932506148393,2022-07-21,Treatment follow-up,pas de greffe,2022-03-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,107.8281061853075,192.24204054292045,2.3996003811365374,29.176637688715587,111.2689207293827,0.8344826184848368,2022-09-07,Symptoms management,allo-greffe,2022-12-27,Protocole 3 LAL thiotepa Bu Flu
Female,56,47.30201567104436,184.90842239453053,1.5587157368429032,13.834588983023602,87.12384121437485,0.6334165732404197,2022-06-25,Treatment follow-up,allo-greffe,2022-03-20,Protocole 3 LAL thiotepa Bu Flu
Male,37,83.18204684031018,159.75646657915547,1.9212893447160366,32.59212744314275,124.78329740958404,0.953625538835525,2022-08-10,Cancer diagnosis,pas de greffe,2022-04-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,50,49.1394249523374,158.41561535519142,1.4704923818255171,19.580965064185627,76.63274073481169,0.8015409680175872,2022-07-05,Treatment follow-up,pas de greffe,2022-01-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,51.17927076623681,193.29727529621994,1.6577104014909858,13.697541626556218,78.05958520175653,0.8832976849055922,2022-07-07,Cancer diagnosis,greffe haplo-identique,2022-10-04,Protocole 2 LAM Endoxan TBI
Female,67,79.70621156881145,170.3483588165041,1.942065218625958,27.467318282921163,90.66919584114396,0.891297662181023,2022-04-07,Symptoms management,auto-greffe,2022-07-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,117.2996191297354,182.81023431402468,2.440603913085902,35.099068545260195,102.49485812343156,1.3351845951779755,2022-02-26,Treatment follow-up,greffe haplo-identique,2022-09-11,Protocole 3 LAL thiotepa Bu Flu
Female,34,86.19301844337346,165.20285212033542,1.9888112362040944,31.5818093908081,81.52803235122006,1.5564619124632324,2022-11-22,Cancer diagnosis,pas de greffe,2022-04-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,67.67202672492601,165.25710101226562,1.7625173723482555,24.779293716094344,74.04771053015119,0.9646697143473967,2022-11-04,Treatment follow-up,auto-greffe,2022-02-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,56.632640549115806,162.8915587925383,1.600779245796575,21.343697291422163,123.99931533063486,0.6597028604332914,2022-03-30,Symptoms management,auto-greffe,2022-11-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,77,81.99631814277745,162.2096472515412,1.922136675816285,31.1631243110054,86.73078108020442,0.8272354691304155,2022-04-16,Symptoms management,greffe haplo-identique,2022-01-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,44,112.82988735004993,168.84980136001596,2.3004410245361955,39.57519344902226,111.41495324766258,1.350266238192069,2022-09-24,Cancer diagnosis,auto-greffe,2022-02-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,70.16316088320383,166.5066310718368,1.8014370454980249,25.307315439712283,79.31663126625655,0.7740213470074782,2022-02-20,Treatment follow-up,allo-greffe,2022-06-26,Protocole 3 LAL thiotepa Bu Flu
Female,20,113.01621916527631,171.35142912432153,2.3193324391704246,38.49154225572456,134.49582360652266,1.4004922994971392,2022-01-31,Treatment follow-up,pas de greffe,2022-12-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,78,73.83868441097562,176.37321602837804,1.9019847993366934,23.736609342503257,79.27977519280768,0.8020117542145381,2022-11-12,Cancer diagnosis,greffe haplo-identique,2022-03-10,Protocole 3 LAL thiotepa Bu Flu
Female,78,65.26420280223269,146.32960876236632,1.6287422944508134,30.479694844096574,93.5588490157919,0.6006885589339119,2022-10-13,Cancer diagnosis,pas de greffe,2022-07-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,51,80.25325146256901,152.45755717569338,1.8435484107037463,34.52746735236636,76.1272670329705,1.3031064913010935,2022-12-21,Cancer diagnosis,auto-greffe,2022-06-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,115.67417185224814,192.93914321078557,2.4898725764356073,31.073895987772453,93.3280392543534,1.428794774212502,2022-09-14,Treatment follow-up,auto-greffe,2022-10-21,Protocole 3 LAL thiotepa Bu Flu
Male,53,92.69051083037581,199.54404194296174,2.2666568125307283,23.27864758737686,74.71347678437523,1.499074045814719,2022-04-16,Cancer diagnosis,greffe haplo-identique,2022-07-24,Protocole 3 LAL thiotepa Bu Flu
Male,32,94.40990425488397,192.29460355953648,2.2456448659811326,25.53191347241536,101.29502818395841,1.3980435063914893,2022-01-16,Treatment follow-up,allo-greffe,2022-01-05,Protocole 3 LAL thiotepa Bu Flu
Female,37,79.35963059297632,155.24916070699015,1.849963666578373,32.92616237299556,75.73674678690053,1.4989864926605856,2022-06-28,Symptoms management,auto-greffe,2022-12-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,52.02256362887845,142.34000567134422,1.4341947026092168,25.67661637272438,95.09275771791552,0.4710895828912551,2022-12-28,Cancer diagnosis,pas de greffe,2022-10-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,88.90085856162074,199.8882065231375,2.221750634587852,22.250081828569584,110.82093792291083,1.1810206807678947,2022-03-01,Cancer diagnosis,greffe haplo-identique,2022-12-20,Protocole 3 LAL thiotepa Bu Flu
Male,36,86.24158171953826,183.2530103689152,2.095234637422779,25.681150604426687,116.24825976464939,1.0715960294553173,2022-03-25,Treatment follow-up,auto-greffe,2022-09-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,109.48723846905041,161.0255887042397,2.2129823410251106,42.22539401480712,80.0052644299702,1.5015490787251764,2022-07-15,Symptoms management,pas de greffe,2022-10-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,53.344735386578826,166.50422935673208,1.5707503564097693,19.24159309319039,91.53621737925474,0.9712865011954744,2022-04-12,Symptoms management,auto-greffe,2022-12-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,92.82553715965227,169.35572139609084,2.089692681396301,32.36441227455562,104.65975721692466,0.9115635927306359,2022-01-21,Cancer diagnosis,auto-greffe,2022-08-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,93.88087557416439,160.2583321844333,2.04431410281799,36.55408302843804,79.78525118149422,1.9447732834021463,2022-06-02,Symptoms management,auto-greffe,2022-06-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,70.31347829758904,172.00457959131893,1.832896938529894,23.766135133768866,105.8792604889143,0.7102085751986791,2022-09-12,Treatment follow-up,allo-greffe,2022-01-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,95.43374924940302,167.6518817133349,2.1081618929387655,33.9535447608591,126.54065067905333,0.7227506934719526,2022-06-15,Treatment follow-up,auto-greffe,2022-08-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,25,66.90385586899774,192.92946462353166,1.8935361609415435,17.97438459118117,91.45615303170095,1.1684323230748117,2022-05-05,Cancer diagnosis,greffe haplo-identique,2022-06-06,Protocole 3 LAL thiotepa Bu Flu
Male,79,101.19795522782985,165.8911422812483,2.1594652366108886,36.772685056016364,116.534947988265,0.7357205541559999,2022-10-05,Symptoms management,greffe haplo-identique,2022-02-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,45,80.44786232988744,186.1711034007979,2.039680482615859,23.210792174063553,82.42935351265271,1.2877267683812206,2022-04-15,Symptoms management,greffe haplo-identique,2022-09-27,Protocole 3 LAL thiotepa Bu Flu
Female,66,65.30773420686877,142.63893133015824,1.6086075254066603,32.09877538767461,104.17001682705693,0.6443489209210077,2022-08-03,Treatment follow-up,allo-greffe,2022-10-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,79,85.63973322170432,177.24472139341106,2.053397635295046,27.260177886253334,79.29646682745475,0.9149951819226532,2022-04-24,Symptoms management,auto-greffe,2022-10-31,Protocole 3 LAL thiotepa Bu Flu
Male,29,65.50497302800613,179.32255036201653,1.8063559714993704,20.370629899070856,74.09123257008935,1.3630065247280627,2022-11-03,Symptoms management,greffe haplo-identique,2022-02-27,Protocole 3 LAL thiotepa Bu Flu
Female,53,111.97278894818,162.49692852538954,2.2481618591950063,42.405499436367485,103.59970324774213,1.3059926724773985,2022-07-29,Symptoms management,greffe haplo-identique,2022-11-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,82.62887808166084,164.6310588050154,1.943884976482116,30.486552320464828,110.0518114307931,0.8655262754593396,2022-04-13,Symptoms management,allo-greffe,2022-09-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,112.28392573790815,182.673200538696,2.38695901861628,33.648670735648665,114.0356738370698,1.0530162758750967,2022-08-03,Treatment follow-up,auto-greffe,2022-03-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,51.585694025159896,149.61097033081967,1.4641821511506137,23.04636302291974,87.30454617391057,0.8370667554554959,2022-05-08,Symptoms management,pas de greffe,2022-04-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,92.1413657305622,183.57380969024612,2.1676114310214567,27.34218411278014,116.46319272411361,1.2746514555299913,2022-05-20,Cancer diagnosis,auto-greffe,2022-07-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,54.84650447542067,191.3616144281218,1.7074603982845162,14.97749907492337,77.46352218257589,1.1210476403083396,2022-01-15,Symptoms management,greffe haplo-identique,2022-05-31,Protocole 3 LAL thiotepa Bu Flu
Male,28,59.25735138119826,184.6908039235675,1.743582508083001,17.37207487619918,88.96225744955055,1.0361484160943617,2022-01-22,Symptoms management,greffe haplo-identique,2022-07-29,Protocole 3 LAL thiotepa Bu Flu
Female,27,102.74447875478748,166.6266539230551,2.1807216379483867,37.00577865163226,120.75438528409043,1.3353697341895758,2022-06-05,Symptoms management,allo-greffe,2022-08-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,40,78.65643102946488,191.62680378651825,2.0461807563408816,21.420111390888994,80.30024611631512,1.3604571390508229,2022-03-22,Cancer diagnosis,auto-greffe,2022-10-07,Protocole 3 LAL thiotepa Bu Flu
Male,26,91.5549348284751,178.11456780289643,2.128331874653389,28.859106110558095,92.96205802560769,1.559367157137956,2022-04-22,Symptoms management,pas de greffe,2022-03-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,106.34152833959422,172.38377163351055,2.2565678053462754,35.78575140241391,85.56027215706278,1.5018186615215903,2022-09-27,Symptoms management,pas de greffe,2022-07-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,69.3099601616339,167.9429434210959,1.798156364318719,24.573789186094082,101.72355246059078,0.7570623025193218,2022-07-21,Treatment follow-up,auto-greffe,2022-09-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,92.38697882558469,140.27004400031592,1.8973025870752682,46.9548977230459,116.3894659372719,0.8047990473618711,2022-04-24,Treatment follow-up,allo-greffe,2022-05-11,Protocole 8 Aplasie medullaire thymo
Female,30,58.180225150653854,159.8322954783664,1.6071955333987826,22.77436748403405,88.85452056600604,1.000359402369933,2022-07-17,Cancer diagnosis,allo-greffe,2022-03-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,50,92.49923669184963,141.17561431786743,1.9045731924841744,46.410770282511535,127.01861534966773,0.9102921295946446,2022-02-14,Symptoms management,allo-greffe,2022-10-23,Protocole 9 LAL thiotepa-thymo melphalan
Female,60,105.22967647512976,174.37206885143593,2.2576485057303697,34.60862894030142,77.36884307260769,1.5112267174580536,2022-05-09,Treatment follow-up,greffe haplo-identique,2022-04-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,43.37984374950308,193.813604273935,1.528216450449794,11.548337491724219,83.06843904628944,0.7035438509117965,2022-03-15,Cancer diagnosis,pas de greffe,2022-09-26,Protocole 3 LAL thiotepa Bu Flu
Female,37,88.26808570632912,163.46088120939618,2.001969798877475,33.03513122812004,118.54791210678049,1.06515920981978,2022-06-25,Symptoms management,pas de greffe,2022-09-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,20,58.014789259728914,156.18243376154743,1.5864785410836222,23.783422275184574,119.76820683528882,0.8073203898414896,2022-09-18,Symptoms management,allo-greffe,2022-09-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,52,45.93707228962526,148.88762383986113,1.3783506185294876,20.72268927543242,131.19866250880978,0.4279411809738426,2022-11-15,Cancer diagnosis,allo-greffe,2022-09-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,39,75.15682216833709,161.91189640585813,1.8385368280475174,28.668890749068094,88.77832122481507,1.1875457716660505,2022-10-10,Symptoms management,greffe haplo-identique,2022-09-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,81.76892155705669,166.81014577256806,1.9464986888569313,29.386194323632022,93.68504549286189,1.0425189374485764,2022-08-05,Cancer diagnosis,auto-greffe,2022-05-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,40.59891380794757,156.08915751651165,1.3267598640179357,16.663604196365903,75.26178738901206,0.6817871039601971,2022-02-18,Treatment follow-up,auto-greffe,2022-02-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,107.70995494209951,195.84783461790613,2.420672624740351,28.08137026476884,106.62515741845236,1.3048080006192027,2022-04-23,Cancer diagnosis,greffe haplo-identique,2022-06-05,Protocole 3 LAL thiotepa Bu Flu
Female,45,97.11575618395847,191.81049713776284,2.2747296221233047,26.396415399227443,109.57257587842841,1.169442663345947,2022-09-27,Treatment follow-up,auto-greffe,2022-06-06,Protocole 3 LAL thiotepa Bu Flu
Female,51,66.5561894362643,146.87126172440543,1.6478261368367755,30.854236041213397,104.80033573452334,0.785024634689988,2022-03-07,Treatment follow-up,auto-greffe,2022-08-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,39,92.19997254813165,142.48848406478436,1.9103107890833724,45.412065927758526,127.21595948728341,1.0166654649581819,2022-05-12,Symptoms management,pas de greffe,2022-05-23,Protocole 9 LAL thiotepa-thymo melphalan
Male,68,55.061647819760466,181.84184597381943,1.6677089808997763,16.65181362119873,79.73009098462171,0.6906005893105117,2022-09-02,Symptoms management,pas de greffe,2022-06-19,Protocole 3 LAL thiotepa Bu Flu
Male,47,49.04052918095074,151.15943571097782,1.434973743271231,21.462713280184396,108.92964635805981,0.5815131048026317,2022-06-13,Cancer diagnosis,greffe haplo-identique,2022-08-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,42.79936139269198,182.570352044651,1.4732705941345845,12.84034766912188,120.7201203289433,0.3545337867131881,2022-03-31,Symptoms management,pas de greffe,2022-03-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,113.50237568515413,179.76332541743452,2.380684104291959,35.12390265403264,90.96482015719305,1.611691585897098,2022-05-14,Treatment follow-up,allo-greffe,2022-03-07,Protocole 3 LAL thiotepa Bu Flu
Female,79,87.4411511380633,142.95902824174166,1.8634273973750624,42.78511380610896,130.64337469631477,0.5670558231756158,2022-07-11,Treatment follow-up,allo-greffe,2022-10-28,Protocole 8 Aplasie medullaire thymo
Female,76,88.88708054603426,186.90273041580733,2.1482058439507914,25.445286806480013,96.72870285815242,0.816828262227466,2022-02-13,Cancer diagnosis,allo-greffe,2022-10-12,Protocole 3 LAL thiotepa Bu Flu
Female,48,65.52189407279074,163.42461249819107,1.7246489295726044,24.53304839548269,134.76457577503032,0.6212494620536171,2022-02-07,Treatment follow-up,allo-greffe,2022-10-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,26,55.72848388060031,146.4832033295715,1.5058484905648084,25.971771346842782,96.1171537049246,0.9180126828887045,2022-02-21,Cancer diagnosis,auto-greffe,2022-06-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,22,111.89715135998442,157.92364478547216,2.215551472851774,44.86676046849284,85.50914164171826,2.1446478650269327,2022-04-27,Symptoms management,allo-greffe,2022-03-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,33,44.11483732418344,199.16490008836854,1.5622390598188822,11.121390151195936,84.7760542938944,0.7733262707067247,2022-10-29,Treatment follow-up,greffe haplo-identique,2022-11-30,Protocole 2 LAM Endoxan TBI
Female,69,50.727266914836434,144.35939423142378,1.4262380122041276,24.34172558114268,121.85230834017133,0.41051927716767067,2022-10-14,Cancer diagnosis,greffe haplo-identique,2022-07-30,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,40,117.28090880477649,179.20070001503083,2.41619656095501,36.52144219016901,130.25676009628899,1.2505312660727377,2022-11-04,Symptoms management,allo-greffe,2022-11-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,55.79599418706895,179.67952864685537,1.6687818191652415,17.28247037433041,111.2955680526905,0.6405904809030827,2022-02-28,Symptoms management,greffe haplo-identique,2022-06-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,50,86.02098355007088,196.52062091288755,2.1669805605186894,22.273483707880427,134.1878389449715,0.8013112833696022,2022-08-25,Symptoms management,greffe haplo-identique,2022-09-02,Protocole 3 LAL thiotepa Bu Flu
Female,56,56.02026339754278,194.48103239814992,1.7396422573469914,14.811213556935156,117.75142401866074,0.5550418987157422,2022-12-17,Symptoms management,auto-greffe,2022-12-14,Protocole 3 LAL thiotepa Bu Flu
Female,24,103.85630890443079,151.64103122282242,2.0915755479000273,45.1647307194039,110.78574976732156,1.5103391328428035,2022-08-26,Symptoms management,auto-greffe,2022-03-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,75.62705639030743,181.01444318385646,1.950041986878859,23.080793709442407,98.85434071133596,0.6906568332419941,2022-04-03,Symptoms management,allo-greffe,2022-04-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,115.1900797053979,170.53063329807796,2.335917452511824,39.61049493726294,100.43155569697086,1.6248473412250009,2022-10-02,Cancer diagnosis,greffe haplo-identique,2022-07-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,89.6217472033284,163.3558156261842,2.016613884449996,33.584911295436825,89.67838730470586,1.221450277134302,2022-08-06,Treatment follow-up,pas de greffe,2022-06-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,110.38773840269377,142.05432097402797,2.0870670025083644,54.70310004555398,129.9647990774402,1.4156107292934332,2022-01-21,Symptoms management,allo-greffe,2022-10-23,Protocole 9 LAL thiotepa-thymo melphalan
Female,21,69.0273427520957,197.7275238943569,1.947120777753867,17.655779635175172,89.09252502343473,1.2805435487399703,2022-06-09,Treatment follow-up,allo-greffe,2022-07-05,Protocole 3 LAL thiotepa Bu Flu
Female,58,73.23159693463843,153.12234979636554,1.764888586503421,31.23354896747865,100.88046353669858,0.8267473120215082,2022-12-03,Treatment follow-up,pas de greffe,2022-10-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,35,73.07633010839346,176.81562837353943,1.894512340312569,23.37412872353289,116.69520572140988,0.9132307314248842,2022-03-07,Treatment follow-up,pas de greffe,2022-02-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,119.99945839245918,152.13335863074786,2.2519078725429624,51.8478055194433,133.92285775183882,0.8586994251013961,2022-06-21,Symptoms management,auto-greffe,2022-08-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,49,118.78381551171191,149.09982628050656,2.218022533808236,53.4321926673637,115.95411291916406,1.2947323801247244,2022-12-16,Symptoms management,auto-greffe,2022-04-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,35,76.48421029111532,166.82660560705358,1.882640077819417,27.481545965033668,107.18765555251716,1.040599990421103,2022-05-12,Symptoms management,auto-greffe,2022-03-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,101.16693614865974,167.98238480214224,2.172700776899182,35.85181217102382,133.86201728216568,1.070653417007004,2022-03-07,Treatment follow-up,auto-greffe,2022-10-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,69,43.17169122371488,182.07080874738853,1.4776393275249606,13.02322127260163,83.15777826876624,0.5119435041129905,2022-01-14,Treatment follow-up,greffe haplo-identique,2022-12-01,Protocole 3 LAL thiotepa Bu Flu
Male,61,47.1255258566429,182.0550818335537,1.5437545741075172,14.218395713569572,132.34593423936894,0.39069711133169954,2022-11-11,Cancer diagnosis,greffe haplo-identique,2022-09-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,87.89544503308262,194.9331501369736,2.181598291708653,23.13102975324206,93.87623831247413,1.3264117669024085,2022-02-17,Treatment follow-up,pas de greffe,2022-10-18,Protocole 3 LAL thiotepa Bu Flu
Female,32,105.90389008242828,194.30997577823976,2.390849588462111,28.049279995752425,79.49612195803239,1.9982840824299029,2022-05-09,Cancer diagnosis,greffe haplo-identique,2022-10-07,Protocole 3 LAL thiotepa Bu Flu
Male,67,114.63693902532488,197.76052259414416,2.5094632543767252,29.311995082186133,93.92051914652022,1.237526365806042,2022-11-12,Cancer diagnosis,auto-greffe,2022-09-14,Protocole 3 LAL thiotepa Bu Flu
Male,27,87.60808120653664,167.9206801563427,2.021496185680419,31.06960981015328,113.96778323473077,1.2064463520786974,2022-11-24,Symptoms management,allo-greffe,2022-02-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,65,42.09422052845528,170.8674499318778,1.4134799568762566,14.417959326898174,85.71492997159886,0.5115578627706563,2022-07-03,Symptoms management,auto-greffe,2022-12-17,Protocole 3 LAL thiotepa Bu Flu
Female,33,70.16726253030458,189.18611737243856,1.9202627109591681,19.604510581734036,102.5317151687359,1.0170155479300131,2022-05-23,Cancer diagnosis,allo-greffe,2022-01-06,Protocole 3 LAL thiotepa Bu Flu
Male,59,92.26980238803213,192.33682154896354,2.2202903036080333,24.942197901530214,100.99837520819975,1.0277742337196396,2022-06-17,Symptoms management,auto-greffe,2022-06-17,Protocole 3 LAL thiotepa Bu Flu
Female,54,97.96321456087541,196.31017651365943,2.311275257796665,25.420108534514235,96.6576433448575,1.2105780085562383,2022-11-05,Symptoms management,auto-greffe,2022-09-01,Protocole 3 LAL thiotepa Bu Flu
Female,23,67.67442560472628,169.58879351630034,1.7854990113421882,23.530452409246266,88.74741963911382,1.239145228727445,2022-02-16,Treatment follow-up,greffe haplo-identique,2022-09-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,53,105.44569110518283,169.87350030962264,2.2306220258910248,36.54075918776071,85.74041542893896,1.4860383260489565,2022-04-01,Treatment follow-up,pas de greffe,2022-05-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,99.20150043802319,189.5935783893094,2.28570238716154,27.597579553779095,85.56918839764884,1.4974463799242252,2022-10-29,Symptoms management,allo-greffe,2022-06-18,Protocole 3 LAL thiotepa Bu Flu
Female,32,71.48333337747508,141.70963290983482,1.6774548290071063,35.5963976839964,129.860756668362,0.8256920937250003,2022-01-19,Treatment follow-up,auto-greffe,2022-03-08,Protocole 8 Aplasie medullaire thymo
Female,42,81.80531931330592,189.30829190742622,2.0740744433859013,22.82665475293896,107.81111282003866,1.032788978360655,2022-01-10,Symptoms management,allo-greffe,2022-09-02,Protocole 3 LAL thiotepa Bu Flu
Female,51,112.60019511476776,147.97600829367173,2.1513643866013603,51.422895524055626,108.44492379296854,1.2834750343903896,2022-10-07,Cancer diagnosis,allo-greffe,2022-02-08,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,31,102.44060027753032,157.84985180426693,2.1193705546529813,41.11343446659299,74.27809196739818,2.0878792443851393,2022-12-13,Cancer diagnosis,pas de greffe,2022-09-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,73,101.62987660268442,147.18963135220181,2.038440585316716,46.91016528026193,120.24057386521902,0.786525240548687,2022-10-09,Symptoms management,allo-greffe,2022-05-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,70,52.462674016798225,167.43629674321417,1.562063792855388,18.71333545523492,91.6800939240882,0.5563408078373528,2022-08-29,Cancer diagnosis,auto-greffe,2022-09-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,95.46815707181764,157.43202467847775,2.043264358551666,38.51876705640204,75.97084497558588,1.745336156815915,2022-03-28,Symptoms management,auto-greffe,2022-04-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,41.60649518311641,176.8813241696415,1.4297835852214607,13.298332024924857,82.25064540384872,0.5128757709395054,2022-01-28,Symptoms management,greffe haplo-identique,2022-10-06,Protocole 3 LAL thiotepa Bu Flu
Female,38,58.10437523624218,170.7228189034089,1.6599650875639833,19.93543376834512,85.47720016167554,0.9629998576109523,2022-05-28,Symptoms management,allo-greffe,2022-06-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,119.32290097650045,178.25574554175418,2.4307059259132355,37.55231623188489,129.3325363255999,1.0891869722416474,2022-11-25,Symptoms management,pas de greffe,2022-10-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,97.56506710838737,175.6182499438854,2.1816282363073536,31.634068996418964,107.38546938294084,1.0221187384815051,2022-05-13,Treatment follow-up,pas de greffe,2022-08-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,107.85243741249161,163.08525252851794,2.210401044005889,40.55090802870676,133.71484883690238,1.0754471259861724,2022-06-21,Treatment follow-up,pas de greffe,2022-11-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,26,50.67751853330597,180.85568600497848,1.595594401553772,15.493552445016588,93.97179517001823,0.8538668884555008,2022-12-25,Symptoms management,greffe haplo-identique,2022-11-13,Protocole 3 LAL thiotepa Bu Flu
Male,79,49.87303646430617,182.55674873326058,1.5903056472804113,14.96476928143049,97.3427738754012,0.4340696602332696,2022-02-26,Treatment follow-up,allo-greffe,2022-10-31,Protocole 3 LAL thiotepa Bu Flu
Female,55,104.77682273473158,147.16735006850985,2.0696032463620524,48.37737337241097,81.26691668531716,1.5220813735547505,2022-06-03,Cancer diagnosis,pas de greffe,2022-03-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,59.7328840017789,154.19222138667482,1.599509132521153,25.12398661266878,105.09488024900187,0.9157088612305746,2022-05-07,Treatment follow-up,greffe haplo-identique,2022-11-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,108.75199103082093,147.74348448858638,2.112620680311343,49.82192937051556,116.68371097635213,1.4239251888350484,2022-08-14,Cancer diagnosis,pas de greffe,2022-09-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,47,78.49468745318968,148.87109447870012,1.8016651273443807,35.417630439547324,110.56255546589306,0.9170281101632132,2022-10-17,Symptoms management,auto-greffe,2022-09-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,42,84.12166819462618,178.06414518386322,2.0398156873788515,26.531079327075417,100.76607991761301,1.1362845250953784,2022-03-18,Cancer diagnosis,auto-greffe,2022-12-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,40.31860941738506,189.02598462502388,1.4549975986838692,11.283985698134314,100.54475237119736,0.38986269417586233,2022-10-26,Treatment follow-up,greffe haplo-identique,2022-07-11,Protocole 3 LAL thiotepa Bu Flu
Male,54,63.62411264434883,169.9424716131208,1.7330479698570451,22.030171488302866,108.7732292462709,0.6986596647663226,2022-09-25,Cancer diagnosis,auto-greffe,2022-07-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,92.03819039318195,164.34989635718105,2.04982838387496,34.0744772697088,128.6545691505906,0.8743655381566402,2022-01-17,Treatment follow-up,auto-greffe,2022-04-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,54,80.30914075310515,174.07284950549266,1.9705921961170496,26.50348000107017,99.92537429363443,0.9599644503584722,2022-11-07,Cancer diagnosis,greffe haplo-identique,2022-06-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,108.28674251627676,179.66863735811603,2.324730060306203,33.54522748547245,133.38082699050943,0.7329304141935983,2022-02-11,Treatment follow-up,allo-greffe,2022-04-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,45,106.90758246723769,180.92758660904033,2.31795712775545,32.65870263849186,120.97810417212698,1.1659846773155385,2022-06-15,Cancer diagnosis,greffe haplo-identique,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,74,96.39962435535632,149.36726953603792,1.9999269899353906,43.208029165092,92.82795507265898,0.951936539554023,2022-08-23,Symptoms management,greffe haplo-identique,2022-09-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,101.10177790715932,192.75920371427833,2.3266749166211094,27.21000024746733,108.89431470230676,1.0702843686910009,2022-05-07,Cancer diagnosis,allo-greffe,2022-06-05,Protocole 3 LAL thiotepa Bu Flu
Female,53,48.31259928238684,157.13639646989378,1.4521696177452172,19.56621515411305,75.45041231411433,0.7737230631669261,2022-07-24,Symptoms management,greffe haplo-identique,2022-07-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,41,74.05994698529943,189.03259555156887,1.972008564681842,20.725737900954247,111.97721562176083,0.9094031007947063,2022-10-09,Treatment follow-up,allo-greffe,2022-12-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,74.52729361812914,178.74625169800862,1.9236448609228425,23.32606404454762,87.21706730728384,1.412304478158903,2022-09-03,Treatment follow-up,greffe haplo-identique,2022-05-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,57.42355475674948,149.618350287233,1.5448496448174576,25.651947945066667,84.55160455498755,1.0470289797092525,2022-12-13,Symptoms management,greffe haplo-identique,2022-06-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,29,81.90113432454328,180.54733330302102,2.02669897156194,25.12509776040982,122.02630341235096,1.0347297690700812,2022-08-13,Cancer diagnosis,greffe haplo-identique,2022-08-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,83.69723943010652,149.01503196229194,1.8613127691701392,37.692155436264244,125.0355126217451,0.687981845668454,2022-12-20,Symptoms management,auto-greffe,2022-11-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,30,89.63703038117386,167.5153275486423,2.0423010242255573,31.943195425683832,122.69917643184796,1.1161074349868512,2022-01-02,Symptoms management,auto-greffe,2022-09-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,62.3645970981589,178.53468345264275,1.7586487554031205,19.56558894829706,125.68268777565791,0.5926913869544042,2022-02-07,Cancer diagnosis,allo-greffe,2022-10-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,42.1913305596172,187.65925739357772,1.4830143628270471,11.980728728704088,129.99721216597695,0.45978718028053017,2022-05-22,Treatment follow-up,auto-greffe,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,55.83571610929856,154.574771439084,1.5483676938896729,23.36871674391924,132.130776868741,0.5693080697683714,2022-11-19,Treatment follow-up,auto-greffe,2022-02-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,105.06538536168057,186.90962493982192,2.3355781922797316,30.0743552684803,81.21435220774141,1.5272611430556258,2022-05-24,Symptoms management,greffe haplo-identique,2022-05-02,Protocole 3 LAL thiotepa Bu Flu
Male,67,48.1882131387004,184.58635900865394,1.571878459607917,14.143002424730385,129.99998958854502,0.37582690607417546,2022-08-24,Symptoms management,allo-greffe,2022-12-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,108.71677319834143,186.72981225598474,2.3746732318130968,31.179506181987016,79.55985189860324,1.2715835294757007,2022-11-02,Cancer diagnosis,pas de greffe,2022-04-08,Protocole 3 LAL thiotepa Bu Flu
Male,63,90.6117799715004,178.13270362661666,2.1174487627766347,28.555997991301968,78.98582150143943,1.2268564515718496,2022-04-30,Cancer diagnosis,pas de greffe,2022-10-30,Protocole 3 LAL thiotepa Bu Flu
Male,36,93.90991015140385,181.69330829695565,2.177077695831835,28.446809187973457,125.60456813192616,1.0799579188393653,2022-06-20,Treatment follow-up,auto-greffe,2022-10-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,93.19110603221958,141.39988220426142,1.9132005917543198,46.60970678213284,90.40677070297326,1.3600805135472158,2022-10-12,Symptoms management,greffe haplo-identique,2022-02-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,69,67.44078984311656,147.27938615090554,1.66104369211603,31.091288250131335,77.00989927686003,0.8635787454716203,2022-04-24,Cancer diagnosis,allo-greffe,2022-07-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,47,70.03274228731948,195.90481075764924,1.9521890223709655,18.247817574297517,78.55619086059826,1.1515191584112248,2022-04-05,Cancer diagnosis,auto-greffe,2022-03-31,Protocole 3 LAL thiotepa Bu Flu
Female,49,98.88871488503943,194.16735299518666,2.3094588116846184,26.229759757566598,130.88166414338812,0.9549416169004034,2022-06-28,Treatment follow-up,auto-greffe,2022-08-17,Protocole 3 LAL thiotepa Bu Flu
Male,50,58.02031086512379,146.32945289634264,1.5356938664989779,27.09670939638392,119.43367760489014,0.6072440373253251,2022-01-26,Cancer diagnosis,auto-greffe,2022-09-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,41,45.28754880934852,145.07788842357004,1.3509484274575037,21.51673461324597,90.44256463261708,0.6885074507318552,2022-11-14,Cancer diagnosis,greffe haplo-identique,2022-08-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,104.15261580390477,154.4724016330368,2.114020964601723,43.648405602386276,82.79889459599036,1.9043187542974802,2022-02-05,Symptoms management,pas de greffe,2022-04-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,114.89143084690522,197.65466764640033,2.511574737283831,29.408541650035986,76.55488624807516,1.6675244604476172,2022-11-14,Cancer diagnosis,pas de greffe,2022-12-05,Protocole 3 LAL thiotepa Bu Flu
Female,31,68.27769163074723,174.99481263581248,1.8218002279589331,22.296078235583,126.37934890868445,0.8178934265079693,2022-03-06,Symptoms management,pas de greffe,2022-07-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,46.4000706534712,186.7706414407196,1.5515378534827526,13.301524576833788,127.75309781419492,0.5094904868348017,2022-04-28,Symptoms management,pas de greffe,2022-09-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,60.565817908683556,176.70660403144365,1.7242051311184157,19.39643990592337,116.667377143262,0.6777562158644508,2022-12-10,Treatment follow-up,pas de greffe,2022-12-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,44.53801714519278,147.01809422748073,1.3486510133954333,20.605791476575536,123.86591670624344,0.4045121581521895,2022-01-12,Treatment follow-up,auto-greffe,2022-08-23,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,20,107.86463376510616,171.93223650416755,2.2696920815961925,36.48920893062091,106.34688828979287,1.6904527485433245,2022-09-19,Symptoms management,auto-greffe,2022-11-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,96.63991354770644,173.70416629608667,2.159395209423375,32.0284603828303,124.62163220218326,1.1739702711139142,2022-11-19,Treatment follow-up,auto-greffe,2022-12-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,93.73125258967292,165.15852318905013,2.0736786458402725,34.36231693093095,105.34118669562523,0.803280222822349,2022-11-23,Treatment follow-up,greffe haplo-identique,2022-10-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,62,51.027946912478235,199.64793214409343,1.6822293477732704,12.80201885057548,131.27764135846778,0.4210943710582266,2022-05-15,Cancer diagnosis,pas de greffe,2022-04-05,Protocole 3 LAL thiotepa Bu Flu
Male,23,64.80006437784303,183.76250970087062,1.8187161572911215,19.189409479799547,85.74586978807547,1.2280487080514615,2022-07-07,Treatment follow-up,pas de greffe,2022-12-29,Protocole 3 LAL thiotepa Bu Flu
Male,70,76.91877223803026,189.39611372831777,2.0116408818173888,21.443230639383152,92.90449859517068,0.8049356146005834,2022-02-08,Cancer diagnosis,auto-greffe,2022-04-06,Protocole 3 LAL thiotepa Bu Flu
Male,54,109.26737498444123,189.1522804030197,2.396071620147753,30.53988144853852,100.79667803911197,1.2948225234025137,2022-08-09,Cancer diagnosis,auto-greffe,2022-05-02,Protocole 3 LAL thiotepa Bu Flu
Female,60,59.457766052821185,153.05736123328765,1.5899378723773174,25.380498307192276,92.27595894195663,0.7159414571317574,2022-12-20,Cancer diagnosis,allo-greffe,2022-02-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,50,109.39039603202757,158.69345994093234,2.1959268120919346,43.43713139883555,87.17793221481028,1.5684932134327982,2022-04-05,Symptoms management,auto-greffe,2022-07-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,86.70280524768467,161.08310586013246,1.969655719781395,33.41436096186934,86.54822531033669,0.8904764938139011,2022-11-26,Symptoms management,greffe haplo-identique,2022-07-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,71.93233336340452,199.33437474800374,1.9957306302843918,18.103383512215267,78.55184389200238,1.1192263857475295,2022-04-14,Symptoms management,greffe haplo-identique,2022-01-25,Protocole 3 LAL thiotepa Bu Flu
Female,24,54.82887239675537,168.83564362932924,1.6035609644871072,19.234506088249095,106.61225954931804,0.8285670513084151,2022-03-22,Cancer diagnosis,greffe haplo-identique,2022-08-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,49.91841917967235,174.12246229993704,1.5538409454642954,16.464601497039805,105.10056741861925,0.7850010323287973,2022-03-30,Symptoms management,pas de greffe,2022-05-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,97.91186726036858,198.92895066812383,2.326030536967656,24.74225904023114,112.6327380472992,0.7727129110681541,2022-10-01,Treatment follow-up,allo-greffe,2022-10-10,Protocole 3 LAL thiotepa Bu Flu
Male,79,108.8978632244383,190.14382914866644,2.398278126513226,30.119994419899268,88.08230543749109,1.0474372715157234,2022-12-24,Treatment follow-up,pas de greffe,2022-03-23,Protocole 3 LAL thiotepa Bu Flu
Male,32,117.2788784903401,196.14449328772326,2.5278232947889854,30.483691962124965,124.36884123474002,1.4144886773003942,2022-07-27,Treatment follow-up,auto-greffe,2022-02-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,77.54432446776427,180.87586501629906,1.9738496484740047,23.70220635097493,111.37723353526341,1.0926964638208385,2022-02-14,Symptoms management,greffe haplo-identique,2022-04-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,41.69945364828544,196.84220193454627,1.509986412337326,10.7620234930584,88.50559476209008,0.6151131295201387,2022-09-28,Treatment follow-up,allo-greffe,2022-07-13,Protocole 3 LAL thiotepa Bu Flu
Male,67,51.86765805745771,192.36096366515255,1.6647749837096086,14.017247797813598,114.12899142494328,0.4607772445945871,2022-08-31,Cancer diagnosis,pas de greffe,2022-01-17,Protocole 3 LAL thiotepa Bu Flu
Female,44,103.7680742813291,146.02174157346778,2.0515844098244225,48.66634263523511,132.9451156610687,1.0407109105672971,2022-08-25,Symptoms management,auto-greffe,2022-03-21,Protocole 8 Aplasie medullaire thymo
Female,57,82.20554978766535,151.584299063978,1.8604860956609788,35.77607550752172,109.831577497262,0.8628186279814448,2022-05-22,Treatment follow-up,pas de greffe,2022-11-29,Protocole 6 FlUDARABINE cy (Fanconi)
Male,50,66.56325107262072,145.37210195897117,1.6394816018121243,31.4972317218626,124.75018491479027,0.6669654549819533,2022-04-08,Treatment follow-up,greffe haplo-identique,2022-01-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,45,109.2802077186548,198.6273139081802,2.455494639153653,27.698966990814622,95.16984046571072,1.5150720255127956,2022-06-12,Treatment follow-up,auto-greffe,2022-05-11,Protocole 3 LAL thiotepa Bu Flu
Male,35,50.50696030049935,189.65183433352226,1.631183761328639,14.042264094774152,109.19172045386465,0.6745564907797423,2022-12-13,Symptoms management,auto-greffe,2022-07-16,Protocole 3 LAL thiotepa Bu Flu
Male,52,44.44923595520066,149.28882115965536,1.3576710079723613,19.943883233449082,108.3611142179854,0.5013499938359647,2022-09-13,Treatment follow-up,allo-greffe,2022-04-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,67,71.61374079920019,179.8911845217231,1.8916982861087026,22.129754552317724,119.72284843953776,0.6064705027858281,2022-07-16,Treatment follow-up,allo-greffe,2022-09-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,94.89501497386553,181.93387408126233,2.189914870567319,28.669245512948482,95.04030070440487,1.4838393302261585,2022-12-12,Symptoms management,allo-greffe,2022-02-07,Protocole 3 LAL thiotepa Bu Flu
Female,52,104.85930250565056,144.10363997139385,2.0487534947381043,50.49600993534434,83.22802445977209,1.539882396116163,2022-07-01,Symptoms management,greffe haplo-identique,2022-01-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,69,58.93864016310567,166.67156516167788,1.651884059397174,21.21666328375947,114.8817893753394,0.5059117572475258,2022-07-08,Treatment follow-up,greffe haplo-identique,2022-03-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,26,65.02319800183926,176.96233925286776,1.7878181320714077,20.763789825118543,111.95952216966461,0.919559094582673,2022-12-15,Cancer diagnosis,greffe haplo-identique,2022-02-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,51,96.7559486099633,198.70137327004755,2.310936550215918,24.50619798954346,134.07094902532728,0.8920732195330213,2022-04-24,Treatment follow-up,auto-greffe,2022-12-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,57.618344467211486,164.24750301608626,1.6213565313804548,21.358129915439292,101.68753811912008,0.8971506941150402,2022-07-25,Symptoms management,auto-greffe,2022-10-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,75,108.87204315865807,191.0224630626227,2.4035278378774714,29.836473589975228,117.3541232760699,0.8375271225339362,2022-08-11,Cancer diagnosis,allo-greffe,2022-10-04,Protocole 3 LAL thiotepa Bu Flu
Female,28,114.56196127648764,194.21194851968215,2.486033304379524,30.37306006469371,86.3456627121508,2.063884736319279,2022-02-24,Cancer diagnosis,greffe haplo-identique,2022-05-19,Protocole 3 LAL thiotepa Bu Flu
Female,75,90.45383116838471,184.30210574631042,2.1519262402912513,26.62970598879762,130.71886478566972,0.6246971990429397,2022-10-16,Treatment follow-up,greffe haplo-identique,2022-09-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,111.32924761293575,171.44738117614568,2.3026016657219923,37.87455706341215,101.21906053206831,1.6956548417633832,2022-09-05,Treatment follow-up,allo-greffe,2022-12-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,53,70.3689416073442,197.26618823129542,1.9636567985345463,18.08321781282973,118.76926156332962,0.715918720520141,2022-05-16,Cancer diagnosis,allo-greffe,2022-12-10,Protocole 3 LAL thiotepa Bu Flu
Female,22,82.06669762905499,165.37687999702175,1.9416440918252826,30.006640087807217,89.21676473107767,1.5075440058544443,2022-07-03,Symptoms management,auto-greffe,2022-11-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,76.64508399346504,150.7240469752077,1.7913571236673673,33.73799048914825,111.21225696281671,0.9859079719021698,2022-07-28,Treatment follow-up,pas de greffe,2022-04-20,Protocole 6 FlUDARABINE cy (Fanconi)
Female,35,78.78873571880459,163.9037928822858,1.8939796887266023,29.328248290327544,83.56437829109231,1.3749906591738665,2022-07-01,Treatment follow-up,allo-greffe,2022-04-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,74.12278845486794,187.6120277723752,1.9654181521555107,21.058643567217853,124.74171330731008,0.5942101201725617,2022-05-26,Treatment follow-up,greffe haplo-identique,2022-06-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,60.28474858342592,190.14451052906566,1.7844088666187425,16.674002809376052,90.3357865935871,0.9824738331541776,2022-02-06,Treatment follow-up,allo-greffe,2022-04-08,Protocole 3 LAL thiotepa Bu Flu
Female,38,61.09381385512553,146.39857647972514,1.5762162305932104,28.505163059021225,95.92552978776214,0.9022579267436709,2022-09-17,Symptoms management,greffe haplo-identique,2022-05-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,63,63.930891917881816,172.27549980606847,1.7491050376788595,21.54089413331912,115.55467375946449,0.5916726253087367,2022-10-01,Cancer diagnosis,allo-greffe,2022-07-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,118.8734796554399,176.26950254740976,2.4125694650300877,38.25873601243105,118.89475247229556,0.9165026553733823,2022-04-24,Cancer diagnosis,allo-greffe,2022-12-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,78.6264061255366,187.51113674896874,2.023701695675351,22.3621878813735,124.72682997075685,0.7617198915739712,2022-07-07,Cancer diagnosis,auto-greffe,2022-05-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,96.3660863034797,190.84042286864226,2.2601957056581616,26.459612581622828,104.77566024958043,1.4434766473586191,2022-02-15,Treatment follow-up,pas de greffe,2022-07-06,Protocole 3 LAL thiotepa Bu Flu
Female,66,68.9664055046353,178.8052148585308,1.8507920942634322,21.571345243908027,94.4416318642248,0.7505391170366451,2022-01-17,Symptoms management,pas de greffe,2022-07-14,Protocole 3 LAL thiotepa Bu Flu
Male,27,80.58288085790687,175.86577642555184,1.9840874552775816,26.054342744494562,84.74501861326193,1.4923632887134548,2022-11-29,Treatment follow-up,auto-greffe,2022-06-28,Protocole 3 LAL thiotepa Bu Flu
Male,33,41.907188629655565,153.16554456334885,1.335283715959123,17.863492345303357,123.02901382661638,0.5062118009474512,2022-09-09,Treatment follow-up,auto-greffe,2022-11-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,49,40.69585180683603,144.31069222445313,1.277241661736149,19.541285206806425,122.11540399069708,0.42120021915046246,2022-05-28,Symptoms management,allo-greffe,2022-04-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,46,74.9134315254326,176.30772279146032,1.9154210821313051,24.09999868618671,87.33245779433257,1.1199003117957158,2022-01-29,Symptoms management,auto-greffe,2022-07-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,95.9511431015435,154.55554951970825,2.029626515252883,40.16806820815922,112.57983754596918,1.1245548533655556,2022-12-21,Symptoms management,greffe haplo-identique,2022-06-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,44,80.14591923320069,152.70881443200253,1.8438326861056071,34.36791641401519,93.47927579438877,1.1431541883070737,2022-07-28,Treatment follow-up,greffe haplo-identique,2022-10-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,68,114.73977954477806,155.54889942354623,2.226584730796033,47.422028353350996,126.3759310768896,0.9079243062111891,2022-10-23,Treatment follow-up,greffe haplo-identique,2022-08-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,81.676114614187,173.92556333462548,1.986451627431849,27.000277798989973,96.04506898431957,0.8149605596588008,2022-08-21,Cancer diagnosis,allo-greffe,2022-04-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,72.67267576282957,154.76997384694985,1.7675743051488668,30.338753441556918,121.17268503036308,0.7830000264125155,2022-07-11,Symptoms management,allo-greffe,2022-12-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,67,102.00642306158568,184.96072425407465,2.2892976778454246,29.817311630906815,78.69085112886955,1.314297373249504,2022-05-01,Symptoms management,allo-greffe,2022-06-26,Protocole 3 LAL thiotepa Bu Flu
Male,24,112.89927320321524,152.2377665621914,2.185020543950722,48.71316396420455,120.58116045460466,1.5084717447428,2022-11-28,Cancer diagnosis,allo-greffe,2022-02-17,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,50,44.10470052051124,170.53719440284218,1.4454422513105691,15.165147882664794,81.92252773930441,0.6729635568140386,2022-01-02,Cancer diagnosis,allo-greffe,2022-07-25,Protocole 3 LAL thiotepa Bu Flu
Male,74,76.8564058251618,141.47328778535058,1.7379049024176918,38.399995894547075,80.81949259271177,0.8717167490121674,2022-08-26,Symptoms management,greffe haplo-identique,2022-09-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,52,79.44491156270774,140.8791392692546,1.763214454111543,40.02881253287196,89.93315867324662,1.0796833758192654,2022-03-19,Treatment follow-up,pas de greffe,2022-12-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,49,106.79530360272148,195.49790497437075,2.4082184583579807,27.94267241279109,76.8978280826287,1.755282313877038,2022-10-26,Treatment follow-up,greffe haplo-identique,2022-09-13,Protocole 3 LAL thiotepa Bu Flu
Male,45,74.37281479941561,180.18100240146384,1.929347062982213,22.908477200316362,101.73743716445853,0.9645495310261856,2022-09-21,Cancer diagnosis,auto-greffe,2022-05-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,91.07894010195142,181.1702464641512,2.1409236081890373,27.748800702309143,126.13357073170313,1.0229512867135042,2022-04-01,Treatment follow-up,greffe haplo-identique,2022-07-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,68.945668215399,168.69220796553884,1.7974207601847407,24.227965125021683,128.00445437356976,0.5535809360120051,2022-06-29,Symptoms management,allo-greffe,2022-04-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,78.19768982492252,167.92495020395953,1.9098678815500116,27.730868194180886,111.08303132941319,0.7039571110823376,2022-01-22,Cancer diagnosis,allo-greffe,2022-04-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,117.51252047977522,171.35214202433156,2.365024201126328,40.022578562650835,123.08567489292852,1.4718620659735415,2022-10-26,Treatment follow-up,allo-greffe,2022-12-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,42.64603783729591,161.86124786141932,1.3847122545747366,16.277695475962755,128.63232009683574,0.4420458539522211,2022-02-25,Symptoms management,auto-greffe,2022-07-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,65,105.08773234949894,194.2451485113154,2.3812218022212526,27.851696845732413,77.07912100912985,1.4201820990031184,2022-11-08,Symptoms management,allo-greffe,2022-04-20,Protocole 2 LAM Endoxan TBI
Male,47,62.41289047866786,174.74168381655198,1.7405405908398808,20.44001751642664,124.41088015603583,0.6479871382671953,2022-02-21,Cancer diagnosis,auto-greffe,2022-12-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,82.56154954568989,155.62674049410674,1.8892080091005226,34.08861781477547,81.9181113802229,1.6377638076765562,2022-02-24,Cancer diagnosis,allo-greffe,2022-01-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,63,67.41780762445751,176.65306881393957,1.8188490415620466,21.60390469349038,90.86385324412205,0.7934904502331842,2022-09-04,Treatment follow-up,auto-greffe,2022-07-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,56,90.83930582309512,169.49762475133397,2.068080603084432,31.618886639485257,112.68184674637477,0.9405169793274967,2022-08-04,Treatment follow-up,greffe haplo-identique,2022-05-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,114.53846826496633,148.29253846142822,2.1721213524069296,52.08501241500675,120.05795568894841,0.9407761073190399,2022-01-05,Treatment follow-up,auto-greffe,2022-02-23,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,63,93.32808704264377,155.8343719982071,2.0099560411227073,38.43136888284861,121.59049701958003,0.8208635267138549,2022-01-19,Treatment follow-up,greffe haplo-identique,2022-01-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,30,85.58285158923778,155.76245748000764,1.9243032852962114,35.27452480788552,104.32748272669618,1.2532802996830408,2022-01-28,Symptoms management,auto-greffe,2022-11-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,93.44829890497438,191.40648638731676,2.2290138921027194,25.506924573859617,108.70386896276825,1.0626344921580928,2022-08-05,Treatment follow-up,allo-greffe,2022-04-29,Protocole 3 LAL thiotepa Bu Flu
Male,79,73.52411494080542,179.8019882145369,1.9162885169044115,22.742637326540024,77.80068281813448,0.8006518939259472,2022-01-20,Cancer diagnosis,allo-greffe,2022-09-02,Protocole 3 LAL thiotepa Bu Flu
Female,21,114.5955240766207,141.12337259275853,2.1194933122045527,57.53998728282179,103.67093405224027,1.826943466441587,2022-09-02,Cancer diagnosis,allo-greffe,2022-10-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,35,109.27952279921728,190.9718888945214,2.4077027367307364,29.96400786938281,121.98401276665165,1.3064496497071003,2022-09-19,Cancer diagnosis,greffe haplo-identique,2022-09-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,106.1818216179372,199.10317499867577,2.423332061627035,26.785132591441172,114.23285878013621,1.1489910250129667,2022-01-30,Treatment follow-up,greffe haplo-identique,2022-07-25,Protocole 3 LAL thiotepa Bu Flu
Female,42,119.21015541149077,145.64336221484726,2.1960929855518403,56.1994236616709,121.19057010075166,1.3388687498785525,2022-07-02,Treatment follow-up,pas de greffe,2022-07-16,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,72,60.36024492353937,154.2333634018156,1.6081013295804987,25.374315437909328,118.5789427450838,0.48075060093843014,2022-05-03,Symptoms management,auto-greffe,2022-07-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,48,54.206600375999166,168.35952421270107,1.5921855566494512,19.12391441311647,130.36535824673498,0.5313067083223161,2022-07-08,Symptoms management,pas de greffe,2022-10-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,79,41.83321942962047,143.07224785190817,1.2893983026846627,20.436686718232167,110.98638483506238,0.3193367653207512,2022-04-27,Treatment follow-up,greffe haplo-identique,2022-09-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,35,72.64391571064083,189.35674050698682,1.9547389067363132,20.25991912232769,86.70900644779778,1.2217766998456385,2022-06-14,Treatment follow-up,allo-greffe,2022-12-13,Protocole 3 LAL thiotepa Bu Flu
Male,37,108.84444158448176,192.6791301541192,2.413621778722727,29.318172888402916,122.44092689269232,1.2716991332194472,2022-12-29,Cancer diagnosis,pas de greffe,2022-11-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,68.94682136983391,186.90911759118745,1.8919999370854526,19.735733612248232,97.87364022562134,0.7533672488945609,2022-10-27,Cancer diagnosis,allo-greffe,2022-09-25,Protocole 3 LAL thiotepa Bu Flu
Female,43,98.45742301103228,143.61234928807175,1.9818413031729272,47.73807375904213,91.95896306494573,1.4424263149804857,2022-08-14,Symptoms management,greffe haplo-identique,2022-07-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,69,61.522647550463304,184.22497839809324,1.7743550014314753,18.12750309617935,116.20514971611975,0.5220781220341122,2022-06-03,Cancer diagnosis,auto-greffe,2022-07-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,82.62039509357534,157.09880340406102,1.898798246111606,33.476613115621575,102.73850930377577,0.94938078322235,2022-11-28,Treatment follow-up,pas de greffe,2022-02-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,67,111.61253329279768,174.95660016760996,2.329004875776232,36.46299216196466,94.2477147477274,1.200694443034625,2022-08-27,Cancer diagnosis,greffe haplo-identique,2022-04-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,72.50708306810837,150.88094722332193,1.7432359257137189,31.85016086915991,90.86279180557798,1.1748102478492048,2022-11-27,Symptoms management,auto-greffe,2022-06-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,102.95592087484505,196.29852364826257,2.3693702438376265,26.718819177117055,115.38760203456424,0.8426914657935453,2022-01-15,Symptoms management,greffe haplo-identique,2022-11-24,Protocole 3 LAL thiotepa Bu Flu
Male,66,76.69702005066347,197.75835452041963,2.052605152390956,19.611409619063995,133.9162371410878,0.5886328238658591,2022-05-18,Symptoms management,pas de greffe,2022-06-19,Protocole 3 LAL thiotepa Bu Flu
Male,36,115.3774399129553,152.86093421264076,2.2133875026100434,49.37736148113215,130.96905942750524,1.2724860575847654,2022-11-18,Treatment follow-up,auto-greffe,2022-10-11,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,60,86.32425086426598,179.3767929017448,2.073950020135872,26.82874194990976,105.78085726872371,0.9067409432121171,2022-04-25,Treatment follow-up,pas de greffe,2022-04-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,82.78573262450573,162.54793844930612,1.9333800404651773,31.332320825808505,107.45874417990274,0.8024953093268584,2022-12-16,Treatment follow-up,greffe haplo-identique,2022-02-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,90.54007875231561,148.02464874069597,1.929461881966811,41.32118708506339,75.4434011291028,1.8668315637386084,2022-04-11,Symptoms management,allo-greffe,2022-04-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,69,86.73977232749601,141.13663939572334,1.844071579733654,43.545043969586075,94.5069576743243,0.9050662022382517,2022-05-02,Treatment follow-up,pas de greffe,2022-09-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,57,40.10117244167512,143.67798214576402,1.2650928312555654,19.425697890927136,129.61535341162335,0.35665327630431937,2022-03-18,Symptoms management,auto-greffe,2022-09-15,Protocole 8 Aplasie medullaire thymo
Female,26,66.29897690620875,168.25741412275218,1.7603104534603762,23.418463985866648,98.58623680853384,1.064787372961278,2022-04-05,Cancer diagnosis,allo-greffe,2022-09-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,32,56.80892706825996,153.79248285693075,1.557846264546915,24.01852703855781,123.00168961498065,0.6927822769681011,2022-08-06,Treatment follow-up,pas de greffe,2022-10-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,48,114.4197104363011,199.36928646210353,2.517261299887784,28.78619978974994,74.99191574635614,1.9495829901155395,2022-05-12,Cancer diagnosis,auto-greffe,2022-06-14,Protocole 3 LAL thiotepa Bu Flu
Male,77,79.90008868551467,179.77454953834462,1.9974986060009172,24.722412184972534,79.72295421936677,0.8769441409239921,2022-08-21,Cancer diagnosis,greffe haplo-identique,2022-05-03,Protocole 3 LAL thiotepa Bu Flu
Male,26,47.42903806301588,153.4820437927793,1.4220003220265693,20.133958501606816,107.42216433952218,0.699073393231564,2022-12-22,Cancer diagnosis,greffe haplo-identique,2022-02-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,116.75063626749464,148.59080971520592,2.195201305483832,52.87804102470023,110.9970801178027,1.5485351595660688,2022-06-22,Treatment follow-up,allo-greffe,2022-09-27,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,46,91.10276547897824,142.77692336817265,1.9008311460911484,44.6905317153641,84.64096061498844,1.4052265089308635,2022-06-12,Symptoms management,auto-greffe,2022-08-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,63,115.77144989140668,196.2629509584799,2.512283511537156,30.055559937664516,96.54975661730026,1.2823557329346822,2022-06-27,Cancer diagnosis,greffe haplo-identique,2022-11-12,Protocole 3 LAL thiotepa Bu Flu
Female,75,77.80313801119921,191.82977832493822,2.0361291378545356,21.14292473327356,103.46113930282712,0.678892041119915,2022-08-13,Symptoms management,auto-greffe,2022-01-11,Protocole 3 LAL thiotepa Bu Flu
Male,61,85.78793973139692,142.48163704180376,1.8426434884104408,42.257951992679295,89.15327382318527,1.0558045693154374,2022-06-13,Treatment follow-up,pas de greffe,2022-08-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,55,49.64804632119873,190.86116402985255,1.6224025319698652,13.629095260945313,92.81423939237119,0.6315009129061323,2022-01-31,Cancer diagnosis,greffe haplo-identique,2022-02-02,Protocole 3 LAL thiotepa Bu Flu
Female,54,94.95666923479503,193.33861583090845,2.258243601770133,25.403190355462133,130.90809033978493,0.8664129599328472,2022-08-06,Symptoms management,pas de greffe,2022-10-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,71.5531719547089,184.242561780284,1.9136309077859135,21.07894951128561,96.69337812879976,0.9147231444395653,2022-06-22,Symptoms management,auto-greffe,2022-12-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,31,106.64725569711428,152.97257911679205,2.128778063670667,45.57456231778732,121.20917087028403,1.3320122089040345,2022-10-05,Symptoms management,auto-greffe,2022-03-10,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,37,101.98929681635458,182.4357942623144,2.2734273178853517,30.6432266840682,107.23552160670948,1.360569268296559,2022-06-29,Cancer diagnosis,greffe haplo-identique,2022-01-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,45.003150540659576,193.77851164301623,1.5564064317644253,11.984824719168587,80.09179299999761,0.8350378927524097,2022-11-26,Treatment follow-up,pas de greffe,2022-05-04,Protocole 3 LAL thiotepa Bu Flu
Female,24,105.31717774354388,161.23649771330113,2.171851033899312,40.51095677435145,119.73471699197562,1.4171134280532756,2022-02-26,Cancer diagnosis,greffe haplo-identique,2022-07-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,103.88196477122398,173.01883883314565,2.2344236716795502,34.70190919019711,129.35790722048682,0.9480551538582122,2022-01-05,Cancer diagnosis,allo-greffe,2022-08-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,70,58.20587869544032,150.05523975829223,1.5576065223949613,25.850236436907625,124.38875589792544,0.45493701036865086,2022-10-21,Treatment follow-up,auto-greffe,2022-07-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,53,110.542978887219,188.09447856596051,2.403268837144262,31.244894980036705,87.99152828643194,1.5180184815131366,2022-09-05,Treatment follow-up,allo-greffe,2022-04-05,Protocole 3 LAL thiotepa Bu Flu
Male,49,52.39769697812797,169.06513370051124,1.568671026804225,18.33175711216791,96.77359256230365,0.684327875617377,2022-06-19,Cancer diagnosis,auto-greffe,2022-02-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,68.11237115341501,181.07690821703412,1.8509440218883724,20.773030475436304,134.91179422523751,0.5609621666311368,2022-12-01,Cancer diagnosis,allo-greffe,2022-10-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,68.84620258507104,171.07768215340587,1.8087786520281344,23.523030695610334,134.41017714631164,0.7327444965701339,2022-10-27,Treatment follow-up,greffe haplo-identique,2022-12-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,73,49.87112119335823,195.73807109556643,1.6466866619704654,13.016628904454457,98.24233938746673,0.4723813498091882,2022-04-19,Cancer diagnosis,greffe haplo-identique,2022-11-29,Protocole 3 LAL thiotepa Bu Flu
Male,31,59.22745527189313,162.84933884698248,1.6368289068107866,22.33320611120044,96.86057619077914,0.9256994948768269,2022-10-15,Symptoms management,pas de greffe,2022-07-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,42.72503663256553,199.78539702125443,1.5398266863500458,10.704218405271327,108.29074915012725,0.46577643754190057,2022-02-19,Cancer diagnosis,pas de greffe,2022-08-31,Protocole 3 LAL thiotepa Bu Flu
Female,46,40.25399207336304,155.70342273287315,1.3194784685713865,16.603996674913496,103.66770388642945,0.5069449887907466,2022-03-15,Cancer diagnosis,allo-greffe,2022-12-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,50.947359836473424,193.43250938682706,1.6545287731122436,13.616414121900387,81.39625662311676,0.9214899852471378,2022-01-29,Symptoms management,allo-greffe,2022-05-04,Protocole 3 LAL thiotepa Bu Flu
Female,69,85.4046784872048,146.05304244969534,1.861422181237769,40.03690021067174,122.64596240389936,0.6866797793127116,2022-09-12,Symptoms management,greffe haplo-identique,2022-03-28,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,47,101.64776146006261,181.08711289432523,2.261212780233811,30.99721883266722,86.41538226714374,1.519347849591908,2022-07-05,Symptoms management,auto-greffe,2022-12-30,Protocole 3 LAL thiotepa Bu Flu
Male,52,96.44959339092519,158.63421457378206,2.0615666570683877,38.327163182194134,88.76663787993111,1.3280083506839453,2022-07-20,Treatment follow-up,allo-greffe,2022-10-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,73,56.841684557013636,190.1822870423884,1.732875065092921,15.715449548405903,90.65270525597981,0.5834833632631868,2022-07-28,Treatment follow-up,auto-greffe,2022-01-12,Protocole 3 LAL thiotepa Bu Flu
Male,32,108.5157486528652,199.29642902970954,2.4510089305790395,27.32082042112024,133.86743768863238,1.2159314153595697,2022-07-31,Treatment follow-up,greffe haplo-identique,2022-03-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,44.2027304994901,199.5848397773489,1.5654423305022613,11.096703910388609,89.28148816866094,0.4744650983190111,2022-04-22,Cancer diagnosis,pas de greffe,2022-03-12,Protocole 2 LAM Endoxan TBI
Female,34,102.60813270552775,171.39108027184028,2.2102110701793936,34.930544217531,91.72032192163267,1.6469847683142078,2022-01-10,Treatment follow-up,allo-greffe,2022-08-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,51,55.703404462415236,186.9715090379487,1.7008943391712248,15.934222331347014,97.9823063598349,0.7027350114605299,2022-07-17,Cancer diagnosis,auto-greffe,2022-01-13,Protocole 3 LAL thiotepa Bu Flu
Male,25,107.12128955431396,190.74754227613602,2.3824079035444434,29.441361535180437,127.06222657995376,1.3465567915385868,2022-03-04,Symptoms management,pas de greffe,2022-03-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,101.2265658570581,156.0705874761799,2.0948673785593255,41.55778321363062,91.93547009074328,1.498666438445015,2022-10-14,Cancer diagnosis,greffe haplo-identique,2022-05-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,70,115.7433171900396,175.15658164482568,2.3730666860532157,37.72619482654787,119.91958390431469,0.938364038484819,2022-04-15,Cancer diagnosis,pas de greffe,2022-09-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,74,42.32805034089083,157.01336606309428,1.3587238357811444,17.169395973523773,123.16341607281615,0.31503439941568095,2022-09-30,Treatment follow-up,allo-greffe,2022-03-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,55,94.92730350371176,194.33237838353392,2.2636897524599493,25.136268842716646,82.87811184051294,1.352190017804364,2022-09-03,Cancer diagnosis,auto-greffe,2022-01-11,Protocole 2 LAM Endoxan TBI
Male,68,77.81016180468454,148.01326168855388,1.7886164610628124,35.51690064071828,101.62029660011369,0.7656950865915647,2022-10-14,Cancer diagnosis,pas de greffe,2022-01-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,64,55.106154944000636,162.42685535080875,1.576804033659052,20.88740253735748,100.26406332706742,0.5801441320675272,2022-11-17,Cancer diagnosis,allo-greffe,2022-05-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,47,91.5065677590864,141.6179017420135,1.897291060203058,45.62637390651039,127.66737373209793,0.9258119745105239,2022-03-07,Cancer diagnosis,greffe haplo-identique,2022-04-27,Protocole 8 Aplasie medullaire thymo
Female,21,59.98026513908335,175.19468467192843,1.7084937841382366,19.541888442862938,112.79421846615531,0.8788930024533301,2022-08-04,Symptoms management,greffe haplo-identique,2022-07-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,43.31033705789447,161.37039108676868,1.3933379215566601,16.631976417242043,132.68485673707306,0.3309486146112906,2022-10-03,Symptoms management,auto-greffe,2022-05-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,72,91.85464675349228,144.4440833059539,1.9197699694162151,44.025228349851616,102.22044198114493,0.8486718423575635,2022-06-29,Cancer diagnosis,auto-greffe,2022-05-31,Protocole 6 FlUDARABINE cy (Fanconi)
Female,65,84.14962618754734,160.06197617043557,1.9342781787172547,32.84549732459154,122.64692498592221,0.7147008424556089,2022-05-09,Symptoms management,allo-greffe,2022-08-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,71,87.82567070405472,158.23121000821106,1.9647421477190554,35.078190049180535,130.85934919106808,0.6431811580780602,2022-12-08,Treatment follow-up,auto-greffe,2022-09-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,58,105.64506306647363,161.25590891828898,2.1753601660615347,40.627297255933755,109.65137413402714,1.0972775256360012,2022-12-13,Treatment follow-up,greffe haplo-identique,2022-06-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,30,83.36736895343856,173.78451143742393,2.0060988595472766,27.60412344732761,124.28090316953522,1.024830126195009,2022-04-08,Symptoms management,pas de greffe,2022-07-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,88.62396943849328,166.60789184480595,2.0252196530435542,31.927143173187854,92.1440790265707,1.14881399932271,2022-12-02,Treatment follow-up,allo-greffe,2022-09-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,68.4702089275989,142.7404660994562,1.6476809912598553,33.60527331844335,105.42712452558227,0.7757383219123629,2022-11-09,Treatment follow-up,pas de greffe,2022-08-10,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,77,84.3438191220967,151.5641141218889,1.8844020733745155,36.71643370894255,88.03110812669262,0.8383495709905403,2022-01-23,Cancer diagnosis,allo-greffe,2022-02-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,116.94077472931946,158.43760988819832,2.2686153906554494,46.58535423813823,90.5253631621185,1.5429847926079956,2022-01-07,Symptoms management,auto-greffe,2022-12-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,100.12213688880378,151.31993288433404,2.051454432175289,43.72580665600482,115.75012316251414,1.3575461279243635,2022-10-29,Treatment follow-up,auto-greffe,2022-06-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,59,101.69992569609235,144.11448907741664,2.01772925386873,48.96720806781235,116.66091678257953,0.9807261897429953,2022-10-31,Cancer diagnosis,allo-greffe,2022-01-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,31,67.03996161130311,142.26792531740273,1.6276803750360014,33.12224462911668,92.55510310427609,1.0965473495345337,2022-08-30,Treatment follow-up,pas de greffe,2022-05-08,Protocole 6 FlUDARABINE cy (Fanconi)
Male,52,77.60185113719855,192.60288869543757,2.0375871281396756,20.919268214556574,120.27285171381043,0.788596142803306,2022-09-21,Symptoms management,allo-greffe,2022-05-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,57.90262582482822,176.86747670746252,1.6866379546612285,18.509824415364466,78.18528093627697,0.6685811350123638,2022-05-27,Treatment follow-up,allo-greffe,2022-04-25,Protocole 3 LAL thiotepa Bu Flu
Female,64,113.73186028613931,154.23537639840362,2.207403972978927,47.80949402729228,76.45097689160342,1.5702912094755412,2022-08-27,Treatment follow-up,greffe haplo-identique,2022-01-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,63.82240733907519,180.54160493965963,1.789056226377887,19.580265835339056,81.80901421417782,0.6717864116251935,2022-05-07,Symptoms management,auto-greffe,2022-11-24,Protocole 3 LAL thiotepa Bu Flu
Female,76,49.92378104885236,171.62521436791116,1.542741033262797,16.949047017038392,102.82146200044258,0.4315898004392851,2022-02-15,Treatment follow-up,auto-greffe,2022-02-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,87.98437060391032,188.54268669670677,2.1466258808871292,24.750623785598908,96.06302892059061,1.3356911801115736,2022-01-20,Cancer diagnosis,greffe haplo-identique,2022-05-29,Protocole 3 LAL thiotepa Bu Flu
Male,29,106.22439341114021,142.24813279879757,2.048727357031649,52.49659204669948,130.42629170050455,1.2555950519921717,2022-11-18,Cancer diagnosis,allo-greffe,2022-04-21,Protocole 9 LAL thiotepa-thymo melphalan
Male,70,42.177865963305706,153.99359539927946,1.3432052488521562,17.786040814233257,91.73614614628677,0.4470021937704424,2022-11-14,Cancer diagnosis,pas de greffe,2022-11-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,73,76.93478975663011,187.5587074060948,2.002067661840379,21.86997613799026,112.72237834558436,0.635118749925979,2022-08-03,Treatment follow-up,allo-greffe,2022-08-17,Protocole 3 LAL thiotepa Bu Flu
Female,47,76.32108309752758,147.26297084508784,1.7669236790296738,35.193090783360354,115.44301332287424,0.8539399324691734,2022-08-15,Symptoms management,greffe haplo-identique,2022-07-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,20,45.658868138160315,151.46109280260225,1.3859956373524092,19.903202855448246,106.07736217762857,0.7173831626409862,2022-02-09,Treatment follow-up,allo-greffe,2022-10-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,58,117.57939693179814,195.86202080577914,2.5292367254539907,30.650020286207525,121.33843059948745,1.1036064012554228,2022-07-19,Cancer diagnosis,greffe haplo-identique,2022-12-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,48.555389648774195,175.9419304808316,1.5404661082187572,15.685513393361983,99.53897232393311,0.48102776348910703,2022-10-31,Treatment follow-up,auto-greffe,2022-07-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,75.8819489356098,164.3670097504608,1.8613383059108113,28.087246649389822,77.41603550881212,1.0618658542762327,2022-01-21,Treatment follow-up,allo-greffe,2022-05-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,72.40717219845673,158.32409027572461,1.7844855831862458,28.886011796579044,96.8811240685551,1.1106921411452502,2022-10-25,Symptoms management,greffe haplo-identique,2022-06-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,34,92.83303619630067,170.4697209967429,2.0966389624338118,31.9453796646342,92.61761071256805,1.4756465621716557,2022-03-09,Treatment follow-up,pas de greffe,2022-04-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,61.59534927334376,150.31856489769535,1.6037217571031224,27.259800959984858,104.04134100079614,0.5180241824618866,2022-08-15,Symptoms management,greffe haplo-identique,2022-09-09,Protocole 6 FlUDARABINE cy (Fanconi)
Female,30,116.54690161539334,172.1708930516721,2.360907554635601,39.31708107179807,128.54556204792107,1.3851724129571428,2022-05-08,Symptoms management,auto-greffe,2022-05-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,107.11350241424353,199.68172069451862,2.437474129303884,26.863809516164512,119.22695736854399,0.9607889239998497,2022-10-26,Treatment follow-up,greffe haplo-identique,2022-10-23,Protocole 3 LAL thiotepa Bu Flu
Female,53,114.36486410227835,188.14099669819586,2.444763083241876,32.30916523656914,100.06083835993228,1.3810685551107271,2022-06-20,Treatment follow-up,pas de greffe,2022-07-18,Protocole 3 LAL thiotepa Bu Flu
Female,72,46.35525492241705,176.04363992390017,1.5055958405361007,14.957475309041346,90.38213890442924,0.48438733042792936,2022-03-01,Symptoms management,auto-greffe,2022-05-22,Protocole 3 LAL thiotepa Bu Flu
Male,59,99.58367130928768,163.78575971449777,2.128535442018925,37.12238360039925,113.69639383303584,0.9853578151956875,2022-11-21,Cancer diagnosis,pas de greffe,2022-08-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,61,48.45413522882293,176.3570240457214,1.5406732918204733,15.579206135164974,111.66697440874012,0.4761027529681503,2022-11-05,Treatment follow-up,greffe haplo-identique,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,28,51.30439293542384,196.7565819586505,1.6745212411510284,13.252445115919015,79.28652942193075,1.0065623257439378,2022-10-26,Treatment follow-up,pas de greffe,2022-02-28,Protocole 3 LAL thiotepa Bu Flu
Male,56,67.10482730570878,170.73532835910135,1.7839691019777733,23.020087750056526,86.31959470115953,0.9069663204632948,2022-04-23,Cancer diagnosis,greffe haplo-identique,2022-07-05,Protocole 3 LAL thiotepa Bu Flu
Female,41,78.40552128900028,165.26400316814465,1.8971916612826396,28.707152064919754,122.29364129522978,0.8815469932088821,2022-07-08,Treatment follow-up,pas de greffe,2022-02-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,116.28499656057971,188.33252792359585,2.4664553604222657,32.78483578659835,104.00818029168485,1.645998954768819,2022-02-11,Cancer diagnosis,pas de greffe,2022-09-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,66.83118898222074,192.4821017246593,1.890312122673553,18.0384195333971,85.1979945149023,0.9914223646554009,2022-03-12,Treatment follow-up,pas de greffe,2022-07-21,Protocole 3 LAL thiotepa Bu Flu
Female,32,92.64986425006616,171.140837982717,2.098688440083294,31.63278860133676,127.36644683597258,1.0911413470933702,2022-04-17,Symptoms management,auto-greffe,2022-02-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,71,87.86877585900697,177.8918947015873,2.0837428279332575,27.766571268946507,118.88170193576019,0.7083308490181669,2022-06-18,Cancer diagnosis,auto-greffe,2022-06-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,80.74324951275338,181.1944137865108,2.0159245027393293,24.593289100714014,84.103672553564,0.9067084838672722,2022-04-29,Symptoms management,auto-greffe,2022-06-08,Protocole 3 LAL thiotepa Bu Flu
Male,34,111.82411059853378,156.90824526963073,2.207696447333802,45.419664444261635,100.44670590991853,1.6389779944704057,2022-03-07,Symptoms management,allo-greffe,2022-04-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,84.50125389281135,148.41120309440947,1.866438434947567,38.36452115792099,103.17644133690698,0.9099972909177909,2022-05-30,Cancer diagnosis,pas de greffe,2022-06-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,60,53.77013401508533,140.68283441548257,1.4495722415157282,27.16807700264149,111.0843046789986,0.5378310961457548,2022-02-26,Treatment follow-up,greffe haplo-identique,2022-04-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,64,78.08680465450254,187.03645937201418,2.0141912814833174,22.321588951243932,120.85142213222048,0.6820355028876907,2022-05-16,Treatment follow-up,allo-greffe,2022-11-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,73,57.15800438904189,162.20108228834025,1.6047750078839622,21.725489081570043,121.15206985121827,0.4390242658999598,2022-10-31,Treatment follow-up,auto-greffe,2022-02-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,23,84.10591710053332,167.45498239717213,1.9779306573880457,29.99372483827547,112.7163448637519,1.2125314696246736,2022-10-25,Symptoms management,pas de greffe,2022-09-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,48,43.671153255835506,155.9261289352787,1.3753256052175955,17.96208993661169,102.54716528238481,0.5441596460182184,2022-04-17,Treatment follow-up,allo-greffe,2022-05-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,85.98935370387126,167.22335221213382,1.9985708769654644,30.750404601802927,99.74449192348165,0.9698582954441949,2022-08-24,Treatment follow-up,greffe haplo-identique,2022-11-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,69.24327991175122,195.02533379588004,1.93679243552544,18.20520491057929,123.1926621811397,0.8040767770485703,2022-10-19,Treatment follow-up,pas de greffe,2022-06-04,Protocole 3 LAL thiotepa Bu Flu
Female,46,65.30926374414051,192.331479472287,1.867933150656416,17.655256973852357,129.2534060370925,0.659672148878899,2022-12-11,Treatment follow-up,auto-greffe,2022-01-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,68,87.1451144230966,192.20118723769338,2.156990860105539,23.590161410985687,116.01917522241456,0.7511268224070293,2022-03-17,Treatment follow-up,pas de greffe,2022-11-26,Protocole 3 LAL thiotepa Bu Flu
Male,44,62.112297776183055,142.4894688137993,1.567938164608829,30.592295166198827,108.48893657555377,0.7633626031280694,2022-01-05,Treatment follow-up,auto-greffe,2022-04-18,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,54,92.94499154685295,189.88914343328267,2.2141743401727276,25.77660528979417,98.08954576108226,1.1317987858000806,2022-06-23,Symptoms management,pas de greffe,2022-03-16,Protocole 3 LAL thiotepa Bu Flu
Male,27,100.74257482288353,145.19666847930094,2.015735751965671,47.78589706668717,77.40362221432902,2.042667640759761,2022-02-06,Treatment follow-up,allo-greffe,2022-05-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,50,49.46553080307179,179.52086350975398,1.5705709156347312,15.348743081258522,113.3511368476884,0.5454900164514821,2022-05-04,Treatment follow-up,greffe haplo-identique,2022-03-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,50.00055877235443,178.1623332248074,1.5730557853202984,15.752267365062915,123.31778518089774,0.3716726299786373,2022-12-27,Cancer diagnosis,auto-greffe,2022-07-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,62.558807046705056,195.97560859193567,1.8454147594453527,16.288624618708795,106.81266055849923,0.9680107727908723,2022-06-14,Treatment follow-up,greffe haplo-identique,2022-05-07,Protocole 3 LAL thiotepa Bu Flu
Female,62,78.93740487870835,196.21293568633322,2.074216046466716,20.503479734870474,98.5217538680013,0.8679861918262956,2022-06-18,Treatment follow-up,auto-greffe,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Female,29,117.97963540010463,150.5000031392301,2.2208566601702353,52.08756215861096,107.95024478175344,1.6848991089325587,2022-05-07,Treatment follow-up,pas de greffe,2022-03-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,99.76383308374162,182.8781126799917,2.251210878374149,29.829753519665815,130.83331729932237,0.8260700567077944,2022-06-07,Symptoms management,greffe haplo-identique,2022-12-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,113.57391937092633,185.93532964130915,2.4219714270775743,32.851467694015945,87.08887308631867,1.7750456299392656,2022-04-09,Cancer diagnosis,allo-greffe,2022-03-13,Protocole 3 LAL thiotepa Bu Flu
Female,79,52.22536664954832,196.0625219160549,1.6865017288673378,13.58602246768559,126.64468788557897,0.34937502652441693,2022-03-30,Cancer diagnosis,greffe haplo-identique,2022-09-30,Protocole 3 LAL thiotepa Bu Flu
Male,42,117.94935683668945,180.55071801818391,2.4321824371132235,36.18238057371498,90.46765006386707,1.7745810798168187,2022-04-11,Treatment follow-up,pas de greffe,2022-04-21,Protocole 3 LAL thiotepa Bu Flu
Male,31,109.93353916738339,183.6814177361353,2.3683531743841626,32.58365240271165,98.102364700811,1.6964643407862459,2022-06-26,Treatment follow-up,auto-greffe,2022-02-01,Protocole 3 LAL thiotepa Bu Flu
Male,76,116.81883870764672,170.318802376492,2.3509126303357037,40.27056245105715,102.04916635301231,1.0175386184040618,2022-09-04,Treatment follow-up,auto-greffe,2022-09-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,46.47714958401589,193.24316339351324,1.5795033863641321,12.446040464208746,123.72474803743609,0.579126435187224,2022-12-15,Cancer diagnosis,auto-greffe,2022-03-27,Protocole 3 LAL thiotepa Bu Flu
Male,63,104.2598471025261,145.51597542651245,2.0528755813453974,49.237470548895956,87.6884880072014,1.2715479169086232,2022-04-23,Cancer diagnosis,allo-greffe,2022-05-08,Protocole 6 FlUDARABINE cy (Fanconi)
Male,36,94.93502863669532,163.54090219139556,2.0767068102601454,35.49553343376966,92.667701504369,1.4797860794139108,2022-09-19,Symptoms management,pas de greffe,2022-05-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,89.72673389823423,168.55251406478317,2.0496386251516783,31.582855269348883,110.92185513660624,0.7302735906836932,2022-08-20,Treatment follow-up,greffe haplo-identique,2022-06-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,86.71075890270404,196.13593199151114,2.1735209218041356,22.540246455338465,92.83344548369158,1.0378294931065175,2022-06-17,Cancer diagnosis,pas de greffe,2022-06-17,Protocole 3 LAL thiotepa Bu Flu
Male,43,94.25718974076929,164.46235964276073,2.0751010576503885,34.84828846746329,123.30350731529208,1.029860247999873,2022-09-06,Cancer diagnosis,allo-greffe,2022-05-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,78.36833626384008,182.56041255758208,1.9935281259182707,23.514048514291403,116.90626073972149,1.0707009821986306,2022-01-30,Cancer diagnosis,auto-greffe,2022-09-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,101.60156697565043,181.80420215087202,2.2651705737394576,30.739200790215115,120.68441536915975,1.2160461524042943,2022-09-03,Treatment follow-up,auto-greffe,2022-12-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,28,49.54065458184526,156.63602681161234,1.4681669693255393,20.191957517236496,125.21839386345614,0.6154306734255149,2022-11-11,Treatment follow-up,allo-greffe,2022-09-24,Protocole 6 FlUDARABINE cy (Fanconi)
Female,48,113.29857108036347,197.9078371138728,2.4957004778555945,28.926670426789844,82.45066104775327,1.7558427614863779,2022-01-22,Treatment follow-up,greffe haplo-identique,2022-07-25,Protocole 2 LAM Endoxan TBI
Male,24,60.60902155031506,150.31938295800128,1.5908340510851848,26.82299719797096,103.83170771654963,0.9404436294147687,2022-11-26,Symptoms management,pas de greffe,2022-03-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,57,41.52395039024891,158.04699739409932,1.3501785560024993,16.62364150577927,88.68460087547699,0.5397542164353611,2022-06-15,Symptoms management,pas de greffe,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,78.74285067635392,163.4885485820614,1.8910281130975564,29.460251948950027,91.33716489179295,1.2811939745373842,2022-02-19,Treatment follow-up,allo-greffe,2022-03-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,31,63.953124295614145,153.2394918709022,1.6499279673347833,27.234559761027715,89.06219927938221,1.0870821186118356,2022-11-28,Symptoms management,greffe haplo-identique,2022-09-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,20,48.041137576483905,157.94144768226485,1.4517888216048733,19.258437734656116,133.2626664371516,0.6008326620511869,2022-12-09,Cancer diagnosis,pas de greffe,2022-04-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,46,48.96410861561266,141.14755425471748,1.3855568653228751,24.577128382655484,104.46174883543408,0.6119499696165805,2022-11-08,Cancer diagnosis,greffe haplo-identique,2022-02-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,25,76.31692035971767,196.02996801836008,2.0385454684771354,19.859847015292843,122.12569373204096,0.9981116782645074,2022-07-09,Cancer diagnosis,greffe haplo-identique,2022-06-22,Protocole 3 LAL thiotepa Bu Flu
Female,49,53.19186857129212,168.35937955614787,1.577211849901847,18.7659525412365,127.44428897334186,0.5275137254722865,2022-11-06,Symptoms management,greffe haplo-identique,2022-04-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,109.44239275669125,163.59197933558283,2.23009078379542,40.894185758492625,117.85900361826707,1.1865284205546542,2022-10-29,Cancer diagnosis,auto-greffe,2022-11-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,43.270840308768754,181.94543273087675,1.4788257132497988,13.071126350407592,118.5779946899575,0.43587020465635173,2022-01-25,Treatment follow-up,allo-greffe,2022-08-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,42.30377277530351,190.69906759464916,1.496968234650203,11.632738396539786,120.44946511083222,0.3951179387008871,2022-02-11,Treatment follow-up,auto-greffe,2022-03-15,Protocole 3 LAL thiotepa Bu Flu
Male,31,117.79352545615845,162.2075482636514,2.3038011443394706,44.769196498840884,112.03423807405662,1.5917126089013247,2022-10-01,Cancer diagnosis,auto-greffe,2022-06-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,46,104.33115660426236,185.13688223976493,2.316339608459253,30.43884228084838,84.53432350363092,1.6112995937843035,2022-09-05,Cancer diagnosis,allo-greffe,2022-05-19,Protocole 3 LAL thiotepa Bu Flu
Male,46,93.71595267392016,163.89418228585137,2.065557459772038,34.88883347124289,98.84596920560436,1.2377984012997154,2022-10-09,Symptoms management,allo-greffe,2022-11-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,47.786899469872886,197.84508246176236,1.620562579460272,12.20838827449512,134.65739295586383,0.5717473286200975,2022-10-04,Symptoms management,greffe haplo-identique,2022-01-19,Protocole 3 LAL thiotepa Bu Flu
Male,64,95.42441174353243,156.79962227867543,2.038689102064165,38.812307814448076,99.53931141868055,1.0119194769977407,2022-11-25,Cancer diagnosis,greffe haplo-identique,2022-10-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,39,118.61875988588659,174.1359425472055,2.395353694395181,39.11799054681815,99.29279385097745,1.6758090284498708,2022-06-22,Treatment follow-up,greffe haplo-identique,2022-07-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,73,53.64902723552483,193.941009625291,1.7000609880785993,14.263383112408466,76.91554255512314,0.6490677785753157,2022-09-09,Treatment follow-up,allo-greffe,2022-04-03,Protocole 3 LAL thiotepa Bu Flu
Female,46,108.72534209612367,187.12155513549186,2.3772565359432134,31.05154018739956,112.20876130334747,1.2650257676361847,2022-02-08,Symptoms management,pas de greffe,2022-01-30,Protocole 3 LAL thiotepa Bu Flu
Female,34,49.807493914824555,157.21290118286623,1.4748239649189703,20.152007968322213,74.28203219830935,0.9871525751858973,2022-05-05,Symptoms management,auto-greffe,2022-05-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,109.63416847146084,186.84211390953834,2.385388379391068,31.40482535619817,74.95517255222803,1.5032926775213344,2022-02-16,Cancer diagnosis,auto-greffe,2022-12-26,Protocole 3 LAL thiotepa Bu Flu
Male,64,45.35177703869788,167.68758111452038,1.4534374762824522,16.12844541372943,96.7434218821554,0.4948276510813024,2022-03-26,Cancer diagnosis,pas de greffe,2022-02-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,74,57.18741315832173,173.56666810674028,1.6604742260649399,18.98312899113766,129.028305674881,0.40628135912454777,2022-02-19,Cancer diagnosis,greffe haplo-identique,2022-02-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,105.83806173915823,142.33994768984613,2.045658286574173,52.23820844872501,75.11626779195237,1.2915740639511533,2022-04-09,Treatment follow-up,allo-greffe,2022-05-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,41,51.01106531507354,145.04292977911805,1.4336040795115932,24.247739972786913,104.53847511432662,0.6709511950649609,2022-01-16,Treatment follow-up,auto-greffe,2022-07-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,38,75.19619491023145,169.48092783151407,1.8815124591952763,26.179069080069485,134.45179053788894,0.7923133069728413,2022-12-22,Symptoms management,allo-greffe,2022-09-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,20,56.76451802972334,152.4910472099769,1.5506343503656572,24.411151215414833,109.95245903468185,0.8604403292126211,2022-05-15,Symptoms management,allo-greffe,2022-06-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,57,88.72589128821343,177.31163958031735,2.0904633495909013,28.221226173063204,100.1078105786474,1.0217108455311232,2022-09-27,Symptoms management,pas de greffe,2022-06-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,40,101.40686886939346,179.55237548040196,2.2489407503885284,31.454664899073645,82.55962105901637,1.7059534869840787,2022-10-25,Treatment follow-up,allo-greffe,2022-04-19,Protocole 3 LAL thiotepa Bu Flu
Female,63,76.87313161218972,199.81932779269073,2.0656407052902224,19.25305210559293,77.97703190859468,1.054304601207083,2022-09-22,Symptoms management,allo-greffe,2022-10-06,Protocole 2 LAM Endoxan TBI
Male,32,74.3314506870471,148.5942689907336,1.7516046276567323,33.66421479520267,107.51675871008412,1.037021366419905,2022-12-07,Symptoms management,greffe haplo-identique,2022-10-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,56,54.87267348376406,148.94580347836805,1.5067491165719604,24.734297330067772,111.25870559356284,0.5753987404658009,2022-06-02,Symptoms management,allo-greffe,2022-05-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,60,90.71787458314685,172.12417378063378,2.082649168310994,30.620278008992816,77.23429957838259,1.305089046912667,2022-09-14,Treatment follow-up,greffe haplo-identique,2022-06-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,89.61909609015456,185.72249935095988,2.1502120383449874,25.981936689741907,100.49112025812391,1.4368067656894274,2022-12-22,Treatment follow-up,pas de greffe,2022-11-28,Protocole 3 LAL thiotepa Bu Flu
Female,27,92.98712244162515,175.37947974360503,2.128381829039449,30.23188685198983,111.79278294204167,1.3054342049660281,2022-12-19,Symptoms management,allo-greffe,2022-01-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,71.97892734590835,176.90792866709924,1.8807240733620147,22.999096486858548,78.87547110194339,1.2421012059598509,2022-12-11,Cancer diagnosis,allo-greffe,2022-05-30,Protocole 3 LAL thiotepa Bu Flu
Male,54,101.56388077515885,195.93116636521955,2.351094876202183,26.456490842325113,98.4644307687043,1.232043004778778,2022-09-24,Cancer diagnosis,auto-greffe,2022-09-17,Protocole 3 LAL thiotepa Bu Flu
Male,64,69.62120314403016,152.992833514561,1.7201053861204452,29.74399832763268,83.6237806096799,0.8788056127976137,2022-01-15,Treatment follow-up,auto-greffe,2022-11-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,96.7680195923632,162.37827079516933,2.089193337795516,36.7008420542311,125.53996621541043,1.1241044013828434,2022-03-06,Treatment follow-up,greffe haplo-identique,2022-03-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,45.753417363806115,165.85309287326777,1.4518518614465303,16.6332221502062,98.55326869964333,0.5609695147006234,2022-07-01,Symptoms management,greffe haplo-identique,2022-10-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,91.27909790085181,179.91448408529996,2.1358339385226963,28.199349083783385,129.74907734826718,0.7914428929835446,2022-02-03,Symptoms management,allo-greffe,2022-04-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,113.40288386858352,176.2362313898035,2.3561796338879866,36.51183870762096,132.01799956680873,0.7516211706782887,2022-05-03,Symptoms management,pas de greffe,2022-07-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,52,61.08571406048431,144.44850604942005,1.565579422113158,29.276121835317923,115.80806727211306,0.6446901234402588,2022-04-05,Symptoms management,auto-greffe,2022-09-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,52,60.13573116430913,141.3204004207734,1.536446622688583,30.11084041331572,127.07760359928466,0.5783806500661285,2022-03-23,Symptoms management,allo-greffe,2022-01-16,Protocole 8 Aplasie medullaire thymo
Male,30,114.3204112458554,188.19189322724895,2.4446185016432413,32.279139997312164,95.55108080185082,1.8278828704201486,2022-05-20,Symptoms management,greffe haplo-identique,2022-11-27,Protocole 3 LAL thiotepa Bu Flu
Female,29,55.90590116690781,172.71879663369256,1.6377491306897798,18.740382265877845,132.32208956186955,0.6513520500194642,2022-10-18,Cancer diagnosis,greffe haplo-identique,2022-03-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,29,103.27579813151175,179.4782366621544,2.2691015193561834,32.06084554724085,119.13136867300003,1.3364813753611497,2022-12-21,Treatment follow-up,greffe haplo-identique,2022-10-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,60.76464012687521,189.46263334116702,1.7882819759996,16.927927550721392,85.06748158699145,0.7639159593069473,2022-11-26,Cancer diagnosis,allo-greffe,2022-08-02,Protocole 3 LAL thiotepa Bu Flu
Male,20,72.92582116823965,146.10767044610083,1.7203860876640162,34.16137126982753,102.40253319459491,1.1869143417519947,2022-04-07,Cancer diagnosis,auto-greffe,2022-01-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,35,118.68290775309984,144.28697644360128,2.1810037135857643,57.00775157554505,129.1334267039226,1.340313231756074,2022-06-17,Cancer diagnosis,pas de greffe,2022-11-08,Protocole 8 Aplasie medullaire thymo
Male,65,75.06284301558566,184.12637575903767,1.9593826436058162,22.140784234788043,120.39943555005098,0.6494254820826298,2022-08-03,Cancer diagnosis,allo-greffe,2022-02-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,74.91642235350578,148.02421774317443,1.7551072153856013,34.19097457645611,118.76570265399835,0.604508735696231,2022-11-19,Cancer diagnosis,pas de greffe,2022-09-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,41,106.44865231255086,180.97876784791256,2.3133036702346703,32.50011616362333,126.20858911262224,1.1597221548776442,2022-07-02,Symptoms management,auto-greffe,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,44,109.48632578048301,181.10710334444948,2.346909984895624,33.38019833087916,81.64814190990442,1.7879374140368796,2022-08-31,Treatment follow-up,auto-greffe,2022-06-04,Protocole 3 LAL thiotepa Bu Flu
Female,52,105.25468974533781,143.97560628103642,2.0517003632493735,50.77660072894858,96.64418771862745,1.3311159608935492,2022-03-04,Treatment follow-up,allo-greffe,2022-01-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,74,88.92793052795197,193.35857619305511,2.1854937168292023,23.785446417831498,115.0064684051764,0.7088059548392635,2022-11-22,Symptoms management,allo-greffe,2022-02-04,Protocole 3 LAL thiotepa Bu Flu
Female,43,112.95625007129196,154.61210258483703,2.2025492379173515,47.25233712138943,87.87119387999475,1.7318209018846678,2022-05-29,Cancer diagnosis,greffe haplo-identique,2022-03-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,36,89.74818521978828,178.79714401858777,2.111260760656044,28.074014556731903,80.07198291268539,1.6189965931161747,2022-11-18,Symptoms management,allo-greffe,2022-10-11,Protocole 3 LAL thiotepa Bu Flu
Female,51,78.98868431256436,186.34838056139057,2.022059827414808,22.746450391402135,80.45527978561311,1.2135784076692544,2022-11-17,Cancer diagnosis,auto-greffe,2022-09-30,Protocole 3 LAL thiotepa Bu Flu
Male,69,114.41573487864024,168.68881343720963,2.3154465945054135,40.20806631838057,77.45104444702713,1.456747655958834,2022-05-18,Symptoms management,auto-greffe,2022-02-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,76.38341328372829,161.60015974206647,1.8516938033036112,29.249300877940566,112.19533843327233,1.1157676341478557,2022-11-19,Symptoms management,pas de greffe,2022-01-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,20,54.27974552292334,154.50347383455767,1.5262890037010461,22.738473503171008,130.63514560054725,0.6925107490968081,2022-06-01,Treatment follow-up,greffe haplo-identique,2022-08-21,Protocole 6 FlUDARABINE cy (Fanconi)
Female,52,66.28166587561522,182.83670049230997,1.8347510497060797,19.827440920121933,119.50716496373153,0.6778750461001292,2022-01-17,Cancer diagnosis,allo-greffe,2022-05-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,50.96795217419513,142.24013637102328,1.4190850404994242,25.191432522165705,83.31068431741069,0.6627635095599084,2022-01-10,Symptoms management,greffe haplo-identique,2022-08-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,106.83410164155647,192.7936321557853,2.3919386891515435,28.742499449956753,99.62294585436004,1.3255863792439955,2022-08-25,Cancer diagnosis,greffe haplo-identique,2022-12-14,Protocole 3 LAL thiotepa Bu Flu
Male,64,79.53815276730091,163.37808701770072,1.8999116385917694,29.79805292923422,76.50302535163254,1.097432926949723,2022-09-17,Cancer diagnosis,allo-greffe,2022-05-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,74.16207722051811,144.9529836821672,1.7280379343493548,35.296168750981934,129.9659667467577,0.8797164768867032,2022-03-09,Symptoms management,allo-greffe,2022-01-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,72,114.65848652433765,179.95868806722189,2.394077809622287,35.40467140632537,85.73835545076686,1.2630119861407993,2022-12-09,Symptoms management,pas de greffe,2022-10-02,Protocole 3 LAL thiotepa Bu Flu
Male,25,48.10766776614742,151.63793051784032,1.4235077159079812,20.92177877283546,117.81898846949528,0.6521753158258423,2022-03-06,Cancer diagnosis,greffe haplo-identique,2022-02-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,55,43.74114240010449,174.2004060287285,1.4548505809359327,14.414241550158883,118.72205354703897,0.4349558243307353,2022-08-22,Symptoms management,pas de greffe,2022-07-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,53,103.98519462965348,189.53969672211963,2.3398315617021512,28.944839534783515,119.53669748976178,1.0511314055244525,2022-08-07,Symptoms management,greffe haplo-identique,2022-09-15,Protocole 3 LAL thiotepa Bu Flu
Male,32,110.13571847166301,160.7443715994863,2.21758733113674,42.6242390520039,127.76174916988384,1.2930597677386566,2022-01-26,Symptoms management,auto-greffe,2022-06-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,30,108.70412454567517,183.74122867055638,2.3554563963026798,32.19828872755711,95.00194148040046,1.748130019721049,2022-03-20,Treatment follow-up,pas de greffe,2022-12-02,Protocole 3 LAL thiotepa Bu Flu
Male,21,69.78561522103224,174.02602397537515,1.8367024457791243,23.042920201003568,77.29865104728351,1.492136181979674,2022-07-05,Treatment follow-up,auto-greffe,2022-05-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,58,118.91680683489591,176.4990693557884,2.4145798885291034,38.17318520722281,79.37779244587739,1.706182873487598,2022-05-18,Symptoms management,pas de greffe,2022-01-30,Protocole 3 LAL thiotepa Bu Flu
Female,44,111.68338322524802,199.94367077469602,2.490559152222716,27.936580049373866,97.9327652450705,1.520545011274044,2022-05-20,Cancer diagnosis,auto-greffe,2022-12-12,Protocole 3 LAL thiotepa Bu Flu
Male,73,74.533548457228,195.7869838164786,2.013337378968067,19.443935247159768,96.41310341231333,0.7193794737166893,2022-08-28,Treatment follow-up,greffe haplo-identique,2022-12-22,Protocole 3 LAL thiotepa Bu Flu
Male,44,115.45843101227337,158.38348984397885,2.253805993057702,46.026275787054935,117.09252531667892,1.31472589105654,2022-03-09,Symptoms management,pas de greffe,2022-06-20,Protocole 6 FlUDARABINE cy (Fanconi)
Female,78,83.67356133497604,162.88844132506304,1.945754351428551,31.53608073673675,108.07598702868341,0.666681243009719,2022-06-28,Symptoms management,greffe haplo-identique,2022-12-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,36,68.05712555319943,185.3507239527478,1.8719002148313655,19.810025248256693,132.05199463363033,0.7444396215514734,2022-08-19,Treatment follow-up,auto-greffe,2022-07-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,67.25159016271336,197.84398785893956,1.922478347490135,17.18133251811599,88.8639843831142,0.9880345537776666,2022-02-05,Treatment follow-up,auto-greffe,2022-11-24,Protocole 3 LAL thiotepa Bu Flu
Female,45,69.77149057983559,180.13350332238596,1.8684651328898745,21.502502671593998,100.87062072035167,0.9126503333551709,2022-03-04,Treatment follow-up,allo-greffe,2022-02-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,105.7852889868852,140.50996620184412,2.0319590560862655,53.58102510051641,113.75486602484993,0.9170249371071243,2022-11-27,Symptoms management,allo-greffe,2022-07-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,63,77.89447878981662,195.81609915120816,2.058383466463591,20.31467534863218,80.534826074644,1.0343825355437477,2022-03-23,Treatment follow-up,greffe haplo-identique,2022-09-23,Protocole 3 LAL thiotepa Bu Flu
Female,68,77.85828781669662,193.525073892794,2.045831188246848,20.7888451824191,94.21191318015322,0.8264165877601382,2022-11-02,Treatment follow-up,auto-greffe,2022-03-24,Protocole 3 LAL thiotepa Bu Flu
Male,33,81.85633270866255,188.78437565290727,2.0718481191412916,22.967841779587225,126.28529149823201,0.9632761195697469,2022-12-01,Cancer diagnosis,allo-greffe,2022-10-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,53.00216143027815,140.7518192152636,1.4395360598753033,26.753804358036554,127.05442723379655,0.6720928428262711,2022-04-05,Symptoms management,auto-greffe,2022-10-03,Protocole 8 Aplasie medullaire thymo
Male,75,101.10214115911525,160.1088325049098,2.1204916741650934,39.43935209911252,76.43185087669524,1.1941718704607631,2022-04-29,Treatment follow-up,greffe haplo-identique,2022-03-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,23,76.7520021921707,184.54665587902022,1.9835661863718765,22.53602697363548,124.68845926497262,1.0002690248760993,2022-08-07,Cancer diagnosis,pas de greffe,2022-08-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,55.951185709518626,167.2617973608376,1.612321987266613,19.99934516374199,92.71352055017925,0.8046461886392102,2022-11-20,Treatment follow-up,greffe haplo-identique,2022-07-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,116.62424289533061,171.30043094586304,2.3557130948389857,39.744032228238005,129.46359334494628,0.9133380357488001,2022-01-14,Treatment follow-up,pas de greffe,2022-07-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,50,58.746538421272206,161.279419250412,1.6222932670515453,22.58522281729632,80.07962267404675,0.9170019859545299,2022-12-09,Cancer diagnosis,pas de greffe,2022-04-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,61.57652982661464,141.13703511866998,1.553734645282558,30.91243602331824,119.05128011679308,0.5315943593918394,2022-07-21,Cancer diagnosis,greffe haplo-identique,2022-12-31,Protocole 8 Aplasie medullaire thymo
Male,52,113.44239203946513,160.93926389983534,2.251995107421914,43.797705011750445,76.29819087133102,1.8172359122708623,2022-09-23,Cancer diagnosis,pas de greffe,2022-06-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,65.9830151009161,144.7649737276379,1.62890807389784,31.485106384781794,130.94866187074336,0.7768221033648673,2022-06-22,Cancer diagnosis,greffe haplo-identique,2022-03-23,Protocole 8 Aplasie medullaire thymo
Male,66,56.196301335814326,170.2108797793722,1.6300325397839,19.39693451691087,119.30306453770254,0.4841225992816049,2022-07-03,Cancer diagnosis,allo-greffe,2022-05-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,41,43.16514337519986,165.55883098483298,1.4089368210434021,15.748111659679097,122.2724287831302,0.4854084664186253,2022-06-06,Cancer diagnosis,greffe haplo-identique,2022-03-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,37,106.72272829777386,199.09354516803012,2.4294378823327425,26.92418458318468,94.08164577817526,1.6227691449020443,2022-03-03,Treatment follow-up,auto-greffe,2022-10-08,Protocole 3 LAL thiotepa Bu Flu
Female,39,67.20334708104707,166.80199509177748,1.7645940963830615,24.153964408996767,106.47691547799926,0.8853690159446692,2022-08-14,Symptoms management,greffe haplo-identique,2022-07-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,42,40.53458819303087,156.1288135747102,1.325876771058533,16.628751611678297,130.80566574850394,0.42178661037454784,2022-09-24,Cancer diagnosis,pas de greffe,2022-03-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,56,98.30959381661434,169.47226140500948,2.151275408650359,34.229350024493684,128.133617138517,0.8951165875181261,2022-06-21,Cancer diagnosis,pas de greffe,2022-12-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,48.84430333097878,186.7382994188263,1.5917410227243043,14.007064247438851,123.1754595168567,0.44060276583019253,2022-05-31,Cancer diagnosis,auto-greffe,2022-11-13,Protocole 3 LAL thiotepa Bu Flu
Female,65,103.35355882908559,197.01454704304956,2.378267026522526,26.62740515737237,79.9119286059137,1.3472326221102326,2022-10-25,Cancer diagnosis,greffe haplo-identique,2022-09-01,Protocole 2 LAM Endoxan TBI
Female,30,67.25067038030902,194.20441935935364,1.904700136266365,17.83111088519619,108.61231967377863,0.9459707706850403,2022-06-28,Cancer diagnosis,auto-greffe,2022-08-24,Protocole 3 LAL thiotepa Bu Flu
Male,40,97.29851855743624,143.92023178413976,1.9722537406507847,46.97453917481386,100.33018360520205,1.3469210009774746,2022-10-24,Symptoms management,allo-greffe,2022-12-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,74,49.98054513174903,166.83106725689055,1.5219055751125221,17.957551989124333,111.94427611622933,0.4092705879533674,2022-09-01,Treatment follow-up,pas de greffe,2022-06-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,25,73.42725758705541,192.92835289544615,1.9836974360395967,19.727188526866698,84.87128725507597,1.3818530545248202,2022-11-20,Cancer diagnosis,pas de greffe,2022-08-15,Protocole 3 LAL thiotepa Bu Flu
Female,60,79.28912764639128,192.44422879213673,2.058770872626503,21.409368460434976,132.41963739824277,0.6653018574070014,2022-09-27,Cancer diagnosis,auto-greffe,2022-08-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,98.50602224356803,194.88811015816586,2.309259893116745,25.935348837692757,129.82153647447979,0.7798575135422529,2022-03-18,Symptoms management,pas de greffe,2022-04-30,Protocole 3 LAL thiotepa Bu Flu
Male,50,116.66168154173717,171.52997359504616,2.3576692324322637,39.6504563815679,76.13569531309932,1.9153578532050468,2022-11-17,Symptoms management,pas de greffe,2022-10-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,76,96.57895086581159,159.16704797549133,2.0664103675672063,38.12204240654024,118.69293406516445,0.72327773343301,2022-08-17,Treatment follow-up,allo-greffe,2022-09-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,37,58.32942920475982,171.7759886393849,1.6682988148625657,19.768003671339578,111.43804261712793,0.7487881789878856,2022-10-14,Treatment follow-up,greffe haplo-identique,2022-12-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,73.89822485306229,184.2344564961832,1.9446935842495334,21.77169748020646,86.24261750455611,0.7259545232956474,2022-10-28,Cancer diagnosis,pas de greffe,2022-07-18,Protocole 3 LAL thiotepa Bu Flu
Male,49,98.23777076904946,191.843937699264,2.2880317096149176,26.692075147304536,87.08300816812653,1.4257847719787429,2022-11-24,Treatment follow-up,greffe haplo-identique,2022-07-24,Protocole 3 LAL thiotepa Bu Flu
Male,65,85.29892651679651,180.85973648394656,2.07010073374001,26.07712916599403,93.4059294055146,0.9512570456769158,2022-05-27,Symptoms management,auto-greffe,2022-12-28,Protocole 3 LAL thiotepa Bu Flu
Male,21,88.94791412359328,198.87643022058916,2.2167069943993094,22.488947795758833,127.4368185556803,1.1536001722997211,2022-08-01,Treatment follow-up,auto-greffe,2022-08-15,Protocole 3 LAL thiotepa Bu Flu
Male,73,72.16040505943141,182.86322021546437,1.9145266343595742,21.57974137641451,85.3445684782447,0.7868018670257878,2022-05-23,Symptoms management,greffe haplo-identique,2022-02-13,Protocole 3 LAL thiotepa Bu Flu
Male,32,99.40111740532751,173.3508757002034,2.1877989159447355,33.077995724470924,95.38470620335497,1.563161245054471,2022-04-16,Symptoms management,allo-greffe,2022-05-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,109.0096419618203,187.1155996694215,2.3803247050580523,31.134716937846576,104.81761640821777,1.2711031924570568,2022-07-21,Symptoms management,pas de greffe,2022-03-02,Protocole 3 LAL thiotepa Bu Flu
Male,28,56.74480504464402,161.4603025297811,1.5953085202748638,21.766799881523458,125.16430716113402,0.7052305784146297,2022-01-06,Cancer diagnosis,greffe haplo-identique,2022-12-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,48,71.7979189635686,164.6099328785916,1.8118936243468529,26.497187621206557,106.21776165915344,0.8637141652140219,2022-03-13,Cancer diagnosis,pas de greffe,2022-09-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,58.49684816836696,192.9598912524392,1.7707143458988,15.710802724610478,109.6288677293614,0.6447543699098686,2022-07-05,Cancer diagnosis,auto-greffe,2022-04-22,Protocole 3 LAL thiotepa Bu Flu
Female,64,110.79473253707748,183.4205453573577,2.3759226432806484,32.93238262758389,109.40602698186386,1.0689538655415272,2022-12-08,Symptoms management,allo-greffe,2022-11-19,Protocole 3 LAL thiotepa Bu Flu
Male,72,45.86137054395834,161.5374711436,1.4345275858904656,17.575207847068654,88.96968623500368,0.4868345439641276,2022-08-24,Symptoms management,greffe haplo-identique,2022-06-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,49.75432141161416,176.375206109423,1.561287635771613,15.993950177590584,80.65781701199661,0.9424200829756072,2022-10-20,Cancer diagnosis,pas de greffe,2022-05-09,Protocole 3 LAL thiotepa Bu Flu
Male,77,61.006137930534045,193.26460744878597,1.8097212261615778,16.333109527916903,104.38932860820185,0.5113585018787371,2022-04-09,Treatment follow-up,greffe haplo-identique,2022-09-01,Protocole 3 LAL thiotepa Bu Flu
Female,35,89.9481992353142,147.05645196610055,1.9168451395373904,41.593388838019585,75.83441275998234,1.7297484406365318,2022-07-20,Treatment follow-up,auto-greffe,2022-04-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,25,50.223870195606054,172.68219391509763,1.5521282961974374,16.842829818378743,120.49865396155239,0.6657226361053111,2022-02-18,Treatment follow-up,pas de greffe,2022-09-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,77.95708415072193,172.2820017198929,1.9315079389583234,26.264901018600995,130.5982818294034,0.6383757074153729,2022-10-08,Cancer diagnosis,greffe haplo-identique,2022-10-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,49,73.31713071235542,146.33773765240016,1.7263531761435562,34.23677014010769,80.4067649108413,1.1524491375235801,2022-08-11,Cancer diagnosis,greffe haplo-identique,2022-10-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,86.46007933720097,140.19689225922397,1.8349564351142207,43.988469954393764,100.14702006232622,0.7793965136651276,2022-02-23,Cancer diagnosis,allo-greffe,2022-07-19,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,44,107.17409464791474,193.3639843508594,2.3992828766759144,28.664122478643083,82.63627885725988,1.7292500925739855,2022-08-09,Cancer diagnosis,greffe haplo-identique,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Male,47,47.33500112859758,199.25533405068222,1.6186200794854146,11.922366806137928,83.65128612992224,0.7309038025963868,2022-05-21,Treatment follow-up,allo-greffe,2022-07-16,Protocole 2 LAM Endoxan TBI
Female,26,101.11779339967012,149.3050239107293,2.0478575906255685,45.36059483756067,109.10663719048924,1.4674008566801207,2022-08-03,Treatment follow-up,allo-greffe,2022-09-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,61,89.26664352725075,171.93236761988575,2.0647723422477524,30.1977035893496,101.48182064955726,0.9651516336065689,2022-04-26,Symptoms management,auto-greffe,2022-04-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,52.049677501509095,184.045512365247,1.63124948396851,15.366238804365585,82.7689784803285,0.9869528256807383,2022-04-06,Cancer diagnosis,pas de greffe,2022-10-10,Protocole 3 LAL thiotepa Bu Flu
Female,38,105.46351889809269,193.4216497682271,2.3804135854249084,28.189806281959797,123.0308233539778,1.214383905587895,2022-03-17,Cancer diagnosis,allo-greffe,2022-02-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,84.0665026154419,183.79769232541608,2.071716222428667,24.885299470693298,85.14519433208008,1.2890156677270521,2022-09-26,Treatment follow-up,pas de greffe,2022-02-03,Protocole 3 LAL thiotepa Bu Flu
Female,66,82.54181943236742,175.3939566705697,2.0053633849858343,26.831489779383862,121.19771254215908,0.6999690503269452,2022-02-28,Cancer diagnosis,pas de greffe,2022-01-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,44,41.08022705375643,176.17144169686705,1.4178585990945516,13.236154215557631,100.78691383306536,0.5434598003704877,2022-03-21,Cancer diagnosis,greffe haplo-identique,2022-01-11,Protocole 3 LAL thiotepa Bu Flu
Male,32,89.59794084236174,143.92607040844865,1.8926377494363795,43.25328457493039,115.17832437060488,1.1668594069062752,2022-04-26,Treatment follow-up,allo-greffe,2022-04-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,24,50.63099195915769,185.86210272933937,1.6167854448463574,14.656650902067158,106.07812738451746,0.7689818412450792,2022-01-04,Symptoms management,allo-greffe,2022-06-12,Protocole 3 LAL thiotepa Bu Flu
Female,43,118.89757781568365,165.47720808911168,2.337783804844596,43.420681685741776,84.96652361650295,1.8852302316694178,2022-07-25,Treatment follow-up,auto-greffe,2022-11-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,58,95.82876260439065,178.3388829832929,2.1788117608087174,30.130323602475666,78.86561671448067,1.383851639190599,2022-11-13,Treatment follow-up,auto-greffe,2022-12-11,Protocole 3 LAL thiotepa Bu Flu
Male,21,61.8406300311716,160.0054196387595,1.6578798340436436,24.15485969553907,96.35046228155511,1.0608025811087767,2022-07-29,Cancer diagnosis,allo-greffe,2022-07-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,64.42261901307413,186.80862814269938,1.8283797532235533,18.460544825395303,117.59431534338506,0.6467530386757072,2022-03-22,Treatment follow-up,greffe haplo-identique,2022-11-19,Protocole 3 LAL thiotepa Bu Flu
Female,44,74.30322197224173,185.95770011135687,1.9591137642667318,21.487174643630894,88.45254837965959,1.120046448005311,2022-05-28,Treatment follow-up,allo-greffe,2022-12-26,Protocole 3 LAL thiotepa Bu Flu
Female,76,89.7369838766014,163.94436998516727,2.021541854213877,33.387081263308936,107.91170702175066,0.73918029926294,2022-12-15,Treatment follow-up,pas de greffe,2022-06-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,31,81.62436192784592,145.0044558559613,1.8132150839153502,38.8201405560443,115.73034988458312,1.0677425127328026,2022-04-03,Treatment follow-up,auto-greffe,2022-11-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,47,63.48456294525977,199.64412267446812,1.876338031658892,15.927773640379076,133.53878841239094,0.6140604896837979,2022-07-08,Treatment follow-up,auto-greffe,2022-06-17,Protocole 3 LAL thiotepa Bu Flu
Female,56,52.67936555311576,176.61313762329155,1.6076093394938369,16.88863398843816,79.27612022185139,0.7752556462144823,2022-10-03,Symptoms management,allo-greffe,2022-05-13,Protocole 3 LAL thiotepa Bu Flu
Male,75,84.63090028861004,168.7339663628158,1.9916567281867197,29.72514145499255,96.37830431913916,0.7927395759204252,2022-10-16,Symptoms management,auto-greffe,2022-12-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,93.17222600319587,177.41808658460957,2.1428458530859675,29.59993034923707,85.19106301790765,1.2759663571073445,2022-09-06,Symptoms management,allo-greffe,2022-07-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,106.19839468180355,148.28344811687978,2.0914816749466247,48.298383899898596,100.92572657270011,1.081472026966368,2022-11-11,Cancer diagnosis,auto-greffe,2022-10-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,45,78.72584586285231,153.51484173910933,1.8322410206882118,33.40539390205716,129.93673106122398,0.7994227583652715,2022-05-11,Cancer diagnosis,pas de greffe,2022-11-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,20,79.47157424281448,190.01393499613704,2.0480822020052774,22.011057701728802,128.36286426124613,1.031860924110064,2022-08-02,Symptoms management,pas de greffe,2022-06-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,64.19915022817572,193.33123249123256,1.8567968864046347,17.176126912377665,96.972920426707,0.6252521890055014,2022-02-17,Symptoms management,allo-greffe,2022-11-08,Protocole 3 LAL thiotepa Bu Flu
Female,29,40.10329678174425,142.06266588964766,1.257994573802367,19.871019788030132,118.80922006691037,0.5203797806015132,2022-06-09,Symptoms management,greffe haplo-identique,2022-09-08,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,39,107.66008120985825,192.60322671493833,2.399981425241257,29.022016571723626,98.75681445847103,1.5292430229049958,2022-09-20,Cancer diagnosis,pas de greffe,2022-04-06,Protocole 3 LAL thiotepa Bu Flu
Female,44,105.08354843522037,167.2282921863313,2.2093829167201573,37.57640433638658,103.71302416257873,1.3509527761334101,2022-08-31,Cancer diagnosis,allo-greffe,2022-10-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,66,107.7081774885153,191.96322682859852,2.3965258017552324,29.22890825159092,103.53158246519362,1.069239633663062,2022-03-03,Treatment follow-up,allo-greffe,2022-11-07,Protocole 3 LAL thiotepa Bu Flu
Female,66,118.26773660951618,155.38256181700703,2.2593474902849997,48.984844136782876,85.3962739532956,1.423398772431395,2022-07-12,Symptoms management,allo-greffe,2022-05-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,39,97.15127101037226,144.67081746973702,1.9758931732323626,46.41802048082641,81.76645901455458,1.6667181836987492,2022-04-09,Cancer diagnosis,pas de greffe,2022-04-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,46,74.64961576049845,198.48362621816756,2.028732940089605,18.948646997229435,103.78874455213685,0.9390153142015222,2022-02-01,Symptoms management,auto-greffe,2022-02-20,Protocole 3 LAL thiotepa Bu Flu
Female,49,119.06914652411702,167.9389025034857,2.3568070319635925,42.217899260132214,90.60856452600208,1.660882413142393,2022-08-28,Symptoms management,auto-greffe,2022-04-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,86.9447724510712,174.42294261916587,2.052448609200296,28.578291197709984,115.13346459661612,0.8076071036084962,2022-03-15,Symptoms management,pas de greffe,2022-01-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,53.70627578246524,166.4702254642172,1.5759032540763565,19.37991652820209,77.02088604277621,0.6004484392323596,2022-09-24,Symptoms management,auto-greffe,2022-06-05,Protocole 3 LAL thiotepa Bu Flu
Female,58,116.38190483125169,158.75069386559443,2.2654229520089855,46.18002850904889,98.07392086184635,1.351491376252308,2022-11-10,Cancer diagnosis,allo-greffe,2022-07-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,97.74899800335655,193.1492431307436,2.2900839978006196,26.201508333439097,119.23876012531204,0.9222472846766222,2022-05-01,Treatment follow-up,allo-greffe,2022-10-10,Protocole 3 LAL thiotepa Bu Flu
Male,66,71.78123775385507,162.38687159077242,1.7994081309143146,27.221315711461855,77.90334410856389,0.9470089104517068,2022-11-03,Treatment follow-up,allo-greffe,2022-03-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,54.72633548220187,155.0347618912046,1.535187682216136,22.768697922104504,92.89427628249899,0.9736926187909314,2022-01-04,Treatment follow-up,pas de greffe,2022-12-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,88.62217643945229,193.306805504696,2.181441280972033,23.7163648908803,87.50248231234413,1.1253290458804912,2022-08-08,Cancer diagnosis,auto-greffe,2022-03-20,Protocole 3 LAL thiotepa Bu Flu
Male,26,80.87874136541691,166.7518373982474,1.93553601025235,29.08661136007511,110.18629596359507,1.1621954077140386,2022-12-20,Treatment follow-up,allo-greffe,2022-03-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,76.922205967091,170.66085856161396,1.9095963588032778,26.41094118577576,81.92642129004628,1.0041208261090189,2022-10-20,Cancer diagnosis,pas de greffe,2022-01-19,Protocole 3 LAL thiotepa Bu Flu
Male,24,51.66175526029926,182.64606461530806,1.6189688324339224,15.486330356036284,114.968929246387,0.7239593207047867,2022-07-12,Cancer diagnosis,allo-greffe,2022-04-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,112.38201379437004,155.81030875562894,2.2054400082447736,46.291838965932925,132.04894824610636,1.1465713916909137,2022-12-14,Symptoms management,auto-greffe,2022-04-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,20,113.00012841384289,189.15275042250522,2.436657836713063,31.583017120477468,97.76681870827002,1.9263544609994947,2022-05-07,Treatment follow-up,allo-greffe,2022-12-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,63.765787134009635,143.64539109623914,1.595102002261258,30.903262639563543,114.39306585919468,0.9290450526156065,2022-05-08,Symptoms management,auto-greffe,2022-04-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,27,71.10738648345935,160.04420982729846,1.777976806078375,27.760979374308846,84.60726232487296,1.319024982121673,2022-02-27,Symptoms management,pas de greffe,2022-09-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,93.31091421490086,161.74738252943212,2.047545694490018,35.66628877625971,113.43849584712012,1.1653051357679725,2022-08-09,Treatment follow-up,greffe haplo-identique,2022-03-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,78,45.764296734874605,161.75748137187054,1.4339840941885027,17.490331487502964,131.30589439579808,0.30012471711131017,2022-03-26,Symptoms management,allo-greffe,2022-07-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,39,88.08884878827841,160.23628056859283,1.9801114930311743,34.30830192476214,77.29913185066796,1.5985830188745656,2022-07-15,Symptoms management,allo-greffe,2022-09-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,67.1312001354777,166.56283491073225,1.762381832565496,24.197372124996317,115.71865392416744,0.5801242743410238,2022-08-04,Symptoms management,pas de greffe,2022-02-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,67.73172118026342,151.23229337848602,1.6868135252734346,29.614406656267775,80.29875617965828,1.2769600053418582,2022-04-19,Symptoms management,pas de greffe,2022-05-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,49,40.64368585655507,182.58040209113446,1.4357286677034202,12.192275501620111,116.2902728108227,0.4417317262739254,2022-10-20,Symptoms management,auto-greffe,2022-09-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,32,65.26522116590684,177.15926405374924,1.7921385851404548,20.794767981641716,114.70405282113998,0.8534818896200121,2022-03-19,Treatment follow-up,pas de greffe,2022-09-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,87.85685908433504,169.6957887213925,2.0350361037542957,30.50939133873625,131.5777135482754,0.9552082527307638,2022-01-31,Cancer diagnosis,greffe haplo-identique,2022-09-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,21,93.16661983791953,146.03138424328736,1.9440257814505206,43.68858062012799,93.99485102130447,1.6382144045728884,2022-10-22,Cancer diagnosis,allo-greffe,2022-12-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,62,86.04980139126071,178.157540214658,2.0636012852284114,27.110745279529663,84.20274088713053,1.1070971941260588,2022-04-25,Treatment follow-up,auto-greffe,2022-01-24,Protocole 3 LAL thiotepa Bu Flu
Male,25,43.93559030047874,194.74230012409146,1.5416547668392044,11.5849956584402,111.42243812957835,0.62980942036797,2022-01-12,Symptoms management,pas de greffe,2022-11-02,Protocole 3 LAL thiotepa Bu Flu
Female,53,44.08747164791289,158.9084186801864,1.395017961172443,17.45908106545537,85.57623725754381,0.6225134836699693,2022-07-26,Symptoms management,greffe haplo-identique,2022-11-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,82.81597697659038,194.07105311306577,2.1129352849659107,21.988348140322096,99.94513452308902,0.9667167918384417,2022-04-23,Treatment follow-up,pas de greffe,2022-04-28,Protocole 3 LAL thiotepa Bu Flu
Male,67,50.90733394593832,166.6111401225341,1.53493837637174,18.33885770571538,113.07397610785685,0.45646559913582657,2022-03-03,Treatment follow-up,pas de greffe,2022-12-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,49,107.38757564298908,161.5952015143029,2.195533150016773,41.1241672746556,103.10112056830901,1.3164353880127284,2022-02-25,Symptoms management,pas de greffe,2022-08-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,69,72.08255110351183,195.40871845086193,1.978043290575451,18.87740422406244,129.9052195546269,0.5471789725163184,2022-04-14,Cancer diagnosis,pas de greffe,2022-11-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,54,64.6927596765014,175.9817998927005,1.7783222654995037,20.889121084061944,106.90239224034946,0.7228267372880268,2022-01-28,Treatment follow-up,allo-greffe,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,69.19785153750877,187.6863449937098,1.8993779563972737,19.643879290055793,77.27105909210655,1.3184058295631844,2022-11-26,Cancer diagnosis,allo-greffe,2022-02-03,Protocole 3 LAL thiotepa Bu Flu
Female,54,105.05010615420402,173.49696036242142,2.2500539563594724,34.898981673080186,103.78690433337732,1.2089821590702896,2022-07-02,Cancer diagnosis,greffe haplo-identique,2022-01-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,79.97053620110283,173.59623561958415,1.9637396329022005,26.536851929044115,115.47809989438508,0.663662032854277,2022-06-24,Symptoms management,allo-greffe,2022-01-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,102.19194036689635,185.4494751863266,2.294403923396694,29.714294825882558,120.8263319072378,1.2216755917351418,2022-01-08,Treatment follow-up,allo-greffe,2022-08-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,105.33689483747028,160.24799729650513,2.165385931674458,41.01996549076282,107.42695670801574,1.0622563731133297,2022-03-06,Cancer diagnosis,auto-greffe,2022-06-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,51,111.18984340240081,195.76925152462792,2.458971805226085,29.011899059453842,104.91125925762904,1.3100881816211485,2022-08-10,Cancer diagnosis,greffe haplo-identique,2022-12-03,Protocole 3 LAL thiotepa Bu Flu
Male,26,81.17507461841292,195.26647195206402,2.0983307142678274,21.28959194239269,115.73564038754247,1.1105239582964987,2022-10-13,Cancer diagnosis,auto-greffe,2022-07-23,Protocole 3 LAL thiotepa Bu Flu
Female,31,70.51182082295234,146.57722817784267,1.6943883893278953,32.81927024261185,101.16618109041599,1.0551654804858939,2022-10-12,Symptoms management,auto-greffe,2022-09-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,39,114.01268876780267,170.8187938477129,2.3259114090950535,39.07346140423159,100.03546534184221,1.5987776499228346,2022-04-07,Cancer diagnosis,allo-greffe,2022-11-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,72.5070762011418,185.07080285324548,1.930669343135717,21.16920628234139,122.96596277346424,0.761633311479958,2022-03-02,Treatment follow-up,pas de greffe,2022-11-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,119.87365269568974,173.92214791266528,2.4065121808087517,39.62907711007584,104.65866937815633,1.479445537752229,2022-10-13,Treatment follow-up,greffe haplo-identique,2022-11-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,113.22213173522309,166.89913115029594,2.291086315217272,40.64650193273811,75.07202581491184,1.424392270552637,2022-11-30,Cancer diagnosis,greffe haplo-identique,2022-01-16,Protocole 3 LAL thiotepa Bu Flu
Male,64,112.03241639196642,181.66982691377285,2.377727071447545,33.94517862966771,91.60949183946428,1.2908754011220265,2022-10-20,Treatment follow-up,greffe haplo-identique,2022-11-12,Protocole 3 LAL thiotepa Bu Flu
Male,72,63.01750465595349,162.03241308343803,1.6841481811537824,24.002551075082653,133.76952563795132,0.4449184662293662,2022-06-12,Symptoms management,allo-greffe,2022-01-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,74,113.36877956752147,195.38328574841086,2.4804997622113287,29.697415395527035,90.18293933087202,1.152339700183768,2022-05-04,Symptoms management,auto-greffe,2022-07-26,Protocole 3 LAL thiotepa Bu Flu
Female,70,46.56645422914786,182.47386236491258,1.536334089085618,13.985301732479654,101.41793485078985,0.4463997583689602,2022-06-16,Symptoms management,allo-greffe,2022-12-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,52.11747600714424,173.17559520649763,1.5833749931534753,17.378408322120354,133.12602708659432,0.34255353745806605,2022-05-08,Symptoms management,pas de greffe,2022-12-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,100.53902325989071,197.7293253598612,2.3499121284704803,25.715353131718157,79.1531925021938,1.1996170838597928,2022-03-17,Symptoms management,greffe haplo-identique,2022-08-02,Protocole 3 LAL thiotepa Bu Flu
Male,47,67.60566543718954,167.69973808701369,1.774624560217281,24.03910659458278,104.72962150241656,0.8338040687086944,2022-04-19,Cancer diagnosis,greffe haplo-identique,2022-01-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,78.70072480180092,143.88498350626026,1.7735598610044347,38.014369291108295,125.04398532404984,0.8129547583240808,2022-02-10,Cancer diagnosis,greffe haplo-identique,2022-02-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,79,107.48385257749528,155.74084674601673,2.156361790141953,44.313715122055754,129.26710585150573,0.7044538348241404,2022-07-11,Cancer diagnosis,pas de greffe,2022-03-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,36,48.91124082224107,145.0181172904868,1.4036674244420302,23.257560287061786,93.14423046329998,0.7584964707439101,2022-08-04,Cancer diagnosis,allo-greffe,2022-12-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,76,105.60790701390312,177.73852660006645,2.2834302771371533,33.42976197119739,103.28061279299018,0.908918843380844,2022-11-30,Symptoms management,pas de greffe,2022-03-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,85.88824204612533,166.35860507955493,1.9922243389075738,31.034387139241687,110.0694548815496,0.8128224028575989,2022-09-05,Treatment follow-up,greffe haplo-identique,2022-01-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,42.23749650892798,177.97427536876808,1.4450286266452503,13.334713898424976,78.77381883197755,0.595763317971016,2022-03-15,Cancer diagnosis,pas de greffe,2022-10-09,Protocole 3 LAL thiotepa Bu Flu
Male,28,114.0422327434728,173.1009873867369,2.341700657623002,38.059810459669585,100.3361157133819,1.7680476013126045,2022-04-15,Treatment follow-up,allo-greffe,2022-11-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,42.48352741156648,175.42122053068766,1.438798904081101,13.805632622447028,113.95734737833811,0.3572685866486188,2022-07-03,Symptoms management,greffe haplo-identique,2022-08-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,116.46672906771806,169.5413763509657,2.342003507519194,40.51823040137316,125.74282131948767,1.3378872686261998,2022-09-15,Symptoms management,auto-greffe,2022-01-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,57,69.59549557838363,178.19638544898726,1.8560461078144148,21.91711319744829,90.34137300212683,0.8880553623454838,2022-05-15,Cancer diagnosis,pas de greffe,2022-05-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,45.61438116309368,186.60616136073062,1.5376681996244013,13.099352496781492,80.2745135656135,0.9391577997146638,2022-08-09,Treatment follow-up,pas de greffe,2022-11-18,Protocole 3 LAL thiotepa Bu Flu
Female,49,107.19943156910398,154.82407572319448,2.1471591639198757,44.72141027838928,105.91579099751137,1.2792065203816376,2022-04-28,Treatment follow-up,greffe haplo-identique,2022-11-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,78,51.95141623403729,193.26082120070635,1.6700110914410247,13.909443349211221,128.12731049488752,0.3491522735027885,2022-12-16,Cancer diagnosis,allo-greffe,2022-11-28,Protocole 3 LAL thiotepa Bu Flu
Male,58,102.32928721571653,196.84528266007442,2.3654361511370405,26.408876522959382,97.0289039468187,1.2011028000664172,2022-09-05,Cancer diagnosis,auto-greffe,2022-12-13,Protocole 3 LAL thiotepa Bu Flu
Male,25,108.18043437010891,157.87990194839062,2.1781437287469694,43.40052918257189,83.56313028030331,2.0677563562541477,2022-06-01,Cancer diagnosis,auto-greffe,2022-08-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,74,80.45958346177238,193.1974609756205,2.077965567299102,21.55633631858106,89.59109721842489,0.823236018568632,2022-05-04,Treatment follow-up,allo-greffe,2022-01-03,Protocole 3 LAL thiotepa Bu Flu
Female,55,65.92902683229558,179.3060983994506,1.812110231851529,20.506263986203173,107.35642815412376,0.7249950490854528,2022-10-01,Symptoms management,greffe haplo-identique,2022-03-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,106.39138685129551,194.45514473342467,2.3972410373732203,28.136339421806962,125.5276351221282,0.7886956207006636,2022-07-29,Symptoms management,allo-greffe,2022-04-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,100.885475723944,191.12121374073732,2.3142886217518255,27.61918484683338,110.7891284901873,1.4923854665838074,2022-07-22,Symptoms management,allo-greffe,2022-10-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,109.63975149141537,162.3653240380961,2.2237164698839935,41.58928703187167,88.97999089434113,1.660026126812637,2022-07-31,Symptoms management,greffe haplo-identique,2022-07-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,63.88770346435936,188.01651673386314,1.8266502027462737,18.07279290384001,76.949347306684,1.2915102666119387,2022-04-14,Cancer diagnosis,greffe haplo-identique,2022-01-24,Protocole 3 LAL thiotepa Bu Flu
Female,23,70.47653595318941,166.26047153838817,1.8041204459028903,25.495676137165376,93.37167352500181,1.2265429824738763,2022-05-23,Symptoms management,greffe haplo-identique,2022-03-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,65.7986767099829,172.03120401663017,1.7732131520302785,22.233237217516216,122.6047443393079,0.7453794017397422,2022-10-11,Cancer diagnosis,pas de greffe,2022-06-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,43.92348241606261,144.55265668409936,1.32803698848873,21.02057587152456,113.76972845651798,0.39679781047465273,2022-06-08,Symptoms management,allo-greffe,2022-11-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,77,57.48749172170775,148.7322230798081,1.541125350285345,25.987423350054918,76.44070385091344,0.6580467306345086,2022-11-03,Treatment follow-up,auto-greffe,2022-11-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,73,96.79906763683834,182.35599652836237,2.2143402856238397,29.109254029117146,98.75576265119676,0.9121180146236897,2022-04-12,Cancer diagnosis,auto-greffe,2022-10-10,Protocole 3 LAL thiotepa Bu Flu
Female,76,85.52631371111153,185.87781338677087,2.1014177872498636,24.753957670912502,101.31354564488315,0.7503773506447412,2022-02-21,Symptoms management,allo-greffe,2022-10-22,Protocole 3 LAL thiotepa Bu Flu
Female,52,83.71058780923853,161.31725466460193,1.9367758296648623,32.16760643257896,122.92741062556567,0.8323037159497246,2022-06-06,Symptoms management,pas de greffe,2022-09-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,62,73.14280427888795,153.90551272810256,1.7683231852452688,30.87900195155896,78.29712903467473,1.0120171575346506,2022-08-10,Symptoms management,auto-greffe,2022-06-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,52.64380990919488,170.0423794677491,1.5768885239616799,18.2067724796199,128.39197126132817,0.5979518970698009,2022-08-11,Cancer diagnosis,pas de greffe,2022-10-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,118.81037145641562,157.27487753595088,2.27827216577294,48.03254986757442,81.86559723316137,1.632696424455145,2022-11-13,Treatment follow-up,greffe haplo-identique,2022-04-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,103.09084289102216,186.9546584414672,2.313805986844931,29.494939399805013,85.99505043776249,1.8481495773839147,2022-07-24,Cancer diagnosis,allo-greffe,2022-03-24,Protocole 3 LAL thiotepa Bu Flu
Male,60,46.95107667209491,172.08378053795172,1.4981023898828112,15.854979276690841,101.45645402304424,0.5141896932170056,2022-10-26,Symptoms management,auto-greffe,2022-08-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,108.60987772241666,149.43692073949902,2.123304924504581,48.63551340488246,120.50924022144775,1.2892991747230362,2022-11-05,Cancer diagnosis,greffe haplo-identique,2022-06-17,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,37,72.39639770899817,173.71378889463955,1.869064869300605,23.991001145358794,128.03161876722768,0.8089179059206502,2022-10-09,Cancer diagnosis,allo-greffe,2022-06-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,30,71.1104700804884,145.56414058751008,1.695675419677964,33.56021607173714,126.3017166053935,0.8601703830814157,2022-09-04,Cancer diagnosis,auto-greffe,2022-04-29,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,20,116.22201855245098,160.75844815464956,2.2781371132214407,44.97185520171974,94.14916880363133,2.0574091807235777,2022-06-03,Symptoms management,auto-greffe,2022-01-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,84.88925782731923,183.17010546267875,2.078272139494635,25.30134133846163,93.34796087505993,1.098840498636779,2022-06-30,Cancer diagnosis,auto-greffe,2022-09-26,Protocole 3 LAL thiotepa Bu Flu
Female,75,119.57197336081069,199.2512340682227,2.5725507905640494,30.118085158243492,88.18975669176741,1.2240301418730781,2022-09-02,Treatment follow-up,allo-greffe,2022-12-04,Protocole 3 LAL thiotepa Bu Flu
Female,42,102.79811765711545,165.88560940208538,2.176434928509993,37.35663398124776,119.08989112993527,1.17490795244531,2022-03-30,Cancer diagnosis,greffe haplo-identique,2022-06-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,47.307126492648514,162.77485903813442,1.4625330809497055,17.854673517602613,121.79630101906254,0.38841184910241566,2022-12-12,Cancer diagnosis,auto-greffe,2022-12-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,56,76.75676685763122,144.85024182394122,1.7573841230135012,36.582907923269005,133.5710648224235,0.6704263490970522,2022-07-05,Treatment follow-up,greffe haplo-identique,2022-06-14,Protocole 8 Aplasie medullaire thymo
Male,24,112.15838515358003,140.2836454408111,2.090586516327333,56.99249393477177,119.18537278986213,1.516122459454878,2022-11-18,Symptoms management,allo-greffe,2022-09-16,Protocole 8 Aplasie medullaire thymo
Female,70,47.922459848246405,197.13460858211218,1.6199430172142237,12.331427456342457,126.30483697359547,0.36887962111662775,2022-10-05,Treatment follow-up,allo-greffe,2022-08-05,Protocole 3 LAL thiotepa Bu Flu
Male,21,89.4950804636889,164.5784091862975,2.0227153073635127,33.041019753843905,128.26219206129431,1.153227446324423,2022-04-07,Treatment follow-up,allo-greffe,2022-09-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,76.3863287834861,185.99773515735777,1.9865998416273487,22.080063898986545,117.29826699576745,0.5698126613239913,2022-10-22,Treatment follow-up,allo-greffe,2022-07-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,54.02801275676667,194.53721123245055,1.7086754885105737,14.27623282719022,125.385420034142,0.44286481533322447,2022-04-13,Treatment follow-up,greffe haplo-identique,2022-10-09,Protocole 3 LAL thiotepa Bu Flu
Female,42,96.14144114668534,151.49123670880644,2.0113970972572974,41.892435132891066,126.89986779531775,1.0312003160953387,2022-05-08,Cancer diagnosis,auto-greffe,2022-11-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,83.46106279054752,199.9714705272303,2.153152176202711,20.871219721890917,132.14117959905326,0.6052883646891638,2022-03-23,Cancer diagnosis,greffe haplo-identique,2022-04-21,Protocole 3 LAL thiotepa Bu Flu
Female,30,95.24095065065838,161.73459005834044,2.0685311556117183,36.40976681442446,117.56126868554641,1.2377121271777771,2022-07-04,Treatment follow-up,pas de greffe,2022-07-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,79,116.71672822224541,187.45029313304306,2.4652352219745244,33.21703447233913,106.08577983907009,0.9321230989201796,2022-04-07,Symptoms management,auto-greffe,2022-09-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,77.98220957253106,198.7723363204045,2.0750305210713442,19.7371141005559,93.73772593319168,1.143888835522333,2022-01-19,Treatment follow-up,pas de greffe,2022-08-31,Protocole 3 LAL thiotepa Bu Flu
Female,58,59.929678851464615,164.09794905844507,1.6528037951762633,22.255412287520443,107.25110573076981,0.6363873350634459,2022-10-09,Cancer diagnosis,allo-greffe,2022-10-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,113.80458304157489,162.9980724375386,2.269968653132467,42.83460976696071,94.39470894984392,1.8251816832532115,2022-12-23,Symptoms management,auto-greffe,2022-09-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,25,68.7505023096672,169.88016291348248,1.801183756801036,23.822675660761224,97.48058726986574,1.126478954973287,2022-06-21,Symptoms management,allo-greffe,2022-11-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,115.9740911446064,155.00267180275716,2.2345950408239816,48.27059024173539,120.48032219502454,0.8823813018787958,2022-03-06,Cancer diagnosis,greffe haplo-identique,2022-07-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,88.71671522617054,155.5221413090436,1.9577065324477314,36.67929664016485,92.318859696224,0.8542057677353242,2022-08-22,Symptoms management,auto-greffe,2022-11-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,70,102.11804297530212,153.38525757822427,2.085891917219033,43.40454853003549,103.74075166596435,0.9570147610854958,2022-07-13,Treatment follow-up,greffe haplo-identique,2022-03-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,78,106.70645356327076,197.70942909133402,2.4207937182275114,27.298320107044862,92.01449816664096,0.9986047266615073,2022-03-22,Symptoms management,allo-greffe,2022-10-02,Protocole 3 LAL thiotepa Bu Flu
Female,41,94.14534467263164,164.9879039945023,2.0771804533213793,34.585546231842734,128.31994072457155,1.0088053983965142,2022-10-19,Cancer diagnosis,auto-greffe,2022-11-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,83.25044925208493,193.00928963219215,2.1126674865693276,22.347562531791446,87.58816273820412,1.4785182699133277,2022-07-09,Treatment follow-up,allo-greffe,2022-01-20,Protocole 3 LAL thiotepa Bu Flu
Male,23,56.98224877612127,155.2281140244049,1.5674862227275768,23.648239904144614,133.28512846247804,0.6947223244584589,2022-02-15,Treatment follow-up,auto-greffe,2022-07-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,37,106.52920813139065,159.6802158131776,2.173745292297463,41.779811570777454,128.54964708382718,1.1855026752575804,2022-04-24,Cancer diagnosis,pas de greffe,2022-03-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,62,61.243868761088905,170.456049851607,1.7028887177908283,21.078406583626546,104.83421010278283,0.6328804731406894,2022-10-27,Symptoms management,allo-greffe,2022-01-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,88.76878909675412,192.17781036709465,2.1768600933424365,24.035536141644474,118.4689257423918,0.9990669259524363,2022-05-01,Cancer diagnosis,auto-greffe,2022-01-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,56,42.743758130127354,179.25711506581067,1.4588925374975188,13.302090503581242,130.1687804230381,0.3831004458704755,2022-04-04,Cancer diagnosis,greffe haplo-identique,2022-09-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,114.1891623090755,186.84457658554035,2.4344532629580047,32.7087459929746,133.9523649438447,0.7222238732832053,2022-07-16,Cancer diagnosis,pas de greffe,2022-06-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,66.54653395218799,199.71661277469934,1.9214034477742443,16.683879976225036,132.55114699992515,0.425342998926981,2022-12-04,Cancer diagnosis,auto-greffe,2022-03-03,Protocole 3 LAL thiotepa Bu Flu
Female,43,53.6613432190297,185.9295721715884,1.6647681342446394,15.522604760120311,128.0349935013308,0.5646405883421172,2022-12-21,Cancer diagnosis,pas de greffe,2022-05-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,109.11725760673517,161.39387444736988,2.211765067782261,41.890866876410584,125.09519749395113,0.957078147463222,2022-05-27,Cancer diagnosis,allo-greffe,2022-11-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,69,60.988963400898456,175.93182052458494,1.7264204588804344,19.704365668296845,113.2317449758177,0.5311398713993063,2022-11-01,Symptoms management,allo-greffe,2022-05-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,80.52043709009068,169.44728668305106,1.946790063686687,28.043801585661704,76.49415619099166,1.754391906074632,2022-10-19,Symptoms management,allo-greffe,2022-06-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,79.69179857469534,171.0907720224649,1.9461165990821734,27.224534117474494,82.23701664264274,0.8748369987326642,2022-11-29,Cancer diagnosis,allo-greffe,2022-12-15,Protocole 3 LAL thiotepa Bu Flu
Male,28,68.28505518500906,175.6795091633828,1.8254592251827193,22.125008486784427,104.51468377786549,1.016327975313211,2022-10-05,Cancer diagnosis,auto-greffe,2022-03-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,90.60506187885048,188.63700176516744,2.1789056387690118,25.462362174778082,111.08559128731254,0.8043046555926179,2022-01-05,Cancer diagnosis,pas de greffe,2022-08-06,Protocole 3 LAL thiotepa Bu Flu
Female,50,81.1963313316717,169.37985714775365,1.9545547235083882,28.3017234265298,85.39577869118563,1.1885296406936539,2022-01-19,Cancer diagnosis,auto-greffe,2022-12-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,57.84422001765462,140.25069419362626,1.5011747263546003,29.406946419371128,86.87758669630193,0.6750603255976572,2022-03-06,Cancer diagnosis,greffe haplo-identique,2022-07-29,Protocole 6 FlUDARABINE cy (Fanconi)
Male,51,56.65883313524448,196.26126642389002,1.7575183217966228,14.709517671584743,93.81695382277265,0.7465240591095142,2022-11-16,Treatment follow-up,pas de greffe,2022-08-11,Protocole 3 LAL thiotepa Bu Flu
Female,26,94.732462493378,198.51910672116506,2.2855952198060936,24.03777146758457,96.48137920108432,1.5546322705638669,2022-10-28,Treatment follow-up,greffe haplo-identique,2022-05-23,Protocole 3 LAL thiotepa Bu Flu
Male,48,63.67326150661451,166.21600951100223,1.714603569356483,23.046840321925636,78.5759012879135,1.0354355121383763,2022-03-07,Cancer diagnosis,allo-greffe,2022-06-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,81.85733526184234,149.9681475121454,1.8466179994714595,36.396493837982675,117.0038714865583,1.1077193075000658,2022-07-24,Cancer diagnosis,pas de greffe,2022-04-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,73,42.30202157737583,157.16768631583864,1.3589733520605876,17.125158612649475,87.69710399430517,0.448867515540927,2022-10-09,Symptoms management,auto-greffe,2022-04-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,49.13496010897208,173.71776606327975,1.5398065810840402,16.281789514583032,99.41469611783218,0.8031439343982245,2022-03-09,Treatment follow-up,allo-greffe,2022-01-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,119.76741771483228,194.554410240581,2.5441260952953804,31.64146082805829,134.38027416530213,1.138828937568548,2022-10-26,Symptoms management,pas de greffe,2022-09-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,108.08781053276391,177.86629539662826,2.3109148282898326,34.16562740635165,129.6376423769551,1.076951257198824,2022-07-07,Symptoms management,allo-greffe,2022-12-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,108.27753990665852,150.70459466456097,2.129027083677007,47.674417284978276,77.0997677943913,2.165089192848497,2022-12-27,Cancer diagnosis,allo-greffe,2022-08-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,28,116.5119701806237,140.85888878477667,2.1351389916875103,58.72216109668412,127.61654076648585,1.4201986781229945,2022-05-18,Cancer diagnosis,allo-greffe,2022-05-22,Protocole 9 LAL thiotepa-thymo melphalan
Female,35,89.87004235237467,186.83106412343818,2.159637035187511,25.74641537400604,130.95543604582159,1.0008021231336135,2022-01-19,Symptoms management,greffe haplo-identique,2022-05-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,42.61839163626024,177.1051525565668,1.447981041969912,13.58734688811184,108.28423035413758,0.5630365264148078,2022-12-07,Cancer diagnosis,pas de greffe,2022-09-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,58.85007669277243,140.93512154639663,1.5178605842609385,29.62842491311462,100.70301397995138,0.86847204871427,2022-11-05,Symptoms management,pas de greffe,2022-06-08,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,27,112.719567832944,172.2325585409468,2.322234290834401,37.99870610774985,87.30798051369743,2.0262420282168634,2022-12-01,Cancer diagnosis,greffe haplo-identique,2022-12-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,42.333284084372956,170.456233544936,1.4157813075206918,14.569887056072911,100.93473128194637,0.5359159228577713,2022-06-05,Cancer diagnosis,pas de greffe,2022-06-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,95.6512439602903,158.2432607888345,2.050485358720971,38.19796051711669,88.75848693427184,1.4219091244881714,2022-07-24,Symptoms management,greffe haplo-identique,2022-01-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,60.01634168308805,178.7036288688719,1.7260373732758492,18.79328829467503,127.90016504899341,0.527899118563377,2022-05-18,Symptoms management,allo-greffe,2022-06-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,71.87200891409724,154.72455118185073,1.7575523006104312,30.02211754038402,105.74397250522546,1.113919158140351,2022-02-06,Cancer diagnosis,pas de greffe,2022-10-01,Protocole 6 FlUDARABINE cy (Fanconi)
Female,62,99.05686880751085,176.2565697435404,2.202235222169346,31.88555408776771,81.86171746245772,1.310888791504004,2022-08-31,Symptoms management,greffe haplo-identique,2022-07-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,108.90127219267634,178.50102512167058,2.323729564696876,34.178383939650125,123.9201418688594,0.9764466996452438,2022-01-02,Treatment follow-up,allo-greffe,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,67.53840101547354,191.11214543861314,1.8935129549156742,18.491587570612648,82.92147973331177,0.6900508092437991,2022-04-22,Treatment follow-up,greffe haplo-identique,2022-09-20,Protocole 3 LAL thiotepa Bu Flu
Male,41,99.85869878303077,145.08480882147765,2.006100433822457,47.43970929492905,100.25261698011397,1.3695972729959076,2022-04-08,Treatment follow-up,greffe haplo-identique,2022-10-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,21,81.44888529394211,170.95656825695818,1.9666823387939798,27.868497980787765,107.04425544547931,1.2575818018292724,2022-04-09,Treatment follow-up,pas de greffe,2022-03-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,88.30158311351124,152.07951461468767,1.9313827731857536,38.17922025294203,113.99533175659928,0.6992979953572578,2022-07-15,Symptoms management,greffe haplo-identique,2022-11-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,55,66.19050535299903,143.19164042841797,1.6225774285823698,32.28199514992489,84.50259709562577,0.9247238724637694,2022-03-27,Treatment follow-up,auto-greffe,2022-12-19,Protocole 6 FlUDARABINE cy (Fanconi)
Male,60,75.10030888754093,183.1383411225151,1.954606097533374,22.391499146124907,114.18823688516733,0.7307651815023554,2022-08-08,Cancer diagnosis,greffe haplo-identique,2022-02-26,Protocole 3 LAL thiotepa Bu Flu
Male,64,110.55381693532622,155.33872815475377,2.1841149564899442,45.81569209191825,83.66814968490601,1.3947445484743128,2022-09-18,Symptoms management,greffe haplo-identique,2022-12-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,70,65.90912920335133,158.83122102584645,1.705255558243932,26.12605426623128,107.18134417216892,0.5978495656471958,2022-04-27,Treatment follow-up,allo-greffe,2022-12-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,61,61.50710739466189,151.40791520869766,1.6083689893407913,26.830461575819008,74.45794456041592,0.9063769548899135,2022-10-05,Symptoms management,auto-greffe,2022-11-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,48.233432179794875,188.34398172731045,1.5885420175183658,13.59704927642035,87.01458603998903,0.7775798275552693,2022-07-01,Cancer diagnosis,allo-greffe,2022-04-29,Protocole 3 LAL thiotepa Bu Flu
Male,37,93.40803352159615,171.35551285031497,2.1085791351071066,31.8117870747471,82.31839620650054,1.6232748382588966,2022-02-17,Cancer diagnosis,pas de greffe,2022-09-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,101.60340888297324,144.06360282602554,2.016415490080172,48.95530220225806,115.91424733526983,1.0226293409869798,2022-10-06,Cancer diagnosis,greffe haplo-identique,2022-01-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,34,116.84075326545394,156.0756356627143,2.25067859132505,47.96496405997521,106.93639113456217,1.6085782547321161,2022-07-18,Treatment follow-up,allo-greffe,2022-05-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,57.72442979950401,189.64042105282118,1.7437893900140418,16.050842375901695,123.4794086290396,0.6882377333960629,2022-02-02,Treatment follow-up,auto-greffe,2022-10-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,98.3132478002415,188.83792616111032,2.2709071748704392,27.56979892812275,90.3767668057927,1.344660826785732,2022-04-29,Symptoms management,pas de greffe,2022-02-16,Protocole 3 LAL thiotepa Bu Flu
Male,53,49.44583630974012,163.36321708220257,1.4979273542390286,18.527685587071005,93.58894318980123,0.6383986202989151,2022-04-08,Cancer diagnosis,auto-greffe,2022-04-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,87.36910023251157,184.22903063096777,2.1144952538592245,25.741967001942868,110.22889392303748,1.0788373979084098,2022-06-06,Treatment follow-up,pas de greffe,2022-04-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,63.696118447233054,184.87492643610506,1.808607138426146,18.636181843709807,80.35725927155094,0.6935789516288368,2022-12-05,Cancer diagnosis,greffe haplo-identique,2022-08-31,Protocole 3 LAL thiotepa Bu Flu
Male,23,75.30160956218973,159.31849290645812,1.8255089814501508,29.66688036697918,104.27128601725806,1.173526482816233,2022-01-22,Cancer diagnosis,auto-greffe,2022-12-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,113.37348111898669,188.18235252548817,2.434411199116108,32.01501390911709,83.26627099712213,2.0045446531385145,2022-12-15,Cancer diagnosis,greffe haplo-identique,2022-09-20,Protocole 3 LAL thiotepa Bu Flu
Male,42,90.97116147286698,191.46603701629505,2.199614093046229,24.815340745623406,131.65657857875698,0.9404912387065567,2022-05-20,Treatment follow-up,auto-greffe,2022-09-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,74,50.5883615698415,163.83265532705374,1.5173099006531459,18.84732300712953,118.10457661323721,0.39264070963323905,2022-01-07,Treatment follow-up,auto-greffe,2022-01-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,40.93415307935743,179.81626106110497,1.4299015463809008,12.659830270330248,124.42127439785094,0.49806401536091705,2022-06-12,Symptoms management,pas de greffe,2022-07-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,89.18727322401762,196.01303412466976,2.2036502564523865,23.21309152081505,105.62642582326578,1.1727293794679465,2022-01-26,Symptoms management,pas de greffe,2022-01-16,Protocole 3 LAL thiotepa Bu Flu
Male,44,62.45672723718076,180.7354107999887,1.7707611557396181,19.12021282842623,110.11085024726543,0.7562891043819646,2022-09-27,Cancer diagnosis,auto-greffe,2022-01-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,109.88443689059747,194.85563174608478,2.438783927913673,28.940782024511964,90.83163041674948,1.2601662501179243,2022-03-16,Symptoms management,pas de greffe,2022-07-17,Protocole 3 LAL thiotepa Bu Flu
Male,68,62.29377713389553,144.1209486806605,1.5791909195533096,29.990965023632167,92.89172569567137,0.670606307153559,2022-01-09,Treatment follow-up,greffe haplo-identique,2022-08-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,35,84.1526839098114,193.2147555640148,2.125215038249725,22.541737698387518,93.30425428017153,1.3152954812396151,2022-04-23,Symptoms management,auto-greffe,2022-07-09,Protocole 3 LAL thiotepa Bu Flu
Male,72,88.00269576528743,191.09019391181613,2.1613044028594897,24.10011826249911,128.48116055627466,0.6468937294137892,2022-04-28,Symptoms management,auto-greffe,2022-02-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,44,98.45372447031087,192.59985065277792,2.2950534143621693,26.541181869844248,97.14906807447701,1.351239237070652,2022-04-25,Cancer diagnosis,auto-greffe,2022-09-06,Protocole 3 LAL thiotepa Bu Flu
Female,45,56.000947613286925,173.42532526712785,1.6424898574946167,18.619599725458567,120.62759701318699,0.6125475516510385,2022-07-11,Symptoms management,auto-greffe,2022-06-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,42.65727899394306,146.87437899841558,1.3192233997063012,19.774297450207257,98.05400786552536,0.38065878113711704,2022-08-26,Cancer diagnosis,pas de greffe,2022-06-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,95.98490308216451,174.32595069564886,2.155913024053978,31.58485198728715,103.88307683627619,0.8213071507814544,2022-08-26,Symptoms management,allo-greffe,2022-11-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,55.783036161975154,142.59681473802704,1.4864651650731897,27.43358087400563,83.49629966215099,0.640252840004507,2022-03-20,Treatment follow-up,greffe haplo-identique,2022-05-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,71,114.4502575570071,197.24581181344894,2.5041539913206763,29.417190534642824,105.79774544739041,1.03670920738104,2022-01-02,Cancer diagnosis,pas de greffe,2022-04-06,Protocole 3 LAL thiotepa Bu Flu
Female,55,81.68562524234308,179.07557087799688,2.0157642590341855,25.472580825005217,111.99548163815876,0.861056332615658,2022-06-18,Cancer diagnosis,pas de greffe,2022-08-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,108.60364178770821,168.26182192116383,2.2530132067025033,38.359524442705684,128.21927375236214,0.929363626047992,2022-06-08,Treatment follow-up,allo-greffe,2022-09-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,62.43589212197808,147.89781122272407,1.6015731664157482,28.54373678874377,89.39812576508572,1.0864041950009353,2022-12-27,Cancer diagnosis,auto-greffe,2022-12-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,62.756205476917664,158.68281649181344,1.6631906616681305,24.922802492561832,100.49492044547193,1.0234392684628728,2022-05-24,Treatment follow-up,allo-greffe,2022-08-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,104.97150620976552,194.11288161199968,2.3790942229209784,27.8588198718542,119.19573999288544,1.3332288294059869,2022-04-13,Treatment follow-up,auto-greffe,2022-10-18,Protocole 3 LAL thiotepa Bu Flu
Female,51,89.70303251888016,158.716685404074,1.988674041226306,35.60917850350851,104.9707766533102,1.0563217567034402,2022-01-29,Cancer diagnosis,greffe haplo-identique,2022-07-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,65,84.71532626607811,173.6001235404897,2.0211789124147357,28.110070057758445,119.6993351233717,0.7372232388443279,2022-07-09,Symptoms management,allo-greffe,2022-11-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,52.704511810544126,157.37517889188723,1.5178916275356316,21.280181185366892,89.86428111953906,0.5294702350970047,2022-09-21,Symptoms management,auto-greffe,2022-08-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,44.74719309063407,177.38756639681878,1.4848864234004306,14.220649971156355,130.70623640546512,0.5420531134698142,2022-05-05,Symptoms management,allo-greffe,2022-11-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,80.30830775002849,177.80024806039458,1.9915681314025426,25.403628292733288,117.85978413171097,0.7097797425636487,2022-02-04,Symptoms management,auto-greffe,2022-12-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,55.29905877734507,160.60904405757705,1.5706977366332346,21.43767808022539,91.45802766799272,0.8649691860631443,2022-04-04,Symptoms management,auto-greffe,2022-11-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,50.883561970593256,160.02591023633565,1.5039474281971703,19.869955433173008,99.05741412261108,0.5992903828367573,2022-10-05,Symptoms management,greffe haplo-identique,2022-10-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,70.21665914421101,155.20147432950623,1.7398698084813664,29.150665715041338,88.02391781646193,1.1411538400363754,2022-09-08,Symptoms management,greffe haplo-identique,2022-05-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,115.8618242504241,199.74566405471222,2.5354649487865863,29.039266393882667,129.5996772831927,0.9560809630494644,2022-05-27,Cancer diagnosis,allo-greffe,2022-03-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,79.9196113045968,176.08772557069034,1.9771516116148335,25.77479353392066,111.21662626332005,0.6287698363188478,2022-09-08,Symptoms management,allo-greffe,2022-12-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,95.47183402961588,176.5242662268857,2.163657875464408,30.638424966984097,81.04788205974093,1.750591745814975,2022-02-01,Cancer diagnosis,auto-greffe,2022-08-14,Protocole 3 LAL thiotepa Bu Flu
Male,53,58.56403658924181,142.46004107710388,1.5223369332619652,28.856580954942118,78.35416787973264,0.9031412043575303,2022-09-24,Symptoms management,allo-greffe,2022-03-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,62,41.94133877818138,190.76451504339673,1.4907976194986827,11.525163720793014,101.71778055282117,0.4466913266892908,2022-11-21,Treatment follow-up,auto-greffe,2022-11-16,Protocole 3 LAL thiotepa Bu Flu
Male,20,62.593945307370774,149.13020927055558,1.610266382617581,28.144988237067185,78.10162843944387,1.3357370936233213,2022-08-14,Treatment follow-up,greffe haplo-identique,2022-03-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,94.84221054802882,158.06055803901884,2.0406162416776863,37.96248610829319,78.97968125654242,1.4176620718429422,2022-12-02,Cancer diagnosis,allo-greffe,2022-07-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,114.15590624055095,154.35312338284717,2.2123592661347655,47.91456416451294,105.48740670680941,1.4128404730439714,2022-01-04,Symptoms management,greffe haplo-identique,2022-12-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,113.93985105101399,165.56316291133956,2.2891193188679932,41.56695566881937,93.54876741128986,1.7931265729723411,2022-12-05,Symptoms management,auto-greffe,2022-04-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,92.9405822627605,199.09143978993407,2.267136859173788,23.447698129958663,80.06168093415829,1.5961855799204525,2022-05-29,Cancer diagnosis,allo-greffe,2022-06-02,Protocole 3 LAL thiotepa Bu Flu
Male,75,42.123352559804786,151.7690355056151,1.3326061131674527,18.287594385859602,79.0083949750214,0.48131627820705686,2022-09-13,Cancer diagnosis,auto-greffe,2022-01-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,91.10977812700914,186.04502430946056,2.1699027683329866,26.322605198858877,108.12927218096732,1.1117645403462546,2022-06-21,Treatment follow-up,allo-greffe,2022-09-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,73.73118042413878,169.892010545033,1.8653521027554854,25.54496283015933,79.47852106553826,1.0951858879660012,2022-05-30,Symptoms management,greffe haplo-identique,2022-02-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,112.17857907417658,164.05109199840436,2.2609620860222326,41.6823008113973,77.50310968566336,1.9097737309561638,2022-06-08,Symptoms management,auto-greffe,2022-07-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,42.51303109899743,193.51832388566254,1.5117181653830765,11.35214377406558,87.6589300168742,0.7072658808494473,2022-06-21,Symptoms management,allo-greffe,2022-12-06,Protocole 3 LAL thiotepa Bu Flu
Female,38,103.70917528256122,190.5223267598118,2.34277336725649,28.57099908401337,82.58884574478424,1.7789488438222134,2022-08-08,Treatment follow-up,greffe haplo-identique,2022-11-17,Protocole 3 LAL thiotepa Bu Flu
Female,74,47.877081070576764,175.18107028008112,1.526357165118404,15.601031513547296,99.28535820222339,0.4420321899358627,2022-04-26,Cancer diagnosis,allo-greffe,2022-04-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,51.95444398134331,154.99132570582628,1.4955942844250434,21.627579414018427,126.12740242557331,0.44624704780550184,2022-12-02,Treatment follow-up,greffe haplo-identique,2022-04-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,32,99.53824365987371,192.21260662252973,2.305338326128005,26.941776983169813,100.94797218792814,1.4790526471582306,2022-01-04,Treatment follow-up,pas de greffe,2022-02-19,Protocole 3 LAL thiotepa Bu Flu
Male,34,57.58189619323965,152.98495576796398,1.564285765502925,24.603025214736924,81.47526610518685,1.0404795372369307,2022-07-28,Treatment follow-up,allo-greffe,2022-08-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,95.30138245909035,160.87138298743307,2.0636581056200067,36.824902855478,80.58682538799096,1.8067386773396379,2022-09-30,Treatment follow-up,greffe haplo-identique,2022-01-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,43.431232066739504,186.424909608384,1.4996910341265726,12.496669015328115,84.20962812113738,0.5515674500110194,2022-12-27,Treatment follow-up,pas de greffe,2022-11-02,Protocole 3 LAL thiotepa Bu Flu
Female,46,55.48942627452038,172.58920527103072,1.631025238382367,18.628718351630276,103.39100195884143,0.7006850439086537,2022-12-26,Symptoms management,pas de greffe,2022-12-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,101.71271637015926,178.7896992498512,2.2475410001022467,31.81927391146761,131.8194747348133,0.9752244297556777,2022-09-30,Treatment follow-up,auto-greffe,2022-01-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,115.8156801254972,189.7593393869351,2.4707796200605125,32.163332643434764,112.04830043593144,1.2202491609480544,2022-04-19,Treatment follow-up,allo-greffe,2022-07-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,32,100.4097364082543,189.13337993172195,2.2967871778340485,28.06980912930091,96.49624872637882,1.5608337795540492,2022-04-05,Treatment follow-up,greffe haplo-identique,2022-02-16,Protocole 3 LAL thiotepa Bu Flu
Female,43,61.39619894851006,143.65021447856182,1.5652100628564847,29.75287428247453,122.43393489303077,0.6755833148356787,2022-09-06,Treatment follow-up,greffe haplo-identique,2022-02-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,74,65.12044142439424,146.68060897955164,1.628897548543814,30.267177736896635,94.56931762169236,0.6312167569100532,2022-11-01,Symptoms management,auto-greffe,2022-07-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,59,76.96228183200881,176.2398708265037,1.9410637553632948,24.778191427612043,81.56705338095614,1.061489455266074,2022-06-04,Treatment follow-up,pas de greffe,2022-07-07,Protocole 3 LAL thiotepa Bu Flu
Male,71,97.5348447821087,161.23465886410156,2.0900556495652345,37.51828611546972,87.10487357522383,1.0730845368309498,2022-11-15,Symptoms management,allo-greffe,2022-06-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,115.73897977830075,172.02231118189943,2.3516948259180146,39.11200621431223,80.62319415000374,2.2530228519693742,2022-12-10,Symptoms management,allo-greffe,2022-11-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,56,94.89098980250415,142.41412096059685,1.9374823941712338,46.78631813963557,111.75795502086102,0.9905885871741612,2022-06-27,Cancer diagnosis,pas de greffe,2022-10-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,20,95.51751652511768,140.54098730512726,1.9310421824449162,48.35896773606071,96.87258734016122,1.6433530397633667,2022-02-16,Cancer diagnosis,greffe haplo-identique,2022-01-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,50,92.64119959768057,165.9981418405063,2.0668190126032937,33.62000059297623,106.76380013984092,1.0846513457316251,2022-07-05,Treatment follow-up,pas de greffe,2022-08-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,63,110.47081537991204,195.56456814340967,2.4497265891785895,28.884656881327345,113.7655303821851,1.0384727200269361,2022-06-18,Treatment follow-up,auto-greffe,2022-04-12,Protocole 3 LAL thiotepa Bu Flu
Female,71,53.81473043866627,142.08813077858954,1.4573982198485458,26.655422288585044,82.47218357832806,0.6253314483269482,2022-07-18,Cancer diagnosis,pas de greffe,2022-04-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,40,75.01931204320057,147.9469828716322,1.7558537709534345,34.27368898353019,90.97906744015955,1.1452468340304958,2022-05-22,Treatment follow-up,greffe haplo-identique,2022-11-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,66,85.35215817218317,154.47578407172105,1.9137544220038576,35.76792040914006,120.91095499637201,0.7255178114950459,2022-08-29,Symptoms management,greffe haplo-identique,2022-10-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,63,99.17962692308166,155.88757038468424,2.072362518741098,40.81309157602785,105.78665307365841,1.002651071124338,2022-11-13,Treatment follow-up,greffe haplo-identique,2022-12-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,45,74.37430902680677,188.95354568598043,1.975776176493681,20.831131109623666,89.71460478357076,1.0938327052942145,2022-11-24,Symptoms management,greffe haplo-identique,2022-10-22,Protocole 3 LAL thiotepa Bu Flu
Male,73,74.08004630342268,190.0796907932656,1.9777310439059383,20.503585400810284,88.94860048471412,0.7750048709907403,2022-03-21,Symptoms management,greffe haplo-identique,2022-01-31,Protocole 3 LAL thiotepa Bu Flu
Male,56,105.34039678440696,181.80029502154852,2.3064471965131523,31.871740635598997,118.2384059905133,1.03940110281653,2022-08-28,Cancer diagnosis,greffe haplo-identique,2022-09-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,84.46464871280492,181.60046259896694,2.0641664499733845,25.61185764090697,100.3239707982999,0.9705454167049169,2022-07-21,Treatment follow-up,allo-greffe,2022-02-28,Protocole 3 LAL thiotepa Bu Flu
Male,73,73.27606626133856,185.72388012096752,1.9443018845717204,21.2435283227951,124.88217652029402,0.5460142708008038,2022-08-08,Treatment follow-up,greffe haplo-identique,2022-11-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,69.29541785647667,140.97305324929363,1.6472862052658626,34.86842300809343,78.3239858247311,1.0813341367979488,2022-03-15,Cancer diagnosis,pas de greffe,2022-01-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,45.51545253462628,152.48124572661192,1.3884696714058862,19.576092222669462,120.51530841975237,0.5035648237715648,2022-04-07,Symptoms management,greffe haplo-identique,2022-10-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,69,44.366755723100624,165.46436637940053,1.4280053225111367,16.204987909422464,128.767695386009,0.3397634061194484,2022-06-12,Cancer diagnosis,allo-greffe,2022-08-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,94.39541536024001,169.36272059751101,2.1073327241735864,32.90904343593833,84.57183339736083,1.0541479596300973,2022-07-07,Treatment follow-up,pas de greffe,2022-02-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,51,89.01591967215452,177.64523972181172,2.0958460496113513,28.20723614363755,76.02041624765732,1.4474212692293065,2022-06-04,Treatment follow-up,allo-greffe,2022-08-03,Protocole 3 LAL thiotepa Bu Flu
Male,33,85.17627190926969,154.45295401726924,1.9116402794288159,35.70476587795789,102.37199857586737,1.2364846427568577,2022-10-04,Symptoms management,pas de greffe,2022-07-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,64,59.706473382786605,150.6626519907412,1.580746625707228,26.303297956535157,113.55593912096862,0.5549995902432966,2022-07-05,Treatment follow-up,auto-greffe,2022-01-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,84.1421280000716,178.14549814843096,2.0405297043661235,26.513300097205025,98.0703105482872,0.9294757148260052,2022-06-23,Symptoms management,greffe haplo-identique,2022-02-14,Protocole 3 LAL thiotepa Bu Flu
Male,58,69.69932250180482,192.3214602582733,1.9296427045900542,18.84399849820435,111.84972048764315,0.7097003337541506,2022-01-23,Treatment follow-up,greffe haplo-identique,2022-09-13,Protocole 3 LAL thiotepa Bu Flu
Female,72,51.460893634728,156.64386016748543,1.4963875970902738,20.972517710841792,103.13339027560329,0.4712533445238866,2022-12-12,Symptoms management,pas de greffe,2022-08-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,62.46133747386551,191.02935399096202,1.820557679137845,17.116346332484866,86.99565520688064,0.8675619021981317,2022-01-17,Treatment follow-up,greffe haplo-identique,2022-01-23,Protocole 3 LAL thiotepa Bu Flu
Female,76,103.5012775750067,154.78221515110118,2.109512648695884,43.201974387676266,80.22669719206635,1.1467645913675504,2022-09-27,Symptoms management,allo-greffe,2022-06-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,54.70086038689458,187.70955762375553,1.6888420017592918,15.52463452568585,115.88124434046915,0.7605127512933186,2022-01-16,Treatment follow-up,pas de greffe,2022-06-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,52.30220509602739,152.60982816956738,1.489018182542724,22.457168246117263,89.53169886298588,0.8438087352588315,2022-03-02,Cancer diagnosis,pas de greffe,2022-02-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,58,63.870064753893836,156.12953818032128,1.6643320076078454,26.20156343623076,133.89010176549587,0.543288160376686,2022-08-21,Treatment follow-up,auto-greffe,2022-02-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,77.8844110563471,199.4911024792383,2.0774748980684903,19.570570202611126,93.04153730616257,0.9068506506586655,2022-08-30,Symptoms management,allo-greffe,2022-02-19,Protocole 3 LAL thiotepa Bu Flu
Female,67,112.95165293415651,171.80278792430553,2.3217216357901935,38.2676837881553,85.66686241565705,1.3368112553944178,2022-08-13,Symptoms management,pas de greffe,2022-09-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,62.450990214919415,177.389127935195,1.7542113369541081,19.846564115714155,98.020485166458,0.9999273057709697,2022-05-15,Cancer diagnosis,pas de greffe,2022-06-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,56.07941059971544,151.22699794929824,1.5348471613885553,24.521372723077498,125.33387042846125,0.5593002355229741,2022-11-20,Treatment follow-up,pas de greffe,2022-11-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,46,99.47087181045544,168.1913254364571,2.15575056355221,35.16322812607442,78.41441505677759,1.656133623059782,2022-10-11,Treatment follow-up,pas de greffe,2022-12-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,82.53308183924048,187.7827784032201,2.0748688993359,23.405425521460923,106.69348519398514,1.1495859351912194,2022-12-31,Symptoms management,pas de greffe,2022-07-01,Protocole 3 LAL thiotepa Bu Flu
Female,39,50.40588488083395,151.51947614100717,1.4565439757224286,21.955550102281258,94.9964800345428,0.7443250018774134,2022-05-18,Symptoms management,greffe haplo-identique,2022-08-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,95.24242096307114,174.4299671881811,2.148199010767924,31.303163384391024,119.97894512523499,0.7056232212792287,2022-06-15,Treatment follow-up,allo-greffe,2022-11-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,111.29824965590439,190.65329992492138,2.42781214795715,30.619611851453207,125.27192166999393,1.4560762083171144,2022-09-13,Treatment follow-up,auto-greffe,2022-07-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,86.60956555132177,157.22517442712945,1.9448796057328805,35.03657859547749,95.14074122619641,0.9988353964364175,2022-03-10,Symptoms management,pas de greffe,2022-07-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,77,72.00684090744787,153.08720337116443,1.7498671297267714,30.72528919194258,90.06268165142899,0.6995792778841512,2022-11-19,Treatment follow-up,pas de greffe,2022-09-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,46,71.2386221871509,160.18010892464056,1.780372172513622,27.765042459931184,130.5224532723146,0.7125668927821617,2022-02-15,Symptoms management,pas de greffe,2022-10-31,Protocole 6 FlUDARABINE cy (Fanconi)
Female,21,49.5595854284214,193.218236650481,1.6309349487681781,13.274905438278084,122.09037924770608,0.6709044723809658,2022-03-09,Treatment follow-up,allo-greffe,2022-09-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,106.86342413859822,184.69288783102928,2.341468817719495,31.327716643820583,74.33560662518381,1.3377485909178366,2022-01-18,Cancer diagnosis,greffe haplo-identique,2022-12-19,Protocole 3 LAL thiotepa Bu Flu
Male,30,112.9439188086311,141.41025849509393,2.1063019696310183,56.4808234831511,107.76733473763332,1.6011643018829067,2022-06-13,Symptoms management,pas de greffe,2022-01-01,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,53,70.49327116420193,182.1004103870264,1.8883306567004496,21.258167022964365,125.89757528328654,0.6765767262137145,2022-01-11,Symptoms management,allo-greffe,2022-01-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,77.43946406288865,174.73259557927278,1.938728001951018,25.363809474597087,96.2893121848947,0.77072748826403,2022-08-29,Symptoms management,pas de greffe,2022-02-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,48.70046841735683,169.0041872444157,1.5120426841507526,17.050542783361312,87.51059992154913,0.8270347511756443,2022-09-26,Cancer diagnosis,greffe haplo-identique,2022-08-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,68.05940636371696,176.93540057901092,1.8289431016098057,21.739957435636637,133.69169474639705,0.4525131513654638,2022-03-11,Cancer diagnosis,allo-greffe,2022-12-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,66.58778943203384,174.13293044475495,1.7946778498938292,21.960022464764968,118.269282879482,0.6255760659143677,2022-11-26,Treatment follow-up,pas de greffe,2022-07-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,117.35558218843174,167.88703614331095,2.339425432100354,41.63604103405983,87.46374683454749,2.068550636750247,2022-08-13,Cancer diagnosis,greffe haplo-identique,2022-11-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,104.17509443777901,178.82220933399435,2.2747906219243044,32.577742806602885,128.35664867715445,0.8003342186389387,2022-12-31,Treatment follow-up,pas de greffe,2022-08-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,64,43.701489500445646,167.10709264549246,1.4242765078274522,15.64971643644306,112.10309402477175,0.41149042699976546,2022-04-28,Symptoms management,auto-greffe,2022-06-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,104.8813067186983,194.37950246042442,2.3797044761307227,27.758574338444976,98.0030056266663,1.5755495401353121,2022-05-20,Symptoms management,greffe haplo-identique,2022-02-16,Protocole 3 LAL thiotepa Bu Flu
Female,43,94.51312195496715,174.2375343847691,2.138777775093397,31.132118538581047,95.62091046206508,1.3316143673390917,2022-09-17,Cancer diagnosis,allo-greffe,2022-09-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,50.887963241763174,159.8223704284696,1.5030556757241247,19.922321003644228,109.87644814145955,0.6303823372685295,2022-01-19,Symptoms management,auto-greffe,2022-09-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,91.03533391406324,168.40011993952854,2.063597260305363,32.101490427586505,96.46994426528497,1.5072431050142745,2022-03-31,Cancer diagnosis,pas de greffe,2022-11-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,103.2593054830862,167.53467418775952,2.1921269542617465,36.78915297696641,134.98123592144725,0.7862397969599592,2022-06-01,Cancer diagnosis,greffe haplo-identique,2022-12-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,79.00590421228841,193.4026202635794,2.060201506524567,21.121990379028716,102.59885370491516,1.251325816116971,2022-09-19,Treatment follow-up,greffe haplo-identique,2022-02-13,Protocole 3 LAL thiotepa Bu Flu
Male,36,119.72432192321497,164.3231434656864,2.337702868660724,44.33890029712303,105.99555013309569,1.6315319978028908,2022-04-20,Cancer diagnosis,greffe haplo-identique,2022-07-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,27,92.27113879449125,141.17509054461686,1.9022199293024287,46.29666747057471,119.28795026179428,1.2139903975695854,2022-01-02,Symptoms management,auto-greffe,2022-10-15,Protocole 8 Aplasie medullaire thymo
Female,38,98.12831925057958,186.02088883384317,2.2517843027970765,28.357695181988948,130.13008912210452,1.0682780583349905,2022-10-06,Cancer diagnosis,auto-greffe,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,114.91775996678115,193.63434683213154,2.486185464531924,30.649427173579706,111.72543763217297,1.0857158632422752,2022-02-16,Cancer diagnosis,greffe haplo-identique,2022-10-24,Protocole 3 LAL thiotepa Bu Flu
Female,60,118.0339860958872,190.85156915538414,2.5014979656678196,32.40526697550688,83.10538246583397,1.578103241312826,2022-09-19,Treatment follow-up,greffe haplo-identique,2022-05-28,Protocole 3 LAL thiotepa Bu Flu
Female,54,112.95504477194262,193.16135283250387,2.4618505492935188,30.2736757664597,112.14066628117723,1.2031186381711947,2022-07-29,Treatment follow-up,auto-greffe,2022-10-03,Protocole 3 LAL thiotepa Bu Flu
Male,79,41.84354952041584,177.24201555974346,1.4353121084485463,13.319721910816822,117.90405084977908,0.3006748687160881,2022-06-27,Symptoms management,greffe haplo-identique,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,114.01491062088033,185.69000222979554,2.4250675252581,33.06622436571589,96.60309771833583,1.7375766310326153,2022-10-27,Cancer diagnosis,allo-greffe,2022-02-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,105.1526111398285,148.77563399104025,2.084609368425687,47.50687267548969,122.13164827632853,0.9446837350976279,2022-02-12,Cancer diagnosis,allo-greffe,2022-01-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,27,112.52331600434114,152.37052734675464,2.1823303674937193,48.466379755174565,89.77837849260014,1.967055945302418,2022-04-11,Treatment follow-up,greffe haplo-identique,2022-11-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,30,114.06148603256595,197.29701435892233,2.5002216928130805,29.302049585379425,134.2630249067683,1.297904644870548,2022-04-29,Symptoms management,auto-greffe,2022-08-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,28,101.77710326014638,170.260334607685,2.1939692376346263,35.10937681348016,74.20650441849345,2.133504867872691,2022-11-16,Cancer diagnosis,greffe haplo-identique,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,118.36003764937341,158.71724697438185,2.2843537456827145,46.98474249170069,122.98738418830848,0.8287121821808273,2022-11-14,Cancer diagnosis,auto-greffe,2022-08-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,34,116.08415054316592,198.0303122450427,2.526975606594422,29.601218130792777,109.5006002709359,1.5607372530796995,2022-08-30,Symptoms management,pas de greffe,2022-08-16,Protocole 3 LAL thiotepa Bu Flu
Male,51,111.76456308952234,166.33948636541754,2.272471734218935,40.393679241215324,95.8707870943044,1.4410376972032277,2022-10-06,Symptoms management,pas de greffe,2022-11-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,74,100.32954990580319,171.02241892170235,2.183180803464429,34.30226316002376,94.2376601149895,0.9759235741644968,2022-11-02,Cancer diagnosis,pas de greffe,2022-06-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,73.98990139927022,147.23018448692343,1.7395359241590709,34.13333601262813,96.84960210746881,1.0080120333166622,2022-05-09,Treatment follow-up,allo-greffe,2022-02-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,53,72.2320288415924,153.63992863391937,1.7557622400023825,30.600013628102715,125.08246771506211,0.6977825891828062,2022-03-30,Treatment follow-up,auto-greffe,2022-05-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,38,48.858439437092485,157.0271820658878,1.4598423682925759,19.814810214724417,112.32779083485764,0.6161976659688907,2022-01-04,Cancer diagnosis,allo-greffe,2022-11-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,43,71.35104685095709,167.32302688870305,1.821070589483911,25.485251548277112,83.0206749431772,1.1578527392389995,2022-05-12,Cancer diagnosis,pas de greffe,2022-10-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,54.86443710869256,182.60265497543014,1.6681986192513647,16.45419926329593,108.1301721216409,0.6130992568700027,2022-08-02,Cancer diagnosis,pas de greffe,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,111.80293359500467,147.82543728805607,2.1426435870962623,51.162864815752016,122.50515637561998,1.2802291379193662,2022-02-15,Treatment follow-up,greffe haplo-identique,2022-08-10,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,34,79.21174632302726,156.6231788473716,1.8564000041271733,32.290704440937034,91.43824713456345,1.275366674802639,2022-08-09,Treatment follow-up,pas de greffe,2022-07-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,71.96876397508274,180.87700808728198,1.90157060110501,21.997701909777067,115.8178670616808,0.8285280535832413,2022-12-30,Treatment follow-up,auto-greffe,2022-10-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,74.48695483913914,158.2674019426245,1.8096083693108969,29.737008260251432,84.14666227479529,0.9835599050182336,2022-06-26,Symptoms management,pas de greffe,2022-03-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,54.45207751170456,175.81140813235197,1.630720394919643,17.616529254063618,93.80571254810964,0.7417208686795619,2022-06-01,Symptoms management,auto-greffe,2022-02-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,30,46.289458682215006,161.54211308818452,1.4412279649691884,17.738242307878245,88.72480744332223,0.7970713981569014,2022-03-11,Treatment follow-up,auto-greffe,2022-11-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,112.08245862193861,163.78148938745792,2.258135416131171,41.78380794788963,126.0965769960502,1.432055482775817,2022-08-10,Symptoms management,greffe haplo-identique,2022-08-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,102.93180714193163,193.10610490099896,2.349749416167087,27.603082907421747,133.4363329431809,1.2320854906181455,2022-12-21,Cancer diagnosis,greffe haplo-identique,2022-01-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,88.45073225480834,152.7666624190957,1.9373753117650439,37.90043998808398,94.68514928739796,1.1157978473278933,2022-07-19,Symptoms management,allo-greffe,2022-10-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,47,114.26896897549273,161.63277873829762,2.265049115181808,43.7390584913345,109.27895004913063,1.3506482098670718,2022-06-09,Cancer diagnosis,greffe haplo-identique,2022-12-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,47,99.20588114921571,171.656743433953,2.174943069981,33.667873030375894,113.63538892595842,1.1276498547580978,2022-01-20,Cancer diagnosis,allo-greffe,2022-06-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,78.75722516787901,184.14970556376372,2.007148324370504,23.224605664780253,90.41938215236478,1.2944347176033386,2022-07-20,Cancer diagnosis,allo-greffe,2022-03-10,Protocole 3 LAL thiotepa Bu Flu
Male,66,80.78938583821967,173.18246913493044,1.9714141370654514,26.936827932372115,119.80363221831468,0.6930802840228356,2022-10-04,Treatment follow-up,allo-greffe,2022-12-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,69,86.92199888987253,145.69225419871125,1.8755637639656366,40.9502709040196,95.08634592127056,0.9014411908967553,2022-03-30,Cancer diagnosis,greffe haplo-identique,2022-11-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,33,95.38582436041062,189.33016678959717,2.2397553211803047,26.60995881758017,90.87107443771242,1.5599456075724552,2022-11-10,Treatment follow-up,pas de greffe,2022-11-09,Protocole 3 LAL thiotepa Bu Flu
Female,30,71.05926958168862,142.20662224475575,1.6754020003827486,35.1383283745192,104.60363974022209,1.0378489050824093,2022-05-24,Treatment follow-up,allo-greffe,2022-10-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,78,57.72669264589125,188.76091277242534,1.739775144728294,16.201399775890987,90.59752686768837,0.5486805011539645,2022-01-16,Cancer diagnosis,pas de greffe,2022-07-19,Protocole 3 LAL thiotepa Bu Flu
Female,34,47.87325353937408,163.76422730401794,1.4757226454261634,17.850684041343854,123.76285590108424,0.5694767399927761,2022-09-10,Symptoms management,greffe haplo-identique,2022-10-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,96.82284281815114,173.2492917422777,2.1586060923351136,32.257811080392294,111.17479437583103,0.7741390452294828,2022-02-02,Treatment follow-up,greffe haplo-identique,2022-01-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,109.0045030425611,196.98569282382556,2.4422398390250346,28.091509115987606,95.27786391161764,1.287078245547531,2022-03-03,Symptoms management,greffe haplo-identique,2022-03-22,Protocole 3 LAL thiotepa Bu Flu
Male,41,77.54902186335862,178.3455802864547,1.9600542300368782,24.381006030706235,129.99174323486164,0.8202821379929132,2022-04-19,Treatment follow-up,pas de greffe,2022-01-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,109.2289946236227,175.0643156667126,2.3047113096358087,35.64040868516654,111.34434016154044,0.9401266949216871,2022-05-13,Symptoms management,pas de greffe,2022-10-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,118.19710081573012,162.35327742944247,2.308780744852862,44.841972066445486,90.27877240178181,1.7820289636352566,2022-11-21,Symptoms management,pas de greffe,2022-05-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,66,96.94155842471886,173.64788437506797,2.162412267229617,32.149261718069134,118.23093855687722,0.8427098753355592,2022-05-19,Treatment follow-up,allo-greffe,2022-08-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,96.66308435239358,172.9895225086853,2.1552069252508588,32.30137790506177,78.08116292189271,1.8053906056051123,2022-01-02,Treatment follow-up,pas de greffe,2022-08-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,102.66533838634368,196.9988094638009,2.370240812619631,26.454322265151976,133.3252885966685,1.1122749422112905,2022-03-09,Cancer diagnosis,pas de greffe,2022-04-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,75.11445870730374,156.20347608709997,1.805326959805479,30.785212338470192,85.41936427112967,1.2091213930686018,2022-05-29,Treatment follow-up,allo-greffe,2022-05-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,57.519771697233125,197.524762493118,1.7765118165127807,14.742599143626048,120.2574771980708,0.4318032681293124,2022-05-11,Symptoms management,greffe haplo-identique,2022-03-04,Protocole 3 LAL thiotepa Bu Flu
Female,65,48.08791010704112,190.16455871100044,1.5937914443273427,13.29770650046188,109.42328073887069,0.4577780220984882,2022-10-25,Symptoms management,greffe haplo-identique,2022-08-23,Protocole 3 LAL thiotepa Bu Flu
Female,55,53.892784220991004,148.5965712044935,1.491483503456923,24.406923728976427,80.65481883603167,0.7888360141976369,2022-04-04,Cancer diagnosis,pas de greffe,2022-04-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,52.34975566137324,174.45005800308653,1.592728085146674,17.20174172251354,101.69781326925627,0.4647120185176209,2022-06-02,Treatment follow-up,allo-greffe,2022-06-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,107.40889092555956,178.0549271156766,2.304866966836226,33.87912930017077,130.9794686189622,0.9908861638405552,2022-06-07,Symptoms management,auto-greffe,2022-04-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,103.63700597251163,199.36627461724748,2.3956977522927003,26.07422870842987,98.68646455472094,1.5460752791757586,2022-05-20,Symptoms management,pas de greffe,2022-11-14,Protocole 3 LAL thiotepa Bu Flu
Female,66,64.02695154033832,184.27108328263324,1.8103342017753092,18.85595125084139,76.11485210431505,0.8645550264201826,2022-08-07,Cancer diagnosis,auto-greffe,2022-02-11,Protocole 3 LAL thiotepa Bu Flu
Male,44,89.27870454259795,161.66303879890643,2.0022949802376853,34.16067187693436,85.76149082093767,1.3880154319146016,2022-11-08,Treatment follow-up,auto-greffe,2022-06-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,59.946224236819,147.86171804552023,1.5691249955520203,27.41891957797273,108.37100929637317,0.7375431815333316,2022-10-28,Cancer diagnosis,auto-greffe,2022-08-01,Protocole 6 FlUDARABINE cy (Fanconi)
Female,69,87.82889287582464,141.38621389861353,1.8572526480006666,43.93627951626318,97.4017391553848,0.8891940523081517,2022-10-29,Treatment follow-up,allo-greffe,2022-06-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,53,118.52100187335128,198.24111682883546,2.5547198030228535,30.158368434429548,118.1260183176278,1.2123736946635177,2022-04-05,Cancer diagnosis,greffe haplo-identique,2022-12-17,Protocole 3 LAL thiotepa Bu Flu
Male,22,118.45373464433091,176.62171758962387,2.4107111714519283,37.97174451835556,82.21370737074072,2.3613155976600217,2022-01-21,Symptoms management,allo-greffe,2022-02-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,83.27454666285578,151.53409945514247,1.8722337695392317,36.26532153778433,114.17242863943707,0.9725003681445306,2022-01-31,Symptoms management,allo-greffe,2022-03-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,81.65095271157779,148.56206462705313,1.8356223674817789,36.99520207072165,81.87583382922382,0.9002981978314395,2022-05-07,Treatment follow-up,greffe haplo-identique,2022-01-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,46,62.601715981567025,190.70210663743285,1.8210405386911108,17.213740698894128,76.4927045379005,1.068468144521552,2022-06-26,Treatment follow-up,allo-greffe,2022-05-08,Protocole 2 LAM Endoxan TBI
Female,75,74.39255308261828,190.41264007173362,1.9836332010100621,20.51813648607223,100.93862145811538,0.6653542795114318,2022-12-03,Treatment follow-up,auto-greffe,2022-03-24,Protocole 3 LAL thiotepa Bu Flu
Female,75,44.665158333217974,153.15812655612612,1.3784887027152044,19.04095764996438,89.82182111818496,0.4489188916699836,2022-06-23,Cancer diagnosis,allo-greffe,2022-10-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,66,49.58646235216362,193.77838321863914,1.6337401282651842,13.205427626866593,128.64223897281877,0.3961674213003746,2022-05-06,Treatment follow-up,allo-greffe,2022-01-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,92.60519343615285,144.9577144746619,1.9310214042335125,44.070976896013775,113.42486542599988,0.8618033271425969,2022-12-27,Symptoms management,pas de greffe,2022-04-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,79,65.14829571396801,169.46792068901968,1.751233391631891,22.684439728200257,107.24535949366182,0.5146617450803591,2022-05-26,Treatment follow-up,allo-greffe,2022-06-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,44.159790958003065,173.63149693324522,1.4594072815413472,14.647718664249222,129.28741634650385,0.4316976137715615,2022-05-10,Treatment follow-up,allo-greffe,2022-01-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,53.196346201644474,163.2473891354461,1.5531477561680778,19.961322687111878,97.33030192744029,0.6300562573611016,2022-06-17,Symptoms management,pas de greffe,2022-12-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,115.00553725684826,173.66487781552706,2.355397028093117,38.13245451772638,111.79933151166901,1.4572941439892526,2022-09-02,Symptoms management,allo-greffe,2022-01-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,58.39706463270413,180.71632584797618,1.7121545037311814,17.881182712131242,98.79613422890081,0.6403437460301258,2022-12-20,Treatment follow-up,allo-greffe,2022-12-23,Protocole 3 LAL thiotepa Bu Flu
Male,39,69.60742328095245,150.98094769731648,1.7085889836130905,30.535937865199724,107.01638028490135,0.9124186997069262,2022-08-04,Symptoms management,greffe haplo-identique,2022-12-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,25,90.31460690415378,195.48915058944638,2.21456829185941,23.6326638063419,126.29127318499422,1.1422206261811514,2022-09-09,Treatment follow-up,pas de greffe,2022-07-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,96.1408262924143,165.57736787756323,2.1028251474750177,35.0675884775714,96.6633241049559,1.0636637371489839,2022-07-01,Cancer diagnosis,auto-greffe,2022-08-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,42,88.76707767609432,174.90561022431973,2.0767134751791825,29.016461004952635,106.1054314062305,1.1386962394339826,2022-08-05,Treatment follow-up,auto-greffe,2022-11-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,28,70.94832284437919,141.15238443513422,1.6678766392197453,35.60948524371885,107.39365738047371,1.0276589926249178,2022-07-23,Symptoms management,pas de greffe,2022-09-29,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,27,50.943502388931336,169.53339111714888,1.5488907065829138,17.724675841187878,116.63412710163597,0.6855025950953347,2022-05-04,Cancer diagnosis,pas de greffe,2022-07-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,114.89224439996744,191.14351574994052,2.4698688408165403,31.446446294265375,121.51856306745808,0.8141553498981382,2022-12-01,Cancer diagnosis,allo-greffe,2022-01-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,93.8358642158743,186.57193071415745,2.2052423875964284,26.95729098457568,132.98355435700384,0.6468183925482603,2022-09-19,Symptoms management,allo-greffe,2022-11-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,44.000509274410106,151.6504035958374,1.361442759016931,19.132448907760317,124.54801978306801,0.5544556625928566,2022-09-16,Cancer diagnosis,allo-greffe,2022-01-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,58,118.97695478393514,182.89146848216748,2.4585378432430987,35.5693521370798,116.33409848376127,1.1647619537462934,2022-04-13,Cancer diagnosis,pas de greffe,2022-06-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,102.61373628883837,182.24980433190274,2.279213641222576,30.89380205937352,127.11138124026672,0.8633348888747799,2022-04-21,Symptoms management,auto-greffe,2022-06-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,59.82437331557361,181.75785622154086,1.7379385812280765,18.108887658419377,128.999695474611,0.5088433084346662,2022-07-30,Cancer diagnosis,greffe haplo-identique,2022-10-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,49.847373742267536,194.0344811330546,1.6391147085415696,13.239892374396206,105.66640414135342,0.6420944746974292,2022-02-21,Cancer diagnosis,pas de greffe,2022-06-12,Protocole 3 LAL thiotepa Bu Flu
Female,38,89.90489144888201,173.6867847347329,2.082686001276123,29.80229914656343,110.57186593341929,1.1518776662646628,2022-06-15,Cancer diagnosis,greffe haplo-identique,2022-10-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,51,119.25914352358316,173.66253036398862,2.3985438078451047,39.54389431528898,117.30936551124609,1.2566562931155176,2022-10-03,Cancer diagnosis,greffe haplo-identique,2022-02-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,50,116.80279129218538,140.59763515969348,2.1358186197784588,59.08771418131245,99.83997503327807,1.4623750563495905,2022-06-14,Cancer diagnosis,auto-greffe,2022-04-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,26,109.61466185516042,180.42474239215295,2.343857049562411,33.67258521696385,110.05022449317651,1.5770667323636256,2022-05-02,Treatment follow-up,auto-greffe,2022-09-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,112.19960198156312,155.48814061520733,2.2013699957753317,46.40841926809498,97.01023651648451,1.5581633706084692,2022-05-10,Symptoms management,greffe haplo-identique,2022-10-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,105.398904741113,194.14071224580414,2.384103514039941,27.964229695261942,98.19419640670456,0.9690164234176354,2022-05-29,Symptoms management,allo-greffe,2022-09-01,Protocole 3 LAL thiotepa Bu Flu
Female,38,106.48441613954826,190.54682282091315,2.3740651479015487,29.328012349723952,111.23661186566319,1.3561445313215774,2022-10-14,Cancer diagnosis,greffe haplo-identique,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Female,31,81.32457245681965,198.43201722253914,2.117217707955372,20.653720427989843,101.28562560028335,1.21553641897705,2022-06-19,Treatment follow-up,auto-greffe,2022-12-19,Protocole 3 LAL thiotepa Bu Flu
Male,43,112.04733124582664,158.225027518678,2.219152244900275,44.75598886916211,132.97565355070162,1.1351901687590955,2022-06-11,Cancer diagnosis,pas de greffe,2022-04-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,37,64.6912335978049,153.94365893550446,1.663230224016701,27.29743392666938,123.32866983976231,0.7503884031127758,2022-05-20,Treatment follow-up,greffe haplo-identique,2022-10-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,101.38057069791626,148.4273955608474,2.044481329848999,46.01787898204337,120.38421818442563,1.2398197316394814,2022-06-14,Cancer diagnosis,greffe haplo-identique,2022-01-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,38,115.31301551189243,191.98302203623075,2.4798152483873483,31.286190256337523,94.63074402609331,1.7262899810178989,2022-12-16,Treatment follow-up,greffe haplo-identique,2022-05-30,Protocole 3 LAL thiotepa Bu Flu
Female,38,101.48969421021877,196.56864019640255,2.3540562620041494,26.265972018460516,85.13265316520857,1.6888592267739606,2022-09-15,Symptoms management,allo-greffe,2022-03-05,Protocole 3 LAL thiotepa Bu Flu
Female,28,41.20273387030346,177.74855393830742,1.4263128809540275,13.04108965674745,105.61808313568038,0.60683871239825,2022-06-06,Treatment follow-up,pas de greffe,2022-08-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,57.24147988022365,194.95960806563437,1.7606640542187877,15.059881929237731,92.75309931510839,0.9685641046300004,2022-09-22,Symptoms management,allo-greffe,2022-02-27,Protocole 3 LAL thiotepa Bu Flu
Female,25,84.24743868019715,169.19816489197828,1.9898710190988949,29.42831589985977,108.64227178448115,1.2385775722018377,2022-11-07,Treatment follow-up,greffe haplo-identique,2022-03-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,70,66.57132613930692,160.36755337779238,1.7220692251277665,25.885359530157732,132.52829266562543,0.4883645698110212,2022-09-02,Cancer diagnosis,greffe haplo-identique,2022-05-20,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,101.8540086262656,183.105377813069,2.2760844015843396,30.379171564848946,96.51762535023605,0.9380348535114381,2022-10-02,Symptoms management,allo-greffe,2022-11-07,Protocole 3 LAL thiotepa Bu Flu
Female,69,90.11500440542619,181.27788001096408,2.1301967146900322,27.422527523780907,85.81545160389867,1.0355175607790004,2022-11-17,Cancer diagnosis,pas de greffe,2022-01-01,Protocole 3 LAL thiotepa Bu Flu
Male,63,113.2482378619891,182.96394226636338,2.3990938135255915,33.829878227291594,100.17059028072742,1.2090644418207948,2022-11-14,Symptoms management,allo-greffe,2022-07-20,Protocole 3 LAL thiotepa Bu Flu
Female,36,115.13514711485468,198.29563773575666,2.51831057914606,29.280709744018097,93.42811399775016,1.7800458180537655,2022-02-05,Cancer diagnosis,auto-greffe,2022-03-06,Protocole 3 LAL thiotepa Bu Flu
Female,46,46.62025815460241,172.33364698305843,1.4938986198566249,15.697645473664885,101.05660887398408,0.6022895257753349,2022-09-11,Cancer diagnosis,greffe haplo-identique,2022-04-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,50,116.44484772604541,153.36155333828418,2.2272406149953987,49.50935630756932,80.01265030987024,1.8191630835105734,2022-05-27,Symptoms management,pas de greffe,2022-03-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,56,113.17364086795294,184.76940619952015,2.4101075598755504,33.1501243195928,88.0911278960921,1.4988559858342156,2022-03-01,Treatment follow-up,auto-greffe,2022-06-23,Protocole 3 LAL thiotepa Bu Flu
Male,38,63.9067790828437,144.3604384992851,1.600834040558256,30.665534893278334,115.84382603340211,0.7815229071818702,2022-08-02,Treatment follow-up,allo-greffe,2022-10-30,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,34,84.21025316648722,167.01465221596013,1.9765532672375539,30.189493442899764,113.53593114846603,1.0919556901201912,2022-05-26,Symptoms management,auto-greffe,2022-11-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,54.78189921653624,159.7109232620629,1.5589586714928836,21.476714507767884,79.30895687028854,0.8538318618927405,2022-11-16,Symptoms management,greffe haplo-identique,2022-02-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,83.16837049958872,185.9286818279017,2.07253102756315,24.05832635819858,81.68640709268223,1.371663669769784,2022-07-20,Cancer diagnosis,greffe haplo-identique,2022-02-17,Protocole 3 LAL thiotepa Bu Flu
Female,20,82.43228447859295,170.32822288226205,1.9748800612923174,28.413458882042995,105.29229703644495,1.304816635827604,2022-05-25,Symptoms management,pas de greffe,2022-12-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,106.86618970167885,195.02582709627234,2.406107220017721,28.096748767268288,75.0848371604143,2.2732825887478456,2022-06-19,Treatment follow-up,greffe haplo-identique,2022-10-15,Protocole 3 LAL thiotepa Bu Flu
Female,39,71.95026757078767,166.79004256965294,1.8257866030099035,25.86379053055693,77.91197785656897,1.2954392794298233,2022-05-04,Cancer diagnosis,greffe haplo-identique,2022-09-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,83.07523349974113,193.24255859901598,2.111718012905123,22.246721216030238,89.22871038712937,1.1508652175028227,2022-07-01,Treatment follow-up,greffe haplo-identique,2022-08-16,Protocole 3 LAL thiotepa Bu Flu
Male,33,60.14395086505058,168.1730779022412,1.676188909250247,21.265666960595908,90.5726133048647,0.9868390718264911,2022-09-03,Symptoms management,pas de greffe,2022-10-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,42.38936695854128,160.0936047674485,1.3729799869265562,16.53898920456892,100.10278846910774,0.7057640052924679,2022-05-09,Cancer diagnosis,allo-greffe,2022-02-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,72,40.324196616022974,151.86473481829745,1.3042476999163175,17.4844450047092,126.84729840414121,0.3002347227715575,2022-03-26,Treatment follow-up,allo-greffe,2022-03-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,62,71.76266787102732,164.71390678397597,1.81202077084289,26.45075296447848,115.82869103858853,0.6711885414272077,2022-07-17,Cancer diagnosis,allo-greffe,2022-02-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,33,75.02591238369762,169.71614096150282,1.880684591805526,26.047436579337667,106.7756300245253,1.0442161941732586,2022-04-16,Cancer diagnosis,pas de greffe,2022-02-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,78.55646105758966,182.58206064918792,1.9960377791739206,23.564905464146744,86.00068048395283,0.7992599946719818,2022-12-06,Cancer diagnosis,pas de greffe,2022-01-30,Protocole 3 LAL thiotepa Bu Flu
Male,44,92.24235667850569,140.01501255015071,1.8940927708123114,47.052335256560674,114.03390770687508,1.0785371770370296,2022-10-28,Treatment follow-up,pas de greffe,2022-09-13,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,51,85.02913564313617,171.91527588651232,2.015068741071838,28.76993145965476,118.29745140645329,0.8884845623218623,2022-10-22,Symptoms management,auto-greffe,2022-06-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,91.59210465823519,187.037427825856,2.1814337579033323,26.18189012061754,112.1955493243186,0.7823462471796686,2022-06-04,Cancer diagnosis,greffe haplo-identique,2022-06-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,92.10632602102166,166.9986282489995,2.067044998876264,33.026583662637506,86.13936346757187,1.143525964159844,2022-03-21,Symptoms management,greffe haplo-identique,2022-10-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,25,115.84954567592156,165.64288298060927,2.3087787017859456,42.222969501146444,133.59095885747087,1.3851047284221385,2022-02-26,Cancer diagnosis,pas de greffe,2022-07-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,53,44.22780745977892,186.03096995177623,1.5117816862327156,12.77982507369444,86.59003912695833,0.6171833914469418,2022-09-25,Cancer diagnosis,pas de greffe,2022-08-22,Protocole 3 LAL thiotepa Bu Flu
Female,78,65.01717661372234,157.49355113386014,1.6865304646581802,26.21214460911424,86.6105923571838,0.6464222408762457,2022-10-09,Treatment follow-up,pas de greffe,2022-07-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,67,109.0505218279512,149.49114788937118,2.12799381826035,48.797412580352685,78.48330565192477,1.4087723687283733,2022-08-26,Cancer diagnosis,allo-greffe,2022-03-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,55.60749369743653,169.02352627318783,1.6158051546412455,19.46430966492225,104.73014672802762,0.6120786136086598,2022-07-02,Treatment follow-up,pas de greffe,2022-04-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,104.104256112801,186.60273790361262,2.322961425163265,29.89733391914703,93.95265483407674,1.2773356243191112,2022-07-09,Symptoms management,auto-greffe,2022-08-17,Protocole 3 LAL thiotepa Bu Flu
Female,63,79.91312483982306,146.4407223643714,1.8029709839239325,37.26442189781006,117.30316990534872,0.728562130649184,2022-09-20,Cancer diagnosis,allo-greffe,2022-09-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,42,66.1685938309249,158.95842945624352,1.7092928813053323,26.1869415597689,113.00663513379523,0.7969692059518393,2022-01-24,Treatment follow-up,pas de greffe,2022-07-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,62,62.125492729804456,144.61433128869987,1.5797535485622132,29.70620534731772,130.60924184110456,0.5152975101550107,2022-03-20,Cancer diagnosis,auto-greffe,2022-02-17,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,37,49.75940775270519,173.86741212537336,1.5502275330176976,16.460340792674778,116.95301262139805,0.6086512489611801,2022-10-10,Cancer diagnosis,greffe haplo-identique,2022-09-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,99.0367692173034,178.64260510433778,2.216866310188536,31.033186948111787,81.19724221694288,1.4060500531727553,2022-09-28,Cancer diagnosis,allo-greffe,2022-02-10,Protocole 3 LAL thiotepa Bu Flu
Female,74,47.35023230492921,176.79897306645205,1.5249291828702358,15.148256067012959,111.75979233822446,0.3883720495962882,2022-02-27,Symptoms management,pas de greffe,2022-06-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,78.88624511224604,147.3192268479238,1.796714643675436,36.348159303446316,95.81465248497571,0.8576263636170699,2022-06-03,Treatment follow-up,greffe haplo-identique,2022-04-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,66,86.90747860282576,180.51945205332805,2.0875617367263684,26.669147722356435,84.67227095234176,1.0549094080747776,2022-01-25,Treatment follow-up,auto-greffe,2022-03-11,Protocole 3 LAL thiotepa Bu Flu
Female,58,59.50450781758191,143.0752413673427,1.5378214947022246,29.068384280299675,125.95627104403133,0.5380361154749939,2022-08-13,Symptoms management,auto-greffe,2022-09-30,Protocole 8 Aplasie medullaire thymo
Male,79,116.90116230024748,157.62026631830446,2.2623729144592817,47.05380141566996,75.3604138918265,1.3142345880231192,2022-06-30,Treatment follow-up,greffe haplo-identique,2022-06-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,112.81973025284599,163.11732256059327,2.2609518847681906,42.40185812244021,132.69572737340133,1.2635120813612613,2022-12-17,Symptoms management,auto-greffe,2022-06-19,Protocole 6 FlUDARABINE cy (Fanconi)
Male,70,55.62197549374174,159.30070635306407,1.5688477711812965,21.918508914970968,127.9857505515229,0.4225229792057669,2022-09-28,Cancer diagnosis,greffe haplo-identique,2022-12-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,21,40.244274192096185,168.26827373478685,1.3715192859272543,14.213453748702712,117.64422640770559,0.5653897696345908,2022-12-16,Symptoms management,auto-greffe,2022-09-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,116.82340468217862,191.45090721387942,2.492541474647539,31.872417217725108,82.31234867998887,1.2812849513192328,2022-07-04,Treatment follow-up,greffe haplo-identique,2022-05-18,Protocole 3 LAL thiotepa Bu Flu
Female,43,66.67043046268907,168.32919833397048,1.7656113288450213,23.529589418206307,85.30128760314435,1.0529722118889235,2022-06-02,Symptoms management,auto-greffe,2022-08-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,67.4142874646088,150.8879728129855,1.6809393186025718,29.61029273674077,100.75190248598699,1.1151863439003062,2022-02-10,Symptoms management,auto-greffe,2022-05-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,50,88.79416227598679,142.7499447776686,1.8764151519939156,43.57451043295312,109.48646254469953,1.013757319994415,2022-07-18,Symptoms management,pas de greffe,2022-01-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,30,81.37459237980266,169.0527652745768,1.9548088756318884,28.473723793267318,106.4441876472452,1.1679575621882714,2022-04-27,Cancer diagnosis,allo-greffe,2022-05-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,73.25032226962911,143.7819980436739,1.7104318568769485,35.43239516968761,92.79012327355643,1.1731649229136023,2022-10-20,Symptoms management,greffe haplo-identique,2022-12-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,73,109.12144225407067,190.0473468190781,2.4001296597763546,30.212486926726115,94.56632825432708,1.0737813997247363,2022-10-11,Treatment follow-up,greffe haplo-identique,2022-06-15,Protocole 3 LAL thiotepa Bu Flu
Female,48,44.466615337458784,161.9308495181053,1.4142643157004822,16.95800992081054,119.56739635990147,0.47520021896414033,2022-02-13,Cancer diagnosis,greffe haplo-identique,2022-10-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,80.48493461900907,169.49301296989935,1.9466234346841318,28.01631396710449,77.59818252501123,1.2244737390901033,2022-12-08,Treatment follow-up,auto-greffe,2022-09-21,Protocole 3 LAL thiotepa Bu Flu
Male,47,68.98609572585403,142.2680809578381,1.6511376088162644,34.08369104376363,76.57427122397337,1.163668147123866,2022-07-14,Treatment follow-up,pas de greffe,2022-03-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,48.37361723517836,192.73910666552365,1.6093034873723973,13.021735823182633,116.44642083873958,0.4673421389648329,2022-08-27,Treatment follow-up,auto-greffe,2022-08-14,Protocole 3 LAL thiotepa Bu Flu
Female,25,76.77415407996905,140.04905018567078,1.728209362132764,39.14305376985559,116.73591573120004,1.0504512190678377,2022-02-27,Treatment follow-up,pas de greffe,2022-07-10,Protocole 8 Aplasie medullaire thymo
Male,70,85.45277953332847,166.2083141715981,1.9862697049936322,30.932904771325347,84.63457256912724,0.9816212062168975,2022-12-14,Symptoms management,allo-greffe,2022-06-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,46.479316592671694,162.36243467918274,1.4478427443202364,17.6314741043181,75.86274724821192,0.7743549230088203,2022-09-04,Symptoms management,allo-greffe,2022-07-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,105.06120527806826,177.5228411042683,2.276129978884812,33.33756682118008,130.10443391333783,0.7738679768993411,2022-01-31,Cancer diagnosis,allo-greffe,2022-01-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,100.81780861781178,163.13341748314153,2.1374149536677445,37.88361241421883,114.66374256933817,0.8792474967128024,2022-07-31,Cancer diagnosis,greffe haplo-identique,2022-05-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,100.24789981071856,163.9851964769843,2.1369222121537397,37.27914935002107,95.40403227770511,1.1821186651605875,2022-02-21,Symptoms management,auto-greffe,2022-10-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,37,83.21851424905866,155.86826312727396,1.898180801307829,34.253469380971296,92.82658538576317,1.2824850487533774,2022-12-11,Symptoms management,greffe haplo-identique,2022-09-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,35,53.03975628928656,159.23388787066548,1.531677240229706,20.91849915397166,103.15884432222092,0.7498110811220227,2022-05-15,Symptoms management,auto-greffe,2022-05-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,63,40.29515467070911,144.3946299676635,1.2713077200014262,19.32639016248331,89.85866154492675,0.47956900937227953,2022-05-18,Cancer diagnosis,auto-greffe,2022-06-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,25,96.18140504039583,152.6775685156239,2.0196770271220217,41.26108530689395,100.41989953974777,1.5298071218869347,2022-07-28,Cancer diagnosis,pas de greffe,2022-06-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,77,97.56430424394551,166.20167115040044,2.1223251406816543,35.31995806465416,117.01325390040532,0.7295649284833419,2022-03-06,Treatment follow-up,greffe haplo-identique,2022-04-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,69.31030892960082,187.65782948336795,1.9007763132285498,19.68178380391337,131.94164319488442,0.8463333192393729,2022-05-06,Cancer diagnosis,greffe haplo-identique,2022-07-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,116.22415752435873,158.5512348418955,2.2624644683487456,46.23354016403408,78.51428695392869,1.603650862404243,2022-09-26,Treatment follow-up,allo-greffe,2022-05-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,99.01296738197411,189.05326151449293,2.2802731571136086,27.7028039183732,101.65375625317193,1.1228306037752949,2022-05-04,Cancer diagnosis,greffe haplo-identique,2022-09-04,Protocole 3 LAL thiotepa Bu Flu
Male,24,111.77304557224903,153.43276729976824,2.18261105684563,47.47892187273666,118.27614956623788,1.5225283905892621,2022-05-08,Treatment follow-up,greffe haplo-identique,2022-12-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,60,83.16231983284786,172.06329375568743,1.9936832654664673,28.08989599218058,102.6081232149603,0.9005386191351841,2022-12-09,Treatment follow-up,auto-greffe,2022-11-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,53,74.44164037692707,181.82236771220565,1.9390114398345566,22.517559384795554,130.1387713442081,0.6911876800922082,2022-10-13,Treatment follow-up,greffe haplo-identique,2022-12-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,76,117.00424983600507,160.5643299962313,2.2844102680286977,45.38407556666844,84.87030759025451,1.2254436278718879,2022-04-25,Symptoms management,greffe haplo-identique,2022-11-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,91.71210107339851,196.25433785255157,2.235999507380816,23.811574500339617,82.80684235876586,1.5228710017653955,2022-04-29,Treatment follow-up,allo-greffe,2022-07-12,Protocole 3 LAL thiotepa Bu Flu
Male,57,75.29833345422657,164.48072970735814,1.8548079289825226,27.83269856944543,109.32210761078832,0.7940045010728226,2022-09-10,Symptoms management,pas de greffe,2022-07-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,54,69.093767900306,184.06867659608352,1.8795683915349557,20.392905044572213,126.23363029389611,0.653777183006714,2022-10-08,Treatment follow-up,greffe haplo-identique,2022-03-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,53.730678209378446,191.58898439401173,1.6910061164335366,14.637983454452897,130.56044324180894,0.5201392205411209,2022-07-01,Cancer diagnosis,allo-greffe,2022-01-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,92.95078850922283,160.10925837860123,2.0332159675087995,36.259364361522465,80.25269866213203,1.5121288175290561,2022-12-14,Treatment follow-up,auto-greffe,2022-02-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,40.37219799956211,150.51780039102124,1.2992235330557245,17.819957681821055,97.83006027736249,0.5043827777998244,2022-01-06,Symptoms management,allo-greffe,2022-11-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,42,48.72915216224093,159.00195602999742,1.4670482940509117,19.27453551874972,88.6736266351507,0.7479765174818989,2022-10-30,Symptoms management,auto-greffe,2022-04-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,115.39480991714726,142.38520541707126,2.1363594237053594,56.918905952381735,86.17060638374927,1.8041239208316442,2022-04-04,Cancer diagnosis,allo-greffe,2022-05-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,25,93.64114011660759,158.97782485557428,2.0335290051160877,37.05045890262032,82.29745333074096,1.8173795646797062,2022-12-08,Symptoms management,auto-greffe,2022-10-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,41,112.55554068950603,187.77377146879982,2.4229790189729083,31.922509146896193,117.70749036561253,1.314817501990375,2022-06-19,Cancer diagnosis,allo-greffe,2022-05-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,71.49407231193845,195.80832514514788,1.971965640702948,18.646946719086515,112.23508823999899,0.6458501229445267,2022-03-23,Treatment follow-up,pas de greffe,2022-05-08,Protocole 3 LAL thiotepa Bu Flu
Male,78,114.37789313779855,176.3093703059294,2.3667778328377724,36.79521151768222,88.52382990078391,1.1126052132722453,2022-01-11,Symptoms management,auto-greffe,2022-02-20,Protocole 3 LAL thiotepa Bu Flu
Male,40,106.34109502611555,190.0342563206295,2.369273852048887,29.44674779935089,75.7788820447699,1.9490385887032629,2022-12-27,Treatment follow-up,allo-greffe,2022-07-28,Protocole 3 LAL thiotepa Bu Flu
Male,31,69.68560734224116,183.3158201686113,1.883736996850405,20.736869615417785,122.47032990723507,0.8614026495298969,2022-07-24,Treatment follow-up,auto-greffe,2022-04-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,94.32289543458413,176.1023905658238,2.1480279955707497,30.414915964646756,76.84341396496454,1.5343360375293362,2022-09-28,Cancer diagnosis,allo-greffe,2022-03-01,Protocole 3 LAL thiotepa Bu Flu
Male,23,69.37550725840298,166.64185758110705,1.792024258901698,24.982619610837666,85.48943869421588,1.3187032341871299,2022-05-20,Treatment follow-up,allo-greffe,2022-07-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,107.23705541672713,173.66209437647694,2.2744359275332884,35.55779417120206,84.34082362023327,1.2008353354829242,2022-06-04,Cancer diagnosis,pas de greffe,2022-08-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,69.15836884748153,147.8028961688085,1.6850492252922196,31.657663129894555,120.94833128438634,0.9132931591764624,2022-01-01,Treatment follow-up,allo-greffe,2022-03-16,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,42,111.90827591797328,140.65464025494106,2.0910137288189254,56.565818589134764,129.73256516978165,1.174104571029641,2022-01-20,Treatment follow-up,greffe haplo-identique,2022-08-16,Protocole 9 LAL thiotepa-thymo melphalan
Male,51,47.488471047953205,194.58313051411176,1.6021214546690807,12.542318203087964,120.4166294448143,0.487482725456581,2022-05-19,Cancer diagnosis,allo-greffe,2022-10-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,40.393463272947855,152.50369961490426,1.3081106593292935,17.3680208425772,121.54939644382725,0.5077132208090578,2022-02-28,Cancer diagnosis,pas de greffe,2022-04-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,39,117.18659744628187,142.13847625144732,2.1510155481453053,58.00355789869938,115.3122842640056,1.425578860051662,2022-03-21,Symptoms management,pas de greffe,2022-11-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,76,72.89650479977576,157.13858551338944,1.7837891670625363,29.52167715103488,76.64128841016809,0.8454567309539065,2022-11-20,Symptoms management,pas de greffe,2022-01-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,55.18104007118782,165.07701952792908,1.5906953082608342,20.249609092053095,125.10974374405728,0.47781618192275827,2022-01-12,Symptoms management,greffe haplo-identique,2022-04-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,52,108.77252753311669,147.12842538251732,2.1084176992885744,50.24884066627289,114.6053901440165,1.1600169952843593,2022-08-03,Symptoms management,auto-greffe,2022-09-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,66,42.65220588734341,163.0007958712093,1.3896785704794847,16.053215920507128,97.64492821574574,0.44894281951190096,2022-08-20,Cancer diagnosis,pas de greffe,2022-05-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,87.17695847109646,142.52627697726115,1.8577919487246954,42.91526821907603,100.92414885560771,0.8157987463375703,2022-08-16,Symptoms management,pas de greffe,2022-02-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,29,65.08177238545724,169.16522428767118,1.748775176343673,22.74244713570238,76.02084619356691,1.3198274436300228,2022-08-13,Symptoms management,pas de greffe,2022-12-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,60.96031013358293,151.36268961566623,1.6009646832825049,26.607832337501048,74.14134418367718,1.2219065519214287,2022-01-19,Cancer diagnosis,auto-greffe,2022-10-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,61.54079580400203,198.24131837863382,1.8408881080017132,15.65938686293862,82.06767842917661,1.2081377444106955,2022-12-06,Cancer diagnosis,pas de greffe,2022-06-14,Protocole 2 LAM Endoxan TBI
Female,26,110.9512196000753,169.7225181342351,2.287096678505383,38.51706150882189,95.6412991581168,1.83678772573299,2022-10-26,Treatment follow-up,auto-greffe,2022-09-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,53.50361190959092,156.14536447816357,1.5233680687616435,21.944460574149748,86.16154773241078,0.8710808915679237,2022-10-03,Treatment follow-up,pas de greffe,2022-01-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,74,40.71387125833699,164.53899618324564,1.3641256364813836,15.03850664792508,120.81150246712765,0.3089196632053349,2022-05-11,Cancer diagnosis,pas de greffe,2022-01-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,76.10667990225335,147.39181897122228,1.7652118213037404,35.032894360055465,121.59926563964564,1.0344423432264531,2022-07-21,Treatment follow-up,greffe haplo-identique,2022-09-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,66,74.61328378420586,179.9143821149585,1.9310333193514302,23.050714447582717,105.2956628842017,0.7282909181622101,2022-01-29,Treatment follow-up,auto-greffe,2022-10-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,85.93147942655541,191.1636722048966,2.136129493394527,23.51481463504981,76.24518009549612,1.7688289649258244,2022-11-28,Treatment follow-up,auto-greffe,2022-08-11,Protocole 3 LAL thiotepa Bu Flu
Female,26,88.98758102765058,168.5393898465556,2.041099418499824,31.327559731657768,119.99345205522116,1.1742057660691279,2022-09-28,Symptoms management,auto-greffe,2022-10-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,62,52.98506160502225,146.96942562367082,1.470750382054168,24.53010740820208,103.7855638685562,0.5530680883339242,2022-07-16,Symptoms management,allo-greffe,2022-04-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,62,96.93430407187776,149.83527346675675,2.0086049580436804,43.1766921409124,108.91772942288412,0.9641420483235918,2022-03-29,Treatment follow-up,greffe haplo-identique,2022-06-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,61,119.95513059146846,169.49170107404814,2.3764702546533387,41.756294411669245,113.84479470139537,1.1561128929939095,2022-01-06,Treatment follow-up,auto-greffe,2022-05-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,61,50.9345542805018,165.8058195327673,1.5316336154408996,18.527335713401598,103.25379946673064,0.5412539308401697,2022-11-09,Cancer diagnosis,allo-greffe,2022-10-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,99.458881394227,159.1653813152624,2.0969826724169924,39.25964266233132,127.73308159284304,1.1571548019939466,2022-05-11,Cancer diagnosis,auto-greffe,2022-11-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,73.62766318324614,159.94246747606542,1.808635928908936,28.78150061426925,126.03722691361801,0.5192657226844274,2022-09-06,Cancer diagnosis,auto-greffe,2022-10-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,62.13316758501155,184.9101500541401,1.786450028959009,18.171969227598094,86.86168011945256,1.1623813537430352,2022-08-30,Cancer diagnosis,greffe haplo-identique,2022-11-02,Protocole 3 LAL thiotepa Bu Flu
Male,22,90.29737479755862,144.76899327625617,1.9055664107593477,43.08479348967315,119.17086210599317,1.2418082880019046,2022-09-26,Treatment follow-up,allo-greffe,2022-10-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,72,40.8113327856349,196.1667638959854,1.491254792563793,10.605470064283631,133.53527467036875,0.2886431065867209,2022-10-21,Cancer diagnosis,allo-greffe,2022-05-04,Protocole 3 LAL thiotepa Bu Flu
Male,25,89.84718040428004,140.07025362015747,1.869708633442027,45.79442628759309,131.2957126380657,1.0929977092345615,2022-11-08,Cancer diagnosis,pas de greffe,2022-10-01,Protocole 9 LAL thiotepa-thymo melphalan
Female,28,106.66518496555841,155.20390898630097,2.1444277700460925,44.28099594891724,120.33960380899289,1.3787948090712923,2022-04-12,Treatment follow-up,greffe haplo-identique,2022-07-04,Protocole 6 FlUDARABINE cy (Fanconi)
Female,65,54.00601034751425,142.00916422034572,1.4595802661806045,26.77992475504847,97.24923921230814,0.5784750732686527,2022-04-02,Cancer diagnosis,allo-greffe,2022-04-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,53,49.13721367848175,144.69172149952922,1.4053220307924028,23.47054415469093,131.6668709159168,0.4509420842297434,2022-02-24,Cancer diagnosis,auto-greffe,2022-08-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,34,113.53229922599819,141.00178369295185,2.1087289943383536,57.104485108477206,74.02841470123363,2.257846186968421,2022-09-04,Cancer diagnosis,auto-greffe,2022-06-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,50,88.2877335102446,194.84748426644208,2.185980759169746,23.254701123363557,127.82339748121572,0.8633761037686677,2022-02-03,Treatment follow-up,pas de greffe,2022-12-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,105.85351183139254,179.61686302543146,2.2981318340109382,32.81036459656042,80.18658577125817,1.1734133535152886,2022-01-09,Treatment follow-up,allo-greffe,2022-08-23,Protocole 3 LAL thiotepa Bu Flu
Male,32,110.35238598070057,194.69071014556926,2.4429367795999912,29.113288844770413,76.43906264202309,2.165497237273158,2022-03-07,Symptoms management,allo-greffe,2022-08-22,Protocole 3 LAL thiotepa Bu Flu
Male,78,117.65179546566144,169.2975771397053,2.3521954235749303,41.04847938150229,117.51866149423145,0.862086642491464,2022-09-29,Symptoms management,pas de greffe,2022-10-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,50,92.96820857333762,177.66487473523082,2.141986690132735,29.453120517532867,118.18161645715887,0.9833192691081403,2022-03-21,Symptoms management,allo-greffe,2022-09-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,100.484077873959,145.09821900099894,2.0124653715080925,47.727983723831436,74.42681430833098,2.231424957174086,2022-01-23,Cancer diagnosis,greffe haplo-identique,2022-09-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,72.61516864897206,166.39181643580812,1.8320123886874151,26.22789429958157,111.7860893756729,0.6225241173619207,2022-05-30,Symptoms management,greffe haplo-identique,2022-03-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,117.84322805186152,150.36518486529314,2.218578046303348,52.120676667536266,92.50604772793926,1.5392928793309508,2022-05-21,Cancer diagnosis,pas de greffe,2022-02-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,34,49.89388546260309,144.47825953519418,1.4150561171719993,23.90244476256186,111.20146747530691,0.6605568127719693,2022-03-31,Symptoms management,pas de greffe,2022-12-30,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,50,112.6445473205994,169.68467818745668,2.304226416444576,39.122348355893706,83.77860228299447,1.6806879121129745,2022-06-30,Treatment follow-up,greffe haplo-identique,2022-04-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,75.67400274552845,162.17883769583213,1.846371953698885,28.771224064018156,79.25739007845577,1.418921014066449,2022-02-13,Treatment follow-up,auto-greffe,2022-11-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,62.78867590710369,187.97525128802226,1.8106718467402587,17.76969512121209,76.37034634657486,1.0505383124242738,2022-01-03,Symptoms management,greffe haplo-identique,2022-12-10,Protocole 3 LAL thiotepa Bu Flu
Male,62,62.08825826013994,173.351700692978,1.7290897703753538,20.661091615441865,120.99304216620578,0.5559185766188224,2022-06-03,Symptoms management,allo-greffe,2022-05-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,85.90187532485973,192.5053073770191,2.1432430588605733,23.180202733861783,97.42238680930942,0.9429791893042797,2022-08-31,Symptoms management,pas de greffe,2022-08-27,Protocole 3 LAL thiotepa Bu Flu
Male,54,89.01365130895752,170.31578523361372,2.052128293530902,30.686461603262963,130.58438299036538,0.8142004338569625,2022-12-28,Symptoms management,allo-greffe,2022-02-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,75.69362401198511,169.32748473603507,1.886870643015439,26.400027798125066,76.34434064918706,1.1429521420775015,2022-11-20,Cancer diagnosis,greffe haplo-identique,2022-05-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,80.10269781939824,186.36700881675594,2.0363706952671223,23.062642845040767,113.1309252112239,1.1702543636831768,2022-05-14,Cancer diagnosis,auto-greffe,2022-03-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,101.22752236208683,186.59893107373972,2.2906177883323484,29.07236108754109,111.10079727518426,1.2274976505246156,2022-07-08,Cancer diagnosis,allo-greffe,2022-11-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,54.808193924257424,150.2278087132052,1.5123303277438358,24.285375682394573,115.84945201393023,0.7227892688482194,2022-10-21,Treatment follow-up,allo-greffe,2022-08-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,50,51.44574932852636,159.41215741493286,1.5093300473212372,20.244479654143735,126.9386359886968,0.5066005803495806,2022-02-10,Treatment follow-up,greffe haplo-identique,2022-10-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,83.77816887639813,152.50467602053953,1.8838909574254046,36.02172810674586,88.9340666669815,1.0597788172542908,2022-07-25,Symptoms management,auto-greffe,2022-11-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,52,73.79446329888671,158.48513210976517,1.802415452239121,29.379657330864745,88.6990133113762,1.0168459552558933,2022-01-10,Cancer diagnosis,pas de greffe,2022-10-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,92.47253930519938,141.74400697856228,1.9081279552221941,46.02601472976385,93.95928687161302,0.8474854771638723,2022-02-10,Symptoms management,allo-greffe,2022-02-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,50,116.87629295734513,164.49943217317082,2.310969242666882,43.1914338695467,97.60074019146289,1.4968673998792104,2022-12-17,Symptoms management,allo-greffe,2022-02-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,85.16565385719646,197.07610984370532,2.159225411169982,21.927873799721695,109.83344604848045,0.7754072818547856,2022-09-02,Symptoms management,allo-greffe,2022-04-02,Protocole 3 LAL thiotepa Bu Flu
Female,66,53.39139525216804,179.2996428419906,1.6307000967162406,16.607812049524465,112.02469307792668,0.4898428021271742,2022-11-10,Symptoms management,greffe haplo-identique,2022-06-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,40.45636914852039,197.92778072510978,1.49140494554654,10.326981359998534,105.16608092719521,0.37400443916747605,2022-06-15,Treatment follow-up,auto-greffe,2022-11-20,Protocole 3 LAL thiotepa Bu Flu
Female,71,108.51098672446477,196.175185001247,2.431686822816836,28.19587463922491,91.75718434108083,1.1333139345731638,2022-12-08,Cancer diagnosis,auto-greffe,2022-07-06,Protocole 3 LAL thiotepa Bu Flu
Male,66,55.57926011625512,150.02060008163443,1.5218805941931264,24.69510996882012,103.55903808992221,0.5515996431254673,2022-12-25,Symptoms management,allo-greffe,2022-07-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,24,109.3780360998571,140.93459467923324,2.069295987672022,55.06744157062879,114.34491471037984,1.541128171010786,2022-03-01,Cancer diagnosis,greffe haplo-identique,2022-01-16,Protocole 8 Aplasie medullaire thymo
Male,22,114.1766222734444,174.5965171031047,2.3531799161241462,37.454675510643426,133.36022530877918,1.4031379834695976,2022-01-30,Treatment follow-up,allo-greffe,2022-09-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,32,91.99296657763986,147.4249620246487,1.9409376030559256,42.32652115606596,134.86250934532282,1.023186136282918,2022-04-30,Cancer diagnosis,greffe haplo-identique,2022-03-02,Protocole 8 Aplasie medullaire thymo
Female,42,50.14537994282688,175.0070181238155,1.5613200804020435,16.372688381317843,93.7503458047266,0.7280339419039111,2022-02-22,Treatment follow-up,auto-greffe,2022-11-20,Protocole 3 LAL thiotepa Bu Flu
Male,36,71.7926233378577,173.97091700926757,1.86263168934799,23.720646292383414,127.6121847117465,0.8126218994424572,2022-04-01,Treatment follow-up,allo-greffe,2022-11-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,112.42339913525167,190.81970639511002,2.4411176865736106,30.875234553122603,103.96465252642466,1.3817400205397121,2022-06-22,Cancer diagnosis,greffe haplo-identique,2022-05-07,Protocole 3 LAL thiotepa Bu Flu
Female,53,68.09798657877886,168.1299009301414,1.7833573002308647,24.090419206286445,99.24916234569679,0.8290756835751989,2022-01-10,Treatment follow-up,greffe haplo-identique,2022-07-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,91.49310754521221,150.2636373952446,1.9542039538971336,40.521040027410166,112.54105984175658,0.914597269059779,2022-01-23,Treatment follow-up,allo-greffe,2022-11-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,58,41.5024005263233,171.4559828620245,1.4059234681018347,14.117829379935886,92.43547495625113,0.5113472164665875,2022-05-20,Symptoms management,greffe haplo-identique,2022-06-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,77.38132018903408,158.42634127560535,1.8453574962761132,30.830555479790284,79.9532367943867,1.5996116173813435,2022-05-25,Cancer diagnosis,allo-greffe,2022-07-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,79.4628226488563,162.35580841966453,1.8930612194760907,30.14590504397894,119.44117470229801,0.8593307920036555,2022-03-25,Treatment follow-up,auto-greffe,2022-11-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,73,73.44785935439342,168.1290049324046,1.8520795749995138,25.983273068083648,86.00154409945239,0.7947219353045205,2022-09-17,Symptoms management,allo-greffe,2022-04-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,73.74323828507292,192.36287668623345,1.9850455811079988,19.928732542152872,86.92993721201866,1.2371137717121947,2022-08-12,Cancer diagnosis,auto-greffe,2022-04-07,Protocole 3 LAL thiotepa Bu Flu
Female,77,84.6177083965398,199.68680408973165,2.1664768993243566,21.22083785573383,113.04564769202459,0.6549610388246369,2022-02-14,Treatment follow-up,allo-greffe,2022-08-10,Protocole 3 LAL thiotepa Bu Flu
Male,54,79.40609624953785,199.7973918542909,2.0992810229528884,19.891806067810336,107.80586106119597,0.8797867721351618,2022-07-03,Treatment follow-up,greffe haplo-identique,2022-04-21,Protocole 3 LAL thiotepa Bu Flu
Female,61,104.32798781868983,191.96749512080083,2.3586473579237994,28.310362810482378,78.58357963710691,1.4566781910803024,2022-05-03,Symptoms management,auto-greffe,2022-02-15,Protocole 3 LAL thiotepa Bu Flu
Male,56,119.17813981776027,185.65077225742678,2.4791079092964723,34.57825576019877,133.13650750148042,1.04435038690777,2022-03-17,Symptoms management,auto-greffe,2022-09-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,105.6199175348463,151.54074161430682,2.108561952853212,45.9924989917777,125.34244629102858,1.2054588391866152,2022-12-12,Treatment follow-up,pas de greffe,2022-04-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,42,106.61690708218312,196.9892111770568,2.4153663412189794,27.475221190720486,106.00431817282131,1.368976843238329,2022-03-16,Symptoms management,greffe haplo-identique,2022-10-02,Protocole 3 LAL thiotepa Bu Flu
Female,77,65.3902816024405,168.93779592000058,1.7517364439404168,22.911818489342743,125.85687262827386,0.4546155899736039,2022-01-01,Symptoms management,allo-greffe,2022-06-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,56,97.3879451343644,167.32376983909552,2.127551939355865,34.78483285614597,117.54283544151025,0.9666201167995688,2022-09-22,Treatment follow-up,auto-greffe,2022-05-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,51,87.6330373823122,154.71436287091774,1.940653494247617,36.61057908163372,134.5793668397655,0.8049092052696732,2022-09-21,Cancer diagnosis,allo-greffe,2022-11-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,58,74.56639959096054,198.36230989901708,2.026982107011147,18.950682695359834,116.99081870113953,0.725893236079788,2022-01-15,Symptoms management,auto-greffe,2022-01-09,Protocole 3 LAL thiotepa Bu Flu
Male,57,50.19567393813358,171.2789189597679,1.5453748887658039,17.11033305072893,120.0724354540398,0.4819129156300686,2022-11-11,Treatment follow-up,allo-greffe,2022-09-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,118.87724413944757,158.6958886568292,2.2891853172268073,47.20275828771098,103.4292601743865,1.3888075427234987,2022-02-14,Symptoms management,auto-greffe,2022-08-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,47,108.20532486213526,151.5764011110323,2.1344641354351794,47.09615482373878,74.81053828039346,1.8682556561271007,2022-03-17,Cancer diagnosis,greffe haplo-identique,2022-05-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,58,61.90767443584399,157.56650058806645,1.6460875854584238,24.93542130426771,94.89232937316623,0.7430101359896767,2022-08-28,Symptoms management,pas de greffe,2022-04-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,103.25303802679713,197.02655824954007,2.3771826643709475,26.598264283828573,87.15789735060059,1.3327497715196583,2022-04-20,Treatment follow-up,greffe haplo-identique,2022-09-02,Protocole 3 LAL thiotepa Bu Flu
Male,48,74.78735276477346,170.1532791301798,1.880108840702205,25.83137443415749,91.50628272230364,1.044317554802856,2022-04-08,Treatment follow-up,auto-greffe,2022-02-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,24,106.78376530773618,182.86004380152337,2.328953269977752,31.935049344806707,97.3992082733614,1.7663440373224049,2022-04-29,Cancer diagnosis,auto-greffe,2022-05-01,Protocole 3 LAL thiotepa Bu Flu
Male,61,84.1450013667495,168.20572314994587,1.9828200179113082,29.740398599223216,95.50796940294013,0.9666812724182432,2022-11-08,Symptoms management,greffe haplo-identique,2022-05-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,104.62165862505044,173.29380414307886,2.2441457926305817,34.83818571438957,119.36778391265378,1.2416584402198696,2022-01-15,Cancer diagnosis,pas de greffe,2022-04-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,62.16828220061748,150.88355021947942,1.614188059527455,27.307697217388924,115.77945444559163,0.6861083415788318,2022-03-19,Symptoms management,pas de greffe,2022-01-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,22,44.13912248634334,155.92886752970935,1.3826869356287823,18.153929535252455,120.94197936049352,0.598130754851891,2022-05-03,Symptoms management,greffe haplo-identique,2022-08-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,91.92636891954592,152.46586380867112,1.9731273290637115,39.545299457832094,76.0363156184355,1.0914400885600855,2022-05-27,Cancer diagnosis,greffe haplo-identique,2022-08-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,80.12594584789956,181.84320180400158,2.0117956697490778,24.231429189969404,131.31655655530386,0.6610218107975907,2022-01-28,Treatment follow-up,greffe haplo-identique,2022-11-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,97.69880519240675,153.3063147928164,2.0397333556476034,41.56896049292789,92.11621763618407,1.5467137915024434,2022-06-13,Cancer diagnosis,pas de greffe,2022-11-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,20,100.0182133562445,191.01240232636553,2.3036637009559384,27.41296168602315,119.96582087940527,1.3895376286215588,2022-04-02,Cancer diagnosis,auto-greffe,2022-10-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,87.05072172102629,150.67708985956313,1.9087917512787234,38.34227949223196,93.53113169345517,0.8790075456774953,2022-06-26,Cancer diagnosis,pas de greffe,2022-02-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,101.79529299264132,155.92867787064995,2.0997887095952987,41.86737224016815,133.82169831338405,0.8451983686387173,2022-12-09,Symptoms management,greffe haplo-identique,2022-10-16,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,37,109.52007713710096,171.74570309116035,2.2858017466835423,37.129746191032375,123.08800571249789,1.2728661406644646,2022-12-27,Symptoms management,allo-greffe,2022-09-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,118.06955839591043,179.58096930507855,2.4268776088583093,36.61148259464775,124.04660225880622,0.846058792929913,2022-08-16,Cancer diagnosis,auto-greffe,2022-08-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,41.48553247557095,154.64840573980194,1.3349647788335326,17.34625690697211,107.07714286486456,0.49505702223921527,2022-02-19,Symptoms management,auto-greffe,2022-05-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,78,44.57388110524412,169.23802410646837,1.4475645797346197,15.56268610397263,93.87006022837794,0.408895703184685,2022-10-09,Treatment follow-up,pas de greffe,2022-10-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,86.6901662330595,194.25604311172177,2.1628227870290466,22.973161170728606,91.26973422697192,1.3455837235677481,2022-08-27,Cancer diagnosis,auto-greffe,2022-08-15,Protocole 3 LAL thiotepa Bu Flu
Female,37,118.72056985626426,182.86441992849913,2.455705835416018,35.5032039416017,100.43255761966518,1.6910489465952372,2022-12-23,Symptoms management,greffe haplo-identique,2022-10-29,Protocole 3 LAL thiotepa Bu Flu
Female,36,104.80331156468891,198.76378784719444,2.4054973605338557,26.52775369985943,98.28830287717928,1.540188981980513,2022-04-23,Treatment follow-up,pas de greffe,2022-05-15,Protocole 3 LAL thiotepa Bu Flu
Female,69,45.86160242242456,184.0480060066392,1.5312246803454501,13.539012582026388,116.83527838703169,0.3870803095303181,2022-10-26,Symptoms management,auto-greffe,2022-10-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,40.97934334052087,147.41203594397976,1.295381586152379,18.858150881789896,83.04451217880606,0.7264862943392203,2022-04-15,Symptoms management,auto-greffe,2022-08-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,112.17387657624285,166.43798419210816,2.277303101402341,40.49364156621212,86.1026452363475,1.302792455078832,2022-08-17,Treatment follow-up,greffe haplo-identique,2022-01-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,106.27239928529787,181.52364760945832,2.3148646203801624,32.25180801691661,92.45704919380692,1.8837790725848145,2022-04-11,Treatment follow-up,auto-greffe,2022-10-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,115.4969414654779,169.78052306184082,2.3338767899291306,40.06773097500565,128.44596552483924,0.8492321597777356,2022-03-29,Symptoms management,allo-greffe,2022-12-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,20,44.03537766822933,199.6221595650953,1.5626221896575454,11.050558454801518,119.49094985948847,0.6142079898102648,2022-01-06,Symptoms management,pas de greffe,2022-01-22,Protocole 3 LAL thiotepa Bu Flu
Male,30,67.81458041866702,161.04210728425673,1.741726708312746,26.14834398027224,74.60020042871037,1.3888114023496672,2022-02-05,Cancer diagnosis,pas de greffe,2022-07-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,43.812595328685326,156.8724008254581,1.3817246686262463,17.80352070206689,102.86684778353683,0.6980283465929182,2022-05-31,Symptoms management,auto-greffe,2022-10-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,49,88.61727537532653,182.76333157698434,2.1210576818384825,26.530183921036823,134.02281284206794,0.8356964559642948,2022-06-01,Symptoms management,allo-greffe,2022-04-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,58,84.5525894633242,154.90692311691254,1.9074256557036233,35.235890943329586,114.34861342958784,0.8421265617344772,2022-01-03,Treatment follow-up,greffe haplo-identique,2022-07-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,20,40.17061278927679,140.75221494741794,1.253229464433321,20.276732934474346,130.38281159127308,0.5134957629640696,2022-04-02,Cancer diagnosis,auto-greffe,2022-07-20,Protocole 8 Aplasie medullaire thymo
Female,29,99.95337594867588,181.58605289969836,2.245374196265618,30.31324921361498,117.2360425280619,1.3143977278488468,2022-11-27,Cancer diagnosis,pas de greffe,2022-09-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,41.51124627000896,180.81500939815533,1.4439390938641123,12.696874169298685,80.79275534628097,0.5780240054148589,2022-02-14,Treatment follow-up,pas de greffe,2022-12-23,Protocole 3 LAL thiotepa Bu Flu
Female,46,76.07641427572688,168.82068211153063,1.8888026888472378,26.693082784615758,96.5687484075114,1.0285106407850642,2022-02-21,Symptoms management,greffe haplo-identique,2022-01-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,73,41.04172647741947,193.88356561316442,1.4867298443566135,10.91801346726591,118.73179884677845,0.32166283130637907,2022-03-17,Symptoms management,greffe haplo-identique,2022-10-18,Protocole 3 LAL thiotepa Bu Flu
Male,69,96.88142733658935,188.23425796784107,2.2507038149560765,27.342813226008484,126.10552349084747,0.7575865775922839,2022-05-14,Cancer diagnosis,auto-greffe,2022-03-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,84.45707128976613,162.88707110012902,1.9548348165570297,31.8319166423999,80.71668221935555,1.7003020574222723,2022-11-21,Cancer diagnosis,greffe haplo-identique,2022-04-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,32,105.60238117648508,149.37862990263332,2.0932921316671775,47.32566960287916,78.28638376169648,2.0233859855745493,2022-10-21,Cancer diagnosis,pas de greffe,2022-04-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,78,41.45145205834428,186.92940350463266,1.4670922874541834,11.862726245566963,84.06070227110403,0.4246253597074665,2022-11-15,Symptoms management,greffe haplo-identique,2022-06-03,Protocole 3 LAL thiotepa Bu Flu
Male,63,118.52605192370174,167.57607887458727,2.3488845476724376,42.20751370523937,106.76420854350879,1.187261437901076,2022-09-15,Symptoms management,auto-greffe,2022-04-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,103.35947916378134,143.5995653792124,2.0304881929217555,50.12380840838657,75.4913971979655,1.5212841462766022,2022-04-22,Treatment follow-up,greffe haplo-identique,2022-12-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,20,81.80801791022674,169.93820356236708,1.965134120434269,28.327863726145285,86.82768006687795,1.5703137111578382,2022-05-15,Symptoms management,allo-greffe,2022-01-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,112.93178719649237,142.44924256525096,2.113912088711383,55.65393960859651,127.55199369521111,0.9468630706554406,2022-07-12,Cancer diagnosis,pas de greffe,2022-03-31,Protocole 8 Aplasie medullaire thymo
Male,77,43.410804803221254,176.23361065541923,1.4577801686058018,13.977205782583582,126.30015334782561,0.30074749076678403,2022-09-11,Cancer diagnosis,greffe haplo-identique,2022-08-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,70,90.05096692780961,161.09149777574322,2.0073784132651697,34.70109198511394,132.4098017237014,0.6612014370545161,2022-12-07,Symptoms management,auto-greffe,2022-12-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,65,66.33239466531268,159.01667857229003,1.7117207944560995,26.232538569890178,101.11082234889247,0.6833714021691061,2022-08-23,Cancer diagnosis,greffe haplo-identique,2022-04-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,75.67292227171693,178.47154589989375,1.9368834804479522,23.757598282219796,122.6363960243037,0.8227347913553092,2022-11-17,Treatment follow-up,greffe haplo-identique,2022-03-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,87.60587571937648,191.0132830816611,2.1559920337413434,24.010770511049007,75.84502280019228,1.6042559273607924,2022-03-14,Cancer diagnosis,pas de greffe,2022-01-11,Protocole 3 LAL thiotepa Bu Flu
Female,29,67.13789448787907,197.89108325756283,1.9210811964329955,17.144122670386356,81.96255470834596,1.2628236683257925,2022-11-29,Treatment follow-up,pas de greffe,2022-06-30,Protocole 3 LAL thiotepa Bu Flu
Male,21,110.75410828570459,181.7064079676814,2.3643610356158833,33.544348269827616,97.47456008182378,1.877945679555215,2022-12-06,Cancer diagnosis,auto-greffe,2022-12-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,68.13101721030515,186.29977265094317,1.8777049390114922,19.629996550162815,122.17313019186622,0.6738386664877279,2022-07-18,Cancer diagnosis,pas de greffe,2022-12-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,52.545711137479145,141.22270031165078,1.4357196430740065,26.34682284678739,93.73089985268183,0.8954056521719191,2022-05-24,Treatment follow-up,auto-greffe,2022-02-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,45,82.17956432056008,171.2803467549955,1.9773540312048874,28.012299913621224,124.76859588108411,0.8690597888347873,2022-12-26,Symptoms management,allo-greffe,2022-12-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,37,110.53529606818488,170.66519338012282,2.2891366445553407,37.949937455724246,109.53753194906315,1.4435863129438753,2022-12-27,Cancer diagnosis,pas de greffe,2022-12-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,42,86.75457785096619,187.77808819039566,2.1272444859371005,24.603821900951,113.63240986461386,1.039163210508272,2022-04-21,Treatment follow-up,pas de greffe,2022-12-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,42.74149595133955,177.8800415684412,1.4532395876226978,13.508131315572113,131.90000340643184,0.33304593323174664,2022-01-21,Symptoms management,pas de greffe,2022-07-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,89.7976426625775,170.72686450228002,2.06363150588404,30.807836955502474,97.97074642832406,0.7765436228718071,2022-06-03,Treatment follow-up,pas de greffe,2022-11-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,28,111.20447912836627,194.90432161337174,2.453695261170304,29.27381625745383,118.18523423860331,1.4636747680472022,2022-06-22,Cancer diagnosis,allo-greffe,2022-08-31,Protocole 3 LAL thiotepa Bu Flu
Female,46,90.53315380671648,166.4301779579396,2.0458256211087047,32.684624098797855,106.40415487931753,1.1108218663865244,2022-07-07,Cancer diagnosis,allo-greffe,2022-05-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,49.6972121921835,141.76816329042242,1.3989562074335045,24.72718065103622,116.73740750604182,0.561711210932618,2022-11-03,Treatment follow-up,auto-greffe,2022-11-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,68,108.46571983417732,151.78959487522914,2.1385332247100712,47.07696961008826,112.90181946619572,0.960708342407656,2022-12-19,Symptoms management,pas de greffe,2022-01-01,Protocole 6 FlUDARABINE cy (Fanconi)
Female,20,101.9743709275291,159.31599824003234,2.1243396816696447,40.176514471473396,117.98709007023038,1.4404735702698503,2022-05-19,Symptoms management,auto-greffe,2022-03-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,40,84.87606917401808,153.89250755071225,1.9048032208251675,35.838539734484776,124.50366693149223,0.9468269675400279,2022-12-28,Symptoms management,pas de greffe,2022-04-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,25,48.56741733851137,183.99398568775104,1.5755169072996233,14.346228878184306,87.15345928925969,0.8900731982599672,2022-07-07,Cancer diagnosis,pas de greffe,2022-08-22,Protocole 3 LAL thiotepa Bu Flu
Female,78,119.76746313463997,195.41301470976768,2.5497342473329425,31.364031472847472,94.1110435684454,1.0958660040765766,2022-06-06,Treatment follow-up,auto-greffe,2022-03-30,Protocole 3 LAL thiotepa Bu Flu
Female,37,47.8670696856412,147.65976107191312,1.4011939425792082,21.95394233067392,77.41804801076556,0.8845030871540027,2022-03-20,Treatment follow-up,auto-greffe,2022-02-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,69,78.78745476306817,187.6546870291328,2.0265484590928318,22.373722042255036,105.52424750450967,0.7362590721597447,2022-04-23,Treatment follow-up,allo-greffe,2022-05-22,Protocole 3 LAL thiotepa Bu Flu
Female,79,111.4272507036406,144.38205735646858,2.1139809537514918,53.45212350353455,100.05178080434021,0.9435478529049417,2022-10-13,Cancer diagnosis,pas de greffe,2022-02-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,54,118.42244615630808,193.7596237655722,2.5246280591100603,31.543324423386565,107.53543040645715,1.3153714303674744,2022-12-04,Symptoms management,auto-greffe,2022-06-12,Protocole 3 LAL thiotepa Bu Flu
Female,39,106.80790070335031,157.1645858510107,2.159373589702574,43.24082727901452,102.10750318699952,1.4673529850530278,2022-01-15,Cancer diagnosis,allo-greffe,2022-01-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,46,93.30541504952714,187.97733815163366,2.2072672619316887,26.405588929620762,86.81371503581299,1.4031815471907287,2022-11-22,Treatment follow-up,allo-greffe,2022-04-15,Protocole 3 LAL thiotepa Bu Flu
Male,48,54.15803757634677,154.28504044475213,1.5234988073761027,22.751774878087428,104.15853517356554,0.6643904581395512,2022-04-02,Treatment follow-up,auto-greffe,2022-01-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,43,71.49704876929829,197.14981108741483,1.978750283089391,18.394813330370035,92.7986263077052,1.0379724006464828,2022-12-30,Cancer diagnosis,greffe haplo-identique,2022-02-08,Protocole 3 LAL thiotepa Bu Flu
Male,43,98.39267750085637,154.35456170111217,2.0539500298370594,41.297507541735214,90.10917006206572,1.4710689438355187,2022-03-10,Treatment follow-up,pas de greffe,2022-07-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,105.26381317639598,172.71641798553276,2.247269253716944,35.286765662380844,102.20198189812032,1.5735479057085409,2022-12-07,Symptoms management,greffe haplo-identique,2022-08-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,85.25680576424612,190.2623088786991,2.1227050818556084,23.551768938008383,79.21222373678414,1.6892067138829627,2022-10-17,Cancer diagnosis,greffe haplo-identique,2022-03-07,Protocole 3 LAL thiotepa Bu Flu
Female,50,57.95596258441157,169.29762508581888,1.650909414796,20.220709580068384,82.3972996176928,0.8792151389262117,2022-12-08,Symptoms management,auto-greffe,2022-07-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,82.3921677322449,186.7318893154199,2.067287886837558,23.629196102710356,95.37693093950702,1.1758073347947942,2022-02-11,Treatment follow-up,auto-greffe,2022-03-11,Protocole 3 LAL thiotepa Bu Flu
Female,31,88.11433347271179,140.73293974956195,1.855965545633859,44.489245553870546,95.72518743909185,1.3935236270084674,2022-03-03,Treatment follow-up,greffe haplo-identique,2022-09-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,55,94.28166012116893,182.42604007643243,2.185776616860885,28.33045561819005,111.56780468658832,0.9976420881966742,2022-01-13,Symptoms management,auto-greffe,2022-09-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,46.99364268958017,195.08167301605417,1.5957929443976855,12.348271439946824,122.76114545939726,0.5529412897961455,2022-07-03,Treatment follow-up,greffe haplo-identique,2022-12-15,Protocole 3 LAL thiotepa Bu Flu
Male,27,93.38734377985364,149.9339300615991,1.9721626222476831,41.54207382823162,129.94848148133406,1.1278796505041706,2022-12-19,Treatment follow-up,pas de greffe,2022-08-06,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,78,94.24911790998812,169.28291581982467,2.1052029127094487,32.88902753285639,79.10735447975794,1.025934480788117,2022-11-19,Symptoms management,pas de greffe,2022-07-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,54.82647569441755,199.6851985305007,1.7438810232549506,13.749869650026815,76.43772272601787,0.9364356679089604,2022-02-27,Symptoms management,auto-greffe,2022-03-24,Protocole 2 LAM Endoxan TBI
Male,77,54.21083948466773,172.220657582236,1.6104025052533468,18.277451759785922,92.36009656247347,0.513582015551478,2022-12-22,Cancer diagnosis,auto-greffe,2022-02-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,55.50944640940175,147.22558675682276,1.5066897876333054,25.60945336236991,118.37843018547105,0.6252202795439626,2022-08-12,Treatment follow-up,auto-greffe,2022-08-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,27,101.33253047157744,142.49215088814665,2.002712758973142,49.90763655860717,118.49930002009071,1.342081995110108,2022-05-07,Symptoms management,pas de greffe,2022-08-05,Protocole 8 Aplasie medullaire thymo
Female,33,70.32245853419818,148.59258224025945,1.7037047624287032,31.849292237090182,119.39213853783079,0.8753255303757546,2022-06-21,Cancer diagnosis,allo-greffe,2022-04-28,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,36,65.09230055908571,197.27175779755447,1.8886262313574778,16.726296547708642,119.72628474180796,0.7853096930339072,2022-11-15,Symptoms management,pas de greffe,2022-03-15,Protocole 3 LAL thiotepa Bu Flu
Female,56,107.93680050386415,168.32992279885067,2.246540135900981,38.09315044764052,79.61358119477268,1.5817184124205221,2022-08-16,Treatment follow-up,allo-greffe,2022-01-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,58,102.72982959061531,150.13348767144672,2.069835447319724,45.5765471836762,105.59347995356008,1.108002705561521,2022-03-15,Cancer diagnosis,greffe haplo-identique,2022-05-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,50,55.827963882482756,163.49695294326065,1.592316794259611,20.88490299500889,122.201951646054,0.571062523250273,2022-11-17,Symptoms management,auto-greffe,2022-07-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,48,84.70331410570405,185.05753981445983,2.08666313381843,24.73357160185977,123.53807372246769,0.8761024776179235,2022-08-24,Treatment follow-up,allo-greffe,2022-04-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,46.844155817083866,151.97808202688498,1.4062642547671544,20.281193010358308,122.33179041246981,0.585027489868285,2022-11-10,Treatment follow-up,greffe haplo-identique,2022-11-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,25,119.29475392974294,192.53672771603425,2.5259003650690923,32.180602642589946,114.56120861190053,1.6632177181074537,2022-06-13,Treatment follow-up,pas de greffe,2022-10-05,Protocole 3 LAL thiotepa Bu Flu
Male,67,114.84243426911767,166.30144255043203,2.3032864494117384,41.52506841079637,74.26469601852213,1.5678710655379329,2022-03-26,Cancer diagnosis,auto-greffe,2022-07-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,71.3815899851975,171.64275458022047,1.8448225397473252,24.228987515592763,130.44169499740218,0.790443125503568,2022-10-05,Cancer diagnosis,auto-greffe,2022-12-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,50,72.47113456943627,164.5875556363518,1.8202447098136614,26.7529125356293,98.07111318604163,0.9237064337176176,2022-11-20,Treatment follow-up,pas de greffe,2022-07-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,41,67.90008021185801,154.6905193424677,1.7081096334323256,28.37545879777049,132.9395715436994,0.7022936000708785,2022-11-28,Treatment follow-up,auto-greffe,2022-03-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,74,112.37122313497434,192.13397419848974,2.44894136348681,30.440149149754287,107.55135782910321,0.9577466674485783,2022-09-21,Cancer diagnosis,greffe haplo-identique,2022-12-02,Protocole 3 LAL thiotepa Bu Flu
Male,41,78.22322126240446,181.93911456219942,1.9882895786387802,23.631078494703498,121.66285717981127,0.8840572359470621,2022-05-27,Symptoms management,greffe haplo-identique,2022-03-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,69.39268474188758,151.7448901896403,1.7102619459962247,30.13599526058814,78.45356001141337,0.9827850136478812,2022-01-28,Treatment follow-up,allo-greffe,2022-07-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,83.56186375443326,158.33278773334231,1.9170711773455906,33.3323858984404,120.05976629185159,0.9183362612100431,2022-06-27,Cancer diagnosis,allo-greffe,2022-09-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,77.18902758515974,197.47806561280046,2.0577185218134213,19.79328330657277,114.45931110967055,0.6369140925985686,2022-10-26,Treatment follow-up,allo-greffe,2022-07-18,Protocole 3 LAL thiotepa Bu Flu
Male,40,65.20998478943281,165.5992424503427,1.7319484917706964,23.779209188621834,80.6017927435571,1.1236651225216867,2022-01-02,Cancer diagnosis,auto-greffe,2022-05-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,98.68279522620423,188.9314041070586,2.2757342565579006,27.646053120882673,104.28034973502069,1.1171857635506381,2022-06-22,Symptoms management,greffe haplo-identique,2022-12-04,Protocole 3 LAL thiotepa Bu Flu
Male,44,51.359396561859256,183.68703894332154,1.6188177678962488,15.221690447310108,117.25947063573571,0.5839971393742827,2022-06-30,Treatment follow-up,allo-greffe,2022-07-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,48.93889401599729,179.46921863948862,1.5619632473741871,15.194072919809653,81.34146521590347,0.8356216101211845,2022-03-04,Cancer diagnosis,auto-greffe,2022-06-23,Protocole 3 LAL thiotepa Bu Flu
Female,43,86.31005443511732,167.39929544851643,2.0033473586975585,30.800242717537735,116.77363812666451,0.9957626156176785,2022-01-30,Symptoms management,allo-greffe,2022-01-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,84.55280670290838,140.6956457750175,1.8178292718053037,42.71365289287776,104.58797231760937,0.9544050188467708,2022-11-07,Treatment follow-up,pas de greffe,2022-03-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,40,66.53103711944159,169.03865037524403,1.7674775436838157,23.283714225739374,75.58528889120194,1.222515909867779,2022-07-01,Cancer diagnosis,greffe haplo-identique,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,54.36147145938298,193.91744846299784,1.711207974899735,14.45630916163745,98.54844661748334,0.873401182514629,2022-09-30,Treatment follow-up,allo-greffe,2022-07-02,Protocole 3 LAL thiotepa Bu Flu
Male,79,78.11406040345167,148.58191926958108,1.7955451831225737,35.383214509216714,81.0408753680475,0.8166245433709421,2022-06-09,Cancer diagnosis,pas de greffe,2022-07-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,109.56987676953827,184.22489283357663,2.3679279975479024,32.28453593115882,82.28172132342368,2.200909929031699,2022-02-09,Cancer diagnosis,pas de greffe,2022-11-12,Protocole 3 LAL thiotepa Bu Flu
Female,70,92.65629393594192,152.6313611200584,1.9820203118551525,39.7729103257624,84.42464277323624,1.0670167504911758,2022-08-11,Treatment follow-up,pas de greffe,2022-05-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,114.38604537686348,173.47180735926509,2.347738511620362,38.01152021584302,83.72376790785567,2.2011506800022196,2022-12-11,Cancer diagnosis,allo-greffe,2022-01-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,40.755025124659554,185.31714673818792,1.4484287436300174,11.867246281615325,89.81527272166902,0.7184612129462767,2022-01-06,Treatment follow-up,greffe haplo-identique,2022-09-03,Protocole 3 LAL thiotepa Bu Flu
Male,60,42.94179336777592,187.5646012781791,1.4957681370375897,12.20614209691444,76.29088013485709,0.6254103197870078,2022-07-07,Treatment follow-up,greffe haplo-identique,2022-01-09,Protocole 3 LAL thiotepa Bu Flu
Female,75,64.76515891707285,150.3955240678822,1.6448902375296155,28.633313794259625,121.33352714476564,0.4818828531607721,2022-04-15,Treatment follow-up,greffe haplo-identique,2022-10-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,45,112.19114568398929,178.8395110493168,2.3608031612489726,35.07774247377506,98.26376895663142,1.5064553849336861,2022-12-16,Treatment follow-up,greffe haplo-identique,2022-04-30,Protocole 3 LAL thiotepa Bu Flu
Male,70,51.8079846810193,165.06806797914774,1.5412696729562807,19.013871841675048,118.38006591538272,0.42548442261756103,2022-04-21,Symptoms management,pas de greffe,2022-05-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,58,48.88094887037585,154.4157016431546,1.4479857673489303,20.500134454778582,93.69110657397059,0.5941862742635518,2022-06-04,Cancer diagnosis,auto-greffe,2022-07-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,64,56.02549896688394,159.88921273533373,1.5774340031025884,21.91529922743301,104.40797712288314,0.5664129151517204,2022-09-22,Cancer diagnosis,auto-greffe,2022-02-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,78,109.7012510700414,186.7038098151612,2.38523476111462,31.470614292336073,93.17320531746621,1.0138640811737099,2022-12-28,Treatment follow-up,allo-greffe,2022-01-07,Protocole 3 LAL thiotepa Bu Flu
Male,49,70.27684238406759,168.46121688834285,1.8134468704567903,24.763519746886562,121.63270659531872,0.7302486536860248,2022-06-30,Treatment follow-up,allo-greffe,2022-07-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,32,73.67627122273474,190.56757886467938,1.9748634711385051,20.287550097269833,105.63755095726226,1.0461659308896025,2022-05-11,Cancer diagnosis,auto-greffe,2022-05-19,Protocole 3 LAL thiotepa Bu Flu
Female,53,74.40838669011215,193.6754770436489,2.0007692817913654,19.836845902566818,102.66299999926042,0.8757793354749672,2022-02-22,Treatment follow-up,pas de greffe,2022-10-08,Protocole 3 LAL thiotepa Bu Flu
Male,26,119.03461154282823,149.42367053331142,2.222772828975624,53.313164061453456,118.82874888533304,1.5860763497393653,2022-07-26,Treatment follow-up,allo-greffe,2022-01-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,62,65.21912108305952,186.96376830569358,1.840411536350416,18.65778293610588,122.83746589041921,0.5751832091929524,2022-09-22,Treatment follow-up,pas de greffe,2022-01-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,109.16967723187756,190.97318914061248,2.406500537803976,29.933481044382194,95.68472064777521,1.1092386065311313,2022-04-26,Treatment follow-up,auto-greffe,2022-08-24,Protocole 3 LAL thiotepa Bu Flu
Female,70,64.87862728765445,173.0520867399452,1.7659890081569145,21.664465129113818,134.9535381626746,0.46739377162751833,2022-08-06,Cancer diagnosis,allo-greffe,2022-06-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,44,59.59719419152673,159.35460074323996,1.6242166561323648,23.469108931071233,90.9609505664043,0.8735938344299944,2022-05-30,Symptoms management,pas de greffe,2022-03-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,104.30736639511152,173.29005969295423,2.240748247363399,34.73502994482505,107.53693536866722,1.6031412523086999,2022-12-31,Symptoms management,pas de greffe,2022-11-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,85.15580814036099,176.80040941917636,2.0450198140602627,27.242549083963183,90.3410767037704,1.1913459929846553,2022-01-27,Cancer diagnosis,allo-greffe,2022-04-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,83.59630836148926,172.46765881127033,2.0012259845440212,28.104234677509506,78.71210334503819,1.2243093817598796,2022-09-05,Symptoms management,pas de greffe,2022-06-10,Protocole 3 LAL thiotepa Bu Flu
Male,25,64.9826510113499,142.5276142580272,1.6039726910263292,31.988906420162095,102.93695213348882,1.0083039385083223,2022-10-29,Treatment follow-up,greffe haplo-identique,2022-06-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,59,75.2554951431253,195.24977687052944,2.020287289456105,19.740453477035086,118.62241281108393,0.713713623165362,2022-10-31,Treatment follow-up,allo-greffe,2022-12-21,Protocole 3 LAL thiotepa Bu Flu
Male,40,52.89272028322395,143.16179856985772,1.4503081058671958,25.807243032714563,85.31853775242736,0.8610334100854614,2022-02-18,Symptoms management,auto-greffe,2022-09-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,75,80.02504957526628,143.82438881285367,1.7880431455210244,38.686628010705725,84.24002149232156,0.85760705116511,2022-02-28,Symptoms management,greffe haplo-identique,2022-05-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,61,46.861389164363764,178.78739061378192,1.5255441187066439,14.660250354389825,114.67631521837964,0.44836946022750046,2022-04-22,Cancer diagnosis,pas de greffe,2022-07-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,23,63.36772353606431,141.8787115977015,1.5803068418802013,31.479920981471167,75.82758830676113,1.357982668913697,2022-02-07,Cancer diagnosis,allo-greffe,2022-12-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,79,102.08767797845726,150.92943815804838,2.0688184953513606,44.81520785150211,132.4105072267235,0.6532030668103906,2022-10-14,Cancer diagnosis,pas de greffe,2022-12-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,33,64.83636951573453,195.30358699416416,1.875483310606009,16.998016609967596,134.05194660679385,0.7187814245179751,2022-10-27,Symptoms management,allo-greffe,2022-05-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,96.01128085840386,197.16207536816597,2.29309248933974,24.69877998982478,125.31350640774198,0.9577108207514833,2022-10-12,Treatment follow-up,greffe haplo-identique,2022-03-30,Protocole 3 LAL thiotepa Bu Flu
Female,25,44.584322328987405,163.48991649978944,1.4229358475784657,16.68016052383882,114.28447292218605,0.6231036339911483,2022-03-24,Cancer diagnosis,allo-greffe,2022-08-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,79,49.724077223739286,189.13203666393505,1.6162728039605159,13.900695617124518,85.84846141833265,0.49071750975434064,2022-11-24,Symptoms management,greffe haplo-identique,2022-09-27,Protocole 3 LAL thiotepa Bu Flu
Male,35,90.92205732220067,186.3611501084889,2.1695070595257393,26.179327740893875,95.3829907299771,1.3901290566949824,2022-06-29,Symptoms management,auto-greffe,2022-05-01,Protocole 3 LAL thiotepa Bu Flu
Male,33,119.32770529524318,144.95749183041156,2.191995847616009,56.788442446330514,79.93531639985015,2.218471592901401,2022-11-25,Treatment follow-up,allo-greffe,2022-01-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,65,81.34104326713108,151.65854561561332,1.851130609530728,35.36518746941711,95.52676066375967,0.8869792382210021,2022-09-23,Cancer diagnosis,auto-greffe,2022-10-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,48.41522400754983,148.07197531969305,1.4111596742418913,22.081888139053028,130.38691461919885,0.43836348028104644,2022-12-25,Symptoms management,allo-greffe,2022-06-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,36,91.41979204234808,160.54350569788124,2.0191344339599406,35.46947372087271,128.55663905662004,1.0271800172815433,2022-06-01,Treatment follow-up,auto-greffe,2022-01-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,40,91.08879403844682,164.84281863235014,2.042284502103737,33.521611504316304,92.25535905995432,1.3713264490149597,2022-04-02,Cancer diagnosis,greffe haplo-identique,2022-06-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,91.10464462113092,154.59724587410767,1.9779708418791055,38.11860624346073,93.66627740607397,1.5265224830473225,2022-01-16,Symptoms management,allo-greffe,2022-04-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,112.14343228993945,168.38403884543354,2.2902670913484577,39.55232335190931,112.2246311176352,1.0131553013656185,2022-01-28,Symptoms management,pas de greffe,2022-09-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,110.99581184098481,178.40245437602746,2.3453218955739805,34.874255278273104,89.99333558963104,1.627373919753481,2022-05-07,Symptoms management,allo-greffe,2022-09-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,53.26700311691344,156.80328987681924,1.5231948633829937,21.664462707275668,104.42106547068543,0.8006009298718944,2022-04-18,Symptoms management,greffe haplo-identique,2022-11-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,73,71.41205298869374,192.57500157047085,1.9544945507760827,19.256249235321942,101.57952490677405,0.6541956432976497,2022-08-30,Symptoms management,auto-greffe,2022-12-05,Protocole 3 LAL thiotepa Bu Flu
Female,23,74.86955553460481,149.91763157627432,1.7657439762601401,33.31193265575858,76.17265760937491,1.5972007746879402,2022-01-23,Cancer diagnosis,auto-greffe,2022-12-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,42,55.70968787939505,197.69676540683525,1.7490969968323635,14.253830755705069,96.88772025640372,0.7826283348241425,2022-05-31,Symptoms management,auto-greffe,2022-05-25,Protocole 3 LAL thiotepa Bu Flu
Male,76,44.745500846767655,146.5604509127679,1.3496831706840504,20.831271949980476,78.0705259387634,0.5094595950545756,2022-04-12,Treatment follow-up,allo-greffe,2022-07-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,112.63265522222493,159.34328501652445,2.232789565844765,44.36053648145854,111.78907898711626,0.867609177610121,2022-03-29,Symptoms management,pas de greffe,2022-07-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,45.93098189735101,191.8095967001094,1.5643602804848344,12.484324982006617,116.62801540678498,0.34459652785829753,2022-06-05,Symptoms management,auto-greffe,2022-12-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,31,55.413621472899706,188.03017254690562,1.7012603830198498,15.673336022547906,107.90610630171959,0.7774357607376734,2022-07-19,Treatment follow-up,pas de greffe,2022-11-19,Protocole 3 LAL thiotepa Bu Flu
Male,20,64.09867241249577,156.05172987213777,1.6668923774228497,26.321574245884953,126.85883685990565,0.8421259671919431,2022-02-17,Cancer diagnosis,allo-greffe,2022-11-25,Protocole 6 FlUDARABINE cy (Fanconi)
Male,73,55.24066351013439,155.86091357484182,1.5464888799731307,22.73968536505255,132.68340132067448,0.38742228349794994,2022-01-03,Treatment follow-up,pas de greffe,2022-03-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,70,76.8383256455518,181.17294107130274,1.9664565879463334,23.409450731802217,130.81913898602716,0.5710473887076439,2022-12-31,Symptoms management,allo-greffe,2022-09-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,58,91.50530866468453,165.36730450437008,2.050202309916922,33.46162250546771,119.25929625841192,0.8738470088465464,2022-01-04,Cancer diagnosis,pas de greffe,2022-12-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,119.42396673934938,182.8423155900805,2.4628210233826144,35.72218925072536,87.68927409853556,2.1374253927792535,2022-11-06,Treatment follow-up,pas de greffe,2022-09-22,Protocole 3 LAL thiotepa Bu Flu
Female,21,78.66877081341849,164.17894755144698,1.8941251276654405,29.185519609003002,120.19817038604961,1.0817302442117842,2022-02-10,Symptoms management,greffe haplo-identique,2022-08-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,87.34123736074189,189.94453250599616,2.1467022835413134,24.20838102088478,108.79497663477368,1.2934093312274084,2022-10-14,Treatment follow-up,allo-greffe,2022-02-09,Protocole 3 LAL thiotepa Bu Flu
Male,27,93.11264950775586,155.78488870777565,2.0073160453182717,38.367016412360236,134.26993978658462,1.088368183598836,2022-06-29,Symptoms management,greffe haplo-identique,2022-08-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,32,68.00528388552988,162.80018389377977,1.7536685929718372,25.65859522714965,114.62470100585577,0.8899297004324015,2022-12-28,Cancer diagnosis,auto-greffe,2022-01-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,53.06030692158478,168.36279674456685,1.5752761371196613,18.718778056885515,83.39334021302209,0.6804506248683041,2022-07-07,Cancer diagnosis,auto-greffe,2022-06-23,Protocole 3 LAL thiotepa Bu Flu
Male,23,67.05864965697002,160.40254191550383,1.728549316495002,26.063474536553443,93.60380741054405,1.1641653123642197,2022-09-13,Symptoms management,auto-greffe,2022-10-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,109.84836103451913,179.13343841455963,2.3379427457297526,34.23262930308338,124.39804730055738,1.05474135178343,2022-05-13,Treatment follow-up,allo-greffe,2022-11-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,48.02188434686772,196.38774837872896,1.6185478522244254,12.451177252245586,118.5531195326089,0.6638588085228838,2022-05-31,Cancer diagnosis,greffe haplo-identique,2022-05-27,Protocole 3 LAL thiotepa Bu Flu
Female,46,58.498528817903015,147.35736312390765,1.5474162114485939,26.940227644781444,119.28724714707286,0.6402451319534381,2022-02-03,Symptoms management,greffe haplo-identique,2022-04-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,22,75.41467574203575,193.93174923988641,2.015585108391593,20.05201581888235,127.50948732968217,0.9693104154141602,2022-12-16,Symptoms management,pas de greffe,2022-09-21,Protocole 3 LAL thiotepa Bu Flu
Female,78,76.08866893653467,185.32320548396018,1.9791269138692917,22.15441975137487,103.96807690935182,0.6302011174837007,2022-04-18,Treatment follow-up,pas de greffe,2022-11-27,Protocole 3 LAL thiotepa Bu Flu
Male,29,56.70555940913395,150.30950248610557,1.5387029551417672,25.098788825402146,110.9615204620257,0.7878503321848969,2022-05-08,Treatment follow-up,greffe haplo-identique,2022-08-15,Protocole 6 FlUDARABINE cy (Fanconi)
Female,29,48.9958513695753,179.89834208584082,1.5647392781112548,15.13927181752,114.79170593230812,0.6580202833292782,2022-04-08,Treatment follow-up,allo-greffe,2022-01-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,54.26490079886218,161.74100158003324,1.561414903741076,20.743343404486954,126.16973709472938,0.710850511532227,2022-11-27,Treatment follow-up,auto-greffe,2022-05-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,69,44.4430059833081,188.6872138032646,1.5262360175019005,12.482985966626233,111.59570684459369,0.39271888901916896,2022-08-27,Symptoms management,auto-greffe,2022-08-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,88.56577475424517,194.35030565390974,2.1866250881440097,23.447441993565455,110.98240748543466,1.2524423132036522,2022-10-17,Treatment follow-up,auto-greffe,2022-12-29,Protocole 3 LAL thiotepa Bu Flu
Male,31,116.27602514474052,172.45928485329551,2.3601365392497105,39.09462173707478,94.20204240162539,1.8686323355952044,2022-08-31,Symptoms management,pas de greffe,2022-09-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,53,109.86206509995581,151.92264781560849,2.1531976108205546,47.59953567888063,125.90463083356772,1.0543694417768823,2022-12-29,Cancer diagnosis,allo-greffe,2022-10-06,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,41,90.87071721376802,150.88912221495,1.9515949855487436,39.91242281357638,77.75598145176767,1.6069147843813953,2022-08-17,Cancer diagnosis,auto-greffe,2022-08-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,105.2964783462502,167.20494826452443,2.211465842070555,37.66305936394327,114.11120828469248,0.8714890981223715,2022-10-10,Treatment follow-up,pas de greffe,2022-05-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,112.65781730269444,155.31890251615985,2.2046597459396806,46.6995511502469,122.22845095662046,1.0881166459408105,2022-07-19,Symptoms management,pas de greffe,2022-11-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,74,52.25781114517005,169.09306042980236,1.5667050720380795,18.276778390470557,107.2737337956012,0.44654913980167155,2022-11-15,Cancer diagnosis,pas de greffe,2022-07-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,42.17113863809321,192.75557201683955,1.5026570865181064,11.350145922594603,74.521733759666,0.5423116965024181,2022-09-15,Symptoms management,greffe haplo-identique,2022-01-02,Protocole 2 LAM Endoxan TBI
Female,47,73.51248827720114,198.06267397647807,2.0110859420587617,18.739407146991674,118.68839618261015,0.8000245495380375,2022-05-05,Cancer diagnosis,greffe haplo-identique,2022-01-10,Protocole 3 LAL thiotepa Bu Flu
Male,21,60.044124981742414,198.64490875394984,1.8202151680050982,15.216530576901388,94.20313376959515,1.0534638444052036,2022-04-19,Symptoms management,auto-greffe,2022-12-28,Protocole 3 LAL thiotepa Bu Flu
Female,26,92.37555235997405,143.36132888521743,1.9179765048114772,44.94620333930586,79.83321137461925,1.8320857788156732,2022-12-31,Cancer diagnosis,greffe haplo-identique,2022-04-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,46,53.91305584892727,141.62032212589813,1.4563256977098809,26.880837347800817,86.69113814720701,0.8119225457742089,2022-10-31,Cancer diagnosis,auto-greffe,2022-06-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,115.93539045811512,157.4679514311146,2.2519194549567523,46.755388912004655,120.89493164305202,1.4118264169948485,2022-08-07,Treatment follow-up,allo-greffe,2022-05-19,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,119.49324109825622,152.9345617639766,2.2530625121474483,51.089547371768745,99.00153969580839,1.7769481716218078,2022-03-11,Cancer diagnosis,auto-greffe,2022-01-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,77,84.60774509178643,156.82939401694475,1.9198510787070175,34.39974252337309,113.66304184357014,0.6513267263883371,2022-04-13,Treatment follow-up,allo-greffe,2022-09-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,62,108.0540340944985,151.35212038976056,2.131392813844573,47.16979254455041,104.46503820773749,1.1205522818354405,2022-09-19,Cancer diagnosis,allo-greffe,2022-03-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,31,59.9646708512394,172.66934989763598,1.6959150867033759,20.112448561845063,128.38282117068292,0.7071027735625188,2022-10-20,Treatment follow-up,greffe haplo-identique,2022-08-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,119.34966880902793,153.23713205115845,2.253934890089813,50.826849137844576,74.56496558056196,2.0674587278092313,2022-12-26,Cancer diagnosis,pas de greffe,2022-01-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,74,118.95620851068087,188.915372375864,2.4984804508171785,33.33132023347543,130.47776884978975,0.8357223770458925,2022-01-23,Symptoms management,allo-greffe,2022-01-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,87.18446288801213,170.25563003697798,2.030575018343465,30.077111935615783,123.7531031352642,0.7925661519922278,2022-03-21,Cancer diagnosis,allo-greffe,2022-06-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,112.65836094720053,188.82488127476202,2.430860708934208,31.596937261386742,101.31998684184796,0.9883614122721103,2022-04-26,Symptoms management,pas de greffe,2022-02-10,Protocole 3 LAL thiotepa Bu Flu
Female,78,50.392122354427116,185.36053155433746,1.610789194581324,14.6665550755034,108.53166184496065,0.39982080559916006,2022-07-29,Cancer diagnosis,allo-greffe,2022-11-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,111.178142587907,140.7719649027525,2.0850503315493145,56.103127129141754,82.26543054956993,1.9333334606404677,2022-02-11,Symptoms management,greffe haplo-identique,2022-01-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,27,110.17281405638981,170.2852183818038,2.2828345988978387,37.99448315673221,114.12737083556044,1.5150625978999201,2022-06-23,Treatment follow-up,allo-greffe,2022-03-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,114.16543746687289,160.04116452049453,2.2528481701682797,44.572935766023,112.56904292748709,0.9719239090409924,2022-05-20,Treatment follow-up,greffe haplo-identique,2022-03-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,95.26588208835156,163.1460263390768,2.0778093504405595,35.7918702429273,74.15003748207728,1.5881207799480315,2022-06-07,Treatment follow-up,pas de greffe,2022-12-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,54,112.59500308766754,156.36605740399384,2.211462356564661,46.050478271804174,132.96467787571174,1.0114601716704203,2022-09-17,Symptoms management,greffe haplo-identique,2022-01-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,72,108.68692202620619,149.8009257518118,2.126643255921346,48.43377225975924,98.81452723718144,1.0388023154230384,2022-12-05,Treatment follow-up,auto-greffe,2022-11-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,50,97.62150272603527,140.1709512745565,1.9496223923536289,49.68547513015793,96.97038819568827,1.2583932134136793,2022-05-13,Treatment follow-up,greffe haplo-identique,2022-12-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,59,58.68062664374088,193.5123433145809,1.7760306529666974,15.670303177894036,110.39498741482109,0.5979954934561236,2022-07-26,Cancer diagnosis,greffe haplo-identique,2022-02-02,Protocole 3 LAL thiotepa Bu Flu
Female,24,85.10702283331888,196.61075842958502,2.1559321461018275,22.016629877750542,128.55618475554428,1.0665910036229012,2022-01-31,Treatment follow-up,auto-greffe,2022-10-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,76.05163651397082,149.0025952265522,1.7741892680420472,34.25475758072991,111.36244542910649,0.8441649476254419,2022-04-03,Symptoms management,greffe haplo-identique,2022-04-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,45.797647788097976,179.14494753746848,1.5096373010261503,14.270330926170145,130.95690299914986,0.31085814740404605,2022-12-08,Treatment follow-up,allo-greffe,2022-11-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,32,52.85037073529668,166.8733200157477,1.5651869633318276,18.979039301887937,86.70648451693731,0.9142978929962186,2022-02-06,Treatment follow-up,allo-greffe,2022-10-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,52.7264642275027,196.54927910764928,1.6966755512055296,13.648525594231394,79.76781547103228,1.0465821066709509,2022-01-10,Symptoms management,auto-greffe,2022-01-03,Protocole 2 LAM Endoxan TBI
Male,43,106.36074433577676,180.33816869046595,2.3082522160277237,32.70439034072795,112.23005551650476,1.276766349992423,2022-05-22,Treatment follow-up,allo-greffe,2022-04-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,115.7248373638306,154.90252669472525,2.2314712205300236,48.22914639946497,128.60777661916856,1.0373013542175473,2022-01-21,Symptoms management,greffe haplo-identique,2022-07-16,Protocole 6 FlUDARABINE cy (Fanconi)
Male,34,96.67640581026707,185.00082472881218,2.228926922105788,28.2470544486306,129.6941348106697,1.0974216621763497,2022-05-30,Treatment follow-up,auto-greffe,2022-05-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,87.91349285154146,160.85379991898506,1.9819476524453423,33.97761455663005,119.40212996229633,0.8078636287338022,2022-10-04,Symptoms management,greffe haplo-identique,2022-12-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,45,118.47357672359679,195.22363488515316,2.534694934845088,31.08541793203432,77.00926453334954,2.0298765813263544,2022-10-10,Treatment follow-up,pas de greffe,2022-12-23,Protocole 3 LAL thiotepa Bu Flu
Male,32,60.27441280843917,176.0681395844239,1.7169420270842526,19.44336538255989,110.86946117926556,0.8154781149921133,2022-06-07,Symptoms management,allo-greffe,2022-11-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,91.55600850497203,141.05256046960986,1.8940117201622944,46.01769936966568,107.92945581285002,1.0957142647321887,2022-09-30,Cancer diagnosis,auto-greffe,2022-11-01,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,32,93.86787692767233,145.87960088310743,1.9503139648922545,44.10906605898658,77.72172243821245,1.8116147066020534,2022-10-06,Symptoms management,allo-greffe,2022-04-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,88.63687919818702,192.38057417741626,2.176389320860579,23.94925584329258,111.974518745497,0.9345051118492476,2022-06-12,Treatment follow-up,auto-greffe,2022-08-16,Protocole 3 LAL thiotepa Bu Flu
Female,78,41.91403181137579,156.76953617085613,1.3510123083286567,17.05438613745207,128.8711945883377,0.28006754045800164,2022-03-08,Cancer diagnosis,allo-greffe,2022-06-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,33,53.635398352382815,167.62175742699952,1.5803005807724964,19.089331994289232,125.91118768684643,0.6330506677340599,2022-01-21,Treatment follow-up,allo-greffe,2022-02-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,66,83.34896034456364,185.04227333770007,2.069828300883102,24.34211312400611,99.82914163533752,0.8581082421397914,2022-06-12,Treatment follow-up,pas de greffe,2022-06-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,75.74800131959192,153.2334405658856,1.7956062778495914,32.25997839273322,77.547403037139,1.0988956192862966,2022-03-03,Treatment follow-up,allo-greffe,2022-11-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,61.74312268159214,159.81415910462403,1.6555819077569982,24.174532393065398,76.37059276687648,0.6961801270563842,2022-03-05,Symptoms management,allo-greffe,2022-05-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,69.26109100201259,174.49791647409643,1.8322660584774062,22.74619912258079,112.59644430544157,0.5638662376076757,2022-04-29,Treatment follow-up,auto-greffe,2022-03-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,72.10597912796447,166.56913154530275,1.826550355373086,25.988561155319477,103.86557310494383,1.1377560868592584,2022-09-02,Cancer diagnosis,auto-greffe,2022-07-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,44.096903249945555,184.57305349496318,1.503616019478305,12.944089217216284,112.9772635009777,0.43910619374985516,2022-03-30,Cancer diagnosis,greffe haplo-identique,2022-08-26,Protocole 3 LAL thiotepa Bu Flu
Female,66,53.10178091428511,197.863788616005,1.708387767747182,13.563645969621613,122.95158520112052,0.443888790005035,2022-05-29,Treatment follow-up,auto-greffe,2022-05-06,Protocole 3 LAL thiotepa Bu Flu
Female,67,84.67171146112753,146.09000996978662,1.853651888953489,39.67320631588335,86.09136876152655,0.997169735928368,2022-02-23,Symptoms management,greffe haplo-identique,2022-05-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,64,43.925852556191536,174.30530153527314,1.458357997410569,14.457693265412683,92.25487790971852,0.5025878170211937,2022-05-05,Symptoms management,greffe haplo-identique,2022-06-19,Protocole 3 LAL thiotepa Bu Flu
Male,79,60.563613623886056,173.52351009099493,1.708574033434144,20.113846517448817,123.18795576097673,0.4165248055564451,2022-08-16,Symptoms management,pas de greffe,2022-07-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,93.85794425885777,170.36468615254643,2.1075314164380075,32.33790513726164,114.72160363494888,1.0794858090843442,2022-11-12,Cancer diagnosis,greffe haplo-identique,2022-10-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,86.76285985189119,143.5448684443371,1.8599853123146324,42.107408680132686,111.2709967428482,1.0504880541885948,2022-03-07,Symptoms management,auto-greffe,2022-02-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,71,48.46198807891453,179.45705842792756,1.5542813475303996,15.048046930086636,133.35951690487553,0.34825215067893295,2022-08-09,Treatment follow-up,greffe haplo-identique,2022-09-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,108.22175339526702,182.8535989618731,2.3445407684832964,32.36737956914915,124.22326306220232,1.1010841953480275,2022-08-22,Symptoms management,pas de greffe,2022-08-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,51,53.00367143069665,147.9248057316663,1.4757820713335987,24.222777387590487,81.7033103323316,0.8019066414649269,2022-07-26,Symptoms management,allo-greffe,2022-11-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,64,99.06847661968624,153.06665545597255,2.052375343169036,42.28382815545603,113.49295764780783,0.9213988519080183,2022-06-22,Cancer diagnosis,greffe haplo-identique,2022-05-12,Protocole 6 FlUDARABINE cy (Fanconi)
Female,21,44.182387787680824,148.10377029364764,1.3482064435484014,20.142666120486002,77.35780084715739,0.9439729142367739,2022-01-18,Cancer diagnosis,auto-greffe,2022-12-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,73.20336971550236,158.44837812754648,1.7949740948991517,29.15784861562825,84.23412860651732,1.3277098411289574,2022-08-21,Symptoms management,pas de greffe,2022-12-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,45.418197595242106,171.19727223426355,1.4696439041578744,15.496592546732893,106.9582840976929,0.536691063981128,2022-10-14,Treatment follow-up,pas de greffe,2022-03-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,118.74665090529172,158.2627284981013,2.284802992496958,47.409357760144225,127.2667187468304,1.4643755523423942,2022-06-01,Symptoms management,allo-greffe,2022-06-12,Protocole 6 FlUDARABINE cy (Fanconi)
Female,54,40.95885115686036,194.8877209955538,1.4890691682834594,10.783973517573706,94.72367198653173,0.5164820069696505,2022-09-04,Symptoms management,allo-greffe,2022-07-03,Protocole 3 LAL thiotepa Bu Flu
Female,49,68.36329269338535,178.09146342035507,1.8390002446981186,21.5544411356818,113.6013587425477,0.7605860264298715,2022-12-02,Cancer diagnosis,greffe haplo-identique,2022-07-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,106.67714180740484,183.4349330202202,2.3314465205955672,31.703505120311515,112.72734921163854,1.2223414205296654,2022-07-11,Treatment follow-up,allo-greffe,2022-09-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,46.950398807219656,140.43098209930284,1.3533180022173275,23.80747952231257,132.90401848038425,0.37289131557616656,2022-05-25,Treatment follow-up,greffe haplo-identique,2022-03-31,Protocole 8 Aplasie medullaire thymo
Male,35,56.74726957273778,156.6399568839402,1.5713484883969862,23.12809487489585,130.37012696446723,0.6347806565850123,2022-05-30,Treatment follow-up,auto-greffe,2022-02-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,24,91.73483217445172,189.5819176775607,2.1979324502726647,25.523512843144076,119.88736977919973,1.2327821326330777,2022-11-19,Treatment follow-up,auto-greffe,2022-02-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,73,58.7667788447513,162.52086039289873,1.628805583205083,22.24916213888357,125.7445230148262,0.4348957014186627,2022-03-22,Treatment follow-up,pas de greffe,2022-08-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,70,102.7654038601454,164.79000700726405,2.1688906292681365,37.84296786052183,122.83590475880362,0.8133681231449073,2022-08-18,Treatment follow-up,auto-greffe,2022-04-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,66.33998821106383,185.54215491366696,1.849088692184165,19.27037639469972,131.7163356524876,0.8044537746041543,2022-06-01,Symptoms management,auto-greffe,2022-08-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,113.35590177436784,140.26120016626143,2.1015493509949112,57.61944023284555,75.21748882723952,1.6116975092857124,2022-12-03,Treatment follow-up,greffe haplo-identique,2022-12-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,72,42.40070140902536,195.0147662663799,1.515545636507383,11.149054726985172,126.45001546247032,0.3166872438871856,2022-05-14,Cancer diagnosis,auto-greffe,2022-12-23,Protocole 3 LAL thiotepa Bu Flu
Female,72,93.99864628315122,160.458074207838,2.046870359077907,36.50887478341728,108.64982527957363,0.8170882837499669,2022-12-10,Symptoms management,pas de greffe,2022-05-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,39,59.22624375959999,181.0818832829221,1.7260101518757853,18.061931237489127,99.95837239288593,0.8311585774993027,2022-04-14,Treatment follow-up,allo-greffe,2022-09-28,Protocole 3 LAL thiotepa Bu Flu
Female,37,91.4477954946965,175.28826801248442,2.110142549543963,29.762372009826553,134.30952946965715,0.9740273263171632,2022-12-10,Cancer diagnosis,allo-greffe,2022-03-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,71,115.61572767752548,147.2050556080065,2.1742955194940135,53.35455052492502,112.32374683889117,0.9864201365173735,2022-12-07,Treatment follow-up,allo-greffe,2022-08-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,35,116.4722399251176,162.41629722272734,2.2923174795798724,44.15330499555206,115.92082943261792,1.4652703118340735,2022-01-29,Cancer diagnosis,auto-greffe,2022-05-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,69,58.012536701422796,155.8422081274367,1.5847188515653434,23.88645331197424,84.27848854656877,0.6787830205735603,2022-02-24,Symptoms management,auto-greffe,2022-07-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,24,46.462050708998355,153.28802481341322,1.4065398819209385,19.773425781337984,113.48909393642008,0.6595834326090522,2022-02-02,Symptoms management,allo-greffe,2022-09-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,107.17900400654403,173.68821992705597,2.2739912549579864,35.52785505998524,100.63332887695363,1.5679826277734814,2022-08-08,Symptoms management,allo-greffe,2022-04-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,28,85.07511347163012,177.94207281727643,2.050639604577805,26.868612901229756,124.34522176138634,1.0642875015677487,2022-04-30,Symptoms management,greffe haplo-identique,2022-07-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,44,43.1679065165286,180.31773019346474,1.470443897477534,13.276516014428246,123.66197395594601,0.4654398344733627,2022-05-06,Symptoms management,allo-greffe,2022-08-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,84.76456551204248,156.65230951041556,1.9205442625658355,34.541463641837055,96.70313531601685,0.7548018888156558,2022-01-03,Treatment follow-up,auto-greffe,2022-10-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,45.30251856739828,143.12914428324063,1.3420662672440062,22.113943590656127,116.9563086394756,0.4680426725648498,2022-02-25,Treatment follow-up,greffe haplo-identique,2022-01-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,73,58.75691263621454,155.3091766449418,1.592123645021298,24.35929602383786,101.68052416137161,0.5377290482309833,2022-03-16,Treatment follow-up,pas de greffe,2022-08-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,117.46624889239557,165.41579134657357,2.323238431649115,42.929829790155395,82.95243159535661,1.8880901039027274,2022-04-24,Symptoms management,pas de greffe,2022-04-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,82.13385387483163,194.35673001786415,2.1057637346945697,21.743178640764466,134.29035802207176,0.552151466222603,2022-01-29,Symptoms management,greffe haplo-identique,2022-09-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,58.04707823735807,162.32804364251334,1.6178405230974342,22.028922520817126,132.49340118638574,0.4076884633790495,2022-09-03,Symptoms management,allo-greffe,2022-10-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,66,66.38482649901903,146.75141603619926,1.6450318548121767,30.825080785357084,111.81147339896212,0.6102133115970408,2022-10-29,Cancer diagnosis,auto-greffe,2022-11-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,81.9474587552823,183.62797193506043,2.0444943450143596,24.30288405388076,87.581142194581,0.8966882520516463,2022-01-26,Cancer diagnosis,greffe haplo-identique,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Male,28,52.30673285025201,167.67570745765968,1.5608552174533477,18.60446987214537,108.24467664244864,0.7516861928179269,2022-12-29,Treatment follow-up,auto-greffe,2022-07-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,64.5669173308855,179.77993635060386,1.7956611509182423,19.976877540601198,133.2073820855415,0.46451351374077826,2022-03-04,Treatment follow-up,pas de greffe,2022-06-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,51,54.24939227190191,160.60098389394966,1.555680074090167,21.032866932314832,75.20494831745314,0.8916737270433133,2022-05-15,Treatment follow-up,allo-greffe,2022-04-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,69.63303084029371,155.3616778117203,1.7335179791446012,28.848782752891573,129.10906516074212,0.6966409734544963,2022-03-04,Cancer diagnosis,pas de greffe,2022-08-30,Protocole 6 FlUDARABINE cy (Fanconi)
Female,37,53.40849348263933,182.72552988278764,1.6464688875705995,15.996017400190889,124.50647961663408,0.6136533399763302,2022-09-04,Symptoms management,auto-greffe,2022-04-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,108.96822936196303,199.25629525125333,2.4558663148307653,27.44579350564142,108.85969050636636,1.6127174739018342,2022-03-06,Treatment follow-up,greffe haplo-identique,2022-09-24,Protocole 3 LAL thiotepa Bu Flu
Male,25,59.48502461541298,176.9614130460298,1.7099832691693981,18.99548954998178,111.13684935228565,0.8548991964312825,2022-08-16,Treatment follow-up,allo-greffe,2022-11-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,47.237439584216474,192.64402587273761,1.5898995891970031,12.72844230543713,79.93579066958078,0.9849038248601966,2022-04-22,Cancer diagnosis,pas de greffe,2022-10-28,Protocole 3 LAL thiotepa Bu Flu
Female,20,77.92630402233974,175.96657290486962,1.9516677097886537,25.166552500423094,97.24588414765316,1.3355544505448413,2022-02-02,Symptoms management,greffe haplo-identique,2022-05-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,68.75921325244852,188.5207572545224,1.897552440395023,19.346951710321033,78.36149873491422,1.1943228582924894,2022-01-29,Treatment follow-up,pas de greffe,2022-07-03,Protocole 3 LAL thiotepa Bu Flu
Male,57,101.26267616930718,197.54201542128715,2.357236678910174,25.94958639132496,112.99912895978571,1.0330465719592221,2022-07-26,Cancer diagnosis,greffe haplo-identique,2022-06-03,Protocole 3 LAL thiotepa Bu Flu
Female,54,52.80854859654991,177.32801211590856,1.6128335094685369,16.793821788781116,115.5405497069952,0.5459284870141538,2022-05-06,Cancer diagnosis,auto-greffe,2022-05-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,23,84.38325347931126,173.87842687748406,2.0188299258196998,27.91032292163611,132.40679207628554,1.0356174691165252,2022-10-08,Symptoms management,auto-greffe,2022-11-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,115.67538022778355,191.51286635446286,2.4806654368258836,31.538789678164836,86.855859790041,1.5722740307795493,2022-01-03,Treatment follow-up,allo-greffe,2022-04-30,Protocole 3 LAL thiotepa Bu Flu
Female,72,40.404053459987814,182.59926708795314,1.4315638835025697,12.117886403541174,118.92458229138421,0.32087044653077057,2022-09-20,Treatment follow-up,auto-greffe,2022-08-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,113.50674569784368,141.47670913246168,2.112039617530497,56.70897191585195,119.1640668429431,1.2832627672720074,2022-08-28,Treatment follow-up,greffe haplo-identique,2022-03-15,Protocole 8 Aplasie medullaire thymo
Female,46,110.38833975356121,174.75056597070625,2.314832898246859,36.14814532680726,96.47875411976204,1.4937807971164074,2022-04-11,Cancer diagnosis,allo-greffe,2022-07-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,74.28683889699255,174.7412969205966,1.898901624989204,24.32880452362763,77.59530049169626,1.0371428204429394,2022-11-26,Symptoms management,greffe haplo-identique,2022-06-21,Protocole 3 LAL thiotepa Bu Flu
Female,25,78.61976428620736,188.78033210827272,2.0304532343122275,22.060647023561412,96.99790638328956,1.2945973712834353,2022-12-29,Symptoms management,greffe haplo-identique,2022-02-27,Protocole 3 LAL thiotepa Bu Flu
Female,50,93.67595210010019,167.77644172552056,2.0894322672947623,33.27868500290359,122.28011658067763,0.9575959150142669,2022-03-07,Treatment follow-up,pas de greffe,2022-11-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,73.52052605275614,152.73860484648415,1.7661494979566867,31.514539625131608,84.76379208204949,1.361269692304937,2022-11-11,Treatment follow-up,allo-greffe,2022-06-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,45.145592417501504,160.2043074780187,1.417403570003453,17.59004613245957,109.6277451235168,0.6463099202758466,2022-01-21,Cancer diagnosis,pas de greffe,2022-11-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,116.47584064304202,176.44622499572196,2.3893119874806854,37.412015976369375,112.81994400021136,1.6633186862392042,2022-11-02,Treatment follow-up,allo-greffe,2022-01-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,115.894280919074,142.84792070331582,2.1444538964692472,56.795530293297695,131.03777734356493,1.474056861928367,2022-12-27,Treatment follow-up,pas de greffe,2022-03-22,Protocole 9 LAL thiotepa-thymo melphalan
Male,50,73.2528068882111,169.12974602360893,1.8551151974203361,25.608508045288097,113.21388736256785,0.80878777986859,2022-01-29,Treatment follow-up,allo-greffe,2022-06-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,65,99.03813373497444,183.0108309936065,2.243821836045565,29.569832327556714,128.9440714143418,0.8000734078660702,2022-12-30,Cancer diagnosis,allo-greffe,2022-05-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,52,119.61686522005394,143.96381553604107,2.187115065784868,57.71460396276679,117.06977418851716,1.2488141523967362,2022-02-09,Symptoms management,auto-greffe,2022-07-01,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,43,77.55631865332177,191.2352587592289,2.029744282339335,21.20709836170434,105.58279758316193,0.9896081402958206,2022-01-31,Symptoms management,greffe haplo-identique,2022-09-20,Protocole 3 LAL thiotepa Bu Flu
Female,21,50.3058393518873,174.62724399997708,1.562118405236733,16.496598317270063,78.46777223590334,1.0595990048410606,2022-02-07,Cancer diagnosis,allo-greffe,2022-09-17,Protocole 3 LAL thiotepa Bu Flu
Female,76,102.46445670022761,194.95143795598236,2.3555839788496815,26.960029052703362,86.1820533321367,1.0568269557915726,2022-07-13,Treatment follow-up,auto-greffe,2022-03-28,Protocole 3 LAL thiotepa Bu Flu
Male,57,114.07433415668899,167.53423224824118,2.3040638007279783,40.64253823342908,126.31124891927635,1.0410977530169843,2022-10-15,Symptoms management,pas de greffe,2022-03-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,32,77.8475411250243,162.59580304006215,1.8751061795059907,29.44599520319841,121.46496141566969,0.9613579943266854,2022-03-03,Cancer diagnosis,allo-greffe,2022-03-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,57,73.76746297420766,151.65718698584206,1.7628390868260866,32.072946139197185,132.88575047029687,0.6399293508803979,2022-11-14,Treatment follow-up,allo-greffe,2022-01-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,54,96.90469677488878,147.32732909861016,1.9914198001087806,44.64555187581689,107.512333117725,1.0765953388491456,2022-08-15,Treatment follow-up,greffe haplo-identique,2022-06-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,78,49.62063483427449,158.35462552315892,1.4773904403262823,19.787950215125573,125.12972574793659,0.3414766534552675,2022-05-20,Treatment follow-up,greffe haplo-identique,2022-02-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,74,79.49603429386718,173.13016985762664,1.9552750531365244,26.521614241968827,91.65154694652854,0.7950914872379944,2022-12-14,Cancer diagnosis,allo-greffe,2022-08-09,Protocole 3 LAL thiotepa Bu Flu
Male,38,98.82833121492628,164.38205800374203,2.1243041000515546,36.57401472057065,95.53445252983329,1.4655111203024678,2022-08-01,Cancer diagnosis,allo-greffe,2022-08-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,69,54.7989487188001,178.97149074560969,1.650542801583759,17.108207765281414,128.69213249196088,0.41990020028763136,2022-10-02,Treatment follow-up,auto-greffe,2022-11-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,41.16034136348923,173.45926805916372,1.4082734391579723,13.679932326520975,127.23681044231283,0.39088855110394394,2022-01-30,Cancer diagnosis,pas de greffe,2022-05-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,62.59315588058865,164.48996263355414,1.6911490071607016,23.133856903090877,127.75565460968286,0.5920160396823031,2022-02-03,Cancer diagnosis,allo-greffe,2022-11-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,81.18168264738716,155.62360267767943,1.8733352554128961,33.52023994106026,101.29942106005407,0.8904480268918115,2022-07-29,Symptoms management,allo-greffe,2022-05-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,56,52.39117641573799,163.3213865762809,1.541698159730662,19.64138161424686,79.44908233049499,0.7693359993439902,2022-06-06,Treatment follow-up,greffe haplo-identique,2022-03-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,66.72348588835723,175.8917720025423,1.8055556367846821,21.566897737024046,115.91729543044741,0.7115214513277871,2022-02-25,Symptoms management,allo-greffe,2022-07-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,31,99.88113176114211,144.55098233735382,2.002631304686673,47.80148184661698,112.75086181377303,1.341088956220903,2022-05-04,Cancer diagnosis,greffe haplo-identique,2022-01-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,43,105.28058816868318,195.2537359046749,2.3895855148596206,27.615289348999458,126.4223032588772,1.1219250424431448,2022-09-11,Symptoms management,auto-greffe,2022-09-28,Protocole 3 LAL thiotepa Bu Flu
Male,68,84.17453722186657,156.09263873607233,1.9104264815704903,34.54744169784372,86.81032996972479,0.9696373375290999,2022-10-23,Symptoms management,allo-greffe,2022-04-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,90.61870656305773,191.12428005684876,2.19338874369897,24.807679020718545,109.85707311332173,1.1227509060819705,2022-01-28,Cancer diagnosis,greffe haplo-identique,2022-01-13,Protocole 3 LAL thiotepa Bu Flu
Female,23,65.35959740618961,186.12888556932177,1.8382743286446066,18.866086195493914,130.36633252158012,0.8146991921206099,2022-08-16,Symptoms management,allo-greffe,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,68.32976161737056,161.929261653142,1.7531390772963047,26.05908931151472,106.5008937275224,0.7841638709771248,2022-10-24,Symptoms management,allo-greffe,2022-04-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,45,52.367363970039726,191.42640687863482,1.668706778257608,14.290815687555144,130.73334923246628,0.5285248780523849,2022-12-21,Cancer diagnosis,pas de greffe,2022-11-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,111.18091747788873,196.95287404358803,2.466295086656252,28.66194169812201,76.16075889592629,1.4192684031256437,2022-01-06,Treatment follow-up,allo-greffe,2022-02-18,Protocole 2 LAM Endoxan TBI
Male,30,75.96283187530496,182.7560693215053,1.9637456109337106,22.743512049441737,107.61995308189819,1.0783718367526478,2022-12-13,Symptoms management,greffe haplo-identique,2022-02-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,108.06210028219279,159.67948041162828,2.1893238444558003,42.38138866181439,77.74384606593262,2.181490516934993,2022-06-12,Cancer diagnosis,auto-greffe,2022-05-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,77.17612093500927,171.97127446951214,1.920074931683566,26.09583071662971,101.5610019071384,1.266498614720486,2022-08-12,Treatment follow-up,greffe haplo-identique,2022-10-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,24,104.0969010313348,166.21819952853212,2.1923350986972943,37.67737635300176,121.38311955433812,1.3816721344745115,2022-11-11,Cancer diagnosis,greffe haplo-identique,2022-03-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,62,63.32867588709196,165.43912847987002,1.7059569607167584,23.137900037240872,114.42674038462583,0.5995632254641016,2022-12-19,Symptoms management,allo-greffe,2022-07-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,39,98.96064815588673,193.25654248932395,2.304873623018381,26.496842257987357,131.28397022611279,1.0574009749131705,2022-11-03,Cancer diagnosis,allo-greffe,2022-04-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,89.3807366719453,144.7053622051635,1.8954530295682603,42.68494051056848,106.68706698685557,1.3497633971811156,2022-04-29,Symptoms management,allo-greffe,2022-11-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,56,95.35894351510942,181.04720376681144,2.189905507700673,29.092281929489907,90.41835213988216,1.230415044453747,2022-02-20,Symptoms management,pas de greffe,2022-01-23,Protocole 3 LAL thiotepa Bu Flu
Male,79,62.716718892505405,192.39835885697562,1.8308008104995046,16.942621280847074,103.77014229592369,0.5120451487776567,2022-08-22,Treatment follow-up,auto-greffe,2022-11-06,Protocole 3 LAL thiotepa Bu Flu
Male,68,97.15274742331388,140.62253860275072,1.948066418478864,49.12982521376448,111.41624264962005,0.8719801091196213,2022-03-21,Symptoms management,auto-greffe,2022-12-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,51,106.30306977148766,192.56556639210592,2.3845749003733507,28.667415649295762,90.59471894931644,1.450442224598866,2022-03-20,Treatment follow-up,allo-greffe,2022-03-18,Protocole 3 LAL thiotepa Bu Flu
Female,31,77.80007723540689,177.5515039057779,1.9588489191594816,24.679213646378535,74.43566987412349,1.5823149396056508,2022-09-03,Symptoms management,auto-greffe,2022-09-25,Protocole 3 LAL thiotepa Bu Flu
Female,68,96.6601561569693,159.45872641189158,2.0691722308667893,38.01464246747585,77.37090270691223,1.2493088845444449,2022-10-24,Cancer diagnosis,allo-greffe,2022-02-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,45.60558357483547,190.29849033520946,1.5526566574340517,12.593525660529371,109.39474436128211,0.5037421783042869,2022-03-09,Treatment follow-up,greffe haplo-identique,2022-06-30,Protocole 3 LAL thiotepa Bu Flu
Female,63,73.2690662376524,150.52715168894463,1.7503161498285607,32.336347926097936,121.29617413076379,0.6459989063877325,2022-10-08,Symptoms management,pas de greffe,2022-07-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,31,68.04003320998658,164.8602920883108,1.7651801724766383,25.034123304143005,127.92673352215022,0.8051878402601016,2022-08-08,Cancer diagnosis,allo-greffe,2022-09-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,52.33055384083298,141.12686067140237,1.432290975709172,26.274591302651764,112.90986492371665,0.5600285909507909,2022-10-06,Treatment follow-up,allo-greffe,2022-11-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,49,91.69990613841131,177.327168249458,2.1253028989525213,29.162069016455487,88.77260210635575,1.3055660162088931,2022-12-24,Treatment follow-up,pas de greffe,2022-09-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,39,114.45658107266281,198.2685544396354,2.510707120147839,29.116092375912768,75.07110978082919,2.1387341804044206,2022-12-24,Treatment follow-up,greffe haplo-identique,2022-12-22,Protocole 3 LAL thiotepa Bu Flu
Male,41,106.13786293164227,170.00829190839622,2.2388189336627162,36.722321710315846,78.7318321969573,1.853628417612872,2022-08-03,Cancer diagnosis,allo-greffe,2022-11-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,99.990000184434,198.08718949064652,2.345606893375581,25.48260303322609,98.64824410195236,1.6752579005261554,2022-11-01,Symptoms management,greffe haplo-identique,2022-03-29,Protocole 3 LAL thiotepa Bu Flu
Male,69,91.52861622693557,143.93731987263254,1.9129953034265872,44.178409138457795,118.99304555919883,0.7585097517409369,2022-01-18,Symptoms management,auto-greffe,2022-04-28,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,79,55.448688225179055,181.43220297911438,1.671673949551792,16.84467082672812,77.22359089100357,0.6083291428878136,2022-10-05,Symptoms management,pas de greffe,2022-09-18,Protocole 3 LAL thiotepa Bu Flu
Female,57,79.00748940402373,185.45788390608675,2.0174627765809383,22.970881494494623,123.40672007863655,0.7380317539023444,2022-03-14,Symptoms management,pas de greffe,2022-09-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,54,108.0373497829024,170.09949214716855,2.2593692784465875,37.33944755714811,83.6228721210514,1.5431736433769656,2022-12-14,Treatment follow-up,greffe haplo-identique,2022-07-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,67.62659220909588,163.59331556253164,1.7530337544827557,25.268903364392532,83.60357050494514,1.0897626415592518,2022-08-14,Symptoms management,pas de greffe,2022-09-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,64.64006593710951,187.68540651835906,1.8357557520889751,18.35019907205642,97.44869990614782,0.5804085405905203,2022-04-25,Treatment follow-up,auto-greffe,2022-09-09,Protocole 3 LAL thiotepa Bu Flu
Male,69,88.58500745635187,141.5019735545592,1.8659934338352924,44.24204894562967,89.66252605374426,0.9742605297357817,2022-10-02,Treatment follow-up,auto-greffe,2022-07-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,119.54108164178251,144.8768047773028,2.193344094951065,56.95337471107407,134.20721818898443,0.8041224122964363,2022-04-24,Symptoms management,greffe haplo-identique,2022-05-22,Protocole 8 Aplasie medullaire thymo
Male,46,100.2446771181234,188.50962347737268,2.291111225969486,28.209427304171335,120.14162416906304,1.0893393195872887,2022-12-26,Cancer diagnosis,allo-greffe,2022-10-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,84.47670836764081,162.9487541852673,1.9554322047240615,31.815217338269672,85.4524108467057,1.3318395308616287,2022-01-25,Symptoms management,pas de greffe,2022-08-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,53,60.75175503391847,155.1578484377931,1.6181360676101184,25.235466143917986,93.11044002656877,0.7884010712981055,2022-07-14,Treatment follow-up,greffe haplo-identique,2022-10-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,90.5637895010373,164.60572952338907,2.0349255131891253,33.42448241628039,100.49880301351232,1.4393255718703808,2022-08-20,Treatment follow-up,greffe haplo-identique,2022-07-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,52,88.1244837435571,145.0263521342764,1.8841718200610955,41.89891138526667,93.03330503998116,1.1577327313798962,2022-06-18,Cancer diagnosis,pas de greffe,2022-07-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,60,50.836251497628766,175.6642821513408,1.5749879740807178,16.474285535103487,108.30917629957156,0.5215137425662207,2022-07-20,Symptoms management,greffe haplo-identique,2022-02-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,89.53896637607662,144.44158952350637,1.895400179649281,42.91682236748059,110.8736619058133,0.6954131170425527,2022-09-23,Treatment follow-up,auto-greffe,2022-04-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,64,81.6254119593194,171.7731396813024,1.9735088104715661,27.66399379839387,131.18183710187958,0.6567994394014777,2022-10-02,Cancer diagnosis,auto-greffe,2022-08-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,56,99.58297024984182,151.75172117449884,2.048840263761863,43.243200036500745,117.64970692837915,0.9875088939139902,2022-01-11,Symptoms management,greffe haplo-identique,2022-10-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,43.360841087469886,156.04485017055853,1.3709522188330387,17.807330398226835,96.22337053533717,0.45062691990763315,2022-07-09,Cancer diagnosis,greffe haplo-identique,2022-12-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,30,66.10218320780125,193.1770701247977,1.8833647549691221,17.71351109330004,120.77378994280747,0.8361867803875142,2022-03-31,Treatment follow-up,pas de greffe,2022-10-04,Protocole 3 LAL thiotepa Bu Flu
Female,33,57.674910638334254,188.54828708600976,1.7380149603544048,16.223395200569637,76.38004443367036,1.1221690975370147,2022-11-15,Treatment follow-up,allo-greffe,2022-10-20,Protocole 3 LAL thiotepa Bu Flu
Male,78,109.81700337562378,159.7947555141116,2.207825803672282,43.00753441499603,98.21239463918151,0.9628585286316783,2022-12-27,Cancer diagnosis,pas de greffe,2022-05-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,34,63.17684828892961,140.92784631433753,1.5726284761406522,31.810048142738925,117.62966686596718,0.7907049510469545,2022-08-07,Cancer diagnosis,greffe haplo-identique,2022-05-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,55,87.68860444255847,180.30459397503213,2.0956739979361654,26.973019967995747,75.42496175438536,1.3725067500953294,2022-06-21,Symptoms management,allo-greffe,2022-08-19,Protocole 3 LAL thiotepa Bu Flu
Female,29,82.74361050623185,191.24758259145693,2.096592174366001,22.622602195533926,128.35022312139878,0.9938671168218629,2022-02-28,Treatment follow-up,pas de greffe,2022-09-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,75.19490953354429,193.31492992601733,2.0094428931692545,20.12137469422846,82.30194555705721,1.154748044134207,2022-01-20,Treatment follow-up,allo-greffe,2022-09-25,Protocole 3 LAL thiotepa Bu Flu
Male,54,107.00108138215376,185.8055298629978,2.350023204502743,30.993519554129957,100.38306139482452,1.2731913674536608,2022-03-25,Symptoms management,pas de greffe,2022-05-18,Protocole 3 LAL thiotepa Bu Flu
Female,26,95.34907051744517,154.70139499539272,2.024203150526347,39.840795741130066,102.84140686382506,1.4679822676144825,2022-04-13,Treatment follow-up,pas de greffe,2022-03-08,Protocole 6 FlUDARABINE cy (Fanconi)
Female,32,57.32233232674113,176.89576551769503,1.6782992265814973,18.318460763113702,81.53064338095446,1.054615723910716,2022-10-24,Cancer diagnosis,allo-greffe,2022-08-25,Protocole 3 LAL thiotepa Bu Flu
Female,78,44.255863336694986,193.03679427589012,1.5404734108588807,11.87655881733433,88.67217322487119,0.42977649317783784,2022-04-10,Cancer diagnosis,allo-greffe,2022-12-22,Protocole 3 LAL thiotepa Bu Flu
Male,66,47.767501847239785,186.40771999072825,1.5727038914801819,13.746898943199646,82.60321708592777,0.5943397682378606,2022-12-25,Treatment follow-up,greffe haplo-identique,2022-11-06,Protocole 3 LAL thiotepa Bu Flu
Male,27,78.07446409429294,150.59896848628566,1.8072334410578494,34.424292041927934,126.8911461050873,0.9656586585189075,2022-12-14,Cancer diagnosis,auto-greffe,2022-01-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,45,86.79355518884117,192.30625258508863,2.1532238973031887,23.469328730707126,96.28758865184987,1.189346164037504,2022-12-25,Symptoms management,allo-greffe,2022-04-03,Protocole 3 LAL thiotepa Bu Flu
Male,38,73.38501794680792,154.65670580078012,1.7755660389158252,30.681027074031103,110.59955364791202,0.9399866936980226,2022-01-04,Symptoms management,pas de greffe,2022-08-23,Protocole 6 FlUDARABINE cy (Fanconi)
Male,28,109.95371495373038,178.14402795974792,2.332594982643645,34.64713846240665,106.69535355450832,1.603060549987935,2022-08-13,Symptoms management,greffe haplo-identique,2022-02-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,80.83337669255934,176.22799517981093,1.9892142445185756,26.028007307280088,99.43571612741565,1.0387323233851078,2022-09-10,Cancer diagnosis,allo-greffe,2022-09-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,109.73278411011728,171.68503566847392,2.2876162359021013,37.22815488268381,126.04790148759267,0.979384667788646,2022-09-17,Symptoms management,auto-greffe,2022-11-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,75,53.65037060847538,155.34144248519607,1.5215239035061316,22.23299954232343,101.1599841830103,0.4787897383144125,2022-08-05,Treatment follow-up,auto-greffe,2022-04-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,29,54.86766649789619,140.2357436206033,1.4619629129719678,27.899668732427298,92.39266593328216,0.9155234526804509,2022-06-09,Cancer diagnosis,pas de greffe,2022-10-29,Protocole 6 FlUDARABINE cy (Fanconi)
Male,37,101.70169061243367,144.84269287000183,2.0228381284264305,48.47691692233644,86.74671418766061,1.6771807425497236,2022-11-09,Treatment follow-up,greffe haplo-identique,2022-05-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,48,102.685069834773,168.11902706422998,2.1898321875485083,36.330683362220206,83.57292782790317,1.5699904712519173,2022-02-22,Cancer diagnosis,pas de greffe,2022-07-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,117.8473605904545,153.15235075038973,2.239084653265267,50.24264860262212,115.33328244038188,1.461739342131181,2022-04-06,Treatment follow-up,auto-greffe,2022-08-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,29,118.98310624684969,186.72740829414275,2.484250784680076,34.1247252874177,134.72931125954437,1.3614876160382068,2022-01-27,Symptoms management,allo-greffe,2022-12-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,114.34069773400759,147.36927285434737,2.16347877546014,52.648615710752274,100.93547556835804,1.3058779849320927,2022-01-23,Treatment follow-up,allo-greffe,2022-10-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,39,104.0085002476651,198.73206861839404,2.3961673337108826,26.33497605201959,120.03666447270933,1.2154687360593066,2022-02-28,Symptoms management,greffe haplo-identique,2022-04-07,Protocole 3 LAL thiotepa Bu Flu
Male,44,108.62573643053074,168.28606931990367,2.2534047209398174,38.35627294554016,128.0018321774193,1.131501891628843,2022-11-21,Symptoms management,pas de greffe,2022-10-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,25,100.99758804784777,142.83567188723646,2.0018087895565198,49.503697518795754,119.98666562531055,1.3444459947292617,2022-09-21,Treatment follow-up,auto-greffe,2022-08-31,Protocole 8 Aplasie medullaire thymo
Female,20,72.40038841943161,149.31161930944575,1.7328700689846388,32.475338397021595,103.86097543860282,1.1618157207055908,2022-12-04,Cancer diagnosis,allo-greffe,2022-07-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,33,50.533037065057194,194.4212880484225,1.6519935898438904,13.368656618486375,93.06137724782141,0.8069696589658967,2022-09-08,Treatment follow-up,auto-greffe,2022-12-09,Protocole 3 LAL thiotepa Bu Flu
Male,70,103.42466913117477,197.5913343036441,2.382565049452523,26.490390006906892,89.67644037411773,1.1212728921422475,2022-08-04,Symptoms management,auto-greffe,2022-07-11,Protocole 3 LAL thiotepa Bu Flu
Male,68,76.02219742025014,175.48055923111934,1.9250121007761116,24.68780049707401,74.23642770744584,1.0240551676306642,2022-05-13,Cancer diagnosis,pas de greffe,2022-12-19,Protocole 3 LAL thiotepa Bu Flu
Male,58,115.8226011956282,198.3678145371858,2.526277249739713,29.434109217364803,107.43908570938234,1.2277568513633643,2022-09-14,Treatment follow-up,allo-greffe,2022-12-05,Protocole 3 LAL thiotepa Bu Flu
Female,24,65.39388678462981,147.86590880508757,1.638895842709886,29.908941091233125,127.8916319754305,0.8237975852689052,2022-12-12,Treatment follow-up,pas de greffe,2022-04-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,26,62.19318626067279,149.32584177881702,1.6061556838960505,27.89156374620401,88.98871956429846,1.106573343170546,2022-10-20,Cancer diagnosis,greffe haplo-identique,2022-01-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,99.66920628658607,178.86195987196476,2.2252983305179765,31.154804429685075,130.54001445688152,1.1558762620750043,2022-09-08,Cancer diagnosis,auto-greffe,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,80.06928554670375,161.13865275366402,1.8931350248217216,30.83660067188708,95.54830224466795,0.8612757153624662,2022-02-16,Symptoms management,allo-greffe,2022-12-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,21,98.74400385947698,186.57588616420992,2.2622045555094705,28.36610504906252,131.66745956270233,1.239500601057979,2022-04-16,Cancer diagnosis,greffe haplo-identique,2022-01-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,86.43043495300549,148.84115888707439,1.8903560879662062,39.01401197484024,96.00216026998238,1.3754534009809916,2022-05-03,Cancer diagnosis,allo-greffe,2022-11-19,Protocole 6 FlUDARABINE cy (Fanconi)
Male,54,56.97611935883096,157.7863320758758,1.5802648239339891,22.885167998419096,85.30204808252239,0.7978097919562498,2022-05-15,Treatment follow-up,pas de greffe,2022-05-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,79.39248400863684,188.29250464180845,2.0377690458849678,22.393053899077017,74.1269964965935,1.0264069426461486,2022-07-12,Treatment follow-up,pas de greffe,2022-10-19,Protocole 2 LAM Endoxan TBI
Male,32,73.30775786563422,143.44210203416654,1.7090786084627814,35.62842752454243,134.1658197201578,0.8195950133037505,2022-07-23,Symptoms management,greffe haplo-identique,2022-07-06,Protocole 8 Aplasie medullaire thymo
Male,31,84.85148723817635,174.27012514037443,2.026702254302669,27.939174664982954,130.325082412068,0.9856561864999642,2022-07-02,Symptoms management,greffe haplo-identique,2022-02-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,111.98733312514787,148.0312722865535,2.145902257954147,51.10483128444399,94.97840970224837,1.784999136603217,2022-07-23,Treatment follow-up,pas de greffe,2022-09-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,29,45.33554265079666,161.24720062152764,1.4249979864604518,17.43630475512928,104.51073795012579,0.6687570702383895,2022-08-13,Cancer diagnosis,auto-greffe,2022-11-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,116.96301342006467,173.17904589822768,2.3720328289294397,38.99939443830188,108.17578220899603,1.6368636566500614,2022-09-29,Symptoms management,allo-greffe,2022-03-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,40.57909434773208,168.95332062036545,1.38001335921638,14.215720839251214,99.70690393818609,0.5878654844955051,2022-02-07,Cancer diagnosis,allo-greffe,2022-02-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,82.16785733062203,159.5545223197419,1.9083335681531224,32.27629869835449,118.97672935092214,1.0934836429771397,2022-10-27,Cancer diagnosis,allo-greffe,2022-02-08,Protocole 6 FlUDARABINE cy (Fanconi)
Male,47,94.77352187927892,181.46342861592925,2.1856811944906798,28.78119322477517,86.50515720374,1.415127179131651,2022-09-07,Symptoms management,auto-greffe,2022-10-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,87.3688176327488,199.27989360236032,2.1991695833009715,22.000345091950273,119.15877525742198,0.7943145792746178,2022-04-04,Cancer diagnosis,auto-greffe,2022-08-06,Protocole 3 LAL thiotepa Bu Flu
Female,67,46.0324187121186,193.9755477316774,1.5749041975357954,12.23403788918639,124.83945908166017,0.37385421407801056,2022-12-13,Cancer diagnosis,allo-greffe,2022-06-09,Protocole 3 LAL thiotepa Bu Flu
Female,48,87.5418278598408,155.5353590484202,1.9447828804790162,36.1873964377079,126.11027884088199,0.8869935368748868,2022-12-18,Cancer diagnosis,pas de greffe,2022-04-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,42,55.28895689473026,183.40236228181845,1.6783031528725643,16.437226739963343,122.15223500886788,0.6160707050975973,2022-04-28,Symptoms management,auto-greffe,2022-08-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,86.32322267460081,183.358804235326,2.0968311334113054,25.675807395313022,120.80673353631263,0.932893056846112,2022-09-04,Treatment follow-up,auto-greffe,2022-06-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,115.43458802254433,142.4626795027633,2.137308842458799,56.876614841119476,79.31756977989988,1.8393969154628875,2022-04-14,Cancer diagnosis,auto-greffe,2022-02-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,71,42.99934835422138,178.6873870120555,1.4609206762857292,13.467099777538502,89.92997485334752,0.4582199528762379,2022-06-05,Cancer diagnosis,auto-greffe,2022-04-17,Protocole 3 LAL thiotepa Bu Flu
Male,74,108.37958025665498,160.94482835723073,2.2012075563348334,41.84016731742812,96.97775927652037,1.0244405450256044,2022-01-07,Symptoms management,pas de greffe,2022-01-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,49,98.02543847755709,157.0729611263547,2.0680872729931985,39.73158873670415,131.2934737335324,0.943636107699414,2022-07-05,Symptoms management,auto-greffe,2022-12-30,Protocole 6 FlUDARABINE cy (Fanconi)
Male,54,88.92473331307447,156.33982095702981,1.965146084816999,36.38173036687679,82.30946820965401,1.2904427156418885,2022-06-28,Cancer diagnosis,allo-greffe,2022-08-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,87.29347557185463,148.75586559215537,1.8992261961738601,39.44878088042605,88.27225658533625,1.6069816643594015,2022-01-07,Treatment follow-up,greffe haplo-identique,2022-04-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,79,111.06435871841072,181.1063096872323,2.363757375290824,33.86160589822201,104.76756990249734,0.8981423630486918,2022-12-04,Symptoms management,auto-greffe,2022-05-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,105.8874102390812,162.12639779379518,2.1837241630969215,40.28439630141843,93.86826262234149,1.613727779221246,2022-08-16,Treatment follow-up,pas de greffe,2022-12-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,74,56.14045093283408,151.70293257274244,1.5380968617875979,24.39427662028436,92.06907564764464,0.5589507623462395,2022-11-11,Treatment follow-up,auto-greffe,2022-06-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,32,115.79456951779066,170.2953382074423,2.3404222896862814,39.92847043081573,95.23492814495218,1.8238251202575444,2022-09-27,Treatment follow-up,allo-greffe,2022-10-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,59.55900658209771,172.73394381847754,1.6904849811055538,19.961449189627665,113.49001571495299,0.6195497961729618,2022-03-31,Cancer diagnosis,auto-greffe,2022-12-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,78.22439133855809,195.2915804075244,2.059973368957019,20.51044828680443,81.88165979641526,1.2472425320386267,2022-09-26,Cancer diagnosis,greffe haplo-identique,2022-10-02,Protocole 3 LAL thiotepa Bu Flu
Male,47,71.11106802166721,141.72483431542884,1.673171002531485,35.40342556186398,98.46668855931298,0.932821013264045,2022-07-21,Cancer diagnosis,greffe haplo-identique,2022-06-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,44,116.85227555645565,181.57514210664507,2.427702877415894,35.44250332020559,132.56143885754733,1.1753269685213863,2022-10-17,Symptoms management,allo-greffe,2022-12-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,46.49603358338729,189.58431672346103,1.564796646111775,12.936330156569483,99.68857122012626,0.5247144897463447,2022-03-20,Treatment follow-up,auto-greffe,2022-10-18,Protocole 3 LAL thiotepa Bu Flu
Male,61,68.78861295845002,174.02327600367363,1.8235206925964085,22.714431538633075,104.52940943731578,0.7220589418819646,2022-03-08,Cancer diagnosis,auto-greffe,2022-09-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,103.25891830713402,162.9119535061753,2.161668086503631,38.906455627421856,100.90154002375614,1.705605257739754,2022-01-12,Cancer diagnosis,auto-greffe,2022-08-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,43,55.305038908550294,182.2168386619214,1.6731133115634222,16.65665102497686,98.93923318299338,0.7530700918275438,2022-07-06,Symptoms management,allo-greffe,2022-04-22,Protocole 3 LAL thiotepa Bu Flu
Male,68,92.7548153568073,192.67560554853068,2.2280777849237743,24.985209772347833,104.2040767513427,0.8901265502130379,2022-02-07,Treatment follow-up,pas de greffe,2022-07-08,Protocole 3 LAL thiotepa Bu Flu
Male,74,112.27712938474183,191.8177511824018,2.445900565106436,30.515023596419667,131.61361280482538,0.7819913133806167,2022-11-08,Cancer diagnosis,allo-greffe,2022-02-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,69.14282424161948,155.60965351445574,1.7287833650069666,28.55446605144462,76.57310913996123,1.1412472118070822,2022-09-22,Treatment follow-up,greffe haplo-identique,2022-02-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,66.18837700514501,145.76398261005912,1.6370604952819479,31.151666193335803,125.1630758705048,0.8519831338255702,2022-02-24,Symptoms management,allo-greffe,2022-03-29,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,32,41.25975753203603,140.56459257923296,1.2692584238453508,20.882130002759943,131.9768909342069,0.46894297827418335,2022-01-19,Cancer diagnosis,greffe haplo-identique,2022-05-03,Protocole 9 LAL thiotepa-thymo melphalan
Female,43,88.95147857577882,192.79542251876754,2.182597706587673,23.93093872136044,94.80384764783804,1.2640563817827912,2022-02-21,Cancer diagnosis,greffe haplo-identique,2022-12-01,Protocole 3 LAL thiotepa Bu Flu
Female,54,66.80920506221881,187.99378799092352,1.8678356110979908,18.9038083920702,119.86954180683473,0.6657227734540891,2022-07-04,Symptoms management,auto-greffe,2022-11-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,28,82.85827982291892,178.39953277818068,2.0263458084287596,26.03445481668961,97.57106258392386,1.3209926600056805,2022-04-05,Symptoms management,allo-greffe,2022-02-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,89.65986068155019,192.40412302045507,2.189046397189237,24.219730769068747,115.33091367028574,1.0473493437922368,2022-02-06,Treatment follow-up,pas de greffe,2022-04-27,Protocole 3 LAL thiotepa Bu Flu
Female,72,107.89786770415466,188.43978834359254,2.376520060514244,30.38558812023888,115.51423173746493,0.8821730464536343,2022-12-15,Cancer diagnosis,allo-greffe,2022-05-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,112.61304628525744,168.1970767366249,2.293782973579922,39.80630072995298,106.4959010990391,1.218993556613762,2022-12-07,Cancer diagnosis,auto-greffe,2022-07-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,94.57606873113872,188.99163143385837,2.2282333263583647,26.478666495881765,111.94837833811059,1.372830173778239,2022-02-22,Cancer diagnosis,pas de greffe,2022-06-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,112.50691710716862,148.96899969671412,2.157676405844442,50.69760242257218,93.00453506060745,1.7641353439489216,2022-11-28,Symptoms management,greffe haplo-identique,2022-01-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,75,49.04017008798664,144.33319959409235,1.4021931886074452,23.54070632005336,86.59992220047712,0.5112288169426659,2022-01-05,Symptoms management,auto-greffe,2022-02-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,35,81.08818463590647,160.74755061332684,1.9028288198760497,31.381149622031,132.80992357142196,0.8903973394008947,2022-03-16,Treatment follow-up,allo-greffe,2022-03-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,35,64.79295992883814,195.59703083383275,1.8762633211471917,16.935705944944722,83.55068624128069,1.1309270752927723,2022-09-01,Symptoms management,auto-greffe,2022-10-24,Protocole 2 LAM Endoxan TBI
Female,42,60.345209063812035,153.18704052757295,1.6024377251292825,25.71572331000864,95.20336106319975,0.8627482647860721,2022-04-12,Cancer diagnosis,allo-greffe,2022-07-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,51,112.85360090928036,194.2838235385197,2.4678842200436226,29.897999980063055,86.45392536474931,1.6135714997822408,2022-01-19,Treatment follow-up,auto-greffe,2022-09-25,Protocole 3 LAL thiotepa Bu Flu
Male,44,117.13786975404271,187.61656046503006,2.4707738454589356,33.277828713818664,110.88591433075825,1.4085091626051582,2022-01-22,Treatment follow-up,greffe haplo-identique,2022-07-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,82.08748715057982,158.373460748778,1.9003274150793779,32.7274484463027,134.81030404130283,0.786510138500594,2022-06-26,Cancer diagnosis,auto-greffe,2022-11-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,48,83.63924924924699,178.15917968673932,2.034501033277131,26.350794685294034,104.33431613455346,1.0243262044568142,2022-02-06,Cancer diagnosis,greffe haplo-identique,2022-04-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,32,69.4602983093171,148.540403897091,1.6929314455568212,31.48092199106288,106.76829486067874,0.975855684498222,2022-02-13,Symptoms management,pas de greffe,2022-09-09,Protocole 6 FlUDARABINE cy (Fanconi)
Female,55,47.4510903341032,171.45921785936875,1.50332287831357,16.140780054356696,108.67912596613391,0.5154499340429949,2022-05-27,Cancer diagnosis,pas de greffe,2022-10-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,68.30958085063321,167.54366736739,1.7830091365787846,24.33467696593189,131.89859628591535,0.6042104558842489,2022-01-22,Cancer diagnosis,auto-greffe,2022-06-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,78,59.263180683761114,150.6045986441282,1.5745640967557668,26.128139760360895,115.58811608001692,0.4415002605565833,2022-03-13,Cancer diagnosis,auto-greffe,2022-12-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,39,103.05615900141586,164.3009599263853,2.1687314424603934,38.17629256792438,127.23188839796231,1.1362315810179766,2022-02-04,Cancer diagnosis,pas de greffe,2022-07-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,118.78920588932641,180.6866736763611,2.4417449635227166,36.38519722060527,129.14238867685316,1.1753399412880445,2022-02-25,Cancer diagnosis,pas de greffe,2022-12-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,31,103.48386288037301,174.46917062313176,2.2394656933206543,33.99658068776626,88.45111404763556,1.771182555253366,2022-05-15,Symptoms management,auto-greffe,2022-03-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,25,61.876825694053316,169.91450661440126,1.7089446311710739,21.43221753130459,111.3468131607716,0.8875964945347167,2022-08-26,Treatment follow-up,auto-greffe,2022-02-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,54,104.60902979515473,163.42012082087703,2.1791448557276185,39.17041021191356,87.86567121115858,1.422053377106369,2022-12-18,Symptoms management,allo-greffe,2022-01-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,50.3864741842912,157.38413909660702,1.4841787723264568,20.341924773758567,99.30411644586383,0.5708200776171208,2022-12-09,Symptoms management,auto-greffe,2022-10-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,82.29468019952915,154.54109698678468,1.8795618693233822,34.45750124362494,108.83926214067837,1.218180563218311,2022-09-09,Treatment follow-up,greffe haplo-identique,2022-09-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,29,74.43797147601737,185.7983266973497,1.9600489324241281,21.563086881485617,83.57870488242907,1.3730595553052898,2022-01-19,Cancer diagnosis,greffe haplo-identique,2022-08-03,Protocole 3 LAL thiotepa Bu Flu
Female,51,108.11352992038655,163.02397258624572,2.212659105261219,40.67964025254157,131.90704669139518,1.0131402297914633,2022-04-16,Cancer diagnosis,allo-greffe,2022-09-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,66,47.532632859799435,195.09068760503013,1.6049553496987352,12.488744822826842,100.50738464169368,0.48606362554086263,2022-04-28,Treatment follow-up,auto-greffe,2022-11-19,Protocole 3 LAL thiotepa Bu Flu
Male,50,91.62365797961965,174.02633739034593,2.1045538994509387,30.25364221561415,109.15896285414019,1.0491998960045146,2022-11-24,Treatment follow-up,allo-greffe,2022-08-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,54.62535536368505,189.3593225229755,1.695076226100187,15.234243501818796,115.41567478611104,0.5061598689065288,2022-02-22,Cancer diagnosis,allo-greffe,2022-05-14,Protocole 3 LAL thiotepa Bu Flu
Female,49,103.4817744878959,168.33186514934354,2.199702006870683,36.520035942132466,104.61641723582437,1.2501810751455402,2022-11-09,Cancer diagnosis,auto-greffe,2022-07-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,76.55190700700622,198.95541850601307,2.0568595733418134,19.339465674533848,125.65327306649502,0.5753851174742939,2022-02-05,Cancer diagnosis,pas de greffe,2022-08-22,Protocole 3 LAL thiotepa Bu Flu
Female,78,111.54804690164006,165.0840075237961,2.2616856185631344,40.930963167354776,86.53786728219377,1.1099795456769959,2022-12-17,Treatment follow-up,pas de greffe,2022-08-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,98.88170496201028,145.44839609976282,1.9987624914719353,46.741007899215084,110.82615904963555,0.8674395265492503,2022-09-17,Cancer diagnosis,allo-greffe,2022-12-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,73,83.34965600926878,165.83744126866503,1.959485028946845,30.306698961429714,88.09329285560214,0.8804471139500283,2022-02-12,Cancer diagnosis,auto-greffe,2022-05-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,72.88032249009774,186.026672920627,1.940624463801338,21.06007182939241,117.89312170313434,0.6954634979283965,2022-02-03,Cancer diagnosis,allo-greffe,2022-03-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,50.05333875560639,167.27966509575424,1.5250597205029721,17.887380742873745,115.59586520765978,0.4630724893309768,2022-07-14,Treatment follow-up,auto-greffe,2022-06-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,29,106.53125261375457,194.43988206562895,2.3987221247597046,28.177751553730698,126.40126365609333,1.2993199305326284,2022-04-15,Treatment follow-up,pas de greffe,2022-04-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,115.03697522819024,167.74100820578997,2.315192468944184,40.88452494526365,112.9640335630504,1.4850944167771325,2022-03-17,Symptoms management,allo-greffe,2022-02-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,47.55347227092625,150.94299638790483,1.4120378883434508,20.871626763726784,103.16300674399454,0.7042363390200639,2022-03-01,Symptoms management,allo-greffe,2022-09-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,45,110.07982925206483,150.7843137659444,2.1472405750200605,48.416726116701504,90.62323974870935,1.6027259625100583,2022-03-11,Symptoms management,allo-greffe,2022-05-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,29,60.866138803688045,142.64157052954195,1.552957897317528,29.914622602753116,79.53099222560954,1.1798582501795667,2022-07-03,Symptoms management,greffe haplo-identique,2022-11-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,56,47.54564105333502,157.38096354036762,1.4417176099976416,19.195804029576813,98.35488551794225,0.563977216486162,2022-05-14,Symptoms management,auto-greffe,2022-10-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,58.7850558530016,173.30025010586172,1.6822162037202448,19.573502975124082,90.16555292897814,0.6972435631584101,2022-01-01,Symptoms management,auto-greffe,2022-11-06,Protocole 3 LAL thiotepa Bu Flu
Male,63,47.18534365415352,186.60037293430693,1.5638985050630576,13.551335814615511,93.35277200076735,0.5405528143258737,2022-12-27,Treatment follow-up,pas de greffe,2022-01-19,Protocole 3 LAL thiotepa Bu Flu
Female,30,57.19152542131652,140.16587456464805,1.4922298916540542,29.110327940210215,86.97563363724518,1.004602530179023,2022-12-06,Treatment follow-up,greffe haplo-identique,2022-04-09,Protocole 6 FlUDARABINE cy (Fanconi)
Female,74,44.70657892103033,175.39416714244214,1.4758493953240372,14.532527205618447,113.64107005757648,0.3606181344196074,2022-07-14,Cancer diagnosis,allo-greffe,2022-04-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,71.41902552105228,142.19525166122995,1.6795705723790295,35.32187357425253,128.9413097704481,0.7385171403247808,2022-12-02,Treatment follow-up,auto-greffe,2022-03-30,Protocole 8 Aplasie medullaire thymo
Male,71,112.7627176569801,171.44421685978335,2.3173569606870994,38.36364414381037,113.44899052772561,0.9525362066710467,2022-01-05,Treatment follow-up,greffe haplo-identique,2022-08-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,46.99439755151207,175.3579815155449,1.5129847888980008,15.282521338637041,122.88979280091198,0.4673911127871753,2022-03-29,Cancer diagnosis,auto-greffe,2022-11-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,50,56.80824725748754,153.64236229107263,1.557076436632281,24.06519793288582,127.37842177786236,0.5574751836358567,2022-12-13,Treatment follow-up,greffe haplo-identique,2022-06-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,70,59.154722814534296,195.279078236538,1.7913123482643918,15.512364137047248,88.3893279401408,0.6506615381059826,2022-08-07,Cancer diagnosis,greffe haplo-identique,2022-04-16,Protocole 2 LAM Endoxan TBI
Male,65,76.07777362451964,152.24720799486764,1.7937103557213077,32.82155256238196,124.39848062718487,0.6370470158423831,2022-10-02,Symptoms management,greffe haplo-identique,2022-07-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,76.11585222481524,191.51925880335642,2.0122990997918015,20.751534163031433,103.51366586972514,0.7046833649376993,2022-03-06,Treatment follow-up,allo-greffe,2022-05-21,Protocole 3 LAL thiotepa Bu Flu
Female,77,116.41491574794789,162.88068635731707,2.2950273164227015,43.88028571889199,96.89987206695375,1.051219667339409,2022-08-06,Symptoms management,auto-greffe,2022-05-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,75.13397337984335,184.50661423669322,1.9623338600917088,22.07051553250767,108.04498748957465,0.6277873976339217,2022-12-31,Treatment follow-up,allo-greffe,2022-04-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,101.23181928326852,157.7478915639621,2.1061488057536866,40.68084032408991,129.3979754470316,0.7280008169185196,2022-10-01,Treatment follow-up,auto-greffe,2022-12-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,72,90.19281808279041,194.0301423127172,2.2048006541401652,23.9570617498577,128.65691046211793,0.6620872960583105,2022-07-27,Symptoms management,greffe haplo-identique,2022-10-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,106.2208147229262,185.2247432318596,2.337776907717918,30.960760890420588,88.18107623771778,1.238036521751797,2022-05-15,Treatment follow-up,allo-greffe,2022-09-17,Protocole 3 LAL thiotepa Bu Flu
Male,31,67.72545063892512,159.1218673702846,1.7301734156950055,26.74805268055553,101.97406024977771,1.0054400792331415,2022-09-27,Cancer diagnosis,greffe haplo-identique,2022-09-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,99.3309324855293,162.41686930137166,2.1169303693402117,37.65496451682645,78.55000686300275,1.3523730697236844,2022-04-21,Symptoms management,allo-greffe,2022-08-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,83.87716497802325,189.43238267965506,2.100862998217205,23.374121614138073,120.99833679581909,0.6643255207679551,2022-11-15,Symptoms management,greffe haplo-identique,2022-09-25,Protocole 3 LAL thiotepa Bu Flu
Female,53,62.46317918385088,195.76601647118395,1.8430174356313576,16.298569070918198,112.00931652104605,0.6738398542021115,2022-08-12,Treatment follow-up,pas de greffe,2022-02-10,Protocole 3 LAL thiotepa Bu Flu
Female,30,79.8165616617024,189.2008889194247,2.0481268147102236,22.29701213906846,89.58849405955444,1.3611342671338695,2022-07-19,Treatment follow-up,greffe haplo-identique,2022-05-09,Protocole 3 LAL thiotepa Bu Flu
Male,41,62.04408378040814,164.72780307600377,1.6849320473447842,22.8647555574219,114.52124987344504,0.7449326242276967,2022-12-18,Cancer diagnosis,pas de greffe,2022-06-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,60,118.86928817358611,192.84026762658496,2.523378761368706,31.96496336011621,123.2366542588081,1.0717346040745843,2022-09-24,Treatment follow-up,auto-greffe,2022-04-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,74.92848654357009,171.4826995785535,1.8892193528770553,25.48040560213688,102.62620046659652,0.851795810784382,2022-04-14,Treatment follow-up,allo-greffe,2022-09-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,49.24003864225778,177.7368054559448,1.5591813351173691,15.587039817362044,75.81564711260675,0.965185569531753,2022-09-28,Cancer diagnosis,pas de greffe,2022-12-23,Protocole 3 LAL thiotepa Bu Flu
Male,79,59.05078950906045,187.5954431321531,1.7541743091880777,16.779582045548953,97.4610670769113,0.5133243726170414,2022-05-01,Symptoms management,auto-greffe,2022-03-14,Protocole 3 LAL thiotepa Bu Flu
Female,46,64.42166382720156,171.92157507616727,1.7540012918245467,21.79571771493754,99.1217879073835,0.8485123491347998,2022-01-15,Treatment follow-up,pas de greffe,2022-03-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,48.103963906552764,145.19805570856616,1.39289885880595,22.81703786484913,81.0991211372085,0.8814871757866326,2022-11-16,Treatment follow-up,allo-greffe,2022-09-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,100.75105389910324,174.48978622494445,2.209828415711675,33.09097599789758,96.60860661625065,1.0428786567568171,2022-07-12,Symptoms management,pas de greffe,2022-01-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,65.65099908753027,182.27339652623346,1.8231863582616374,19.76035610571336,101.42267947444992,0.818116507285602,2022-12-07,Cancer diagnosis,allo-greffe,2022-04-05,Protocole 3 LAL thiotepa Bu Flu
Female,35,60.016282791990676,145.84076852188852,1.5592751882962688,28.217023817911706,133.16011498486077,0.6572819927969459,2022-10-17,Treatment follow-up,pas de greffe,2022-08-26,Protocole 8 Aplasie medullaire thymo
Male,27,48.24769815292424,145.33642736631086,1.395642830601544,22.841658696826762,76.10530941799308,0.9949645090784814,2022-06-24,Symptoms management,auto-greffe,2022-02-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,56.998184079902344,150.26367264278352,1.5424328252809982,25.243700613257687,113.83651415074146,0.47288533647825964,2022-05-25,Symptoms management,allo-greffe,2022-07-25,Protocole 6 FlUDARABINE cy (Fanconi)
Male,20,83.9932853166413,173.61447553005934,2.012630270338303,27.86587619015796,127.11085140824963,1.1013128093325275,2022-07-22,Treatment follow-up,auto-greffe,2022-09-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,88.32078020512215,163.6999641505939,2.0040312534524407,32.958370250820884,88.53909231720593,1.1222260713356498,2022-09-20,Cancer diagnosis,allo-greffe,2022-06-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,96.46198919556262,154.4200592863709,2.034130041351288,40.45281830037877,129.3599313625977,0.9528219820157366,2022-03-03,Treatment follow-up,pas de greffe,2022-04-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,20,106.51756536499379,180.68365383713396,2.3121648650839246,32.62747777775303,106.38994455142861,1.6686659285032883,2022-01-12,Treatment follow-up,auto-greffe,2022-04-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,51.19213755626029,176.53933398834903,1.5844229469731368,16.425564216635905,131.00623784577684,0.4721696251336826,2022-04-25,Cancer diagnosis,pas de greffe,2022-08-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,65.1759274291739,177.54273799510042,1.7928494241124704,20.67670794698646,98.91404432767888,0.5582472584885232,2022-10-27,Cancer diagnosis,greffe haplo-identique,2022-11-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,49,67.77994776444963,195.3310567757511,1.9177191910817126,17.76473078767592,115.29544355803708,0.7430156841006011,2022-06-13,Treatment follow-up,greffe haplo-identique,2022-03-24,Protocole 3 LAL thiotepa Bu Flu
Female,56,98.11150808180105,173.89969840141546,2.1769985495537734,32.44309615804642,86.24281026003096,1.3272228229844958,2022-01-27,Treatment follow-up,greffe haplo-identique,2022-06-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,57.68094288249644,143.99352872529298,1.5189252876305461,27.81931304340379,114.95955034851009,0.5853748832428751,2022-09-21,Cancer diagnosis,greffe haplo-identique,2022-07-28,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,52,76.37201683780447,195.12135103050258,2.0345495752074614,20.059710953449798,83.15158690396117,1.1225711932942994,2022-06-19,Symptoms management,auto-greffe,2022-05-29,Protocole 3 LAL thiotepa Bu Flu
Female,73,100.60545069400018,184.72364912155703,2.2720650160466236,29.483328575363387,134.23212011318753,0.6974408284956743,2022-12-30,Symptoms management,greffe haplo-identique,2022-10-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,56.308569585264664,181.5050928069315,1.6849243428777303,17.09215664773309,105.61879939893103,0.844122785754478,2022-07-20,Treatment follow-up,greffe haplo-identique,2022-04-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,77.45258246248078,177.22255250349014,1.9526580432542529,24.660275727009175,119.15723319784536,0.6048640856146493,2022-09-29,Cancer diagnosis,allo-greffe,2022-11-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,56.445531981360574,166.4332045032563,1.6154128099471525,20.377439863735912,87.03342233025221,0.6845806274643512,2022-11-25,Treatment follow-up,pas de greffe,2022-07-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,55.69756369625884,166.73693834402658,1.6061376414602346,20.034225305728583,107.65593220017976,0.5604802829203775,2022-01-22,Cancer diagnosis,pas de greffe,2022-12-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,70.46547245423639,187.62042619408146,1.9163595387139023,20.01779013347876,131.60234906004004,0.48338546451989434,2022-10-09,Cancer diagnosis,allo-greffe,2022-10-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,80.1936606142585,148.23325452531202,1.8171533984924724,36.496292665244155,89.3393704067584,0.997366188540271,2022-04-15,Treatment follow-up,pas de greffe,2022-04-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,48.00781043649585,154.86672966486424,1.4370893230445245,20.016845822641848,110.44524436043677,0.6278642007312972,2022-12-02,Treatment follow-up,auto-greffe,2022-10-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,93.75637411496862,149.13587029353212,1.9707893546327682,42.15378513158338,121.66523392529737,0.9097472199669776,2022-11-12,Treatment follow-up,greffe haplo-identique,2022-07-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,61,107.31893656841478,195.87477237927283,2.4164409246476906,27.971731510814948,119.38043207000692,0.9863653534028876,2022-03-20,Cancer diagnosis,auto-greffe,2022-11-08,Protocole 3 LAL thiotepa Bu Flu
Female,33,41.89572585083813,162.57932409443106,1.3755179621666207,15.85035858129035,86.94083538150325,0.7161387789959262,2022-05-19,Cancer diagnosis,greffe haplo-identique,2022-06-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,81.08284782294794,158.54909855814634,1.8897098859389732,32.25532628400861,127.04481022844422,0.7534570383908163,2022-06-13,Treatment follow-up,greffe haplo-identique,2022-01-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,39,43.49687440076834,147.4901753762317,1.334932544455508,19.9954814943782,82.75406753558885,0.737322655299674,2022-09-09,Treatment follow-up,pas de greffe,2022-03-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,66.1330494437336,188.2732618982529,1.8597404939974649,18.656976085866688,85.47219940936074,1.1176208933814915,2022-04-16,Symptoms management,pas de greffe,2022-04-17,Protocole 3 LAL thiotepa Bu Flu
Female,52,99.40866566914274,179.4500919184752,2.2260387208260424,30.870017394050308,88.54843531997109,1.372124530752524,2022-05-23,Symptoms management,greffe haplo-identique,2022-09-01,Protocole 3 LAL thiotepa Bu Flu
Female,61,114.75477593662697,141.72093844478835,2.1254512290047565,57.1350656034538,115.05509504950712,1.0943582308077753,2022-08-05,Cancer diagnosis,greffe haplo-identique,2022-02-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,73,103.5721817440119,149.43593608929373,2.073470382108143,46.380243877716204,99.65007189908242,0.9671811297889032,2022-03-05,Treatment follow-up,pas de greffe,2022-05-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,49,101.57531246510918,191.05741164799213,2.321799845840374,27.826615511729734,131.6470875834446,0.9751822935596267,2022-09-21,Treatment follow-up,allo-greffe,2022-06-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,73.677944341607,199.26318145726268,2.01944035101723,18.555957973064277,103.98724594154217,0.6101219042963231,2022-05-25,Cancer diagnosis,auto-greffe,2022-06-01,Protocole 3 LAL thiotepa Bu Flu
Male,24,110.2274295987444,174.69199120027486,2.3127574428165936,36.11966302875177,93.39759419859914,1.901426242287711,2022-06-06,Symptoms management,pas de greffe,2022-01-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,117.956258697012,187.1891685572155,2.4765642638998835,33.66352256032588,99.06912195085161,1.4056238086614918,2022-01-06,Symptoms management,greffe haplo-identique,2022-09-24,Protocole 3 LAL thiotepa Bu Flu
Male,78,47.29838868467371,197.54926386474057,1.6110522671228187,12.119801710375908,113.53417319164562,0.3587392842970175,2022-10-25,Treatment follow-up,auto-greffe,2022-08-27,Protocole 3 LAL thiotepa Bu Flu
Female,31,54.02282303874752,140.12331736510063,1.450082102811298,27.514172393205158,126.7233542244382,0.6453786837106831,2022-12-11,Symptoms management,greffe haplo-identique,2022-10-03,Protocole 9 LAL thiotepa-thymo melphalan
Male,76,52.88056531640832,143.02518603744622,1.4494493870417584,25.850624938680745,86.20415189758228,0.5452747450466691,2022-08-09,Treatment follow-up,allo-greffe,2022-03-08,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,66.93468740297735,167.4384131981248,1.7644197855470034,23.874871365908913,90.53716027484656,0.7393062384526041,2022-11-08,Symptoms management,pas de greffe,2022-09-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,118.4888290793019,155.99460110476656,2.265907815840692,48.69207384106729,74.41792688550849,1.680664149625554,2022-04-30,Symptoms management,auto-greffe,2022-11-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,52,74.90109317452307,147.66499261886472,1.7527969213327506,34.350499780784375,110.28102535411772,0.8301136143110873,2022-07-31,Treatment follow-up,auto-greffe,2022-06-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,27,113.5938118815299,179.38535118012197,2.379137672692972,35.30048913478879,82.82997064423313,2.152351082514198,2022-09-21,Symptoms management,greffe haplo-identique,2022-10-02,Protocole 3 LAL thiotepa Bu Flu
Female,25,101.55971995457051,180.2380182361246,2.254928100432201,31.26285868666238,111.11981289428755,1.459806648058573,2022-11-14,Cancer diagnosis,pas de greffe,2022-09-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,104.3878396168654,186.833680902133,2.3275621675096785,29.904708220257795,114.05990345394108,1.3600917028844641,2022-05-18,Treatment follow-up,auto-greffe,2022-03-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,44,81.11734216617383,156.40481900737268,1.877286991901074,33.159918339729096,97.75588980115715,1.1063932458858845,2022-11-10,Treatment follow-up,auto-greffe,2022-01-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,80.18515570646804,199.28484860605735,2.10684642003534,20.190422861642908,114.24281091922988,0.6238965357014642,2022-11-21,Treatment follow-up,greffe haplo-identique,2022-12-26,Protocole 3 LAL thiotepa Bu Flu
Male,74,68.80874400612343,165.048830790641,1.7761383475255774,25.25914967235424,94.43487703449628,0.6679172355206487,2022-08-27,Treatment follow-up,greffe haplo-identique,2022-08-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,118.69884263335035,198.4282751372354,2.557842330978389,30.14667159364698,82.73258144646722,1.2155343816523345,2022-05-16,Symptoms management,pas de greffe,2022-01-19,Protocole 3 LAL thiotepa Bu Flu
Male,75,118.29732454378646,170.50913266995227,2.3670641805325525,40.689245051252776,89.06995079662306,1.1990148732937786,2022-12-13,Treatment follow-up,pas de greffe,2022-12-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,108.05273527349429,172.9325715516242,2.2782691635703687,36.13118172058788,98.27974592681778,1.2979506175675741,2022-07-26,Treatment follow-up,allo-greffe,2022-09-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,107.39648532847741,189.21007443085227,2.375833010792282,29.99863927140575,101.6432029451956,1.7316544678886445,2022-11-12,Cancer diagnosis,allo-greffe,2022-02-04,Protocole 3 LAL thiotepa Bu Flu
Female,53,102.78617050791065,167.66121609427861,2.187924837795329,36.56532704076246,115.19939543051407,1.0781302763459981,2022-09-25,Symptoms management,auto-greffe,2022-04-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,32,107.6660014457988,191.4846476015955,2.393067902268368,29.363692304821395,121.98733448381488,1.3238997544464395,2022-06-27,Treatment follow-up,greffe haplo-identique,2022-12-27,Protocole 3 LAL thiotepa Bu Flu
Male,36,75.18077262094023,170.78544335916888,1.8885460003923171,25.775380290454066,128.2066467924236,0.8470266718478399,2022-01-13,Treatment follow-up,allo-greffe,2022-05-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,45,111.47903287631854,179.59255945724288,2.358248222261375,34.56340440055745,94.53574171466525,1.5559235896689438,2022-07-07,Cancer diagnosis,greffe haplo-identique,2022-10-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,25,64.17150591828096,193.04408143122237,1.8550179254938628,17.219845434906965,85.84589805159251,1.1939551872885534,2022-08-27,Treatment follow-up,auto-greffe,2022-08-28,Protocole 3 LAL thiotepa Bu Flu
Female,58,100.49306456087047,186.81994192973283,2.2836440473264745,28.79317951015521,124.46684200759522,0.9195254960496639,2022-01-12,Cancer diagnosis,allo-greffe,2022-07-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,44,89.26886369420357,155.69898046011738,1.9649053598937225,36.82378864109935,114.5274713052602,1.0392716283329366,2022-08-04,Symptoms management,greffe haplo-identique,2022-05-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,65.5587459623691,158.08173422497836,1.6966994311952728,26.234165516098145,115.06730763323304,0.5064378584504982,2022-06-29,Treatment follow-up,auto-greffe,2022-05-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,40,118.16951565407182,152.10307150203033,2.234449117349831,51.07748292546926,83.95202325408798,1.9549776281220246,2022-04-16,Symptoms management,allo-greffe,2022-03-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,78,47.46105458729733,192.07948362631038,1.5913215033675803,12.863982037800398,121.47996634566732,0.3364278298685117,2022-04-17,Treatment follow-up,pas de greffe,2022-07-13,Protocole 3 LAL thiotepa Bu Flu
Male,21,117.31256490537898,155.71247471028894,2.252592937781058,48.38354845533413,83.58671650168507,2.3196460926397897,2022-06-20,Cancer diagnosis,pas de greffe,2022-01-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,46.01267235316071,160.75830578627205,1.4334224053906164,17.804534195899684,127.60948429012943,0.5458690928110193,2022-11-22,Treatment follow-up,greffe haplo-identique,2022-06-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,56,119.48096851378108,161.3568485195508,2.3141516646643363,45.890620323715254,124.93687761457869,1.1157191209476185,2022-02-25,Symptoms management,auto-greffe,2022-08-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,72,45.995786390719395,153.4227519964388,1.4000793755578165,19.540627740094816,133.9489796403779,0.3243060532539773,2022-04-28,Cancer diagnosis,auto-greffe,2022-04-13,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,72,66.40766190644119,189.80525142588044,1.8711644446972446,18.43324271706905,130.83356871842508,0.4793750409045506,2022-10-19,Symptoms management,auto-greffe,2022-07-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,80.14042361970795,166.6992320089049,1.9263773622379057,28.839281469215805,106.66589187150345,0.8452371699172732,2022-07-21,Symptoms management,pas de greffe,2022-12-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,98.56902860420071,168.09426362325306,2.145336562515858,34.88467575383789,112.4666187384129,1.1198817546078843,2022-06-04,Treatment follow-up,auto-greffe,2022-04-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,92.76364832341427,188.09377822916625,2.2015313543753945,26.219774990906895,93.68611807918012,1.113922814857592,2022-10-07,Treatment follow-up,allo-greffe,2022-06-13,Protocole 3 LAL thiotepa Bu Flu
Female,70,49.3942595892689,143.50913748684877,1.4032232330580001,23.98376561350948,132.66999167287648,0.36196728602582817,2022-03-19,Symptoms management,allo-greffe,2022-05-21,Protocole 8 Aplasie medullaire thymo
Female,60,66.40034323822368,165.34558348225653,1.746345668352616,24.287629333288212,132.26687072855032,0.5577977217363514,2022-08-25,Symptoms management,greffe haplo-identique,2022-11-25,Protocole 6 FlUDARABINE cy (Fanconi)
Male,48,109.44751813328332,178.83581070305132,2.3317337156670592,34.22133456842546,117.99581618163829,1.1852081796557992,2022-10-16,Cancer diagnosis,pas de greffe,2022-02-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,69.5643748807065,176.80728011992167,1.8483842731108218,22.25289917452042,100.16007771521376,0.8199335614302655,2022-12-19,Treatment follow-up,greffe haplo-identique,2022-05-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,97.650414851358,194.0496273543312,2.2942577238801776,25.932743621622222,88.34693887643594,1.243469418464242,2022-03-28,Symptoms management,auto-greffe,2022-01-17,Protocole 3 LAL thiotepa Bu Flu
Female,44,117.11751357617926,176.77786337329474,2.3981349126624427,37.47710907229564,106.48882007134114,1.4664138889286535,2022-10-24,Cancer diagnosis,auto-greffe,2022-07-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,118.57235869230249,167.45874534983233,2.3485207176116,42.283194715091824,125.00050057606727,0.843177840770304,2022-02-03,Symptoms management,greffe haplo-identique,2022-01-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,112.84213964517326,177.02044588404127,2.355570576933763,36.01011030914566,100.79142331684088,1.3217038759351107,2022-01-30,Symptoms management,greffe haplo-identique,2022-06-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,97.71438934170767,166.8107314089301,2.1278450728943814,35.116445425238844,115.34640100681034,0.9294993036693509,2022-08-06,Cancer diagnosis,greffe haplo-identique,2022-04-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,56,48.636883525889644,167.19435659234017,1.5029427105004987,17.398928781581663,106.25001449532955,0.5340519815430129,2022-04-19,Treatment follow-up,allo-greffe,2022-08-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,67.05685140747855,159.6921799569517,1.7246943998470532,26.295162480448937,122.89565446265843,0.894244220237928,2022-09-25,Symptoms management,pas de greffe,2022-01-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,61,45.92313882556532,171.9553020477907,1.4810588561840843,15.531035827376844,97.94445851420093,0.5144536934297377,2022-11-18,Cancer diagnosis,auto-greffe,2022-12-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,32,93.10224905541598,180.87144355132628,2.162787436550868,28.459034543274715,86.259058346536,1.6189995144867262,2022-09-04,Cancer diagnosis,allo-greffe,2022-04-18,Protocole 3 LAL thiotepa Bu Flu
Female,40,46.332022150181615,180.76777001613817,1.5252810601134257,14.178792741421736,132.14309435388188,0.48697233161356474,2022-10-14,Cancer diagnosis,pas de greffe,2022-02-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,40,119.22713780968361,181.12064354424635,2.4491776356808037,36.34454306101605,117.017221138347,1.415118606876816,2022-01-05,Treatment follow-up,pas de greffe,2022-11-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,60.671592352052066,158.40554585709677,1.6339043818536547,24.179350377614288,103.46909747284201,0.602662204318525,2022-09-13,Symptoms management,allo-greffe,2022-11-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,37,80.81828402596219,191.2981677978275,2.0723302543226145,22.084522014685067,99.06330941756354,1.1670824029962086,2022-05-29,Cancer diagnosis,pas de greffe,2022-06-28,Protocole 3 LAL thiotepa Bu Flu
Male,77,62.12598545167548,184.4792505963859,1.7842641837500055,18.2548487585522,112.56324990814974,0.4829305951504896,2022-06-23,Cancer diagnosis,greffe haplo-identique,2022-10-19,Protocole 3 LAL thiotepa Bu Flu
Male,29,57.51020815472154,183.7625530206355,1.7133643540690313,17.030637605550545,78.43276972966703,1.1304148917701635,2022-03-22,Treatment follow-up,auto-greffe,2022-03-07,Protocole 3 LAL thiotepa Bu Flu
Male,77,55.8447954397284,158.15113384962916,1.5663047204588156,22.327396490390488,101.5968226560433,0.4809618522735933,2022-05-29,Treatment follow-up,pas de greffe,2022-12-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,46,75.50979999489286,192.6018168563232,2.00992845847488,20.355536846634756,76.49174191434129,1.2887958414206047,2022-03-29,Treatment follow-up,auto-greffe,2022-08-06,Protocole 3 LAL thiotepa Bu Flu
Female,54,112.64140255656339,193.88423608834026,2.463026158486441,29.96491497598436,82.83207499348578,1.6242970794670835,2022-02-26,Symptoms management,greffe haplo-identique,2022-02-19,Protocole 3 LAL thiotepa Bu Flu
Male,27,92.2780377141444,171.81399606816387,2.0985880444424136,31.25944572401153,107.78333921907694,1.3436701319888757,2022-07-15,Symptoms management,pas de greffe,2022-01-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,83.19670894736684,156.04165502010594,1.8989874609302526,34.16843214692118,89.1458986126247,1.529516938052971,2022-06-12,Symptoms management,allo-greffe,2022-06-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,65,115.46538263104,169.01377021176998,2.328282607859319,40.421052682465074,97.03832763901731,1.239473547896406,2022-06-11,Cancer diagnosis,pas de greffe,2022-10-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,71.19871127343632,147.61681020371506,1.7086484789641943,32.673864195144276,122.18908809175672,0.5260421805898621,2022-01-11,Symptoms management,pas de greffe,2022-08-11,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,54,83.95403751863688,168.0531043911583,1.9796700504530425,29.726823745609863,130.9284671393865,0.7659024495876806,2022-09-24,Treatment follow-up,auto-greffe,2022-07-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,38,42.867077229164295,153.2522761509026,1.3508718539959002,18.251980930008084,117.4086782279009,0.5172391029741729,2022-11-29,Symptoms management,allo-greffe,2022-05-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,20,117.72325720483833,167.10316608399825,2.337610900556933,42.15925354213085,100.601045863709,1.950331897548493,2022-12-11,Cancer diagnosis,auto-greffe,2022-03-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,55.82863539024149,162.91381038070628,1.5894841685782661,21.03493670895115,97.15193560048854,0.8699605445502887,2022-06-28,Cancer diagnosis,auto-greffe,2022-09-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,35,58.648095926775135,163.68009834293827,1.6329528561032407,21.89082666830371,133.92074585084617,0.6386499170323031,2022-05-02,Symptoms management,pas de greffe,2022-05-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,110.0918464591127,144.68751990788118,2.103496839012512,52.58876971552347,123.06345197561822,0.9939935202507882,2022-11-20,Symptoms management,auto-greffe,2022-05-27,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,77,93.30443364936113,179.196819654551,2.1550881504035067,29.056391991308942,104.92902470196044,0.778062882744641,2022-12-18,Treatment follow-up,allo-greffe,2022-01-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,66.95856177195489,185.93277895270523,1.8596438925037913,19.368420087861285,129.22353468414607,0.4533906435361465,2022-04-04,Cancer diagnosis,greffe haplo-identique,2022-09-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,94.4937997594862,192.94486501125004,2.2504378240068306,25.382644273733508,112.8615717292075,0.9651677788244789,2022-06-21,Treatment follow-up,allo-greffe,2022-09-28,Protocole 3 LAL thiotepa Bu Flu
Male,78,81.29584033683979,170.07855993150926,1.9597816951067402,28.104067809038604,101.74652786939737,0.6880308632352176,2022-12-29,Treatment follow-up,greffe haplo-identique,2022-11-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,51.71695010851316,198.07655353704087,1.6868704782114998,13.181558571628585,100.39921429450212,0.6510457185216256,2022-01-19,Symptoms management,auto-greffe,2022-07-26,Protocole 3 LAL thiotepa Bu Flu
Female,25,96.12066138265168,148.87298729821714,1.993724181380423,43.369552832531085,114.03095798516833,1.3463541751095114,2022-08-04,Symptoms management,allo-greffe,2022-04-01,Protocole 6 FlUDARABINE cy (Fanconi)
Female,27,74.45703559954346,199.50672240847965,2.0313295545252843,18.70641968391024,84.631109859323,1.380770984402171,2022-08-14,Treatment follow-up,allo-greffe,2022-03-05,Protocole 3 LAL thiotepa Bu Flu
Male,33,83.0659391374357,188.12938937008278,2.083476288920504,23.46981616211238,97.23626536356896,1.2695388355924366,2022-05-24,Treatment follow-up,allo-greffe,2022-06-29,Protocole 3 LAL thiotepa Bu Flu
Female,53,88.83829441195466,152.80860426033857,1.9418816600543678,38.04561371882393,95.78377357057846,1.1207145888373975,2022-07-23,Symptoms management,auto-greffe,2022-02-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,72.16323759048285,166.10853844544295,1.8247473132255838,26.153637235334585,119.08554252802969,0.9257999621346797,2022-12-03,Treatment follow-up,auto-greffe,2022-12-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,36,59.45082116096798,145.63129447583037,1.5507972898661995,28.03163554115697,109.59729712100889,0.7835358225012211,2022-05-11,Symptoms management,auto-greffe,2022-08-07,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,28,67.51590935198149,150.04813123768574,1.6775176789164312,29.987823055013394,107.90277616712387,0.9733275788770609,2022-07-28,Treatment follow-up,allo-greffe,2022-12-01,Protocole 6 FlUDARABINE cy (Fanconi)
Female,59,98.19843364306979,192.58459402651914,2.291985158304106,26.476554966550072,91.72133553166391,1.2044442790556193,2022-04-27,Symptoms management,greffe haplo-identique,2022-05-21,Protocole 3 LAL thiotepa Bu Flu
Male,61,74.72415510854606,180.73655497365831,1.9368779551722395,22.87541667211497,96.03346810968189,0.8537544788889174,2022-05-08,Treatment follow-up,allo-greffe,2022-11-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,103.35500667920186,162.40153937254127,2.1592830720301635,39.18783189221301,98.23776986874866,1.4904612858288724,2022-02-18,Cancer diagnosis,allo-greffe,2022-10-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,63,119.79045952676069,165.93877574351308,2.3498157256133654,43.50372727072858,104.03224610638414,1.2314378111891946,2022-12-24,Symptoms management,allo-greffe,2022-06-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,61,108.9065306331557,192.77580685731058,2.4149157056163473,29.30548168663025,98.34130207848042,1.2151015192015855,2022-01-28,Treatment follow-up,greffe haplo-identique,2022-04-29,Protocole 3 LAL thiotepa Bu Flu
Female,63,41.65410279307459,188.41635070951915,1.4765118466949867,11.733311709688705,125.65487804486949,0.35451666909791163,2022-06-02,Treatment follow-up,pas de greffe,2022-03-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,32,83.26127871881124,149.56022505129803,1.8598518148291832,37.22295578824469,76.82585180320929,1.6256496367671862,2022-05-16,Cancer diagnosis,greffe haplo-identique,2022-07-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,62,92.10893318324835,194.7225780877854,2.2320698499597533,24.292327668157146,121.79691336824452,0.8192709885306673,2022-11-28,Symptoms management,greffe haplo-identique,2022-01-14,Protocole 3 LAL thiotepa Bu Flu
Female,31,47.32070563361305,141.2715681122793,1.362704652218448,23.710552850394805,120.79534832375143,0.5930550428242173,2022-06-02,Symptoms management,allo-greffe,2022-03-26,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,64,108.25134854074801,152.56334770455436,2.141857198198501,46.50856026052106,119.9207487786999,0.952840217495898,2022-09-12,Treatment follow-up,greffe haplo-identique,2022-07-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,52,50.02245274976714,178.72229693658196,1.575870804581816,15.660567939955941,101.94506500487746,0.5997205785086447,2022-12-29,Treatment follow-up,greffe haplo-identique,2022-07-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,66.01133324734812,195.79100538427826,1.8947607077921564,17.219995412448124,119.67233589817032,0.704822999165962,2022-07-03,Symptoms management,pas de greffe,2022-08-14,Protocole 3 LAL thiotepa Bu Flu
Female,58,101.98449408484734,145.60826597291373,2.030994921749457,48.101883918148076,89.9898673400548,1.2906898363710435,2022-04-18,Cancer diagnosis,pas de greffe,2022-02-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,26,96.05917950570714,169.1253717695802,2.1243328655906932,33.58314342600623,105.43770369376324,1.4424982293410171,2022-09-23,Treatment follow-up,greffe haplo-identique,2022-01-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,50,103.40778131690607,164.3438754161823,2.172711793141966,38.2865445753272,124.85895612007701,1.0352459339947016,2022-10-17,Cancer diagnosis,allo-greffe,2022-11-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,30,94.02479926704896,145.1155289795594,1.946824942397999,44.64929813373802,80.79130348564888,1.7780255136709155,2022-05-06,Cancer diagnosis,allo-greffe,2022-03-30,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,55.21998477889497,182.75871875855276,1.67431027823214,16.532558689697076,98.27738796072681,0.8272105149431651,2022-07-23,Treatment follow-up,allo-greffe,2022-08-08,Protocole 3 LAL thiotepa Bu Flu
Female,62,119.25210110731365,189.51972637802038,2.505584073173254,33.20146125853466,130.22453950697417,0.9920540067847277,2022-03-07,Cancer diagnosis,allo-greffe,2022-12-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,40.45920614415256,166.47323667650505,1.3678221741329268,14.599181582186336,74.72097423764484,0.9024508971977729,2022-09-26,Treatment follow-up,greffe haplo-identique,2022-08-29,Protocole 3 LAL thiotepa Bu Flu
Female,45,112.1213028325471,198.31159991851678,2.485231654174032,28.509650868773644,78.70616911893661,1.8796217854628596,2022-12-21,Symptoms management,pas de greffe,2022-03-11,Protocole 2 LAM Endoxan TBI
Female,31,54.441011592208085,160.78066813448692,1.55929669132812,21.060007828348503,122.07410324089729,0.6751443620001416,2022-01-16,Treatment follow-up,greffe haplo-identique,2022-07-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,53.75587557495227,167.40570840491034,1.5810545383409895,19.181625782067535,80.91730323424626,1.0149501879795848,2022-04-02,Symptoms management,allo-greffe,2022-07-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,79.59126991516698,181.7805051650099,2.0047264465579357,24.086340534735143,105.13051921916626,0.6624371466347202,2022-12-10,Treatment follow-up,auto-greffe,2022-11-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,116.25480748621405,162.97560371957954,2.2941167166961636,43.768909298450005,78.67130028318329,1.2724882655570036,2022-11-27,Treatment follow-up,auto-greffe,2022-03-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,65.98204103539105,148.97514014166478,1.6524126981545346,29.730221184999184,134.79811766030284,0.6934411233325278,2022-03-09,Treatment follow-up,auto-greffe,2022-03-29,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,55,48.307633780250484,146.5791458005304,1.402467240175324,22.48388691446968,86.03504337717953,0.6628676315649407,2022-08-08,Cancer diagnosis,auto-greffe,2022-10-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,75.44415516297013,172.6699958656415,1.9022604944933912,25.30415518642895,100.99305039792375,0.7988998479295538,2022-05-11,Treatment follow-up,auto-greffe,2022-10-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,57.89725239189402,181.99581212924548,1.7108361721939958,17.479747901131727,118.29639810458342,0.482627745233428,2022-10-01,Symptoms management,pas de greffe,2022-04-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,32,80.38338506315297,173.64657389013664,1.9690874517786785,26.658386067573012,76.54164427215022,1.5752872667069273,2022-07-18,Treatment follow-up,auto-greffe,2022-08-28,Protocole 3 LAL thiotepa Bu Flu
Female,49,104.19509107604343,162.40586595380879,2.168069673589646,39.50425132632743,111.0023784333986,1.1863801456001386,2022-11-27,Symptoms management,auto-greffe,2022-05-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,38,90.67514531668569,160.68383641117265,2.011773003032236,35.1191402863481,127.89479936837222,1.0043915507096952,2022-05-08,Treatment follow-up,allo-greffe,2022-08-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,27,73.06866407035925,145.41245871677495,1.7179682846656243,34.55635536756951,133.49989173519103,0.8590060066541118,2022-02-14,Treatment follow-up,pas de greffe,2022-09-04,Protocole 8 Aplasie medullaire thymo
Male,39,93.16742063809643,184.75722713762357,2.186661223104206,27.29362377395246,85.51244156631981,1.5283528909958246,2022-03-29,Symptoms management,greffe haplo-identique,2022-05-22,Protocole 3 LAL thiotepa Bu Flu
Female,42,78.97205113676469,190.947744013167,2.0466459692667955,21.659296907805686,92.50560934344682,1.1619807385993932,2022-01-31,Symptoms management,pas de greffe,2022-12-08,Protocole 3 LAL thiotepa Bu Flu
Female,32,59.37144276529867,198.89556060617412,1.811131965926394,15.008159043390174,109.35721444340648,0.8143693546074734,2022-06-24,Symptoms management,greffe haplo-identique,2022-02-08,Protocole 3 LAL thiotepa Bu Flu
Female,60,106.51389096869099,188.85840487457915,2.3638506453884274,29.863012449299916,80.51376059425712,1.4699197611623118,2022-06-05,Symptoms management,pas de greffe,2022-01-21,Protocole 3 LAL thiotepa Bu Flu
Female,46,115.19374033206968,149.33792405264452,2.1859903708394888,51.652180523299144,115.9044951466159,1.2975495684228315,2022-07-22,Treatment follow-up,greffe haplo-identique,2022-05-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,49.8694332179489,197.16298011332867,1.6526414941787917,12.828730583065264,101.61832850846804,0.49075234704134296,2022-11-24,Treatment follow-up,auto-greffe,2022-03-07,Protocole 3 LAL thiotepa Bu Flu
Male,25,41.12742903940695,164.51842380466516,1.3709505826961255,15.195062181768021,89.84053412764571,0.7311804659495488,2022-12-05,Symptoms management,auto-greffe,2022-08-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,117.01447531164591,154.8465001487505,2.243464704471309,48.8019080032416,89.31209523097715,1.819687514655232,2022-04-09,Symptoms management,pas de greffe,2022-09-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,62,64.11840396530505,148.07498595931352,1.6239810281199012,29.24282350604248,131.00341671703683,0.5302274248753526,2022-11-02,Symptoms management,pas de greffe,2022-06-17,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,53,105.66085808696775,195.9621973551059,2.3982362688922163,27.515000946355052,93.64438580477236,1.3633869853261344,2022-04-08,Cancer diagnosis,greffe haplo-identique,2022-02-25,Protocole 3 LAL thiotepa Bu Flu
Male,51,88.44141910420731,147.30626959430384,1.9023359562702535,40.758035147833084,116.29691885222596,0.9400371214998244,2022-08-13,Cancer diagnosis,allo-greffe,2022-06-18,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,27,111.75182737437007,159.7986663938156,2.227217557944356,43.76312562201307,127.74281127893286,1.3729796837353967,2022-01-25,Symptoms management,allo-greffe,2022-04-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,32,75.96422743846705,151.18035484357586,1.786080349969168,33.236738844791695,93.26950798410493,1.2216890988330227,2022-03-26,Treatment follow-up,greffe haplo-identique,2022-11-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,45,60.122426211924484,173.32115923663517,1.7013465751158054,20.013973841649197,92.1994936181023,0.8603973637906145,2022-06-18,Treatment follow-up,auto-greffe,2022-09-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,69.29134670987362,151.2537009733982,1.7062444656238518,30.287747916834363,103.58701078462192,0.7246625328192886,2022-08-17,Symptoms management,greffe haplo-identique,2022-05-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,85.20999599333257,149.29704866742202,1.8798345759643178,38.2285741235781,97.1047949153077,1.4503216648070223,2022-03-09,Symptoms management,auto-greffe,2022-03-30,Protocole 6 FlUDARABINE cy (Fanconi)
Female,68,74.25551329837735,188.37415762273866,1.9711685596807447,20.925992149979642,130.93136501444667,0.5671331181049258,2022-05-16,Cancer diagnosis,pas de greffe,2022-08-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,102.26863640178203,164.11199305580357,2.1591864303093775,37.97185604337719,74.24664035750392,1.5878565122939559,2022-05-26,Treatment follow-up,pas de greffe,2022-01-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,79.85580160820844,161.17264840658393,1.8908089858742194,30.74141040392496,84.82963085341103,1.0721122354294323,2022-05-31,Cancer diagnosis,allo-greffe,2022-07-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,91.97493370706519,149.818917779196,1.956441286764611,40.9766237700256,98.77642968358221,1.0087377306020258,2022-02-13,Treatment follow-up,pas de greffe,2022-10-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,46,60.99516916053646,155.2451474680378,1.6218305870532528,25.30809008343247,82.87194079126138,0.9609112710437006,2022-12-29,Symptoms management,greffe haplo-identique,2022-11-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,65,105.70946473720115,160.49302015799853,2.170869721701347,41.039454022034576,106.74615666163871,1.0315502610267697,2022-01-15,Symptoms management,pas de greffe,2022-05-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,43,66.7894296180399,148.75469033101925,1.6612613113248327,30.183277613561668,130.4050650344368,0.6900054362705071,2022-11-28,Treatment follow-up,auto-greffe,2022-11-30,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,67,110.67728173518144,193.41862350029265,2.4385245701934006,29.584341549794893,104.47178567066717,1.0741126466189272,2022-08-17,Symptoms management,allo-greffe,2022-08-02,Protocole 3 LAL thiotepa Bu Flu
Male,63,115.52330364698734,160.3371784449821,2.2683009152349682,44.936694862557644,121.94597654188408,1.0131187497334584,2022-06-13,Treatment follow-up,pas de greffe,2022-08-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,52,43.92915245666005,172.32374919952437,1.4500992543126485,14.793214501481936,104.2721112926111,0.5149141574898032,2022-10-20,Cancer diagnosis,greffe haplo-identique,2022-10-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,117.85913858625311,188.59562221159797,2.484827155569341,33.1359974191473,101.11246626962733,1.4408410369890656,2022-12-17,Cancer diagnosis,greffe haplo-identique,2022-09-10,Protocole 3 LAL thiotepa Bu Flu
Male,25,63.3419063564397,171.74683660822367,1.738355867659379,21.474034017431947,97.79501966499424,1.0345220112127933,2022-06-26,Symptoms management,pas de greffe,2022-06-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,57.91183550973805,163.0486987566242,1.6195377789211658,21.783750577162806,122.14203496664604,0.7572992428944756,2022-07-31,Symptoms management,greffe haplo-identique,2022-08-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,35,111.72739392382769,196.9120522501131,2.4720925925495303,28.81476432461227,86.25051291259437,1.8890992911624764,2022-07-08,Treatment follow-up,auto-greffe,2022-10-15,Protocole 3 LAL thiotepa Bu Flu
Female,51,100.34661862933945,187.6512902233681,2.287051258677609,28.49703219612773,95.62964499382899,1.297082826754821,2022-07-29,Cancer diagnosis,pas de greffe,2022-07-19,Protocole 3 LAL thiotepa Bu Flu
Female,45,46.19404891055584,163.3404180498086,1.4477334066724494,17.31405147272042,110.30703159074719,0.5525529997721425,2022-10-12,Symptoms management,auto-greffe,2022-12-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,35,61.10920313762983,184.8902141490296,1.7715728773068151,17.876346728733214,111.8473629677359,0.7967786235134648,2022-11-08,Treatment follow-up,greffe haplo-identique,2022-03-10,Protocole 3 LAL thiotepa Bu Flu
Male,72,104.09415989547554,168.89076543586395,2.2098606254536906,36.493419255507916,88.72747613759766,1.1080124814993457,2022-01-06,Treatment follow-up,auto-greffe,2022-06-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,71.6467072527172,185.37703767805544,1.9207676669827993,20.848958271762882,132.77286549398323,0.5920815149560344,2022-12-11,Treatment follow-up,allo-greffe,2022-06-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,83.66695196534417,189.37452151248928,2.097908283322904,23.329791131122274,96.2071861777888,1.1595384958836574,2022-07-01,Cancer diagnosis,pas de greffe,2022-09-26,Protocole 3 LAL thiotepa Bu Flu
Male,31,47.36959699736605,168.98554677362432,1.4911570124725795,16.58824982560673,92.4716467714364,0.7755058882287384,2022-11-07,Treatment follow-up,greffe haplo-identique,2022-03-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,90.04247496212804,174.72571352667893,2.0905033740881342,29.494006961644804,108.47950612665474,1.0721367348129103,2022-04-14,Symptoms management,auto-greffe,2022-06-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,92.73080361603155,172.2762090906303,2.1065579687739184,31.244487847844724,131.9302425873876,0.6052556545792398,2022-05-23,Treatment follow-up,greffe haplo-identique,2022-09-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,61,79.61694912062704,176.29561129061054,1.9745687795281601,25.616661495706335,101.88365798007891,0.8574239242349232,2022-11-21,Treatment follow-up,greffe haplo-identique,2022-07-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,28,89.11758297279225,172.84129477540586,2.0684937104268837,29.831038811733496,129.56294342112358,1.0699614228462238,2022-07-06,Treatment follow-up,auto-greffe,2022-01-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,63.72303789675004,141.6912978296841,1.5836841665033832,31.74023335806079,104.44292158661418,0.9914500189114798,2022-10-26,Cancer diagnosis,greffe haplo-identique,2022-10-17,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,70,76.26960142650604,150.16913655659854,1.7836713224674745,33.82128542252473,116.23632443124839,0.637933122452954,2022-10-20,Cancer diagnosis,greffe haplo-identique,2022-09-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,37,69.02768531568624,165.49402235139047,1.7813594447078056,25.203374182237575,101.55302334610526,0.9723781278175284,2022-10-07,Cancer diagnosis,allo-greffe,2022-02-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,46.47896172999859,146.05923155615042,1.373224250705385,21.787048249083323,88.85060643485545,0.4504589443399561,2022-07-14,Symptoms management,allo-greffe,2022-05-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,46,68.37498421100983,150.88236090867133,1.6928426983471625,30.03449243649429,134.41766671744847,0.6641042258630404,2022-03-23,Symptoms management,pas de greffe,2022-12-11,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,35,97.46279426307495,183.98021675823645,2.2317921308013093,28.79364236135416,107.90321430446542,1.3172289866416795,2022-12-25,Treatment follow-up,greffe haplo-identique,2022-04-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,50,68.761165645477,148.77058736119756,1.6856946310314904,31.06769800847793,115.59158339179316,0.7435788535357037,2022-06-25,Treatment follow-up,pas de greffe,2022-09-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,23,72.25213317816628,167.25585687447463,1.832165722559784,25.827835077708897,127.03271212011725,0.9242478921767968,2022-10-18,Symptoms management,greffe haplo-identique,2022-08-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,32,104.2244918505834,188.7799162990325,2.337822517730164,29.245443249217363,113.3016558927364,1.3798274751066335,2022-09-28,Treatment follow-up,auto-greffe,2022-11-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,85.213124780869,186.46312015711754,2.100866562277115,24.508718120479596,98.49057582396009,1.4419844076110233,2022-06-01,Cancer diagnosis,auto-greffe,2022-09-22,Protocole 3 LAL thiotepa Bu Flu
Male,75,90.462067103159,185.97268002577084,2.161755527590533,26.15581205407498,100.2166372247366,0.814906049276378,2022-09-13,Treatment follow-up,greffe haplo-identique,2022-09-28,Protocole 3 LAL thiotepa Bu Flu
Female,67,85.36230420195172,159.5397182480495,1.9449848586516945,33.537330296514526,86.20459532747114,1.003982344926473,2022-02-06,Treatment follow-up,pas de greffe,2022-02-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,79.79153733302917,173.26514459659728,1.9596692077428732,26.57874202941324,111.00781673191918,1.1380874293059522,2022-12-02,Symptoms management,auto-greffe,2022-03-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,87.62787500395436,175.87610949841712,2.0690610953944173,28.328826186058095,105.26818855165162,1.318006297361625,2022-09-28,Symptoms management,allo-greffe,2022-06-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,56.44841797374774,146.87045592399676,1.5175459798994801,26.16874461101846,126.76418611110853,0.46385684469099264,2022-05-17,Cancer diagnosis,pas de greffe,2022-07-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,55,45.6226321113914,191.28758330405512,1.556977399443304,12.468286603734933,95.47028486391316,0.5641551386899545,2022-11-22,Symptoms management,pas de greffe,2022-06-02,Protocole 3 LAL thiotepa Bu Flu
Male,60,90.35332449737558,151.03906889046615,1.9469978316516026,39.60641533929158,78.9801871471885,1.2711109760700976,2022-05-13,Symptoms management,auto-greffe,2022-09-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,58,71.67010372263209,145.9085445494676,1.7043474249595607,33.66484213619802,131.23586491589586,0.6219662959323643,2022-10-31,Symptoms management,pas de greffe,2022-02-28,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,58,105.43758470586499,143.25181992999734,2.0483140694875552,51.38012453511461,98.20419263610827,1.2227756317670533,2022-02-25,Treatment follow-up,pas de greffe,2022-09-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,40,72.80623658336378,174.46570845269198,1.8784000021657663,23.919297801601214,110.70800167134021,0.913391728744638,2022-11-11,Symptoms management,auto-greffe,2022-09-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,28,74.5749879571805,181.78859628666527,1.94056709772848,22.566277247912677,81.2850116589841,1.4271454780490167,2022-12-28,Treatment follow-up,pas de greffe,2022-07-28,Protocole 3 LAL thiotepa Bu Flu
Female,21,71.86509432988882,176.47218932339547,1.8769205373228757,23.07626155436081,97.5112848588492,1.2180849742496749,2022-07-23,Cancer diagnosis,greffe haplo-identique,2022-05-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,40.31086296159029,185.31535468315002,1.4405074209488127,11.738140003756902,132.964309063047,0.4631772320688028,2022-02-14,Treatment follow-up,greffe haplo-identique,2022-12-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,76.55684958441327,143.9366661542243,1.7495505534319742,36.952274429069455,94.52472726433217,0.8324110633982877,2022-10-14,Cancer diagnosis,pas de greffe,2022-09-15,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,100.5916295543998,155.05428047774294,2.0814766888651914,41.84025508704521,75.05716175402625,1.2843586062076036,2022-04-05,Symptoms management,allo-greffe,2022-07-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,85.6464393684893,160.53063938893246,1.954260138006838,33.23482846023742,84.54538031811887,0.8582558433608666,2022-10-20,Treatment follow-up,pas de greffe,2022-06-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,89.61717058240507,152.10186547187868,1.9458601942396823,38.73665779868586,127.87371064690748,0.6326897819717903,2022-08-30,Symptoms management,pas de greffe,2022-10-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,51,81.31483274461145,171.9661548744129,1.9708570556251548,27.49690490810476,114.39077001924176,0.8786912461280597,2022-03-10,Symptoms management,allo-greffe,2022-05-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,100.92579773856343,183.38816947014368,2.267438428637841,30.0095552980423,88.84181946437775,1.6409131276633144,2022-12-23,Treatment follow-up,greffe haplo-identique,2022-06-18,Protocole 3 LAL thiotepa Bu Flu
Female,76,76.90598363901377,165.52973579444873,1.880471804921584,28.067781531245313,81.95734468135265,0.8341030887661717,2022-08-08,Treatment follow-up,auto-greffe,2022-08-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,118.33805513264969,194.92394649955497,2.5312996622035224,31.145408834963284,125.34217964403881,0.8785560850310619,2022-10-29,Treatment follow-up,greffe haplo-identique,2022-09-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,95.68995218266502,178.28350222793225,2.176895074995889,30.10537379492712,93.19890513132484,1.4830519695981779,2022-05-15,Cancer diagnosis,allo-greffe,2022-09-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,82.10511610417807,147.42058150555957,1.833635123695507,37.77930634036101,130.70125229894063,0.8463104601376561,2022-11-08,Symptoms management,greffe haplo-identique,2022-09-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,47,99.69380064900477,191.69746053532467,2.304045259943736,27.129102948255653,118.03019897598398,1.091001796903119,2022-04-09,Symptoms management,pas de greffe,2022-08-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,44.07998372269854,159.98574682215923,1.3996199003642769,17.221811824345963,101.9119949425167,0.36644893259256417,2022-07-22,Symptoms management,greffe haplo-identique,2022-05-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,43,80.67943631271979,169.18640028167755,1.947210498130304,28.185903120730018,74.77623576793499,1.453578511416158,2022-12-11,Symptoms management,auto-greffe,2022-06-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,117.68970847853716,147.22811807713705,2.1938825487871387,54.29464094662761,130.82867645982614,0.8121128819964327,2022-09-30,Symptoms management,pas de greffe,2022-01-10,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,63,63.750134593272556,190.24559924116312,1.8354671338049933,17.61375158891535,86.60301426263395,0.787238502653099,2022-12-11,Treatment follow-up,allo-greffe,2022-10-14,Protocole 3 LAL thiotepa Bu Flu
Female,73,54.82107672345479,156.6282904383046,1.5443923227079979,22.346378250403138,116.38094142126621,0.43833686928078447,2022-03-11,Treatment follow-up,greffe haplo-identique,2022-10-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,50,60.00530170652268,142.8657712017284,1.5431482704464519,29.399046417507662,110.90834390772457,0.6762938160501131,2022-09-29,Treatment follow-up,auto-greffe,2022-07-08,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,73,40.28338032864202,145.73064970602923,1.2769889919094055,18.968111962164894,75.51557173960168,0.4963999145849933,2022-10-08,Symptoms management,greffe haplo-identique,2022-06-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,41,53.77201943804902,150.142498022606,1.4975410699384664,23.853333074820924,128.78847711082835,0.5740927168794119,2022-07-07,Cancer diagnosis,greffe haplo-identique,2022-02-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,69,99.93365887451891,184.7805913477494,2.264815456203997,29.268406842602637,113.70944070707134,0.8666447638592797,2022-02-24,Cancer diagnosis,greffe haplo-identique,2022-09-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,85.90908562649895,148.1942518316569,1.8805460694791671,39.1179763323748,133.60442059768644,0.7501792688885353,2022-05-18,Treatment follow-up,pas de greffe,2022-03-30,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,72,81.60377063821878,177.90632950054578,2.008165781921535,25.782642537255885,134.7307167961649,0.5720316024265241,2022-09-15,Cancer diagnosis,greffe haplo-identique,2022-03-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,95.4377074874036,164.0881942563388,2.0856787521340707,35.44584443204573,116.83895177459992,0.9643146747935308,2022-02-02,Treatment follow-up,auto-greffe,2022-10-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,44,75.06984425093015,172.40277863471283,1.896066816431047,25.256722499748168,120.56209906330236,0.8302204958736821,2022-08-28,Symptoms management,pas de greffe,2022-08-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,26,118.39546684077094,146.93257599399837,2.1982411484921363,54.8401822050081,82.83841573221264,2.262953576641837,2022-04-08,Treatment follow-up,allo-greffe,2022-05-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,72,92.65766650205819,179.72193592179966,2.150750205144603,28.68660692440463,111.1091132396344,0.7876043270574743,2022-01-25,Symptoms management,allo-greffe,2022-05-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,44.6380892056073,142.34942743318612,1.3285546072632723,22.028967717032128,117.09670224283104,0.6194614670589731,2022-03-11,Symptoms management,greffe haplo-identique,2022-04-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,52,72.80919157421697,149.52664315177262,1.7390062621035254,32.56484697968786,118.41131488482597,0.7515245651194657,2022-01-30,Symptoms management,pas de greffe,2022-05-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,48,78.24187821716066,176.1723342551423,1.9567585385887383,25.209477813669093,95.6060891289059,1.0457046636714276,2022-08-20,Cancer diagnosis,auto-greffe,2022-10-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,105.27344701987145,177.75937369066364,2.279945297133099,33.316074198315796,117.17356461182919,1.0357019581729319,2022-06-20,Treatment follow-up,pas de greffe,2022-10-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,89.9119255554902,174.51536855500137,2.087729549974101,29.522283137430247,98.66528357725628,1.4428636257323737,2022-07-16,Cancer diagnosis,allo-greffe,2022-07-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,98.93706223168535,140.13307718965353,1.9624499270774272,50.38226559094308,132.25140931862353,1.0701962629743589,2022-01-31,Symptoms management,greffe haplo-identique,2022-08-13,Protocole 9 LAL thiotepa-thymo melphalan
Female,37,95.57308855550212,162.42612760410455,2.076560101414675,36.226288388038896,98.74117735373468,1.3846564975104119,2022-04-20,Cancer diagnosis,auto-greffe,2022-08-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,114.65226330494225,191.636455262639,2.47046741683959,31.219530985925044,79.08374088316393,1.3692156176742842,2022-11-29,Symptoms management,greffe haplo-identique,2022-01-25,Protocole 3 LAL thiotepa Bu Flu
Female,23,57.86427633207011,165.07044889213134,1.6288784543831536,21.235958182392917,79.1936878493171,1.1873351474491887,2022-09-04,Symptoms management,auto-greffe,2022-09-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,45.323437920859256,148.22126997957986,1.3660463560206644,20.630121461348942,123.06582516711582,0.3836313975612985,2022-11-18,Cancer diagnosis,auto-greffe,2022-09-10,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,27,42.05932993188853,192.14195868086767,1.4982732685326192,11.392470753274413,77.20506562933956,0.8549928836997617,2022-11-30,Symptoms management,auto-greffe,2022-10-17,Protocole 2 LAM Endoxan TBI
Female,30,57.6893858578006,150.78579907843047,1.5544506125702748,25.373187683891476,104.62393381945732,0.8424129977686259,2022-07-13,Cancer diagnosis,auto-greffe,2022-05-04,Protocole 6 FlUDARABINE cy (Fanconi)
Female,67,73.01606857141914,175.18972269301378,1.88500403810067,23.790369920645183,81.17734767621863,0.9119561399096886,2022-05-05,Cancer diagnosis,pas de greffe,2022-07-01,Protocole 3 LAL thiotepa Bu Flu
Female,25,99.21328156888222,175.29314507706704,2.1979414712424017,32.287911062740136,79.06990380126501,2.0041210428141922,2022-07-15,Cancer diagnosis,allo-greffe,2022-12-08,Protocole 3 LAL thiotepa Bu Flu
Male,22,59.35926365071383,163.23197178042687,1.6405732102209003,22.278094989331375,95.11470441026104,1.0227991376618946,2022-05-14,Cancer diagnosis,allo-greffe,2022-01-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,44,107.47311568360936,174.0132321824726,2.279238678498301,35.49239381901107,103.28950907922984,1.387338257830495,2022-08-10,Symptoms management,greffe haplo-identique,2022-12-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,82.55965174580189,164.68541807870054,1.9433912773086253,30.44090494883889,80.97929613432238,1.685032647359593,2022-03-20,Symptoms management,greffe haplo-identique,2022-08-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,62.08696240995617,178.77793313436626,1.7559247970358223,19.425517104929153,96.17298114994477,0.7352392614648797,2022-09-09,Symptoms management,greffe haplo-identique,2022-05-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,65.01631346776321,170.05012809732716,1.7524611608954348,22.483732715837,102.25334857600052,0.6093423958658535,2022-11-08,Cancer diagnosis,greffe haplo-identique,2022-10-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,114.18918436050993,144.19200702320242,2.1386111584445278,54.92152618773923,118.59897187193417,1.6046960969697381,2022-12-17,Treatment follow-up,auto-greffe,2022-08-01,Protocole 8 Aplasie medullaire thymo
Female,40,70.20062900922325,164.30809854766733,1.7899822989003493,26.002976522759546,128.67007955123677,0.7577587109915175,2022-08-31,Symptoms management,allo-greffe,2022-06-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,29,68.14555028415452,151.398475451066,1.6928880994221869,29.72997191867432,91.61425386763614,1.146739933138845,2022-01-18,Symptoms management,pas de greffe,2022-06-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,89.8941054348537,165.91503063697925,2.0354349287688147,32.655756709166624,130.55848059469338,1.013676775841387,2022-04-18,Symptoms management,greffe haplo-identique,2022-05-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,28,97.997614458134,159.49081384987986,2.083647928598793,38.52513378149434,112.19172475547464,1.3587520285813512,2022-08-28,Treatment follow-up,allo-greffe,2022-07-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,103.76912953980045,169.21506240202768,2.208525131952784,36.240162537689685,96.60680677896454,1.1487318833038955,2022-08-06,Symptoms management,auto-greffe,2022-07-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,79.2627222324829,149.97013312009534,1.8171284584832224,35.241909362236896,89.87776678213694,1.1881080784336042,2022-10-17,Cancer diagnosis,greffe haplo-identique,2022-08-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,104.15089721677535,156.14021886275836,2.1253851864086997,42.720216798324515,112.32727456045647,0.8370639803275585,2022-06-21,Treatment follow-up,auto-greffe,2022-11-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,38,56.91118147193307,163.5026966294249,1.607718504160098,21.288632355857825,87.75597599907346,0.9187314349139758,2022-01-14,Cancer diagnosis,allo-greffe,2022-09-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,59.18465172657186,184.2281355029791,1.7403286756928278,17.438020453484185,128.5795516953865,0.485867986860038,2022-06-02,Symptoms management,auto-greffe,2022-05-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,40,90.56058118085343,170.2556961006019,2.06951784429109,31.241789340601432,122.8048748970842,1.0242149188199203,2022-01-10,Symptoms management,allo-greffe,2022-10-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,23,53.24457870942739,168.82336718216513,1.5801660480540005,18.681436973139952,109.03933245204712,0.7934975247658455,2022-05-04,Treatment follow-up,greffe haplo-identique,2022-10-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,57.88015196614769,180.7125063098526,1.7045419169088682,17.723653230403375,119.63534419797075,0.6383535356320656,2022-10-13,Cancer diagnosis,pas de greffe,2022-03-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,49.952888339555926,158.8068675420708,1.484443565961082,19.807152528560643,86.22958590265912,0.5310259485216996,2022-01-26,Cancer diagnosis,allo-greffe,2022-01-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,53.7428062033472,166.95958634107754,1.5787544926055146,19.279582253609796,84.51901306210141,0.9096423065050918,2022-11-10,Treatment follow-up,greffe haplo-identique,2022-05-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,71.50221162738261,154.0943315618244,1.7494511445588385,30.112453931458123,91.6582212566107,1.2893253307725352,2022-01-27,Cancer diagnosis,auto-greffe,2022-11-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,38,67.41389389382847,169.45022579552477,1.7813306154907522,23.478216841638197,91.69155007634274,1.0415683481201283,2022-12-29,Treatment follow-up,pas de greffe,2022-08-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,80.12452676165272,170.04054423539355,1.9453947141015129,27.711530017738784,91.18218662998122,1.3547088160119365,2022-03-29,Symptoms management,auto-greffe,2022-04-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,47.43529139181539,148.51989057253684,1.398916672801257,21.504647675547297,111.88873727012017,0.6064848105858442,2022-04-02,Symptoms management,auto-greffe,2022-05-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,39,47.032087240952656,155.05638331525628,1.4232811609631817,19.56207650592622,87.96770950030441,0.7499975524983498,2022-01-31,Symptoms management,auto-greffe,2022-07-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,55,84.46539226954087,174.12041863212247,2.021217280495077,27.859890043636252,91.52131977865069,1.0895394465153536,2022-12-01,Treatment follow-up,auto-greffe,2022-05-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,74.31437665446543,183.16408376380514,1.9444882724706685,22.15094218748343,99.645240244276,0.9633114732160879,2022-09-13,Symptoms management,greffe haplo-identique,2022-01-06,Protocole 3 LAL thiotepa Bu Flu
Male,41,54.2169913464928,172.8147383484776,1.6132692113278195,18.154063801683332,75.70146624382214,0.9847677568267889,2022-08-07,Cancer diagnosis,pas de greffe,2022-02-16,Protocole 3 LAL thiotepa Bu Flu
Male,43,110.76715336985609,199.544058231624,2.477842212164637,27.818479836712978,118.67390965785658,1.2574623263226068,2022-05-23,Symptoms management,auto-greffe,2022-11-11,Protocole 3 LAL thiotepa Bu Flu
Male,59,80.1860686583008,156.5392492251912,1.8672816684874984,32.72294846355275,95.36223745021948,0.9459648772154599,2022-07-07,Cancer diagnosis,allo-greffe,2022-07-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,64.17901730652756,150.35138116928215,1.6371896562676882,28.390838483451095,118.36298133267536,0.48950600915586856,2022-08-10,Symptoms management,allo-greffe,2022-12-19,Protocole 6 FlUDARABINE cy (Fanconi)
Male,61,56.79989662986155,197.06481546767773,1.763303492812003,14.62612778284543,105.06660023729304,0.59316765424459,2022-08-31,Treatment follow-up,allo-greffe,2022-05-24,Protocole 3 LAL thiotepa Bu Flu
Female,63,119.83495587090776,194.94381688358717,2.5473888424964253,31.53294913139298,124.82771924700141,1.026669625780782,2022-05-30,Symptoms management,auto-greffe,2022-05-09,Protocole 3 LAL thiotepa Bu Flu
Male,43,62.91937209134731,172.66268651143582,1.7371614633348698,21.10509891806666,103.35873047382019,0.8201182028953262,2022-07-30,Treatment follow-up,allo-greffe,2022-05-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,117.58465332091492,152.24779031462197,2.2299728226433224,50.728105902510464,101.4955438280762,1.3194259582261338,2022-07-11,Treatment follow-up,greffe haplo-identique,2022-04-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,41,46.38979493734465,183.92221278836377,1.5394906928081824,13.713682362574296,111.94885488712598,0.5697777623823128,2022-03-08,Cancer diagnosis,auto-greffe,2022-08-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,86.71133240793147,140.31118421760405,1.8383695777058036,44.04445896256969,102.53723499612208,1.1862688728435926,2022-08-06,Treatment follow-up,greffe haplo-identique,2022-09-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,50,110.31480093346006,142.01956186264997,2.0861221131520726,54.69371819481531,123.63489933875655,1.115328292450826,2022-01-01,Treatment follow-up,allo-greffe,2022-08-21,Protocole 8 Aplasie medullaire thymo
Male,57,87.43429017269114,178.28470781569098,2.080878345295468,27.507657063237,76.3354620311714,1.32038641078368,2022-06-20,Cancer diagnosis,auto-greffe,2022-12-17,Protocole 3 LAL thiotepa Bu Flu
Male,58,66.69855564490175,195.01201669699518,1.9008053736865973,17.538549882839167,94.43144722681161,0.8044168140986424,2022-04-03,Treatment follow-up,greffe haplo-identique,2022-05-14,Protocole 3 LAL thiotepa Bu Flu
Female,36,68.23339485106406,166.52781244239037,1.7766039685673682,24.60500317164805,127.15350883657538,0.7751209464842805,2022-10-25,Cancer diagnosis,allo-greffe,2022-08-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,103.0203129594134,183.3838236211109,2.2908185643479735,30.63379610976789,91.2279143935518,1.8507366671858558,2022-12-09,Treatment follow-up,auto-greffe,2022-09-04,Protocole 3 LAL thiotepa Bu Flu
Female,66,101.49375693896948,148.5989666851932,2.046804243891833,45.9629346584812,109.4882823240813,0.9527323449671923,2022-01-10,Treatment follow-up,allo-greffe,2022-07-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,69.70999163173143,179.00830465203128,1.8617992655928544,21.754478241310256,99.70327078600621,0.6311992659626453,2022-05-30,Cancer diagnosis,greffe haplo-identique,2022-08-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,59.93947785753514,167.5389808258391,1.6701795505178134,21.35409728710547,110.02698269354667,0.47667437424346804,2022-10-31,Treatment follow-up,auto-greffe,2022-08-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,39,113.31404258202177,160.82484870615653,2.2499206007309476,43.810421409171184,109.40595482093283,1.4528863726329087,2022-06-02,Symptoms management,auto-greffe,2022-07-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,30,46.488017564595935,198.9398495720619,1.6028030326417466,11.74620175485692,81.08865389582412,0.8758729705807857,2022-07-03,Treatment follow-up,auto-greffe,2022-05-17,Protocole 3 LAL thiotepa Bu Flu
Female,57,119.5178621396981,150.72826813904035,2.2369821170991657,52.60698324704526,84.96241804276782,1.621629170827017,2022-01-28,Symptoms management,pas de greffe,2022-09-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,79.78805083218096,158.11766520083083,1.8720087479399754,31.913693519782644,129.54098245712015,0.9324481050691726,2022-02-08,Symptoms management,allo-greffe,2022-01-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,52,46.433674858326114,194.69281439526924,1.584675119252661,12.249918794008037,116.20039263478319,0.4883999785582425,2022-03-21,Treatment follow-up,pas de greffe,2022-01-22,Protocole 3 LAL thiotepa Bu Flu
Male,29,65.12196483756226,186.3743329568298,1.8361389711867604,18.748014954168564,92.86791851891421,1.0810661427440196,2022-12-13,Symptoms management,auto-greffe,2022-02-10,Protocole 3 LAL thiotepa Bu Flu
Female,68,48.96532421677048,199.58141223871675,1.6476050428416198,12.292733083406905,124.04363397220646,0.39474274212042015,2022-11-16,Cancer diagnosis,auto-greffe,2022-06-13,Protocole 3 LAL thiotepa Bu Flu
Female,32,116.60998113180034,152.8717430189602,2.2252572303884812,49.897787638312515,122.28686876299338,1.4303659376274218,2022-10-04,Treatment follow-up,allo-greffe,2022-06-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,23,51.051546150142286,156.45290894613134,1.4895154787703648,20.856508885893778,78.46326362504414,1.0572943140680449,2022-09-19,Symptoms management,pas de greffe,2022-10-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,54.94372722352508,151.72280868613134,1.5217147321760522,23.868018724299485,84.26197673341173,0.7697911315548511,2022-11-13,Cancer diagnosis,allo-greffe,2022-06-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,78,99.1245940531024,190.13206460649923,2.288058597285133,27.420204754686385,79.83642690310694,1.0691521731940516,2022-08-07,Treatment follow-up,allo-greffe,2022-05-13,Protocole 3 LAL thiotepa Bu Flu
Female,66,46.934111097109906,179.18471510253758,1.528422873197373,14.617956863447395,113.44317185597154,0.4252158646146297,2022-01-27,Cancer diagnosis,allo-greffe,2022-08-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,97.42536500366428,168.5356982865202,2.135653160674196,34.299534973703224,102.2822169695533,0.859909543644115,2022-09-21,Cancer diagnosis,auto-greffe,2022-07-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,42.563384695732566,158.17056129022916,1.3675073072865875,17.01315445375309,121.07358949975708,0.43455449670134055,2022-01-08,Cancer diagnosis,auto-greffe,2022-12-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,70,108.21333723532871,159.55082890637016,2.189972580664302,42.50917349029923,125.5353285623866,0.8380701465144107,2022-09-01,Treatment follow-up,auto-greffe,2022-08-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,45,112.04038795194339,157.24259142100965,2.2121834955899997,45.3141897430422,74.0739216098485,1.9957235181259403,2022-11-03,Cancer diagnosis,greffe haplo-identique,2022-02-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,74,91.03584634450752,156.94549174601437,1.9921837314206332,36.958534659690145,89.10896761541304,0.9364885269006802,2022-04-05,Symptoms management,pas de greffe,2022-02-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,39,111.05737486069587,150.98910680839262,2.1582177468857457,48.714266930715276,94.02844848075992,1.656826418281251,2022-02-09,Treatment follow-up,greffe haplo-identique,2022-10-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,74,71.70584792006099,172.83386413227618,1.8554124112463724,24.00473390382346,90.39974851115798,0.7271077815584429,2022-09-27,Treatment follow-up,greffe haplo-identique,2022-02-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,63.247933390076284,173.45292820602117,1.7456723672403986,21.022437391667857,94.36787745425698,0.6050663668111804,2022-12-12,Treatment follow-up,allo-greffe,2022-10-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,75.96149944369745,158.72105905841445,1.8300493040845178,30.15257619978267,100.09285615129937,0.8643145078105903,2022-07-11,Symptoms management,pas de greffe,2022-06-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,58,92.78046702776612,189.97156155970382,2.2126938209832816,25.70865575715287,76.07227298878442,1.3890296536745197,2022-12-18,Treatment follow-up,greffe haplo-identique,2022-01-09,Protocole 3 LAL thiotepa Bu Flu
Male,71,92.60046540332245,165.27079030850777,2.0618325250006992,33.9016598203416,101.73378917636119,0.8722973300871023,2022-12-16,Treatment follow-up,allo-greffe,2022-03-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,30,57.15877081523695,191.178791225691,1.7422482850554613,15.638801170844747,77.05449101187313,1.133300586505155,2022-03-30,Treatment follow-up,pas de greffe,2022-01-22,Protocole 3 LAL thiotepa Bu Flu
Female,21,64.48740168451413,171.8788405618401,1.754677861569843,21.82880935661684,108.3836616541254,0.9833894041236916,2022-10-09,Treatment follow-up,greffe haplo-identique,2022-04-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,51.07385388172777,174.37734729578702,1.5728709733820723,16.796488474080473,129.0014839687191,0.626868256277925,2022-06-27,Treatment follow-up,auto-greffe,2022-10-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,55.880593178285025,197.70308378218303,1.7518058614949135,14.296644577930897,94.96019394790993,0.7600984846507904,2022-08-18,Symptoms management,allo-greffe,2022-02-25,Protocole 3 LAL thiotepa Bu Flu
Male,46,85.84372338583611,174.9436682356985,2.0424533086006034,28.048658138520565,95.0789286094203,1.178744350773517,2022-04-23,Treatment follow-up,pas de greffe,2022-05-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,50.43325158715271,192.89993878331097,1.643891989541645,13.553541494728723,112.78069093917443,0.621083114286931,2022-04-26,Treatment follow-up,allo-greffe,2022-06-09,Protocole 3 LAL thiotepa Bu Flu
Male,47,70.36647449208485,172.26502244608972,1.8349751972159063,23.71218542235174,132.38338262622875,0.6865667559567894,2022-09-08,Treatment follow-up,allo-greffe,2022-06-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,69,118.58998933754359,142.56642824738984,2.1671122109688863,58.34632294869823,121.94525356497259,0.9589787444247889,2022-11-03,Cancer diagnosis,auto-greffe,2022-05-14,Protocole 8 Aplasie medullaire thymo
Female,29,45.89455576416674,182.97186091290095,1.5272899268112214,13.708582823951954,121.71923437828161,0.5812894499746792,2022-04-19,Treatment follow-up,greffe haplo-identique,2022-01-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,40,53.00472578258529,160.73862612518468,1.5383890203386748,20.515121249053134,128.84744720540007,0.5713553220862707,2022-11-09,Treatment follow-up,allo-greffe,2022-01-10,Protocole 6 FlUDARABINE cy (Fanconi)
Female,56,111.7435843520693,189.56839293722743,2.4257330911767276,31.095012889900335,131.2977759214013,0.9929148773659044,2022-01-13,Symptoms management,greffe haplo-identique,2022-01-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,40,112.1466873671183,178.84411430740323,2.360365730529059,35.06203712400647,114.84545468200389,1.3562512198777839,2022-09-24,Symptoms management,greffe haplo-identique,2022-10-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,39,116.64032608987497,186.30476375990955,2.456886489320091,33.604760572108844,114.47511555578492,1.4293102622106217,2022-07-31,Symptoms management,greffe haplo-identique,2022-04-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,119.2391262326087,151.1051423744934,2.237163701976513,52.22281715913452,126.13397722398457,1.3654868992298044,2022-09-16,Treatment follow-up,auto-greffe,2022-12-28,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,20,96.50761566511855,195.7688461886377,2.2908746854020112,25.181084104822908,87.20108902005833,1.8445414835534049,2022-04-17,Cancer diagnosis,greffe haplo-identique,2022-01-20,Protocole 3 LAL thiotepa Bu Flu
Female,78,91.9063127514549,176.89075406202306,2.12507365661006,29.372105276828126,95.54845420401134,0.8282870481876207,2022-05-18,Symptoms management,pas de greffe,2022-04-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,72.47387627818966,177.7415288153593,1.8916202320923952,22.94054163423928,85.68670240072781,0.9985147622174813,2022-10-18,Symptoms management,pas de greffe,2022-12-16,Protocole 3 LAL thiotepa Bu Flu
Male,55,69.20755029234581,179.36288812863495,1.8569139647351955,21.512372047656353,93.68284492780171,0.8721272079961433,2022-06-17,Cancer diagnosis,auto-greffe,2022-03-10,Protocole 3 LAL thiotepa Bu Flu
Male,69,107.07157770610935,154.72676584696546,2.145203883899976,44.7242747086165,77.05495657122705,1.3702489386596741,2022-03-06,Symptoms management,pas de greffe,2022-06-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,70,67.32787627372076,147.82318258129544,1.6627137245429946,30.811285571011172,110.55293211201558,0.5920933641272937,2022-09-09,Treatment follow-up,allo-greffe,2022-07-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,57,98.12897496289624,199.77369883391046,2.3335469123155024,24.58785486303106,96.30575698222827,1.174601656619691,2022-03-27,Cancer diagnosis,pas de greffe,2022-09-03,Protocole 3 LAL thiotepa Bu Flu
Female,62,85.33676652739688,174.2282321708747,2.0322451986826344,28.11247764269987,91.98584316254717,1.0050259970401005,2022-04-06,Symptoms management,allo-greffe,2022-01-25,Protocole 3 LAL thiotepa Bu Flu
Male,56,77.89076163320433,140.83517633259888,1.7456102999375287,39.270250061588214,117.51623372115493,0.7732766134622963,2022-11-09,Symptoms management,allo-greffe,2022-06-26,Protocole 8 Aplasie medullaire thymo
Male,41,70.96584126395214,141.19373126382027,1.6683268331819245,35.59742018216371,127.94926874930492,0.762630632372913,2022-12-17,Treatment follow-up,auto-greffe,2022-09-09,Protocole 8 Aplasie medullaire thymo
Female,79,119.21583198446321,141.0455037939541,2.161201895709371,59.926020867853126,82.15835039176426,1.2293613688240834,2022-11-29,Cancer diagnosis,auto-greffe,2022-06-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,28,88.55534183039725,193.86943852067265,2.1837896723271215,23.5611269210619,94.42456956597894,1.45886557483475,2022-07-06,Cancer diagnosis,greffe haplo-identique,2022-10-27,Protocole 3 LAL thiotepa Bu Flu
Female,63,79.9299911387533,155.36035714118702,1.8572644137734031,33.115349502148455,105.88078425314983,0.8073295411512825,2022-01-31,Cancer diagnosis,auto-greffe,2022-10-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,63,110.88418591581942,185.17375886894956,2.3882142041210366,32.33781911313163,101.85181200102336,1.164284407657141,2022-08-31,Symptoms management,auto-greffe,2022-05-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,67.99862102688252,150.5551780321975,1.6863458600251466,29.999133594200476,113.83489223615501,0.7715696868892642,2022-08-04,Treatment follow-up,auto-greffe,2022-01-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,56,40.073614997611564,186.4161268852526,1.4405215199658998,11.531652864020465,110.77273173827521,0.4220582998802444,2022-10-09,Cancer diagnosis,greffe haplo-identique,2022-12-27,Protocole 3 LAL thiotepa Bu Flu
Male,53,43.276846152726506,147.8021311358951,1.3329593319433226,19.81044409458857,110.87280278582543,0.47164727916992155,2022-11-23,Symptoms management,auto-greffe,2022-12-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,65.99545938409804,162.02648782493372,1.723450390640698,25.13865397369107,74.70534178271008,0.8466014218954415,2022-11-15,Symptoms management,pas de greffe,2022-07-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,66.53816632143838,159.1311123822848,1.7149904779949436,26.276083358754445,90.4923945766111,0.7557148756999679,2022-05-10,Treatment follow-up,auto-greffe,2022-09-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,30,102.98359826116021,184.540190112259,2.2976203149224133,30.240302744465897,93.10478391510216,1.6898815107337777,2022-05-11,Cancer diagnosis,greffe haplo-identique,2022-09-22,Protocole 3 LAL thiotepa Bu Flu
Male,45,61.26328430165637,163.48787676664912,1.667983169565151,22.920768150352416,112.9660285605298,0.7155558281570339,2022-08-10,Cancer diagnosis,greffe haplo-identique,2022-05-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,56.535744970487116,150.13061209585,1.5354827324288773,25.08329632110615,114.83940561730117,0.4649525131455425,2022-12-11,Cancer diagnosis,allo-greffe,2022-01-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,51,65.70947558163499,198.76648978973063,1.904734000624468,16.63189233013249,92.52623150301757,0.8778506543746383,2022-09-26,Symptoms management,pas de greffe,2022-09-13,Protocole 3 LAL thiotepa Bu Flu
Female,43,61.68210485807181,195.18336799532102,1.8287306595953843,16.19099616250383,75.05404251897728,1.107195556551455,2022-04-12,Symptoms management,greffe haplo-identique,2022-06-02,Protocole 3 LAL thiotepa Bu Flu
Male,59,65.9771380929748,154.32494927142278,1.681758214329409,27.70264185105005,134.05347844135167,0.5536915656169991,2022-07-01,Symptoms management,pas de greffe,2022-02-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,71,82.07843550143166,155.48437362938853,1.8828107042117959,33.95123470506676,103.53762044474982,0.7597093727960079,2022-05-11,Symptoms management,greffe haplo-identique,2022-11-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,22,77.32750724746339,180.51525842774655,1.9691224042387017,23.730461019520817,127.99497172537755,0.9901263364099464,2022-06-11,Treatment follow-up,auto-greffe,2022-11-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,62.14331160300745,150.48187352804328,1.6117142320848554,27.44264791638157,92.83525522104664,1.0970614844805147,2022-11-25,Cancer diagnosis,pas de greffe,2022-08-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,39,77.98307766268802,142.11818614241108,1.7545823772833613,38.61011179100165,128.95796395175674,0.8482836192176648,2022-05-26,Treatment follow-up,pas de greffe,2022-01-12,Protocole 9 LAL thiotepa-thymo melphalan
Male,77,92.52382954434711,165.66682927600158,2.0634470534820304,33.71184172267495,92.08724275799409,0.8791483861023272,2022-10-24,Treatment follow-up,pas de greffe,2022-08-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,47.30206101183482,177.34755879374808,1.5265160994130316,15.0393696681016,92.0159583491349,0.742536408522439,2022-10-05,Treatment follow-up,allo-greffe,2022-12-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,95.04935970718441,182.4341616050622,2.1947063995794625,28.558596819617957,119.49542374326913,1.082658528241193,2022-04-04,Treatment follow-up,greffe haplo-identique,2022-10-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,63.52590851329612,182.70166649752335,1.795541496097456,19.031186590957912,132.7500194064927,0.45195241132095954,2022-08-29,Treatment follow-up,allo-greffe,2022-01-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,67.41732847840203,195.207715798626,1.9119785198638346,17.69202643577344,92.92724345063635,0.9471610742703981,2022-08-18,Cancer diagnosis,greffe haplo-identique,2022-01-21,Protocole 3 LAL thiotepa Bu Flu
Male,31,115.35273590518345,173.89503376384144,2.3605124152385595,38.14639846561503,85.00952507019676,2.054254803159876,2022-08-30,Cancer diagnosis,auto-greffe,2022-12-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,58.55442771014133,170.50169520803118,1.6653018734114122,20.141988240424233,100.61407793102828,0.7436290035853959,2022-10-29,Treatment follow-up,pas de greffe,2022-02-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,65.18773921439718,157.92571426677478,1.6910565629601315,26.13726974054446,76.83905301776137,1.201853661562558,2022-08-17,Symptoms management,allo-greffe,2022-04-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,39,94.55466159620815,187.03441478619263,2.2164145092765173,27.029617153238785,75.8549507127683,1.7485896019458114,2022-09-24,Treatment follow-up,pas de greffe,2022-11-07,Protocole 3 LAL thiotepa Bu Flu
Male,45,87.19725453501188,147.3549303401438,1.8892198101522744,40.15812878637864,115.44205362011675,0.9966206374466368,2022-06-13,Treatment follow-up,auto-greffe,2022-08-31,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,61,101.85767510382905,176.29381074964076,2.233387915884796,32.773258849124325,76.44385728866192,1.4619945747346352,2022-01-11,Treatment follow-up,auto-greffe,2022-12-26,Protocole 3 LAL thiotepa Bu Flu
Female,44,100.2630496335403,145.56016805825647,2.013448282776165,47.32120700075695,96.16198403043961,1.3901966304661175,2022-08-21,Symptoms management,auto-greffe,2022-11-20,Protocole 6 FlUDARABINE cy (Fanconi)
Female,37,48.33747899261405,169.07893083441186,1.5067302039794308,16.90849722272982,92.41484363757706,0.7482504583962412,2022-03-12,Symptoms management,greffe haplo-identique,2022-11-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,108.43131642437663,165.0686839572285,2.229761740007318,39.79471079163189,98.99316098143862,1.6277991583770621,2022-12-19,Treatment follow-up,pas de greffe,2022-10-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,58,106.12015070467847,193.20074527919303,2.3864485587772566,28.430222808741416,105.55046145509512,1.1450358327063346,2022-11-27,Symptoms management,greffe haplo-identique,2022-04-07,Protocole 3 LAL thiotepa Bu Flu
Female,41,94.13658659424682,199.24898307157548,2.282580115956319,23.7118926228575,82.46772638723048,1.569557113279794,2022-05-07,Cancer diagnosis,greffe haplo-identique,2022-08-26,Protocole 2 LAM Endoxan TBI
Female,48,106.5197187428995,172.01299156820343,2.2560274502103725,36.000415491999334,95.94812754278419,1.4185636863431643,2022-03-22,Cancer diagnosis,auto-greffe,2022-03-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,52.550907557412614,156.26521478202673,1.5103236276125938,21.52066039985101,107.42756183323928,0.6318514023464414,2022-03-28,Cancer diagnosis,allo-greffe,2022-11-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,63.37295076846941,159.3132331537959,1.6746599722382447,24.968946933344167,125.0668996928078,0.7459932775042705,2022-07-18,Symptoms management,auto-greffe,2022-04-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,29,114.57983842039488,164.83322882646496,2.290473308998742,42.17146358790508,118.64620826044899,1.4888290165751563,2022-02-17,Treatment follow-up,auto-greffe,2022-12-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,40,60.93826381576989,144.25568638289548,1.5626447554036438,29.2835816341172,110.1592408453204,0.7683102831177329,2022-11-10,Treatment follow-up,pas de greffe,2022-11-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,55,83.05940515723466,197.66227019714393,2.1355269050962162,21.258922977461214,100.25945213153126,0.9780249155049471,2022-12-05,Treatment follow-up,pas de greffe,2022-04-23,Protocole 3 LAL thiotepa Bu Flu
Male,27,104.80573758091575,140.21521002456103,2.020406897047056,53.30829655456467,92.65125785070957,1.7753324283768568,2022-08-07,Cancer diagnosis,allo-greffe,2022-10-26,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,74,89.84176223216852,153.2605947097614,1.9557040441200544,38.24875021335015,120.86187482262702,0.6813972465153516,2022-07-21,Cancer diagnosis,auto-greffe,2022-09-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,47,73.03631338091644,176.1946254131879,1.890664630178644,23.526294545680283,98.83116041798934,0.9545427884420429,2022-07-28,Symptoms management,greffe haplo-identique,2022-09-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,111.25102026294743,161.57594895314438,2.234545017757855,42.61383029221298,102.4428524187565,1.7647195842253764,2022-02-21,Cancer diagnosis,allo-greffe,2022-08-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,88.98760262548564,148.5319863404471,1.9161235011256572,40.33569355472461,133.30837561973595,1.0847394516223163,2022-02-06,Cancer diagnosis,auto-greffe,2022-07-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,32,44.14760858424134,155.92531379230525,1.3828040876821532,18.158247443903736,121.2679786489528,0.5460750118385342,2022-02-22,Cancer diagnosis,allo-greffe,2022-02-20,Protocole 6 FlUDARABINE cy (Fanconi)
Female,26,41.389020122782306,159.0377284575743,1.3522014707928995,16.3638246312413,134.17384222671257,0.4884157307180287,2022-04-28,Treatment follow-up,pas de greffe,2022-09-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,111.98279958943561,165.46384712152454,2.2686942421374052,40.90205094990147,112.28097098314745,0.9557884000010112,2022-04-23,Symptoms management,allo-greffe,2022-04-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,81.63608646438767,160.7088185881913,1.9090165450839383,31.60841800277723,77.09056713458749,1.2795807339902718,2022-12-30,Treatment follow-up,greffe haplo-identique,2022-06-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,52,52.087411987235974,155.48380002890912,1.4998841389927056,21.545793200628317,85.99803840725045,0.740277262225049,2022-12-29,Symptoms management,allo-greffe,2022-03-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,41.571693878111866,158.43259120872045,1.3526015244340732,16.56184325491395,87.36377753814367,0.43619205955577994,2022-05-07,Symptoms management,pas de greffe,2022-03-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,61.381995696774574,178.83300249958194,1.7461963894475372,19.19312395494936,134.3697574700406,0.7042550234586319,2022-06-10,Treatment follow-up,greffe haplo-identique,2022-05-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,54.61149584565953,169.50447515072815,1.6035458054396106,19.007357139904958,114.13112994995424,0.624705475445339,2022-09-23,Cancer diagnosis,allo-greffe,2022-05-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,75,65.70376236583456,199.80580578434336,1.9096242491484337,16.457885336556927,87.83754588013173,0.6752909133095916,2022-07-08,Treatment follow-up,greffe haplo-identique,2022-05-16,Protocole 3 LAL thiotepa Bu Flu
Male,79,109.02626570512379,186.33051691106493,2.3755069894959515,31.402423018707964,87.21952921361492,1.0590457887597335,2022-09-10,Symptoms management,pas de greffe,2022-11-12,Protocole 3 LAL thiotepa Bu Flu
Male,22,55.108305123858756,178.62301818683187,1.653582960690084,17.271983229561386,103.75798536284357,0.8704524151770361,2022-06-17,Treatment follow-up,greffe haplo-identique,2022-03-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,95.78104663727834,164.85468716013898,2.0943014268392433,35.24333348427992,84.0617556705818,1.5192171655740283,2022-01-11,Treatment follow-up,greffe haplo-identique,2022-02-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,60.0102806888442,171.04964032882918,1.688583966906631,20.51073990868578,81.53344510733979,1.001805574619701,2022-11-17,Cancer diagnosis,allo-greffe,2022-09-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,21,42.436913642180265,173.7973514795391,1.4313380682246684,14.049390479426478,90.45575442148197,0.7753933210092513,2022-08-05,Cancer diagnosis,pas de greffe,2022-04-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,56,48.97923784009633,153.99295226063694,1.4474553758687017,20.65429295520671,79.21069597570006,0.7213980819498035,2022-12-22,Treatment follow-up,auto-greffe,2022-03-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,108.1182757781433,183.763316821483,2.3492417787454682,32.01706141805483,80.86365290219254,1.4298944609106643,2022-10-14,Symptoms management,allo-greffe,2022-04-23,Protocole 3 LAL thiotepa Bu Flu
Male,46,54.87928267238004,177.96634912090286,1.6471073617083225,17.32736977713868,80.58778818260416,0.8890671154230234,2022-05-04,Cancer diagnosis,greffe haplo-identique,2022-03-30,Protocole 3 LAL thiotepa Bu Flu
Male,77,54.23433693252589,149.3888765927672,1.5001857910034997,24.301764732466896,90.09033774034597,0.5267495494659239,2022-08-11,Treatment follow-up,greffe haplo-identique,2022-07-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,109.12157821092556,164.44438824549363,2.2326137630140077,40.35269300788541,91.79826921946768,1.320789586155147,2022-12-17,Cancer diagnosis,pas de greffe,2022-04-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,91.76334444949734,177.23998307665647,2.125515206647706,29.210960260337107,78.23518387171114,1.4335647111856762,2022-07-08,Cancer diagnosis,greffe haplo-identique,2022-12-07,Protocole 3 LAL thiotepa Bu Flu
Female,70,100.22271387395482,191.73569717485222,2.310379473243066,27.26215638173038,85.18957622749429,1.1437872321312321,2022-08-23,Cancer diagnosis,auto-greffe,2022-05-12,Protocole 3 LAL thiotepa Bu Flu
Female,42,65.8898989576708,148.0026541834963,1.6458601204248515,30.080138662132583,125.26932753960287,0.7159252415793598,2022-01-28,Treatment follow-up,greffe haplo-identique,2022-12-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,21,99.8344790864331,152.6549185650854,2.057521720887586,42.84093615709214,121.35656589391488,1.3596644505771291,2022-05-26,Treatment follow-up,auto-greffe,2022-10-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,41,91.84313448179701,169.03489560400644,2.0766355434448984,32.143558754569106,91.44936080499735,1.3809206406784413,2022-07-24,Treatment follow-up,greffe haplo-identique,2022-11-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,112.28304036310412,162.16669322421598,2.248985534317255,42.69635903323499,100.52168144563618,0.9463499377071577,2022-01-16,Symptoms management,auto-greffe,2022-06-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,74,107.77350118298236,176.997040865675,2.301906866124571,34.40170603817148,125.47408462465262,0.7873528336941553,2022-03-29,Treatment follow-up,allo-greffe,2022-06-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,42.99112723499286,142.47933794157865,1.3044099715328887,21.177517812261332,90.89453056478027,0.6437758201197409,2022-04-13,Treatment follow-up,allo-greffe,2022-10-23,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,58.46978910926516,174.8777060022895,1.6853175261213091,19.11888813046221,100.04905037705356,0.6331121714431076,2022-03-28,Treatment follow-up,auto-greffe,2022-09-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,64.14950099815375,195.22006925987105,1.8651236202584642,16.83233466942248,126.5211552207997,0.8098330145650893,2022-03-12,Cancer diagnosis,pas de greffe,2022-10-06,Protocole 3 LAL thiotepa Bu Flu
Male,64,106.19916359921248,153.32178346422418,2.1267244744912417,45.17658219497688,85.81659799140242,1.3062638202429415,2022-09-26,Symptoms management,pas de greffe,2022-11-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,76,60.32199357377122,196.58904544492225,1.8149566214591601,15.608352268450284,87.71872140912888,0.6112668878661063,2022-03-01,Symptoms management,greffe haplo-identique,2022-08-04,Protocole 3 LAL thiotepa Bu Flu
Female,55,42.36887069936976,146.93215649315144,1.3150147379864752,19.625158957303253,108.33146557012358,0.46172001295762494,2022-12-30,Symptoms management,auto-greffe,2022-06-16,Protocole 6 FlUDARABINE cy (Fanconi)
Male,50,99.98334980100765,152.24095687673216,2.056261497465082,43.13846357810335,85.41394610252298,1.4632175769194193,2022-09-13,Treatment follow-up,auto-greffe,2022-04-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,66,63.2615729275739,193.55860109874084,1.8442720303661506,16.885543213434936,116.96446207664792,0.5558854175691524,2022-08-03,Symptoms management,pas de greffe,2022-04-26,Protocole 3 LAL thiotepa Bu Flu
Male,39,61.75650357895439,146.38315118114602,1.5846583578362547,28.82043396895899,101.92403538539855,0.8499531099435016,2022-06-11,Treatment follow-up,pas de greffe,2022-01-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,32,70.86056318141856,142.7917691415338,1.6764964442286072,34.753476175236514,125.20383302865068,0.8489424181431016,2022-08-28,Symptoms management,allo-greffe,2022-11-03,Protocole 8 Aplasie medullaire thymo
Male,21,76.94243014118396,161.43012753680344,1.8574793486726184,29.525463167580227,74.58381696669821,1.7050446581776442,2022-04-13,Symptoms management,allo-greffe,2022-03-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,106.50194975297177,152.66616330697025,2.1251956807614687,45.69534660356067,103.18744943343904,1.032121157541264,2022-04-10,Treatment follow-up,greffe haplo-identique,2022-03-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,26,46.92061855319792,151.40980067352774,1.404777711025477,20.467073696086267,78.85569349202906,0.9421130686448941,2022-01-15,Symptoms management,auto-greffe,2022-05-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,57,112.36250148463688,161.888573327996,2.2478511381188957,42.87350679161067,93.82961857294669,1.3804702261078814,2022-03-28,Symptoms management,allo-greffe,2022-11-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,55.725269687588266,162.35509664146852,1.5852866499907734,21.140746856555616,85.11830056049003,0.6364946806133438,2022-08-08,Cancer diagnosis,allo-greffe,2022-09-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,27,75.98827582111818,190.75260019997566,2.006583691362513,20.88361398892886,94.64709651595452,1.2600426396626192,2022-11-20,Cancer diagnosis,pas de greffe,2022-07-24,Protocole 3 LAL thiotepa Bu Flu
Male,72,85.44009635009195,154.6496039766155,1.9158169902351778,35.724331032519224,129.09985731175567,0.6250465803055119,2022-12-11,Symptoms management,pas de greffe,2022-10-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,31,105.95382973963807,150.6210200626151,2.105473944726838,46.703076505016014,134.83542798575215,1.1896155778510427,2022-07-16,Symptoms management,greffe haplo-identique,2022-12-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,59,79.18863208930455,178.6731484849695,1.9824845676584395,24.80528722765659,99.32128323279017,0.8969599284341119,2022-12-31,Cancer diagnosis,greffe haplo-identique,2022-03-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,25,77.51402066807816,173.11884284976648,1.9306833535975008,25.863755335761127,106.68181784452933,1.1605268718356014,2022-10-16,Cancer diagnosis,pas de greffe,2022-08-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,109.88367254701545,162.1588035386975,2.2247724520762193,41.78804977965026,125.38027129022797,1.4363274872068688,2022-06-16,Cancer diagnosis,pas de greffe,2022-06-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,41,64.36597816288315,194.3307606615682,1.8640077414836091,17.044068553926074,87.27986654451107,1.014016444775719,2022-11-06,Cancer diagnosis,auto-greffe,2022-11-20,Protocole 3 LAL thiotepa Bu Flu
Male,33,52.516346519685506,191.06411329585035,1.6694966957241042,14.385874225048369,124.31336346768938,0.627809624812789,2022-11-19,Treatment follow-up,greffe haplo-identique,2022-07-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,51,91.34212278570726,188.09526842859444,2.1846065692206484,25.817569720436076,130.8756692219989,0.8627196602629427,2022-06-04,Symptoms management,auto-greffe,2022-09-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,118.26576651917512,194.20636177818858,2.5258642216629816,31.356829621140548,94.4689567765052,1.3562259120268383,2022-09-10,Cancer diagnosis,allo-greffe,2022-02-23,Protocole 3 LAL thiotepa Bu Flu
Male,52,116.78718213826055,152.22607234785173,2.222239488386571,50.398440213666,107.63257930117587,1.3261773545413569,2022-01-08,Cancer diagnosis,auto-greffe,2022-04-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,54,54.72223404826459,193.74392141388898,1.716108340681145,14.578325670548274,79.18939516061846,0.8253967379592217,2022-03-07,Symptoms management,allo-greffe,2022-02-25,Protocole 3 LAL thiotepa Bu Flu
Male,42,58.52293622140891,150.996939071233,1.5667361894940968,25.667869363824224,91.30798056658766,0.8723905429900088,2022-05-24,Symptoms management,allo-greffe,2022-01-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,57,50.134643594278366,176.39222792624977,1.567319144261171,16.113097708898707,105.46623351761446,0.5479867925940545,2022-11-29,Treatment follow-up,greffe haplo-identique,2022-10-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,55.94243450167766,194.03453120254372,1.7364366492636925,14.858785410469228,122.93875364351099,0.5372036878929615,2022-01-12,Treatment follow-up,allo-greffe,2022-07-03,Protocole 3 LAL thiotepa Bu Flu
Male,45,64.64089377944832,174.05790519210944,1.7678658320915608,21.336336292595913,78.09925021239316,1.0920728169510943,2022-10-28,Cancer diagnosis,auto-greffe,2022-11-17,Protocole 3 LAL thiotepa Bu Flu
Female,77,56.66000160659783,142.17499312943875,1.4958865207936838,28.030455205866293,102.12697385464327,0.48544962740535597,2022-04-04,Symptoms management,greffe haplo-identique,2022-03-31,Protocole 6 FlUDARABINE cy (Fanconi)
Female,79,48.554420390992696,147.25499090218094,1.4092827897094302,22.391785631532674,109.81755844165076,0.37458840395022763,2022-07-17,Treatment follow-up,greffe haplo-identique,2022-11-12,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,67.21125788193106,196.39533378732423,1.9148525781656707,17.42527711192306,110.32607009135012,0.6092055832885197,2022-11-08,Cancer diagnosis,greffe haplo-identique,2022-09-07,Protocole 3 LAL thiotepa Bu Flu
Female,27,107.8844103977348,164.1815195187643,2.218146525535708,40.02304718047456,105.58821723909168,1.6035746503559953,2022-03-22,Cancer diagnosis,greffe haplo-identique,2022-04-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,63.62726569096359,155.93204585714926,1.660114597072573,26.16811902062761,88.12578973868723,0.9626734070262176,2022-09-25,Symptoms management,greffe haplo-identique,2022-07-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,94.91377206346947,163.9210898311516,2.0788865179752563,35.3231615728411,74.51015104606527,1.4153742175611574,2022-01-19,Symptoms management,greffe haplo-identique,2022-08-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,39,68.61751271382892,163.67351988086585,1.7662633054733912,25.614042570492657,123.05264943483081,0.7822271397116114,2022-06-13,Treatment follow-up,greffe haplo-identique,2022-03-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,61.71227061836747,157.44765995790027,1.6428678008246096,24.89425335796569,86.8818427697461,0.6708399509208477,2022-02-25,Treatment follow-up,auto-greffe,2022-10-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,33,71.21395429797985,163.5311129284238,1.7985871926461363,26.62957999357537,106.55612907353554,0.9932028281109105,2022-04-15,Symptoms management,auto-greffe,2022-01-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,33,69.41649930789288,166.01340914669066,1.789170330778129,25.186995941255944,124.80383415407577,0.8265822249382183,2022-02-20,Treatment follow-up,auto-greffe,2022-08-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,32,111.5990458362227,151.10157525991266,2.164280200035494,48.87902085340828,100.81101174791596,1.6605186859241559,2022-07-30,Symptoms management,greffe haplo-identique,2022-01-04,Protocole 6 FlUDARABINE cy (Fanconi)
Female,78,46.224867466486785,154.65329593534747,1.4091790466504086,19.32668261167276,127.64458855975153,0.3118404582141556,2022-10-30,Treatment follow-up,auto-greffe,2022-01-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,45,74.60814434030158,149.70797810232784,1.7614257513567102,33.28866267494908,93.97392949819532,1.0475384192805368,2022-04-20,Treatment follow-up,auto-greffe,2022-08-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,29,97.87732769594187,156.53262371747974,2.0629667759147616,39.94591504559275,108.86531593190215,1.3860632492504008,2022-12-24,Cancer diagnosis,allo-greffe,2022-01-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,52,51.74702387260485,173.98781179746672,1.58143319761132,17.09415844118668,123.47085209771072,0.5122371915025775,2022-08-13,Symptoms management,allo-greffe,2022-10-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,93.06297871744746,140.39037343292955,1.9050478511723667,47.21742407265781,74.49785274695351,1.3186036990276504,2022-11-07,Treatment follow-up,pas de greffe,2022-07-08,Protocole 6 FlUDARABINE cy (Fanconi)
Female,26,101.97744283805183,147.49080014119622,2.044011214400183,46.87855907472751,90.29015637490217,1.78828225552242,2022-03-21,Cancer diagnosis,allo-greffe,2022-01-09,Protocole 6 FlUDARABINE cy (Fanconi)
Female,70,93.45582639164878,190.7124263774388,2.225058514228085,25.694986802557043,107.09097124251534,0.8484359620601838,2022-09-02,Symptoms management,pas de greffe,2022-12-28,Protocole 3 LAL thiotepa Bu Flu
Female,71,116.99562555751638,173.7902327979763,2.376546105052552,38.736367639632306,113.73962717097221,0.985767323269087,2022-02-27,Cancer diagnosis,auto-greffe,2022-02-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,61.226090695043176,192.0070319915759,1.8070725216648582,16.607423539399985,93.93817066468421,1.0229169592772613,2022-11-10,Symptoms management,pas de greffe,2022-02-22,Protocole 3 LAL thiotepa Bu Flu
Male,68,73.88320433574714,147.72327711452638,1.7411896530340933,33.85695182568189,111.5215988031097,0.6625013013504875,2022-05-09,Symptoms management,auto-greffe,2022-03-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,35,115.25405621512212,194.38491732059072,2.4946414899539744,30.502194801364755,130.1400165622949,1.2915230566297884,2022-07-19,Treatment follow-up,pas de greffe,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,83.36944743213365,141.16726580353006,1.8080865381165188,41.83491748219095,117.22953024411953,0.7803051857875459,2022-10-16,Treatment follow-up,greffe haplo-identique,2022-02-08,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,69,93.9706004218995,185.45563614261567,2.200213214412218,27.321964891912312,130.73803411694394,0.7087872616390208,2022-12-21,Cancer diagnosis,allo-greffe,2022-09-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,62,110.28938702793279,198.9360869839474,2.4687231906389653,27.86804996412972,116.1853024282095,1.0283587233771407,2022-05-05,Cancer diagnosis,allo-greffe,2022-03-01,Protocole 3 LAL thiotepa Bu Flu
Female,22,83.89932694984755,145.22979967239817,1.8397374847134664,39.77837157798112,108.61504917043078,1.2659541727740111,2022-08-20,Symptoms management,allo-greffe,2022-09-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,24,90.26205941002985,195.95328482457109,2.2165505631514937,23.50715884245413,117.88366495323183,1.2336077851410872,2022-03-21,Treatment follow-up,greffe haplo-identique,2022-06-24,Protocole 3 LAL thiotepa Bu Flu
Male,21,60.26425630100562,184.20090843168177,1.756000091480393,17.761362008771908,79.02151540152653,1.2604595482951515,2022-04-03,Symptoms management,auto-greffe,2022-12-03,Protocole 3 LAL thiotepa Bu Flu
Male,72,107.19179738833786,185.87971296543935,2.3525860788829442,31.023983937007035,99.79985371380043,1.0143972537650232,2022-07-26,Symptoms management,allo-greffe,2022-01-11,Protocole 3 LAL thiotepa Bu Flu
Male,28,119.20853189701594,168.8365185223358,2.3644798290798072,41.8190885397782,86.07698197503117,2.154298278206537,2022-09-21,Treatment follow-up,pas de greffe,2022-11-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,25,112.85726642292448,152.27880490910326,2.1849084430468837,48.66879652367013,105.15524262107913,1.7142096711192867,2022-01-21,Treatment follow-up,pas de greffe,2022-03-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,75,55.77334399551625,192.35726220559738,1.72630045626064,15.073340501807078,102.72414938676515,0.4901567533251814,2022-05-30,Cancer diagnosis,greffe haplo-identique,2022-05-16,Protocole 3 LAL thiotepa Bu Flu
Female,21,55.0411020461756,191.40285305072467,1.7106710806884864,15.024163692155481,125.2804470532169,0.7261365397880107,2022-10-28,Symptoms management,pas de greffe,2022-03-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,82.68188207945708,156.19424011538942,1.894028169354569,33.89068326324818,107.99348032457529,1.010192000832522,2022-07-27,Treatment follow-up,pas de greffe,2022-03-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,113.16742213450377,179.62342514881698,2.3762435328722336,35.07482203557945,119.47524068671808,0.9603595793310447,2022-01-12,Cancer diagnosis,auto-greffe,2022-04-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,115.74550001638227,184.60489045953605,2.436253119928934,33.96391235506072,104.26552789004165,1.4338833477685409,2022-06-03,Symptoms management,greffe haplo-identique,2022-02-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,74.66829772260373,180.86190365184592,1.9368251848889848,22.826643443621514,80.92110647616914,0.9739923231052416,2022-06-26,Symptoms management,greffe haplo-identique,2022-01-23,Protocole 3 LAL thiotepa Bu Flu
Male,49,103.08995730830836,199.52872902585267,2.3903398269014304,25.89437823949569,76.19937596915354,1.7099123180581635,2022-07-17,Symptoms management,pas de greffe,2022-04-17,Protocole 2 LAM Endoxan TBI
Female,57,66.23733096356776,196.64187652272668,1.9021211154723554,17.12974130583586,134.83775714047817,0.5662874020854695,2022-03-31,Symptoms management,allo-greffe,2022-08-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,50.49317914962316,140.9742186481931,1.4061606986639346,25.406996234620635,132.49440810316284,0.4128547375083721,2022-07-12,Treatment follow-up,greffe haplo-identique,2022-02-19,Protocole 8 Aplasie medullaire thymo
Male,20,86.52017242968513,152.92864279747425,1.917131287473494,36.99471685305508,96.02328456295658,1.5017220879198865,2022-11-16,Cancer diagnosis,pas de greffe,2022-07-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,61.94047069039392,140.71487024405448,1.5559871193460046,31.28200003507484,98.10905387063703,1.034701132893265,2022-07-23,Symptoms management,greffe haplo-identique,2022-08-10,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,21,76.11686352877459,196.17401755741366,2.0366196750108774,19.778707677176605,105.01098661132126,1.198010461706675,2022-02-16,Symptoms management,greffe haplo-identique,2022-08-29,Protocole 3 LAL thiotepa Bu Flu
Male,40,54.71699751511296,147.11945402142067,1.495357147985692,25.28028986660967,111.3136348624933,0.6827180693180996,2022-01-18,Symptoms management,greffe haplo-identique,2022-05-15,Protocole 6 FlUDARABINE cy (Fanconi)
Female,59,119.20470850295224,162.4739461987375,2.319462305742962,45.15709051387313,119.34568075097953,1.1236711393488834,2022-02-14,Symptoms management,auto-greffe,2022-03-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,49,81.38573207314806,148.42689459565617,1.83180477762684,36.942226947346725,120.614845117765,0.852818095325727,2022-02-25,Treatment follow-up,pas de greffe,2022-09-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,34,45.00592948226676,141.52610010589876,1.3301538842958387,22.46966805096603,80.3486908057064,0.8246398149259412,2022-06-05,Cancer diagnosis,greffe haplo-identique,2022-07-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,112.44600178088793,185.2273225007518,2.4053223297390494,32.774337378367875,120.19282150646252,1.5462508543691962,2022-02-14,Cancer diagnosis,allo-greffe,2022-07-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,42,49.20276156163653,188.9287838552489,1.606913700247895,13.784569923267036,98.67921542429163,0.6786679968110916,2022-08-16,Treatment follow-up,allo-greffe,2022-09-17,Protocole 3 LAL thiotepa Bu Flu
Male,73,96.52830384345208,182.58864633167215,2.212651271129292,28.953904475937186,104.24603826284837,0.861662955319149,2022-10-16,Treatment follow-up,auto-greffe,2022-07-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,23,103.68045243054951,153.17982521185337,2.1003804933866843,44.18692140384058,130.71178974493307,1.2889482695356789,2022-10-19,Cancer diagnosis,allo-greffe,2022-12-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,73,63.4503550676946,174.30197783289648,1.752737730150774,20.88475699794943,124.30855343337845,0.4749800297681021,2022-09-17,Treatment follow-up,pas de greffe,2022-10-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,41,60.941824441306494,186.50146119649668,1.7768370232807287,17.52068066740987,133.92586600982295,0.6256820366623604,2022-05-04,Cancer diagnosis,allo-greffe,2022-07-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,51.43509274235978,157.83223430684563,1.5016764344212903,20.647530589366944,129.6654228380112,0.567466299516265,2022-09-24,Cancer diagnosis,pas de greffe,2022-06-28,Protocole 6 FlUDARABINE cy (Fanconi)
Male,20,119.05184788004226,178.4146342292779,2.4290254043452957,37.40030921776439,79.85053321897705,2.484889436149454,2022-04-27,Cancer diagnosis,pas de greffe,2022-04-21,Protocole 3 LAL thiotepa Bu Flu
Male,39,64.19067567953365,156.22026881143958,1.6689887665094199,26.30250946833796,115.47920556291294,0.7797529688990952,2022-12-14,Cancer diagnosis,pas de greffe,2022-11-25,Protocole 6 FlUDARABINE cy (Fanconi)
Female,79,64.64391914511046,152.83526782414444,1.656625644675319,27.674546553291457,75.8003849488618,0.7225262097049088,2022-10-28,Treatment follow-up,greffe haplo-identique,2022-06-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,62.047096786520484,146.20551046991451,1.5874181920171702,29.026453922485782,88.02219368497806,0.802806044244741,2022-09-20,Treatment follow-up,allo-greffe,2022-12-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,28,51.559087680809895,150.39784363307575,1.4676488763100064,22.794076688314078,97.0033393859702,0.8268068479801198,2022-09-15,Cancer diagnosis,greffe haplo-identique,2022-01-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,55.2779725371671,140.47610598810823,1.4686761167174809,28.012197888257635,93.96509858243479,0.7516936178876745,2022-11-07,Symptoms management,pas de greffe,2022-03-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,109.38915177708765,180.58108425881525,2.3424590375914907,33.545150301968214,120.10291077436395,0.9866947741825526,2022-11-21,Cancer diagnosis,allo-greffe,2022-07-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,67.52199394685609,169.8566797239557,1.7848950871872,23.403456168741915,99.50332377165324,1.1309838939285082,2022-10-30,Symptoms management,allo-greffe,2022-02-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,66.98780419501618,181.97362349648944,1.8401398995306208,20.229206902794537,131.7331999319779,0.5438244503199223,2022-12-12,Cancer diagnosis,allo-greffe,2022-01-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,89.65947696901912,153.89049950216662,1.9577298145120194,37.85930023226051,116.39980037616508,0.8558574907752781,2022-08-20,Cancer diagnosis,pas de greffe,2022-03-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,73,76.44169868251002,158.6024437957129,1.8351385217880556,30.388592104698116,89.93220154881938,0.7909652622759274,2022-06-06,Cancer diagnosis,auto-greffe,2022-09-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,85.96403806264766,152.96606772878118,1.9111936982863824,36.73893839230959,133.51287177949007,0.7511738486563071,2022-10-14,Cancer diagnosis,greffe haplo-identique,2022-03-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,76,106.26503416041376,140.6973760418808,2.0379191096810167,53.68072714442121,96.67530685913036,0.9770624082965512,2022-02-06,Cancer diagnosis,greffe haplo-identique,2022-07-23,Protocole 6 FlUDARABINE cy (Fanconi)
Female,60,95.05490639712876,152.24438235426982,2.0049643605985867,41.010209253701674,99.67836068266098,1.0595736320315345,2022-05-31,Cancer diagnosis,greffe haplo-identique,2022-10-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,85.90492166275808,199.33571391207008,2.180973208366593,21.619607958264652,94.24648167850981,1.0760670394517098,2022-08-07,Cancer diagnosis,greffe haplo-identique,2022-06-02,Protocole 3 LAL thiotepa Bu Flu
Female,37,69.27902775238249,181.85393687324978,1.8707295026511481,20.948665857247505,129.71091658826015,0.764064433753514,2022-02-13,Treatment follow-up,allo-greffe,2022-12-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,78,65.70780509299698,154.58040278141064,1.6797105386509223,27.49844217097534,118.48104052508445,0.47755928544806825,2022-04-02,Cancer diagnosis,auto-greffe,2022-03-01,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,89.47715713458767,150.05445315140074,1.9312090256978418,39.73876814076556,101.81936659783867,0.7811406949764748,2022-10-14,Cancer diagnosis,pas de greffe,2022-06-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,116.01013802196553,170.10022608383986,2.3412574200839766,40.094625542422584,126.11068571662517,1.5204023119062346,2022-09-09,Cancer diagnosis,auto-greffe,2022-05-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,82.77048164594413,180.4829976945201,2.037063835256741,25.409896203838095,97.60603834326017,1.224897192907435,2022-06-25,Treatment follow-up,greffe haplo-identique,2022-08-28,Protocole 3 LAL thiotepa Bu Flu
Female,41,103.58023217960498,178.2808358927725,2.264850398232582,32.58873905964305,90.45175218271169,1.5745722532744757,2022-08-31,Cancer diagnosis,greffe haplo-identique,2022-03-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,54.39190690272311,184.8876491958581,1.6713593770843842,15.911769677766948,94.90516382374645,0.6049584363507978,2022-05-31,Symptoms management,allo-greffe,2022-03-08,Protocole 3 LAL thiotepa Bu Flu
Male,55,98.91543138705454,173.64525427580654,2.1842997374575845,32.80486178315784,119.82696710638277,0.9745315672597159,2022-12-02,Cancer diagnosis,greffe haplo-identique,2022-01-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,77.18748259731527,170.38489338046878,1.911339044335901,26.587940814373702,112.03881025530643,0.8324633930500454,2022-03-21,Treatment follow-up,allo-greffe,2022-06-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,72,76.66229441199104,192.58448984772278,2.0251178881932623,20.669939148256375,134.38163968745053,0.5387884700928443,2022-02-22,Symptoms management,greffe haplo-identique,2022-11-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,103.75746395419569,163.60439441564571,2.17148036143353,38.76407443763961,123.10696338455165,1.3812943649876384,2022-09-25,Treatment follow-up,allo-greffe,2022-07-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,32,60.95072905977534,152.79393395486827,1.6083896078635425,26.107583718330442,94.18496643143266,0.9707079277479157,2022-10-03,Treatment follow-up,pas de greffe,2022-05-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,95.7438220151507,157.20753215806414,2.0447527681566062,38.740396361194264,78.16892351899341,1.9052946815827894,2022-03-27,Symptoms management,greffe haplo-identique,2022-08-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,41,59.29623121557314,197.39003367736314,1.8031211425210185,15.21866820853124,120.43962502220685,0.6769559263106307,2022-03-04,Cancer diagnosis,allo-greffe,2022-10-30,Protocole 3 LAL thiotepa Bu Flu
Male,63,82.81918650146707,183.77428592618173,2.0561585582703583,24.522315316098716,122.83859600683645,0.7210316771487113,2022-07-18,Symptoms management,greffe haplo-identique,2022-05-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,65.99508360422762,182.13997554929108,1.8272887409468037,19.893034485170187,84.32221261745674,1.0217977608075177,2022-01-06,Treatment follow-up,auto-greffe,2022-11-15,Protocole 3 LAL thiotepa Bu Flu
Male,76,119.79432382308207,150.60409118285125,2.238645130197148,52.81565876808632,132.21591159222476,0.8053784307497615,2022-03-04,Symptoms management,auto-greffe,2022-08-25,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,21,100.054108266316,193.56292203644858,2.319408782294131,26.704877272536454,102.63304907223291,1.6112471393259873,2022-04-06,Cancer diagnosis,pas de greffe,2022-11-24,Protocole 3 LAL thiotepa Bu Flu
Female,79,60.08578715772948,169.8743452387904,1.6838310940280579,20.821698973330523,88.94576908336758,0.5723264259149815,2022-08-21,Treatment follow-up,greffe haplo-identique,2022-11-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,23,110.56433342230488,149.83446769751328,2.1451721016597447,49.248339648390534,75.21051553053192,2.3888553421537058,2022-03-10,Treatment follow-up,pas de greffe,2022-11-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,89.60543099295515,161.37460513273405,2.0041651797802236,34.408357977759636,121.26995336385579,1.0672888328857921,2022-11-12,Cancer diagnosis,auto-greffe,2022-06-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,53,78.6797045826939,199.76940428078504,2.089510689230649,19.715362719324393,97.22848064085443,0.9778133842825932,2022-08-05,Symptoms management,allo-greffe,2022-04-10,Protocole 3 LAL thiotepa Bu Flu
Female,26,52.412930876689245,140.38838389682098,1.4296626118185087,26.59353657961791,85.14054073430482,0.9747076990470744,2022-01-24,Symptoms management,auto-greffe,2022-09-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,78,87.04900983503819,168.034343139509,2.015717627144742,30.829588657666847,131.3059909694033,0.5708716641698287,2022-11-28,Cancer diagnosis,allo-greffe,2022-12-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,85.87549590465939,163.22651921548936,1.9732346739428726,32.232041911156266,110.73446809590958,0.9155305978308926,2022-09-18,Treatment follow-up,allo-greffe,2022-10-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,61,50.83701184224566,174.26734435042897,1.5687248048848341,16.739712276827415,98.09563033574508,0.5686236880661615,2022-01-20,Symptoms management,auto-greffe,2022-01-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,76,77.10516918651837,199.00135368409676,2.064517231983092,19.470245749294637,112.2361354449964,0.6106583044226652,2022-09-16,Symptoms management,auto-greffe,2022-08-29,Protocole 3 LAL thiotepa Bu Flu
Male,44,86.54751887923419,140.319800163956,1.8366886382397496,43.95585247251633,110.97549447811264,1.039839402218102,2022-12-30,Symptoms management,allo-greffe,2022-12-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,70,85.28984081239827,185.0837520356883,2.0940234894738228,24.89778508728567,128.7494618936835,0.644046797151527,2022-11-14,Symptoms management,pas de greffe,2022-11-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,86.4151837541966,170.67064121233028,2.024059097032638,29.66691706241216,76.33229942927447,1.7924789632587794,2022-10-19,Symptoms management,auto-greffe,2022-07-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,85.32679315293493,180.82332977091676,2.0702304525897564,26.096153556580653,128.8652795284271,0.6897286571389224,2022-05-15,Cancer diagnosis,auto-greffe,2022-11-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,87.75482160993978,143.69213208832386,1.8715469996000311,42.50157361364078,104.1488844508163,0.8308874847718719,2022-03-13,Symptoms management,auto-greffe,2022-05-31,Protocole 6 FlUDARABINE cy (Fanconi)
Female,39,77.7205145789705,191.156446662785,2.0314730150885847,21.26952393354218,93.177373906393,1.1700760190812087,2022-07-15,Symptoms management,greffe haplo-identique,2022-08-01,Protocole 3 LAL thiotepa Bu Flu
Female,79,119.35054728489713,199.30650727633727,2.570524196479527,30.045639899846908,134.59627483191886,0.7512573139221063,2022-09-14,Cancer diagnosis,auto-greffe,2022-05-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,39,58.967837566884256,195.03739948736953,1.7873734370453198,15.501702807319374,129.88289886416234,0.6368719274501723,2022-01-06,Treatment follow-up,greffe haplo-identique,2022-05-12,Protocole 3 LAL thiotepa Bu Flu
Female,42,101.37412414576892,181.73041707653658,2.2621745844417527,30.695299016799336,108.16076542090683,1.2757070109203597,2022-03-10,Symptoms management,pas de greffe,2022-05-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,68,92.84368745897915,171.9515429490212,2.105852645449512,31.400764848884297,114.42011121256843,0.8114280477012924,2022-07-24,Treatment follow-up,greffe haplo-identique,2022-11-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,118.44026872938448,149.42287257664194,2.217210784239592,53.04753666105777,130.65946530607968,1.1456907411446273,2022-01-13,Cancer diagnosis,allo-greffe,2022-02-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,30,93.25496315886303,192.60279855026224,2.2336546337970313,25.138928829495725,123.92447174127291,1.1496749461966507,2022-04-03,Treatment follow-up,greffe haplo-identique,2022-09-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,75,95.91316986342088,195.65697397266942,2.2831557461112872,25.05460610895068,119.54678623151446,0.7243045261060774,2022-01-06,Cancer diagnosis,greffe haplo-identique,2022-03-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,95.80028610503352,181.35532130525544,2.1968343175600147,29.127700463410306,76.6162899316728,1.4066893863469228,2022-10-08,Treatment follow-up,allo-greffe,2022-03-04,Protocole 3 LAL thiotepa Bu Flu
Male,59,66.44469168862042,171.30283111547112,1.7781204026580124,22.642856249132077,88.17402315431414,0.8477585061404861,2022-08-04,Treatment follow-up,greffe haplo-identique,2022-12-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,109.20090939726538,199.33668053192616,2.458982783722576,27.48221996518871,118.9916740377584,0.9432111019466767,2022-08-21,Symptoms management,pas de greffe,2022-02-06,Protocole 3 LAL thiotepa Bu Flu
Female,32,47.286140544748214,141.5203257618756,1.363405663720511,23.610013180196326,98.62206343524038,0.7192022590735753,2022-03-02,Symptoms management,pas de greffe,2022-11-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,20,51.23080697194424,175.51783741539828,1.5804289544966865,16.629863263181914,106.85823147644761,0.7990463355683851,2022-10-27,Cancer diagnosis,auto-greffe,2022-12-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,47.69494115852431,149.9399739811243,1.4094303652678257,21.214727370384246,74.97954141049516,0.7156193248713216,2022-07-27,Cancer diagnosis,auto-greffe,2022-06-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,100.23411580283934,158.941608050651,2.1036589517657123,39.677139878439135,132.3463170125862,1.0518921332198945,2022-01-21,Cancer diagnosis,greffe haplo-identique,2022-12-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,40,53.92696005817012,160.3084558344632,1.5496368476707358,20.984231923087002,134.196147389634,0.5581274656036282,2022-05-24,Treatment follow-up,auto-greffe,2022-12-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,78,92.56391488789828,199.22492880335176,2.2632964744974338,23.321385816570483,123.12941199936122,0.6473499247955957,2022-04-16,Symptoms management,allo-greffe,2022-02-06,Protocole 3 LAL thiotepa Bu Flu
Male,71,79.7192762890738,186.53854526495337,2.03242587869075,22.910057347193316,88.79226456064985,0.8604087321688411,2022-10-09,Treatment follow-up,pas de greffe,2022-06-24,Protocole 3 LAL thiotepa Bu Flu
Male,62,71.96421080934833,155.857220535492,1.7651048028984977,29.62529700748694,103.55569201857764,0.7528434879543653,2022-07-01,Treatment follow-up,pas de greffe,2022-01-30,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,79,69.64848019788667,193.61331766132946,1.9354064546685914,18.579806655993742,131.42321825835234,0.4489902237187367,2022-02-06,Symptoms management,auto-greffe,2022-04-14,Protocole 3 LAL thiotepa Bu Flu
Male,49,75.2208634982321,151.21309166129888,1.7775122539818444,32.89724496078939,118.05194567904095,0.8053303403107087,2022-03-08,Symptoms management,pas de greffe,2022-06-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,56,77.97108423472658,192.58450509732458,2.0423313658963527,21.02281602164611,116.89672038807802,0.7781763649016089,2022-12-22,Cancer diagnosis,pas de greffe,2022-12-10,Protocole 3 LAL thiotepa Bu Flu
Female,26,67.8164689800274,196.54225919019527,1.9241738504006496,17.555907577578616,109.85547310216423,0.977430371495328,2022-04-23,Treatment follow-up,greffe haplo-identique,2022-08-04,Protocole 3 LAL thiotepa Bu Flu
Female,79,104.28147991300999,151.7516096178886,2.096616482582697,45.283561182423796,122.13668068060989,0.7233665321195232,2022-01-25,Symptoms management,greffe haplo-identique,2022-11-22,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,72,49.292466731265144,153.58432785599112,1.4501484953929107,20.897135038326542,117.14410359036114,0.3974079354441919,2022-04-15,Cancer diagnosis,allo-greffe,2022-04-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,33,98.47684720132209,172.8069775348793,2.1741847975495836,32.9770336478628,115.81589551778416,1.2636222010700027,2022-01-01,Symptoms management,allo-greffe,2022-11-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,76.28931753973154,170.71916163234127,1.9020492115878045,26.175753435835613,83.81678167068154,0.8722668004938394,2022-08-15,Symptoms management,allo-greffe,2022-05-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,118.31883342091217,195.31210029248948,2.533612915471345,31.016699219663828,98.60876426785056,1.5665119773728542,2022-03-23,Treatment follow-up,pas de greffe,2022-11-30,Protocole 3 LAL thiotepa Bu Flu
Female,74,116.56274014352522,143.0328355375577,2.15202096494047,56.97551396254304,77.45952015692595,1.3794195761661239,2022-10-21,Cancer diagnosis,greffe haplo-identique,2022-09-08,Protocole 6 FlUDARABINE cy (Fanconi)
Male,66,95.15327074356897,191.55218883083165,2.2501121753113265,25.932804329008565,130.05596882696537,0.7519563925837732,2022-11-12,Treatment follow-up,pas de greffe,2022-11-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,50,76.66924711004569,143.1352292080204,1.7459532781631186,37.42209723904535,98.94683307233107,0.9685662078492162,2022-03-05,Treatment follow-up,auto-greffe,2022-01-31,Protocole 6 FlUDARABINE cy (Fanconi)
Male,65,58.680491890656796,177.02401012052485,1.698680532904633,18.72532639573676,92.09388689225722,0.663730400016811,2022-11-29,Symptoms management,allo-greffe,2022-06-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,54.94247882664244,157.84212931780542,1.5520808476933727,22.052731382915674,122.990000636981,0.5149725044259841,2022-06-29,Treatment follow-up,allo-greffe,2022-04-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,36,49.59119862343178,191.56449931410936,1.6244582972900585,13.513708530739653,111.73802858968814,0.6410685086273986,2022-03-21,Symptoms management,pas de greffe,2022-01-17,Protocole 3 LAL thiotepa Bu Flu
Female,26,104.65711270398296,162.3084515615348,2.172219417240023,39.72706491940939,84.59399200743998,1.9588518189337356,2022-07-04,Symptoms management,greffe haplo-identique,2022-08-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,77,59.05658983434043,187.9379716434738,1.755861272175008,16.720116331914404,101.94371953897608,0.5068925907229742,2022-05-09,Treatment follow-up,greffe haplo-identique,2022-06-17,Protocole 3 LAL thiotepa Bu Flu
Male,62,85.36497392843046,181.9327108101487,2.0770358897983163,25.790403142463724,94.89992787665108,0.9744867443524462,2022-05-20,Symptoms management,pas de greffe,2022-03-27,Protocole 3 LAL thiotepa Bu Flu
Female,25,66.0085099886273,173.2219676428078,1.7821743883214336,21.998546891935057,94.95697948519195,1.11029499444066,2022-07-02,Treatment follow-up,greffe haplo-identique,2022-04-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,117.98626511742174,156.04126861233684,2.261435537671321,48.45655208058387,106.36289006520667,1.8333939304349713,2022-03-17,Symptoms management,pas de greffe,2022-09-14,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,64.06431123581527,184.9718473506719,1.81430228390184,18.72426993442865,109.02565781485364,0.563124003696298,2022-06-02,Cancer diagnosis,auto-greffe,2022-11-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,40,111.4882771317444,140.81564631825472,2.0882803798297833,56.22472999317,129.03083072502133,1.200060702388533,2022-04-10,Treatment follow-up,allo-greffe,2022-02-20,Protocole 9 LAL thiotepa-thymo melphalan
Male,59,119.63589852052584,199.20978103811473,2.572970675469422,30.14672917534626,99.09447257246245,1.3582027568406794,2022-09-01,Treatment follow-up,pas de greffe,2022-02-01,Protocole 3 LAL thiotepa Bu Flu
Male,44,102.61231789911065,153.5973141202778,2.0923787914555994,43.49429092045552,113.21267015925909,1.208490389574045,2022-09-12,Symptoms management,allo-greffe,2022-02-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,58,97.0359953047464,179.3293167511416,2.1985726896650193,30.173818743926862,92.3356970862371,1.1968634056191294,2022-12-06,Cancer diagnosis,pas de greffe,2022-03-21,Protocole 3 LAL thiotepa Bu Flu
Female,39,67.20840512815077,143.42342881785333,1.6363288779781457,32.672576816754585,89.63331877474761,1.0518237914472603,2022-11-16,Cancer diagnosis,greffe haplo-identique,2022-01-18,Protocole 6 FlUDARABINE cy (Fanconi)
Male,77,89.07495494764484,199.8555315159235,2.2237432446851675,22.300944937842438,81.37469979075757,0.9577987480089187,2022-04-09,Symptoms management,allo-greffe,2022-07-17,Protocole 3 LAL thiotepa Bu Flu
Male,51,109.75368383046062,182.08769932344546,2.356126516420154,33.10227854256167,94.27263364852584,1.4391000104443326,2022-02-01,Symptoms management,greffe haplo-identique,2022-11-23,Protocole 3 LAL thiotepa Bu Flu
Male,32,48.12159797365173,145.3889311971111,1.394069551995792,22.76550836117937,129.4140545676319,0.5577631981444103,2022-06-28,Cancer diagnosis,pas de greffe,2022-06-06,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,37,78.83566126401394,170.1008287580304,1.9300267209359308,27.246445641778333,74.78251649793226,1.5080903729717277,2022-04-24,Symptoms management,allo-greffe,2022-02-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,83.13820224031727,185.5443686847063,2.070012429395125,24.149329284671037,91.85544496117218,1.3953597979375953,2022-07-06,Symptoms management,allo-greffe,2022-04-26,Protocole 3 LAL thiotepa Bu Flu
Female,59,108.07780687254957,144.461853738352,2.082541204659994,51.788121290631,110.16126315953875,1.1037231168594324,2022-11-23,Treatment follow-up,auto-greffe,2022-09-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,40,44.77762279384464,169.70485697100565,1.452868816412228,15.547926876364157,79.8203927791527,0.779138520920328,2022-03-21,Treatment follow-up,auto-greffe,2022-10-14,Protocole 3 LAL thiotepa Bu Flu
Male,30,89.60815112696338,186.43830090894227,2.1542201117614317,25.77966348195709,121.50931470650258,1.1266736408661606,2022-04-08,Treatment follow-up,greffe haplo-identique,2022-07-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,57.21447691043947,160.49196317680472,1.5970862115367053,22.212597788420343,82.48113068911643,0.7514730880682282,2022-12-29,Symptoms management,auto-greffe,2022-05-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,108.74428252484647,189.0898957330927,2.389935206245907,30.413737096524454,103.52192516246032,1.0358573326304665,2022-08-29,Treatment follow-up,allo-greffe,2022-11-16,Protocole 3 LAL thiotepa Bu Flu
Male,75,91.2509325801208,150.47767274271442,1.9530053742216347,40.298898892550945,78.11552142972711,1.0545831689664888,2022-05-30,Cancer diagnosis,pas de greffe,2022-01-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,42,95.57548533038317,182.9495238965704,2.2038784964351454,28.555117054297657,104.17842126380818,1.2487120984834381,2022-03-17,Symptoms management,greffe haplo-identique,2022-10-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,87.26938192851915,190.3051094962273,2.1478548266930395,24.096890410706674,119.88102415963053,0.9402901956157094,2022-02-01,Treatment follow-up,greffe haplo-identique,2022-11-25,Protocole 3 LAL thiotepa Bu Flu
Male,56,52.98035732118383,184.172925242578,1.646338309724498,15.619362734369846,124.25688655940571,0.49744057320447715,2022-03-14,Treatment follow-up,allo-greffe,2022-11-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,22,85.97263890557119,149.46139524825145,1.8892672421397767,38.485948394476964,100.76173771256768,1.3983443105430216,2022-03-12,Treatment follow-up,auto-greffe,2022-02-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,54,62.47482632988736,179.16547218602494,1.763309054585076,19.462401185516566,95.1156801141338,0.7845468711133868,2022-05-17,Treatment follow-up,pas de greffe,2022-12-14,Protocole 3 LAL thiotepa Bu Flu
Male,34,102.11289658147048,171.20438379498788,2.2036696375182907,34.837809019775875,85.0723228101716,1.7671185005512278,2022-02-23,Symptoms management,auto-greffe,2022-09-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,105.89307378649374,178.70878567037613,2.292743542576099,33.15703954814183,90.49107967421918,1.2352159210896532,2022-03-09,Symptoms management,allo-greffe,2022-03-31,Protocole 3 LAL thiotepa Bu Flu
Female,20,74.32282726954489,174.34431850288064,1.8972028144903306,24.451562893078858,108.3082758321405,1.1436926479612186,2022-05-13,Symptoms management,greffe haplo-identique,2022-09-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,93.6789370808963,186.09402846505304,2.200573838274174,27.050611037094587,133.74359635718733,0.9436440265333016,2022-11-18,Symptoms management,auto-greffe,2022-06-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,93.85975444520676,161.48644239472526,2.0519014101694215,35.992107701955455,121.2792099739357,1.279108895976943,2022-06-14,Treatment follow-up,auto-greffe,2022-11-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,66,102.12890513701909,174.04631231879233,2.222058562600476,33.71467862786327,126.67903767259472,0.8285965941728248,2022-02-02,Symptoms management,auto-greffe,2022-10-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,107.2838152352727,148.4436512038387,2.103277947540847,48.686768909557976,109.20177629510357,1.6373942328763371,2022-05-17,Cancer diagnosis,greffe haplo-identique,2022-07-26,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,25,90.69995485898413,158.6118617908228,1.9990337043825739,36.05252984852891,130.61806960912617,1.1090960376986008,2022-06-14,Cancer diagnosis,auto-greffe,2022-06-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,64,66.8652901238295,144.20359461556106,1.6365796982043397,32.1550034599344,75.15749866620772,0.9390949634647222,2022-02-09,Symptoms management,pas de greffe,2022-02-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,87.82327234771856,157.22467279031497,1.9584563974272051,35.52779187294269,131.1366082750544,0.6790097836940392,2022-08-19,Cancer diagnosis,auto-greffe,2022-01-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,22,76.92290438855795,195.62828738028543,2.0445249411436928,20.099829234629237,74.13320628353202,1.7005617269716662,2022-11-26,Cancer diagnosis,allo-greffe,2022-01-11,Protocole 3 LAL thiotepa Bu Flu
Male,74,68.11702489470869,172.72954538012183,1.8078396209833094,22.83086738142732,130.96210867987259,0.4767837566369256,2022-09-15,Treatment follow-up,auto-greffe,2022-08-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,41,47.434521653326,167.2175910507748,1.4843523132549343,16.964091256412104,100.9234056991146,0.6462570978606547,2022-02-27,Treatment follow-up,auto-greffe,2022-02-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,72.66713635626124,175.78934140640473,1.8837099949270155,23.515432342453355,124.38579884846399,0.5598656731941201,2022-02-12,Treatment follow-up,allo-greffe,2022-09-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,33,42.7501597988942,151.95801309014027,1.3433198244074633,18.51358522916064,76.90756115710944,0.8260759608424962,2022-07-09,Symptoms management,auto-greffe,2022-10-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,72.17315541998315,193.25713236486175,1.9683592328376092,19.32433826924987,131.36504574455398,0.5875625411954482,2022-02-20,Symptoms management,pas de greffe,2022-06-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,52,68.16217246478281,190.0576475910566,1.896981678098754,18.870035826505035,120.08925710587008,0.6937283476402568,2022-02-27,Symptoms management,allo-greffe,2022-01-21,Protocole 3 LAL thiotepa Bu Flu
Female,66,67.66467244036987,187.23435661699847,1.8759554165864833,19.30149276600772,114.07254613104172,0.6096492892771509,2022-08-08,Cancer diagnosis,allo-greffe,2022-05-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,112.35457129805951,184.29986599123788,2.3983172592544126,33.07811160040833,128.95785399334693,1.1495663917826209,2022-09-02,Symptoms management,greffe haplo-identique,2022-05-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,47,47.03385841365783,180.34094999952504,1.5349747291135707,14.461785018045,126.20595521311223,0.48137242822698045,2022-05-19,Cancer diagnosis,pas de greffe,2022-08-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,57,102.06678600715222,148.22600742536355,2.0499967601992783,46.45533732708282,82.11479125326795,1.4328761111423072,2022-07-04,Treatment follow-up,auto-greffe,2022-03-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,44,58.08955421783839,141.35168486981047,1.5102479893885403,29.073416145646004,107.20878787728141,0.7224476695490263,2022-07-11,Symptoms management,allo-greffe,2022-06-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,64,40.85304822678464,198.70192376212964,1.501626828384725,10.347139947892147,86.74802849564252,0.4971025020969517,2022-10-08,Treatment follow-up,auto-greffe,2022-04-30,Protocole 3 LAL thiotepa Bu Flu
Male,59,53.341295656737,156.53001211358225,1.5229278868992246,21.77049595105252,76.00201256207511,0.7895706388671805,2022-10-01,Treatment follow-up,greffe haplo-identique,2022-01-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,83.75155559238753,181.4772897307022,2.0547374338638287,25.43011434527355,112.52294148669,0.8890327516255017,2022-11-10,Treatment follow-up,pas de greffe,2022-01-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,112.67227886268677,186.8036421394384,2.417964712297672,32.288390670752726,98.97871884478558,1.6759019989962771,2022-02-19,Treatment follow-up,pas de greffe,2022-02-08,Protocole 3 LAL thiotepa Bu Flu
Male,42,99.89893352163193,163.7658770346046,2.1317726363412337,37.24894880786827,84.48077233974414,1.6095206594184326,2022-01-08,Cancer diagnosis,allo-greffe,2022-08-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,40,118.98790556380789,161.28678325847264,2.3088703668346304,45.74095833735374,100.23232895569753,1.64877920798167,2022-04-03,Cancer diagnosis,allo-greffe,2022-11-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,21,95.19099852255933,189.97854798183403,2.2412947448750793,26.37465299478196,104.58866927150086,1.5042697081665013,2022-12-26,Treatment follow-up,auto-greffe,2022-11-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,61.42625164746255,152.58699837160026,1.6135577805397125,26.382682737260556,75.5996375199761,1.1510706403088864,2022-06-10,Symptoms management,auto-greffe,2022-08-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,71.58264507219175,176.1969740707268,1.871767247052532,23.05742743804998,108.14115495802517,0.7906471200377434,2022-12-14,Treatment follow-up,auto-greffe,2022-09-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,53.49277052155482,154.58302228868888,1.5155741612611913,22.385742487178323,108.04973688237115,0.4263149581787015,2022-10-23,Cancer diagnosis,greffe haplo-identique,2022-04-23,Protocole 6 FlUDARABINE cy (Fanconi)
Male,70,113.13479790841438,181.71969499535626,2.389724587180982,34.26038247320525,106.73273842996412,1.0305382045955402,2022-06-04,Cancer diagnosis,allo-greffe,2022-12-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,84.20644480616174,156.68943185543583,1.9144378341698638,34.29777288323754,82.9182563209996,1.6925594061412164,2022-02-28,Symptoms management,pas de greffe,2022-05-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,100.5633118501717,189.97614199049968,2.3036583231341643,27.863870296529875,120.4177664371569,0.8119224381397574,2022-04-21,Symptoms management,pas de greffe,2022-08-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,49.82049659489668,162.88975611948888,1.5014112379963789,18.77675354625784,80.51296085923194,0.5242513924079985,2022-08-08,Cancer diagnosis,pas de greffe,2022-03-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,72.9178079769911,163.75683237424397,1.8212319745150414,27.191598979414284,130.38817317669236,0.7145797994347663,2022-11-07,Symptoms management,auto-greffe,2022-07-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,47,85.37220160958168,164.3610405294915,1.974269477331663,31.602301875974938,114.73180282040153,0.9611321740638982,2022-01-12,Symptoms management,pas de greffe,2022-12-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,49,42.65186559598962,165.16829564463197,1.398882088049192,15.63452377563746,103.65687753161545,0.5200544363369598,2022-10-26,Symptoms management,allo-greffe,2022-06-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,59,48.496011163023226,184.4310457115054,1.5762270398039826,14.2573221123024,133.98192507390385,0.40720427422062466,2022-09-07,Treatment follow-up,greffe haplo-identique,2022-11-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,57.604438329741924,155.37434435600701,1.5767628439199666,23.861477319401967,124.66615868226967,0.5519164307746374,2022-08-23,Symptoms management,auto-greffe,2022-09-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,43,56.50421043545025,171.88131031359714,1.64249283170095,19.1259712691103,112.16930802260484,0.6786502412265804,2022-08-13,Treatment follow-up,auto-greffe,2022-09-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,103.58799212750178,178.2048815599785,2.2644527097020744,32.61896840989644,133.80437641032697,0.8494419238510303,2022-10-19,Cancer diagnosis,pas de greffe,2022-07-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,74,111.16025977428028,199.94217195783958,2.48471012028607,27.806142366650217,121.15277033838939,0.841061285750908,2022-08-09,Symptoms management,auto-greffe,2022-02-08,Protocole 3 LAL thiotepa Bu Flu
Male,52,86.10951503965745,140.14079504939426,1.8308662111275944,43.84519332233974,111.56140379901701,0.9433814853733072,2022-12-12,Symptoms management,greffe haplo-identique,2022-02-05,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,60,61.707651529992454,157.54548253493067,1.6433165766885722,24.861487462888107,99.04136924470433,0.6922769523323531,2022-05-30,Symptoms management,greffe haplo-identique,2022-05-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,31,98.89127239682054,189.25040342160165,2.2800592826097614,27.611139930542635,116.20153297403948,1.288368532307382,2022-01-22,Cancer diagnosis,auto-greffe,2022-06-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,62.061175988223624,184.18844464738817,1.781927130809876,18.293434072400814,129.03279799154967,0.5611341181978864,2022-03-02,Symptoms management,greffe haplo-identique,2022-08-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,53.22911784289397,146.22491003656754,1.470395163052646,24.894679707870147,101.70831618103473,0.5015444149323682,2022-08-29,Cancer diagnosis,greffe haplo-identique,2022-04-19,Protocole 6 FlUDARABINE cy (Fanconi)
Female,69,65.68561358515129,192.990445620801,1.8765138952526133,17.63594124468002,84.22983067604243,0.7690068100171567,2022-11-18,Treatment follow-up,allo-greffe,2022-06-19,Protocole 3 LAL thiotepa Bu Flu
Female,62,60.58667334622298,190.14842902057939,1.788890155342079,16.756820744132547,82.55455285347918,0.7950568505680594,2022-01-03,Symptoms management,greffe haplo-identique,2022-12-30,Protocole 3 LAL thiotepa Bu Flu
Female,49,67.90864352702178,161.14651453186013,1.7434991325688602,26.150694218659886,91.25265289132105,0.9405642169717381,2022-12-25,Treatment follow-up,auto-greffe,2022-03-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,52,111.16808664909178,192.22744645327555,2.4363883461460936,30.08495299616929,94.11907494093424,1.443619223730301,2022-03-23,Cancer diagnosis,greffe haplo-identique,2022-02-20,Protocole 3 LAL thiotepa Bu Flu
Male,25,80.76301433813845,149.43160021733235,1.830948939676074,36.16826078540782,74.12659634522862,1.7402185935228083,2022-10-13,Symptoms management,greffe haplo-identique,2022-05-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,26,105.56417792082033,151.1748871643034,2.1054593511586113,46.19098928427754,88.13795991457195,1.8963824652847623,2022-06-22,Cancer diagnosis,greffe haplo-identique,2022-12-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,42,106.42798995467906,189.03605873109657,2.3640083521017896,29.78287042163343,99.84341977274266,1.4508749799461735,2022-01-09,Cancer diagnosis,allo-greffe,2022-06-23,Protocole 3 LAL thiotepa Bu Flu
Female,29,84.2815448218702,187.7552976799194,2.096578332595604,23.908266470161294,114.30276912133561,1.136753284858053,2022-07-20,Treatment follow-up,allo-greffe,2022-07-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,87.93366192224909,150.2699797200752,1.915854146165644,38.94132313646881,107.02903538351941,1.312256981484662,2022-07-30,Symptoms management,auto-greffe,2022-03-09,Protocole 6 FlUDARABINE cy (Fanconi)
Female,59,93.0509289861345,180.164890102831,2.1579639577590295,28.666877532918637,86.94633401261581,1.2039874515492743,2022-10-26,Cancer diagnosis,allo-greffe,2022-12-21,Protocole 3 LAL thiotepa Bu Flu
Male,57,114.9326389182121,192.35798102216344,2.478138323187198,31.061538173233348,79.15898999721252,1.6737428318746592,2022-08-11,Cancer diagnosis,pas de greffe,2022-04-18,Protocole 3 LAL thiotepa Bu Flu
Male,68,40.83987043511662,156.45886156933565,1.3322662015984388,16.68337930545807,87.10758174561438,0.4688440387931305,2022-12-03,Treatment follow-up,greffe haplo-identique,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,53,67.18709068217257,188.469487502818,1.8754789423618956,18.914886367987947,130.74153172985217,0.6209534198261325,2022-09-07,Symptoms management,auto-greffe,2022-03-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,66.19425844991433,151.67016605910288,1.669971238213541,28.77530905432214,75.3756840867371,0.9513737423802942,2022-01-15,Treatment follow-up,auto-greffe,2022-04-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,59.81371112089324,162.9348058870581,1.6453415223718506,22.530613304952578,129.5029662091662,0.4233820799563379,2022-12-02,Cancer diagnosis,auto-greffe,2022-12-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,62,62.91385346906448,194.4410163488338,1.843384086925344,16.64065901579138,126.30441693616703,0.5396222574380136,2022-02-22,Treatment follow-up,allo-greffe,2022-05-05,Protocole 3 LAL thiotepa Bu Flu
Male,33,58.79373485379535,171.26719890104033,1.6724431796808852,20.04391995893977,130.826135365827,0.667863667956126,2022-04-16,Treatment follow-up,pas de greffe,2022-04-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,29,74.09259720853453,161.49566452690934,1.823125614517621,28.408812662021077,121.71696388467402,0.9384565940322488,2022-01-12,Treatment follow-up,pas de greffe,2022-09-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,32,61.67945727550109,147.15815206573376,1.5878562551335367,28.482092500335014,96.50975593379945,0.9586511230710694,2022-06-21,Treatment follow-up,auto-greffe,2022-02-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,46,107.54574199052679,174.78742303878877,2.2850749502246237,35.20244765438239,113.50153066475531,1.237048875990851,2022-04-14,Symptoms management,pas de greffe,2022-11-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,47.94031506795061,168.68253137295355,1.4987674288189516,16.84847758457507,74.51138265233604,1.0723264321380301,2022-01-13,Cancer diagnosis,auto-greffe,2022-10-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,60,75.10320955912464,189.90546078699197,1.9904291565379943,20.824931941334214,97.28769119161919,0.8577447938083888,2022-04-11,Symptoms management,auto-greffe,2022-11-15,Protocole 3 LAL thiotepa Bu Flu
Male,23,119.44499786355922,175.4556510631405,2.412772717250276,38.800135834551945,99.09570710774958,1.9586935417619586,2022-04-22,Treatment follow-up,allo-greffe,2022-08-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,43.232221195072086,199.90127247935672,1.549388412407002,10.818733730056406,98.18607043928479,0.5198093648366274,2022-11-30,Cancer diagnosis,auto-greffe,2022-04-04,Protocole 3 LAL thiotepa Bu Flu
Male,22,43.95320665533121,194.47313589190796,1.5408978200645935,11.621744688509304,80.76117752138036,0.8919436817199626,2022-04-15,Cancer diagnosis,greffe haplo-identique,2022-08-17,Protocole 3 LAL thiotepa Bu Flu
Male,42,95.61852221616988,164.1022306538648,2.0877428526401163,35.50692464109052,120.15744554139195,1.0831408110421268,2022-07-20,Treatment follow-up,allo-greffe,2022-07-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,62,83.96932180502056,173.21702945893645,2.010038452420138,27.98591253713929,112.48013883092915,0.8087362465430985,2022-12-25,Treatment follow-up,pas de greffe,2022-12-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,63,51.56004276244755,169.88963396529832,1.5598715039803175,17.864032805074704,98.1112287902392,0.5620213095639395,2022-09-21,Cancer diagnosis,pas de greffe,2022-10-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,104.94967316558319,147.229185003687,2.071744758958023,48.41648695990101,76.73369792235762,2.0325734276049965,2022-07-15,Symptoms management,auto-greffe,2022-01-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,46.486636205870404,140.32126936577652,1.346091440776344,23.609191350948592,78.7097106321133,0.9597390617736437,2022-06-07,Cancer diagnosis,auto-greffe,2022-05-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,34,78.89005522127721,159.54028889408872,1.869799617968102,30.99427712308988,119.91627564247909,0.9685398565527152,2022-06-16,Cancer diagnosis,greffe haplo-identique,2022-08-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,46.62440057976252,173.90805069107114,1.5007737466855544,15.416077574716626,87.94673119234422,0.6258640245366821,2022-04-14,Cancer diagnosis,pas de greffe,2022-04-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,53.477124992261544,154.24042860744584,1.513672381210344,22.47872136934332,100.66592309792063,0.6492855629259863,2022-06-23,Cancer diagnosis,allo-greffe,2022-04-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,78.35820337612022,172.94102275013904,1.9401709426927674,26.199223741422376,113.77966467635781,1.1286761059782209,2022-05-07,Symptoms management,greffe haplo-identique,2022-12-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,45,54.495061395251454,199.91811293014374,1.7396160047351923,13.634928306357303,123.69614026232163,0.5812890026733152,2022-07-25,Symptoms management,auto-greffe,2022-12-26,Protocole 3 LAL thiotepa Bu Flu
Female,55,70.6635945582198,160.73774917008126,1.7762559826746893,27.350165615917053,126.2440771690049,0.6608016867163834,2022-05-24,Symptoms management,allo-greffe,2022-09-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,77,118.90322133375082,180.19203569246218,2.439570402898836,36.620345494975645,110.18001881831898,0.9442757387670168,2022-05-20,Cancer diagnosis,pas de greffe,2022-03-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,58.06653663656769,169.27405424416997,1.6523685081648236,20.264931095084382,128.9656164464097,0.7504136662748481,2022-02-13,Treatment follow-up,greffe haplo-identique,2022-11-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,50,45.52029098702087,143.54952387646549,1.3472622546302526,22.090295064388197,98.65731739486878,0.5767475260454985,2022-01-29,Treatment follow-up,greffe haplo-identique,2022-01-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,29,115.2645150341234,172.47370148105117,2.3499466635409183,38.748050718151575,125.69354152121704,1.4137517212657367,2022-02-19,Cancer diagnosis,auto-greffe,2022-10-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,39,41.30354140032295,181.7537697386327,1.4440562424666057,12.503178617482886,80.90466232115317,0.7161477269369763,2022-07-18,Cancer diagnosis,auto-greffe,2022-12-29,Protocole 3 LAL thiotepa Bu Flu
Female,74,49.49729783875631,166.3466318307663,1.5123297682164816,17.88765734834389,99.12258838994295,0.45774150731785657,2022-03-09,Cancer diagnosis,pas de greffe,2022-09-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,50.21140899598748,198.20961955890078,1.6626939548190933,12.780650315223319,75.52903129299803,0.5909299085122325,2022-01-30,Cancer diagnosis,pas de greffe,2022-09-14,Protocole 2 LAM Endoxan TBI
Male,74,96.86053722430856,147.55246173004943,1.9924866312071943,44.48913423031682,115.72470008999431,0.7672417877938082,2022-10-13,Symptoms management,allo-greffe,2022-06-19,Protocole 6 FlUDARABINE cy (Fanconi)
Male,28,102.78200661846111,161.48794439722369,2.1472239810869187,39.41276278566003,130.42099485800813,1.2259001825631137,2022-05-21,Symptoms management,pas de greffe,2022-02-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,57,72.43405384638683,151.56402704501681,1.74629742408792,31.531927530784102,85.6865096388946,0.9744867421997481,2022-04-07,Symptoms management,auto-greffe,2022-04-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,63,79.04932862622752,184.02489889088514,2.0101855019316193,23.342373301137638,83.75903497054867,1.0093104029446822,2022-09-19,Treatment follow-up,pas de greffe,2022-08-06,Protocole 3 LAL thiotepa Bu Flu
Female,24,88.04378910132579,165.24600316412273,2.010312596782666,32.243100502253384,88.24444714356187,1.607447623924723,2022-07-02,Symptoms management,allo-greffe,2022-04-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,103.17278696271103,152.5038983806687,2.0906041271080036,44.36119852586341,104.36655397009193,1.016021835329185,2022-12-11,Cancer diagnosis,allo-greffe,2022-03-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,51,105.5630273256887,142.73865422475293,2.0458579059189343,51.81179526895518,103.80566167212993,1.2570377077500328,2022-08-10,Symptoms management,auto-greffe,2022-04-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,71,52.36277781207007,161.8646861633102,1.5343913557344946,19.98565832514832,121.77172408368105,0.41209070316479746,2022-01-18,Symptoms management,greffe haplo-identique,2022-01-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,30,102.49876698613313,165.22651060468786,2.168941985444219,37.54561121776034,108.8569070660107,1.4385429705078565,2022-05-22,Cancer diagnosis,allo-greffe,2022-10-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,23,105.29335879783135,143.29255785646615,2.047203696335287,51.280672193722644,106.96996917952345,1.59953031078585,2022-04-12,Cancer diagnosis,pas de greffe,2022-03-19,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,37,64.51652172385988,145.20847642759705,1.6131702589698662,30.597574991058707,105.41559891318997,0.8755295186739221,2022-07-13,Cancer diagnosis,pas de greffe,2022-12-18,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,74,80.20217832308171,182.72563351578953,2.017630199807536,24.02078585484616,86.8257252432737,0.8467382593907019,2022-04-08,Treatment follow-up,allo-greffe,2022-10-22,Protocole 3 LAL thiotepa Bu Flu
Male,74,114.97963234636822,164.9089683966617,2.2949928925614356,42.279745630962125,121.3513035336126,0.86853616935652,2022-12-08,Treatment follow-up,auto-greffe,2022-01-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,54.804025569942766,197.78159740861662,1.7351935308045894,14.010082731837377,90.94855691663852,0.9457200463639526,2022-05-10,Symptoms management,pas de greffe,2022-09-29,Protocole 3 LAL thiotepa Bu Flu
Female,50,70.02669713853456,166.7712646614373,1.8011139178187034,25.17799823556507,89.01187821598563,0.9833897809769852,2022-11-25,Cancer diagnosis,pas de greffe,2022-04-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,90.12703624399448,174.36793052319263,2.089342320368228,29.642980171680854,121.5076735131448,0.8344568934860319,2022-03-25,Cancer diagnosis,auto-greffe,2022-09-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,59.32983369492039,148.55954373378302,1.564716252544655,26.88264625051123,94.60242290469634,0.6881220371744176,2022-04-29,Symptoms management,allo-greffe,2022-10-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,29,72.0700932484522,193.3278379935478,1.9673131219816766,19.282631224627135,126.25206191142657,0.8800494720050287,2022-11-25,Symptoms management,auto-greffe,2022-02-21,Protocole 3 LAL thiotepa Bu Flu
Male,58,90.92076215828627,163.33517974562082,2.0310478295788146,34.080314826499894,104.8900934722635,0.987210921103463,2022-06-10,Symptoms management,allo-greffe,2022-11-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,75,97.99898425999207,184.20888921617393,2.2393131409012237,28.880213988761575,95.39878122341399,0.9273840200067598,2022-02-01,Cancer diagnosis,auto-greffe,2022-10-08,Protocole 3 LAL thiotepa Bu Flu
Male,49,106.84448175931367,147.7641695306899,2.094157621422429,48.93434981839023,104.64178954169276,1.2904935392077166,2022-12-23,Treatment follow-up,greffe haplo-identique,2022-10-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,23,93.13712269668869,151.31992209646523,1.9786009472711223,40.67528447506106,124.33297016868161,1.217278282476375,2022-01-10,Symptoms management,allo-greffe,2022-03-09,Protocole 6 FlUDARABINE cy (Fanconi)
Female,64,117.94633776745127,160.199389068667,2.2909805793124396,45.95817235401261,133.74735119890198,0.9308514222664273,2022-09-24,Symptoms management,allo-greffe,2022-07-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,71,40.465192492610775,143.49839707668818,1.270027368481273,19.651129194782193,96.83618573031099,0.40046127914846485,2022-02-07,Cancer diagnosis,pas de greffe,2022-04-27,Protocole 6 FlUDARABINE cy (Fanconi)
Male,33,46.98146692869611,197.1648184625255,1.6040826729611877,12.08558637020723,79.48671284514661,0.8783817762731602,2022-07-13,Treatment follow-up,greffe haplo-identique,2022-10-19,Protocole 3 LAL thiotepa Bu Flu
Female,28,40.4509534316038,153.67022659290367,1.3140382181713266,17.129681937750426,86.25779908682834,0.729484243792384,2022-06-19,Treatment follow-up,greffe haplo-identique,2022-09-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,32,71.6846277507954,183.41142735925342,1.911062814791966,21.309499671698447,76.66463789181137,1.4025624405600718,2022-08-25,Cancer diagnosis,auto-greffe,2022-05-28,Protocole 3 LAL thiotepa Bu Flu
Male,34,42.03915443161446,147.9884583320127,1.3145879850859086,19.195449224783395,91.8931686646989,0.6735101015341337,2022-12-13,Symptoms management,allo-greffe,2022-07-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,33,42.319305031905856,144.37384703547986,1.3027535870997107,20.303058647015085,86.15075206611158,0.7300132374254066,2022-04-07,Cancer diagnosis,allo-greffe,2022-08-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,57,90.12397452267666,145.7735494016011,1.910329498363949,42.41142641669921,118.80666373194745,0.8744704363482193,2022-12-27,Cancer diagnosis,pas de greffe,2022-02-07,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,65,81.33309515347315,155.5113115505628,1.8744048166301968,33.63127494674031,108.26444255521659,0.7825466248994136,2022-10-09,Symptoms management,allo-greffe,2022-08-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,62,68.29332103147411,180.41786899792987,1.8500251835590769,20.98065946342196,95.85735870507682,0.7718179607374461,2022-01-15,Cancer diagnosis,auto-greffe,2022-09-29,Protocole 3 LAL thiotepa Bu Flu
Male,69,63.73821410485527,180.71803046226734,1.788749137604556,19.51627464178549,95.98542597398304,0.654817754814289,2022-01-11,Treatment follow-up,greffe haplo-identique,2022-10-14,Protocole 3 LAL thiotepa Bu Flu
Male,32,51.845216346072704,159.71234842875816,1.516604509479822,20.325053611341772,88.46683106843747,0.8790619442325031,2022-03-01,Symptoms management,allo-greffe,2022-01-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,111.30571675415348,168.43474737225705,2.282040405388578,39.23323246978284,114.00573052684484,1.166156248440514,2022-07-18,Symptoms management,auto-greffe,2022-02-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,45,70.02081222313026,191.4828428214583,1.929866444799894,19.097099508707334,131.1153806972767,0.7046356513779761,2022-11-26,Cancer diagnosis,greffe haplo-identique,2022-07-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,41.171522844640165,147.62563722321772,1.2993558548790276,18.89180092106969,117.9598554602025,0.35872522979877375,2022-10-02,Cancer diagnosis,auto-greffe,2022-07-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,70,93.3537641376631,164.48776536030732,2.065292019369537,34.50361766988746,88.14465313360604,1.0296779304940575,2022-11-04,Cancer diagnosis,greffe haplo-identique,2022-05-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,52,94.65879208639467,173.84651961963627,2.138022291980403,31.320519511723013,129.4179566558087,0.8939569299830379,2022-07-10,Symptoms management,auto-greffe,2022-03-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,38,47.206320676244204,171.51813952707099,1.4996981452119427,16.04648955814265,84.6960599154567,0.7895954194890249,2022-08-02,Symptoms management,greffe haplo-identique,2022-11-18,Protocole 3 LAL thiotepa Bu Flu
Female,49,50.875078548510324,156.66192577592815,1.4879318028177417,20.728991387612723,103.90106775318264,0.6188622300933192,2022-10-07,Symptoms management,auto-greffe,2022-07-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,26,51.64245052080807,174.98600740816795,1.5843598627951068,16.86553793671394,86.69504729373244,0.9431589909349306,2022-06-28,Cancer diagnosis,greffe haplo-identique,2022-12-19,Protocole 3 LAL thiotepa Bu Flu
Female,75,101.64371296115448,148.85939750646065,2.0501098799628794,45.86992259826037,89.48922875336018,1.0253936321773007,2022-12-11,Symptoms management,greffe haplo-identique,2022-02-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,42,110.764389179116,178.03585968851945,2.3404672640295128,34.94501127145006,126.59358127357586,1.1909185229646322,2022-10-02,Treatment follow-up,pas de greffe,2022-08-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,32,59.939185421208606,159.85473283311225,1.631424264573552,23.456317880237354,95.87271519361244,0.9377931766117659,2022-02-16,Treatment follow-up,greffe haplo-identique,2022-07-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,66,113.06780915676676,190.56038464891714,2.4464398852847733,31.136782690862958,130.49266164758177,0.8905372927957066,2022-05-03,Cancer diagnosis,pas de greffe,2022-11-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,90.37696514743587,166.6854922853631,2.045627377742954,32.52835864034351,90.2982670971058,1.5847132628753027,2022-10-18,Symptoms management,pas de greffe,2022-08-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,56,115.66015461663761,183.9133502819923,2.4307889968347878,34.194578663983826,104.74183357938719,1.2882803598284436,2022-08-31,Cancer diagnosis,pas de greffe,2022-04-30,Protocole 3 LAL thiotepa Bu Flu
Female,28,44.43633943115964,143.5820269727489,1.3312754626438126,21.55450806170736,88.83266006560146,0.7781281638942977,2022-10-13,Treatment follow-up,allo-greffe,2022-02-19,Protocole 6 FlUDARABINE cy (Fanconi)
Male,57,79.36051107008545,143.56163388746387,1.7789763469920334,38.505934796210674,91.85737268520434,0.9959465519245961,2022-08-29,Treatment follow-up,allo-greffe,2022-10-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,73,57.99787670309735,195.54986396725832,1.7749395059864017,15.166908195895871,127.33883284263928,0.42383179719565867,2022-04-23,Cancer diagnosis,greffe haplo-identique,2022-09-06,Protocole 3 LAL thiotepa Bu Flu
Male,66,91.17086654660541,148.65662977389573,1.940300216918332,41.25603790730052,94.6961751524355,0.9895161073454876,2022-02-04,Symptoms management,auto-greffe,2022-09-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,66,64.17509326117417,194.016016191681,1.8597338469420388,17.04870291169259,121.82707151459367,0.5414045820903619,2022-04-15,Treatment follow-up,greffe haplo-identique,2022-04-13,Protocole 3 LAL thiotepa Bu Flu
Female,49,88.79021960447606,188.67899135186235,2.157213292195055,24.941239820445603,98.43392632334017,1.140063961600731,2022-06-21,Symptoms management,auto-greffe,2022-05-23,Protocole 3 LAL thiotepa Bu Flu
Male,55,42.487720697461796,158.92671454884865,1.3695532380951339,16.82168989762212,134.62124367861753,0.3725943494626047,2022-04-08,Symptoms management,allo-greffe,2022-06-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,67,58.19695706529102,159.56887616449166,1.6061014769294328,22.856193529910037,94.7026389617646,0.623058119420148,2022-07-29,Cancer diagnosis,allo-greffe,2022-03-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,53,40.917024573145966,156.6807870203579,1.334469475594019,16.66758030181055,129.96230438475013,0.38042880915824134,2022-11-18,Treatment follow-up,allo-greffe,2022-02-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,44,63.58512419291208,172.45740485556195,1.7452893349534584,21.379218742411062,91.7097599677556,0.9244399464174528,2022-03-25,Treatment follow-up,auto-greffe,2022-04-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,20,41.11657230328447,166.95833949375117,1.3808969143912644,14.750293736007897,111.23334463337653,0.6160708439662599,2022-01-07,Cancer diagnosis,auto-greffe,2022-06-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,47,41.49610831911812,159.17685316182946,1.3545417368471928,16.377497404071004,102.44030717522797,0.5232231471203118,2022-01-11,Symptoms management,greffe haplo-identique,2022-08-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,49,84.34323586104985,173.16839054972218,2.0142259616022904,28.12632674798419,110.8828288118429,0.9613795012265258,2022-01-09,Treatment follow-up,pas de greffe,2022-08-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,73,69.19854325122309,142.12815122900437,1.6528646025777856,34.256006958309555,127.43063886446568,0.5053187320771818,2022-12-09,Treatment follow-up,pas de greffe,2022-03-09,Protocole 8 Aplasie medullaire thymo
Male,41,45.81853769267185,176.02676345038094,1.496782558251598,14.787127477159,89.33347184918432,0.7052282646507154,2022-01-01,Treatment follow-up,auto-greffe,2022-12-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,73,83.53260157883037,156.8362734403927,1.9076557707188406,33.95963223218252,97.59631362490549,0.7964617062068327,2022-04-04,Treatment follow-up,auto-greffe,2022-12-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,36,109.1305261942291,186.54826170999058,2.3780308124014216,31.35911776976467,130.202570103432,1.2106748903292048,2022-10-16,Treatment follow-up,auto-greffe,2022-04-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,44,89.68873308402235,197.10910706356708,2.2160065490686325,23.084714527506808,126.07218782819403,0.9485436836261507,2022-01-22,Symptoms management,auto-greffe,2022-10-08,Protocole 3 LAL thiotepa Bu Flu
Male,75,40.36501322799212,182.27947828053965,1.4296185924910072,12.148692661534161,112.78734065289233,0.32309155203938084,2022-01-13,Treatment follow-up,auto-greffe,2022-08-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,63.077264786694876,191.17521713869232,1.830210202872214,17.258763140446945,102.67931208934192,0.7166988242686391,2022-02-27,Treatment follow-up,auto-greffe,2022-11-08,Protocole 3 LAL thiotepa Bu Flu
Female,32,107.45776730477127,160.6047926967063,2.189509866616125,41.66014819379944,132.71279800353648,1.2145524273616901,2022-01-30,Cancer diagnosis,pas de greffe,2022-05-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,21,83.26415803556614,141.92846160712247,1.8118095510198442,41.33511060651609,91.88814221544426,1.497659510450201,2022-05-31,Cancer diagnosis,pas de greffe,2022-06-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,42,79.3729632086555,185.17194484730624,2.020564137784326,23.148466083243473,78.96570482348135,1.3681309169165914,2022-03-21,Symptoms management,allo-greffe,2022-12-19,Protocole 3 LAL thiotepa Bu Flu
Male,24,93.57858452791308,195.3668200896014,2.25352504656004,24.51742504951101,101.98773170437589,1.4782709133289051,2022-10-15,Cancer diagnosis,allo-greffe,2022-02-11,Protocole 3 LAL thiotepa Bu Flu
Female,29,115.77919333210272,172.3692532435386,2.354474056379673,38.968251465723014,121.44167611744848,1.4697830988517862,2022-01-14,Treatment follow-up,pas de greffe,2022-12-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,65,86.04852521886491,179.9704335085473,2.074058714641568,26.566913750575683,133.51164822419506,0.6713562571394733,2022-07-11,Cancer diagnosis,allo-greffe,2022-08-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,83.28961572126221,140.25491286463685,1.8013712211900874,42.34037429604994,74.45397566257637,0.9477642085790119,2022-05-09,Treatment follow-up,greffe haplo-identique,2022-07-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,21,53.616832139358344,155.13279188182088,1.5200263942918157,22.278909737612892,122.47880962792843,0.7235268610462217,2022-08-26,Treatment follow-up,greffe haplo-identique,2022-01-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,35,109.23776479610395,168.5532724554438,2.2615372556995506,38.45018445869316,87.98947696635523,1.8105014275956979,2022-03-07,Symptoms management,pas de greffe,2022-12-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,88.07129824158164,180.43620311905704,2.1010083993219566,27.05123135664686,78.6339458550697,1.4311318925867778,2022-11-24,Symptoms management,pas de greffe,2022-06-28,Protocole 3 LAL thiotepa Bu Flu
Female,29,64.92774780251204,145.40314264633116,1.619387622205937,30.710207586982634,111.00187221226548,0.9017590652656778,2022-11-18,Treatment follow-up,pas de greffe,2022-09-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,57,95.92272462230667,155.03212857558418,2.0324522802219467,39.909665365636855,109.56725680707434,1.00922108073945,2022-10-17,Cancer diagnosis,greffe haplo-identique,2022-12-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,101.01009198348457,145.39139466506793,2.0197633351958744,47.784534709368955,100.72815814370043,1.559909489538441,2022-06-12,Symptoms management,auto-greffe,2022-08-11,Protocole 6 FlUDARABINE cy (Fanconi)
Female,68,89.4538154263634,183.76033981815738,2.136850194976714,26.49081369975073,93.0030408531351,0.96183753354499,2022-01-05,Treatment follow-up,allo-greffe,2022-05-01,Protocole 3 LAL thiotepa Bu Flu
Male,35,105.65212321782761,166.2113127284039,2.2086055236391813,38.243450560102914,110.83487861274685,1.3901401341750437,2022-09-10,Treatment follow-up,greffe haplo-identique,2022-02-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,28,113.2102679264462,146.801443551987,2.1486061862227954,52.53214881222369,118.09259458958238,1.4912438991703847,2022-11-19,Cancer diagnosis,allo-greffe,2022-02-26,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,59,91.65483173842556,188.78632912658736,2.1923591574306682,25.716643279558692,76.38784537657521,1.3498441433635273,2022-06-23,Symptoms management,pas de greffe,2022-09-24,Protocole 3 LAL thiotepa Bu Flu
Female,57,44.475493055653175,170.92602791685093,1.4531593328222518,15.223144531833992,95.64121553405263,0.5360697243753898,2022-11-27,Symptoms management,allo-greffe,2022-02-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,23,79.06469127887294,193.94280770945437,2.0638440548125123,21.02012151463537,112.15796021732062,1.145528351970931,2022-10-10,Symptoms management,allo-greffe,2022-03-17,Protocole 3 LAL thiotepa Bu Flu
Male,41,118.92386881990632,155.10847721254422,2.263607015662296,49.43083660881974,102.29279722035801,1.598551648510672,2022-10-10,Treatment follow-up,greffe haplo-identique,2022-06-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,43,92.38045936152928,166.42726395270637,2.0665743994345314,33.35271331479867,88.80027035400613,1.4015386130559728,2022-07-12,Cancer diagnosis,greffe haplo-identique,2022-01-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,54,48.95621216105557,140.45517418975356,1.3820429028104646,24.816030991504242,86.7898653549382,0.673759262071366,2022-07-04,Treatment follow-up,allo-greffe,2022-08-03,Protocole 6 FlUDARABINE cy (Fanconi)
Female,46,108.67958521735447,167.12298476308112,2.2461607160477377,38.91128789579456,116.77826379794112,1.2150140928751512,2022-04-19,Symptoms management,pas de greffe,2022-07-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,45,60.404509092420106,167.56859878143283,1.6767941426604285,21.512163152691528,114.53497286412173,0.6958607659159268,2022-06-18,Treatment follow-up,auto-greffe,2022-11-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,113.90681121210582,144.6415314215485,2.1392921735071493,54.44571072795889,86.02269428942864,1.6919673733381755,2022-12-19,Symptoms management,auto-greffe,2022-09-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,88.57805071234633,149.5016598622137,1.917939114493523,39.630914116803176,81.14910054037549,0.9702639284149096,2022-11-17,Symptoms management,auto-greffe,2022-12-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,47,51.79205042947663,154.83558296124062,1.4925046362300955,21.60337268205267,120.84239138194452,0.5535976603328743,2022-01-17,Symptoms management,greffe haplo-identique,2022-07-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,34,48.297854040882655,171.19282822679048,1.5154982890257052,16.479980786109508,82.30677003066518,0.8639043176902826,2022-10-23,Cancer diagnosis,pas de greffe,2022-11-30,Protocole 3 LAL thiotepa Bu Flu
Male,60,46.30980881582878,148.7584578574946,1.3833308979012795,20.927129080953524,82.33481377668711,0.6249524443968328,2022-10-25,Cancer diagnosis,greffe haplo-identique,2022-07-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,63,86.57469557832125,186.15048911837104,2.1158083513805845,24.984036733273932,115.54223361816105,0.8013245400957161,2022-04-26,Symptoms management,allo-greffe,2022-01-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,86.18227038652351,151.65919739770004,1.9054260209502676,37.469717980436386,119.04353704616301,1.1663733861223124,2022-04-05,Cancer diagnosis,greffe haplo-identique,2022-02-07,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,56,102.69000300081498,180.25972702261458,2.267577752487735,31.603177358618378,124.23708920111969,0.9643255832161839,2022-09-21,Treatment follow-up,allo-greffe,2022-10-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,68.95688708407855,167.97796746658446,1.7937575191639759,24.4384132252694,74.6039984401373,0.8729552071528486,2022-09-16,Symptoms management,pas de greffe,2022-11-20,Protocole 3 LAL thiotepa Bu Flu
Female,62,57.47569925480822,168.4998338633808,1.640176631377177,20.243486371832518,83.52915695336009,0.7454324110339395,2022-11-03,Symptoms management,auto-greffe,2022-11-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,47.227801088806544,161.24473101990134,1.454421809825511,18.1646343971676,90.40016914335928,0.6167581707025932,2022-03-18,Treatment follow-up,auto-greffe,2022-06-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,100.49599782325188,183.0784574238353,2.26069386218959,29.982944277791272,105.42758902564762,1.3636383922445376,2022-01-25,Treatment follow-up,auto-greffe,2022-12-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,74.14748996315042,156.70695454029868,1.7965574594927582,30.19394869461118,125.21381582776002,0.9129241285197495,2022-04-02,Treatment follow-up,auto-greffe,2022-09-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,25,100.31298091201373,166.34982968639324,2.1529725762076475,36.250367607774194,133.08849876775665,1.2038765466098933,2022-04-30,Treatment follow-up,allo-greffe,2022-08-27,Protocole 6 FlUDARABINE cy (Fanconi)
Female,53,103.26657899081243,174.8566670678751,2.2395963067428837,33.77500312175748,130.70757926410133,0.9546535121867195,2022-12-18,Symptoms management,auto-greffe,2022-09-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,61.800928316390575,189.28496802806544,1.80262052613478,17.248953309044175,80.53427295237415,0.8633100145705079,2022-07-17,Cancer diagnosis,allo-greffe,2022-01-31,Protocole 3 LAL thiotepa Bu Flu
Male,42,74.83324040688767,190.4701407433177,1.9898002295441637,20.62722215277163,129.69373730621425,0.7853606281525773,2022-08-10,Symptoms management,allo-greffe,2022-08-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,51.85625129973079,192.80542450850027,1.666513871768121,13.94962784417201,99.8195943876504,0.7070968406315818,2022-08-03,Cancer diagnosis,allo-greffe,2022-12-25,Protocole 3 LAL thiotepa Bu Flu
Male,37,46.800858375809604,182.65584124132204,1.5409638179335716,14.027707060885872,94.50784262582187,0.7084198103998456,2022-08-01,Treatment follow-up,greffe haplo-identique,2022-04-11,Protocole 3 LAL thiotepa Bu Flu
Female,21,50.43457054709671,170.27544772769977,1.5445036132525947,17.394993281000225,74.61974049984097,1.1170922985477914,2022-02-11,Treatment follow-up,allo-greffe,2022-12-28,Protocole 3 LAL thiotepa Bu Flu
Female,30,117.0974412512745,153.38054553371296,2.2336112650271573,49.77449345567997,131.14045345175654,1.3641775963825586,2022-10-17,Symptoms management,greffe haplo-identique,2022-08-20,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,57,55.0314071611982,196.35066682654383,1.7324880545126347,14.274005405755728,134.37522030990567,0.4721032874138748,2022-02-10,Cancer diagnosis,allo-greffe,2022-03-19,Protocole 3 LAL thiotepa Bu Flu
Female,38,109.5766008643469,156.86222199446448,2.1850774897384464,44.532912459933435,122.22250917666636,1.2700894371819518,2022-06-17,Symptoms management,auto-greffe,2022-03-11,Protocole 6 FlUDARABINE cy (Fanconi)
Male,52,46.4166169503162,160.89232574532454,1.4403006490126198,17.93093039917039,128.7336057410063,0.44068850857163644,2022-07-16,Symptoms management,auto-greffe,2022-09-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,44,81.11625626212927,172.0899634771216,1.96915757351199,27.390301559349517,106.90433934421466,1.0116989545322765,2022-08-10,Treatment follow-up,pas de greffe,2022-11-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,109.02017948845746,163.37819210911408,2.2243301006667218,40.84310216521236,132.66706993126905,1.0956768653536268,2022-11-20,Treatment follow-up,greffe haplo-identique,2022-02-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,114.41418767432447,197.37123573113857,2.5045552724794065,29.370555529574332,75.50286109152333,2.4414170054749245,2022-10-14,Treatment follow-up,greffe haplo-identique,2022-05-24,Protocole 3 LAL thiotepa Bu Flu
Female,71,74.0936353568098,182.52219401415613,1.938193093795365,22.24075584494202,125.52120523237532,0.5656924694024654,2022-02-21,Symptoms management,auto-greffe,2022-12-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,54.912145007449965,168.95388710948257,1.6053400772048478,19.236764693254845,86.75132436685266,0.6681491049632141,2022-11-25,Cancer diagnosis,pas de greffe,2022-12-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,110.10767272709134,175.33951756510058,2.315780778831778,35.81442382933566,131.66317471875556,1.3124996842995305,2022-05-03,Symptoms management,allo-greffe,2022-09-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,49,112.36455313303603,150.70034476215685,2.168805155955323,49.4767127496695,132.50139910692855,1.0718098915710492,2022-07-02,Treatment follow-up,allo-greffe,2022-12-26,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,39,86.96120297734888,161.63010628391362,1.975934974175087,33.28748792481986,112.03895679799643,1.088793099755363,2022-05-03,Symptoms management,auto-greffe,2022-05-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,71,95.74517277323625,156.55389245086184,2.0405118830162863,39.06511858575061,100.95875919927377,0.9088442776247139,2022-11-04,Symptoms management,pas de greffe,2022-03-24,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,46,115.6318139789171,157.4595907220212,2.2489094952125117,46.63791238131059,85.02523177055252,1.775517149386075,2022-09-03,Symptoms management,greffe haplo-identique,2022-07-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,42,68.14459419832217,191.17159399684925,1.9022874165915866,18.645957370700163,77.28222342695415,1.2001772233321164,2022-04-06,Cancer diagnosis,pas de greffe,2022-05-28,Protocole 2 LAM Endoxan TBI
Male,24,87.41994691858652,190.06728711207262,2.148363210957041,24.198909009335047,94.62919722551949,1.48836988944989,2022-01-11,Treatment follow-up,greffe haplo-identique,2022-05-29,Protocole 3 LAL thiotepa Bu Flu
Male,67,67.62838954540027,189.340352267459,1.8859703588314534,18.86438642087262,113.71892434453599,0.6029574508266564,2022-07-15,Treatment follow-up,greffe haplo-identique,2022-07-19,Protocole 3 LAL thiotepa Bu Flu
Female,76,90.92599010628723,142.69657878484975,1.8984516871791635,44.65405646248679,79.75713058265002,1.0133652217207727,2022-05-28,Cancer diagnosis,allo-greffe,2022-05-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,70.0205745938691,181.8836284738218,1.8808683112206752,21.16598340109895,91.09487904664043,1.131631624178161,2022-04-23,Cancer diagnosis,pas de greffe,2022-05-26,Protocole 3 LAL thiotepa Bu Flu
Male,53,48.275961191880306,145.37759308340438,1.3962492456840097,22.842097500306696,103.49685587875587,0.56362536438007,2022-03-20,Treatment follow-up,auto-greffe,2022-03-07,Protocole 6 FlUDARABINE cy (Fanconi)
Female,51,65.76564048592418,183.18171640982,1.8293185514012482,19.599040301965154,87.64289397317151,0.9275553926696501,2022-08-22,Cancer diagnosis,auto-greffe,2022-01-02,Protocole 3 LAL thiotepa Bu Flu
Male,38,51.90034510167899,153.16434770832421,1.4859791481391416,22.123552956384255,94.32778031130562,0.7794680278852366,2022-10-01,Cancer diagnosis,auto-greffe,2022-01-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,51,105.08173414239103,180.86380106042014,2.2976728479904622,32.12357885830051,98.54133464504069,1.3181544538251337,2022-08-03,Symptoms management,auto-greffe,2022-10-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,45.72563748202907,156.71084404732372,1.4108412821601946,18.619227971684673,75.21771776687434,0.7936608796215423,2022-07-30,Treatment follow-up,pas de greffe,2022-08-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,31,70.81265198724523,153.9115327952392,1.7399619894198162,29.892933274822212,103.40117401987932,1.0367627645662525,2022-03-13,Treatment follow-up,auto-greffe,2022-09-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,79,91.20510990888639,140.67996237916776,1.887880309792646,46.08447921364404,118.47104748464707,0.6522352721245456,2022-11-17,Treatment follow-up,greffe haplo-identique,2022-07-04,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,74,110.1628220249925,188.86379406418163,2.4040341403367793,30.88429078279014,91.75638088346142,1.1005511102764591,2022-09-20,Symptoms management,greffe haplo-identique,2022-04-07,Protocole 3 LAL thiotepa Bu Flu
Male,69,84.968145791047,162.9996960238679,1.9614182748185864,31.980301367551093,107.83962764819738,0.7769688609126129,2022-03-06,Cancer diagnosis,pas de greffe,2022-10-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,59.93670412503815,162.76664901973166,1.6461821557537633,22.623615586243055,83.31382258542358,1.0391461657272318,2022-02-17,Cancer diagnosis,allo-greffe,2022-10-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,34,95.52302489119191,151.1498364608139,2.0026572341201736,41.8112068569852,117.60159395863865,1.1958266486435567,2022-12-15,Treatment follow-up,allo-greffe,2022-02-18,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,77,85.32568082090918,191.84036605865117,2.1323506749129946,23.18460885373146,88.80348413621945,0.8407324492333141,2022-05-02,Symptoms management,greffe haplo-identique,2022-10-23,Protocole 3 LAL thiotepa Bu Flu
Male,48,55.69604874464695,163.08567679997753,1.588432823449761,20.94077475842084,103.87598806465216,0.6851166927205881,2022-04-12,Cancer diagnosis,allo-greffe,2022-11-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,43,116.35941407346664,141.76528342301202,2.1405947586710967,57.8977577403427,127.31988715978822,1.2312451094760473,2022-03-14,Symptoms management,greffe haplo-identique,2022-06-05,Protocole 9 LAL thiotepa-thymo melphalan
Female,33,108.81294147574988,169.36451501922224,2.262560684321552,37.93461710034934,81.91277507512032,1.9741502007653404,2022-08-06,Symptoms management,auto-greffe,2022-10-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,77.46703439536856,187.57762952248868,2.0090823415195427,22.016832787674936,133.42428217249451,0.5886706988394744,2022-04-11,Symptoms management,greffe haplo-identique,2022-06-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,108.91921114683197,143.04124360608338,2.0803271253870697,53.23312144906388,122.45008859253,1.124227694216807,2022-10-19,Symptoms management,pas de greffe,2022-06-14,Protocole 8 Aplasie medullaire thymo
Male,32,97.60960371342196,186.34986368034805,2.2478098195730793,28.10828774664408,112.20372049658778,1.3048979563434846,2022-05-06,Symptoms management,allo-greffe,2022-04-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,95.36835796111845,173.93436073968073,2.1465627806617427,31.52343495427921,130.60452113987242,0.8620501329707587,2022-11-10,Symptoms management,pas de greffe,2022-01-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,58,83.95479197905648,181.16354798860553,2.0554499362515357,25.580195237673724,131.2113914375919,0.7287109656130953,2022-10-16,Treatment follow-up,greffe haplo-identique,2022-12-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,71.46307737016494,141.34938412076133,1.6750839094776326,35.767935436349696,111.63057754076314,0.9158055489917611,2022-10-19,Symptoms management,greffe haplo-identique,2022-01-13,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,39,40.2323848701062,186.2324475620351,1.4426610737739773,11.600189265682834,104.44353861426555,0.5403598555888007,2022-12-17,Treatment follow-up,allo-greffe,2022-11-02,Protocole 3 LAL thiotepa Bu Flu
Female,68,74.26668446880652,172.963193395605,1.8889593628818602,24.824850734886162,88.77849325629549,0.8365391407849794,2022-09-03,Treatment follow-up,pas de greffe,2022-12-29,Protocole 3 LAL thiotepa Bu Flu
Female,49,89.95939139112178,175.02042612256437,2.0913001680905934,29.367639125211163,130.1443177451104,0.8736353396014273,2022-06-29,Symptoms management,greffe haplo-identique,2022-11-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,21,69.09118518813813,161.96445050679762,1.7630714868487156,26.33802701319316,90.42552771285332,1.2628333879554705,2022-04-10,Cancer diagnosis,pas de greffe,2022-09-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,117.70665009956764,144.75813421902924,2.1755583608700397,56.171373871778485,98.86095298712952,1.7032599538838367,2022-12-19,Treatment follow-up,pas de greffe,2022-05-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,26,59.96652222583434,141.93040744050748,1.5375912739215511,29.768569362766616,87.06908079729715,1.090478877861142,2022-09-06,Symptoms management,pas de greffe,2022-01-29,Protocole 6 FlUDARABINE cy (Fanconi)
Male,67,96.75060489122902,162.7636961881016,2.0914831300971204,36.520658666729375,129.6484160402732,0.7566182934469841,2022-10-30,Cancer diagnosis,allo-greffe,2022-07-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,58,108.12199514189909,148.57380644224654,2.1124036058455906,48.98121467102938,114.74865377933224,1.0731188110355527,2022-06-28,Treatment follow-up,auto-greffe,2022-01-02,Protocole 6 FlUDARABINE cy (Fanconi)
Female,20,106.82886008586524,159.7772480763786,2.1774616516368086,41.846459605590276,99.03890326901109,1.7977592063948,2022-02-11,Cancer diagnosis,allo-greffe,2022-06-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,39,53.32290702899257,159.9103758371966,1.5390189970434354,20.852615242584825,96.22681209221393,0.7773320907181296,2022-02-22,Cancer diagnosis,greffe haplo-identique,2022-03-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,22,118.55446544627213,158.71583530644972,2.286219041015993,47.06276061065226,80.6386953782082,2.4094833781321823,2022-08-12,Cancer diagnosis,greffe haplo-identique,2022-08-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,28,48.938196131402634,143.57423759271165,1.3970469051547352,23.740776505703494,102.31199220807002,0.7440582597224239,2022-01-21,Treatment follow-up,pas de greffe,2022-06-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,50,82.25650227995527,198.29880115237967,2.1285992909464033,20.91847696673859,80.55253543760955,1.2764418561298032,2022-11-11,Treatment follow-up,auto-greffe,2022-02-17,Protocole 3 LAL thiotepa Bu Flu
Female,54,63.141689894578874,190.98769015926888,1.830246302923801,17.31033402950824,111.89568002246423,0.6740138733887889,2022-02-15,Treatment follow-up,auto-greffe,2022-01-10,Protocole 3 LAL thiotepa Bu Flu
Female,64,76.75048248822199,150.7169253882563,1.7925460433176872,33.787578085057035,95.35503198689676,0.8496080017375981,2022-10-23,Symptoms management,allo-greffe,2022-04-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,38,72.83222376592998,172.1556962684311,1.8662560704077689,24.574278511177788,128.4539690632571,0.8032370227313909,2022-08-15,Treatment follow-up,auto-greffe,2022-02-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,52,67.24130171261618,158.28546688488177,1.7194411911633005,26.838239808061154,120.10615480121066,0.6842597978457657,2022-09-17,Cancer diagnosis,auto-greffe,2022-03-01,Protocole 6 FlUDARABINE cy (Fanconi)
Female,22,116.1808406047326,164.51799898870746,2.3042134966378307,42.924740388961844,90.0490743737173,2.1144857966962256,2022-03-28,Treatment follow-up,allo-greffe,2022-02-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,47,73.29802822950182,181.77142380791094,1.9237901648098645,22.184062180941233,85.9262385464236,1.1018359630078378,2022-01-02,Symptoms management,pas de greffe,2022-05-22,Protocole 3 LAL thiotepa Bu Flu
Male,29,48.83777559014635,166.90131207977157,1.5047230111527048,17.532198262947762,109.99111936570426,0.6845240882688196,2022-08-08,Cancer diagnosis,greffe haplo-identique,2022-10-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,87.05626289204284,156.11318282956154,1.9429809775848623,35.720774247781655,134.6285101491687,0.9340364470287705,2022-12-14,Treatment follow-up,greffe haplo-identique,2022-08-23,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,71,116.19153569447656,146.48720679287672,2.1743820014009283,54.14708679413337,107.88649321830954,1.0321053023930278,2022-11-01,Treatment follow-up,greffe haplo-identique,2022-08-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,35,117.29737638845357,165.71903280537123,2.3236948406998352,42.711371615407025,91.98684024409977,1.8595994105885185,2022-09-30,Symptoms management,pas de greffe,2022-07-31,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,67,40.40778439395338,146.90672564371548,1.2841096456984544,18.723269142621184,88.68625868862996,0.46195435716243166,2022-04-15,Symptoms management,greffe haplo-identique,2022-04-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,73,107.66172080154138,185.93451043376368,2.3580847542545076,31.141627658696628,134.3120416688445,0.7459138523078885,2022-08-25,Cancer diagnosis,auto-greffe,2022-11-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,64,96.07614645652441,144.0232578620226,1.9605271127583028,46.31805502207953,91.51954690551995,1.1081098363964565,2022-01-16,Cancer diagnosis,allo-greffe,2022-01-02,Protocole 6 FlUDARABINE cy (Fanconi)
Male,23,91.96911614524333,146.47148265123073,1.9344000505408672,42.868260126685584,85.68867162434753,1.7441023521895258,2022-04-25,Cancer diagnosis,pas de greffe,2022-08-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,65,90.09318783613483,198.1445135507317,2.2268232778024113,22.94710225764337,126.74730486625995,0.7404265578795945,2022-11-18,Cancer diagnosis,auto-greffe,2022-04-02,Protocole 3 LAL thiotepa Bu Flu
Female,61,99.01630860306793,178.62063055162994,2.2165009635794313,31.034410132222632,96.24799150501948,1.1287808967528807,2022-12-09,Symptoms management,allo-greffe,2022-02-04,Protocole 3 LAL thiotepa Bu Flu
Female,30,97.84769626371148,142.5934974812116,1.9686744857279184,48.1228303296747,91.45760097332207,1.6345228211491551,2022-11-20,Symptoms management,greffe haplo-identique,2022-05-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,74,46.98815228771921,198.2412031549852,1.6085697445891287,11.956402259336267,121.1901469404431,0.3554123335750763,2022-08-27,Treatment follow-up,allo-greffe,2022-09-23,Protocole 3 LAL thiotepa Bu Flu
Male,27,110.35223728295983,194.97249009325776,2.4447023501179896,29.029159783223367,134.0369866875119,1.292118765244463,2022-05-06,Symptoms management,pas de greffe,2022-07-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,32,54.93669602395438,185.83235739003158,1.683994567270781,15.908156849099026,122.96774871216385,0.6701354208640573,2022-04-03,Treatment follow-up,auto-greffe,2022-07-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,42,87.16111597535667,144.81296525875192,1.8724656694415114,41.563095896821466,88.03026036416063,1.347672526698579,2022-05-20,Treatment follow-up,auto-greffe,2022-10-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,30,78.03983436609542,177.08467170110535,1.9592840563391067,24.885959938182154,131.2307634313208,0.9085333469722322,2022-11-02,Cancer diagnosis,allo-greffe,2022-06-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,105.57415956736372,140.01329317298664,2.0263394578920555,53.85413960647357,91.48589728314315,1.0097445875787938,2022-09-27,Treatment follow-up,allo-greffe,2022-10-06,Protocole 6 FlUDARABINE cy (Fanconi)
Male,66,115.06088890945624,175.00980014252832,2.3650688956529122,37.5666948522187,75.4694031252205,1.5669532262800863,2022-12-14,Cancer diagnosis,allo-greffe,2022-01-25,Protocole 3 LAL thiotepa Bu Flu
Female,24,111.26479588076438,191.27843705872206,2.431423694494096,30.410653057448556,102.1207694999836,1.7553720932257377,2022-11-13,Symptoms management,pas de greffe,2022-03-28,Protocole 3 LAL thiotepa Bu Flu
Male,27,98.92772654090365,180.72337198087698,2.2285117307592803,30.289310436891864,107.67875110684648,1.4418960957959006,2022-03-22,Treatment follow-up,pas de greffe,2022-10-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,28,56.7914930604739,156.26937736683405,1.5701000729158363,23.256027000649503,79.47022011662209,1.1116405920214278,2022-09-17,Treatment follow-up,pas de greffe,2022-04-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,50,76.60086682679618,155.76740181527924,1.8205553183948096,31.570432550185632,126.82994931642698,0.7549564125000685,2022-01-19,Treatment follow-up,greffe haplo-identique,2022-04-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,41,53.73844846736269,145.97665442178146,1.4761585770997825,25.218445429383745,123.96415163004406,0.5960623750577547,2022-01-01,Treatment follow-up,allo-greffe,2022-02-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,47,59.249204443474014,181.48260910971288,1.7282537919720249,17.98922669400024,74.6299978838671,1.0254619399191705,2022-07-25,Cancer diagnosis,pas de greffe,2022-02-27,Protocole 3 LAL thiotepa Bu Flu
Male,78,88.06442681009047,194.41967700740253,2.1808164511039227,23.29807710000649,107.35468113080556,0.7063805287391391,2022-12-17,Symptoms management,auto-greffe,2022-03-29,Protocole 3 LAL thiotepa Bu Flu
Male,50,118.02997308211708,142.96113887474687,2.1649800726036443,57.75057458889857,123.46977555237962,1.1949277925920947,2022-11-03,Symptoms management,auto-greffe,2022-08-13,Protocole 8 Aplasie medullaire thymo
Female,46,60.63677081406257,174.15550279405113,1.712716110364755,19.992249460935213,101.47761750034746,0.7801195471205983,2022-04-08,Cancer diagnosis,allo-greffe,2022-04-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,84.87542805007443,152.7930482186692,1.8979795815137515,36.3558905465362,87.60195577335932,1.0899854428292535,2022-07-29,Cancer diagnosis,auto-greffe,2022-01-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,75,40.84170167085471,165.29764842168808,1.3694115974603849,14.947565951467764,123.19646247645052,0.29928603414343324,2022-04-23,Cancer diagnosis,pas de greffe,2022-03-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,79,108.96366281803266,148.68131472547975,2.121376691698169,49.29114517688383,111.72917348642682,0.8262518523452733,2022-05-02,Treatment follow-up,pas de greffe,2022-09-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,38,71.6092959310838,183.86209924537016,1.9124036268653595,21.182878489424947,113.76138134032614,0.8917481607009516,2022-03-07,Treatment follow-up,allo-greffe,2022-08-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,107.26280401079804,145.68417343097906,2.0834328604361265,50.538738513547166,111.78098248351999,1.5193351252046434,2022-02-25,Cancer diagnosis,allo-greffe,2022-04-07,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,52,104.32366806903376,182.63577062175585,2.30055751165018,31.275997213126324,77.13646003885924,1.6530017757293185,2022-01-11,Treatment follow-up,pas de greffe,2022-05-10,Protocole 3 LAL thiotepa Bu Flu
Male,66,91.35475290721263,170.19983303216495,2.078231332133587,31.53645608997254,110.17214016338401,0.8522334665839445,2022-07-04,Treatment follow-up,pas de greffe,2022-03-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,31,82.1562788402438,184.5500888557747,2.052231073194542,24.121940560801132,79.27202138712273,1.56897068489421,2022-09-30,Cancer diagnosis,auto-greffe,2022-04-05,Protocole 3 LAL thiotepa Bu Flu
Male,47,44.41764260585817,193.4828481327678,1.5450684989062615,11.865077025323933,130.32601027378718,0.4402251572450667,2022-06-10,Treatment follow-up,allo-greffe,2022-05-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,54.765393924186505,155.95469293364303,1.5402849838076957,22.516937378779208,117.78234726123017,0.5295504809183714,2022-09-24,Treatment follow-up,greffe haplo-identique,2022-03-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,61,56.99930302539509,152.54350688311052,1.554105099172552,24.495262201462683,116.2894007040576,0.5378039748420481,2022-11-19,Treatment follow-up,auto-greffe,2022-12-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,26,109.64051146520308,173.34191628009876,2.297661634944708,36.489160029510174,117.83251200417591,1.4732561797580903,2022-03-08,Treatment follow-up,greffe haplo-identique,2022-12-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,42.47839704534928,182.89956682547952,1.4690586951282703,12.698217633654126,110.24358310949748,0.40136876004495703,2022-03-23,Symptoms management,greffe haplo-identique,2022-07-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,39,91.6050932286621,186.25917812804406,2.17704497587348,26.404883546651448,131.67294285536698,0.9759149171107864,2022-02-04,Cancer diagnosis,pas de greffe,2022-05-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,40,55.03227814608198,149.6699990738302,1.5126027071789994,24.566765454709326,122.36686827261144,0.624627570569637,2022-10-27,Treatment follow-up,auto-greffe,2022-01-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,37,106.62761835706937,178.391664924437,2.298639595599311,33.50584625296005,93.98676711481642,1.6229596622896998,2022-02-06,Symptoms management,allo-greffe,2022-07-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,30,99.8266250154677,161.91331411545985,2.118913485545497,38.078625549477536,81.8475555654311,1.8633775715789573,2022-07-01,Symptoms management,allo-greffe,2022-07-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,113.62591473500731,175.26355831236992,2.3519780170077254,36.990835692289636,75.95149633160221,2.1401577510674117,2022-03-14,Treatment follow-up,greffe haplo-identique,2022-02-20,Protocole 3 LAL thiotepa Bu Flu
Male,40,74.72663706257005,163.74309857776404,1.843605397261422,27.87079963431214,110.36710938475638,0.9403797607711104,2022-02-16,Symptoms management,greffe haplo-identique,2022-01-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,75,90.36581417012705,188.09741090756242,2.1729125154933064,25.541037248550364,75.97935702105389,1.0737159684173299,2022-08-19,Cancer diagnosis,greffe haplo-identique,2022-03-06,Protocole 3 LAL thiotepa Bu Flu
Male,44,83.58912867559937,188.13007588711568,2.090031174746124,23.617468068841063,95.75659251181358,1.1639112111650785,2022-07-20,Treatment follow-up,pas de greffe,2022-10-31,Protocole 3 LAL thiotepa Bu Flu
Male,30,83.94102085360487,171.22009801352903,1.9980817062810456,28.632862252421447,83.51776673361067,1.5355203008859755,2022-05-12,Cancer diagnosis,auto-greffe,2022-11-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,56.8213285543366,145.61020496726715,1.5160040033395346,26.79956578148758,90.73040702343522,0.6349636859698681,2022-01-18,Symptoms management,pas de greffe,2022-05-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,51,71.47125436142808,140.86792813392142,1.672324357412865,36.016968005454935,126.02451389470843,0.7010256093113899,2022-10-19,Treatment follow-up,pas de greffe,2022-11-13,Protocole 8 Aplasie medullaire thymo
Female,77,88.92123070022961,162.56922031276707,2.003875075405152,33.645641966817145,90.39763748337904,0.8607091847616782,2022-10-03,Cancer diagnosis,pas de greffe,2022-01-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,27,104.31189588274026,174.07351469930632,2.2458565763334475,34.42456352236591,128.35245304534817,1.2754857550310554,2022-06-17,Symptoms management,allo-greffe,2022-06-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,61.01266109351535,141.8015809114005,1.5502411818337578,30.342951429637214,74.19861937632956,1.2905358994393488,2022-01-19,Cancer diagnosis,pas de greffe,2022-02-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,62,55.50047338685181,161.5272784906104,1.578047353633837,21.271834022039798,95.59291113049062,0.6289745978515169,2022-06-15,Treatment follow-up,allo-greffe,2022-05-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,74,98.61909728035246,186.94766579870245,2.263024650019002,28.217655622026765,105.38398319869123,0.8578233278885887,2022-08-12,Symptoms management,auto-greffe,2022-08-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,43,59.776525764898025,171.36468472786183,1.6868433283493907,20.35579260846439,78.21988508837836,1.0295625439326432,2022-02-11,Treatment follow-up,pas de greffe,2022-07-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,54,106.3546287769076,177.3441265860189,2.2889449746323542,33.8160421804022,82.11737444821286,1.546989249682388,2022-11-11,Treatment follow-up,pas de greffe,2022-08-01,Protocole 3 LAL thiotepa Bu Flu
Male,33,103.77103400945904,187.06324067719532,2.322100695863844,29.65508933415417,102.31032248444349,1.5073287123730341,2022-12-19,Cancer diagnosis,pas de greffe,2022-03-28,Protocole 3 LAL thiotepa Bu Flu
Male,62,81.79997205800768,168.80180327347767,1.9584562224642217,28.70773917231876,78.77203211551118,1.1249758831437495,2022-03-19,Symptoms management,allo-greffe,2022-09-06,Protocole 3 LAL thiotepa Bu Flu
Female,41,99.31810196939009,186.17027870990353,2.266303814374849,28.655481707910134,90.74562217383485,1.5048923235801794,2022-03-01,Cancer diagnosis,greffe haplo-identique,2022-08-30,Protocole 3 LAL thiotepa Bu Flu
Male,76,105.90724131239463,152.18587532691666,2.115917598596789,45.72744778169794,122.21451510619886,0.7702830549518501,2022-04-23,Treatment follow-up,allo-greffe,2022-05-22,Protocole 6 FlUDARABINE cy (Fanconi)
Male,46,59.23096807036782,155.12259841630623,1.597572957279323,24.614934759881653,129.41839763631677,0.5975141157481203,2022-02-16,Treatment follow-up,pas de greffe,2022-03-17,Protocole 6 FlUDARABINE cy (Fanconi)
Male,65,107.07717602533349,194.90490417864348,2.4077344545430486,28.18716352723229,108.4489225508587,1.0284908545226104,2022-04-02,Symptoms management,pas de greffe,2022-04-17,Protocole 3 LAL thiotepa Bu Flu
Female,20,81.42654131866749,143.0309535010646,1.7986504080299612,39.80209394114967,86.14766427274604,1.575328865192612,2022-01-01,Treatment follow-up,pas de greffe,2022-02-04,Protocole 6 FlUDARABINE cy (Fanconi)
Female,24,53.86810074358961,149.3242463583634,1.494788497329315,24.158557581277297,102.71383034671595,0.8449445936296422,2022-08-14,Cancer diagnosis,greffe haplo-identique,2022-04-15,Protocole 6 FlUDARABINE cy (Fanconi)
Female,43,67.04594991791825,174.35391269506738,1.8019837601428306,22.055106160894166,116.81751282695231,0.7732213385951968,2022-09-16,Treatment follow-up,allo-greffe,2022-01-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,63,103.7140084981275,187.52375797200713,2.324318336625789,29.493398885818674,91.04108137148208,1.2183112121307695,2022-07-27,Symptoms management,auto-greffe,2022-02-24,Protocole 3 LAL thiotepa Bu Flu
Male,26,91.42851338175154,159.85305435505526,2.0148839999154506,35.77995421576648,77.33816022939044,1.8718031619198876,2022-06-22,Cancer diagnosis,pas de greffe,2022-08-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,56.724919557931486,157.11055409124728,1.5733972040820925,22.980695492469703,113.99357791616353,0.4907037262581501,2022-08-09,Treatment follow-up,auto-greffe,2022-06-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,20,52.32975010907383,168.73431067831046,1.5661190809541141,18.37984554959483,87.68844789975464,0.9946150521616628,2022-07-27,Cancer diagnosis,allo-greffe,2022-08-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,37,66.26103243246764,176.71410230384606,1.8034888152342046,21.218553825367653,97.7100322848552,0.9701162290763632,2022-05-05,Symptoms management,greffe haplo-identique,2022-03-18,Protocole 3 LAL thiotepa Bu Flu
Female,23,109.68417737415369,150.87260424630566,2.144005693209447,48.18625878559237,100.87815314770826,1.7668522139974259,2022-05-24,Cancer diagnosis,greffe haplo-identique,2022-01-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,42,89.51178060831279,178.28379379329533,2.105449268237801,28.16154401477435,123.81122436604034,0.9840422771453698,2022-03-07,Symptoms management,pas de greffe,2022-01-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,55.80273870385185,194.41966047049726,1.7359875121260036,14.763018133123799,108.08445333880249,0.6597017170583565,2022-03-06,Treatment follow-up,pas de greffe,2022-10-14,Protocole 3 LAL thiotepa Bu Flu
Female,69,82.12057445169648,186.04218000425533,2.0600627481136056,23.726252011663632,100.33997561381607,0.8070563145173298,2022-07-14,Cancer diagnosis,greffe haplo-identique,2022-01-06,Protocole 3 LAL thiotepa Bu Flu
Male,34,43.52695027002212,181.0731610329487,1.4796360734538057,13.275475109365718,86.07023993612785,0.7445238156724375,2022-05-23,Symptoms management,pas de greffe,2022-09-20,Protocole 3 LAL thiotepa Bu Flu
Male,79,88.89340635646136,164.2211978611133,2.0137155869059553,32.96181497539327,133.05758349952515,0.5660141067757553,2022-10-24,Cancer diagnosis,greffe haplo-identique,2022-02-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,35,98.62565512676343,157.333154742232,2.076126565640734,39.842758513489315,78.74897253648152,1.8264248505155534,2022-08-04,Treatment follow-up,auto-greffe,2022-12-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,71.77500319278677,161.23261461966513,1.792923700823433,27.61006486762465,125.04210330304358,0.9088439177948439,2022-08-17,Cancer diagnosis,allo-greffe,2022-01-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,37,94.0987445463703,155.94781115745505,2.0189720462452447,38.69236376966526,85.54104927899597,1.5736711545653965,2022-05-06,Treatment follow-up,pas de greffe,2022-03-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,30,96.64248125210577,156.83744605864018,2.051906968079415,39.28878047156123,121.82038677874941,1.2120158140232467,2022-07-02,Cancer diagnosis,pas de greffe,2022-03-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,32,102.47279063336495,190.05077691166207,2.325882954933286,28.370648617636192,98.07370524118522,1.5672823370142088,2022-07-30,Cancer diagnosis,greffe haplo-identique,2022-10-10,Protocole 3 LAL thiotepa Bu Flu
Male,57,75.18371187457319,147.789839110168,1.7568428660564508,34.4218819339648,87.68130915704859,0.9884673613234697,2022-08-19,Treatment follow-up,allo-greffe,2022-03-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,31,113.2933947951897,184.92192674977983,2.4123773920225777,33.130483262991014,82.69913309524244,2.073946910270658,2022-12-03,Symptoms management,greffe haplo-identique,2022-08-26,Protocole 3 LAL thiotepa Bu Flu
Female,37,50.23306454536248,170.82650759582793,1.543907289073919,17.21389499303828,85.61386159303666,0.8393639560324877,2022-09-12,Treatment follow-up,greffe haplo-identique,2022-03-16,Protocole 3 LAL thiotepa Bu Flu
Male,65,99.59676754027242,169.5445780467638,2.1657749400514246,34.64794104908357,76.48541836648509,1.356423682712192,2022-07-25,Treatment follow-up,greffe haplo-identique,2022-10-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,70.94014417025537,169.37952046530458,1.8269439875633104,24.726933950196756,131.15787898990897,0.7887774467816403,2022-12-01,Symptoms management,greffe haplo-identique,2022-09-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,58,77.94435020713172,156.6499275073387,1.8416460639536731,31.763199648048236,91.78467090139651,0.9671544663262069,2022-09-23,Symptoms management,greffe haplo-identique,2022-12-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,74,44.99336797299794,199.04354395985837,1.5772373364733085,11.356704145874058,76.87020378982731,0.5365397593413539,2022-10-03,Cancer diagnosis,pas de greffe,2022-07-22,Protocole 2 LAM Endoxan TBI
Female,40,82.04385051888167,191.59338985436767,2.0895945538161733,22.350384137690444,94.70688722409837,1.2031837992701007,2022-07-08,Cancer diagnosis,allo-greffe,2022-05-26,Protocole 3 LAL thiotepa Bu Flu
Female,69,58.96063873468948,153.13993736407127,1.5837042129464831,25.14115638224549,79.98316219828158,0.7269247598682043,2022-02-04,Treatment follow-up,greffe haplo-identique,2022-10-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,33,83.99579694392978,186.23686080785396,2.084540553154967,24.217330558525788,77.38710956290477,1.6130217012891532,2022-11-30,Symptoms management,pas de greffe,2022-03-03,Protocole 3 LAL thiotepa Bu Flu
Male,42,108.44055813768985,183.0874607017026,2.348410007413112,32.35001910638288,121.74742938233246,1.2123430393982444,2022-08-12,Treatment follow-up,allo-greffe,2022-08-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,118.88886899767054,184.6695859775947,2.469545516843597,34.861851174426086,100.00140048703852,1.2384083749769592,2022-02-13,Symptoms management,greffe haplo-identique,2022-05-31,Protocole 3 LAL thiotepa Bu Flu
Male,55,75.95840213063758,174.0104292054039,1.916127036825188,25.08564452555572,114.07870691095668,0.7860635525649924,2022-03-03,Symptoms management,allo-greffe,2022-09-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,72,53.251815907003575,165.62627291558928,1.5652386927189317,19.412253939801023,129.2312878370648,0.3891734156000818,2022-12-22,Treatment follow-up,auto-greffe,2022-09-12,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,20,73.86490182302441,159.02970334055723,1.8063709339903768,29.20664199930386,121.71398024056717,1.0114546370245874,2022-03-16,Cancer diagnosis,auto-greffe,2022-02-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,74,115.27064058052125,140.73441579982617,2.122795998269695,58.199342366588375,116.70361469830056,0.9054111489060545,2022-08-12,Treatment follow-up,pas de greffe,2022-03-22,Protocole 8 Aplasie medullaire thymo
Female,31,45.12019637313841,140.13242519313206,1.3252675351454983,22.9770201338962,122.72325705985256,0.5565934737249145,2022-07-12,Cancer diagnosis,greffe haplo-identique,2022-01-18,Protocole 8 Aplasie medullaire thymo
Male,60,86.32396373283805,173.5633816230016,2.0400625712471503,28.655973532150192,111.80884498092375,0.8578526616125366,2022-09-06,Cancer diagnosis,greffe haplo-identique,2022-09-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,61.9138310010557,152.40737722124987,1.6189952814246154,26.65481659809558,133.37926472190225,0.4126167328942068,2022-06-04,Cancer diagnosis,pas de greffe,2022-04-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,76,106.9445866636679,157.0557101354193,2.160006301662699,43.356213339014104,103.1257226502772,0.9218054658828975,2022-01-28,Cancer diagnosis,allo-greffe,2022-02-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,64,92.15021386771302,181.56002547161145,2.155792917868583,27.954767043934808,84.38805968776038,1.1526473123519991,2022-08-07,Treatment follow-up,pas de greffe,2022-05-02,Protocole 3 LAL thiotepa Bu Flu
Male,78,87.44670951994411,198.20857525607343,2.19422776245994,22.258638322550574,88.84682674256872,0.8475410541775815,2022-07-09,Treatment follow-up,allo-greffe,2022-11-20,Protocole 2 LAM Endoxan TBI
Female,69,81.57843347977035,182.6040633918035,2.034190627917322,24.4655220133414,77.42059343164826,1.039069789002101,2022-08-10,Treatment follow-up,auto-greffe,2022-09-12,Protocole 3 LAL thiotepa Bu Flu
Male,34,106.02923020100158,177.50530820833842,2.286479048785226,33.65138307243098,133.40071322953628,1.1701480833797244,2022-06-12,Symptoms management,allo-greffe,2022-12-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,72,91.33400733205501,183.01615970758385,2.1548136857212024,27.268022059950138,101.50694748565176,0.8497930235346752,2022-04-01,Treatment follow-up,allo-greffe,2022-04-15,Protocole 3 LAL thiotepa Bu Flu
Male,24,70.76153744933032,153.9795282430524,1.7397180609864609,29.844979911086966,80.11411340257138,1.4230289069174413,2022-05-28,Treatment follow-up,greffe haplo-identique,2022-02-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,77,69.15585836168698,144.69162239993173,1.6671893634374568,33.03255779253565,101.17547579581382,0.5980834346516589,2022-11-16,Symptoms management,pas de greffe,2022-02-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,30,119.86384948301867,156.3295230141889,2.281462641007399,49.04629608487937,111.47072019858476,1.642811002501994,2022-05-12,Cancer diagnosis,greffe haplo-identique,2022-01-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,71,63.87886448510513,176.98946046784405,1.7721523135345651,20.392119935867775,83.17843818882153,0.7359749288943269,2022-12-14,Treatment follow-up,pas de greffe,2022-03-08,Protocole 3 LAL thiotepa Bu Flu
Male,54,110.93668834519507,167.0081293572299,2.2685855111853925,39.77406454415659,77.93351975434906,1.700265963819611,2022-11-13,Cancer diagnosis,auto-greffe,2022-12-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,43,70.24940797339644,148.1269048401432,1.7001492883756881,32.016567709997766,117.2114528534741,0.8074429692295167,2022-09-08,Cancer diagnosis,auto-greffe,2022-04-16,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,77,84.6813020878619,142.50727623879035,1.830884858089676,41.697829422580085,111.35363986635622,0.6654128182590838,2022-02-14,Cancer diagnosis,auto-greffe,2022-01-18,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,63,69.49956963898258,148.49833623552107,1.6931701414534057,31.51656950373723,122.28482082871253,0.6078099320748888,2022-04-03,Treatment follow-up,allo-greffe,2022-05-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,25,99.026040067526,186.030646540856,2.262120333899062,28.61412180966657,89.44130112290769,1.7683842899062108,2022-03-12,Treatment follow-up,allo-greffe,2022-01-30,Protocole 3 LAL thiotepa Bu Flu
Male,26,103.26403047254637,159.44844379727883,2.1386190351539613,40.61706163935354,127.07189922923402,1.2866840156892596,2022-08-01,Symptoms management,allo-greffe,2022-07-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,66,73.8385032755128,183.6072263763836,1.9405957551885125,21.902986964857984,111.54249566838567,0.6803646660064196,2022-05-15,Treatment follow-up,allo-greffe,2022-01-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,82.37960650455237,197.4270944121348,2.125504276833093,21.135192380430222,105.78829919409313,0.8544303633134145,2022-12-07,Symptoms management,pas de greffe,2022-12-24,Protocole 3 LAL thiotepa Bu Flu
Female,63,59.918258942932916,187.87538451829082,1.768329872645847,16.975376704464612,87.5608652535836,0.7318252162278706,2022-07-08,Symptoms management,allo-greffe,2022-07-31,Protocole 3 LAL thiotepa Bu Flu
Male,43,68.2389111206808,150.2687584484537,1.6877151263681818,30.220016132767334,111.88099413308095,0.8217032588455127,2022-11-12,Treatment follow-up,greffe haplo-identique,2022-11-05,Protocole 6 FlUDARABINE cy (Fanconi)
Male,66,65.5107230001029,171.64254648157453,1.767329067452628,22.236298446258235,134.8500845323361,0.49929865108476035,2022-08-16,Cancer diagnosis,pas de greffe,2022-04-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,40,118.14826678710276,171.62888736527128,2.373327222183476,40.10943837454311,107.53483441344066,1.5259689186035248,2022-08-04,Symptoms management,greffe haplo-identique,2022-10-05,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,77.036256427718,194.91368364828878,2.042290415930161,20.27731798037827,89.7495583721014,1.2517559157001674,2022-12-25,Symptoms management,allo-greffe,2022-02-27,Protocole 3 LAL thiotepa Bu Flu
Female,59,96.72089439564118,184.93169525727404,2.2290231397648474,28.281184966042826,134.94802545740956,0.8063178829499641,2022-12-09,Symptoms management,pas de greffe,2022-10-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,43.802474805146836,144.81515307247938,1.3274099774729191,20.886738679278732,134.6061703425906,0.474559293442935,2022-04-13,Cancer diagnosis,allo-greffe,2022-11-27,Protocole 8 Aplasie medullaire thymo
Male,61,68.70114039878416,156.14563732088,1.7262180363312718,28.177615387124607,118.75254379397904,0.6347688691901248,2022-07-01,Cancer diagnosis,auto-greffe,2022-10-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,65,105.97286487008827,169.71389284720593,2.235140278550369,36.792549651017154,122.04386741090431,0.9044977289574078,2022-06-27,Cancer diagnosis,greffe haplo-identique,2022-08-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,44,58.53112774126355,154.75612351078613,1.5862298448025696,24.439437551290247,89.64394490687071,0.8705719470076179,2022-03-29,Cancer diagnosis,allo-greffe,2022-10-23,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,36,64.32940807093055,186.9824512432674,1.8279063925804284,18.399577791651776,98.82138103247559,0.9402849376484522,2022-08-12,Treatment follow-up,pas de greffe,2022-02-02,Protocole 3 LAL thiotepa Bu Flu
Male,23,106.30237038727414,146.65581620525901,2.080989407689648,49.424736905235406,103.74955184524322,1.664984077588962,2022-11-09,Cancer diagnosis,greffe haplo-identique,2022-04-30,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,49,99.11120468561114,167.10795313201555,2.144908088387,35.49184005056347,113.45050432149793,1.1041427370966699,2022-06-05,Treatment follow-up,pas de greffe,2022-06-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,24,92.2867918670712,151.58092750131522,1.9712459051836204,40.16524577351094,132.28581869718275,1.1239623207548204,2022-11-22,Treatment follow-up,auto-greffe,2022-08-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,26,64.81423850713028,197.99989463108375,1.8880628222691438,16.532575117611735,89.91495359846196,1.141329002528804,2022-04-17,Symptoms management,allo-greffe,2022-12-19,Protocole 3 LAL thiotepa Bu Flu
Male,29,107.63558540334513,174.7842949530479,2.286008767516375,35.233116769663944,109.27347280232203,1.5185588039622024,2022-10-23,Treatment follow-up,allo-greffe,2022-11-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,107.77274087737075,179.79499996410277,2.32002154816251,33.3390874315233,120.50366642739037,1.3787932526190831,2022-03-15,Cancer diagnosis,auto-greffe,2022-12-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,60,86.50709810251558,174.67232896944813,2.0487391988702415,28.35329405252765,115.78252597835643,0.8301684306805656,2022-11-06,Symptoms management,auto-greffe,2022-02-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,29,50.378871549340076,197.08222414652786,1.6607210661951914,12.970404661401071,122.40306272695668,0.6345219248733281,2022-01-05,Cancer diagnosis,pas de greffe,2022-08-28,Protocole 3 LAL thiotepa Bu Flu
Female,73,71.01274038330155,141.98551489726933,1.6735508248090993,35.22477202060951,112.87927113656156,0.5854157225994162,2022-11-13,Cancer diagnosis,pas de greffe,2022-09-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,72,114.0556346752209,164.04415510610548,2.2797514621717503,42.383344417296954,84.71624727583726,1.2715295352479707,2022-03-30,Treatment follow-up,pas de greffe,2022-12-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,103.64391126222336,190.58061204556128,2.342394314178833,28.535557325011105,83.30905488212049,1.969808200689833,2022-12-04,Symptoms management,auto-greffe,2022-03-08,Protocole 3 LAL thiotepa Bu Flu
Male,54,99.21549401843237,162.14551725935092,2.1139318026002294,37.7371941493235,116.63896776862107,1.0160188991745274,2022-06-16,Cancer diagnosis,pas de greffe,2022-04-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,43,44.364344106863754,150.90463291423208,1.363694436888972,19.481792740116493,93.74736913559087,0.6375499473338221,2022-01-08,Treatment follow-up,allo-greffe,2022-03-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,33,107.5254024434,185.87460284886504,2.3562117356357426,31.12224874634483,118.89052909497708,1.3440489878733461,2022-09-28,Cancer diagnosis,greffe haplo-identique,2022-10-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,103.50373859935779,186.85432992176595,2.3178127692803536,29.644880553918735,97.89164524997256,1.674105272523542,2022-12-04,Symptoms management,greffe haplo-identique,2022-12-20,Protocole 3 LAL thiotepa Bu Flu
Male,26,111.00538035437128,185.5391384508887,2.391875289063842,32.24578529850153,133.340305872668,1.3181199618835435,2022-03-26,Symptoms management,greffe haplo-identique,2022-12-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,55,62.83286806774097,194.42094942197173,1.8421022007354417,16.622669295104675,126.79100326815549,0.5850390765658618,2022-11-02,Symptoms management,pas de greffe,2022-11-12,Protocole 3 LAL thiotepa Bu Flu
Male,22,97.88381789165408,171.24717299192676,2.1578234336943907,33.37828963717011,81.39672270241584,1.9708496388871686,2022-05-19,Cancer diagnosis,allo-greffe,2022-08-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,35,79.19128707690254,160.24875326515496,1.8775208996866506,30.838133395381234,84.77744274554743,1.3622408262589598,2022-04-01,Cancer diagnosis,allo-greffe,2022-05-21,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,56,99.23800392057429,196.24904266081205,2.325902648255476,25.76694476872506,89.33147137808851,1.2960457211171414,2022-05-05,Cancer diagnosis,greffe haplo-identique,2022-10-23,Protocole 3 LAL thiotepa Bu Flu
Male,76,102.24677391147428,166.04149458478173,2.171610203712997,37.08654244278807,81.63988712857349,1.1132551066797618,2022-03-23,Symptoms management,greffe haplo-identique,2022-08-24,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,73.42561566332807,150.0339971392533,1.7493124530622879,32.6188193319706,129.7063759962005,0.7154761597797226,2022-09-12,Symptoms management,greffe haplo-identique,2022-09-21,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,68,91.25691288018037,152.91045432687662,1.9687937655789096,39.0293587239293,81.24510823403024,1.1232296302358373,2022-07-28,Symptoms management,pas de greffe,2022-01-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,28,92.54670984487504,196.79750987511292,2.249256793587977,23.895811616450274,100.266778097793,1.4357851262276888,2022-02-08,Symptoms management,greffe haplo-identique,2022-12-26,Protocole 3 LAL thiotepa Bu Flu
Male,62,109.8274553749447,163.25469207914375,2.2317063357858724,41.20781405500001,110.8959073407328,1.072895710725248,2022-12-23,Symptoms management,auto-greffe,2022-11-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,62,107.4440324841118,141.21419481686215,2.05295332895486,53.87975240211342,89.30433826740165,1.3033823901058557,2022-12-31,Cancer diagnosis,auto-greffe,2022-08-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,79,62.69163804308627,179.32551616737223,1.7671548343983232,19.49509870236093,99.48451558700147,0.5338896066812083,2022-05-11,Cancer diagnosis,allo-greffe,2022-05-16,Protocole 3 LAL thiotepa Bu Flu
Male,48,47.333996394382794,140.1447275280414,1.3574496130923106,24.100144486045167,103.69685779518007,0.5832609590313649,2022-04-25,Symptoms management,pas de greffe,2022-09-12,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,55,44.18168817023599,157.00614426279554,1.388123884423977,17.92293003137611,132.26854770658585,0.3943411969631703,2022-04-27,Symptoms management,auto-greffe,2022-05-24,Protocole 6 FlUDARABINE cy (Fanconi)
Female,28,81.94186292755361,157.8788513690083,1.8956739638537594,32.87440620890688,93.32895259421426,1.3657618195259784,2022-08-03,Symptoms management,pas de greffe,2022-06-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,79,89.07801647629395,188.73172852887188,2.161008510928166,25.008100326678573,128.47801605853746,0.5874069150928373,2022-12-19,Symptoms management,greffe haplo-identique,2022-12-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,76,102.83336239057016,173.4476453735983,2.2258709014984035,34.181980288547244,102.40427816299,0.8926134227573511,2022-09-21,Cancer diagnosis,pas de greffe,2022-04-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,46,95.98214013410055,178.44605225211154,2.1812097811407827,30.142310565146655,89.44611561422471,1.4009553732510955,2022-08-03,Symptoms management,greffe haplo-identique,2022-07-23,Protocole 3 LAL thiotepa Bu Flu
Male,65,107.50744537774253,157.73258166943765,2.170344756799237,43.211139484271904,103.59775604434526,1.0809782619282364,2022-01-31,Cancer diagnosis,allo-greffe,2022-12-14,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,118.63832534512622,171.36471095086773,2.376413166147587,40.4000797325957,76.3637717442657,1.3593950679208118,2022-11-06,Symptoms management,pas de greffe,2022-11-30,Protocole 3 LAL thiotepa Bu Flu
Male,58,109.0724400616396,193.5138781014982,2.4213764950219425,29.12666735479852,130.9747066108001,0.9484380097856041,2022-10-24,Cancer diagnosis,pas de greffe,2022-10-01,Protocole 3 LAL thiotepa Bu Flu
Female,29,56.30188234758346,147.68785232800334,1.51978654257199,25.812695889924736,93.73585181240472,0.9259929216792069,2022-05-21,Cancer diagnosis,greffe haplo-identique,2022-01-16,Protocole 6 FlUDARABINE cy (Fanconi)
Male,54,45.705330082186926,166.6437021049207,1.454543209207221,16.458454051329284,120.52794479143685,0.4529445656161753,2022-12-24,Cancer diagnosis,auto-greffe,2022-08-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,45,92.56331385479726,152.276292384706,1.978720001853781,39.918508508354016,76.97384975511088,1.586670675997603,2022-10-27,Cancer diagnosis,allo-greffe,2022-07-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,59,108.5158799708821,167.76260486887756,2.248759330383561,38.55697686141781,74.34363908015467,1.6421090826024758,2022-10-02,Treatment follow-up,allo-greffe,2022-10-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,115.95939996772148,167.20585780801463,2.320745267180443,41.47658420585963,113.6033175500228,1.063270371306326,2022-10-31,Cancer diagnosis,allo-greffe,2022-08-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,56,86.44453573060565,145.5443426894795,1.8694557386820296,40.80814822876041,94.38803615010036,1.0684824313114605,2022-05-25,Treatment follow-up,pas de greffe,2022-12-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,73,76.69105008518629,156.74562193693737,1.8273376461246182,31.214317645975246,92.52070381795679,0.7713439238267944,2022-07-12,Treatment follow-up,allo-greffe,2022-05-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,53.4696962347434,151.2125400691462,1.4986372128241872,23.38471597122683,115.95795714844485,0.51875187993421,2022-08-28,Cancer diagnosis,auto-greffe,2022-10-28,Protocole 6 FlUDARABINE cy (Fanconi)
Female,55,80.93259502702364,159.3203921447221,1.8925447871550116,31.884582338960307,86.37864955660896,1.1061231586176188,2022-10-29,Symptoms management,auto-greffe,2022-01-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,44,100.80389557174942,176.91353923496115,2.225706750067743,32.20736344264872,105.30856308790416,1.276298813264349,2022-03-27,Cancer diagnosis,pas de greffe,2022-01-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,26,92.47524951603451,152.49331820744706,1.9791873788924441,39.76709644112826,88.56558210567083,1.6532285068973702,2022-12-17,Symptoms management,pas de greffe,2022-09-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,22,40.29336764661129,162.23037470361746,1.3475088261286254,15.309789656407862,127.53106626724373,0.5178060096632915,2022-04-26,Treatment follow-up,pas de greffe,2022-11-07,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,61.14020429609218,171.76187373487102,1.7079516687825542,20.723988722986437,91.68865284049099,0.6668241096578945,2022-03-18,Symptoms management,auto-greffe,2022-01-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,38,88.26809684353614,186.92091725559206,2.1408171873271513,25.26317647213388,78.27929745370156,1.59743986719224,2022-07-29,Symptoms management,allo-greffe,2022-07-24,Protocole 3 LAL thiotepa Bu Flu
Male,79,57.7538825424731,175.90574417969486,1.6798842294684426,18.66470551762742,121.73593589896785,0.4019386087457691,2022-02-22,Treatment follow-up,pas de greffe,2022-06-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,31,40.935239571098975,157.14283597435337,1.3367331277629455,16.577084953623345,127.67332356938893,0.485390390240846,2022-09-15,Cancer diagnosis,auto-greffe,2022-10-14,Protocole 6 FlUDARABINE cy (Fanconi)
Male,55,62.34589696554857,181.5570622370687,1.7732062842646223,18.913921569240816,128.8403082929893,0.5712714910724692,2022-04-08,Symptoms management,pas de greffe,2022-05-09,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,21,100.11633853440013,170.9566328855224,2.1804403309543363,34.255715823296754,106.9099234805137,1.547752108832942,2022-03-29,Symptoms management,auto-greffe,2022-11-01,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,32,106.42399913929677,166.48398838903378,2.218476193560522,38.39676461940335,109.9249841145237,1.4522267161997566,2022-12-05,Treatment follow-up,pas de greffe,2022-01-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,47.43539887292145,180.8362423265352,1.543628417204042,14.505463436537648,126.09214619329232,0.4179958890294016,2022-03-20,Treatment follow-up,pas de greffe,2022-11-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,70,75.1975252351634,144.22534723452182,1.735686638722087,36.15100387126771,94.17860641773566,0.7762772021223537,2022-03-29,Treatment follow-up,pas de greffe,2022-03-29,Protocole 6 FlUDARABINE cy (Fanconi)
Female,68,79.68500994424934,187.78804473852125,2.038783148269262,22.596477892426783,100.09783013411254,0.7960713018202912,2022-10-26,Treatment follow-up,pas de greffe,2022-04-30,Protocole 3 LAL thiotepa Bu Flu
Female,38,92.3147417370849,174.69866063318224,2.116552604417989,30.247668747447843,98.62635775892876,1.3260067636334334,2022-10-19,Cancer diagnosis,pas de greffe,2022-05-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,43.129625850859185,178.20298873815537,1.4611475921516006,13.581437004630867,81.36217905726592,0.46383249633641194,2022-05-04,Symptoms management,pas de greffe,2022-01-16,Protocole 3 LAL thiotepa Bu Flu
Male,63,88.27493424131035,188.80168951535356,2.15164386294501,24.76427682474025,108.3955050949003,0.8709322210862551,2022-08-22,Treatment follow-up,allo-greffe,2022-05-27,Protocole 3 LAL thiotepa Bu Flu
Male,79,99.13154288440123,191.58896355276266,2.2968885691426055,27.006660787026668,92.22115623273692,0.910706929794773,2022-03-23,Cancer diagnosis,auto-greffe,2022-08-04,Protocole 3 LAL thiotepa Bu Flu
Male,52,98.33909634742675,148.47087694662986,2.0138749183850613,44.61117537161293,132.1333442627535,0.9096282966248784,2022-07-13,Treatment follow-up,pas de greffe,2022-10-08,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,70,97.0023192874069,188.9607734775854,2.2564496006920614,27.166819811914404,123.04265439514916,0.766464368652553,2022-06-03,Symptoms management,greffe haplo-identique,2022-03-29,Protocole 3 LAL thiotepa Bu Flu
Female,30,99.77634903109072,183.57883735003048,2.255661158936091,29.60618021023304,75.01051435453832,2.032196287536548,2022-04-22,Symptoms management,pas de greffe,2022-01-12,Protocole 3 LAL thiotepa Bu Flu
Male,63,77.3691580570955,198.03421826603991,2.0630169879826887,19.72819691495675,125.61375020092022,0.6587019026432885,2022-07-10,Cancer diagnosis,pas de greffe,2022-03-11,Protocole 3 LAL thiotepa Bu Flu
Male,37,72.77775962416281,161.1670011053388,1.805037185350387,28.0186000789917,120.60636894974712,0.863243203968883,2022-03-29,Cancer diagnosis,greffe haplo-identique,2022-08-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,42,95.14706590559607,146.77138502789714,1.969550614586495,44.16849641321836,92.54918931033218,1.3993178066581937,2022-01-16,Treatment follow-up,greffe haplo-identique,2022-07-24,Protocole 6 FlUDARABINE cy (Fanconi)
Male,61,64.44514850077653,182.8851463873597,1.8093937303785586,19.267854594339344,115.51846993696088,0.6121155265305225,2022-06-02,Symptoms management,pas de greffe,2022-08-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,66,76.44258254733931,198.038167072607,2.050646844695293,19.49115408234067,99.51520028810359,0.7894873083774601,2022-11-11,Symptoms management,pas de greffe,2022-06-09,Protocole 3 LAL thiotepa Bu Flu
Female,68,92.61512786623837,141.1867511182929,1.9058410951481262,46.46158713459422,104.5110861178256,0.8861751542972603,2022-05-02,Symptoms management,pas de greffe,2022-12-01,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,23,76.31752986222372,177.21040632085615,1.9382308998649558,24.302215215685504,111.24125460650788,1.1148380739213481,2022-02-05,Symptoms management,greffe haplo-identique,2022-05-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,89.91334748689506,160.99327959742828,2.005232370262749,34.690349221260945,78.8999238382671,1.250380458404973,2022-08-18,Treatment follow-up,greffe haplo-identique,2022-01-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,93.10287327756622,193.89338879002167,2.239297484447799,24.76492869262787,89.79335164467895,0.9792539182272878,2022-03-18,Cancer diagnosis,greffe haplo-identique,2022-03-03,Protocole 3 LAL thiotepa Bu Flu
Female,29,63.970701147826084,146.80912166945228,1.6151610212204308,29.68076087809257,82.95724741465189,1.1888231670700304,2022-03-09,Cancer diagnosis,allo-greffe,2022-06-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,25,53.48123258091121,177.12431380031984,1.6221407856157595,17.046885589053197,93.48838918077254,0.9137114661895882,2022-04-09,Cancer diagnosis,auto-greffe,2022-09-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,53,74.56629571937957,152.95086638712198,1.7799016462806658,31.874155432724756,128.89166450682077,0.6990439684805914,2022-06-28,Cancer diagnosis,greffe haplo-identique,2022-05-04,Protocole 6 FlUDARABINE cy (Fanconi)
Male,40,107.92544884004877,174.9527313001666,2.290187525762109,35.26000825401446,95.39263988746602,1.5713629154106825,2022-04-29,Treatment follow-up,greffe haplo-identique,2022-10-29,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,105.26813811215818,185.1111455453896,2.3265559689146085,30.7207493374784,81.81612909632328,1.2866428572809223,2022-04-25,Treatment follow-up,auto-greffe,2022-01-07,Protocole 3 LAL thiotepa Bu Flu
Male,37,97.06553671215876,167.42947592588547,2.124698144716453,34.62591228835289,92.21371409163382,1.5058242059155758,2022-02-27,Symptoms management,auto-greffe,2022-12-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,79,112.37727708190283,157.9934735920942,2.2207904222865653,45.01945259332825,125.35592857749413,0.7595055734261097,2022-07-09,Symptoms management,allo-greffe,2022-07-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,43,105.0042119106663,199.99185504043402,2.415228717434495,26.25319124593718,116.27587023524453,1.2166239429279424,2022-08-29,Treatment follow-up,pas de greffe,2022-08-25,Protocole 3 LAL thiotepa Bu Flu
Male,25,45.37221088454956,147.94197773671928,1.3654928508445996,20.730372292650703,129.21918493236703,0.5608261925973755,2022-03-23,Cancer diagnosis,greffe haplo-identique,2022-11-15,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,46,76.46811809320121,197.7981989814906,2.0497463283659663,19.545002774434554,124.26422623008094,0.8033959525455946,2022-03-13,Treatment follow-up,allo-greffe,2022-12-30,Protocole 3 LAL thiotepa Bu Flu
Male,28,68.52142059132376,174.36341916073007,1.8217535188241687,22.53801195152652,97.79005974971406,1.0899765962736738,2022-08-01,Cancer diagnosis,greffe haplo-identique,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,59,87.20191709782597,150.82824575591724,1.911406708742864,38.33192881826175,122.09858820442102,0.8034667572962327,2022-10-06,Symptoms management,allo-greffe,2022-10-16,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,42,60.651406769392395,199.13551328420428,1.8316544599556872,15.294787337974226,104.57715233407991,0.7894009524625097,2022-06-04,Cancer diagnosis,pas de greffe,2022-12-08,Protocole 3 LAL thiotepa Bu Flu
Male,49,47.709633859621974,190.2238608048213,1.5877579187123618,13.184877520286703,84.43962429228874,0.7141158743128143,2022-08-28,Cancer diagnosis,auto-greffe,2022-11-20,Protocole 3 LAL thiotepa Bu Flu
Male,59,100.1806248777927,179.72038670534243,2.236347508489615,31.016232783657415,75.12172345727141,1.500274458580831,2022-01-05,Cancer diagnosis,pas de greffe,2022-06-11,Protocole 3 LAL thiotepa Bu Flu
Male,36,79.54945402578068,140.57208893755868,1.7624503875008066,40.25677738910344,94.83807447427077,1.2115889906358326,2022-03-23,Treatment follow-up,auto-greffe,2022-07-13,Protocole 6 FlUDARABINE cy (Fanconi)
Female,45,56.720440876873504,181.99860449657996,1.6933727920289197,17.123931501726794,128.41533621735056,0.5827923113074289,2022-05-03,Treatment follow-up,greffe haplo-identique,2022-05-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,48.50440779480742,144.84191839923977,1.3969680935490802,23.120257669771046,90.97073451838497,0.7701589169439764,2022-01-18,Cancer diagnosis,pas de greffe,2022-01-15,Protocole 6 FlUDARABINE cy (Fanconi)
Male,73,54.25618287047634,184.02357183515818,1.665367540845512,16.021468649837722,107.57406046362004,0.4693361222562976,2022-12-04,Treatment follow-up,allo-greffe,2022-08-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,33,69.38280565566805,141.52833167808902,1.6515676670289638,34.638979040733794,85.68304126039777,1.2033951746832807,2022-06-26,Treatment follow-up,pas de greffe,2022-09-11,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,55.55720820558723,147.073494262873,1.5065590616336504,25.68452819085112,101.8842122694835,0.54529751929218,2022-10-28,Cancer diagnosis,pas de greffe,2022-08-01,Protocole 6 FlUDARABINE cy (Fanconi)
Male,20,106.7506621562072,187.46172916380658,2.3577097949059667,30.377032106028278,130.86823740927343,1.3595183505370412,2022-05-21,Cancer diagnosis,greffe haplo-identique,2022-01-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,48.69438735582623,163.89330806076956,1.4889112565655027,18.128274292217185,86.08053463571014,0.8249559383868801,2022-07-30,Cancer diagnosis,pas de greffe,2022-12-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,69.250217588181,176.52466479630155,1.8427313247538435,22.223392228522098,89.82627715798338,0.7816423922624347,2022-06-27,Treatment follow-up,pas de greffe,2022-02-10,Protocole 3 LAL thiotepa Bu Flu
Male,43,40.50870993891415,143.58053198611285,1.2710737065677573,19.64976208472294,86.19614948044028,0.6331400480440648,2022-10-24,Cancer diagnosis,auto-greffe,2022-09-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,37,94.64501833840406,149.1215664233273,1.980012162475787,42.561492184016615,78.9364981153114,1.7152389581797098,2022-04-14,Symptoms management,pas de greffe,2022-11-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,34,116.94103268507251,165.52813687565174,2.3188258082651054,42.679887997064135,107.25104780037935,1.6052354782492857,2022-08-17,Cancer diagnosis,allo-greffe,2022-04-11,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,40,63.23522343781322,165.0498354477861,1.702690944008847,23.21287143652131,98.04781197563447,0.8957537904161548,2022-06-20,Treatment follow-up,auto-greffe,2022-08-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,102.45764316614701,170.17942668218654,2.2007689926997327,35.37775329852015,110.4735524401696,0.9145593502943922,2022-11-26,Symptoms management,pas de greffe,2022-09-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,71,86.99073626628737,140.5964596884559,1.843199930731288,44.00725062150933,74.98414666609855,1.1117833030282804,2022-08-16,Symptoms management,pas de greffe,2022-10-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,72.62280551703395,188.0359200116339,1.9476264792206721,20.53957171703605,90.86726732982144,1.2543291111085542,2022-08-19,Cancer diagnosis,auto-greffe,2022-12-09,Protocole 3 LAL thiotepa Bu Flu
Female,70,106.42213711317861,142.1624709611123,2.0500158520370686,52.65771977973102,134.3809987727843,0.769944914702979,2022-03-19,Treatment follow-up,pas de greffe,2022-12-15,Protocole 9 LAL thiotepa-thymo melphalan
Female,79,64.5389327339096,146.7191632247153,1.6218215244779046,29.981136824881293,124.04568935619528,0.44079579302158606,2022-06-26,Treatment follow-up,allo-greffe,2022-07-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,51,47.41209876911391,174.01715860215631,1.513872766483916,15.656873195311016,130.14282446376188,0.45032542002281567,2022-01-19,Symptoms management,pas de greffe,2022-07-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,42,111.19378498683511,158.31063594707567,2.211281605177581,44.367026869414104,89.69199961996273,1.6874090986192691,2022-12-27,Cancer diagnosis,pas de greffe,2022-01-19,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,43,42.63226049551293,166.79949801492404,1.4054496759531996,15.32317926252183,112.38882839642613,0.5110394826835651,2022-10-20,Treatment follow-up,auto-greffe,2022-07-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,44.37893685045064,145.15506925481242,1.3376832846361768,21.06262421140628,105.04667079492648,0.4283363826085837,2022-10-01,Cancer diagnosis,auto-greffe,2022-03-21,Protocole 6 FlUDARABINE cy (Fanconi)
Male,44,50.55365397774321,174.3326577814026,1.5646398998652613,16.633936876569777,113.8113022680063,0.5922511264443424,2022-11-16,Treatment follow-up,allo-greffe,2022-05-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,23,56.48374834626907,195.31730796386748,1.750575593491548,14.806146758345268,79.86955659157495,1.1491999577767695,2022-08-19,Cancer diagnosis,greffe haplo-identique,2022-04-23,Protocole 3 LAL thiotepa Bu Flu
Female,69,46.77109871546519,150.8660975916708,1.4000171768070324,20.549168757209518,119.64165414730527,0.3854970114790381,2022-07-14,Symptoms management,auto-greffe,2022-07-05,Protocole 6 FlUDARABINE cy (Fanconi)
Female,71,96.74672675052511,195.97598375221713,2.2949240455684112,25.190139583730165,89.2437732576122,1.0389028808574223,2022-06-09,Cancer diagnosis,allo-greffe,2022-04-18,Protocole 3 LAL thiotepa Bu Flu
Male,31,112.02065165397758,187.4011492665415,2.4148153173886993,31.897275897621586,134.78574157490388,1.2581955471217678,2022-12-18,Treatment follow-up,allo-greffe,2022-08-28,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,113.45724126105323,188.05916716342267,2.4345130873095426,32.08065320036928,88.62887623442305,1.9735469338624902,2022-03-20,Treatment follow-up,greffe haplo-identique,2022-06-01,Protocole 3 LAL thiotepa Bu Flu
Male,79,104.5349166394881,153.83308388073306,2.1135100215221105,44.17350746216525,98.98178415038282,0.8947535663791056,2022-12-29,Treatment follow-up,auto-greffe,2022-06-29,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,37,48.292263549037386,163.38228614182728,1.4804372872759741,18.091210410206827,82.91637829823637,0.8331860041202248,2022-04-16,Symptoms management,greffe haplo-identique,2022-06-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,25,79.10851587439055,182.33428382165476,2.001679474435225,23.795046939728387,133.07219057532535,0.9495137862788362,2022-05-13,Symptoms management,auto-greffe,2022-04-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,46.080356956468194,140.67283696677816,1.3418741600947734,23.28602410039148,79.17691774134093,0.6304916650825299,2022-03-15,Symptoms management,auto-greffe,2022-02-03,Protocole 6 FlUDARABINE cy (Fanconi)
Male,67,60.95360476949232,161.86849562744425,1.655501628166884,23.263482788273535,116.92098282953756,0.5285636599857642,2022-11-18,Treatment follow-up,auto-greffe,2022-07-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,61,50.8776709921337,163.1641074491676,1.5185345436128634,19.110760214557242,132.89927821997773,0.4200482649354857,2022-06-03,Cancer diagnosis,pas de greffe,2022-11-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,73,88.69814421937438,188.41652563229027,2.1545943265913277,24.984838756170326,111.3265718478147,0.7414092565756746,2022-04-15,Treatment follow-up,pas de greffe,2022-05-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,35,79.36234233358377,162.8256602692768,1.8945994732823372,29.934277569784825,82.2802504749985,1.4066163941934504,2022-05-19,Treatment follow-up,auto-greffe,2022-10-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,67.71460494704462,177.33301015879243,1.8263529784619705,21.532932394455386,133.19910631632956,0.5154320285622843,2022-06-01,Treatment follow-up,auto-greffe,2022-03-30,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,26,51.84577137756877,150.89442012732917,1.4741511312609255,22.770207042361424,111.02387465036736,0.7393827523403972,2022-08-25,Cancer diagnosis,pas de greffe,2022-03-26,Protocole 6 FlUDARABINE cy (Fanconi)
Female,63,59.00126853614525,191.79855582175338,1.7729728719554714,16.038756117251094,79.68512740865968,0.7918488794974076,2022-09-21,Cancer diagnosis,greffe haplo-identique,2022-07-01,Protocole 2 LAM Endoxan TBI
Male,75,80.91727849229797,142.05011265241492,1.7868585504359442,40.10126776651182,120.20481879766547,0.6077154110108026,2022-05-01,Symptoms management,pas de greffe,2022-10-29,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,61,81.77007828692706,192.9602310890912,2.093533244330325,21.96133781395276,129.64512239084306,0.6920425956233599,2022-11-19,Symptoms management,allo-greffe,2022-07-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,50.960216511412284,142.73039157630424,1.4214206173839607,25.014875743737118,117.41912766479231,0.4761973889399212,2022-04-20,Cancer diagnosis,pas de greffe,2022-10-24,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,47,118.17302899090187,198.662161246661,2.5536743321251225,29.94249982760339,96.82249831766575,1.576494772380105,2022-09-21,Cancer diagnosis,pas de greffe,2022-08-13,Protocole 3 LAL thiotepa Bu Flu
Male,45,57.33881454116434,183.65433457086644,1.7103055144265127,16.999899110251604,117.16561132194343,0.6457131870330662,2022-10-16,Symptoms management,pas de greffe,2022-03-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,58,88.93723270188048,196.19097490070527,2.2015576801660237,23.106042171437085,126.42852152330067,0.8011612009085276,2022-09-25,Symptoms management,greffe haplo-identique,2022-10-05,Protocole 3 LAL thiotepa Bu Flu
Male,36,76.8235260718902,181.86932523959067,1.9700425016016485,23.226048343663766,112.26283748181518,0.9884599207208682,2022-12-11,Cancer diagnosis,pas de greffe,2022-12-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,59,62.24003786429229,180.7729409839465,1.7678702418824235,19.04596583755488,128.6652036493782,0.5442034101787021,2022-06-07,Symptoms management,greffe haplo-identique,2022-12-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,62.367369790075735,146.5233710073577,1.5932389496543355,29.049832023627527,116.62835631883539,0.5421801803200941,2022-10-16,Treatment follow-up,greffe haplo-identique,2022-08-30,Protocole 6 FlUDARABINE cy (Fanconi)
Female,30,118.67900903084698,188.66085949461956,2.493886071070682,33.34343160009933,109.08005515411647,1.6622209479986108,2022-05-22,Treatment follow-up,allo-greffe,2022-10-17,Protocole 3 LAL thiotepa Bu Flu
Male,26,42.05488120936945,143.1610088886818,1.2932108213696245,20.51950642047386,128.13386735381033,0.5196666316509816,2022-09-18,Cancer diagnosis,allo-greffe,2022-01-13,Protocole 8 Aplasie medullaire thymo
Female,61,42.38652385682782,152.53775605132589,1.3401435698312854,18.216842131114614,88.50470226127806,0.5254798300000775,2022-08-24,Symptoms management,allo-greffe,2022-12-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,37,111.72988107054113,193.14799500547207,2.448378290429927,29.949455287238802,92.92647983706306,1.7200242855134467,2022-04-26,Treatment follow-up,allo-greffe,2022-10-07,Protocole 3 LAL thiotepa Bu Flu
Female,25,83.92894685930987,183.57445041015086,2.068763069324314,24.905043249754073,103.55768166804472,1.2944783704323028,2022-05-04,Symptoms management,auto-greffe,2022-07-02,Protocole 3 LAL thiotepa Bu Flu
Male,31,91.19629293120474,184.1164836872855,2.159651513799871,26.902450494076703,120.63443038108908,1.1444581297417882,2022-12-09,Symptoms management,auto-greffe,2022-07-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,72,73.20157636973364,160.57297086923214,1.8069460569639402,28.390663894085378,93.62051163001921,0.7384580678237047,2022-05-29,Symptoms management,auto-greffe,2022-05-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,49,61.530115991614025,158.03841270003764,1.6435160365444739,24.635558683483907,109.71346453777835,0.7088212031356225,2022-11-30,Symptoms management,greffe haplo-identique,2022-02-28,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,43,59.35440961617634,151.05735028259141,1.5781423541802384,26.011731634553296,129.128412477901,0.6192562743344968,2022-12-06,Symptoms management,auto-greffe,2022-05-27,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,66,109.50658794550256,194.22067681233742,2.4306174127726647,29.030152739100718,114.84740409127377,0.9799824253860253,2022-03-04,Symptoms management,pas de greffe,2022-09-16,Protocole 3 LAL thiotepa Bu Flu
Male,66,93.44017596845681,189.45202006422343,2.2175079914913405,26.03365629756775,120.18365214020102,0.7990748716805006,2022-05-07,Treatment follow-up,pas de greffe,2022-10-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,53.925233235128935,165.45315202691256,1.5742811245258814,19.69889846256967,80.48426419862707,0.7816779184610302,2022-04-02,Cancer diagnosis,greffe haplo-identique,2022-05-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,96.50346664366208,163.35395510156002,2.0925942801841337,36.16459505413759,129.42260691352223,0.9527700615564316,2022-04-13,Cancer diagnosis,pas de greffe,2022-12-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,28,90.06284474247835,194.86623681496303,2.2079532774732193,23.717694128443718,92.08221865648133,1.5214420387821388,2022-09-03,Symptoms management,greffe haplo-identique,2022-07-18,Protocole 3 LAL thiotepa Bu Flu
Female,33,85.18476583785024,147.69009931662964,1.869413642983033,39.05342870179909,91.77467585510468,1.379400426419333,2022-06-09,Treatment follow-up,pas de greffe,2022-05-20,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,72,100.9506137951642,166.97633150719562,2.1638676250149493,36.20754951278452,79.09526134281221,1.2054103462515933,2022-11-18,Treatment follow-up,greffe haplo-identique,2022-12-21,Protocole 3 LAL thiotepa Bu Flu
Male,55,106.51060014517,182.23552330644043,2.3219971621153395,32.07205258420662,96.2951401647331,1.3057946695111426,2022-04-12,Treatment follow-up,pas de greffe,2022-04-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,55,62.463337312609745,188.68829475366857,1.8093968149434905,17.5442684875206,119.5506812454334,0.6168215782188095,2022-06-26,Treatment follow-up,allo-greffe,2022-08-04,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,75,86.50467331040153,176.0921976773829,2.0570203661683304,27.897118238006303,77.054346602229,1.0134989157937762,2022-01-28,Treatment follow-up,pas de greffe,2022-05-11,Protocole 3 LAL thiotepa Bu Flu
Male,43,41.988292954126024,177.33652341973718,1.4381757249313138,13.351554670373192,116.5349621129777,0.48541279213816124,2022-04-01,Treatment follow-up,allo-greffe,2022-11-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,86.98570109735722,160.76529127236213,1.9709192422042328,33.656060894959616,110.42924400907197,0.6673614371498071,2022-12-12,Treatment follow-up,greffe haplo-identique,2022-09-15,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,26,95.19204517297972,147.2635548308366,1.9733163684371104,43.894499154124944,93.9445642032478,1.604358266695122,2022-04-27,Treatment follow-up,pas de greffe,2022-04-20,Protocole 6 FlUDARABINE cy (Fanconi)
Male,58,96.72646572436096,150.67905062607957,2.012092058430916,42.60293985414707,132.17120321116494,0.8334697301572346,2022-07-24,Symptoms management,greffe haplo-identique,2022-08-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,79,60.088483875634466,141.69881842558829,1.5378978406833301,29.92669713884326,83.84046278728734,0.6072044111712416,2022-06-18,Treatment follow-up,pas de greffe,2022-07-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,42,82.24160405772261,159.74122356177685,1.9103064370135752,32.22979617562129,85.31516546214007,1.3120757660400013,2022-03-27,Treatment follow-up,auto-greffe,2022-06-15,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,48,88.43330433994878,167.13130322627578,2.026215232270193,31.659223118783554,134.9730132741248,0.8371904009548266,2022-02-11,Cancer diagnosis,greffe haplo-identique,2022-06-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,60,75.90976175900492,193.7322503173604,2.0211499041817986,20.225244583324837,119.06795731650604,0.7083700907711408,2022-04-29,Treatment follow-up,allo-greffe,2022-09-03,Protocole 3 LAL thiotepa Bu Flu
Female,43,119.22754141543979,194.4221676853268,2.5375226900891326,31.54169490642786,81.04282484480491,1.9819890731029648,2022-09-29,Treatment follow-up,pas de greffe,2022-08-21,Protocole 3 LAL thiotepa Bu Flu
Male,48,55.14153763290206,150.2867867925296,1.5172200922198502,24.413906337739753,105.77497420559533,0.6661181621549586,2022-05-10,Symptoms management,pas de greffe,2022-11-22,Protocole 6 FlUDARABINE cy (Fanconi)
Female,37,76.20365784902522,191.8953885507372,2.0154356113041203,20.694109453208124,76.34404575430281,1.4279249286894604,2022-09-15,Cancer diagnosis,allo-greffe,2022-10-30,Protocole 3 LAL thiotepa Bu Flu
Female,45,50.12827646346977,170.55506966369617,1.5410703066689386,17.23270710033369,105.65040294975277,0.6260409240536187,2022-06-08,Symptoms management,greffe haplo-identique,2022-09-23,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,46,90.40282192525062,167.637524114423,2.0517543469286426,32.169144477638675,99.80479557171547,1.182567488128385,2022-06-14,Cancer diagnosis,auto-greffe,2022-07-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,62,74.26927135542425,181.11684027804017,1.9330039775241308,22.640785864325185,75.70187467428198,1.0628320322038676,2022-03-24,Symptoms management,pas de greffe,2022-11-07,Protocole 3 LAL thiotepa Bu Flu
Male,69,56.91341410316829,154.0817597489874,1.5607440353828226,23.972436617508624,104.73483927276914,0.5358575084288494,2022-04-28,Cancer diagnosis,allo-greffe,2022-03-04,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,25,89.00942473908776,165.02920426216784,2.0199803723279763,32.68243326432,89.45190030304343,1.5893215314471125,2022-06-05,Treatment follow-up,auto-greffe,2022-02-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,61.79726567531715,146.17125274590495,1.5840335065929196,28.923132111933803,88.64240645353922,0.7068350639234832,2022-10-24,Treatment follow-up,auto-greffe,2022-06-27,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,23,78.77132320378196,181.4601042403547,1.9926150126926276,23.92245954255643,74.52851981329945,1.7175089553208027,2022-12-20,Treatment follow-up,allo-greffe,2022-12-15,Protocole 3 LAL thiotepa Bu Flu
Male,42,76.1234216739532,149.1959334796511,1.776177618457255,34.19828513788895,134.7130926695867,0.7691341131210327,2022-08-29,Treatment follow-up,pas de greffe,2022-02-14,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,34,103.27216877567014,195.3455655891189,2.3672393801816582,27.063015325332728,85.14684264668342,1.7856162023472,2022-06-09,Cancer diagnosis,pas de greffe,2022-10-11,Protocole 3 LAL thiotepa Bu Flu
Male,56,105.89509013010586,178.59621987650524,2.2920431691153933,33.19948137003445,81.53076414516624,1.5153086459300833,2022-12-11,Cancer diagnosis,auto-greffe,2022-03-01,Protocole 3 LAL thiotepa Bu Flu
Female,44,62.93281828787988,193.5984210464282,1.8396628806912276,16.790883912617346,116.35550128399031,0.721155626144729,2022-07-18,Symptoms management,greffe haplo-identique,2022-12-25,Protocole 3 LAL thiotepa Bu Flu
Male,47,107.7727637144223,180.93231091723013,2.3273479895931044,32.92128357693861,99.69222685742565,1.3963624933722025,2022-03-31,Treatment follow-up,greffe haplo-identique,2022-09-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,20,85.69877851484253,151.58140770395048,1.8995863208859227,37.29776085006757,93.61970361731002,1.5256542373664215,2022-05-18,Symptoms management,allo-greffe,2022-02-18,Protocole 6 FlUDARABINE cy (Fanconi)
Female,62,60.508754696091145,188.73543515604138,1.781084730993145,16.986790140438078,99.00674581284969,0.662087723241357,2022-06-19,Treatment follow-up,pas de greffe,2022-03-08,Protocole 3 LAL thiotepa Bu Flu
Male,43,93.45820176859434,153.50472418775928,1.9962656445899198,39.66193780625171,82.14652636803912,1.5327363412479738,2022-07-22,Treatment follow-up,allo-greffe,2022-01-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,66,91.20138948549574,188.1956866161167,2.183505598456474,25.750289996547195,117.15216514513193,0.8001112168906713,2022-12-29,Treatment follow-up,greffe haplo-identique,2022-06-19,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,56,103.14930209684725,173.55616729923966,2.2299848985238686,34.24413434041095,99.19084307672,1.21322542196,2022-05-31,Symptoms management,greffe haplo-identique,2022-09-16,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,49.04575710216203,171.6001796451475,1.5290030093680211,16.6558180011419,118.5017275097679,0.528849493052863,2022-04-07,Treatment follow-up,greffe haplo-identique,2022-02-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,41,116.47095871502195,162.56774098518008,2.2933733431998817,44.07059444769795,112.80878621463818,1.4196373669728775,2022-03-10,Symptoms management,greffe haplo-identique,2022-05-10,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,63,94.06588243838641,199.70102144354104,2.2843095726872273,23.586937785867292,79.11504864655588,1.2715436204168462,2022-09-02,Cancer diagnosis,allo-greffe,2022-09-03,Protocole 2 LAM Endoxan TBI
Male,41,116.81176019199812,178.4743356065273,2.406467056085877,36.672035837690444,94.20046379302372,1.7050464912455379,2022-05-17,Symptoms management,pas de greffe,2022-11-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,40,85.76159313657563,175.84139030041933,2.046707231649735,27.736433875895226,105.87814909761626,1.1250038352198697,2022-08-12,Symptoms management,allo-greffe,2022-08-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,108.1533526294117,144.7611005935532,2.0854255067755556,51.610282227041594,127.13227336011582,0.8270841860611127,2022-06-17,Treatment follow-up,auto-greffe,2022-01-03,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,55,85.26689554751472,187.8217561618037,2.109171642572775,24.17066823446617,101.65137423339358,0.9902700086717088,2022-12-25,Treatment follow-up,allo-greffe,2022-07-24,Protocole 3 LAL thiotepa Bu Flu
Male,26,44.07833372996552,175.01563719319415,1.4638607310962355,14.390353473397925,77.3083148517534,0.9027579401552888,2022-05-20,Cancer diagnosis,pas de greffe,2022-08-13,Protocole 3 LAL thiotepa Bu Flu
Female,74,44.104202285938634,184.4999090519018,1.5034424674506133,12.956498782394723,118.81370237694978,0.3402709560146412,2022-03-06,Treatment follow-up,auto-greffe,2022-12-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,78,55.12846276759567,184.2486135623992,1.6797273946119822,16.239304506466247,129.06599220351487,0.36780976163571477,2022-02-17,Symptoms management,greffe haplo-identique,2022-12-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,89.31426872595415,151.5637431180679,1.939129592967379,38.880353243469884,98.83326060075579,0.9036863519736104,2022-01-13,Symptoms management,auto-greffe,2022-05-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,45,109.94214636891387,157.77063602945316,2.195047605094172,44.168419468354315,86.1505615176135,1.6838259865213216,2022-07-20,Cancer diagnosis,allo-greffe,2022-09-05,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,65,105.51021151101199,172.52996187983467,2.248683118944174,35.44585372378755,101.16770902449612,1.086378958105681,2022-09-09,Symptoms management,auto-greffe,2022-03-31,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,74,89.94300676267486,173.67586742235318,2.083061963531499,29.81868234361468,111.21404734157738,0.741343006301107,2022-04-20,Cancer diagnosis,allo-greffe,2022-05-22,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,24,55.4787712851686,160.1475935304192,1.5709862183199401,21.6314683166554,132.0893444134246,0.6766818719954445,2022-05-20,Symptoms management,greffe haplo-identique,2022-04-13,Protocole 6 FlUDARABINE cy (Fanconi)
Male,68,65.50636705167331,192.17373033706028,1.869982391268012,17.737625182634137,98.05867800632888,0.6680323290453235,2022-10-08,Symptoms management,greffe haplo-identique,2022-10-26,Protocole 3 LAL thiotepa Bu Flu
Male,58,96.91799340286553,148.09849944509023,1.9967619198337607,44.187873034309256,119.66650101839599,0.9223870078975733,2022-10-21,Symptoms management,auto-greffe,2022-02-06,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,20,42.94330443057051,172.7426610210561,1.4354771448676005,14.391174820907322,90.57942049042637,0.7901593282826924,2022-03-04,Symptoms management,pas de greffe,2022-01-12,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,57,58.62755750856209,197.4114718831187,1.7930229301283218,15.043781887984618,124.21967125575196,0.5440728089040856,2022-09-16,Symptoms management,pas de greffe,2022-04-28,Protocole 3 LAL thiotepa Bu Flu
Female,30,60.33747444746278,190.51962661387438,1.7869490683653768,16.622934151560756,107.14591629085987,0.8603431266370325,2022-04-15,Cancer diagnosis,allo-greffe,2022-03-20,Protocole 3 LAL thiotepa Bu Flu
Female,65,80.34249289880873,143.86330854558554,1.7918284303116216,38.819077917736635,131.36518623000802,0.6370797253928372,2022-07-29,Treatment follow-up,auto-greffe,2022-10-02,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,26,74.44638726219125,191.05099300489348,1.9876742559576515,20.3960011839637,92.95976464942166,1.268005001335842,2022-09-26,Cancer diagnosis,auto-greffe,2022-12-26,Protocole 3 LAL thiotepa Bu Flu
Female,63,112.71406861931641,198.70621117505277,2.4942704077695343,28.546656001360496,75.32832170294392,1.6002139934965114,2022-10-20,Symptoms management,auto-greffe,2022-09-11,Protocole 2 LAM Endoxan TBI
Male,76,83.47587717444239,191.968244833506,2.1098128950161428,22.651773119034075,125.41459078580682,0.5916439167540047,2022-11-16,Symptoms management,pas de greffe,2022-06-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,56.47401688505276,171.6545767339927,1.640970534713467,19.166283368403946,89.00571190516385,0.6609362440088183,2022-06-08,Cancer diagnosis,allo-greffe,2022-09-07,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,78.48733095058029,158.38239482738402,1.8582407629830338,31.288572520832393,115.04246042921187,0.6538196872153025,2022-09-14,Symptoms management,auto-greffe,2022-05-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,24,83.18366023311707,184.0250809204192,2.0620836149158577,24.563146103396736,85.94338901576572,1.559376710637763,2022-01-24,Cancer diagnosis,allo-greffe,2022-10-17,Protocole 3 LAL thiotepa Bu Flu
Male,32,86.18723416869398,186.90785949324044,2.115358615125818,24.671060382939377,134.46311494814958,0.9614595891437816,2022-01-23,Treatment follow-up,allo-greffe,2022-09-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,24,92.34982412913442,150.62047058021307,1.965661746668009,40.70690395116459,95.70582650259364,1.554616194235294,2022-12-12,Cancer diagnosis,allo-greffe,2022-06-16,Protocole 6 FlUDARABINE cy (Fanconi)
Male,64,72.26706029869158,144.62125035947403,1.7038642861481632,34.55223658061541,131.95891274212443,0.5780730940927283,2022-09-09,Treatment follow-up,auto-greffe,2022-12-18,Protocole 8 Aplasie medullaire thymo
Female,25,119.86276263540125,198.32822488679875,2.5697043141352336,30.47300154185415,112.71007442286862,1.6985834591851363,2022-09-07,Cancer diagnosis,allo-greffe,2022-10-27,Protocole 3 LAL thiotepa Bu Flu
Male,53,116.49905947041657,148.6421596892211,2.1932137632963875,52.727648766049924,114.51761810341347,1.2292405237853155,2022-08-14,Treatment follow-up,allo-greffe,2022-03-31,Protocole 6 FlUDARABINE cy (Fanconi)
Female,31,54.96067253361268,178.0753061386942,1.6488328015609168,17.331838721001834,97.0364336593174,0.8574547552583899,2022-12-02,Cancer diagnosis,allo-greffe,2022-07-21,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,65,90.70883136122724,187.03953400702545,2.170902113313841,25.92881972187912,113.19544934271244,0.8347364364021721,2022-01-18,Symptoms management,pas de greffe,2022-04-13,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,36,78.07159446950917,193.9099908208683,2.0506680596381996,20.76312303868438,91.95011547438676,1.2264267458349727,2022-10-08,Treatment follow-up,auto-greffe,2022-08-13,Protocole 3 LAL thiotepa Bu Flu
Female,22,110.39373399800178,150.14859486883654,2.145762234558314,48.966817485551225,100.27926697495485,1.804192127745279,2022-07-16,Cancer diagnosis,allo-greffe,2022-10-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,69,110.10864829837467,166.05230621258664,2.253626397602547,39.932969634674805,76.42052598002682,1.4208141088276593,2022-11-15,Cancer diagnosis,pas de greffe,2022-04-11,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,37,70.95241961565581,199.23269030369892,1.9815847644684157,17.874998395854128,75.1387449654493,1.3508527206297936,2022-05-13,Cancer diagnosis,allo-greffe,2022-10-13,Protocole 3 LAL thiotepa Bu Flu
Male,36,60.86613488763742,181.11676268730875,1.7499108952027902,18.554891975573497,120.24242544145353,0.7311707999108977,2022-10-02,Symptoms management,pas de greffe,2022-11-27,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,79.59104532318854,162.6114112412472,1.8960787168793152,30.099700260585237,83.2362829674088,1.407747936805088,2022-06-23,Treatment follow-up,allo-greffe,2022-07-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,67,50.10159767091394,164.1891052960711,1.5116341870354046,18.585014426193233,130.94313821541766,0.3879352052075687,2022-04-25,Symptoms management,pas de greffe,2022-10-18,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,77,77.0838438281298,163.17572269642918,1.869210463513774,28.9502469833791,124.06370291304789,0.543659118387639,2022-07-18,Cancer diagnosis,auto-greffe,2022-06-08,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,55,66.87454686168739,195.19019848711417,1.9041807859191033,17.552736806947085,84.1930900886639,0.9377149328963212,2022-07-24,Cancer diagnosis,greffe haplo-identique,2022-08-03,Protocole 3 LAL thiotepa Bu Flu
Female,75,69.10226619002621,161.66249009781697,1.761568463336787,26.440749533165874,88.21077872090916,0.7072150503037454,2022-12-05,Treatment follow-up,allo-greffe,2022-03-20,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,64,45.93727713627692,179.00235989763235,1.5113350439875188,14.336651760494101,105.90986411837116,0.4578359956547364,2022-07-25,Cancer diagnosis,pas de greffe,2022-11-17,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,30,97.46956753471144,141.0326768059386,1.9540836170367801,49.00377547041329,94.35859799648077,1.5781480697148167,2022-09-10,Cancer diagnosis,pas de greffe,2022-07-31,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Female,61,46.86005625965163,193.22480423688657,1.585921148146741,12.550963128393025,116.00419916321076,0.4432244300944168,2022-04-13,Symptoms management,greffe haplo-identique,2022-05-16,Protocole 3 LAL thiotepa Bu Flu
Male,21,98.0596801216796,174.88829823576708,2.1826010592629195,32.0604023646432,81.51002762997206,1.9883548676594274,2022-09-14,Cancer diagnosis,pas de greffe,2022-05-11,Protocole 3 LAL thiotepa Bu Flu
Male,22,97.25443556050524,172.26922791398204,2.157283948575819,32.77132515965744,129.5770500782279,1.230072869686773,2022-06-30,Treatment follow-up,allo-greffe,2022-01-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,25,44.83678788057611,186.4027594669223,1.5236743770836454,12.904162325068997,86.90763399384882,0.8240278866755126,2022-02-21,Cancer diagnosis,allo-greffe,2022-03-25,Protocole 3 LAL thiotepa Bu Flu
Male,22,62.87605269549266,180.59345030480284,1.7759976302713183,19.278856839991775,105.20542536324956,0.9794824153225808,2022-04-03,Cancer diagnosis,greffe haplo-identique,2022-03-08,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,61,102.17430450899022,189.61806610117756,2.319847577980762,28.417264155993326,114.9458929702781,0.9753103355885221,2022-04-27,Cancer diagnosis,greffe haplo-identique,2022-04-15,Protocole 3 LAL thiotepa Bu Flu
Male,74,46.87611130084076,180.70981837936276,1.5339648662775212,14.354500274159582,113.6239376646105,0.37817531741659405,2022-12-20,Symptoms management,pas de greffe,2022-06-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,70,84.51648948846452,140.11232780371262,1.8136674079538684,43.051546107471566,114.31732531621057,0.7187782691522109,2022-03-01,Symptoms management,greffe haplo-identique,2022-03-26,Protocole 8 Aplasie medullaire thymo
Female,24,88.44670159997872,170.2716541846541,2.0453175648977178,30.506819410606038,122.97897758871258,1.1587140052946214,2022-07-10,Treatment follow-up,greffe haplo-identique,2022-08-25,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,70,65.68273891821453,179.28828463821222,1.8086325091216648,20.433719626158197,91.20972298580932,0.7001251215579705,2022-05-29,Treatment follow-up,auto-greffe,2022-09-29,Protocole 3 LAL thiotepa Bu Flu
Male,49,65.80979950025217,181.7489485641647,1.8227620878757145,19.922633856607067,122.3765961536873,0.6796746843973082,2022-08-12,Symptoms management,pas de greffe,2022-06-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,70.51296213167207,141.04364489576284,1.662110872709754,35.44556585250731,117.9910779522624,0.5727121339648434,2022-04-13,Cancer diagnosis,greffe haplo-identique,2022-11-14,Protocole 8 Aplasie medullaire thymo
Male,31,64.48842107813022,154.69548154825029,1.66467108470977,26.94799675967921,134.16545864163606,0.7276709305108132,2022-03-24,Symptoms management,pas de greffe,2022-03-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,27,114.94480618646624,151.44180358438592,2.198954850323225,50.11847016585122,97.7622155172092,1.8452884535471368,2022-07-22,Treatment follow-up,greffe haplo-identique,2022-03-09,Protocole 6 FlUDARABINE cy (Fanconi)
Male,44,53.20124716229844,169.74455251783345,1.5838264050635065,18.464184108920254,120.6712516266072,0.5878367486888421,2022-08-11,Cancer diagnosis,allo-greffe,2022-10-03,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,48,59.825608658317115,169.12476997588718,1.676470523898789,20.91571367361628,121.99650647020962,0.6266067406142837,2022-07-20,Symptoms management,pas de greffe,2022-09-16,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,68,98.02671457255042,183.51308711270082,2.2353961251447823,29.107865869464554,81.58995729671531,1.201455642586748,2022-01-27,Cancer diagnosis,greffe haplo-identique,2022-07-10,Protocole 3 LAL thiotepa Bu Flu
Male,28,53.51367370488744,143.07384646544426,1.4583482985379714,26.142328044836937,108.94642216955623,0.7640773397796473,2022-09-15,Cancer diagnosis,auto-greffe,2022-02-27,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,70,94.22657904708817,150.59311827994503,1.9853543179124322,41.54924836767461,121.43041849559746,0.754417016827454,2022-10-28,Cancer diagnosis,greffe haplo-identique,2022-09-06,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,79,40.9944539355023,196.70641167740678,1.4966510701050197,10.594685606172623,89.17668893626416,0.389467390820552,2022-01-01,Treatment follow-up,auto-greffe,2022-06-10,Protocole 2 LAM Endoxan TBI
Male,32,105.31314998187185,199.6302906469587,2.41659165054995,26.425896204767614,95.87070553459687,1.6477371694714529,2022-08-07,Treatment follow-up,allo-greffe,2022-01-12,Protocole 3 LAL thiotepa Bu Flu
Male,56,96.9614578671141,180.54983231680708,2.205194307330649,29.744382539691873,116.45333559166298,0.9713908173624264,2022-07-14,Treatment follow-up,allo-greffe,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,34,74.99885428898116,168.0210146814942,1.8709314077919221,26.56607673860323,112.16407948206319,0.9844058849794384,2022-02-16,Symptoms management,pas de greffe,2022-02-06,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,67,95.20113381356002,198.61449837360604,2.2917924472741835,24.13349524720554,89.66520341372305,1.0764863972685768,2022-07-02,Treatment follow-up,allo-greffe,2022-09-24,Protocole 3 LAL thiotepa Bu Flu
Female,72,57.822607792009215,160.11814414859273,1.6036805453470389,22.55363661924989,75.97134464396697,0.7188268280412732,2022-09-30,Cancer diagnosis,allo-greffe,2022-08-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,38,78.20050636067305,157.127323385807,1.8474784806946505,31.674235411853267,90.96809193960775,1.2178341692729786,2022-05-06,Symptoms management,auto-greffe,2022-09-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,41,100.48653194916977,187.57086270233134,2.288154611111998,28.561243121626813,93.72668742447172,1.4741690464783563,2022-12-31,Symptoms management,pas de greffe,2022-01-14,Protocole 3 LAL thiotepa Bu Flu
Female,26,80.02378584407111,169.44219288346147,1.940747690700668,27.872502743138437,84.24532493082971,1.5039923899691467,2022-11-18,Symptoms management,allo-greffe,2022-03-18,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,61,100.01265774244553,144.2443624532954,2.001822922940675,48.06813490974161,90.83708718063083,1.2080540447130896,2022-11-29,Treatment follow-up,greffe haplo-identique,2022-05-21,Protocole 6 FlUDARABINE cy (Fanconi)
Female,79,64.42757695382043,151.8644943789468,1.6485904246888399,27.935683474710324,98.50186626834308,0.5541466064257866,2022-09-02,Symptoms management,allo-greffe,2022-03-17,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,27,59.27760074159056,152.7122523404334,1.5857364152014357,25.41808643105828,124.51286711364793,0.747174997415892,2022-06-14,Symptoms management,allo-greffe,2022-06-17,Protocole 6 FlUDARABINE cy (Fanconi)
Female,49,89.38222655839479,147.69699104283708,1.9149619894243384,40.973953806972396,82.66181378389537,1.366643167383702,2022-09-14,Treatment follow-up,allo-greffe,2022-04-26,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,75,84.52868442435926,155.06310021732253,1.9081171539950674,35.155006652053665,112.27268349330555,0.6796899789756273,2022-11-11,Symptoms management,greffe haplo-identique,2022-06-22,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,57,48.9795290712918,194.77751585104443,1.6278915299706131,12.910318599568829,112.81224903270171,0.5004998407844756,2022-10-16,Cancer diagnosis,allo-greffe,2022-05-16,Protocole 3 LAL thiotepa Bu Flu
Female,35,119.63990614287259,183.86130223732943,2.4719059753210466,35.39120910341607,82.09464373674284,2.125289241579757,2022-02-20,Cancer diagnosis,auto-greffe,2022-10-31,Protocole 3 LAL thiotepa Bu Flu
Male,79,109.14944940854531,182.63763615827222,2.3531773690028386,32.72208694327534,108.8568456288209,0.8494995289277097,2022-08-15,Symptoms management,allo-greffe,2022-12-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,36,64.57799712065122,167.55364431749703,1.7336761488148322,23.002594036206265,103.71452619931192,0.8993853859488858,2022-04-20,Treatment follow-up,greffe haplo-identique,2022-02-25,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,65,87.45927838965589,165.17164852948986,2.0031775584763,32.05788620714403,91.93250307609051,0.9909815564775888,2022-04-23,Cancer diagnosis,allo-greffe,2022-12-26,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,79,71.6859230529046,193.09904440661728,1.9609013827915818,19.225322449465146,119.40337896268906,0.508644793460251,2022-05-02,Symptoms management,allo-greffe,2022-11-30,Protocole 3 LAL thiotepa Bu Flu
Female,71,51.440208417271364,185.98234308764467,1.6301815245174478,14.871654586854877,88.52678583460917,0.5568581976079454,2022-05-06,Symptoms management,pas de greffe,2022-08-27,Protocole 3 LAL thiotepa Bu Flu
Male,73,112.00241321167344,144.96607576952496,2.12371204890642,53.295999917164394,81.2135737619944,1.2833380310930944,2022-03-02,Treatment follow-up,greffe haplo-identique,2022-04-13,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,52,64.94701935201266,182.45010568388835,1.8142637429721742,19.510616208092177,93.89131025053507,0.8454423535821753,2022-08-29,Symptoms management,greffe haplo-identique,2022-06-03,Protocole 3 LAL thiotepa Bu Flu
Female,37,65.95135201667001,168.90925312167357,1.7590870115789161,23.116220047962123,94.65337727253382,0.9967639374577781,2022-02-18,Treatment follow-up,allo-greffe,2022-02-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,68,104.86030273065126,170.46615966153956,2.2282986227314385,36.08566828806905,97.15062104035417,1.0793580278513573,2022-08-19,Symptoms management,allo-greffe,2022-03-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,29,43.017407568793836,174.92045838360272,1.4457432393070815,14.059278071276415,87.21369612089605,0.7604138602644795,2022-12-25,Cancer diagnosis,auto-greffe,2022-05-02,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,45,91.29942799341487,144.4343802733792,1.913894829162576,43.764995883010556,126.00707360157864,0.9560139728961822,2022-01-06,Treatment follow-up,allo-greffe,2022-11-09,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,43,50.726190729683374,186.27778282226913,1.6201133653874145,14.618746330381715,77.26498724871126,0.8844814945705203,2022-01-03,Treatment follow-up,allo-greffe,2022-08-18,Protocole 3 LAL thiotepa Bu Flu
Male,53,63.25622873600893,141.64856774377614,1.5776348508419846,31.52672953857571,128.61334692504914,0.5942976491174012,2022-03-02,Symptoms management,greffe haplo-identique,2022-12-02,Protocole 8 Aplasie medullaire thymo
Male,69,98.31260581999061,148.64925707932326,2.014812909475024,44.49218366930671,127.49462302612991,0.7604018950784333,2022-09-19,Symptoms management,pas de greffe,2022-12-18,Protocole 7 ATGAM ENDOXAN (APLASIE MEDULLAIRE)
Male,63,68.58004121028875,167.66888030307325,1.7872028673684268,24.394550130016402,100.34945393620096,0.7308713819084981,2022-01-05,Cancer diagnosis,auto-greffe,2022-03-03,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,71,111.51795749492406,159.36301173435834,2.2218509281462246,43.91063818883328,107.06348870553606,0.9982056182250059,2022-12-15,Symptoms management,greffe haplo-identique,2022-08-06,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,52,44.593469206547795,144.34556959034649,1.33716841296042,21.402491980333576,97.47612963242644,0.5591433434601003,2022-09-15,Symptoms management,greffe haplo-identique,2022-12-16,Protocole 6 FlUDARABINE cy (Fanconi)
Female,76,114.82239734070714,182.23576000599195,2.41089810634807,34.57477841616124,121.27408253575726,0.8416007036099106,2022-06-13,Symptoms management,auto-greffe,2022-06-10,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,48,96.79675295142212,186.19890536133803,2.237524018622585,27.919429653994886,120.9057607087062,1.0229846713454938,2022-02-03,Cancer diagnosis,auto-greffe,2022-06-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Female,71,98.08739633326866,154.82164616674953,2.0538616858471377,40.921339843757856,95.26047645033488,0.9867725313662199,2022-01-05,Symptoms management,pas de greffe,2022-11-02,Protocole 5 BISULVEX ENDOXAN (LAM)
Male,22,113.854174981694,144.4409431128797,2.137314281190734,54.57180639781535,86.45877317465471,2.158188642743887,2022-03-21,Symptoms management,allo-greffe,2022-02-10,Protocole 6 FlUDARABINE cy (Fanconi)
Male,70,105.59490606483111,187.7077734422438,2.346450315800463,29.969427845104658,108.60504227394277,0.9452757632628644,2022-02-12,Cancer diagnosis,auto-greffe,2022-08-04,Protocole 3 LAL thiotepa Bu Flu
Female,47,103.23261571577369,156.88052028852604,2.121005164239879,41.94487357113653,113.7276020815147,1.1724693582943992,2022-05-05,Cancer diagnosis,greffe haplo-identique,2022-02-07,Protocole 6 FlUDARABINE cy (Fanconi)
Male,44,104.23853330296849,151.83183505750173,2.096738723926876,45.21709006396767,109.44493125217767,1.269905417094035,2022-08-22,Treatment follow-up,greffe haplo-identique,2022-08-26,Protocole 6 FlUDARABINE cy (Fanconi)
Male,42,101.7074531172511,189.48432401763253,2.3137252310624152,28.327366773746405,98.30778134579501,1.4081809458577947,2022-10-25,Symptoms management,allo-greffe,2022-08-27,Protocole 3 LAL thiotepa Bu Flu
Female,41,42.01243307680616,172.52468048365503,1.418937551765495,14.114820844749449,104.4613153033798,0.5529998862530063,2022-11-05,Symptoms management,pas de greffe,2022-04-01,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,69,88.85320133599149,151.57729190529358,1.934204375305645,38.67272657127368,122.29524918661201,0.7164557059899734,2022-09-25,Treatment follow-up,greffe haplo-identique,2022-09-06,Protocole 6 FlUDARABINE cy (Fanconi)
Female,28,83.40691905166148,184.59955711951875,2.06806943774732,24.47601832493201,85.09017979873792,1.5247834310547421,2022-08-04,Symptoms management,auto-greffe,2022-09-24,Protocole 3 LAL thiotepa Bu Flu
Female,42,115.67598038716872,197.78823417531942,2.5209867940769293,29.569384367045696,113.67772889393314,1.3850370140711805,2022-11-25,Treatment follow-up,auto-greffe,2022-06-21,Protocole 3 LAL thiotepa Bu Flu
Female,62,50.35052164984711,161.24894208735466,1.5017553016372664,19.36467561345215,74.64514380068013,0.7307427607032628,2022-03-25,Symptoms management,allo-greffe,2022-05-14,Protocole 4 THYMO FLUDARABINE BISULVEX (LAM / SUJET AGE)
Male,77,103.38677461047996,153.00194505111236,2.0961855309084902,44.164272715484564,87.76943587138207,1.0306939640894548,2022-12-08,Symptoms management,pas de greffe,2022-09-09,Protocole 5 BISULVEX ENDOXAN (LAM)
Female,57,118.81836938148997,196.08687947988554,2.54398655203167,30.90199497238223,115.74644985420463,1.1833725871273235,2022-03-20,Symptoms management,auto-greffe,2022-04-11,Protocole 3 LAL thiotepa Bu Flu
